STUDYID|DOMAIN|USUBJID|TRSEQ|TRLNKID|TRTESTCD|TRTEST|TRORRES|TRORRESU|TRSTRESC|TRSTRESN|TRSTRESU|TRMETHOD|TRLOBXFL|TRBLFL|TREVAL|TREVALID|TRACPTFL|VISITNUM|VISIT|VISITDY|TAETORD|EPOCH|TRDTC|TRDY
e|TR|35f5401f-575a-44dc-9141-8084716a5b70|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|g/cage/day|TUMOR MERGED|1|mL/m2/h|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||VENDOR|RADIOLOGIST|U|1|Visit_1|10|6|FOLLOW-UP|2020-10-20|10
e|TR|35f5401f-575a-44dc-9141-8084716a5b70|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mIU/L|FURTHER ENLARGEMENT|1|PA|ELECTRONEUROGRAPHY|||FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|3|SCREENING|2020-11-04|25
e|TR|35f5401f-575a-44dc-9141-8084716a5b70|3|[?]|SUMDIAM|Sum of Diameter|[?]|TABLET|EQUIVOCAL|1|10^7 CFU|TARGETED GENOME SEQUENCING|Y|Y|CAREGIVER|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-11-19|40
e|TR|35f5401f-575a-44dc-9141-8084716a5b70|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|MBP|ENLARGEMENT|1|10^6 organisms|ROMANOWSKY STAIN|||STUDY SUBJECT|OPTOMETRIST|U|4|Visit_4|65|1|TREATMENT|2020-12-14|65
e|TR|35f5401f-575a-44dc-9141-8084716a5b70|5|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|BAU/mL|ENLARGEMENT|1|breaths/min|MULTI-SLICE SPIRAL CT|Y||FAMILY MEMBER|RATER|NA|5|Visit_5|90|1|WASHOUT|2021-01-08|90
e|TR|8a863a88-67d8-4e50-bafa-c3146591f046|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|cmol/L|PATHOLOGICAL|1|mEq/ug|AMSLER GRID|Y||HEALTH CARE PROFESSIONAL|READER|NA|1|Visit_1|10|2|WASHOUT|2020-12-29|10
e|TR|8a863a88-67d8-4e50-bafa-c3146591f046|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|MONTHS|DIFFUSELY INCREASED|1|/2000 RBC|PET/SPECT SCAN||Y|SIBLING|ADJUDICATOR 1|U|2|Visit_2|25|6|TREATMENT|2021-01-13|25
e|TR|8a863a88-67d8-4e50-bafa-c3146591f046|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|OD Unit|ENLARGEMENT FROM NADIR|1|kg/L|IMPULSE OSCILLOMETRY|||SIBLING|RADIOLOGIST 1|N|3|Visit_3|40|1|FOLLOW-UP|2021-01-28|40
e|TR|8a863a88-67d8-4e50-bafa-c3146591f046|4|[?]|VOLUME|Volume|[?]|ug/mL/h|UNEQUIVOCAL|1|pmol/dL|AMSLER GRID|||ADJUDICATION COMMITTEE|HEMATOLOGIST|NA|4|Visit_4|65|7|FOLLOW-UP|2021-02-22|65
e|TR|8a863a88-67d8-4e50-bafa-c3146591f046|5|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|10^7 CFU|PRESENT|1|GPL U|MEDIASTINOSCOPY|||PROXY|ADJUDICATOR 3|NA|5|Visit_5|90|4|TREATMENT|2021-03-19|90
e|TR|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|/500 WBC|FOCALLY INCREASED|1|APL U/mL|TOTAL BODY RADIOGRAPHY|Y||GUARDIAN|FORENSIC PATHOLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-08-03|10
e|TR|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|2|[?]|DIAMETER|Diameter|[?]|mmol/L|ABSENT|1|dmol|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y||INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|2|FOLLOW-UP|2020-08-18|25
e|TR|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|/min|TUMOR MERGED|1|fmol/L/sec|GIEMSA STAIN|||STUDY SUBJECT|RATER 1|NA|3|Visit_3|40|2|SCREENING|2020-09-02|40
e|TR|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|mph|ENLARGEMENT|1|cy/cm|HEMATOXYLIN AND EOSIN STAIN|Y||SIBLING|ADJUDICATOR 2|N|4|Visit_4|65|4|TREATMENT|2020-09-27|65
e|TR|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|5|[?]|LESSCIND|Lesion Success Indicator|[?]|nmol/mL/min|FOCALLY INCREASED|1|10^8 PFU|MRI|Y||HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|Y|5|Visit_5|90|1|TREATMENT|2020-10-22|90
e|TR|0558cb35-f542-4f9a-a7e7-18b1d71be69c|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|uV2|PATHOLOGICAL|1|umol/mol|LC/MS/MS|Y||CLINICAL RESEARCH ASSOCIATE|RATER|NA|1|Visit_1|10|6|TREATMENT|2020-12-20|10
e|TR|0558cb35-f542-4f9a-a7e7-18b1d71be69c|2|[?]|VDIAM|Viable Diameter|[?]|EU|TUMOR MERGED|1|mg/m2|INCISION-INDUCED BLEEDING METHOD||Y|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|2|FOLLOW-UP|2021-01-04|25
e|TR|0558cb35-f542-4f9a-a7e7-18b1d71be69c|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|um2|EQUIVOCAL|1|10^3 DNA copies/mL|RAJI CELL RIA|||SIGNIFICANT OTHER|RADIOLOGIST|N|3|Visit_3|40|7|FOLLOW-UP|2021-01-19|40
e|TR|0558cb35-f542-4f9a-a7e7-18b1d71be69c|4|[?]|ORVERLN|Organ Vertical Length|[?]|DAYS|EQUIVOCAL|1|10^9/L|CONTACT SPECULAR MICROSCOPY|||VENDOR|ENDOCRINOLOGIST|NA|4|Visit_4|65|4|SCREENING|2021-02-13|65
e|TR|0558cb35-f542-4f9a-a7e7-18b1d71be69c|5|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|CARTRIDGE|FURTHER ENLARGEMENT|1|CYLINDER|FUNDUS PHOTOGRAPHY|||SIGNIFICANT OTHER|DERMATOLOGIST|Y|5|Visit_5|90|4|FOLLOW-UP|2021-03-10|90
e|TR|a9cf4d21-c2a8-4f32-b932-f05d2d317400|1|[?]|RADIODEN|Radiodensity|[?]|PIXELS/in|PALPABLE|1|mg/m2/h|LIGHT SCATTERING SPECTROSCOPY|Y||PARENT|MICROSCOPIST 3|N|1|Visit_1|10|4|FOLLOW-UP|2020-07-03|10
e|TR|a9cf4d21-c2a8-4f32-b932-f05d2d317400|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mm/min|INCREASED|1|nsec|CT SCAN|Y||DOMESTIC PARTNER|OPHTHALMOLOGIST|U|2|Visit_2|25|4|SCREENING|2020-07-18|25
e|TR|a9cf4d21-c2a8-4f32-b932-f05d2d317400|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|g/m2/day|PRESENT|1|mg/kg/h|SISH|Y||INVESTIGATOR|UROLOGIST|NA|3|Visit_3|40|2|SCREENING|2020-08-02|40
e|TR|a9cf4d21-c2a8-4f32-b932-f05d2d317400|4|[?]|VOLUME|Volume|[?]|mAnson U/mL|NORMAL|1|/500 WBC|IN VITRO GENE EXPRESSION ASSAY|Y||SPOUSE|ONCOLOGIST 1|U|4|Visit_4|65|4|TREATMENT|2020-08-27|65
e|TR|a9cf4d21-c2a8-4f32-b932-f05d2d317400|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|L/kg|PRESENT|1|days/month|MECHANICAL CLOT DETECTION|Y||FRIEND|OPHTHALMOLOGIST|N|5|Visit_5|90|1|WASHOUT|2020-09-21|90
e|TR|0389257f-50de-4a05-8f2a-69c068374337|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|Osm|NORMAL|1|Gravitational Unit|INDIRECT IMMUNOFLUORESCENCE|||GUARDIAN|RADIOLOGIST 1|U|1|Visit_1|10|1|TREATMENT|2020-10-08|10
e|TR|0389257f-50de-4a05-8f2a-69c068374337|2|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|ng/mol|NORMAL|1|Hz/s|PULMONARY ANGIOGRAPHY|Y||ADJUDICATION COMMITTEE|RATER|U|2|Visit_2|25|3|TREATMENT|2020-10-23|25
e|TR|0389257f-50de-4a05-8f2a-69c068374337|3|[?]|SUMDIAM|Sum of Diameter|[?]|copies/mL|NORMAL|1|/MBP|CELL BASED BIOASSAY|Y||INTERVIEWER|PATHOLOGIST|Y|3|Visit_3|40|7|WASHOUT|2020-11-07|40
e|TR|0389257f-50de-4a05-8f2a-69c068374337|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|um2|DECREASED|1|mU/g|DOUBLE IMMUNODIFFUSION||Y|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|7|FOLLOW-UP|2020-12-02|65
e|TR|0389257f-50de-4a05-8f2a-69c068374337|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|mU/g|EQUIVOCAL|1|nmol/L/min|TEST STRIP|||ADJUDICATOR|NEUROLOGIST 2|U|5|Visit_5|90|4|WASHOUT|2020-12-27|90
e|TR|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|V|FURTHER ENLARGEMENT|1|POUCH|POLYSOMNOGRAPHY|||SIGNIFICANT OTHER|OPTOMETRIST|Y|1|Visit_1|10|6|TREATMENT|2020-12-15|10
e|TR|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|nU/cL|NON-PATHOLOGICAL|1|umol/L/h|FORCED OSCILLATION TECHNIQUE|||GUARDIAN|MICROSCOPIST 3|U|2|Visit_2|25|5|SCREENING|2020-12-30|25
e|TR|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|3|[?]|DIAMETER|Diameter|[?]|mCi/kg|TUMOR MERGED|1|POINT|SLOAN LETTER EYE CHART 100%|Y||CLINICAL RESEARCH ASSOCIATE|INTERNIST|Y|3|Visit_3|40|1|TREATMENT|2021-01-14|40
e|TR|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|U/g/h|UNCHANGED|1|fmol|TRANSCRIPTION-MEDIATED AMPLIFICATION|||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|3|SCREENING|2021-02-08|65
e|TR|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|Gravitational Unit|FURTHER ENLARGEMENT FROM NADIR|1|BEAM BREAKS|FLUORESCEIN STAIN|||SPOUSE|CARDIOLOGIST|N|5|Visit_5|90|2|TREATMENT|2021-03-05|90
e|TR|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|Sv|PATHOLOGICAL|1|pkat/L|KINETIC MICROPARTICLE IMMUNOASSAY|||PROXY|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|1|WASHOUT|2020-12-22|10
e|TR|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|2|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|foz_br|PRESENT|1|nmol/L|ROMANOWSKY STAIN|Y||FAMILY MEMBER|MICROSCOPIST|Y|2|Visit_2|25|7|TREATMENT|2021-01-06|25
e|TR|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|mg/kg/week|DECREASED|1|KIT|GC/MS-EI|||INVESTIGATOR|READER 1|N|3|Visit_3|40|3|FOLLOW-UP|2021-01-21|40
e|TR|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mL/m2/h|PATHOLOGICAL|1|TAMPON|LYMPHANGIOGRAPHY|||PROXY|MICROSCOPIST 3|Y|4|Visit_4|65|1|TREATMENT|2021-02-15|65
e|TR|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|U/m2|PATHOLOGICAL|1|NEBULE|POLYMERASE CHAIN REACTION||Y|ADJUDICATION COMMITTEE|DERMATOLOGIST|NA|5|Visit_5|90|3|WASHOUT|2021-03-12|90
e|TR|ad402b62-0625-431b-9bd7-ffd6124610f3|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|IU/day|INCREASED|1|pmol|SISH|||INTERVIEWER|MICROSCOPIST 2|Y|1|Visit_1|10|1|TREATMENT|2020-09-25|10
e|TR|ad402b62-0625-431b-9bd7-ffd6124610f3|2|[?]|VSLFLIND|Vessel Failure Indicator|[?]|titer|EQUIVOCAL|1|CIGARETTE|IODINE STAIN|||FAMILY MEMBER|READER 3|NA|2|Visit_2|25|7|SCREENING|2020-10-10|25
e|TR|ad402b62-0625-431b-9bd7-ffd6124610f3|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mL|PRESENT|1|g/kg/day|FLOCCULATION||Y|HEALTH CARE PROFESSIONAL|UROLOGIST|U|3|Visit_3|40|3|WASHOUT|2020-10-25|40
e|TR|ad402b62-0625-431b-9bd7-ffd6124610f3|4|[?]|SUMDIAM|Sum of Diameter|[?]|pmol/day|FOCALLY INCREASED|1|mEq/L|ELECTROCHEMILUMINESCENCE|Y||SIGNIFICANT OTHER|READER|Y|4|Visit_4|65|4|TREATMENT|2020-11-19|65
e|TR|ad402b62-0625-431b-9bd7-ffd6124610f3|5|[?]|LDIAM|Longest Diameter|[?]|mL/g/min|FURTHER ENLARGEMENT|1|mg/kg/h|ICC|||CLINICAL STUDY SPONSOR|READER|Y|5|Visit_5|90|2|FOLLOW-UP|2020-12-14|90
e|TR|d76b0f55-541c-491d-9162-4c133c9509f1|1|[?]|ORSTATE|Organ State|[?]|Watt|FURTHER ENLARGEMENT|1|ELISA unit/mL|CISH|Y|Y|PROXY|READER 1|U|1|Visit_1|10|4|FOLLOW-UP|2020-05-24|10
e|TR|d76b0f55-541c-491d-9162-4c133c9509f1|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|10^11/L|ABSENT|1|g/L|HPLC/MS/MS|||INDEPENDENT ASSESSOR|PATHOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2020-06-08|25
e|TR|d76b0f55-541c-491d-9162-4c133c9509f1|3|[?]|DIAMETER|Diameter|[?]|s/h|ABSENT|1|mkat|AMSLER GRID||Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|Y|3|Visit_3|40|7|FOLLOW-UP|2020-06-23|40
e|TR|d76b0f55-541c-491d-9162-4c133c9509f1|4|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|/10^4|TUMOR MERGED|1|log10 PFU/mL|SIZE EXCLUSION CHROMATOGRAPHY||Y|STUDY SUBJECT|ONCOLOGIST 1|U|4|Visit_4|65|6|TREATMENT|2020-07-18|65
e|TR|d76b0f55-541c-491d-9162-4c133c9509f1|5|[?]|ORSTATE|Organ State|[?]|pmol/10^10 cells|NON-PATHOLOGICAL|1|mL/(min*100mL)|VENTILATION PERFUSION LUNG SCAN|||INTERVIEWER|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|2|FOLLOW-UP|2020-08-12|90
e|TR|146059d8-5652-41cd-b484-c6e5d8ea540f|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|10^7 CFU/mL|NON-PATHOLOGICAL|1|/cmH2O|VIRUS PLAQUE ASSAY|||FAMILY MEMBER|UROLOGIST|N|1|Visit_1|10|6|WASHOUT|2020-08-26|10
e|TR|146059d8-5652-41cd-b484-c6e5d8ea540f|2|[?]|PPD|Product of Perpendicular Diameters|[?]|Bq/mL|ENLARGEMENT|1|ug/L FEU|RADIATION DOSIMETRY|||VENDOR|FORENSIC PATHOLOGIST|N|2|Visit_2|25|3|TREATMENT|2020-09-10|25
e|TR|146059d8-5652-41cd-b484-c6e5d8ea540f|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|/sec|ABSENT|1|/day|IMMUNE REPERTOIRE DEEP SEQUENCING|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|U|3|Visit_3|40|4|FOLLOW-UP|2020-09-25|40
e|TR|146059d8-5652-41cd-b484-c6e5d8ea540f|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|umol/kg/min|FOCALLY INCREASED|1|mph|ENZYMATIC ULTRACENTRIFUGATION|||PROXY|RADIOLOGIST|Y|4|Visit_4|65|3|WASHOUT|2020-10-20|65
e|TR|146059d8-5652-41cd-b484-c6e5d8ea540f|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|m|FURTHER ENLARGEMENT|1|10^9 organisms/mg|DARK FIELD MICROSCOPY|Y||SPOUSE|MICROSCOPIST|U|5|Visit_5|90|7|TREATMENT|2020-11-14|90
e|TR|3d5f1964-b65c-4a0a-bb5b-1689308754d8|1|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|kat|UNCHANGED|1|Watt|OPTICAL DENSITY MEASUREMENT|Y|Y|SIGNIFICANT OTHER|UROLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-11-04|10
e|TR|3d5f1964-b65c-4a0a-bb5b-1689308754d8|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|umol/day|EQUIVOCAL|1|mol/L|ICP-MS|Y||FRIEND|UROLOGIST|U|2|Visit_2|25|7|FOLLOW-UP|2020-11-19|25
e|TR|3d5f1964-b65c-4a0a-bb5b-1689308754d8|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|pmol/L/h|NON-PATHOLOGICAL|1|ug/cm2|CELL BASED BIOASSAY|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|3|Visit_3|40|6|TREATMENT|2020-12-04|40
e|TR|3d5f1964-b65c-4a0a-bb5b-1689308754d8|4|[?]|SUMVOL|Sum of Volume|[?]|CAPLET|INCREASED|1|nmol/L/min|DC SHEATH FLOW|||CAREGIVER|ADJUDICATOR 1|U|4|Visit_4|65|1|WASHOUT|2020-12-29|65
e|TR|3d5f1964-b65c-4a0a-bb5b-1689308754d8|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|nL|UNCHANGED|1|AMPULE|POLYSOMNOGRAPHY||Y|GUARDIAN|UROLOGIST|NA|5|Visit_5|90|1|TREATMENT|2021-01-23|90
e|TR|129dc836-068a-463e-b789-a0d05c60605d|1|[?]|VDIAM|Viable Diameter|[?]|fg|EQUIVOCAL|1|/HPF|DARK FIELD MICROSCOPY||Y|HEALTH CARE PROFESSIONAL|INTERNIST|NA|1|Visit_1|10|3|TREATMENT|2020-07-06|10
e|TR|129dc836-068a-463e-b789-a0d05c60605d|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mEq/uL|ENLARGEMENT FROM NADIR|1|AU/mL|IN VITRO GENE EXPRESSION ASSAY|Y||INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|N|2|Visit_2|25|2|FOLLOW-UP|2020-07-21|25
e|TR|129dc836-068a-463e-b789-a0d05c60605d|3|[?]|VOLUME|Volume|[?]|10^6/g|ABSENT|1|mU|ALCIAN BLUE STAIN|||SPOUSE|PATHOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-08-05|40
e|TR|129dc836-068a-463e-b789-a0d05c60605d|4|[?]|PCHGBL|Percent Change From Baseline|[?]|DAgU|DECREASED|1|nmol/L/min|AUTOMATED COUNT|||INVESTIGATOR|OTOLARYNGOLOGIST|NA|4|Visit_4|65|1|TREATMENT|2020-08-30|65
e|TR|129dc836-068a-463e-b789-a0d05c60605d|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|CCID 50/mL|DIFFUSELY INCREASED|1|copies/mL|ETDRS EYE CHART|||INTERVIEWER|RATER 2|Y|5|Visit_5|90|4|SCREENING|2020-09-24|90
e|TR|9ef8a6d4-8326-4050-be85-e9f8983f55c1|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|DAYS|UNCHANGED|1|mg/h|MICROBIAL CULTURE, SOLID|||SPOUSE|ENDOCRINOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-11-07|10
e|TR|9ef8a6d4-8326-4050-be85-e9f8983f55c1|2|[?]|NEWCONF|New Tumor Confirmed|[?]|deg/mm|PATHOLOGICAL|1|Bq/mg|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||DOMESTIC PARTNER|NEUROLOGIST 1|Y|2|Visit_2|25|2|TREATMENT|2020-11-22|25
e|TR|9ef8a6d4-8326-4050-be85-e9f8983f55c1|3|[?]|ACHNAD|Absolute Change From Nadir|[?]|mMU/mL|ENLARGEMENT|1|IU/kg/h|LANDOLT RING|Y||ADJUDICATOR|ONCOLOGIST 2|NA|3|Visit_3|40|4|FOLLOW-UP|2020-12-07|40
e|TR|9ef8a6d4-8326-4050-be85-e9f8983f55c1|4|[?]|SUMVOL|Sum of Volume|[?]|TABLET|PATHOLOGICAL|1|V/sec|HPLC/MS||Y|FAMILY MEMBER|DERMATOLOGIST|Y|4|Visit_4|65|2|SCREENING|2021-01-01|65
e|TR|9ef8a6d4-8326-4050-be85-e9f8983f55c1|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|mgEq|DECREASED|1|nkat/L|CAPILLARY ELECTROPHORESIS|||STUDY SUBJECT|RADIOLOGIST 2|U|5|Visit_5|90|6|TREATMENT|2021-01-26|90
e|TR|b91c4469-b3be-467f-8512-b73cf561e168|1|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mm|FOCALLY INCREASED|1|ug/cm2|ACRIDINE ORANGE STAIN|||INTERVIEWER|OTOLARYNGOLOGIST|N|1|Visit_1|10|4|FOLLOW-UP|2020-05-18|10
e|TR|b91c4469-b3be-467f-8512-b73cf561e168|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|mV/sec|PATHOLOGICAL|1|Bq/kg|MICROBIAL BIOCHEMICAL IDENTIFICATION|||FRIEND|RADIOLOGIST 2|Y|2|Visit_2|25|6|WASHOUT|2020-06-02|25
e|TR|b91c4469-b3be-467f-8512-b73cf561e168|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|ug/h|PRESENT|1|FEU|ELISA|||VENDOR|INTERNIST|U|3|Visit_3|40|4|TREATMENT|2020-06-17|40
e|TR|b91c4469-b3be-467f-8512-b73cf561e168|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|uOsm|FURTHER ENLARGEMENT FROM NADIR|1|umol/L/sec|DISK DIFFUSION|||CLINICAL STUDY SPONSOR|MICROSCOPIST|U|4|Visit_4|65|6|SCREENING|2020-07-12|65
e|TR|b91c4469-b3be-467f-8512-b73cf561e168|5|[?]|TUMSTATE|Tumor State|[?]|10^4 CFU|EQUIVOCAL|1|U/m2/h|RADIATION DOSIMETRY|Y||CHILD|NEUROLOGIST|Y|5|Visit_5|90|4|WASHOUT|2020-08-06|90
e|TR|3637e1e0-8c0c-45cc-b139-e812a589f940|1|[?]|VDIAM|Viable Diameter|[?]|tsp|NON-PATHOLOGICAL|1|mEq/L|MODIFIED ACID FAST STAIN|||INVESTIGATOR|PATHOLOGIST 1|NA|1|Visit_1|10|2|TREATMENT|2020-08-30|10
e|TR|3637e1e0-8c0c-45cc-b139-e812a589f940|2|[?]|RADIODEN|Radiodensity|[?]|nmol/day|PRESENT|1|foz_us|PELLI-ROBSON EYE CHART|||CAREGIVER|ONCOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-09-14|25
e|TR|3637e1e0-8c0c-45cc-b139-e812a589f940|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mOsm|FOCALLY INCREASED|1|PELLET|KNEMOMETRY|||INTERVIEWER|ADJUDICATOR 2|Y|3|Visit_3|40|1|WASHOUT|2020-09-29|40
e|TR|3637e1e0-8c0c-45cc-b139-e812a589f940|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|10^8 PFU|DIFFUSELY INCREASED|1|OD Unit|MODIFIED ACID FAST STAIN|||FAMILY MEMBER|ADJUDICATOR|NA|4|Visit_4|65|6|WASHOUT|2020-10-24|65
e|TR|3637e1e0-8c0c-45cc-b139-e812a589f940|5|[?]|LESSCIND|Lesion Success Indicator|[?]|10^3 organisms/g|INCREASED|1|mL/min/mmHg|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y|FAMILY MEMBER|MICROSCOPIST|N|5|Visit_5|90|2|FOLLOW-UP|2020-11-18|90
e|TR|23385974-5fcd-4c36-b9fa-2fbb3841f182|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|NEBULE|NON-PATHOLOGICAL|1|10^3 organisms|PLETHYSMOGRAPHY||Y|CHILD|MICROSCOPIST 3|NA|1|Visit_1|10|1|FOLLOW-UP|2020-11-27|10
e|TR|23385974-5fcd-4c36-b9fa-2fbb3841f182|2|[?]|NEWCONF|New Tumor Confirmed|[?]|Pack Year|INCREASED|1|10^7 CFU|SPIRAL CT|||CLINICAL RESEARCH COORDINATOR|READER 1|N|2|Visit_2|25|2|TREATMENT|2020-12-12|25
e|TR|23385974-5fcd-4c36-b9fa-2fbb3841f182|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mg/L FEU|PALPABLE|1|mmol/kg|LISSAMINE GREEN STAIN||Y|INDEPENDENT ASSESSOR|UROLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-12-27|40
e|TR|23385974-5fcd-4c36-b9fa-2fbb3841f182|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|cpm|FURTHER ENLARGEMENT|1|/10^3|BAC ACGH|||DOMESTIC PARTNER|CARDIOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2021-01-21|65
e|TR|23385974-5fcd-4c36-b9fa-2fbb3841f182|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|mU|DIFFUSELY INCREASED|1|IU/day|IVY INCISION METHOD|Y|Y|ADJUDICATION COMMITTEE|RATER 2|Y|5|Visit_5|90|3|TREATMENT|2021-02-15|90
e|TR|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|mL/dL|PALPABLE|1|/day|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|5|WASHOUT|2020-12-06|10
e|TR|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|2|[?]|LESSCIND|Lesion Success Indicator|[?]|nmol/L|ABSENT|1|/10^5|CONTRAST ENHANCED PET/CT SCAN||Y|PARENT|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-12-21|25
e|TR|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|h/wk|UNEQUIVOCAL|1|deg/mm|CLIP SEQUENCING||Y|FRIEND|RATER 2|NA|3|Visit_3|40|5|TREATMENT|2021-01-05|40
e|TR|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|4|[?]|AREA|Area|[?]|mg/mol|UNEQUIVOCAL|1|uCi/kg|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|Y||VENDOR|HEMATOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2021-01-30|65
e|TR|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|5|[?]|VDIAM|Viable Diameter|[?]|uEq/L|FOCALLY INCREASED|1|10^9 organisms|MICRO BROTH DILUTION|||DOMESTIC PARTNER|ONCOLOGIST|NA|5|Visit_5|90|2|SCREENING|2021-02-24|90
e|TR|f1327e16-08c6-4ef0-852e-13c095a94c00|1|[?]|NEWCONF|New Tumor Confirmed|[?]|fg|DIFFUSELY INCREASED|1|SYRINGE|SPIRAL CT SCAN WITHOUT CONTRAST|Y||INDEPENDENT ASSESSOR|RATER 2|N|1|Visit_1|10|3|WASHOUT|2020-05-26|10
e|TR|f1327e16-08c6-4ef0-852e-13c095a94c00|2|[?]|CALCFIND|Calcification Indicator|[?]|g/g/day|ABSENT|1|U/L|MRI|||INVESTIGATOR|RADIOLOGIST 2|Y|2|Visit_2|25|5|SCREENING|2020-06-10|25
e|TR|f1327e16-08c6-4ef0-852e-13c095a94c00|3|[?]|PCHGBL|Percent Change From Baseline|[?]|/10^3|FURTHER ENLARGEMENT FROM NADIR|1|TABLET|PERIODIC ACID SCHIFF STAIN|||PARENT|MICROSCOPIST|Y|3|Visit_3|40|6|TREATMENT|2020-06-25|40
e|TR|f1327e16-08c6-4ef0-852e-13c095a94c00|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mmol/day|PRESENT|1|cd|PANENDOSCOPY|||INVESTIGATOR|NEUROLOGIST|Y|4|Visit_4|65|4|WASHOUT|2020-07-20|65
e|TR|f1327e16-08c6-4ef0-852e-13c095a94c00|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|mJoule/cm2|NON-PATHOLOGICAL|1|SFC/10^6 PBMC|TRANSTHORACIC ECHOCARDIOGRAPHY||Y|CHILD|PHYSIOTHERAPIST|NA|5|Visit_5|90|5|TREATMENT|2020-08-14|90
e|TR|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|kg/L|NORMAL|1|10^3 CFU/g|SCANNING ELECTRON MICROSCOPY|||ADJUDICATOR|RADIOLOGIST 1|NA|1|Visit_1|10|6|TREATMENT|2021-01-15|10
e|TR|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|2|[?]|VOLUME|Volume|[?]|APL U/mL|DIFFUSELY INCREASED|1|mEq|PEAK FLOWMETRY|||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|N|2|Visit_2|25|5|WASHOUT|2021-01-30|25
e|TR|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|g/m2/day|DIFFUSELY INCREASED|1|APL U/mL|TOTAL BODY RADIOGRAPHY|||GUARDIAN|RADIOLOGIST 2|U|3|Visit_3|40|3|TREATMENT|2021-02-14|40
e|TR|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|4|[?]|LPERP|Longest Perpendicular|[?]|pg/L|DIFFUSELY INCREASED|1|/MBP|ENDOSCOPY|Y||PARENT|PATHOLOGIST 2|NA|4|Visit_4|65|1|TREATMENT|2021-03-11|65
e|TR|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|dpm/mL|FURTHER ENLARGEMENT|1|U/mg|PET/MRI SCAN|Y||INVESTIGATOR|ONCOLOGIST 1|U|5|Visit_5|90|3|FOLLOW-UP|2021-04-05|90
e|TR|e8065021-c163-41c8-8a76-5f0c1c3a06c4|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|ug/kg|TUMOR MERGED|1|ug/min|CENTRIFUGATION|||FRIEND|MICROSCOPIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-12-08|10
e|TR|e8065021-c163-41c8-8a76-5f0c1c3a06c4|2|[?]|LPERP|Longest Perpendicular|[?]|10^9 organisms/g|FURTHER ENLARGEMENT|1|Ci|CLOT DETECTION|||ADJUDICATOR|READER 3|Y|2|Visit_2|25|2|FOLLOW-UP|2020-12-23|25
e|TR|e8065021-c163-41c8-8a76-5f0c1c3a06c4|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|IMPLANT|PALPABLE|1|Hz|IMMUNOFLUORESCENT STAIN|Y||SPOUSE|MICROSCOPIST 2|N|3|Visit_3|40|1|TREATMENT|2021-01-07|40
e|TR|e8065021-c163-41c8-8a76-5f0c1c3a06c4|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|L/L|FURTHER ENLARGEMENT FROM NADIR|1|cd*s/m2|LANDOLT RING|Y||INVESTIGATOR|READER 3|U|4|Visit_4|65|1|FOLLOW-UP|2021-02-01|65
e|TR|e8065021-c163-41c8-8a76-5f0c1c3a06c4|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|CIGAR|FURTHER ENLARGEMENT FROM NADIR|1|um/day|DISK DIFFUSION|||INVESTIGATOR|ONCOLOGIST 1|NA|5|Visit_5|90|1|TREATMENT|2021-02-26|90
e|TR|854a9218-995e-47f4-87ab-e58d20f56d19|1|[?]|NEWCONF|New Tumor Confirmed|[?]|usec|NONPALPABLE|1|mL/cm|HEMATOXYLIN AND EOSIN STAIN|||CAREGIVER|PATHOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-11-23|10
e|TR|854a9218-995e-47f4-87ab-e58d20f56d19|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|atm|DECREASED|1|PACKET|WESTERGREN|Y||DOMESTIC PARTNER|ADJUDICATOR|NA|2|Visit_2|25|5|SCREENING|2020-12-08|25
e|TR|854a9218-995e-47f4-87ab-e58d20f56d19|3|[?]|DIAMETER|Diameter|[?]|Siemens|UNCHANGED|1|dB|TURBIDIMETRY|||INDEPENDENT ASSESSOR|PATHOLOGIST 2|Y|3|Visit_3|40|3|TREATMENT|2020-12-23|40
e|TR|854a9218-995e-47f4-87ab-e58d20f56d19|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|Bq/g|TUMOR MERGED|1|10^9 CFU|DOPPLER ULTRASOUND|||CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|NA|4|Visit_4|65|3|TREATMENT|2021-01-17|65
e|TR|854a9218-995e-47f4-87ab-e58d20f56d19|5|[?]|LPERP|Longest Perpendicular|[?]|mol/mg|UNEQUIVOCAL|1|PIPE|MAPH|||PARENT|ONCOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2021-02-11|90
e|TR|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|LB|ENLARGEMENT FROM NADIR|1|GBq/g|PULMONARY ANGIOGRAPHY|||STUDY SUBJECT|ADJUDICATOR 3|Y|1|Visit_1|10|1|TREATMENT|2020-06-21|10
e|TR|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|ft2|INCREASED|1|kg/L|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||Y|FRIEND|MICROSCOPIST 1|U|2|Visit_2|25|2|SCREENING|2020-07-06|25
e|TR|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|3|[?]|SUMDIAM|Sum of Diameter|[?]|mg/m2/min|ENLARGEMENT|1|log10 TCID 50/mL|MIGET|||STUDY SUBJECT|ADJUDICATOR 2|U|3|Visit_3|40|6|TREATMENT|2020-07-21|40
e|TR|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|10^7 PFU|EQUIVOCAL|1|pL|ELECTROGASTROGRAPHY||Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2020-08-15|65
e|TR|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|PA|FOCALLY INCREASED|1|GPS U|ORCHIDOMETERY|||FRIEND|ADJUDICATOR 1|U|5|Visit_5|90|4|TREATMENT|2020-09-09|90
e|TR|08944dcd-a62d-4932-bb15-a8f15cc73229|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|Enzyme U/g Hb|UNEQUIVOCAL|1|mV*min|BIOIMPEDANCE SPECTROSCOPY|||NON-HEALTH CARE PROFESSIONAL|RATER|N|1|Visit_1|10|2|SCREENING|2020-12-23|10
e|TR|08944dcd-a62d-4932-bb15-a8f15cc73229|2|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mol|NONPALPABLE|1|umol/L/min|FREEZING POINT DEPRESSION||Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|2|Visit_2|25|7|TREATMENT|2021-01-07|25
e|TR|08944dcd-a62d-4932-bb15-a8f15cc73229|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|ng/day|FOCALLY INCREASED|1|mU/L|NON-CONTACT SPECULAR MICROSCOPY|Y||PROXY|MICROSCOPIST 2|N|3|Visit_3|40|5|WASHOUT|2021-01-22|40
e|TR|08944dcd-a62d-4932-bb15-a8f15cc73229|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|GBq/mg|PRESENT|1|ft|SLOAN LETTER EYE CHART 100%|||CLINICAL STUDY SPONSOR|NEUROLOGIST|NA|4|Visit_4|65|5|TREATMENT|2021-02-16|65
e|TR|08944dcd-a62d-4932-bb15-a8f15cc73229|5|[?]|PPD|Product of Perpendicular Diameters|[?]|10^5/L|NORMAL|1|fmol/L/sec|MOUSE PROTECTION ASSAY|Y|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|5|Visit_5|90|5|TREATMENT|2021-03-13|90
e|TR|1d7df560-695a-41fe-9226-4cc206b05f48|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|Bq|FURTHER ENLARGEMENT FROM NADIR|1|GPL U|TRIPLE-PHASE SPIRAL CT SCAN|||CAREGIVER|ONCOLOGIST 1|Y|1|Visit_1|10|7|WASHOUT|2020-12-09|10
e|TR|1d7df560-695a-41fe-9226-4cc206b05f48|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|DAYS|FURTHER ENLARGEMENT|1|dpm/mL|TONOMETRY|||INVESTIGATOR|NEUROLOGIST 2|NA|2|Visit_2|25|4|TREATMENT|2020-12-24|25
e|TR|1d7df560-695a-41fe-9226-4cc206b05f48|3|[?]|ORSTATE|Organ State|[?]|vg/mL|DIFFUSELY INCREASED|1|mL/s/m2|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||INVESTIGATOR|NEUROLOGIST|NA|3|Visit_3|40|2|TREATMENT|2021-01-08|40
e|TR|1d7df560-695a-41fe-9226-4cc206b05f48|4|[?]|SUMVOL|Sum of Volume|[?]|AgU/mL|PALPABLE|1|10^6 CFU/mL|MRI|||STUDY SUBJECT|NEUROLOGIST 1|U|4|Visit_4|65|1|WASHOUT|2021-02-02|65
e|TR|1d7df560-695a-41fe-9226-4cc206b05f48|5|[?]|RADIODEN|Radiodensity|[?]|umol|ABSENT|1|/10^3|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||Y|VENDOR|OPTOMETRIST|U|5|Visit_5|90|6|WASHOUT|2021-02-27|90
e|TR|12c802a8-862c-45a4-b12c-a6f920772534|1|[?]|LPERP|Longest Perpendicular|[?]|umol/kg/min|ENLARGEMENT FROM NADIR|1|mEq/uL|RADIATION DOSIMETRY|Y|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 3|Y|1|Visit_1|10|4|WASHOUT|2020-06-17|10
e|TR|12c802a8-862c-45a4-b12c-a6f920772534|2|[?]|SUMDIAM|Sum of Diameter|[?]|IU/dL|NORMAL|1|deg/mm|LAPAROSCOPY|||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|2|WASHOUT|2020-07-02|25
e|TR|12c802a8-862c-45a4-b12c-a6f920772534|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|dpm/0.5 mL|ENLARGEMENT|1|Enzyme U/m2|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||ADJUDICATION COMMITTEE|READER 2|N|3|Visit_3|40|3|SCREENING|2020-07-17|40
e|TR|12c802a8-862c-45a4-b12c-a6f920772534|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|Gravitational Unit|DIFFUSELY INCREASED|1|mL/kg|ENZYMATIC ULTRACENTRIFUGATION|||PROXY|ADJUDICATOR 2|N|4|Visit_4|65|6|SCREENING|2020-08-11|65
e|TR|12c802a8-862c-45a4-b12c-a6f920772534|5|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|umol/kg/min|PALPABLE|1|m/sec2|MS/MS|||CLINICAL STUDY SPONSOR|HEMATOLOGIST|N|5|Visit_5|90|7|TREATMENT|2020-09-05|90
e|TR|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|1|[?]|NEWCONF|New Tumor Confirmed|[?]|mm2|FURTHER ENLARGEMENT|1|kg/L|FLOW MICROSCOPY|||FRIEND|READER 1|N|1|Visit_1|10|4|FOLLOW-UP|2020-11-23|10
e|TR|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|Mile|NORMAL|1|hPa|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||CLINICAL RESEARCH ASSOCIATE|RATER 2|N|2|Visit_2|25|6|TREATMENT|2020-12-08|25
e|TR|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|/sec|TUMOR MERGED|1|EU|FLUORESCENT ENZYME IMMUNOASSAY||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|Y|3|Visit_3|40|2|TREATMENT|2020-12-23|40
e|TR|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|cy/cm|PATHOLOGICAL|1|CFU/g|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||STUDY SUBJECT|DERMATOLOGIST|N|4|Visit_4|65|6|WASHOUT|2021-01-17|65
e|TR|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|5|[?]|NEWCONF|New Tumor Confirmed|[?]|mCi|PALPABLE|1|U.CARR|TRANSMISSION ELECTRON MICROSCOPY|||ADJUDICATION COMMITTEE|CARDIOLOGIST|N|5|Visit_5|90|5|TREATMENT|2021-02-11|90
e|TR|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|1|[?]|SUMDIAM|Sum of Diameter|[?]|uSiemens|TUMOR MERGED|1|s*kPa|URANYL ACETATE STAIN|||CAREGIVER|RATER|Y|1|Visit_1|10|6|TREATMENT|2020-08-16|10
e|TR|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|ms2|ABSENT|1|10^5/L|SIZE EXCLUSION CHROMATOGRAPHY|||CHILD|OTOLARYNGOLOGIST|Y|2|Visit_2|25|3|WASHOUT|2020-08-31|25
e|TR|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|Pack Year|ABSENT|1|nmol/L|OPTICAL COHERENCE TOMOGRAPHY|Y||CAREGIVER|NEUROLOGIST 2|Y|3|Visit_3|40|1|FOLLOW-UP|2020-09-15|40
e|TR|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|days/wk|PALPABLE|1|Arbitrary U|RIA||Y|DOMESTIC PARTNER|RADIOLOGIST 1|U|4|Visit_4|65|6|WASHOUT|2020-10-10|65
e|TR|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|pmol/dL|ABSENT|1|pptr|WHOLE EXOME SEQUENCING|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|5|Visit_5|90|7|TREATMENT|2020-11-04|90
e|TR|96114171-59a0-4543-b3ec-c7796ae8ee92|1|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|DNA copies/ug|EQUIVOCAL|1|ugEq|ENZYMATIC COLORIMETRY|||PARENT|PATHOLOGIST 2|U|1|Visit_1|10|1|TREATMENT|2020-11-24|10
e|TR|96114171-59a0-4543-b3ec-c7796ae8ee92|2|[?]|RADIODEN|Radiodensity|[?]|10^6 IU|FOCALLY INCREASED|1|%(w/v)|ZIEHL NEELSEN ACID FAST STAIN||Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|NA|2|Visit_2|25|7|TREATMENT|2020-12-09|25
e|TR|96114171-59a0-4543-b3ec-c7796ae8ee92|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|ag|NONPALPABLE|1|atm|ANALYTICAL ULTRACENTRIFUGATION|Y||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|Y|3|Visit_3|40|7|WASHOUT|2020-12-24|40
e|TR|96114171-59a0-4543-b3ec-c7796ae8ee92|4|[?]|ORVERLN|Organ Vertical Length|[?]|BE/mL|PRESENT|1|IU|MAGNETIC RESONANCE ANGIOGRAPHY|||SIBLING|ADJUDICATOR 3|N|4|Visit_4|65|7|TREATMENT|2021-01-18|65
e|TR|96114171-59a0-4543-b3ec-c7796ae8ee92|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|g/mol|PATHOLOGICAL|1|umol/dL|RADIOIMMUNOPRECIPITATION ASSAY|||SIGNIFICANT OTHER|UROLOGIST|U|5|Visit_5|90|1|TREATMENT|2021-02-12|90
e|TR|0070d42d-c864-4a83-a3c9-4c8ca7de51de|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|ug/mol|NON-PATHOLOGICAL|1|MASK|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||GUARDIAN|RATER 1|U|1|Visit_1|10|5|FOLLOW-UP|2020-08-15|10
e|TR|0070d42d-c864-4a83-a3c9-4c8ca7de51de|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|Rad|FURTHER ENLARGEMENT|1|gpELISA unit/mL|IMMUNE REPERTOIRE DEEP SEQUENCING|Y|Y|HEALTH CARE PROFESSIONAL|INTERNIST|NA|2|Visit_2|25|2|SCREENING|2020-08-30|25
e|TR|0070d42d-c864-4a83-a3c9-4c8ca7de51de|3|[?]|TUMSTATE|Tumor State|[?]|Pack Year|INCREASED|1|CCID 50/dose|SLIT LAMP PHOTOGRAPHY||Y|SIGNIFICANT OTHER|READER 1|NA|3|Visit_3|40|1|SCREENING|2020-09-14|40
e|TR|0070d42d-c864-4a83-a3c9-4c8ca7de51de|4|[?]|RADIODEN|Radiodensity|[?]|mol/mL|FOCALLY INCREASED|1|breaths/30s|NON-INVASIVE DIELECTRIC SENSING|||FAMILY MEMBER|ONCOLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-10-09|65
e|TR|0070d42d-c864-4a83-a3c9-4c8ca7de51de|5|[?]|LPERP|Longest Perpendicular|[?]|pmol/10^9 cells|NONPALPABLE|1|10^3 CFU|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||FRIEND|NEUROLOGIST 2|Y|5|Visit_5|90|4|TREATMENT|2020-11-03|90
e|TR|a2ec3389-6f5f-44a3-a6dd-f6177a805791|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mm/sec|PATHOLOGICAL|1|PIXELS/in|MICROSCOPY|Y|Y|FAMILY MEMBER|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|5|SCREENING|2020-10-17|10
e|TR|a2ec3389-6f5f-44a3-a6dd-f6177a805791|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|ug/g/day|UNCHANGED|1|cal|MIGET|||CAREGIVER|READER 2|NA|2|Visit_2|25|1|WASHOUT|2020-11-01|25
e|TR|a2ec3389-6f5f-44a3-a6dd-f6177a805791|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|10^6 DNA copies/mL|EQUIVOCAL|1|h*%|BRDU CELLULAR PROLIFERATION ASSAY|||CHILD|CLINICAL PATHOLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-11-16|40
e|TR|a2ec3389-6f5f-44a3-a6dd-f6177a805791|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|v/v|NON-PATHOLOGICAL|1|uOsm|NUCLEIC ACID SEQUENCING|||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|5|SCREENING|2020-12-11|65
e|TR|a2ec3389-6f5f-44a3-a6dd-f6177a805791|5|[?]|RADIODEN|Radiodensity|[?]|mm/2h|PATHOLOGICAL|1|mV2/Hz|ZIEHL NEELSEN ACID FAST STAIN|||ADJUDICATOR|NEUROLOGIST 1|U|5|Visit_5|90|2|TREATMENT|2021-01-05|90
e|TR|cc562042-9641-460d-862e-d6923dd4207d|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mL/cm|ENLARGEMENT|1|mL/min|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||Y|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-05-27|10
e|TR|cc562042-9641-460d-862e-d6923dd4207d|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|U/m2/min|INCREASED|1|CONTAINER|PUPILLOMETRY|||SPOUSE|RADIOLOGIST 2|Y|2|Visit_2|25|7|WASHOUT|2020-06-11|25
e|TR|cc562042-9641-460d-862e-d6923dd4207d|3|[?]|ORVERLN|Organ Vertical Length|[?]|mmHg*min/L|FOCALLY INCREASED|1|nCi|AUTOMATED COUNT|||CAREGIVER|DERMATOLOGIST|U|3|Visit_3|40|4|FOLLOW-UP|2020-06-26|40
e|TR|cc562042-9641-460d-862e-d6923dd4207d|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|U|INCREASED|1|lm|CHROMOGENIC ASSAY||Y|PARENT|ONCOLOGIST 1|NA|4|Visit_4|65|3|SCREENING|2020-07-21|65
e|TR|cc562042-9641-460d-862e-d6923dd4207d|5|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|IU/g|DIFFUSELY INCREASED|1|g|FLUORESCENT SPOT TEST|Y||CAREGIVER|ONCOLOGIST 1|NA|5|Visit_5|90|6|TREATMENT|2020-08-15|90
e|TR|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|fraction of 1|ABSENT|1|log EID 50/dose|RADIOIMMUNOPRECIPITATION ASSAY|Y||VENDOR|READER 2|U|1|Visit_1|10|4|SCREENING|2020-07-30|10
e|TR|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|2|[?]|VSLFLIND|Vessel Failure Indicator|[?]|log10 CFU/mL|ENLARGEMENT|1|GBq/g|SLIT LAMP||Y|CAREGIVER|ADJUDICATOR 3|Y|2|Visit_2|25|5|TREATMENT|2020-08-14|25
e|TR|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|3|[?]|PALPSTAT|Palpable State|[?]|Bq|NORMAL|1|ug/dL|WHOLE GENOME SEQUENCING|||INVESTIGATOR|RADIOLOGIST 1|NA|3|Visit_3|40|7|TREATMENT|2020-08-29|40
e|TR|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|cm|PRESENT|1|MPL U/mL|MICROBIAL CULTURE, LIQUID|||CAREGIVER|MICROSCOPIST 3|Y|4|Visit_4|65|1|TREATMENT|2020-09-23|65
e|TR|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|kDa|TUMOR MERGED|1|mmol/min/kPa|ELECTROCHEMILUMINESCENCE|||FRIEND|NEUROLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-10-18|90
e|TR|d90f2824-692e-403f-b1ca-5b6462c93a75|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|ug/g/h|EQUIVOCAL|1|%(w/v)|THIN SMEAR||Y|ADJUDICATOR|ONCOLOGIST 2|U|1|Visit_1|10|2|TREATMENT|2020-07-15|10
e|TR|d90f2824-692e-403f-b1ca-5b6462c93a75|2|[?]|VDIAM|Viable Diameter|[?]|mEq/kg|NONPALPABLE|1|U/mg|DIGITAL PCR||Y|ADJUDICATOR|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|7|SCREENING|2020-07-30|25
e|TR|d90f2824-692e-403f-b1ca-5b6462c93a75|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|nmol|TUMOR MERGED|1|ft2|INDIA INK STAIN|||CAREGIVER|PATHOLOGIST 1|N|3|Visit_3|40|7|TREATMENT|2020-08-14|40
e|TR|d90f2824-692e-403f-b1ca-5b6462c93a75|4|[?]|LPERP|Longest Perpendicular|[?]|h/wk|NORMAL|1|g/cage/day|CALCULATION|||INDEPENDENT ASSESSOR|DERMATOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2020-09-08|65
e|TR|d90f2824-692e-403f-b1ca-5b6462c93a75|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|Rad|EQUIVOCAL|1|mg/g/h|CELLULOSE TAPE|||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|4|SCREENING|2020-10-03|90
e|TR|ee0e55e1-6107-4a3c-85b4-cb48300153e8|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|fmol/L|DIFFUSELY INCREASED|1|mU/L|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||SPOUSE|READER|NA|1|Visit_1|10|7|SCREENING|2020-05-25|10
e|TR|ee0e55e1-6107-4a3c-85b4-cb48300153e8|2|[?]|DIAMETER|Diameter|[?]|10^6 organisms/mg|UNEQUIVOCAL|1|pmol/10^10 cells|PET SCAN|||FAMILY MEMBER|ADJUDICATOR 1|N|2|Visit_2|25|5|FOLLOW-UP|2020-06-09|25
e|TR|ee0e55e1-6107-4a3c-85b4-cb48300153e8|3|[?]|SUMVOL|Sum of Volume|[?]|cm/min|FURTHER ENLARGEMENT FROM NADIR|1|U/m2/min|IMMUNOCHROMATOGRAPHY|||FRIEND|CARDIOLOGIST|Y|3|Visit_3|40|6|SCREENING|2020-06-24|40
e|TR|ee0e55e1-6107-4a3c-85b4-cb48300153e8|4|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|10^9 CFU/mL|ENLARGEMENT FROM NADIR|1|/LSQN|SPECTROPHOTOMETRY|||CAREGIVER|ONCOLOGIST 1|NA|4|Visit_4|65|1|TREATMENT|2020-07-19|65
e|TR|ee0e55e1-6107-4a3c-85b4-cb48300153e8|5|[?]|VOLUME|Volume|[?]|TABLET|DIFFUSELY INCREASED|1|umol/min|TRIPLE-PHASE SPIRAL CT SCAN||Y|VENDOR|READER 2|N|5|Visit_5|90|2|TREATMENT|2020-08-13|90
e|TR|6aa37bb3-85aa-427f-9e56-a776257f1548|1|[?]|AREA|Area|[?]|ELISA unit/dose|UNCHANGED|1|ug/g/day|PULMONARY ANGIOGRAPHY|||ADJUDICATOR|RATER|N|1|Visit_1|10|3|TREATMENT|2020-11-14|10
e|TR|6aa37bb3-85aa-427f-9e56-a776257f1548|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|log10 copies/mL|NONPALPABLE|1|JDF Unit|PAP STAIN|||FAMILY MEMBER|ONCOLOGIST 1|NA|2|Visit_2|25|3|FOLLOW-UP|2020-11-29|25
e|TR|6aa37bb3-85aa-427f-9e56-a776257f1548|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|uEq/L|PALPABLE|1|Enzyme U/g Hb|HIGH RESOLUTION CT|Y||PROXY|ADJUDICATOR 3|Y|3|Visit_3|40|7|WASHOUT|2020-12-14|40
e|TR|6aa37bb3-85aa-427f-9e56-a776257f1548|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mCi/L|DIFFUSELY INCREASED|1|ug/kg/h|TOTAL BODY RADIOGRAPHY|||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|7|SCREENING|2021-01-08|65
e|TR|6aa37bb3-85aa-427f-9e56-a776257f1548|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|L/min|PATHOLOGICAL|1|nm|TEST STRIP|||NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|5|Visit_5|90|2|FOLLOW-UP|2021-02-02|90
e|TR|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|ug/h|NORMAL|1|umol/mg/min|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-05-18|10
e|TR|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|TUBE|ABSENT|1|DAgU|APPLANATION TONOMETRY|||CAREGIVER|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|7|SCREENING|2020-06-02|25
e|TR|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mU/g|ENLARGEMENT FROM NADIR|1|vg/dose|PERIODIC ACID SCHIFF STAIN|||CHILD|ADJUDICATOR 1|U|3|Visit_3|40|3|TREATMENT|2020-06-17|40
e|TR|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|4|[?]|CALCFIND|Calcification Indicator|[?]|mg/kg/min|NON-PATHOLOGICAL|1|MPS U|AUTOMATED COUNT|||PROXY|NEUROLOGIST|N|4|Visit_4|65|1|TREATMENT|2020-07-12|65
e|TR|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|5|[?]|VOLUME|Volume|[?]|10^9 organisms/mL|ENLARGEMENT FROM NADIR|1|Frames/s|HIGH RESOLUTION MELT ANALYSIS|Y||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|Y|5|Visit_5|90|4|WASHOUT|2020-08-06|90
e|TR|940d4614-b41a-44d3-b878-6e19ee22f24b|1|[?]|CALCFIND|Calcification Indicator|[?]|copies/mL|ABSENT|1|deg|PLAQUE REDUCTION NEUTRALIZATION ASSAY||Y|INTERVIEWER|RADIOLOGIST|Y|1|Visit_1|10|3|WASHOUT|2020-07-06|10
e|TR|940d4614-b41a-44d3-b878-6e19ee22f24b|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|ug/L/h|DIFFUSELY INCREASED|1|ug/m2/day|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||STUDY SUBJECT|OPHTHALMOLOGIST|N|2|Visit_2|25|5|SCREENING|2020-07-21|25
e|TR|940d4614-b41a-44d3-b878-6e19ee22f24b|3|[?]|ORSTATE|Organ State|[?]|umol/mg/min|PALPABLE|1|DISK|WRIGHT-GIEMSA STAIN|Y||STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|7|FOLLOW-UP|2020-08-05|40
e|TR|940d4614-b41a-44d3-b878-6e19ee22f24b|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|SPRAY|DIFFUSELY INCREASED|1|PA|DISK DIFFUSION||Y|SIGNIFICANT OTHER|OPTOMETRIST|N|4|Visit_4|65|2|WASHOUT|2020-08-30|65
e|TR|940d4614-b41a-44d3-b878-6e19ee22f24b|5|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|nkat|UNCHANGED|1|10^3 CFU|RADIAL IMMUNODIFFUSION|||INVESTIGATOR|NEUROLOGIST|N|5|Visit_5|90|4|WASHOUT|2020-09-24|90
e|TR|e2edd4f0-926b-4514-bf3f-7449f248343f|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mmol/s|PRESENT|1|ug/L|TRIPLE-PHASE SPIRAL CT SCAN|Y|Y|INDEPENDENT ASSESSOR|READER 3|U|1|Visit_1|10|7|WASHOUT|2020-11-01|10
e|TR|e2edd4f0-926b-4514-bf3f-7449f248343f|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|CARTRIDGE|PRESENT|1|U/m2|LC/MS||Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|2|Visit_2|25|1|TREATMENT|2020-11-16|25
e|TR|e2edd4f0-926b-4514-bf3f-7449f248343f|3|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|U/mmol|PATHOLOGICAL|1|LENS|AMSLER GRID|Y||CHILD|MICROSCOPIST 2|Y|3|Visit_3|40|1|FOLLOW-UP|2020-12-01|40
e|TR|e2edd4f0-926b-4514-bf3f-7449f248343f|4|[?]|CALCFIND|Calcification Indicator|[?]|10^7 TCID 50/dose|INCREASED|1|cmH2O/mL|NUCLEIC ACID SEQUENCING||Y|CHILD|READER 3|U|4|Visit_4|65|4|TREATMENT|2020-12-26|65
e|TR|e2edd4f0-926b-4514-bf3f-7449f248343f|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|TRANSDUCING UNIT|FOCALLY INCREASED|1|10^6 organisms/g|LISSAMINE GREEN STAIN|Y||INTERVIEWER|ONCOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2021-01-20|90
e|TR|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|1|[?]|VOLUME|Volume|[?]|mol/L|DIFFUSELY INCREASED|1|cycle/min|MECHANICAL CLOT DETECTION|Y||INTERVIEWER|OPTOMETRIST|Y|1|Visit_1|10|7|TREATMENT|2020-06-28|10
e|TR|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|2|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|umol/mg/min|UNCHANGED|1|/200 HPFs|PET/SPECT SCAN|||INDEPENDENT ASSESSOR|HEMATOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-07-13|25
e|TR|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|3|[?]|LDIAM|Longest Diameter|[?]|mmAL|ABSENT|1|anti-Xa IU|IRON HEMATOXYLIN STAIN|||CLINICAL STUDY SPONSOR|ONCOLOGIST|U|3|Visit_3|40|3|SCREENING|2020-07-28|40
e|TR|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|TRANSDUCING UNIT/mL|ABSENT|1|mg/mol|AMSLER GRID|||ADJUDICATOR|ONCOLOGIST|U|4|Visit_4|65|7|FOLLOW-UP|2020-08-22|65
e|TR|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|mg/mol|ENLARGEMENT|1|mg/day|RADIATION DOSIMETRY|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|U|5|Visit_5|90|6|TREATMENT|2020-09-16|90
e|TR|493a53ef-01ab-470c-9bbe-7c2aa48b946b|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|Newton|PRESENT|1|mkat|FLOW MICROSCOPY|||SIBLING|ENDOCRINOLOGIST|NA|1|Visit_1|10|4|WASHOUT|2020-07-13|10
e|TR|493a53ef-01ab-470c-9bbe-7c2aa48b946b|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mEq|EQUIVOCAL|1|log10 TCID 50/dose|RADIATION DOSIMETRY||Y|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|3|TREATMENT|2020-07-28|25
e|TR|493a53ef-01ab-470c-9bbe-7c2aa48b946b|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|nkat|ENLARGEMENT|1|CIGARETTE|KINYOUN STAIN||Y|GUARDIAN|OPTOMETRIST|N|3|Visit_3|40|5|SCREENING|2020-08-12|40
e|TR|493a53ef-01ab-470c-9bbe-7c2aa48b946b|4|[?]|VDIAM|Viable Diameter|[?]|fraction of 1|PALPABLE|1|COAT|TRANSVAGINAL ULTRASOUND|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|NA|4|Visit_4|65|3|SCREENING|2020-09-06|65
e|TR|493a53ef-01ab-470c-9bbe-7c2aa48b946b|5|[?]|RADIODEN|Radiodensity|[?]|SBE/mL|DIFFUSELY INCREASED|1|dpm/mL|TOTAL BODY IRRADIATION||Y|INDEPENDENT ASSESSOR|RATER 1|NA|5|Visit_5|90|2|FOLLOW-UP|2020-10-01|90
e|TR|ba33de14-b676-4389-a863-a7fa3edb8543|1|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|BEAM BREAKS|EQUIVOCAL|1|ug/L|CLINICAL EVALUATION|||STUDY SUBJECT|READER 3|N|1|Visit_1|10|7|TREATMENT|2020-11-03|10
e|TR|ba33de14-b676-4389-a863-a7fa3edb8543|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|nmol/g|FURTHER ENLARGEMENT FROM NADIR|1|mol/day|LIGHT MICROSCOPY|||CLINICAL STUDY SPONSOR|ADJUDICATOR|Y|2|Visit_2|25|6|TREATMENT|2020-11-18|25
e|TR|ba33de14-b676-4389-a863-a7fa3edb8543|3|[?]|PALPSTAT|Palpable State|[?]|Gy/min|PALPABLE|1|RATIO|RULER MEASUREMENT METHOD|Y||INDEPENDENT ASSESSOR|NEUROLOGIST 1|NA|3|Visit_3|40|7|FOLLOW-UP|2020-12-03|40
e|TR|ba33de14-b676-4389-a863-a7fa3edb8543|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|10^6/g|PATHOLOGICAL|1|fmol/L|MEDIASTINOSCOPY|||CHILD|DERMATOLOGIST|N|4|Visit_4|65|4|TREATMENT|2020-12-28|65
e|TR|ba33de14-b676-4389-a863-a7fa3edb8543|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|IU/kg|DECREASED|1|mL/s/m2|TONOMETRY|Y|Y|PARENT|NEUROLOGIST 2|Y|5|Visit_5|90|1|WASHOUT|2021-01-22|90
e|TR|24801f05-79be-433d-8124-85580bc14c4f|1|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|10^6 DNA copies/mL|INCREASED|1|mL/beat|CONTRAST ENHANCED PET SCAN|Y|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-09-09|10
e|TR|24801f05-79be-433d-8124-85580bc14c4f|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|10^3 copies/mL|PALPABLE|1|usec|ORCHIDOMETERY|Y|Y|DOMESTIC PARTNER|ENDOCRINOLOGIST|U|2|Visit_2|25|2|FOLLOW-UP|2020-09-24|25
e|TR|24801f05-79be-433d-8124-85580bc14c4f|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mL/(min*100mL)|NORMAL|1|Enzyme U|TURBIDIMETRY||Y|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|N|3|Visit_3|40|3|WASHOUT|2020-10-09|40
e|TR|24801f05-79be-433d-8124-85580bc14c4f|4|[?]|CALCFIND|Calcification Indicator|[?]|lm|INCREASED|1|DISK|MACRO BROTH DILUTION|||ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|NA|4|Visit_4|65|6|TREATMENT|2020-11-03|65
e|TR|24801f05-79be-433d-8124-85580bc14c4f|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mol/mg|UNEQUIVOCAL|1|/5x10^4 WBC|OLIGO ACGH|Y||FRIEND|RATER 1|N|5|Visit_5|90|1|WASHOUT|2020-11-28|90
e|TR|02df80f9-2337-4abd-9452-41cd83dec8ba|1|[?]|PALPSTAT|Palpable State|[?]|MET|EQUIVOCAL|1|um/s|MAMMOGRAPHY|||INVESTIGATOR|MICROSCOPIST 3|NA|1|Visit_1|10|1|TREATMENT|2020-08-04|10
e|TR|02df80f9-2337-4abd-9452-41cd83dec8ba|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|kV|PRESENT|1|/10^4|ICC|Y||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|2|Visit_2|25|2|WASHOUT|2020-08-19|25
e|TR|02df80f9-2337-4abd-9452-41cd83dec8ba|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|Siemens|ENLARGEMENT FROM NADIR|1|copies/ug|CALCOFLUOR WHITE STAIN|||ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-09-03|40
e|TR|02df80f9-2337-4abd-9452-41cd83dec8ba|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|uU/dL|DIFFUSELY INCREASED|1|mL/mmHg/min/L|LAPAROSCOPY|||INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|4|Visit_4|65|7|FOLLOW-UP|2020-09-28|65
e|TR|02df80f9-2337-4abd-9452-41cd83dec8ba|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|TROCHE|PRESENT|1|/10^5|LC/MS||Y|CAREGIVER|RADIOLOGIST 1|U|5|Visit_5|90|6|TREATMENT|2020-10-23|90
e|TR|d9eea93b-f9f9-466c-aa8a-a250baff18ef|1|[?]|AREA|Area|[?]|mL/(min*100mL)|PALPABLE|1|mL/kg/h|PALM METHOD|||CLINICAL RESEARCH ASSOCIATE|READER 2|Y|1|Visit_1|10|5|WASHOUT|2020-08-03|10
e|TR|d9eea93b-f9f9-466c-aa8a-a250baff18ef|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|10^3 CFU|NONPALPABLE|1|10^3 organisms|EIA||Y|SPOUSE|RADIOLOGIST|NA|2|Visit_2|25|6|FOLLOW-UP|2020-08-18|25
e|TR|d9eea93b-f9f9-466c-aa8a-a250baff18ef|3|[?]|LPERP|Longest Perpendicular|[?]|Pack Year|UNCHANGED|1|MAC50|OPHTHALMOSCOPY|||VENDOR|ADJUDICATOR 2|U|3|Visit_3|40|5|TREATMENT|2020-09-02|40
e|TR|d9eea93b-f9f9-466c-aa8a-a250baff18ef|4|[?]|PPD|Product of Perpendicular Diameters|[?]|NEBULE|UNEQUIVOCAL|1|kN/cm2|LIQUID SCINTILLATION COUNTING||Y|STUDY SUBJECT|MICROSCOPIST 3|Y|4|Visit_4|65|4|WASHOUT|2020-09-27|65
e|TR|d9eea93b-f9f9-466c-aa8a-a250baff18ef|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|10^12/L|FOCALLY INCREASED|1|MPL U|DIGITAL PCR|||ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|N|5|Visit_5|90|7|TREATMENT|2020-10-22|90
e|TR|35a59f6a-2712-4d1b-a954-f1418d4b9168|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|STEPS|PRESENT|1|uIU/dL|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||ADJUDICATOR|NEUROLOGIST 2|N|1|Visit_1|10|1|FOLLOW-UP|2020-11-05|10
e|TR|35a59f6a-2712-4d1b-a954-f1418d4b9168|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|SUPPOSITORY|PALPABLE|1|CIGARETTE|REFLECTANCE SPECTROSCOPY|||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|6|FOLLOW-UP|2020-11-20|25
e|TR|35a59f6a-2712-4d1b-a954-f1418d4b9168|3|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mg/m2/day|PRESENT|1|ng/L|MULTI-SLICE SPIRAL CT|||CAREGIVER|RADIOLOGIST 1|NA|3|Visit_3|40|3|WASHOUT|2020-12-05|40
e|TR|35a59f6a-2712-4d1b-a954-f1418d4b9168|4|[?]|LNSTATE|Lymph Node State|[?]|uU/L|NONPALPABLE|1|kg/cm2|PERFUSION MRI|||GUARDIAN|RATER 2|NA|4|Visit_4|65|3|TREATMENT|2020-12-30|65
e|TR|35a59f6a-2712-4d1b-a954-f1418d4b9168|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|oz|FOCALLY INCREASED|1|SPRAY|WRIGHT STAIN|||PARENT|READER 2|N|5|Visit_5|90|2|TREATMENT|2021-01-24|90
e|TR|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|ug/L/h|FOCALLY INCREASED|1|log10 CFU/mL|FLUORESCENT ENZYME IMMUNOASSAY|Y||FRIEND|MICROSCOPIST 1|Y|1|Visit_1|10|4|SCREENING|2020-11-10|10
e|TR|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|2|[?]|SUMDIAM|Sum of Diameter|[?]|DNA copies/mL|PRESENT|1|/cmH2O|INTRAVASCULAR ULTRASOUND|Y|Y|SIBLING|INTERNIST|U|2|Visit_2|25|7|WASHOUT|2020-11-25|25
e|TR|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|L/h|PALPABLE|1|ft|HIGH RESOLUTION CT|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|3|Visit_3|40|4|TREATMENT|2020-12-10|40
e|TR|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mL/sec/1.73m2|NORMAL|1|log10 TCID 50/mL|PHOROPTER|||INVESTIGATOR|ADJUDICATOR|U|4|Visit_4|65|3|SCREENING|2021-01-04|65
e|TR|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|NEBULE|DIFFUSELY INCREASED|1|nmol BCE/nmol|TRIPLE-PHASE SPIRAL CT SCAN|||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2021-01-29|90
e|TR|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|SUPPOSITORY|DECREASED|1|mg/mL/day|NON-INVASIVE DIELECTRIC SENSING|||PROXY|ADJUDICATOR 3|N|1|Visit_1|10|1|SCREENING|2020-05-13|10
e|TR|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|foz_br|FURTHER ENLARGEMENT|1|10^7/L|PHASE CONTRAST MICROSCOPY|Y||DOMESTIC PARTNER|CARDIOLOGIST|U|2|Visit_2|25|5|TREATMENT|2020-05-28|25
e|TR|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|3|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|USP U|NORMAL|1|uCi/kg|CINEANGIOGRAPHY|||SIGNIFICANT OTHER|OPTOMETRIST|U|3|Visit_3|40|1|WASHOUT|2020-06-12|40
e|TR|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|4|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|mol/L|DIFFUSELY INCREASED|1|U/kg/min|REVERSE TRANSCRIPTASE PCR||Y|CHILD|READER 3|U|4|Visit_4|65|5|TREATMENT|2020-07-07|65
e|TR|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|5|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|CYLINDER|PALPABLE|1|U/g Hb|DISK DIFFUSION|||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|5|Visit_5|90|3|WASHOUT|2020-08-01|90
e|TR|d041952e-4aa6-4b37-9cec-127adce2eabb|1|[?]|SUMVOL|Sum of Volume|[?]|pmol/10^10 cells|ENLARGEMENT FROM NADIR|1|ppb|TWO-COLOR MICROARRAY|||CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-10-09|10
e|TR|d041952e-4aa6-4b37-9cec-127adce2eabb|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|Enzyme U/g Hb|FURTHER ENLARGEMENT|1|vg/dose|INFRARED SPECTROMETRY|||FRIEND|MICROSCOPIST 2|NA|2|Visit_2|25|4|SCREENING|2020-10-24|25
e|TR|d041952e-4aa6-4b37-9cec-127adce2eabb|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|OI50|FOCALLY INCREASED|1|kPa/L/sec|LC/MS|||DOMESTIC PARTNER|NEUROLOGIST|N|3|Visit_3|40|1|FOLLOW-UP|2020-11-08|40
e|TR|d041952e-4aa6-4b37-9cec-127adce2eabb|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|um|INCREASED|1|/kg|TOTAL BODY RADIOGRAPHY|Y||CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|3|FOLLOW-UP|2020-12-03|65
e|TR|d041952e-4aa6-4b37-9cec-127adce2eabb|5|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|uIU/dL|PATHOLOGICAL|1|log10 TCID 50/dose|ZIEHL NEELSEN ACID FAST STAIN|Y||DOMESTIC PARTNER|CLINICAL PATHOLOGIST|Y|5|Visit_5|90|5|WASHOUT|2020-12-28|90
e|TR|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|CARTRIDGE|INCREASED|1|g/g/day|FLUORIMETRY|||CHILD|MICROSCOPIST 1|N|1|Visit_1|10|2|WASHOUT|2020-06-09|10
e|TR|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|copies/mL|FURTHER ENLARGEMENT FROM NADIR|1|dyn|IMMUNOFLUORESCENT STAIN|||SIBLING|PATHOLOGIST 1|NA|2|Visit_2|25|7|TREATMENT|2020-06-24|25
e|TR|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|3|[?]|ORSTATE|Organ State|[?]|DROP|NORMAL|1|nU/cL|PHOTOMETRIC CLOT DETECTION|||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|5|TREATMENT|2020-07-09|40
e|TR|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|Farad|FURTHER ENLARGEMENT|1|EVENTS|LASER CAPTURE MICRODISSECTION|||DOMESTIC PARTNER|MICROSCOPIST|Y|4|Visit_4|65|6|TREATMENT|2020-08-03|65
e|TR|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|mm/min|PALPABLE|1|mL/cage/day|KINETIC MICROPARTICLE IMMUNOASSAY|||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|5|Visit_5|90|4|FOLLOW-UP|2020-08-28|90
e|TR|9fc393da-4665-4be5-a869-856c45ddcf13|1|[?]|VOLUME|Volume|[?]|mmol/min/kPa/L|UNCHANGED|1|g/dL|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|6|WASHOUT|2020-06-18|10
e|TR|9fc393da-4665-4be5-a869-856c45ddcf13|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|DNA copies/ug|EQUIVOCAL|1|pL|PAP STAIN|||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|NA|2|Visit_2|25|5|TREATMENT|2020-07-03|25
e|TR|9fc393da-4665-4be5-a869-856c45ddcf13|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|mL/cage/wk|UNEQUIVOCAL|1|vg/kg|SINGLE-MOLECULE ARRAY|Y|Y|INTERVIEWER|RADIOLOGIST 2|N|3|Visit_3|40|1|TREATMENT|2020-07-18|40
e|TR|9fc393da-4665-4be5-a869-856c45ddcf13|4|[?]|VDIAM|Viable Diameter|[?]|log10 CFU/mL|PATHOLOGICAL|1|pmol/day|ENDOSCOPY|||ADJUDICATOR|MICROSCOPIST 3|U|4|Visit_4|65|6|TREATMENT|2020-08-12|65
e|TR|9fc393da-4665-4be5-a869-856c45ddcf13|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|g/day|UNEQUIVOCAL|1|OI50|SPECTROPHOTOMETRY|Y|Y|INTERVIEWER|ADJUDICATOR 3|NA|5|Visit_5|90|4|FOLLOW-UP|2020-09-06|90
e|TR|cddc1541-4de9-45e7-bb61-15a2d5baca6f|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mmol/L|PATHOLOGICAL|1|kUSP|CARDIAC THERMODILUTION|Y||STUDY SUBJECT|OTOLARYNGOLOGIST|N|1|Visit_1|10|1|TREATMENT|2021-01-19|10
e|TR|cddc1541-4de9-45e7-bb61-15a2d5baca6f|2|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|IU/dL|ABSENT|1|U/mg|FLOCCULATION||Y|FRIEND|RATER 2|NA|2|Visit_2|25|3|SCREENING|2021-02-03|25
e|TR|cddc1541-4de9-45e7-bb61-15a2d5baca6f|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|Bq/uL|INCREASED|1|vp/mL|FLOCCULATION, CHARCOAL ENHANCED|||SPOUSE|DERMATOLOGIST|U|3|Visit_3|40|4|SCREENING|2021-02-18|40
e|TR|cddc1541-4de9-45e7-bb61-15a2d5baca6f|4|[?]|PALPSTAT|Palpable State|[?]|g/dL|EQUIVOCAL|1|mL*cmH2O|FUNDUS PHOTOGRAPHY|Y||GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|5|TREATMENT|2021-03-15|65
e|TR|cddc1541-4de9-45e7-bb61-15a2d5baca6f|5|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|L/s|ENLARGEMENT FROM NADIR|1|mmol/s|TONOMETRY|||STUDY SUBJECT|OPTOMETRIST|NA|5|Visit_5|90|3|SCREENING|2021-04-09|90
e|TR|303c6dbe-59f9-4016-baa1-8506c0c1ee09|1|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|mmol/min/kPa/L|NORMAL|1|bel|GC/MS|||CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-12-26|10
e|TR|303c6dbe-59f9-4016-baa1-8506c0c1ee09|2|[?]|SUMVOL|Sum of Volume|[?]|INHALATION|FURTHER ENLARGEMENT FROM NADIR|1|cal|ULTRASOUND||Y|SIGNIFICANT OTHER|RATER 1|N|2|Visit_2|25|5|SCREENING|2021-01-10|25
e|TR|303c6dbe-59f9-4016-baa1-8506c0c1ee09|3|[?]|PCHGBL|Percent Change From Baseline|[?]|ELISA unit/mL|EQUIVOCAL|1|kBq/uL|MRS|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|3|Visit_3|40|1|SCREENING|2021-01-25|40
e|TR|303c6dbe-59f9-4016-baa1-8506c0c1ee09|4|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|Tbsp|ENLARGEMENT|1|Linear ft*LB|MASS SPECTROMETRY||Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|3|TREATMENT|2021-02-19|65
e|TR|303c6dbe-59f9-4016-baa1-8506c0c1ee09|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|breaths/30s|PATHOLOGICAL|1|mg/mL/min|ICC|||SPOUSE|RATER 1|NA|5|Visit_5|90|1|TREATMENT|2021-03-16|90
e|TR|fee3c810-3d76-4db4-9272-6b4e8fd14088|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mol/mol|PATHOLOGICAL|1|min*mg/mL|MACRO BROTH DILUTION|||DOMESTIC PARTNER|PATHOLOGIST 1|Y|1|Visit_1|10|4|SCREENING|2020-12-15|10
e|TR|fee3c810-3d76-4db4-9272-6b4e8fd14088|2|[?]|ORSTATE|Organ State|[?]|BAG|UNCHANGED|1|ng/dL|MICROBIAL BIOCHEMICAL IDENTIFICATION|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|2|Visit_2|25|7|WASHOUT|2020-12-30|25
e|TR|fee3c810-3d76-4db4-9272-6b4e8fd14088|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|/40 HPFs|PATHOLOGICAL|1|Gy|KLEIHAUER-BETKE|||CLINICAL STUDY SPONSOR|HEMATOLOGIST|Y|3|Visit_3|40|4|WASHOUT|2021-01-14|40
e|TR|fee3c810-3d76-4db4-9272-6b4e8fd14088|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|Ci/mL|NORMAL|1|LOZENGE|INCISION-INDUCED BLEEDING METHOD|||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|Y|4|Visit_4|65|3|FOLLOW-UP|2021-02-08|65
e|TR|fee3c810-3d76-4db4-9272-6b4e8fd14088|5|[?]|NEWCONF|New Tumor Confirmed|[?]|PRESSOR UNITS|UNEQUIVOCAL|1|mg/m2/day|GRAM STAIN||Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|5|Visit_5|90|4|WASHOUT|2021-03-05|90
e|TR|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|cup eq|UNCHANGED|1|cycle/min|IMMUNE REPERTOIRE DEEP SEQUENCING|||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|N|1|Visit_1|10|6|WASHOUT|2020-07-08|10
e|TR|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|2|[?]|LESSCIND|Lesion Success Indicator|[?]|V|DECREASED|1|MPL U|HIGH RESOLUTION CT|Y||CAREGIVER|PATHOLOGIST 2|N|2|Visit_2|25|4|WASHOUT|2020-07-23|25
e|TR|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|amp|TUMOR MERGED|1|U/g Hb|GC/MS/MS|Y||INTERVIEWER|CARDIOLOGIST|U|3|Visit_3|40|3|TREATMENT|2020-08-07|40
e|TR|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|U/L|DIFFUSELY INCREASED|1|ug/mol|CLIP|Y||ADJUDICATOR|ADJUDICATOR 1|U|4|Visit_4|65|2|TREATMENT|2020-09-01|65
e|TR|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|5|[?]|CALCFIND|Calcification Indicator|[?]|IU|PATHOLOGICAL|1|TAMPON|FLOW CYTOMETRY|||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|5|Visit_5|90|7|TREATMENT|2020-09-26|90
e|TR|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|1|[?]|CALCFIND|Calcification Indicator|[?]|10^6 IU/mL|PALPABLE|1|nmol BCE/mmol|IMMUNOCHEMILUMINOMETRIC ASSAY|||SIBLING|ONCOLOGIST|N|1|Visit_1|10|6|SCREENING|2020-08-01|10
e|TR|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mCi/kg|FURTHER ENLARGEMENT FROM NADIR|1|/40 HPFs|DIFFUSION TENSOR MRI|||PARENT|RADIOLOGIST 1|U|2|Visit_2|25|6|WASHOUT|2020-08-16|25
e|TR|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|3|[?]|NEWCONF|New Tumor Confirmed|[?]|mph|DIFFUSELY INCREASED|1|mPa|LISSAMINE GREEN STAIN|||SIGNIFICANT OTHER|ADJUDICATOR|N|3|Visit_3|40|1|FOLLOW-UP|2020-08-31|40
e|TR|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|4|[?]|LPERP|Longest Perpendicular|[?]|KALLIKREIN INHIBITOR UNIT|FOCALLY INCREASED|1|amol|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||INDEPENDENT ASSESSOR|READER 2|NA|4|Visit_4|65|4|FOLLOW-UP|2020-09-25|65
e|TR|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|5|[?]|SUMDIAM|Sum of Diameter|[?]|g/animal|UNCHANGED|1|ug/cm2|OPTICAL DENSITY MEASUREMENT|||FRIEND|OTOLARYNGOLOGIST|N|5|Visit_5|90|5|TREATMENT|2020-10-20|90
e|TR|47fad45a-9a4c-47ee-a863-089d979523b5|1|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|10^3 DNA copies/mL|DIFFUSELY INCREASED|1|mg/kg/h|CT SCAN|||INDEPENDENT ASSESSOR|NEUROLOGIST 1|Y|1|Visit_1|10|3|TREATMENT|2020-10-07|10
e|TR|47fad45a-9a4c-47ee-a863-089d979523b5|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|U|EQUIVOCAL|1|mCi/L|APPLANATION TONOMETRY|||FAMILY MEMBER|ADJUDICATOR|NA|2|Visit_2|25|5|TREATMENT|2020-10-22|25
e|TR|47fad45a-9a4c-47ee-a863-089d979523b5|3|[?]|ORSTATE|Organ State|[?]|mL/100g/min|DIFFUSELY INCREASED|1|IMPLANT|CALIPER MEASUREMENT METHOD|Y||PROXY|NEUROLOGIST|Y|3|Visit_3|40|2|SCREENING|2020-11-06|40
e|TR|47fad45a-9a4c-47ee-a863-089d979523b5|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mEq/uL|TUMOR MERGED|1|mCi|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|4|Visit_4|65|4|SCREENING|2020-12-01|65
e|TR|47fad45a-9a4c-47ee-a863-089d979523b5|5|[?]|DIAMETER|Diameter|[?]|sec|ENLARGEMENT|1|g/kg|ACID FAST STAIN|||INTERVIEWER|RADIOLOGIST 2|Y|5|Visit_5|90|2|FOLLOW-UP|2020-12-26|90
e|TR|317b8b6d-9638-44a3-816f-7f3fca1e01a3|1|[?]|VOLUME|Volume|[?]|mIU/L|INCREASED|1|MESF|NON-CONTACT SPECULAR MICROSCOPY|||CAREGIVER|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-05-23|10
e|TR|317b8b6d-9638-44a3-816f-7f3fca1e01a3|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|BOX|NONPALPABLE|1|CFU/g|COMPLEMENT FIXATION||Y|SIGNIFICANT OTHER|OPTOMETRIST|N|2|Visit_2|25|5|TREATMENT|2020-06-07|25
e|TR|317b8b6d-9638-44a3-816f-7f3fca1e01a3|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|cGy|EQUIVOCAL|1|Henry|NUCLEIC ACID BASED METHOD|||HEALTH CARE PROFESSIONAL|MICROSCOPIST|Y|3|Visit_3|40|3|TREATMENT|2020-06-22|40
e|TR|317b8b6d-9638-44a3-816f-7f3fca1e01a3|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|Bq/ug|PATHOLOGICAL|1|Absorbance U|PHOTOMETRY|Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|U|4|Visit_4|65|4|FOLLOW-UP|2020-07-17|65
e|TR|317b8b6d-9638-44a3-816f-7f3fca1e01a3|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|uV|TUMOR MERGED|1|WEEKS|CELL BASED BIOASSAY|Y|Y|CAREGIVER|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|1|SCREENING|2020-08-11|90
e|TR|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|Ci|PRESENT|1|/day|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||ADJUDICATOR|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|5|SCREENING|2020-07-10|10
e|TR|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|C|FOCALLY INCREASED|1|EU|TRIPLE-PHASE SPIRAL CT SCAN||Y|ADJUDICATION COMMITTEE|RADIOLOGIST 1|Y|2|Visit_2|25|2|TREATMENT|2020-07-25|25
e|TR|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|cup eq|PALPABLE|1|kPa|FLOCCULATION, CHARCOAL ENHANCED|||SIBLING|PATHOLOGIST|N|3|Visit_3|40|2|SCREENING|2020-08-09|40
e|TR|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mm/h|PATHOLOGICAL|1|kPa/L/sec|DROPLET DIGITAL PCR|Y||INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|4|Visit_4|65|4|TREATMENT|2020-09-03|65
e|TR|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|L/min|PALPABLE|1|log10 copies/mL|ENDOSCOPY|Y||STUDY SUBJECT|READER 3|NA|5|Visit_5|90|4|FOLLOW-UP|2020-09-28|90
e|TR|e7cee930-54f6-482e-b782-01aed0f0db06|1|[?]|LESSCIND|Lesion Success Indicator|[?]|/day|FOCALLY INCREASED|1|s^-1(%O2)^-1|COLORIMETRY|||FRIEND|MICROSCOPIST|NA|1|Visit_1|10|3|SCREENING|2021-01-07|10
e|TR|e7cee930-54f6-482e-b782-01aed0f0db06|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mL/cm|NORMAL|1|ng|BETA LACTAMASE|||INDEPENDENT ASSESSOR|RADIOLOGIST 1|U|2|Visit_2|25|7|TREATMENT|2021-01-22|25
e|TR|e7cee930-54f6-482e-b782-01aed0f0db06|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|/40 HPFs|NORMAL|1|SFC/10^6 PBMC|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||PARENT|HEMATOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2021-02-06|40
e|TR|e7cee930-54f6-482e-b782-01aed0f0db06|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|NEEDLE GAUGE|FURTHER ENLARGEMENT FROM NADIR|1|mL/kg/min|TWO-COLOR MICROARRAY||Y|STUDY SUBJECT|NEUROLOGIST 2|N|4|Visit_4|65|7|WASHOUT|2021-03-03|65
e|TR|e7cee930-54f6-482e-b782-01aed0f0db06|5|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|Enzyme U/g Hb|INCREASED|1|PLUG|CRYOSCOPY|Y|Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|N|5|Visit_5|90|5|TREATMENT|2021-03-28|90
e|TR|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|ug/day|ENLARGEMENT FROM NADIR|1|mmol/kg|NUCLEIC ACID BASED METHOD|||CLINICAL RESEARCH ASSOCIATE|READER 1|NA|1|Visit_1|10|2|TREATMENT|2021-01-21|10
e|TR|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|pmol/day|NONPALPABLE|1|ppm|CONGO RED STAIN|Y||SIBLING|ONCOLOGIST|N|2|Visit_2|25|1|FOLLOW-UP|2021-02-05|25
e|TR|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|cm H2O|UNCHANGED|1|um2|WRIGHT-GIEMSA STAIN|||STUDY SUBJECT|ADJUDICATOR 1|NA|3|Visit_3|40|2|WASHOUT|2021-02-20|40
e|TR|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|SPRAY|PALPABLE|1|beats/min|RADIATION DOSIMETRY|||CHILD|RATER 1|NA|4|Visit_4|65|4|WASHOUT|2021-03-17|65
e|TR|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|5|[?]|ORSTATE|Organ State|[?]|nU/cL|PRESENT|1|mph|PHYSICAL EXAMINATION|||FRIEND|RATER 1|U|5|Visit_5|90|6|SCREENING|2021-04-11|90
e|TR|f754ae7d-0776-41c0-988c-8cf2879d85da|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|uV*sec|PRESENT|1|breaths/min|DXA SCAN|||HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-09-17|10
e|TR|f754ae7d-0776-41c0-988c-8cf2879d85da|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|10^6/Ejaculate U|ABSENT|1|Watt|TARGETED TRANSCRIPTOME SEQUENCING|||SPOUSE|HEMATOLOGIST|N|2|Visit_2|25|4|WASHOUT|2020-10-02|25
e|TR|f754ae7d-0776-41c0-988c-8cf2879d85da|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|U/10^12 RBC|ENLARGEMENT|1|MHz|MS/MS|||CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|U|3|Visit_3|40|1|TREATMENT|2020-10-17|40
e|TR|f754ae7d-0776-41c0-988c-8cf2879d85da|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|U/kg/h|NONPALPABLE|1|log10 CFU/g|MICROBIAL CULTURE|||SPOUSE|INTERNIST|NA|4|Visit_4|65|5|SCREENING|2020-11-11|65
e|TR|f754ae7d-0776-41c0-988c-8cf2879d85da|5|[?]|VOLUME|Volume|[?]|mg/min|NORMAL|1|GBq/ug|CYSTOSCOPY|Y||VENDOR|RADIOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-12-06|90
e|TR|8a8d8c31-ae36-4a64-90da-ba5eb473e420|1|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|copies/ug|EQUIVOCAL|1|U/mg|NUCLEAR RADIOLOGY|||SIGNIFICANT OTHER|PATHOLOGIST 1|NA|1|Visit_1|10|6|SCREENING|2020-06-25|10
e|TR|8a8d8c31-ae36-4a64-90da-ba5eb473e420|2|[?]|PCHGBL|Percent Change From Baseline|[?]|s^-1(%O2)^-1|NON-PATHOLOGICAL|1|CCID 50/dose|FISH|||FRIEND|ADJUDICATOR|Y|2|Visit_2|25|1|SCREENING|2020-07-10|25
e|TR|8a8d8c31-ae36-4a64-90da-ba5eb473e420|3|[?]|ACHNAD|Absolute Change From Nadir|[?]|10^9 organisms|ABSENT|1|g/kg/day|SIZE EXCLUSION CHROMATOGRAPHY|||CLINICAL RESEARCH ASSOCIATE|RATER 2|N|3|Visit_3|40|3|TREATMENT|2020-07-25|40
e|TR|8a8d8c31-ae36-4a64-90da-ba5eb473e420|4|[?]|AREA|Area|[?]|g/U|UNCHANGED|1|nmol/L/h|CALIPER MEASUREMENT METHOD|||CAREGIVER|MICROSCOPIST|U|4|Visit_4|65|3|TREATMENT|2020-08-19|65
e|TR|8a8d8c31-ae36-4a64-90da-ba5eb473e420|5|[?]|PCHGBL|Percent Change From Baseline|[?]|Frames/s|NON-PATHOLOGICAL|1|RING|KLEIHAUER-BETKE|||PROXY|UROLOGIST|N|5|Visit_5|90|6|FOLLOW-UP|2020-09-13|90
e|TR|482e40c9-2908-4269-b93c-61c311e9fde3|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|Coulomb|FURTHER ENLARGEMENT FROM NADIR|1|mL/cm|TRIPLE-PHASE MRI SCAN|||FAMILY MEMBER|PATHOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-07-16|10
e|TR|482e40c9-2908-4269-b93c-61c311e9fde3|2|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|eq|DECREASED|1|cmHg|SANGER SEQUENCING|||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-07-31|25
e|TR|482e40c9-2908-4269-b93c-61c311e9fde3|3|[?]|LDIAM|Longest Diameter|[?]|U.CARR|PRESENT|1|fmol|CLOT DETECTION|||ADJUDICATOR|READER 3|N|3|Visit_3|40|6|SCREENING|2020-08-15|40
e|TR|482e40c9-2908-4269-b93c-61c311e9fde3|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mm/sec|ENLARGEMENT|1|CIGARETTE|DROPLET DIGITAL PCR|Y||CHILD|ADJUDICATOR 1|N|4|Visit_4|65|1|TREATMENT|2020-09-09|65
e|TR|482e40c9-2908-4269-b93c-61c311e9fde3|5|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|APL U/mL|ENLARGEMENT FROM NADIR|1|PRESSOR UNITS|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||ADJUDICATOR|ENDOCRINOLOGIST|Y|5|Visit_5|90|6|SCREENING|2020-10-04|90
e|TR|f7cfb281-0556-4316-9373-65edf63c4b23|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|deg/s|FOCALLY INCREASED|1|ug/g/day|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||PARENT|ONCOLOGIST 2|Y|1|Visit_1|10|3|WASHOUT|2020-06-29|10
e|TR|f7cfb281-0556-4316-9373-65edf63c4b23|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|APPLICATION|PATHOLOGICAL|1|nU/cL|SEQUENCING|||CLINICAL STUDY SPONSOR|NEUROLOGIST|U|2|Visit_2|25|4|FOLLOW-UP|2020-07-14|25
e|TR|f7cfb281-0556-4316-9373-65edf63c4b23|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|Torr|PALPABLE|1|mg|MAGNETIC RESONANCE ENTEROGRAPHY|||GUARDIAN|PATHOLOGIST 2|Y|3|Visit_3|40|2|FOLLOW-UP|2020-07-29|40
e|TR|f7cfb281-0556-4316-9373-65edf63c4b23|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|/100 WBC|UNEQUIVOCAL|1|pL|HPLC/MS/MS|||ADJUDICATION COMMITTEE|OPTOMETRIST|NA|4|Visit_4|65|6|TREATMENT|2020-08-23|65
e|TR|f7cfb281-0556-4316-9373-65edf63c4b23|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|BE/mL|PALPABLE|1|mg/mol|OPTICAL DENSITY MEASUREMENT|Y||PARENT|ONCOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-09-17|90
e|TR|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|tsp|EQUIVOCAL|1|mol|AUTOMATED COUNT|||CLINICAL STUDY SPONSOR|MICROSCOPIST 3|N|1|Visit_1|10|5|FOLLOW-UP|2021-01-10|10
e|TR|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|2|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|cm/s|FURTHER ENLARGEMENT FROM NADIR|1|/10^4|CHROMOGENIC ASSAY|||CLINICAL STUDY SPONSOR|UROLOGIST|Y|2|Visit_2|25|3|TREATMENT|2021-01-25|25
e|TR|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mg/kg/week|NORMAL|1|Ci/uL|CALCULATION||Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|3|Visit_3|40|5|SCREENING|2021-02-09|40
e|TR|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|COAT|FURTHER ENLARGEMENT|1|LENS|NUCLEAR RADIOLOGY|||FRIEND|ONCOLOGIST 1|NA|4|Visit_4|65|2|TREATMENT|2021-03-06|65
e|TR|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|5|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|Coulomb|INCREASED|1|uIU/dL|TOTAL BODY RADIOGRAPHY|||FRIEND|OTOLARYNGOLOGIST|U|5|Visit_5|90|7|FOLLOW-UP|2021-03-31|90
e|TR|9ed8a578-a82a-423a-81ca-ee87f98d62f7|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|FEU|FURTHER ENLARGEMENT FROM NADIR|1|Ci/L|REVERSE TRANSCRIPTASE PCR||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|U|1|Visit_1|10|3|TREATMENT|2020-09-02|10
e|TR|9ed8a578-a82a-423a-81ca-ee87f98d62f7|2|[?]|LNSTATE|Lymph Node State|[?]|log10 IU/mL|FURTHER ENLARGEMENT FROM NADIR|1|MPL U|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||SIBLING|INTERNIST|Y|2|Visit_2|25|6|TREATMENT|2020-09-17|25
e|TR|9ed8a578-a82a-423a-81ca-ee87f98d62f7|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|BOLUS|FURTHER ENLARGEMENT FROM NADIR|1|10^5/L|HPLC-FL|||CHILD|UROLOGIST|NA|3|Visit_3|40|3|WASHOUT|2020-10-02|40
e|TR|9ed8a578-a82a-423a-81ca-ee87f98d62f7|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|MONTHS|INCREASED|1|mg/m2|MICRODENSITOMETRY|||CLINICAL STUDY SPONSOR|PATHOLOGIST|Y|4|Visit_4|65|4|FOLLOW-UP|2020-10-27|65
e|TR|9ed8a578-a82a-423a-81ca-ee87f98d62f7|5|[?]|ORSTATE|Organ State|[?]|/5x10^4 WBC|INCREASED|1|Bq/L|MAGNETIC RESONANCE ENTEROGRAPHY|||CAREGIVER|READER 1|N|5|Visit_5|90|1|TREATMENT|2020-11-21|90
e|TR|2214af46-1072-4328-bf3d-f4fe9cd97d9b|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|CAPFUL|UNCHANGED|1|oz|TRANSCRIPTION-MEDIATED AMPLIFICATION|||CHILD|UROLOGIST|N|1|Visit_1|10|4|WASHOUT|2020-10-18|10
e|TR|2214af46-1072-4328-bf3d-f4fe9cd97d9b|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|PELLET|FURTHER ENLARGEMENT FROM NADIR|1|%/min|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||Y|INVESTIGATOR|NEUROLOGIST 2|NA|2|Visit_2|25|5|TREATMENT|2020-11-02|25
e|TR|2214af46-1072-4328-bf3d-f4fe9cd97d9b|3|[?]|SUMVOL|Sum of Volume|[?]|DAgU/mL|EQUIVOCAL|1|pkat/L|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||CLINICAL STUDY SPONSOR|MICROSCOPIST 1|Y|3|Visit_3|40|5|TREATMENT|2020-11-17|40
e|TR|2214af46-1072-4328-bf3d-f4fe9cd97d9b|4|[?]|PCHGBL|Percent Change From Baseline|[?]|nmol/L/min|UNCHANGED|1|g/mol|MICROBIAL CULTURE, SOLID|Y||SPOUSE|MICROSCOPIST|NA|4|Visit_4|65|6|FOLLOW-UP|2020-12-12|65
e|TR|2214af46-1072-4328-bf3d-f4fe9cd97d9b|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|VOXEL|FOCALLY INCREASED|1|Bq/ug|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||INVESTIGATOR|RADIOLOGIST 1|N|5|Visit_5|90|3|TREATMENT|2021-01-06|90
e|TR|7e56eb43-62a6-45ac-9476-1d0655595a04|1|[?]|TUMSTATE|Tumor State|[?]|/min|UNEQUIVOCAL|1|ppm|WHOLE GENOME SEQUENCING|||INTERVIEWER|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|3|TREATMENT|2021-01-24|10
e|TR|7e56eb43-62a6-45ac-9476-1d0655595a04|2|[?]|PPD|Product of Perpendicular Diameters|[?]|/100 WBC|FOCALLY INCREASED|1|TRACE|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y|FRIEND|PATHOLOGIST 1|NA|2|Visit_2|25|2|TREATMENT|2021-02-08|25
e|TR|7e56eb43-62a6-45ac-9476-1d0655595a04|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|mmol/min/kPa|DECREASED|1|Ci/L|IRON HEMATOXYLIN STAIN|||STUDY SUBJECT|OPHTHALMOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2021-02-23|40
e|TR|7e56eb43-62a6-45ac-9476-1d0655595a04|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|U/cL|UNEQUIVOCAL|1|L/day|GC/FID|Y||SPOUSE|MICROSCOPIST 3|U|4|Visit_4|65|4|TREATMENT|2021-03-20|65
e|TR|7e56eb43-62a6-45ac-9476-1d0655595a04|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|CAPFUL|TUMOR MERGED|1|U/kg/day|DARK FIELD MICROSCOPY|||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|3|TREATMENT|2021-04-14|90
e|TR|73a8e85a-0b5f-496b-b164-afc4d1f02de2|1|[?]|VDIAM|Viable Diameter|[?]|beats/min|INCREASED|1|L/min|PALM METHOD|||HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|1|Visit_1|10|2|TREATMENT|2020-06-29|10
e|TR|73a8e85a-0b5f-496b-b164-afc4d1f02de2|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|/cmH2O|FURTHER ENLARGEMENT FROM NADIR|1|kDa|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|||CHILD|PATHOLOGIST 2|Y|2|Visit_2|25|7|FOLLOW-UP|2020-07-14|25
e|TR|73a8e85a-0b5f-496b-b164-afc4d1f02de2|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|in2|NORMAL|1|kIU|LAPAROSCOPY|||FAMILY MEMBER|ADJUDICATOR|NA|3|Visit_3|40|3|FOLLOW-UP|2020-07-29|40
e|TR|73a8e85a-0b5f-496b-b164-afc4d1f02de2|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|mol/L|NONPALPABLE|1|mg/h|FLUORESCENT MICROSCOPY|||CAREGIVER|READER 1|U|4|Visit_4|65|4|WASHOUT|2020-08-23|65
e|TR|73a8e85a-0b5f-496b-b164-afc4d1f02de2|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|10^6 organisms/g|ENLARGEMENT|1|nkat/g Hb|DIRECT SEQUENCING|||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|2|SCREENING|2020-09-17|90
e|TR|84f74359-c79b-4f1c-8119-a4993b071973|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|Bq/g|PALPABLE|1|rpm|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y|ADJUDICATOR|MICROSCOPIST 1|N|1|Visit_1|10|5|SCREENING|2020-05-12|10
e|TR|84f74359-c79b-4f1c-8119-a4993b071973|2|[?]|SUMDIAM|Sum of Diameter|[?]|mL/min/1.73m2|ENLARGEMENT FROM NADIR|1|BE/mL|MUGA||Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|2|FOLLOW-UP|2020-05-27|25
e|TR|84f74359-c79b-4f1c-8119-a4993b071973|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|Ci/g|NORMAL|1|breaths/min|OPTICAL MAPPING|||CAREGIVER|NEUROLOGIST|N|3|Visit_3|40|7|FOLLOW-UP|2020-06-11|40
e|TR|84f74359-c79b-4f1c-8119-a4993b071973|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|BOX|FURTHER ENLARGEMENT FROM NADIR|1|%/s|MICROBIAL CULTURE, LIQUID|||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-07-06|65
e|TR|84f74359-c79b-4f1c-8119-a4993b071973|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|mol/mol|ENLARGEMENT FROM NADIR|1|MnFI|MANUAL COUNT|||CAREGIVER|RATER 2|Y|5|Visit_5|90|5|TREATMENT|2020-07-31|90
e|TR|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|MnFI|INCREASED|1|BAR|SCANNING ELECTRON MICROSCOPY|||INVESTIGATOR|FORENSIC PATHOLOGIST|U|1|Visit_1|10|7|FOLLOW-UP|2020-11-06|10
e|TR|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|2|[?]|SUMVOL|Sum of Volume|[?]|/wk|NORMAL|1|ug/m2/min|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Y||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2020-11-21|25
e|TR|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|3|[?]|ORSTATE|Organ State|[?]|cm H2O|FURTHER ENLARGEMENT FROM NADIR|1|dyn|LC/MS/MS|||GUARDIAN|UROLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-12-06|40
e|TR|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|mm/sec|EQUIVOCAL|1|mg/kg|REVERSE TRANSCRIPTASE PCR|||INVESTIGATOR|RADIOLOGIST 2|NA|4|Visit_4|65|6|FOLLOW-UP|2020-12-31|65
e|TR|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|ug/g/h|FURTHER ENLARGEMENT FROM NADIR|1|mL/animal|ELECTROMYOGRAPHY|||PARENT|ENDOCRINOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2021-01-25|90
e|TR|cd0c969e-61c6-4c65-ac19-4ee247f5009a|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|atm|NONPALPABLE|1|TRANSDUCING UNIT|IODINE STAIN|||SIBLING|READER 3|Y|1|Visit_1|10|4|WASHOUT|2020-09-09|10
e|TR|cd0c969e-61c6-4c65-ac19-4ee247f5009a|2|[?]|LPERP|Longest Perpendicular|[?]|log10 CCID 50/dose|DECREASED|1|deg2|HEMAGGLUTINATION ASSAY|||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2020-09-24|25
e|TR|cd0c969e-61c6-4c65-ac19-4ee247f5009a|3|[?]|BNLNUM|Number of Bone Lesions|[?]|damol/L|FURTHER ENLARGEMENT FROM NADIR|1|CONTAINER|GEL ELECTROPHORESIS|||CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-10-09|40
e|TR|cd0c969e-61c6-4c65-ac19-4ee247f5009a|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|uL/kg/day|PRESENT|1|nmol/g|GRAM STAIN|||STUDY SUBJECT|ONCOLOGIST 2|NA|4|Visit_4|65|6|WASHOUT|2020-11-03|65
e|TR|cd0c969e-61c6-4c65-ac19-4ee247f5009a|5|[?]|LESSCIND|Lesion Success Indicator|[?]|uEq|PATHOLOGICAL|1|umol|FLUORIMETRY|||PARENT|ADJUDICATOR 2|NA|5|Visit_5|90|2|FOLLOW-UP|2020-11-28|90
e|TR|1fff484d-0a68-42cd-8eff-bc4fe4da945c|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|10^12/L|FURTHER ENLARGEMENT FROM NADIR|1|ug/m2|LANDOLT RING|||FAMILY MEMBER|UROLOGIST|U|1|Visit_1|10|7|SCREENING|2021-01-28|10
e|TR|1fff484d-0a68-42cd-8eff-bc4fe4da945c|2|[?]|DIAMETER|Diameter|[?]|in|PALPABLE|1|mV2/Hz|DYNAMOMETRY|Y||ADJUDICATOR|ADJUDICATOR 1|U|2|Visit_2|25|7|TREATMENT|2021-02-12|25
e|TR|1fff484d-0a68-42cd-8eff-bc4fe4da945c|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|10^6 organisms/g|PATHOLOGICAL|1|IU/kg/h|IMPEDANCE CONDUCTIVITY|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|NA|3|Visit_3|40|2|WASHOUT|2021-02-27|40
e|TR|1fff484d-0a68-42cd-8eff-bc4fe4da945c|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|ug/g/h|DIFFUSELY INCREASED|1|NFIU|WEBER GREEN STAIN|||SIBLING|MICROSCOPIST 3|U|4|Visit_4|65|2|WASHOUT|2021-03-24|65
e|TR|1fff484d-0a68-42cd-8eff-bc4fe4da945c|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|g/kg/day|PALPABLE|1|nmol BCE/L|BETA LACTAMASE|||PARENT|ADJUDICATOR 2|N|5|Visit_5|90|3|WASHOUT|2021-04-18|90
e|TR|e2c20e9a-0ac5-4907-96de-472bee70bd79|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mmol/min/kPa/L|ABSENT|1|ng/L|HEMATOXYLIN AND EOSIN STAIN|||ADJUDICATOR|RADIOLOGIST|N|1|Visit_1|10|4|SCREENING|2020-12-04|10
e|TR|e2c20e9a-0ac5-4907-96de-472bee70bd79|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|10^5/L|PALPABLE|1|ug/kg/day|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||PARENT|RATER 1|NA|2|Visit_2|25|6|TREATMENT|2020-12-19|25
e|TR|e2c20e9a-0ac5-4907-96de-472bee70bd79|3|[?]|VOLUME|Volume|[?]|/mm2|ABSENT|1|g/g/day|GEL ELECTROPHORESIS||Y|FRIEND|ONCOLOGIST 2|NA|3|Visit_3|40|3|TREATMENT|2021-01-03|40
e|TR|e2c20e9a-0ac5-4907-96de-472bee70bd79|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|/sec|ABSENT|1|mL/h|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y|DOMESTIC PARTNER|INTERNIST|N|4|Visit_4|65|2|TREATMENT|2021-01-28|65
e|TR|e2c20e9a-0ac5-4907-96de-472bee70bd79|5|[?]|PCHGBL|Percent Change From Baseline|[?]|P|EQUIVOCAL|1|genEq/mL|THICK SMEAR||Y|SIBLING|MICROSCOPIST 1|N|5|Visit_5|90|1|TREATMENT|2021-02-22|90
e|TR|6064ca8c-b723-4d05-914a-bb547d86fcc5|1|[?]|PPD|Product of Perpendicular Diameters|[?]|mg/kg/dose|FURTHER ENLARGEMENT|1|fmol|OPHTHALMOSCOPY|||NON-HEALTH CARE PROFESSIONAL|READER 1|Y|1|Visit_1|10|4|WASHOUT|2020-06-02|10
e|TR|6064ca8c-b723-4d05-914a-bb547d86fcc5|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|m2|FURTHER ENLARGEMENT|1|10^7 TCID 50/dose|MAGNETIC RESONANCE ELASTOGRAPHY|||SPOUSE|CLINICAL PATHOLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-06-17|25
e|TR|6064ca8c-b723-4d05-914a-bb547d86fcc5|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|Log10 ELISA unit/dose|UNCHANGED|1|mEq/mmol|COULOMETRIC TITRATION|Y|Y|NON-HEALTH CARE PROFESSIONAL|RATER 1|U|3|Visit_3|40|3|FOLLOW-UP|2020-07-02|40
e|TR|6064ca8c-b723-4d05-914a-bb547d86fcc5|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|psec|INCREASED|1|PIPE|ORCHIDOMETERY|||CLINICAL STUDY SPONSOR|MICROSCOPIST|N|4|Visit_4|65|4|TREATMENT|2020-07-27|65
e|TR|6064ca8c-b723-4d05-914a-bb547d86fcc5|5|[?]|DIAMETER|Diameter|[?]|Bq/g|TUMOR MERGED|1|ohm|TURBIDIMETRY|||INTERVIEWER|RATER 1|U|5|Visit_5|90|7|WASHOUT|2020-08-21|90
e|TR|8effbbff-acda-4718-89f1-e30a418f6bae|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|U/cL|TUMOR MERGED|1|g/dL|RULER MEASUREMENT METHOD||Y|CLINICAL RESEARCH COORDINATOR|READER|N|1|Visit_1|10|2|TREATMENT|2020-11-06|10
e|TR|8effbbff-acda-4718-89f1-e30a418f6bae|2|[?]|TUMSTATE|Tumor State|[?]|Watt|FURTHER ENLARGEMENT FROM NADIR|1|mL/mmHg/min/L|OPTICAL DENSITY MEASUREMENT|Y||HEALTH CARE PROFESSIONAL|READER 3|NA|2|Visit_2|25|2|TREATMENT|2020-11-21|25
e|TR|8effbbff-acda-4718-89f1-e30a418f6bae|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|Tesla|FURTHER ENLARGEMENT|1|Absorbance U/min|IN VITRO GENE EXPRESSION ASSAY|Y||ADJUDICATOR|MICROSCOPIST 1|NA|3|Visit_3|40|7|TREATMENT|2020-12-06|40
e|TR|8effbbff-acda-4718-89f1-e30a418f6bae|4|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|kg/cm|EQUIVOCAL|1|TRANSDUCING UNIT/mL|FLUORESCEIN STAIN|Y||SIGNIFICANT OTHER|ONCOLOGIST 2|Y|4|Visit_4|65|6|TREATMENT|2020-12-31|65
e|TR|8effbbff-acda-4718-89f1-e30a418f6bae|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|ms2|NORMAL|1|MONTHS|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||PARENT|MICROSCOPIST 1|U|5|Visit_5|90|2|WASHOUT|2021-01-25|90
e|TR|859b16a5-f6a2-40cc-8e01-18c112b1969e|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|AgU/mL|INCREASED|1|ug/m2/min|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||STUDY SUBJECT|MICROSCOPIST 3|NA|1|Visit_1|10|2|SCREENING|2020-08-18|10
e|TR|859b16a5-f6a2-40cc-8e01-18c112b1969e|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|/wk|ENLARGEMENT FROM NADIR|1|cmHg|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||SIGNIFICANT OTHER|RATER|Y|2|Visit_2|25|7|TREATMENT|2020-09-02|25
e|TR|859b16a5-f6a2-40cc-8e01-18c112b1969e|3|[?]|PALPSTAT|Palpable State|[?]|L/kg|DECREASED|1|GBq/mg|HEMATOXYLIN AND EOSIN STAIN|Y||STUDY SUBJECT|READER|NA|3|Visit_3|40|1|TREATMENT|2020-09-17|40
e|TR|859b16a5-f6a2-40cc-8e01-18c112b1969e|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|EVENTS|NON-PATHOLOGICAL|1|deg2|NEPHELOMETRY|||INVESTIGATOR|OPTOMETRIST|NA|4|Visit_4|65|3|TREATMENT|2020-10-12|65
e|TR|859b16a5-f6a2-40cc-8e01-18c112b1969e|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|BOX|NONPALPABLE|1|TRANSDUCING UNIT/mL|NUCLEIC ACID HYBRIDIZATION|Y||FRIEND|MICROSCOPIST 1|NA|5|Visit_5|90|3|TREATMENT|2020-11-06|90
e|TR|36b457ef-4cf6-4043-a836-49368ebf3f1c|1|[?]|BNLNUM|Number of Bone Lesions|[?]|/ms|FOCALLY INCREASED|1|nmol/mol|MICROBIAL BIOCHEMICAL IDENTIFICATION|Y||CHILD|RADIOLOGIST|N|1|Visit_1|10|6|WASHOUT|2020-08-16|10
e|TR|36b457ef-4cf6-4043-a836-49368ebf3f1c|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|ft|FURTHER ENLARGEMENT FROM NADIR|1|umol/L/min|ATOMIC ABSORPTION SPECTROMETRY|||SIBLING|RADIOLOGIST|Y|2|Visit_2|25|2|SCREENING|2020-08-31|25
e|TR|36b457ef-4cf6-4043-a836-49368ebf3f1c|3|[?]|DIAMETER|Diameter|[?]|/40 HPFs|ABSENT|1|msec|CLIP|||STUDY SUBJECT|MICROSCOPIST 3|NA|3|Visit_3|40|4|WASHOUT|2020-09-15|40
e|TR|36b457ef-4cf6-4043-a836-49368ebf3f1c|4|[?]|CALCFIND|Calcification Indicator|[?]|mU|UNEQUIVOCAL|1|nmol/mol|RYAN BLUE STAIN|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|N|4|Visit_4|65|1|FOLLOW-UP|2020-10-10|65
e|TR|36b457ef-4cf6-4043-a836-49368ebf3f1c|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|ug/L/h|FURTHER ENLARGEMENT FROM NADIR|1|kIU|OPTICAL MAPPING|||STUDY SUBJECT|UROLOGIST|U|5|Visit_5|90|7|TREATMENT|2020-11-04|90
e|TR|31f33e38-bba6-4c8a-b563-14afaabae5d7|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|kV|PALPABLE|1|umol/h/mmol|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y||CAREGIVER|RATER 2|U|1|Visit_1|10|6|TREATMENT|2020-07-01|10
e|TR|31f33e38-bba6-4c8a-b563-14afaabae5d7|2|[?]|ORVERLN|Organ Vertical Length|[?]|dpm/mL|ABSENT|1|10^6 organisms/mL|MICROBIAL BIOCHEMICAL IDENTIFICATION|Y|Y|INVESTIGATOR|PATHOLOGIST 1|N|2|Visit_2|25|1|TREATMENT|2020-07-16|25
e|TR|31f33e38-bba6-4c8a-b563-14afaabae5d7|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mg/cm2|PATHOLOGICAL|1|mg/L FEU|INCISION-INDUCED BLEEDING METHOD|Y|Y|VENDOR|OPHTHALMOLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-07-31|40
e|TR|31f33e38-bba6-4c8a-b563-14afaabae5d7|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|usec|FURTHER ENLARGEMENT FROM NADIR|1|uV|MICROBIAL CULTURE|||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|Y|4|Visit_4|65|4|FOLLOW-UP|2020-08-25|65
e|TR|31f33e38-bba6-4c8a-b563-14afaabae5d7|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|g/dL|ENLARGEMENT|1|PIXEL|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||ADJUDICATION COMMITTEE|PATHOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2020-09-19|90
e|TR|6794dffe-333b-425b-8883-26f6e5ba0797|1|[?]|SUMVOL|Sum of Volume|[?]|COAT|ABSENT|1|KALLIKREIN INHIBITOR UNIT|FLOCCULATION, CHARCOAL ENHANCED|Y|Y|FRIEND|PATHOLOGIST 1|NA|1|Visit_1|10|7|TREATMENT|2020-07-09|10
e|TR|6794dffe-333b-425b-8883-26f6e5ba0797|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mm/sec|ENLARGEMENT|1|mmol/min/kPa|ELISPOT|||PARENT|OPTOMETRIST|U|2|Visit_2|25|1|TREATMENT|2020-07-24|25
e|TR|6794dffe-333b-425b-8883-26f6e5ba0797|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|uL|NORMAL|1|U/mg|FLUOROSCOPY|Y||VENDOR|READER 1|NA|3|Visit_3|40|7|FOLLOW-UP|2020-08-08|40
e|TR|6794dffe-333b-425b-8883-26f6e5ba0797|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mL|PATHOLOGICAL|1|uEq/L|CONTRAST ENHANCED CT SCAN|Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|4|Visit_4|65|6|TREATMENT|2020-09-02|65
e|TR|6794dffe-333b-425b-8883-26f6e5ba0797|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|BAU|TUMOR MERGED|1|g/g|FORCED OSCILLATION TECHNIQUE|||INTERVIEWER|READER 3|U|5|Visit_5|90|4|WASHOUT|2020-09-27|90
e|TR|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|1|[?]|AREA|Area|[?]|/sec|ENLARGEMENT|1|/10^3|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||PROXY|READER 2|U|1|Visit_1|10|4|TREATMENT|2020-06-07|10
e|TR|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|2|[?]|ACHNAD|Absolute Change From Nadir|[?]|min/day|NONPALPABLE|1|10^4 CFU/mL|DUKE INCISION METHOD|Y||ADJUDICATION COMMITTEE|READER|U|2|Visit_2|25|4|TREATMENT|2020-06-22|25
e|TR|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mL/min/mmHg|NON-PATHOLOGICAL|1|HOMEOPATHIC DILUTION|WRIGHT STAIN||Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|3|Visit_3|40|1|SCREENING|2020-07-07|40
e|TR|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|dram|DECREASED|1|vg/mL|ELECTRONEUROGRAPHY|Y|Y|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|1|FOLLOW-UP|2020-08-01|65
e|TR|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|5|[?]|BNLNUM|Number of Bone Lesions|[?]|APL U/mL|NONPALPABLE|1|nmol/g|ROMANOWSKY STAIN|Y||DOMESTIC PARTNER|INTERNIST|NA|5|Visit_5|90|7|TREATMENT|2020-08-26|90
e|TR|45897452-8f5a-458d-9a43-13237460ba48|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|tuberculin unit|ENLARGEMENT FROM NADIR|1|SCOOPFUL|ERGOSPIROMETRY|||NON-HEALTH CARE PROFESSIONAL|READER|NA|1|Visit_1|10|4|SCREENING|2020-11-11|10
e|TR|45897452-8f5a-458d-9a43-13237460ba48|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|/kg|DECREASED|1|mL/dose|MICROPARTICLE ENZYME IMMUNOASSAY|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|Y|2|Visit_2|25|3|FOLLOW-UP|2020-11-26|25
e|TR|45897452-8f5a-458d-9a43-13237460ba48|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|U/g/min|FURTHER ENLARGEMENT FROM NADIR|1|%(w/w)|SICKLE CELL SOLUBILITY TEST|Y||SIGNIFICANT OTHER|READER 1|NA|3|Visit_3|40|6|WASHOUT|2020-12-11|40
e|TR|45897452-8f5a-458d-9a43-13237460ba48|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|steps/min|PRESENT|1|pptr|LASER CAPTURE MICRODISSECTION|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|NA|4|Visit_4|65|1|TREATMENT|2021-01-05|65
e|TR|45897452-8f5a-458d-9a43-13237460ba48|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|HOMEOPATHIC DILUTION|FURTHER ENLARGEMENT|1|U|CAPILLARY ELECTROPHORESIS||Y|CAREGIVER|ONCOLOGIST 2|U|5|Visit_5|90|3|TREATMENT|2021-01-30|90
e|TR|16eb981f-2118-4658-a83f-93d925c410c9|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|pkat/L|PRESENT|1|in|SNP ARRAY||Y|SIBLING|FORENSIC PATHOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-12-16|10
e|TR|16eb981f-2118-4658-a83f-93d925c410c9|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|YEARS|NONPALPABLE|1|kV|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||INDEPENDENT ASSESSOR|ONCOLOGIST 2|Y|2|Visit_2|25|1|TREATMENT|2020-12-31|25
e|TR|16eb981f-2118-4658-a83f-93d925c410c9|3|[?]|LESSCIND|Lesion Success Indicator|[?]|GPL U|DECREASED|1|kg/m2|REFLECTANCE SPECTROSCOPY|Y||CAREGIVER|READER 2|Y|3|Visit_3|40|5|TREATMENT|2021-01-15|40
e|TR|16eb981f-2118-4658-a83f-93d925c410c9|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|FEU|NONPALPABLE|1|mEq/g|INDIRECT IMMUNOFLUORESCENCE|||DOMESTIC PARTNER|MICROSCOPIST|N|4|Visit_4|65|7|TREATMENT|2021-02-09|65
e|TR|16eb981f-2118-4658-a83f-93d925c410c9|5|[?]|BNLNUM|Number of Bone Lesions|[?]|dpm/mL|NORMAL|1|MBP|ENZYMATIC COLORIMETRY|||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|5|Visit_5|90|2|TREATMENT|2021-03-06|90
e|TR|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|PATCH|PRESENT|1|mol/mL|DXA SCAN|||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|1|Visit_1|10|7|FOLLOW-UP|2021-01-11|10
e|TR|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|Absorbance U/mL|EQUIVOCAL|1|umol/L/h|IMMUNOFIXATION ELECTROPHORESIS|Y||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|7|TREATMENT|2021-01-26|25
e|TR|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|3|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|10^7 CFU/mL|PALPABLE|1|Bq/uL|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||DOMESTIC PARTNER|INTERNIST|NA|3|Visit_3|40|2|TREATMENT|2021-02-10|40
e|TR|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|Gy/min|EQUIVOCAL|1|10^4/L|FREEZING POINT DEPRESSION|Y||FAMILY MEMBER|OTOLARYNGOLOGIST|N|4|Visit_4|65|1|WASHOUT|2021-03-07|65
e|TR|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|5|[?]|CALCFIND|Calcification Indicator|[?]|dpm/mL|TUMOR MERGED|1|kDa|LIQUID SCINTILLATION COUNTING|||INTERVIEWER|PHYSIOTHERAPIST|U|5|Visit_5|90|6|FOLLOW-UP|2021-04-01|90
e|TR|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|%/s|NONPALPABLE|1|IMPLANT|IMMUNOFLUORESCENT STAIN||Y|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|6|TREATMENT|2021-01-29|10
e|TR|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|ft2|NON-PATHOLOGICAL|1|mL/dL|TRIPLE-PHASE SPIRAL CT SCAN|||INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|N|2|Visit_2|25|2|TREATMENT|2021-02-13|25
e|TR|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|3|[?]|SUMDIAM|Sum of Diameter|[?]|log10 TCID 50/mL|TUMOR MERGED|1|ug/kg/h|NON-INVASIVE DIELECTRIC SENSING|Y||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|NA|3|Visit_3|40|2|SCREENING|2021-02-28|40
e|TR|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|/VF|FURTHER ENLARGEMENT|1|mgEq|FUNCTIONAL MRI|||SIBLING|PHYSIOTHERAPIST|U|4|Visit_4|65|3|FOLLOW-UP|2021-03-25|65
e|TR|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|5|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|s*kPa|NONPALPABLE|1|fg|FUNCTIONAL MRI|||FRIEND|ADJUDICATOR 2|N|5|Visit_5|90|3|TREATMENT|2021-04-19|90
e|TR|874f491c-5d55-4738-86b7-b1200b16d106|1|[?]|TUMSTATE|Tumor State|[?]|kg/cm2|UNCHANGED|1|L/s/kPa|CELLULAR PROLIFERATION ASSAY||Y|PARENT|ADJUDICATOR 2|U|1|Visit_1|10|5|TREATMENT|2021-01-08|10
e|TR|874f491c-5d55-4738-86b7-b1200b16d106|2|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mg/g/h|TUMOR MERGED|1|mL/min/1.73m2|X-RAY|||PROXY|OPTOMETRIST|Y|2|Visit_2|25|7|TREATMENT|2021-01-23|25
e|TR|874f491c-5d55-4738-86b7-b1200b16d106|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|ug/m2/min|DIFFUSELY INCREASED|1|mV2/Hz|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||Y|ADJUDICATOR|UROLOGIST|NA|3|Visit_3|40|1|TREATMENT|2021-02-07|40
e|TR|874f491c-5d55-4738-86b7-b1200b16d106|4|[?]|LPERP|Longest Perpendicular|[?]|U/animal|DECREASED|1|TCID 50/dose|NUCLEIC ACID HYBRIDIZATION|Y||CHILD|INTERNIST|Y|4|Visit_4|65|1|TREATMENT|2021-03-04|65
e|TR|874f491c-5d55-4738-86b7-b1200b16d106|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|1/(s*kPa)|UNEQUIVOCAL|1|log10 TCID 50/mL|LEAD CITRATE STAIN|Y||SPOUSE|READER 2|U|5|Visit_5|90|5|TREATMENT|2021-03-29|90
e|TR|281ccdef-794c-49ad-9616-6f6f68dd4543|1|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mEq/dL|DECREASED|1|APS U|MANUAL CLOT DETECTION|||SIBLING|RADIOLOGIST|Y|1|Visit_1|10|3|TREATMENT|2020-06-04|10
e|TR|281ccdef-794c-49ad-9616-6f6f68dd4543|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|IU/L|ENLARGEMENT FROM NADIR|1|GPL U|RADIOGRAPHY||Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|2|Visit_2|25|6|TREATMENT|2020-06-19|25
e|TR|281ccdef-794c-49ad-9616-6f6f68dd4543|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|Ci/L|PRESENT|1|dpm/0.5 mL|RULER MEASUREMENT METHOD|Y||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|3|Visit_3|40|6|TREATMENT|2020-07-04|40
e|TR|281ccdef-794c-49ad-9616-6f6f68dd4543|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|BOX|INCREASED|1|vp/mL|ORCHIDOMETERY|||ADJUDICATION COMMITTEE|INTERNIST|N|4|Visit_4|65|7|TREATMENT|2020-07-29|65
e|TR|281ccdef-794c-49ad-9616-6f6f68dd4543|5|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|10^3 CFU/g|INCREASED|1|g/kg/day|INTERRUPTER TECHNIQUE|||ADJUDICATOR|ADJUDICATOR 3|N|5|Visit_5|90|5|TREATMENT|2020-08-23|90
e|TR|b1179e10-e8fe-472c-a511-d6d460571857|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|deg/mm|ABSENT|1|lm|IMMUNOCHROMATOGRAPHY|||STUDY SUBJECT|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-08-02|10
e|TR|b1179e10-e8fe-472c-a511-d6d460571857|2|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mEq/ug|NONPALPABLE|1|Enzyme U/g Hb|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||SPOUSE|ADJUDICATOR 2|NA|2|Visit_2|25|7|FOLLOW-UP|2020-08-17|25
e|TR|b1179e10-e8fe-472c-a511-d6d460571857|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|mL/h|DECREASED|1|gMFI|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||SIBLING|RATER 2|NA|3|Visit_3|40|2|TREATMENT|2020-09-01|40
e|TR|b1179e10-e8fe-472c-a511-d6d460571857|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|Absorbance U/min|NORMAL|1|pg|SINGLE-MOLECULE ARRAY|||CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|U|4|Visit_4|65|2|FOLLOW-UP|2020-09-26|65
e|TR|b1179e10-e8fe-472c-a511-d6d460571857|5|[?]|NEWCONF|New Tumor Confirmed|[?]|log10 PFU/mL|DECREASED|1|mkat|PHYSICAL EXAMINATION||Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|N|5|Visit_5|90|3|FOLLOW-UP|2020-10-21|90
e|TR|6362cf42-f286-4151-bdf7-38fcc5639eed|1|[?]|RADIODEN|Radiodensity|[?]|10^5/L|ENLARGEMENT|1|ks|DOUBLE IMMUNODIFFUSION|||ADJUDICATION COMMITTEE|RADIOLOGIST 2|N|1|Visit_1|10|7|TREATMENT|2020-09-07|10
e|TR|6362cf42-f286-4151-bdf7-38fcc5639eed|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mL/s|NORMAL|1|ug/L/h|DUCTOGRAPHY|||STUDY SUBJECT|ONCOLOGIST 2|Y|2|Visit_2|25|4|SCREENING|2020-09-22|25
e|TR|6362cf42-f286-4151-bdf7-38fcc5639eed|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mL/animal/wk|EQUIVOCAL|1|L/L|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||FAMILY MEMBER|MICROSCOPIST 2|U|3|Visit_3|40|5|TREATMENT|2020-10-07|40
e|TR|6362cf42-f286-4151-bdf7-38fcc5639eed|4|[?]|LNSTATE|Lymph Node State|[?]|min|UNCHANGED|1|log10 PFU|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|2|TREATMENT|2020-11-01|65
e|TR|6362cf42-f286-4151-bdf7-38fcc5639eed|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|10^6 organisms/g|NONPALPABLE|1|/10^5|KNEMOMETRY|||INDEPENDENT ASSESSOR|NEUROLOGIST 2|NA|5|Visit_5|90|5|TREATMENT|2020-11-26|90
e|TR|8e28e3ab-0060-43f7-b033-c16bd77c0e29|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|Torr|PATHOLOGICAL|1|/mm2|TURBIDIMETRY||Y|STUDY SUBJECT|ONCOLOGIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-11-30|10
e|TR|8e28e3ab-0060-43f7-b033-c16bd77c0e29|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|cs|PALPABLE|1|mL|CONTRAST ENHANCED X-RAY|||CLINICAL RESEARCH ASSOCIATE|READER 2|U|2|Visit_2|25|2|FOLLOW-UP|2020-12-15|25
e|TR|8e28e3ab-0060-43f7-b033-c16bd77c0e29|3|[?]|ORSTATE|Organ State|[?]|usec|ENLARGEMENT|1|Pack Year|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||GUARDIAN|PHYSIOTHERAPIST|Y|3|Visit_3|40|5|TREATMENT|2020-12-30|40
e|TR|8e28e3ab-0060-43f7-b033-c16bd77c0e29|4|[?]|PPD|Product of Perpendicular Diameters|[?]|pkat|UNEQUIVOCAL|1|ug/L|JAFFE REACTION||Y|FRIEND|HEMATOLOGIST|U|4|Visit_4|65|2|TREATMENT|2021-01-24|65
e|TR|8e28e3ab-0060-43f7-b033-c16bd77c0e29|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|log EID 50/dose|NORMAL|1|GPS U|PHOROPTER|||SPOUSE|FORENSIC PATHOLOGIST|U|5|Visit_5|90|5|TREATMENT|2021-02-18|90
e|TR|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|1|[?]|ORSTATE|Organ State|[?]|kIU|ABSENT|1|damol/L|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||CHILD|UROLOGIST|N|1|Visit_1|10|2|SCREENING|2020-06-27|10
e|TR|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|2|[?]|AREA|Area|[?]|CARTRIDGE|DECREASED|1|EU|RYAN BLUE STAIN|||CAREGIVER|NEUROLOGIST 2|NA|2|Visit_2|25|1|WASHOUT|2020-07-12|25
e|TR|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|cmHg|PALPABLE|1|deg/s|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||PARENT|PHYSIOTHERAPIST|N|3|Visit_3|40|1|TREATMENT|2020-07-27|40
e|TR|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|4|[?]|VOLUME|Volume|[?]|mL/mmHg|UNCHANGED|1|cup eq|DOUBLE IMMUNODIFFUSION||Y|INVESTIGATOR|INTERNIST|N|4|Visit_4|65|4|TREATMENT|2020-08-21|65
e|TR|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|APL U|UNEQUIVOCAL|1|10^3/hpf|HPLC-UV||Y|SIBLING|ADJUDICATOR 2|Y|5|Visit_5|90|3|FOLLOW-UP|2020-09-15|90
e|TR|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|10^6 organisms|FOCALLY INCREASED|1|IU/g|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|Y|VENDOR|MICROSCOPIST 1|NA|1|Visit_1|10|1|SCREENING|2020-06-22|10
e|TR|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|MAC50|UNEQUIVOCAL|1|%(w/w)|ENZYMATIC COLORIMETRY|||INVESTIGATOR|MICROSCOPIST 3|NA|2|Visit_2|25|3|SCREENING|2020-07-07|25
e|TR|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|3|[?]|ORSTATE|Organ State|[?]|DPM|ABSENT|1|mMU/mL|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y||VENDOR|MICROSCOPIST 2|U|3|Visit_3|40|7|TREATMENT|2020-07-22|40
e|TR|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|ng/day|UNCHANGED|1|umol/L/h|SPIRAL CT|Y||CLINICAL STUDY SPONSOR|HEMATOLOGIST|NA|4|Visit_4|65|1|TREATMENT|2020-08-16|65
e|TR|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|/day|PATHOLOGICAL|1|log10 copies/mL|PELLI-ROBSON EYE CHART|Y||STUDY SUBJECT|ONCOLOGIST 1|N|5|Visit_5|90|1|WASHOUT|2020-09-10|90
e|TR|43880587-c397-402d-886b-9b666e3fe455|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|dpm/mg|INCREASED|1|mL/kg/h|X-RAY|||FRIEND|RADIOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-07-21|10
e|TR|43880587-c397-402d-886b-9b666e3fe455|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|TROCHE|EQUIVOCAL|1|POINT|MRI WITHOUT CONTRAST||Y|STUDY SUBJECT|READER|N|2|Visit_2|25|5|WASHOUT|2020-08-05|25
e|TR|43880587-c397-402d-886b-9b666e3fe455|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|mg/kg|UNEQUIVOCAL|1|U/dL|VIRUS PLAQUE ASSAY|||ADJUDICATOR|READER 2|Y|3|Visit_3|40|1|TREATMENT|2020-08-20|40
e|TR|43880587-c397-402d-886b-9b666e3fe455|4|[?]|ORVERLN|Organ Vertical Length|[?]|/MBP|ENLARGEMENT|1|umol|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|5|TREATMENT|2020-09-14|65
e|TR|43880587-c397-402d-886b-9b666e3fe455|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mOsm/kg|FOCALLY INCREASED|1|DRUM|RYAN BLUE STAIN|||VENDOR|READER 3|NA|5|Visit_5|90|7|SCREENING|2020-10-09|90
e|TR|807f83d2-9364-4ee4-855d-304f3e252555|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|U/dL|TUMOR MERGED|1|SUPPOSITORY|PHYSICAL EXAMINATION|||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|Y|1|Visit_1|10|3|WASHOUT|2020-05-14|10
e|TR|807f83d2-9364-4ee4-855d-304f3e252555|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mEq/L|DIFFUSELY INCREASED|1|10^9 organisms|SMEAR|||DOMESTIC PARTNER|INTERNIST|N|2|Visit_2|25|3|SCREENING|2020-05-29|25
e|TR|807f83d2-9364-4ee4-855d-304f3e252555|3|[?]|PALPSTAT|Palpable State|[?]|mJoule/cm2|ABSENT|1|10^9 organisms/mL|HEMAGGLUTINATION ASSAY|Y|Y|FAMILY MEMBER|MICROSCOPIST 1|N|3|Visit_3|40|1|TREATMENT|2020-06-13|40
e|TR|807f83d2-9364-4ee4-855d-304f3e252555|4|[?]|ORVERLN|Organ Vertical Length|[?]|mg/kg/week|DECREASED|1|mU/L|RAJI CELL EIA|||FRIEND|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2020-07-08|65
e|TR|807f83d2-9364-4ee4-855d-304f3e252555|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|Frames/s|INCREASED|1|BU/mL|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||DOMESTIC PARTNER|MICROSCOPIST 2|NA|5|Visit_5|90|1|FOLLOW-UP|2020-08-02|90
e|TR|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|kat|NON-PATHOLOGICAL|1|ug/m2/day|MECHANICAL CLOT DETECTION|||ADJUDICATOR|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|5|SCREENING|2020-12-09|10
e|TR|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|pmol/10^10 cells|PATHOLOGICAL|1|mg/L|CRYOSCOPY||Y|STUDY SUBJECT|MICROSCOPIST 1|Y|2|Visit_2|25|5|SCREENING|2020-12-24|25
e|TR|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|3|[?]|VDIAM|Viable Diameter|[?]|mL/beat|PALPABLE|1|mg/m2/day|ZIEHL NEELSEN ACID FAST STAIN|Y|Y|SIGNIFICANT OTHER|INTERNIST|U|3|Visit_3|40|3|TREATMENT|2021-01-08|40
e|TR|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|MET|UNCHANGED|1|um|GEL ELECTROPHORESIS|||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|3|TREATMENT|2021-02-02|65
e|TR|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|ug/cm2|ENLARGEMENT|1|AFU|ICC|Y|Y|INTERVIEWER|ADJUDICATOR 3|Y|5|Visit_5|90|6|TREATMENT|2021-02-27|90
e|TR|81c33633-6ade-45fe-a78e-0e853d8aa9c2|1|[?]|BNLNUM|Number of Bone Lesions|[?]|fmol/g|ENLARGEMENT|1|fmol|PATHOLOGICAL EVALUATION|||CLINICAL STUDY SPONSOR|INTERNIST|NA|1|Visit_1|10|3|WASHOUT|2020-08-15|10
e|TR|81c33633-6ade-45fe-a78e-0e853d8aa9c2|2|[?]|VDIAM|Viable Diameter|[?]|deg/mm|FURTHER ENLARGEMENT|1|Siemens|CAPILLARY ELECTROPHORESIS|Y||FAMILY MEMBER|NEUROLOGIST 1|N|2|Visit_2|25|1|SCREENING|2020-08-30|25
e|TR|81c33633-6ade-45fe-a78e-0e853d8aa9c2|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|FINGERTIP UNIT|ABSENT|1|IU/mL|CONFOCAL MICROSCOPY|||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|Y|3|Visit_3|40|4|TREATMENT|2020-09-14|40
e|TR|81c33633-6ade-45fe-a78e-0e853d8aa9c2|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|ugEq/L|UNCHANGED|1|10^10/L|NO INFORMATION||Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|NA|4|Visit_4|65|1|TREATMENT|2020-10-09|65
e|TR|81c33633-6ade-45fe-a78e-0e853d8aa9c2|5|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|L/s|PATHOLOGICAL|1|U/g/h|CONTRAST ENHANCED PET SCAN|Y||FAMILY MEMBER|NEUROLOGIST 1|Y|5|Visit_5|90|6|WASHOUT|2020-11-03|90
e|TR|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|1|[?]|TUMSTATE|Tumor State|[?]|10^7 TCID 50/dose|NON-PATHOLOGICAL|1|10^6/L|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||GUARDIAN|HEMATOLOGIST|N|1|Visit_1|10|2|WASHOUT|2020-08-01|10
e|TR|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|nsec|PALPABLE|1|kUSP|PERFUSION MRI|||CAREGIVER|ENDOCRINOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-08-16|25
e|TR|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|kg/cm|PATHOLOGICAL|1|Log10 ELISA unit/dose|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||HEALTH CARE PROFESSIONAL|MICROSCOPIST|Y|3|Visit_3|40|6|SCREENING|2020-08-31|40
e|TR|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|BE/mL|UNCHANGED|1|mL/s|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||PARENT|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|1|TREATMENT|2020-09-25|65
e|TR|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|5|[?]|DIAMETER|Diameter|[?]|SCOOPFUL|DECREASED|1|IMPLANT|GC/MS/MS||Y|PARENT|ONCOLOGIST 1|U|5|Visit_5|90|3|TREATMENT|2020-10-20|90
e|TR|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|/kg|FURTHER ENLARGEMENT FROM NADIR|1|vg/dose|SPECULAR MICROSCOPY|Y||PARENT|NEUROLOGIST|Y|1|Visit_1|10|5|SCREENING|2020-09-01|10
e|TR|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|2|[?]|LNSTATE|Lymph Node State|[?]|kDa|ENLARGEMENT|1|cm/s|ELECTROMYOGRAPHY||Y|FRIEND|RATER 2|NA|2|Visit_2|25|1|TREATMENT|2020-09-16|25
e|TR|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|3|[?]|PALPSTAT|Palpable State|[?]|gtt|INCREASED|1|/40 HPFs|INTRAVASCULAR ULTRASOUND|Y||SIBLING|MICROSCOPIST|NA|3|Visit_3|40|1|WASHOUT|2020-10-01|40
e|TR|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|uEq|FURTHER ENLARGEMENT|1|Weber|TEST STRIP|Y||CLINICAL RESEARCH ASSOCIATE|READER 2|Y|4|Visit_4|65|4|FOLLOW-UP|2020-10-26|65
e|TR|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|IU|NON-PATHOLOGICAL|1|ft2|BAC ACGH|||ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-11-20|90
e|TR|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mL/g/day|ENLARGEMENT|1|mol/g|CHROMOGENIC ASSAY|||INTERVIEWER|OPHTHALMOLOGIST|U|1|Visit_1|10|7|FOLLOW-UP|2021-01-27|10
e|TR|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|2|[?]|LESSCIND|Lesion Success Indicator|[?]|GBq|UNCHANGED|1|L/s/kPa|LASER CAPTURE MICRODISSECTION|||STUDY SUBJECT|NEUROLOGIST 1|NA|2|Visit_2|25|2|SCREENING|2021-02-11|25
e|TR|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|3|[?]|SUMDIAM|Sum of Diameter|[?]|ug/m2|NONPALPABLE|1|g/cage/wk|SICKLE CELL SOLUBILITY TEST|||DOMESTIC PARTNER|RATER 1|N|3|Visit_3|40|1|FOLLOW-UP|2021-02-26|40
e|TR|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|nmol/mol|ENLARGEMENT FROM NADIR|1|cycle/min|SLOAN LETTER EYE CHART 2.5%|||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|U|4|Visit_4|65|3|TREATMENT|2021-03-23|65
e|TR|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|ug/mL/h|NONPALPABLE|1|MESF|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y||ADJUDICATION COMMITTEE|RATER 2|U|5|Visit_5|90|6|TREATMENT|2021-04-17|90
e|TR|21740641-69bb-49a9-a86d-2444914f6d12|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|10^6 IU|PALPABLE|1|10^3 CFU/mL|TWO-COLOR MICROARRAY||Y|CAREGIVER|MICROSCOPIST 1|Y|1|Visit_1|10|5|TREATMENT|2020-05-17|10
e|TR|21740641-69bb-49a9-a86d-2444914f6d12|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|HOURS|NONPALPABLE|1|g/dL|NON-CONTACT SPECULAR MICROSCOPY|||SIGNIFICANT OTHER|READER 1|U|2|Visit_2|25|3|TREATMENT|2020-06-01|25
e|TR|21740641-69bb-49a9-a86d-2444914f6d12|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|genEq|FOCALLY INCREASED|1|s/h|PHOTOGRAPHY|||DOMESTIC PARTNER|RATER|N|3|Visit_3|40|4|TREATMENT|2020-06-16|40
e|TR|21740641-69bb-49a9-a86d-2444914f6d12|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|um/day|UNCHANGED|1|pg/cell|PET/CT SCAN WITHOUT CONTRAST|||INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|NA|4|Visit_4|65|5|SCREENING|2020-07-11|65
e|TR|21740641-69bb-49a9-a86d-2444914f6d12|5|[?]|ORSTATE|Organ State|[?]|10^6/Ejaculate U|INCREASED|1|nmol/mL/min|LYMPHANGIOGRAPHY|Y|Y|VENDOR|PATHOLOGIST|U|5|Visit_5|90|7|TREATMENT|2020-08-05|90
e|TR|c3984f41-30a0-49a4-a8bd-f36fad4621a8|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|STRIP|PRESENT|1|DRINK|SMEAR|||ADJUDICATION COMMITTEE|MICROSCOPIST 1|N|1|Visit_1|10|1|WASHOUT|2020-06-18|10
e|TR|c3984f41-30a0-49a4-a8bd-f36fad4621a8|2|[?]|VOLUME|Volume|[?]|mg/m2|PRESENT|1|mg/g/h|NEURAMINIDASE INHIBITION ASSAY|||CAREGIVER|NEUROLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-07-03|25
e|TR|c3984f41-30a0-49a4-a8bd-f36fad4621a8|3|[?]|VDIAM|Viable Diameter|[?]|umol/L/sec|UNCHANGED|1|KALLIKREIN INHIBITOR UNIT|SMEAR|Y|Y|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|U|3|Visit_3|40|7|WASHOUT|2020-07-18|40
e|TR|c3984f41-30a0-49a4-a8bd-f36fad4621a8|4|[?]|LESSCIND|Lesion Success Indicator|[?]|mm/sec|FURTHER ENLARGEMENT FROM NADIR|1|vg/dose|MULTIPLE BREATH WASHOUT|Y||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|N|4|Visit_4|65|1|TREATMENT|2020-08-12|65
e|TR|c3984f41-30a0-49a4-a8bd-f36fad4621a8|5|[?]|PPD|Product of Perpendicular Diameters|[?]|IU/g Hb|TUMOR MERGED|1|AU/mL|TARGETED TRANSCRIPTOME SEQUENCING|||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2020-09-06|90
e|TR|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|1|[?]|VDIAM|Viable Diameter|[?]|10^3 DNA copies/mL|NON-PATHOLOGICAL|1|IU/g|NO INFORMATION||Y|SPOUSE|MICROSCOPIST 2|NA|1|Visit_1|10|3|TREATMENT|2021-01-21|10
e|TR|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|2|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|fmol/L/sec|PALPABLE|1|RING|JAEGER EYE CHART||Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|2|SCREENING|2021-02-05|25
e|TR|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|3|[?]|LESSCIND|Lesion Success Indicator|[?]|%(v/v)|NONPALPABLE|1|mmHg|NUCLEIC ACID BASED METHOD|||FAMILY MEMBER|NEUROLOGIST 2|Y|3|Visit_3|40|4|TREATMENT|2021-02-20|40
e|TR|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|4|[?]|PPD|Product of Perpendicular Diameters|[?]|10^3 RNA copies/mL|EQUIVOCAL|1|mm/sec|INDIA INK STAIN|||INTERVIEWER|MICROSCOPIST 2|Y|4|Visit_4|65|5|WASHOUT|2021-03-17|65
e|TR|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|5|[?]|BNLNUM|Number of Bone Lesions|[?]|U/cL|ENLARGEMENT FROM NADIR|1|ms/mmHg|TRIPLE-PHASE SPIRAL CT SCAN|Y|Y|SIBLING|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2021-04-11|90
e|TR|0f85b859-187d-4c6b-8873-33c0f18d3e3c|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|Absorbance U|UNCHANGED|1|s^-1(%O2)^-1|PET/CT SCAN WITHOUT CONTRAST|||GUARDIAN|OPHTHALMOLOGIST|NA|1|Visit_1|10|7|SCREENING|2020-07-24|10
e|TR|0f85b859-187d-4c6b-8873-33c0f18d3e3c|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|RING|NORMAL|1|U/m2/min|GRADIENT DIFFUSION|||CLINICAL STUDY SPONSOR|INTERNIST|NA|2|Visit_2|25|3|TREATMENT|2020-08-08|25
e|TR|0f85b859-187d-4c6b-8873-33c0f18d3e3c|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|pm|ABSENT|1|m/sec|MUGA|||DOMESTIC PARTNER|ADJUDICATOR 3|Y|3|Visit_3|40|7|SCREENING|2020-08-23|40
e|TR|0f85b859-187d-4c6b-8873-33c0f18d3e3c|4|[?]|NEWCONF|New Tumor Confirmed|[?]|g/dL|ENLARGEMENT|1|DISK|AMSLER GRID|||DOMESTIC PARTNER|RADIOLOGIST|N|4|Visit_4|65|5|TREATMENT|2020-09-17|65
e|TR|0f85b859-187d-4c6b-8873-33c0f18d3e3c|5|[?]|LNSTATE|Lymph Node State|[?]|mL/g/h|PALPABLE|1|tsp|ACCELERATOR MASS SPECTROMETRY|||SIBLING|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|1|SCREENING|2020-10-12|90
e|TR|5e383a9d-dc97-4352-8add-d55a1a566b9f|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|10^9/g|EQUIVOCAL|1|Log10 ELISA unit|IMMUNE REPERTOIRE DEEP SEQUENCING|||INVESTIGATOR|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-09-27|10
e|TR|5e383a9d-dc97-4352-8add-d55a1a566b9f|2|[?]|PALPSTAT|Palpable State|[?]|Ci/L|TUMOR MERGED|1|dB|PELLI-ROBSON EYE CHART|||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|U|2|Visit_2|25|3|SCREENING|2020-10-12|25
e|TR|5e383a9d-dc97-4352-8add-d55a1a566b9f|3|[?]|DIAMETER|Diameter|[?]|L/s|ENLARGEMENT FROM NADIR|1|pmol/dL|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|U|3|Visit_3|40|2|WASHOUT|2020-10-27|40
e|TR|5e383a9d-dc97-4352-8add-d55a1a566b9f|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|10^4/L|ABSENT|1|10^3/hpf|SIZE EXCLUSION CHROMATOGRAPHY|||DOMESTIC PARTNER|CARDIOLOGIST|U|4|Visit_4|65|2|SCREENING|2020-11-21|65
e|TR|5e383a9d-dc97-4352-8add-d55a1a566b9f|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|pmol/L|DECREASED|1|g/kg/day|MRI||Y|VENDOR|READER|Y|5|Visit_5|90|4|SCREENING|2020-12-16|90
e|TR|3eda746b-fb97-4950-a528-1d4ae5d3653a|1|[?]|LPERP|Longest Perpendicular|[?]|AFU|PATHOLOGICAL|1|kN/cm2|CLIP||Y|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|NA|1|Visit_1|10|3|TREATMENT|2020-06-13|10
e|TR|3eda746b-fb97-4950-a528-1d4ae5d3653a|2|[?]|BNLNUM|Number of Bone Lesions|[?]|Frames/s|PRESENT|1|ft|BETA LACTAMASE|||CLINICAL STUDY SPONSOR|PATHOLOGIST 2|NA|2|Visit_2|25|5|TREATMENT|2020-06-28|25
e|TR|3eda746b-fb97-4950-a528-1d4ae5d3653a|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|steps/min|PRESENT|1|Watt|SPECTROPHOTOMETRY|||INVESTIGATOR|FORENSIC PATHOLOGIST|N|3|Visit_3|40|1|FOLLOW-UP|2020-07-13|40
e|TR|3eda746b-fb97-4950-a528-1d4ae5d3653a|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|IU/dL|TUMOR MERGED|1|U/m2/day|QUANTITATIVE ULTRASOUND|Y|Y|INVESTIGATOR|RATER|NA|4|Visit_4|65|6|SCREENING|2020-08-07|65
e|TR|3eda746b-fb97-4950-a528-1d4ae5d3653a|5|[?]|VDIAM|Viable Diameter|[?]|10^9 organisms/g|NORMAL|1|g/g|ERGOSPIROMETRY|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|N|5|Visit_5|90|1|TREATMENT|2020-09-01|90
e|TR|a3b72841-3401-4dcc-9d06-75438b408d0b|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|log10 TCID 50/dose|ENLARGEMENT|1|IU/L|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||GUARDIAN|RADIOLOGIST 2|N|1|Visit_1|10|4|FOLLOW-UP|2020-11-05|10
e|TR|a3b72841-3401-4dcc-9d06-75438b408d0b|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|/h|ENLARGEMENT|1|mEq/g|AGAR PROPORTION|||SPOUSE|MICROSCOPIST|N|2|Visit_2|25|7|TREATMENT|2020-11-20|25
e|TR|a3b72841-3401-4dcc-9d06-75438b408d0b|3|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|mL/m2|PATHOLOGICAL|1|GLOBULE|GEL ELECTROPHORESIS|Y|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|3|Visit_3|40|4|SCREENING|2020-12-05|40
e|TR|a3b72841-3401-4dcc-9d06-75438b408d0b|4|[?]|PCHGBL|Percent Change From Baseline|[?]|copies/mL|DECREASED|1|U/m2/min|CINEANGIOGRAPHY|||DOMESTIC PARTNER|MICROSCOPIST 3|U|4|Visit_4|65|2|TREATMENT|2020-12-30|65
e|TR|a3b72841-3401-4dcc-9d06-75438b408d0b|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mol/mL|ENLARGEMENT FROM NADIR|1|nmol/kg/day|PEAK FLOWMETRY|||PARENT|ADJUDICATOR|U|5|Visit_5|90|1|TREATMENT|2021-01-24|90
e|TR|4393406e-bda5-42e4-a752-a8121004b7ef|1|[?]|BNLNUM|Number of Bone Lesions|[?]|TRACE|NORMAL|1|m/sec|PHASE-CONTRAST MRI||Y|ADJUDICATOR|OPTOMETRIST|U|1|Visit_1|10|1|FOLLOW-UP|2020-10-28|10
e|TR|4393406e-bda5-42e4-a752-a8121004b7ef|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|L/h/m2|TUMOR MERGED|1|mV2/Hz|SPECT/CT SCAN|||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|3|TREATMENT|2020-11-12|25
e|TR|4393406e-bda5-42e4-a752-a8121004b7ef|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|10^7 CFU/mL|PATHOLOGICAL|1|mg/kg/min|PHOTOMETRY|Y||PROXY|READER 2|Y|3|Visit_3|40|2|FOLLOW-UP|2020-11-27|40
e|TR|4393406e-bda5-42e4-a752-a8121004b7ef|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|ug/mol|NORMAL|1|mL/cage|AURAMINE STAIN|Y||INVESTIGATOR|ONCOLOGIST 1|U|4|Visit_4|65|1|FOLLOW-UP|2020-12-22|65
e|TR|4393406e-bda5-42e4-a752-a8121004b7ef|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|dpm/mL|TUMOR MERGED|1|kPa/L/sec|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|Y|INVESTIGATOR|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|5|TREATMENT|2021-01-16|90
e|TR|d70f5903-3d94-422b-8f69-212f015b54c9|1|[?]|SUMDIAM|Sum of Diameter|[?]|mU/L|NORMAL|1|cal|HIGH RESOLUTION CT|||ADJUDICATOR|MICROSCOPIST 1|Y|1|Visit_1|10|4|TREATMENT|2020-05-19|10
e|TR|d70f5903-3d94-422b-8f69-212f015b54c9|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|CCID 50/mL|INCREASED|1|pmol/L|CLINICAL EVALUATION|||PARENT|HEMATOLOGIST|Y|2|Visit_2|25|5|WASHOUT|2020-06-03|25
e|TR|d70f5903-3d94-422b-8f69-212f015b54c9|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|10^3/L|NORMAL|1|BLOCKS|CELLULAR PROLIFERATION ASSAY|Y||FRIEND|NEUROLOGIST 1|N|3|Visit_3|40|5|FOLLOW-UP|2020-06-18|40
e|TR|d70f5903-3d94-422b-8f69-212f015b54c9|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|APL U/mL|PRESENT|1|amp|HEMAGGLUTINATION INHIBITION ASSAY||Y|SPOUSE|RADIOLOGIST 2|N|4|Visit_4|65|1|WASHOUT|2020-07-13|65
e|TR|d70f5903-3d94-422b-8f69-212f015b54c9|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|Joule|ABSENT|1|tuberculin unit|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|6|TREATMENT|2020-08-07|90
e|TR|ef772266-faf1-4904-8ac3-19cbc3ea7d36|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|L/h|PATHOLOGICAL|1|mL/cm|BETA LACTAMASE||Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|U|1|Visit_1|10|3|TREATMENT|2021-01-06|10
e|TR|ef772266-faf1-4904-8ac3-19cbc3ea7d36|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|%/s|NONPALPABLE|1|/cmH2O|IN VITRO GENE EXPRESSION ASSAY||Y|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2021-01-21|25
e|TR|ef772266-faf1-4904-8ac3-19cbc3ea7d36|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|YEARS|NORMAL|1|KIT|JAEGER EYE CHART||Y|GUARDIAN|NEUROLOGIST|NA|3|Visit_3|40|3|TREATMENT|2021-02-05|40
e|TR|ef772266-faf1-4904-8ac3-19cbc3ea7d36|4|[?]|LESSCIND|Lesion Success Indicator|[?]|kg|INCREASED|1|U.CARR|ELECTROGASTROGRAPHY|||GUARDIAN|FORENSIC PATHOLOGIST|N|4|Visit_4|65|3|FOLLOW-UP|2021-03-02|65
e|TR|ef772266-faf1-4904-8ac3-19cbc3ea7d36|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|cpm|NONPALPABLE|1|10^7/L|ICP-MS|Y||CLINICAL RESEARCH ASSOCIATE|RATER 1|NA|5|Visit_5|90|6|FOLLOW-UP|2021-03-27|90
e|TR|c0f9c36c-1ae5-4f80-b936-0afe3f661746|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|IU/mmol|UNEQUIVOCAL|1|log10 CFU/g|MACRO BROTH DILUTION|Y||SPOUSE|MICROSCOPIST 3|NA|1|Visit_1|10|7|SCREENING|2020-07-14|10
e|TR|c0f9c36c-1ae5-4f80-b936-0afe3f661746|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|Absorbance U|FOCALLY INCREASED|1|SQU/mL|REBOUND TONOMETRY|||INDEPENDENT ASSESSOR|PATHOLOGIST 2|Y|2|Visit_2|25|7|TREATMENT|2020-07-29|25
e|TR|c0f9c36c-1ae5-4f80-b936-0afe3f661746|3|[?]|AREA|Area|[?]|Roentgen|PRESENT|1|10^10/L|MOUSE PROTECTION ASSAY|||INVESTIGATOR|RATER 2|Y|3|Visit_3|40|6|SCREENING|2020-08-13|40
e|TR|c0f9c36c-1ae5-4f80-b936-0afe3f661746|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|nmol|NON-PATHOLOGICAL|1|PIPE|LEAD CITRATE STAIN|||INTERVIEWER|PATHOLOGIST 2|U|4|Visit_4|65|1|TREATMENT|2020-09-07|65
e|TR|c0f9c36c-1ae5-4f80-b936-0afe3f661746|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|10^4 CFU/mL|NORMAL|1|DROP|PLETHYSMOGRAPHY|||ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|5|Visit_5|90|3|TREATMENT|2020-10-02|90
e|TR|f17b5630-e782-4135-8a50-4a9bb2fe63b1|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|EIA unit|FURTHER ENLARGEMENT FROM NADIR|1|10^10/L|TRANSTHORACIC ECHOCARDIOGRAPHY||Y|ADJUDICATOR|RATER|Y|1|Visit_1|10|4|TREATMENT|2020-11-29|10
e|TR|f17b5630-e782-4135-8a50-4a9bb2fe63b1|2|[?]|ORVERLN|Organ Vertical Length|[?]|mL/min/mmHg|NON-PATHOLOGICAL|1|pg/L|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||SPOUSE|CARDIOLOGIST|Y|2|Visit_2|25|3|WASHOUT|2020-12-14|25
e|TR|f17b5630-e782-4135-8a50-4a9bb2fe63b1|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|Enzyme U/g Hb|PATHOLOGICAL|1|PNU/mL|IN SITU HYBRIDIZATION|||FAMILY MEMBER|NEUROLOGIST|NA|3|Visit_3|40|4|FOLLOW-UP|2020-12-29|40
e|TR|f17b5630-e782-4135-8a50-4a9bb2fe63b1|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|EVENTS|NORMAL|1|mL/g/min|WESTERN BLOT|||ADJUDICATION COMMITTEE|RATER 1|Y|4|Visit_4|65|6|FOLLOW-UP|2021-01-23|65
e|TR|f17b5630-e782-4135-8a50-4a9bb2fe63b1|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|dram|ENLARGEMENT|1|TABLET|CLINICAL EVALUATION|||ADJUDICATOR|OPTOMETRIST|U|5|Visit_5|90|4|TREATMENT|2021-02-17|90
e|TR|8bdb40c9-1e44-45ae-bf08-81ea635fd762|1|[?]|BNLNUM|Number of Bone Lesions|[?]|CCID 50/dose|FURTHER ENLARGEMENT|1|deg/mm|CELLULOSE TAPE|||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|U|1|Visit_1|10|1|WASHOUT|2021-01-02|10
e|TR|8bdb40c9-1e44-45ae-bf08-81ea635fd762|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|tuberculin unit|ENLARGEMENT|1|mEq/ug|AMSLER GRID|Y||FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|4|FOLLOW-UP|2021-01-17|25
e|TR|8bdb40c9-1e44-45ae-bf08-81ea635fd762|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|uEq|FURTHER ENLARGEMENT|1|cd*s/m2|HPLC/MS/MS|Y||SIGNIFICANT OTHER|MICROSCOPIST 1|N|3|Visit_3|40|4|SCREENING|2021-02-01|40
e|TR|8bdb40c9-1e44-45ae-bf08-81ea635fd762|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mg/g/min|DIFFUSELY INCREASED|1|ohm|BETA LACTAMASE||Y|PARENT|NEUROLOGIST|N|4|Visit_4|65|4|WASHOUT|2021-02-26|65
e|TR|8bdb40c9-1e44-45ae-bf08-81ea635fd762|5|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|ukat/10^12 RBC|FURTHER ENLARGEMENT|1|HOMEOPATHIC DILUTION|LIGHT MICROSCOPY||Y|SIBLING|ADJUDICATOR 1|U|5|Visit_5|90|6|WASHOUT|2021-03-23|90
e|TR|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|10^6 CFU|NON-PATHOLOGICAL|1|L|IMPEDANCE CONDUCTIVITY|||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|Y|1|Visit_1|10|4|WASHOUT|2021-01-16|10
e|TR|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mg/animal|UNCHANGED|1|CCID 50/mL|NUCLEIC ACID HYBRIDIZATION|||PARENT|PHYSIOTHERAPIST|U|2|Visit_2|25|1|WASHOUT|2021-01-31|25
e|TR|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|3|[?]|SUMVOL|Sum of Volume|[?]|Bq/mg|INCREASED|1|scm|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y|Y|SIGNIFICANT OTHER|RATER 1|NA|3|Visit_3|40|4|SCREENING|2021-02-15|40
e|TR|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|GPL U|NONPALPABLE|1|Bq/mg|IVY INCISION METHOD|Y|Y|VENDOR|ADJUDICATOR 1|NA|4|Visit_4|65|5|SCREENING|2021-03-12|65
e|TR|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|mg/kg/dose|NORMAL|1|kUSP|MICROBIAL CULTURE, LIQUID|||PROXY|NEUROLOGIST 1|U|5|Visit_5|90|3|TREATMENT|2021-04-06|90
e|TR|296f8314-5a07-47b5-8796-31afe709b379|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|MPL U|FOCALLY INCREASED|1|Log10 ELISA unit|STATIC PERIMETRY|||PARENT|CARDIOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-07-08|10
e|TR|296f8314-5a07-47b5-8796-31afe709b379|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|USP U|TUMOR MERGED|1|10^6/hpf|PET/SPECT SCAN|||ADJUDICATOR|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|6|WASHOUT|2020-07-23|25
e|TR|296f8314-5a07-47b5-8796-31afe709b379|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|cm|NONPALPABLE|1|kN/cm2|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|DOMESTIC PARTNER|MICROSCOPIST|U|3|Visit_3|40|5|WASHOUT|2020-08-07|40
e|TR|296f8314-5a07-47b5-8796-31afe709b379|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|U|EQUIVOCAL|1|IU/L|NUCLEAR RADIOLOGY||Y|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|N|4|Visit_4|65|6|WASHOUT|2020-09-01|65
e|TR|296f8314-5a07-47b5-8796-31afe709b379|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|EVENTS|PATHOLOGICAL|1|Farad|PHASE CONTRAST MICROSCOPY|Y||SIGNIFICANT OTHER|MICROSCOPIST 2|U|5|Visit_5|90|6|FOLLOW-UP|2020-09-26|90
e|TR|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|DDU|FOCALLY INCREASED|1|mL/sec/1.73m2|FLUORESCENCE ANGIOGRAPHY||Y|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-12-13|10
e|TR|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|10^6 organisms/g|PRESENT|1|mg/day|RADIATION DOSIMETRY|||INTERVIEWER|ADJUDICATOR 1|N|2|Visit_2|25|7|FOLLOW-UP|2020-12-28|25
e|TR|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|uSiemens|UNCHANGED|1|MONTHS|MECHANICAL CLOT DETECTION|||INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|5|TREATMENT|2021-01-12|40
e|TR|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|APL U|PALPABLE|1|eq|IMPEDANCE CONDUCTIVITY||Y|INTERVIEWER|ADJUDICATOR 1|U|4|Visit_4|65|1|WASHOUT|2021-02-06|65
e|TR|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|fmol/L/sec|FOCALLY INCREASED|1|GBq|CONTRAST ENHANCED X-RAY|Y||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|5|Visit_5|90|4|WASHOUT|2021-03-03|90
e|TR|b06043ae-8251-4df8-ab6d-0ceb269c1a42|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|MPS U|FOCALLY INCREASED|1|DDU|TRANSCRIPTION-MEDIATED AMPLIFICATION|Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|1|Visit_1|10|5|WASHOUT|2021-01-25|10
e|TR|b06043ae-8251-4df8-ab6d-0ceb269c1a42|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|MHz|ENLARGEMENT|1|10^6 CFU|MYELOPEROXIDASE STAIN|Y||SIBLING|OTOLARYNGOLOGIST|NA|2|Visit_2|25|6|WASHOUT|2021-02-09|25
e|TR|b06043ae-8251-4df8-ab6d-0ceb269c1a42|3|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|Ejaculate U|FOCALLY INCREASED|1|days/month|LIGHT SCATTERING SPECTROSCOPY||Y|ADJUDICATOR|PATHOLOGIST 1|NA|3|Visit_3|40|1|SCREENING|2021-02-24|40
e|TR|b06043ae-8251-4df8-ab6d-0ceb269c1a42|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|10^6 IU/mL|PATHOLOGICAL|1|U/10^12 RBC|ELECTRONEUROGRAPHY|Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|4|Visit_4|65|7|TREATMENT|2021-03-21|65
e|TR|b06043ae-8251-4df8-ab6d-0ceb269c1a42|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|pptr|DIFFUSELY INCREASED|1|uCi/kg|CENTRIFUGATION|||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2021-04-15|90
e|TR|d4fb5b9e-e244-4818-be3d-dbb57faacd43|1|[?]|DIAMETER|Diameter|[?]|Arbitrary U|PALPABLE|1|ppm|WEBER GREEN STAIN|||PROXY|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|5|FOLLOW-UP|2020-11-07|10
e|TR|d4fb5b9e-e244-4818-be3d-dbb57faacd43|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|10^7 CFU/mL|PRESENT|1|10^6 CFU/mL|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||ADJUDICATION COMMITTEE|NEUROLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-11-22|25
e|TR|d4fb5b9e-e244-4818-be3d-dbb57faacd43|3|[?]|BNLNUM|Number of Bone Lesions|[?]|mV/sec|DIFFUSELY INCREASED|1|ug/L|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y|ADJUDICATOR|ADJUDICATOR 1|NA|3|Visit_3|40|4|SCREENING|2020-12-07|40
e|TR|d4fb5b9e-e244-4818-be3d-dbb57faacd43|4|[?]|ORSTATE|Organ State|[?]|ELISA unit|PALPABLE|1|DNA copies/mL|MICRONEUTRALIZATION ASSAY|||INDEPENDENT ASSESSOR|NEUROLOGIST 2|NA|4|Visit_4|65|7|TREATMENT|2021-01-01|65
e|TR|d4fb5b9e-e244-4818-be3d-dbb57faacd43|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|Ejaculate U|EQUIVOCAL|1|mL/cm3/min|SICKLE CELL SOLUBILITY TEST|Y||INTERVIEWER|MICROSCOPIST|U|5|Visit_5|90|7|TREATMENT|2021-01-26|90
e|TR|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|mol/L|EQUIVOCAL|1|SACHET|RADIAL IMMUNODIFFUSION|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|NA|1|Visit_1|10|7|WASHOUT|2020-07-13|10
e|TR|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|2|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|10^6 IU/mL|NORMAL|1|10^3 organisms/g|SLIT LAMP PHOTOGRAPHY|Y||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-07-28|25
e|TR|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mL/breath|NONPALPABLE|1|Enzyme U/L|IMPULSE OSCILLOMETRY|||ADJUDICATION COMMITTEE|HEMATOLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-08-12|40
e|TR|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|10^7 CFU/mL|TUMOR MERGED|1|kg/mol|DYNAMIC LIGHT SCATTERING|||INVESTIGATOR|PATHOLOGIST 2|Y|4|Visit_4|65|7|FOLLOW-UP|2020-09-06|65
e|TR|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|nmol/L/min|ENLARGEMENT|1|nkat|SPECT SCAN||Y|FAMILY MEMBER|OPHTHALMOLOGIST|NA|5|Visit_5|90|1|TREATMENT|2020-10-01|90
e|TR|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|U/kg/h|ABSENT|1|mEq/ug|SMEAR|||FAMILY MEMBER|READER 3|U|1|Visit_1|10|5|TREATMENT|2021-01-14|10
e|TR|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mL/breath|NORMAL|1|h*%|KLEIHAUER-BETKE|Y||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|2|Visit_2|25|3|FOLLOW-UP|2021-01-29|25
e|TR|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|3|[?]|ACHNAD|Absolute Change From Nadir|[?]|um/day|FURTHER ENLARGEMENT|1|POINT|BETA LACTAMASE|Y||FRIEND|DERMATOLOGIST|N|3|Visit_3|40|6|TREATMENT|2021-02-13|40
e|TR|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|4|[?]|SUMDIAM|Sum of Diameter|[?]|10^12 IU/L|PALPABLE|1|deg/s|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||GUARDIAN|PATHOLOGIST 2|Y|4|Visit_4|65|1|SCREENING|2021-03-10|65
e|TR|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|kg/cm|NON-PATHOLOGICAL|1|yd|MUGA|||PROXY|MICROSCOPIST 3|N|5|Visit_5|90|6|TREATMENT|2021-04-04|90
e|TR|b1215705-4c22-43bd-aa65-58bd8745f081|1|[?]|SUMDIAM|Sum of Diameter|[?]|%/min|INCREASED|1|Ci/mg|PHYSICAL EXAMINATION|||CLINICAL STUDY SPONSOR|READER 2|U|1|Visit_1|10|4|FOLLOW-UP|2020-07-15|10
e|TR|b1215705-4c22-43bd-aa65-58bd8745f081|2|[?]|VOLUME|Volume|[?]|yd|INCREASED|1|mg/cm2|AGAR DILUTION|||ADJUDICATOR|READER 1|NA|2|Visit_2|25|4|FOLLOW-UP|2020-07-30|25
e|TR|b1215705-4c22-43bd-aa65-58bd8745f081|3|[?]|LPERP|Longest Perpendicular|[?]|uV2|DIFFUSELY INCREASED|1|PACKAGE|DIFFUSION TENSOR MRI|Y||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|U|3|Visit_3|40|6|SCREENING|2020-08-14|40
e|TR|b1215705-4c22-43bd-aa65-58bd8745f081|4|[?]|PALPSTAT|Palpable State|[?]|10^4 CFU/mL|NONPALPABLE|1|g/g|HEMOCYTOMETRY|||STUDY SUBJECT|PATHOLOGIST|Y|4|Visit_4|65|4|TREATMENT|2020-09-08|65
e|TR|b1215705-4c22-43bd-aa65-58bd8745f081|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|gMFI|ABSENT|1|PFU|SPECT SCAN|Y||INTERVIEWER|OTOLARYNGOLOGIST|U|5|Visit_5|90|1|FOLLOW-UP|2020-10-03|90
e|TR|b99c6528-af4e-42f5-8d2d-18943b57d55a|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|keV|TUMOR MERGED|1|uV2|TOLUIDINE BLUE STAIN|Y|Y|CHILD|ADJUDICATOR 2|N|1|Visit_1|10|1|TREATMENT|2020-10-25|10
e|TR|b99c6528-af4e-42f5-8d2d-18943b57d55a|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|PNU/mL|PATHOLOGICAL|1|mMU/mL|TRYPAN BLUE STAIN|||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|6|SCREENING|2020-11-09|25
e|TR|b99c6528-af4e-42f5-8d2d-18943b57d55a|3|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|/4.0 mL|NORMAL|1|g/cage/day|NUCLEIC ACID SEQUENCING||Y|DOMESTIC PARTNER|NEUROLOGIST 2|N|3|Visit_3|40|7|TREATMENT|2020-11-24|40
e|TR|b99c6528-af4e-42f5-8d2d-18943b57d55a|4|[?]|PCHGBL|Percent Change From Baseline|[?]|mL*cmH2O|ABSENT|1|10^7 CFU|CLOT DETECTION||Y|STUDY SUBJECT|ONCOLOGIST 2|NA|4|Visit_4|65|6|TREATMENT|2020-12-19|65
e|TR|b99c6528-af4e-42f5-8d2d-18943b57d55a|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|deg|UNCHANGED|1|ug|IMMUNOCHEMILUMINOMETRIC ASSAY|||PROXY|READER 1|Y|5|Visit_5|90|2|TREATMENT|2021-01-13|90
e|TR|6848e438-51ca-4a7d-8f81-26c375969a64|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mg/cm2|DECREASED|1|steps/min|THERMAL IONIZATION MASS SPECTROMETRY||Y|STUDY SUBJECT|PATHOLOGIST 1|U|1|Visit_1|10|5|FOLLOW-UP|2020-11-12|10
e|TR|6848e438-51ca-4a7d-8f81-26c375969a64|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|GBq/mg|NON-PATHOLOGICAL|1|mL/mmHg/min/L|IMMUNORADIOMETRIC ASSAY|Y|Y|CAREGIVER|NEUROLOGIST 1|U|2|Visit_2|25|1|TREATMENT|2020-11-27|25
e|TR|6848e438-51ca-4a7d-8f81-26c375969a64|3|[?]|LNSTATE|Lymph Node State|[?]|log10 CFU/mL|ABSENT|1|Bq/ug|TOTAL BODY RADIOGRAPHY|Y||FRIEND|RATER 2|N|3|Visit_3|40|3|TREATMENT|2020-12-12|40
e|TR|6848e438-51ca-4a7d-8f81-26c375969a64|4|[?]|VOLUME|Volume|[?]|mg/kg/min|PALPABLE|1|Enzyme U/g Hb|POTENTIOMETRY|||HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|4|Visit_4|65|2|TREATMENT|2021-01-06|65
e|TR|6848e438-51ca-4a7d-8f81-26c375969a64|5|[?]|ORVERLN|Organ Vertical Length|[?]|DPM|PALPABLE|1|umol/mol|PERIPHERAL ANGIOGRAPHY|Y||FAMILY MEMBER|MICROSCOPIST 1|N|5|Visit_5|90|7|FOLLOW-UP|2021-01-31|90
e|TR|a6e11c33-7905-42d2-bda9-671d756d4c51|1|[?]|VDIAM|Viable Diameter|[?]|MET*min|EQUIVOCAL|1|/kg|SINGLE-SLICE SPIRAL CT|Y||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|U|1|Visit_1|10|6|SCREENING|2020-08-06|10
e|TR|a6e11c33-7905-42d2-bda9-671d756d4c51|2|[?]|AREA|Area|[?]|g/U|PALPABLE|1|mEq/mmol|LIGHT MICROSCOPY||Y|ADJUDICATOR|ONCOLOGIST 1|U|2|Visit_2|25|2|TREATMENT|2020-08-21|25
e|TR|a6e11c33-7905-42d2-bda9-671d756d4c51|3|[?]|VDIAM|Viable Diameter|[?]|mL/h|UNCHANGED|1|lm|OSCILLOMETRY|||ADJUDICATOR|OPHTHALMOLOGIST|Y|3|Visit_3|40|2|WASHOUT|2020-09-05|40
e|TR|a6e11c33-7905-42d2-bda9-671d756d4c51|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|nL|FURTHER ENLARGEMENT|1|SCOOPFUL|ATOMIC ABSORPTION SPECTROMETRY|||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-09-30|65
e|TR|a6e11c33-7905-42d2-bda9-671d756d4c51|5|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|EID 50/dose|ENLARGEMENT|1|cup eq|GC/MS|||FAMILY MEMBER|PHYSIOTHERAPIST|U|5|Visit_5|90|3|FOLLOW-UP|2020-10-25|90
e|TR|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|10^6 CFU/mL|PALPABLE|1|rpm|NEXT GENERATION TARGETED SEQUENCING||Y|ADJUDICATION COMMITTEE|UROLOGIST|U|1|Visit_1|10|2|WASHOUT|2020-11-12|10
e|TR|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|kg|FURTHER ENLARGEMENT FROM NADIR|1|mL/cm H2O|TONOMETRY||Y|PROXY|OPHTHALMOLOGIST|Y|2|Visit_2|25|3|SCREENING|2020-11-27|25
e|TR|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|MPL U|INCREASED|1|um2|INTRAVASCULAR ULTRASOUND|||ADJUDICATOR|NEUROLOGIST 1|Y|3|Visit_3|40|5|SCREENING|2020-12-12|40
e|TR|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|ng|ABSENT|1|L/s|ELECTRONEUROGRAPHY|||SPOUSE|ADJUDICATOR 3|N|4|Visit_4|65|2|FOLLOW-UP|2021-01-06|65
e|TR|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|5|[?]|LPERP|Longest Perpendicular|[?]|VIRTUAL PIXEL|INCREASED|1|h*%|ELECTROMYOGRAPHY|Y||PARENT|PHYSIOTHERAPIST|U|5|Visit_5|90|4|TREATMENT|2021-01-31|90
e|TR|8ef37b54-b463-43a4-879f-3ad653c4fef4|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|BAG|ENLARGEMENT|1|TABLET|ELASTOGRAPHY||Y|FAMILY MEMBER|ADJUDICATOR 1|NA|1|Visit_1|10|1|TREATMENT|2020-09-11|10
e|TR|8ef37b54-b463-43a4-879f-3ad653c4fef4|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|Torr|DECREASED|1|mkat|POLYGRAPHY|Y||SIGNIFICANT OTHER|MICROSCOPIST|Y|2|Visit_2|25|1|WASHOUT|2020-09-26|25
e|TR|8ef37b54-b463-43a4-879f-3ad653c4fef4|3|[?]|NEWCONF|New Tumor Confirmed|[?]|10^8/L|DIFFUSELY INCREASED|1|CAPSULE|NON-INVASIVE DIELECTRIC SENSING|Y||FRIEND|FORENSIC PATHOLOGIST|U|3|Visit_3|40|6|SCREENING|2020-10-11|40
e|TR|8ef37b54-b463-43a4-879f-3ad653c4fef4|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|log10 TCID 50/dose|NORMAL|1|Absorbance U/min|CELL BASED BIOASSAY|Y||FRIEND|OPHTHALMOLOGIST|U|4|Visit_4|65|1|TREATMENT|2020-11-05|65
e|TR|8ef37b54-b463-43a4-879f-3ad653c4fef4|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|DNA copies/mL|ABSENT|1|10^6 CFU|RYAN BLUE STAIN|||ADJUDICATION COMMITTEE|READER 3|Y|5|Visit_5|90|1|SCREENING|2020-11-30|90
e|TR|cf10035c-4d44-4512-810b-c267d1c8821b|1|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|min*mg/mL|DIFFUSELY INCREASED|1|IU/mg|MALDI|Y||VENDOR|ADJUDICATOR 1|N|1|Visit_1|10|6|SCREENING|2020-05-27|10
e|TR|cf10035c-4d44-4512-810b-c267d1c8821b|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|10^6 IU/mL|UNEQUIVOCAL|1|P|INFRARED SPECTROMETRY||Y|INTERVIEWER|ADJUDICATOR 3|U|2|Visit_2|25|6|SCREENING|2020-06-11|25
e|TR|cf10035c-4d44-4512-810b-c267d1c8821b|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|EID 50/mL|ENLARGEMENT FROM NADIR|1|pL|ANALYTICAL ULTRACENTRIFUGATION|Y||NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|3|Visit_3|40|2|WASHOUT|2020-06-26|40
e|TR|cf10035c-4d44-4512-810b-c267d1c8821b|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|10^7 PFU|FURTHER ENLARGEMENT|1|10^3 organisms/g|MAPH||Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|4|TREATMENT|2020-07-21|65
e|TR|cf10035c-4d44-4512-810b-c267d1c8821b|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|V/sec|PRESENT|1|U/cL|OLIGO ACGH|||CAREGIVER|ONCOLOGIST 1|Y|5|Visit_5|90|1|WASHOUT|2020-08-15|90
e|TR|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|1|[?]|AREA|Area|[?]|CAN|PATHOLOGICAL|1|fmol/L/sec|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||Y|SPOUSE|RADIOLOGIST 2|Y|1|Visit_1|10|1|WASHOUT|2020-08-01|10
e|TR|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|umol/h/mmol|UNCHANGED|1|mm/h|CONGO RED STAIN|||SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|1|FOLLOW-UP|2020-08-16|25
e|TR|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mmHg/sec|PATHOLOGICAL|1|JDF Unit|REFLECTANCE SPECTROSCOPY|||ADJUDICATOR|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-08-31|40
e|TR|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|ft|FOCALLY INCREASED|1|/sec|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y|SPOUSE|RATER 2|U|4|Visit_4|65|6|TREATMENT|2020-09-25|65
e|TR|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|OI50|NORMAL|1|kg/cm|SPIRAL CT SCAN WITHOUT CONTRAST|||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|5|Visit_5|90|2|TREATMENT|2020-10-20|90
e|TR|a1e0035a-3328-4966-8664-82e53a44eb59|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|V|FURTHER ENLARGEMENT|1|kIU|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||CHILD|ONCOLOGIST 2|N|1|Visit_1|10|7|TREATMENT|2020-08-10|10
e|TR|a1e0035a-3328-4966-8664-82e53a44eb59|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mL/animal/day|DECREASED|1|HEP|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y|FAMILY MEMBER|NEUROLOGIST 1|Y|2|Visit_2|25|2|WASHOUT|2020-08-25|25
e|TR|a1e0035a-3328-4966-8664-82e53a44eb59|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|ng|INCREASED|1|BAU|MICROBIAL CONCENTRATION|||SIBLING|NEUROLOGIST|U|3|Visit_3|40|4|FOLLOW-UP|2020-09-09|40
e|TR|a1e0035a-3328-4966-8664-82e53a44eb59|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|umol/mol|PRESENT|1|MESF|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|Y|4|Visit_4|65|6|FOLLOW-UP|2020-10-04|65
e|TR|a1e0035a-3328-4966-8664-82e53a44eb59|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|WAFER|FOCALLY INCREASED|1|GBq|MRI WITHOUT CONTRAST|Y|Y|INVESTIGATOR|PATHOLOGIST|NA|5|Visit_5|90|6|WASHOUT|2020-10-29|90
e|TR|771377fd-724f-4056-b2ea-84e1adab1f47|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|BOTTLE|DIFFUSELY INCREASED|1|EVENTS|ENZYMATIC ULTRACENTRIFUGATION|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|1|Visit_1|10|2|TREATMENT|2020-11-08|10
e|TR|771377fd-724f-4056-b2ea-84e1adab1f47|2|[?]|RADIODEN|Radiodensity|[?]|K|FOCALLY INCREASED|1|cycle/min|STRESS ECHOCARDIOGRAPHY|||FRIEND|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-11-23|25
e|TR|771377fd-724f-4056-b2ea-84e1adab1f47|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|ng/L|TUMOR MERGED|1|SFC/10^6 PBMC|SLOAN LETTER EYE CHART 2.5%|||PARENT|READER|U|3|Visit_3|40|7|TREATMENT|2020-12-08|40
e|TR|771377fd-724f-4056-b2ea-84e1adab1f47|4|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|U.CARR|PATHOLOGICAL|1|ug/m2|ENDPOINT DILUTION ASSAY|||CAREGIVER|RADIOLOGIST 1|N|4|Visit_4|65|6|FOLLOW-UP|2021-01-02|65
e|TR|771377fd-724f-4056-b2ea-84e1adab1f47|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|CIGAR|UNCHANGED|1|/10^3|CONTRAST ENHANCED SPIRAL CT SCAN|Y|Y|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|NA|5|Visit_5|90|7|SCREENING|2021-01-27|90
e|TR|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|1|[?]|ORVERLN|Organ Vertical Length|[?]|mL/g/h|TUMOR MERGED|1|cd/m2|COMPUTERIZED CORNEAL TOPOGRAPHY||Y|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|5|TREATMENT|2020-08-23|10
e|TR|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|2|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|U/animal|DECREASED|1|cm2|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||SPOUSE|RATER|NA|2|Visit_2|25|7|TREATMENT|2020-09-07|25
e|TR|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mL/s/m2|ENLARGEMENT FROM NADIR|1|Rad|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||CHILD|READER 1|Y|3|Visit_3|40|6|TREATMENT|2020-09-22|40
e|TR|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|PFU/animal|PALPABLE|1|mL/mmHg/min/L|KINETIC MICROPARTICLE IMMUNOASSAY|||CLINICAL STUDY SPONSOR|CARDIOLOGIST|U|4|Visit_4|65|4|TREATMENT|2020-10-17|65
e|TR|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|/cmH2O|FURTHER ENLARGEMENT FROM NADIR|1|DIP|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||INDEPENDENT ASSESSOR|ONCOLOGIST 1|Y|5|Visit_5|90|4|WASHOUT|2020-11-11|90
e|TR|3aea0861-8f67-4717-93ce-c1e322f151d9|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|EID 50/mL|EQUIVOCAL|1|10^7 CFU/mL|CLIP|Y||PROXY|OTOLARYNGOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-08-14|10
e|TR|3aea0861-8f67-4717-93ce-c1e322f151d9|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mg/kg/h|INCREASED|1|mg/L FEU|ELECTROMYOGRAPHY|Y|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 1|U|2|Visit_2|25|6|TREATMENT|2020-08-29|25
e|TR|3aea0861-8f67-4717-93ce-c1e322f151d9|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|U/mg|NORMAL|1|kBq|CLIP SEQUENCING|Y||VENDOR|ADJUDICATOR 1|U|3|Visit_3|40|6|WASHOUT|2020-09-13|40
e|TR|3aea0861-8f67-4717-93ce-c1e322f151d9|4|[?]|ORSTATE|Organ State|[?]|CAPLET|ABSENT|1|mL/cm H2O|PELLI-ROBSON EYE CHART||Y|ADJUDICATOR|NEUROLOGIST 2|U|4|Visit_4|65|6|TREATMENT|2020-10-08|65
e|TR|3aea0861-8f67-4717-93ce-c1e322f151d9|5|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|um/day|INCREASED|1|uL|MEDIASTINOSCOPY|||ADJUDICATOR|NEUROLOGIST 2|Y|5|Visit_5|90|3|WASHOUT|2020-11-02|90
e|TR|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|umol/min|NORMAL|1|Ci/kg|FLOCCULATION|||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|1|Visit_1|10|1|WASHOUT|2020-10-05|10
e|TR|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|2|[?]|VOLUME|Volume|[?]|mOsm/L|NONPALPABLE|1|10^9/dose|LEAD CITRATE STAIN|||CHILD|RATER 2|NA|2|Visit_2|25|7|FOLLOW-UP|2020-10-20|25
e|TR|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|3|[?]|VDIAM|Viable Diameter|[?]|mL/m2|EQUIVOCAL|1|DIOPTER|PAP STAIN|||ADJUDICATOR|ADJUDICATOR 2|Y|3|Visit_3|40|2|TREATMENT|2020-11-04|40
e|TR|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|4|[?]|AREA|Area|[?]|psec|PALPABLE|1|Gy/h|FISH|||HEALTH CARE PROFESSIONAL|READER|NA|4|Visit_4|65|6|SCREENING|2020-11-29|65
e|TR|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|ng/L|PRESENT|1|YEARS|MS/MS|||CAREGIVER|ENDOCRINOLOGIST|U|5|Visit_5|90|4|FOLLOW-UP|2020-12-24|90
e|TR|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|nsec|FOCALLY INCREASED|1|ug/mL/h|DOPPLER ULTRASOUND|Y||PROXY|DERMATOLOGIST|NA|1|Visit_1|10|3|WASHOUT|2020-12-30|10
e|TR|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|SBE/mL|ENLARGEMENT|1|TABLET|GC/MS/MS|||STUDY SUBJECT|PHYSIOTHERAPIST|N|2|Visit_2|25|2|SCREENING|2021-01-14|25
e|TR|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|3|[?]|TUMSTATE|Tumor State|[?]|U.CARR|PRESENT|1|ngEq/L|CALIPER MEASUREMENT METHOD|||STUDY SUBJECT|CARDIOLOGIST|Y|3|Visit_3|40|3|FOLLOW-UP|2021-01-29|40
e|TR|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|4|[?]|RADIODEN|Radiodensity|[?]|mL/g/min|TUMOR MERGED|1|cal|FLUORIMETRY|||STUDY SUBJECT|READER 2|N|4|Visit_4|65|3|WASHOUT|2021-02-23|65
e|TR|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|L/min/m2|NONPALPABLE|1|cmH2O/mL|POPULATION SEQUENCING|||INVESTIGATOR|RADIOLOGIST|U|5|Visit_5|90|1|TREATMENT|2021-03-20|90
e|TR|39f51bd8-5edc-4434-92d4-7d8b683a6c32|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|10^3 DNA copies/mL|NONPALPABLE|1|pg/cell|DIFFUSION TENSOR MRI|Y||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|1|Visit_1|10|3|WASHOUT|2020-09-19|10
e|TR|39f51bd8-5edc-4434-92d4-7d8b683a6c32|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|mL/kg/h|NONPALPABLE|1|VIRTUAL PIXEL|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||FAMILY MEMBER|NEUROLOGIST 1|Y|2|Visit_2|25|7|TREATMENT|2020-10-04|25
e|TR|39f51bd8-5edc-4434-92d4-7d8b683a6c32|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|/200 HPFs|EQUIVOCAL|1|1/(s*kPa)|ENDOSCOPY|||SIGNIFICANT OTHER|RADIOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-10-19|40
e|TR|39f51bd8-5edc-4434-92d4-7d8b683a6c32|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|ms/mmHg|NON-PATHOLOGICAL|1|POINT|TRICHROME STAIN|Y||PROXY|UROLOGIST|NA|4|Visit_4|65|2|TREATMENT|2020-11-13|65
e|TR|39f51bd8-5edc-4434-92d4-7d8b683a6c32|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|pt_us|TUMOR MERGED|1|KALLIKREIN INHIBITOR UNIT|FLUORIMETRY|||SIGNIFICANT OTHER|ONCOLOGIST 2|U|5|Visit_5|90|4|FOLLOW-UP|2020-12-08|90
e|TR|80565a22-8cec-46a2-abd7-91daf0767035|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|L/s|NORMAL|1|pmol/L|IRON HEMATOXYLIN STAIN||Y|PARENT|UROLOGIST|NA|1|Visit_1|10|7|TREATMENT|2021-01-28|10
e|TR|80565a22-8cec-46a2-abd7-91daf0767035|2|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|10^9 organisms/mL|NONPALPABLE|1|uV|IMMUNOASSAY||Y|VENDOR|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2021-02-12|25
e|TR|80565a22-8cec-46a2-abd7-91daf0767035|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mL/100g/min|FOCALLY INCREASED|1|PACK|CENTRIFUGATION|Y||INTERVIEWER|PATHOLOGIST|U|3|Visit_3|40|4|TREATMENT|2021-02-27|40
e|TR|80565a22-8cec-46a2-abd7-91daf0767035|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|s/h|DIFFUSELY INCREASED|1|ug/m2/day|FUNDUS PHOTOGRAPHY|||SPOUSE|HEMATOLOGIST|Y|4|Visit_4|65|4|WASHOUT|2021-03-24|65
e|TR|80565a22-8cec-46a2-abd7-91daf0767035|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|ug/animal|FURTHER ENLARGEMENT FROM NADIR|1|Mile|TEMPLATE INCISION METHOD|||ADJUDICATION COMMITTEE|HEMATOLOGIST|N|5|Visit_5|90|1|WASHOUT|2021-04-18|90
e|TR|585a254e-c36b-44cf-b8a9-335fb98e0fd2|1|[?]|ACHNAD|Absolute Change From Nadir|[?]|ELISA unit/dose|NONPALPABLE|1|min/day|HIGH RESOLUTION MELT ANALYSIS|||FRIEND|ONCOLOGIST 1|N|1|Visit_1|10|3|TREATMENT|2020-10-19|10
e|TR|585a254e-c36b-44cf-b8a9-335fb98e0fd2|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mU/L|UNEQUIVOCAL|1|10^8 PFU|ORCHIDOMETERY|Y||GUARDIAN|CARDIOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-11-03|25
e|TR|585a254e-c36b-44cf-b8a9-335fb98e0fd2|3|[?]|ORVERLN|Organ Vertical Length|[?]|/month|DIFFUSELY INCREASED|1|h*%|IVY INCISION METHOD|Y|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|U|3|Visit_3|40|2|WASHOUT|2020-11-18|40
e|TR|585a254e-c36b-44cf-b8a9-335fb98e0fd2|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|PFU|NON-PATHOLOGICAL|1|mEq|EIA|Y||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-12-13|65
e|TR|585a254e-c36b-44cf-b8a9-335fb98e0fd2|5|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mL*cmH2O|ENLARGEMENT FROM NADIR|1|ug/dL|STRESS ECHOCARDIOGRAPHY|||GUARDIAN|RATER 2|N|5|Visit_5|90|4|TREATMENT|2021-01-07|90
e|TR|9ee3632d-4e99-4a46-b0b9-237467d97ca0|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|uL|DECREASED|1|titer|TRANSVAGINAL ULTRASOUND||Y|INTERVIEWER|FORENSIC PATHOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-09-09|10
e|TR|9ee3632d-4e99-4a46-b0b9-237467d97ca0|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|10^10/L|EQUIVOCAL|1|V|DOUBLE IMMUNODIFFUSION|||INTERVIEWER|ONCOLOGIST 1|N|2|Visit_2|25|6|WASHOUT|2020-09-24|25
e|TR|9ee3632d-4e99-4a46-b0b9-237467d97ca0|3|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|nkat/g Hb|PATHOLOGICAL|1|DIOPTER|CONTACT SPECULAR MICROSCOPY|Y||SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|5|TREATMENT|2020-10-09|40
e|TR|9ee3632d-4e99-4a46-b0b9-237467d97ca0|4|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|RATIO|FOCALLY INCREASED|1|IU/g|LASER CAPTURE MICRODISSECTION|||HEALTH CARE PROFESSIONAL|RATER 1|Y|4|Visit_4|65|7|FOLLOW-UP|2020-11-03|65
e|TR|9ee3632d-4e99-4a46-b0b9-237467d97ca0|5|[?]|PPD|Product of Perpendicular Diameters|[?]|min/day|FURTHER ENLARGEMENT|1|Hz/s|ANALYTICAL ULTRACENTRIFUGATION|||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|5|Visit_5|90|7|TREATMENT|2020-11-28|90
e|TR|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|nmol BCE/mmol|DIFFUSELY INCREASED|1|V/sec|MRS|||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-06-16|10
e|TR|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|kPa|NONPALPABLE|1|copies/mL|LIQUID SCINTILLATION COUNTING||Y|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-07-01|25
e|TR|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|3|[?]|SUMDIAM|Sum of Diameter|[?]|Coulomb|FURTHER ENLARGEMENT|1|mEq/mmol|ENDOSCOPY|||PARENT|ONCOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-07-16|40
e|TR|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|pptr|ABSENT|1|ms2|TARGETED TRANSCRIPTOME SEQUENCING||Y|ADJUDICATION COMMITTEE|OPTOMETRIST|U|4|Visit_4|65|5|SCREENING|2020-08-10|65
e|TR|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|cm H2O|UNCHANGED|1|MdFI|MICROSCOPY|||SIGNIFICANT OTHER|ONCOLOGIST 2|NA|5|Visit_5|90|7|FOLLOW-UP|2020-09-04|90
e|TR|34b2090b-13ac-4fb2-8d87-eca2839a62f2|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|/cmH2O|UNCHANGED|1|mg/min|SMEAR|||SPOUSE|ONCOLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-06-07|10
e|TR|34b2090b-13ac-4fb2-8d87-eca2839a62f2|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|GBq/mg|DIFFUSELY INCREASED|1|pmol/day|GRADIENT DIFFUSION|||STUDY SUBJECT|READER 2|U|2|Visit_2|25|7|TREATMENT|2020-06-22|25
e|TR|34b2090b-13ac-4fb2-8d87-eca2839a62f2|3|[?]|PPD|Product of Perpendicular Diameters|[?]|ng/mol|ABSENT|1|g/cm2|PEAK FLOWMETRY|||SPOUSE|RATER 1|NA|3|Visit_3|40|5|TREATMENT|2020-07-07|40
e|TR|34b2090b-13ac-4fb2-8d87-eca2839a62f2|4|[?]|LNSTATE|Lymph Node State|[?]|mMU/mL|UNEQUIVOCAL|1|U/cL|STRESS ECHOCARDIOGRAPHY|Y||FAMILY MEMBER|RADIOLOGIST 2|NA|4|Visit_4|65|6|TREATMENT|2020-08-01|65
e|TR|34b2090b-13ac-4fb2-8d87-eca2839a62f2|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|grain|PALPABLE|1|mL/day|ZIEHL NEELSEN ACID FAST STAIN|||ADJUDICATOR|INTERNIST|NA|5|Visit_5|90|2|FOLLOW-UP|2020-08-26|90
e|TR|bfc19b4b-51bb-4056-9195-8bd2db53a497|1|[?]|DIAMETER|Diameter|[?]|LENS|EQUIVOCAL|1|/10^5|PET/MRI SCAN|Y||SIGNIFICANT OTHER|MICROSCOPIST 2|U|1|Visit_1|10|4|SCREENING|2020-07-26|10
e|TR|bfc19b4b-51bb-4056-9195-8bd2db53a497|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mCi/kg|ABSENT|1|mCi/kg|MIGET|||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|2|Visit_2|25|3|TREATMENT|2020-08-10|25
e|TR|bfc19b4b-51bb-4056-9195-8bd2db53a497|3|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|mg/kg|UNEQUIVOCAL|1|Gy/min|CT SCAN WITHOUT CONTRAST|||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-08-25|40
e|TR|bfc19b4b-51bb-4056-9195-8bd2db53a497|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|mg/animal|ENLARGEMENT|1|pkat|DIFFUSION WEIGHTED MRI|||FRIEND|RADIOLOGIST|Y|4|Visit_4|65|6|FOLLOW-UP|2020-09-19|65
e|TR|bfc19b4b-51bb-4056-9195-8bd2db53a497|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|ug/mL/h|DIFFUSELY INCREASED|1|IU/L|PET/MRI SCAN|||HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|5|Visit_5|90|4|SCREENING|2020-10-14|90
e|TR|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|1|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|fmol/g|UNEQUIVOCAL|1|tuberculin unit/mL|RADIOGRAPHY|||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|1|Visit_1|10|7|TREATMENT|2020-09-21|10
e|TR|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|Tesla|PALPABLE|1|ng/day|ERGOSPIROMETRY|||INVESTIGATOR|ONCOLOGIST 2|N|2|Visit_2|25|1|FOLLOW-UP|2020-10-06|25
e|TR|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|g/m2|FOCALLY INCREASED|1|Frames/s|NUCLEIC ACID SEQUENCING||Y|PARENT|DERMATOLOGIST|Y|3|Visit_3|40|1|WASHOUT|2020-10-21|40
e|TR|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|4|[?]|AREA|Area|[?]|ECL unit|UNEQUIVOCAL|1|hr/day|MRS|Y||DOMESTIC PARTNER|PHYSIOTHERAPIST|U|4|Visit_4|65|4|TREATMENT|2020-11-15|65
e|TR|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|ppm|ABSENT|1|HEP|ELECTRICAL IMPEDANCE MYOGRAPHY|Y||CHILD|ONCOLOGIST 2|NA|5|Visit_5|90|7|WASHOUT|2020-12-10|90
e|TR|64a70103-14bf-42f4-808b-fbdecec8bd4f|1|[?]|VDIAM|Viable Diameter|[?]|ug/L|NORMAL|1|ug/L FEU|SLIT LAMP|||STUDY SUBJECT|NEUROLOGIST 2|NA|1|Visit_1|10|3|TREATMENT|2020-09-09|10
e|TR|64a70103-14bf-42f4-808b-fbdecec8bd4f|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|STRIP|DIFFUSELY INCREASED|1|pmol/L|IMMUNORADIOMETRIC ASSAY|||ADJUDICATOR|UROLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-09-24|25
e|TR|64a70103-14bf-42f4-808b-fbdecec8bd4f|3|[?]|VDIAM|Viable Diameter|[?]|BP|NORMAL|1|ug/m2/h|PET/CT SCAN WITHOUT CONTRAST||Y|GUARDIAN|OPTOMETRIST|NA|3|Visit_3|40|6|TREATMENT|2020-10-09|40
e|TR|64a70103-14bf-42f4-808b-fbdecec8bd4f|4|[?]|DIAMETER|Diameter|[?]|nmol BCE/L|PRESENT|1|10^7 PFU|DUCTOGRAPHY|||GUARDIAN|FORENSIC PATHOLOGIST|NA|4|Visit_4|65|4|SCREENING|2020-11-03|65
e|TR|64a70103-14bf-42f4-808b-fbdecec8bd4f|5|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|KALLIKREIN INHIBITOR UNIT|FURTHER ENLARGEMENT|1|mmHg/L/min|MICROBIAL CONCENTRATION||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|NA|5|Visit_5|90|6|FOLLOW-UP|2020-11-28|90
e|TR|00f3949b-b14a-47c5-942c-2ab71e03e40f|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|DPM|DIFFUSELY INCREASED|1|pmol/10^10 cells|X-RAY|||INTERVIEWER|READER 2|NA|1|Visit_1|10|4|TREATMENT|2021-01-19|10
e|TR|00f3949b-b14a-47c5-942c-2ab71e03e40f|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|ng/L|FOCALLY INCREASED|1|EU|MRI|Y||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|6|SCREENING|2021-02-03|25
e|TR|00f3949b-b14a-47c5-942c-2ab71e03e40f|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|nmol/L/h|NONPALPABLE|1|PUFF|PELLI-ROBSON EYE CHART|Y|Y|INDEPENDENT ASSESSOR|READER 3|Y|3|Visit_3|40|4|SCREENING|2021-02-18|40
e|TR|00f3949b-b14a-47c5-942c-2ab71e03e40f|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|LOZENGE|FOCALLY INCREASED|1|mJoule/cm2|SLIT LAMP PHOTOGRAPHY||Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|2|FOLLOW-UP|2021-03-15|65
e|TR|00f3949b-b14a-47c5-942c-2ab71e03e40f|5|[?]|ORVERLN|Organ Vertical Length|[?]|BLOCKS|NORMAL|1|foz_us|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|5|Visit_5|90|6|FOLLOW-UP|2021-04-09|90
e|TR|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|C|INCREASED|1|nmol/g|OPHTHALMOSCOPY|Y|Y|FRIEND|OTOLARYNGOLOGIST|U|1|Visit_1|10|6|WASHOUT|2020-12-27|10
e|TR|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mL/breath|NORMAL|1|g/kg|GC/MS-CI|||PARENT|ADJUDICATOR 3|U|2|Visit_2|25|6|WASHOUT|2021-01-11|25
e|TR|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|USP U|NON-PATHOLOGICAL|1|GBq/g|SEQUENCING|||SIBLING|RATER 1|NA|3|Visit_3|40|2|FOLLOW-UP|2021-01-26|40
e|TR|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|HOURS|FURTHER ENLARGEMENT FROM NADIR|1|POINT|MICRONEUTRALIZATION ASSAY||Y|SIGNIFICANT OTHER|RATER 1|Y|4|Visit_4|65|5|WASHOUT|2021-02-20|65
e|TR|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|5|[?]|LESSCIND|Lesion Success Indicator|[?]|mg/kg/week|TUMOR MERGED|1|anti-Xa IU|FLOCCULATION|||FRIEND|OTOLARYNGOLOGIST|U|5|Visit_5|90|2|TREATMENT|2021-03-17|90
e|TR|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|1|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|mg/kg/min|DECREASED|1|g/animal/wk|MICROBIAL CULTURE, LIQUID|||FAMILY MEMBER|ONCOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-07-19|10
e|TR|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|2|[?]|LPERP|Longest Perpendicular|[?]|Frames/s|TUMOR MERGED|1|Newton|DIGITAL PCR ARRAY||Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|NA|2|Visit_2|25|7|WASHOUT|2020-08-03|25
e|TR|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mL/cage/day|FOCALLY INCREASED|1|Farad|WHOLE EXOME SEQUENCING|||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|1|TREATMENT|2020-08-18|40
e|TR|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|umol/mol|ENLARGEMENT|1|cm/s|TOTAL BODY IRRADIATION|Y||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|4|Visit_4|65|7|TREATMENT|2020-09-12|65
e|TR|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|ug/animal|NORMAL|1|nmol/g|TELLER ACUITY CARDS||Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|N|5|Visit_5|90|2|TREATMENT|2020-10-07|90
e|TR|44ca1fe6-76d2-4a94-9854-1ddbde638803|1|[?]|DIAMETER|Diameter|[?]|dL|FOCALLY INCREASED|1|10^6 organisms/mL|JAEGER EYE CHART|||PARENT|PATHOLOGIST|U|1|Visit_1|10|2|WASHOUT|2020-07-19|10
e|TR|44ca1fe6-76d2-4a94-9854-1ddbde638803|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mL/cm H2O|INCREASED|1|PACKAGE|PERIPHERAL ANGIOGRAPHY||Y|INVESTIGATOR|MICROSCOPIST 3|N|2|Visit_2|25|1|TREATMENT|2020-08-03|25
e|TR|44ca1fe6-76d2-4a94-9854-1ddbde638803|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|HOMEOPATHIC DILUTION|ENLARGEMENT|1|g/animal/wk|RAJI CELL EIA|||CHILD|MICROSCOPIST 1|NA|3|Visit_3|40|1|TREATMENT|2020-08-18|40
e|TR|44ca1fe6-76d2-4a94-9854-1ddbde638803|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|cup eq|NONPALPABLE|1|OD Unit|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||Y|PROXY|READER 1|N|4|Visit_4|65|3|WASHOUT|2020-09-12|65
e|TR|44ca1fe6-76d2-4a94-9854-1ddbde638803|5|[?]|VOLUME|Volume|[?]|mU/g|FURTHER ENLARGEMENT FROM NADIR|1|km/h|FLUORESCENT SPOT TEST||Y|INVESTIGATOR|RADIOLOGIST|N|5|Visit_5|90|6|TREATMENT|2020-10-07|90
e|TR|edc935ed-3b94-43fa-9b7f-facf6eb6780e|1|[?]|PCHGBL|Percent Change From Baseline|[?]|MPS U|TUMOR MERGED|1|Newton|IMMUNOCHEMILUMINOMETRIC ASSAY||Y|FAMILY MEMBER|DERMATOLOGIST|NA|1|Visit_1|10|7|FOLLOW-UP|2020-12-04|10
e|TR|edc935ed-3b94-43fa-9b7f-facf6eb6780e|2|[?]|RADIODEN|Radiodensity|[?]|BAG|ENLARGEMENT|1|Ci/uL|CLIP|||GUARDIAN|HEMATOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-12-19|25
e|TR|edc935ed-3b94-43fa-9b7f-facf6eb6780e|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|fraction of 1|UNCHANGED|1|ug/g/h|CYSTOSCOPY|||PARENT|ADJUDICATOR 1|U|3|Visit_3|40|1|WASHOUT|2021-01-03|40
e|TR|edc935ed-3b94-43fa-9b7f-facf6eb6780e|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mg/dL|PALPABLE|1|mgEq|CLINICAL EVALUATION||Y|INVESTIGATOR|READER|NA|4|Visit_4|65|5|SCREENING|2021-01-28|65
e|TR|edc935ed-3b94-43fa-9b7f-facf6eb6780e|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|TABLET|INCREASED|1|in|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|N|5|Visit_5|90|1|WASHOUT|2021-02-22|90
e|TR|f997ad2a-e9b1-4341-96d5-caef4bcb7196|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|mL/kg/h|EQUIVOCAL|1|APPLICATION|CONTRAST ENHANCED X-RAY||Y|FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|7|SCREENING|2020-06-08|10
e|TR|f997ad2a-e9b1-4341-96d5-caef4bcb7196|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|nmol/mL/min|PALPABLE|1|uV*sec|GEL ELECTROPHORESIS|||STUDY SUBJECT|OPHTHALMOLOGIST|N|2|Visit_2|25|5|TREATMENT|2020-06-23|25
e|TR|f997ad2a-e9b1-4341-96d5-caef4bcb7196|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|bel|DECREASED|1|fmol/g|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|U|3|Visit_3|40|3|SCREENING|2020-07-08|40
e|TR|f997ad2a-e9b1-4341-96d5-caef4bcb7196|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|/10^4|UNEQUIVOCAL|1|APPLICATION|MAPH|||CAREGIVER|RADIOLOGIST 1|N|4|Visit_4|65|3|TREATMENT|2020-08-02|65
e|TR|f997ad2a-e9b1-4341-96d5-caef4bcb7196|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|MBq/uL|ENLARGEMENT FROM NADIR|1|fL|INDIRECT IMMUNOFLUORESCENCE|||ADJUDICATION COMMITTEE|READER 1|NA|5|Visit_5|90|1|WASHOUT|2020-08-27|90
e|TR|5a56874f-10e4-4cd0-842f-19552a04d1bd|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|steps/min|FOCALLY INCREASED|1|nmol/L/min|KNEMOMETRY|Y|Y|INTERVIEWER|RATER 2|Y|1|Visit_1|10|6|TREATMENT|2020-06-20|10
e|TR|5a56874f-10e4-4cd0-842f-19552a04d1bd|2|[?]|LNSTATE|Lymph Node State|[?]|mL/g/h|NON-PATHOLOGICAL|1|Ci/uL|MICRONEUTRALIZATION ASSAY|||NON-HEALTH CARE PROFESSIONAL|RATER|U|2|Visit_2|25|2|FOLLOW-UP|2020-07-05|25
e|TR|5a56874f-10e4-4cd0-842f-19552a04d1bd|3|[?]|VDIAM|Viable Diameter|[?]|MPS U|FURTHER ENLARGEMENT FROM NADIR|1|nmol BCE/mmol|MICROBIAL CULTURE, LIQUID|Y||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2020-07-20|40
e|TR|5a56874f-10e4-4cd0-842f-19552a04d1bd|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|ug/dL|PALPABLE|1|mol/mL|IMMUNE REPERTOIRE DEEP SEQUENCING|||CLINICAL RESEARCH ASSOCIATE|READER 1|U|4|Visit_4|65|3|TREATMENT|2020-08-14|65
e|TR|5a56874f-10e4-4cd0-842f-19552a04d1bd|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|CONTAINER|UNEQUIVOCAL|1|/100 HPFs|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||INTERVIEWER|ADJUDICATOR 2|NA|5|Visit_5|90|3|WASHOUT|2020-09-08|90
e|TR|f1d4ebe5-fc72-447b-8872-67e971ff471b|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|CARTRIDGE|FOCALLY INCREASED|1|mL/animal/day|CONFOCAL MICROSCOPY|||VENDOR|MICROSCOPIST|U|1|Visit_1|10|5|TREATMENT|2020-11-08|10
e|TR|f1d4ebe5-fc72-447b-8872-67e971ff471b|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|SBE/mL|NONPALPABLE|1|EID 50/dose|FLOCCULATION||Y|CHILD|HEMATOLOGIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-11-23|25
e|TR|f1d4ebe5-fc72-447b-8872-67e971ff471b|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mL/animal|ENLARGEMENT|1|BU|RADIOGRAPHY||Y|VENDOR|NEUROLOGIST 2|N|3|Visit_3|40|6|SCREENING|2020-12-08|40
e|TR|f1d4ebe5-fc72-447b-8872-67e971ff471b|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mL/g/h|DECREASED|1|vp/mL|NUCLEAR RADIOLOGY|||FAMILY MEMBER|INTERNIST|NA|4|Visit_4|65|6|TREATMENT|2021-01-02|65
e|TR|f1d4ebe5-fc72-447b-8872-67e971ff471b|5|[?]|LNSTATE|Lymph Node State|[?]|m/sec|NORMAL|1|BOLUS|MULTI-SLICE SPIRAL CT|||FRIEND|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2021-01-27|90
e|TR|2a141b73-e336-4701-9067-8d51d532596b|1|[?]|ORSTATE|Organ State|[?]|CYLINDER|UNEQUIVOCAL|1|kBq|IMMUNOFLUORESCENT STAIN|||VENDOR|UROLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-06-12|10
e|TR|2a141b73-e336-4701-9067-8d51d532596b|2|[?]|LDIAM|Longest Diameter|[?]|v/v|NONPALPABLE|1|amol|ALCIAN BLUE STAIN|||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|5|FOLLOW-UP|2020-06-27|25
e|TR|2a141b73-e336-4701-9067-8d51d532596b|3|[?]|LNSTATE|Lymph Node State|[?]|/7.5 mL|ABSENT|1|BEAM BREAKS|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||ADJUDICATION COMMITTEE|READER 1|NA|3|Visit_3|40|4|WASHOUT|2020-07-12|40
e|TR|2a141b73-e336-4701-9067-8d51d532596b|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|Rad|ABSENT|1|TRANSDUCING UNIT|MAPH|||HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|4|Visit_4|65|4|WASHOUT|2020-08-06|65
e|TR|2a141b73-e336-4701-9067-8d51d532596b|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|DISK|NON-PATHOLOGICAL|1|g/kg|CLAUSS METHOD||Y|ADJUDICATOR|CARDIOLOGIST|N|5|Visit_5|90|2|FOLLOW-UP|2020-08-31|90
e|TR|4adf9a2c-3c43-4289-8156-1a109791580c|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|kat|DIFFUSELY INCREASED|1|mL/g/h|IVY INCISION METHOD||Y|GUARDIAN|OPHTHALMOLOGIST|U|1|Visit_1|10|2|WASHOUT|2020-11-22|10
e|TR|4adf9a2c-3c43-4289-8156-1a109791580c|2|[?]|CALCFIND|Calcification Indicator|[?]|Linear ft*LB|EQUIVOCAL|1|/wk|TARGETED TRANSCRIPTOME SEQUENCING||Y|DOMESTIC PARTNER|UROLOGIST|U|2|Visit_2|25|4|WASHOUT|2020-12-07|25
e|TR|4adf9a2c-3c43-4289-8156-1a109791580c|3|[?]|AREA|Area|[?]|Log10 ELISA unit/dose|ENLARGEMENT|1|mg/g/h|SMEAR|||FRIEND|OTOLARYNGOLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-12-22|40
e|TR|4adf9a2c-3c43-4289-8156-1a109791580c|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|DNA copies/mL|EQUIVOCAL|1|Enzyme U/L|X-RAY|||SIGNIFICANT OTHER|READER 2|U|4|Visit_4|65|6|FOLLOW-UP|2021-01-16|65
e|TR|4adf9a2c-3c43-4289-8156-1a109791580c|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|PIXEL|UNCHANGED|1|uEq|ANTIBIOTIC AGAR SCREEN|||CHILD|READER 1|NA|5|Visit_5|90|1|TREATMENT|2021-02-10|90
e|TR|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|cd/m2|ABSENT|1|mL/100g/min|SPIRAL CT|||STUDY SUBJECT|OTOLARYNGOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-05-23|10
e|TR|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mJoule/cm2|DECREASED|1|log EID 50/dose|TRYPAN BLUE STAIN|||NON-HEALTH CARE PROFESSIONAL|INTERNIST|Y|2|Visit_2|25|2|WASHOUT|2020-06-07|25
e|TR|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|RFU|ABSENT|1|mL/mmHg/min/L|MASS SPECTROMETRY|||INDEPENDENT ASSESSOR|PATHOLOGIST 1|NA|3|Visit_3|40|4|TREATMENT|2020-06-22|40
e|TR|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|4|[?]|SUMVOL|Sum of Volume|[?]|BE/mL|NONPALPABLE|1|/40 HPFs|MICROSCOPY|||SIBLING|MICROSCOPIST|U|4|Visit_4|65|4|WASHOUT|2020-07-17|65
e|TR|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|5|[?]|PALPSTAT|Palpable State|[?]|mgEq|FURTHER ENLARGEMENT|1|nmol/L/min|INCISION-INDUCED BLEEDING METHOD|||VENDOR|RADIOLOGIST 1|Y|5|Visit_5|90|2|TREATMENT|2020-08-11|90
e|TR|1b2eda86-2d2c-4fdc-a88e-409ea5180603|1|[?]|AREA|Area|[?]|ug/g/day|DIFFUSELY INCREASED|1|g/cm2|COULOMETRIC TITRATION|Y||DOMESTIC PARTNER|MICROSCOPIST 3|U|1|Visit_1|10|6|TREATMENT|2020-05-19|10
e|TR|1b2eda86-2d2c-4fdc-a88e-409ea5180603|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|Ci|TUMOR MERGED|1|10^5/hpf|FLUOROSCOPY|||STUDY SUBJECT|PATHOLOGIST 2|N|2|Visit_2|25|5|FOLLOW-UP|2020-06-03|25
e|TR|1b2eda86-2d2c-4fdc-a88e-409ea5180603|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|ug/animal|ENLARGEMENT FROM NADIR|1|cm/min|HEMOCYTOMETRY|Y||FAMILY MEMBER|RADIOLOGIST 1|NA|3|Visit_3|40|7|TREATMENT|2020-06-18|40
e|TR|1b2eda86-2d2c-4fdc-a88e-409ea5180603|4|[?]|RADIODEN|Radiodensity|[?]|m|FOCALLY INCREASED|1|kUSP|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||Y|ADJUDICATION COMMITTEE|PATHOLOGIST 2|N|4|Visit_4|65|4|TREATMENT|2020-07-13|65
e|TR|1b2eda86-2d2c-4fdc-a88e-409ea5180603|5|[?]|PALPSTAT|Palpable State|[?]|CAN|UNEQUIVOCAL|1|TROCHE|FLUORESCENT MICROSCOPY|||GUARDIAN|DERMATOLOGIST|N|5|Visit_5|90|7|TREATMENT|2020-08-07|90
e|TR|fc02184a-dfba-4964-be3a-cfa5f5d7200e|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|g|PRESENT|1|nmol/L/h|LC-FL|||SIGNIFICANT OTHER|PATHOLOGIST|NA|1|Visit_1|10|4|WASHOUT|2020-05-26|10
e|TR|fc02184a-dfba-4964-be3a-cfa5f5d7200e|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|ELISA unit/mL|FURTHER ENLARGEMENT FROM NADIR|1|V/sec|TOTAL BODY RADIOGRAPHY|Y||CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|U|2|Visit_2|25|5|WASHOUT|2020-06-10|25
e|TR|fc02184a-dfba-4964-be3a-cfa5f5d7200e|3|[?]|LPERP|Longest Perpendicular|[?]|gMFI|EQUIVOCAL|1|ms2|MALDI-TOF|||VENDOR|ADJUDICATOR 2|NA|3|Visit_3|40|1|SCREENING|2020-06-25|40
e|TR|fc02184a-dfba-4964-be3a-cfa5f5d7200e|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|/4.0 mL|EQUIVOCAL|1|ft|NUCLEAR RADIOLOGY|||GUARDIAN|OPHTHALMOLOGIST|U|4|Visit_4|65|3|WASHOUT|2020-07-20|65
e|TR|fc02184a-dfba-4964-be3a-cfa5f5d7200e|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|VIRTUAL PIXEL|DECREASED|1|Rad|MICROBIAL CULTURE, LIQUID|Y||SIGNIFICANT OTHER|PATHOLOGIST 2|N|5|Visit_5|90|7|SCREENING|2020-08-14|90
e|TR|37c59cfa-b952-4d16-a675-5e3b3a2e0288|1|[?]|AREA|Area|[?]|APPLICATION|PATHOLOGICAL|1|SFC/10^6 PBMC|FLUORESCENT MICROSCOPY|||STUDY SUBJECT|OTOLARYNGOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-05-29|10
e|TR|37c59cfa-b952-4d16-a675-5e3b3a2e0288|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|POINT|ABSENT|1|10^6 DNA copies/mL|CISH|||VENDOR|MICROSCOPIST|N|2|Visit_2|25|7|SCREENING|2020-06-13|25
e|TR|37c59cfa-b952-4d16-a675-5e3b3a2e0288|3|[?]|SUMDIAM|Sum of Diameter|[?]|POUCH|UNEQUIVOCAL|1|TRANSDUCING UNIT/mL|AGAR PROPORTION|||SIGNIFICANT OTHER|READER 3|N|3|Visit_3|40|2|FOLLOW-UP|2020-06-28|40
e|TR|37c59cfa-b952-4d16-a675-5e3b3a2e0288|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|amu|UNCHANGED|1|GBq/mg|SPECT/CT SCAN|Y||PROXY|OPHTHALMOLOGIST|Y|4|Visit_4|65|2|TREATMENT|2020-07-23|65
e|TR|37c59cfa-b952-4d16-a675-5e3b3a2e0288|5|[?]|VOLUME|Volume|[?]|DNA copies/mL|TUMOR MERGED|1|hPa|AGAR PROPORTION||Y|VENDOR|READER 3|Y|5|Visit_5|90|3|FOLLOW-UP|2020-08-17|90
e|TR|11130b2c-e9fd-4a50-87ee-5dfa19199eba|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|RFU|FOCALLY INCREASED|1|/month|ANTIMICROBIAL COMBINATION TESTING|||PROXY|READER 3|U|1|Visit_1|10|2|FOLLOW-UP|2020-12-03|10
e|TR|11130b2c-e9fd-4a50-87ee-5dfa19199eba|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|um2|PALPABLE|1|mL/cage/wk|IVY INCISION METHOD||Y|INTERVIEWER|MICROSCOPIST 3|U|2|Visit_2|25|6|SCREENING|2020-12-18|25
e|TR|11130b2c-e9fd-4a50-87ee-5dfa19199eba|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|cmol/L|NON-PATHOLOGICAL|1|ug/g/h|WHOLE EXOME SEQUENCING||Y|VENDOR|PATHOLOGIST 1|N|3|Visit_3|40|7|SCREENING|2021-01-02|40
e|TR|11130b2c-e9fd-4a50-87ee-5dfa19199eba|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|m/sec|PATHOLOGICAL|1|SYRINGE|DIFFUSION WEIGHTED MRI|||ADJUDICATOR|RATER 1|Y|4|Visit_4|65|1|TREATMENT|2021-01-27|65
e|TR|11130b2c-e9fd-4a50-87ee-5dfa19199eba|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|pt_br|UNEQUIVOCAL|1|ug/cm2|ATOMIC ABSORPTION SPECTROMETRY|||PROXY|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|7|TREATMENT|2021-02-21|90
e|TR|08e4310f-f868-4858-a321-f33a21a771e8|1|[?]|PCHGBL|Percent Change From Baseline|[?]|Linear ft*LB|TUMOR MERGED|1|Enzyme U|NUCLEAR RADIOLOGY||Y|INTERVIEWER|RADIOLOGIST 2|N|1|Visit_1|10|7|TREATMENT|2020-05-15|10
e|TR|08e4310f-f868-4858-a321-f33a21a771e8|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|LB|PATHOLOGICAL|1|beats/min|EPSILOMETER|||FAMILY MEMBER|PHYSIOTHERAPIST|U|2|Visit_2|25|1|TREATMENT|2020-05-30|25
e|TR|08e4310f-f868-4858-a321-f33a21a771e8|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|10^6 organisms/mL|TUMOR MERGED|1|CIGARETTE|HEMAGGLUTINATION ASSAY|||CAREGIVER|RATER 1|N|3|Visit_3|40|2|SCREENING|2020-06-14|40
e|TR|08e4310f-f868-4858-a321-f33a21a771e8|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|cs|ENLARGEMENT FROM NADIR|1|BU|PALM METHOD||Y|PARENT|ENDOCRINOLOGIST|NA|4|Visit_4|65|6|SCREENING|2020-07-09|65
e|TR|08e4310f-f868-4858-a321-f33a21a771e8|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|/4.0 mL|NORMAL|1|bel|AGAR DILUTION|||FRIEND|MICROSCOPIST|U|5|Visit_5|90|1|TREATMENT|2020-08-03|90
e|TR|29edf133-8b5b-46d5-bf7a-f75af4658417|1|[?]|VOLUME|Volume|[?]|gtt|INCREASED|1|Ci/uL|GC/MS|Y||SPOUSE|PATHOLOGIST 2|U|1|Visit_1|10|3|TREATMENT|2020-08-22|10
e|TR|29edf133-8b5b-46d5-bf7a-f75af4658417|2|[?]|LESSCIND|Lesion Success Indicator|[?]|Farad|FURTHER ENLARGEMENT|1|grain|ELASTOGRAPHY|Y||CLINICAL RESEARCH ASSOCIATE|UROLOGIST|Y|2|Visit_2|25|2|WASHOUT|2020-09-06|25
e|TR|29edf133-8b5b-46d5-bf7a-f75af4658417|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|dpm/mL|DIFFUSELY INCREASED|1|fmol/L|TOLUIDINE BLUE STAIN||Y|INTERVIEWER|RADIOLOGIST 1|NA|3|Visit_3|40|7|TREATMENT|2020-09-21|40
e|TR|29edf133-8b5b-46d5-bf7a-f75af4658417|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|MPL U|NON-PATHOLOGICAL|1|/10^5|LIQUID SCINTILLATION COUNTING|||ADJUDICATOR|PHYSIOTHERAPIST|Y|4|Visit_4|65|5|TREATMENT|2020-10-16|65
e|TR|29edf133-8b5b-46d5-bf7a-f75af4658417|5|[?]|TUMSTATE|Tumor State|[?]|Log10 ELISA unit/dose|NORMAL|1|mg/m2/min|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||GUARDIAN|ONCOLOGIST 1|U|5|Visit_5|90|5|WASHOUT|2020-11-10|90
e|TR|49756233-e18f-4187-8d48-3b6b4fa7e5c2|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|SFC/10^6 PBMC|NORMAL|1|mm/2h|PERIPHERAL ANGIOGRAPHY|||CAREGIVER|ADJUDICATOR 1|U|1|Visit_1|10|1|FOLLOW-UP|2020-08-09|10
e|TR|49756233-e18f-4187-8d48-3b6b4fa7e5c2|2|[?]|LNSTATE|Lymph Node State|[?]|pt_us|EQUIVOCAL|1|Weber|CLINICAL EVALUATION|||ADJUDICATOR|PHYSIOTHERAPIST|Y|2|Visit_2|25|2|WASHOUT|2020-08-24|25
e|TR|49756233-e18f-4187-8d48-3b6b4fa7e5c2|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|s*kPa|EQUIVOCAL|1|%(w/w)|LC/MS/MS|Y|Y|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|4|TREATMENT|2020-09-08|40
e|TR|49756233-e18f-4187-8d48-3b6b4fa7e5c2|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|BAG|NORMAL|1|HOURS|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||CHILD|DERMATOLOGIST|Y|4|Visit_4|65|2|WASHOUT|2020-10-03|65
e|TR|49756233-e18f-4187-8d48-3b6b4fa7e5c2|5|[?]|DIAMETER|Diameter|[?]|KIT|ENLARGEMENT FROM NADIR|1|SACHET|TWO-COLOR MICROARRAY|||GUARDIAN|READER 3|N|5|Visit_5|90|4|TREATMENT|2020-10-28|90
e|TR|7a046104-7215-4708-9d85-66683ceb8fe8|1|[?]|NEWCONF|New Tumor Confirmed|[?]|10^6/hpf|TUMOR MERGED|1|mL/min|KINYOUN STAIN|||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|5|SCREENING|2020-10-16|10
e|TR|7a046104-7215-4708-9d85-66683ceb8fe8|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|EID 50/dose|DECREASED|1|amu|PET/CT SCAN WITHOUT CONTRAST|Y||GUARDIAN|MICROSCOPIST 1|Y|2|Visit_2|25|3|TREATMENT|2020-10-31|25
e|TR|7a046104-7215-4708-9d85-66683ceb8fe8|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|pkat|ABSENT|1|ukat/10^12 RBC|RADIOIMMUNOPRECIPITATION ASSAY|Y||ADJUDICATOR|RADIOLOGIST 1|U|3|Visit_3|40|2|TREATMENT|2020-11-15|40
e|TR|7a046104-7215-4708-9d85-66683ceb8fe8|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|/5x10^4 WBC|UNCHANGED|1|L/h|TEST STRIP|||SPOUSE|PHYSIOTHERAPIST|U|4|Visit_4|65|7|TREATMENT|2020-12-10|65
e|TR|7a046104-7215-4708-9d85-66683ceb8fe8|5|[?]|LESSCIND|Lesion Success Indicator|[?]|kIU|ENLARGEMENT|1|amol|LC/MS/MS|Y||CLINICAL STUDY SPONSOR|RATER 1|N|5|Visit_5|90|7|WASHOUT|2021-01-04|90
e|TR|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|Anson U|DIFFUSELY INCREASED|1|mg/cm2|RADIOGRAPHY|||CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|U|1|Visit_1|10|2|TREATMENT|2021-01-26|10
e|TR|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|/VF|INCREASED|1|10^6 IU|DIFFUSION TENSOR MRI|||STUDY SUBJECT|PHYSIOTHERAPIST|NA|2|Visit_2|25|6|TREATMENT|2021-02-10|25
e|TR|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|pmol|DIFFUSELY INCREASED|1|10^4 CFU/mL|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|STUDY SUBJECT|READER 3|NA|3|Visit_3|40|5|TREATMENT|2021-02-25|40
e|TR|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|STRIP|DIFFUSELY INCREASED|1|PACKAGE|APPLANATION TONOMETRY|||PARENT|NEUROLOGIST|U|4|Visit_4|65|3|TREATMENT|2021-03-22|65
e|TR|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|5|[?]|RADIODEN|Radiodensity|[?]|Enzyme U/g Hb|EQUIVOCAL|1|nmol BCE/L|OPTICAL MAPPING|Y||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|5|Visit_5|90|5|SCREENING|2021-04-16|90
e|TR|bcbe7d50-2ebe-483a-9d71-dce4094f864e|1|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|CFU/g|NON-PATHOLOGICAL|1|U/mmol|AURAMINE STAIN||Y|PROXY|RADIOLOGIST 1|Y|1|Visit_1|10|5|FOLLOW-UP|2020-05-25|10
e|TR|bcbe7d50-2ebe-483a-9d71-dce4094f864e|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mg/dL|INCREASED|1|mL/cage/wk|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||ADJUDICATION COMMITTEE|MICROSCOPIST 2|NA|2|Visit_2|25|4|TREATMENT|2020-06-09|25
e|TR|bcbe7d50-2ebe-483a-9d71-dce4094f864e|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mg/kg/week|FURTHER ENLARGEMENT FROM NADIR|1|10^4 CFU|RAJI CELL EIA||Y|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-06-24|40
e|TR|bcbe7d50-2ebe-483a-9d71-dce4094f864e|4|[?]|BNLNUM|Number of Bone Lesions|[?]|cP|UNCHANGED|1|pmol/10^9 cells|INDIA INK STAIN|||SIBLING|CARDIOLOGIST|Y|4|Visit_4|65|4|TREATMENT|2020-07-19|65
e|TR|bcbe7d50-2ebe-483a-9d71-dce4094f864e|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|IU/mL|INCREASED|1|IU/mmol|NUCLEIC ACID BASED METHOD|Y||INDEPENDENT ASSESSOR|ADJUDICATOR 2|U|5|Visit_5|90|6|TREATMENT|2020-08-13|90
e|TR|2550ba24-7bcf-41e2-9eae-536e13d4b345|1|[?]|LNSTATE|Lymph Node State|[?]|ug/animal|TUMOR MERGED|1|%(w/w)|THICK SMEAR|Y|Y|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|3|FOLLOW-UP|2021-01-20|10
e|TR|2550ba24-7bcf-41e2-9eae-536e13d4b345|2|[?]|PCHGBL|Percent Change From Baseline|[?]|copies/uL|DECREASED|1|genEq/mL|AMSLER GRID|||STUDY SUBJECT|MICROSCOPIST 1|NA|2|Visit_2|25|3|TREATMENT|2021-02-04|25
e|TR|2550ba24-7bcf-41e2-9eae-536e13d4b345|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mL/animal/day|PATHOLOGICAL|1|ug/kg/h|MACRO BROTH DILUTION|||CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|N|3|Visit_3|40|7|TREATMENT|2021-02-19|40
e|TR|2550ba24-7bcf-41e2-9eae-536e13d4b345|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|ukat/10^12 RBC|PATHOLOGICAL|1|APS U|TARGETED GENOME SEQUENCING|||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|6|WASHOUT|2021-03-16|65
e|TR|2550ba24-7bcf-41e2-9eae-536e13d4b345|5|[?]|PPD|Product of Perpendicular Diameters|[?]|10^3/L|ENLARGEMENT FROM NADIR|1|U/mmol|TELLER ACUITY CARDS|||STUDY SUBJECT|OPHTHALMOLOGIST|N|5|Visit_5|90|2|TREATMENT|2021-04-10|90
e|TR|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|Ci/kg|DECREASED|1|nmol/g|AMSLER GRID||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|1|Visit_1|10|5|TREATMENT|2020-08-14|10
e|TR|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|2|[?]|RADIODEN|Radiodensity|[?]|um/s|FURTHER ENLARGEMENT FROM NADIR|1|umol/dL|CALIPER MEASUREMENT METHOD|Y||ADJUDICATION COMMITTEE|MICROSCOPIST 3|NA|2|Visit_2|25|4|TREATMENT|2020-08-29|25
e|TR|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|3|[?]|CALCFIND|Calcification Indicator|[?]|mmHg/sec|ENLARGEMENT FROM NADIR|1|10^6 copies/mL|SPECT SCAN|||INTERVIEWER|READER 2|Y|3|Visit_3|40|2|TREATMENT|2020-09-13|40
e|TR|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|IU/day|INCREASED|1|nm|JAEGER EYE CHART||Y|INTERVIEWER|ADJUDICATOR 1|U|4|Visit_4|65|7|SCREENING|2020-10-08|65
e|TR|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|deg/mm|NORMAL|1|mEq/uL|CLIP|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|Y|5|Visit_5|90|2|TREATMENT|2020-11-02|90
e|TR|6ec23671-252e-4dc9-b919-88254fce68a5|1|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|Antibody Unit|FOCALLY INCREASED|1|nmol|DIRECT SEQUENCING|Y||PROXY|RADIOLOGIST 2|U|1|Visit_1|10|3|SCREENING|2020-07-28|10
e|TR|6ec23671-252e-4dc9-b919-88254fce68a5|2|[?]|DIAMETER|Diameter|[?]|AgU/mL|PRESENT|1|PFU|OPTICAL COHERENCE TOMOGRAPHY|Y||SIBLING|ADJUDICATOR 1|U|2|Visit_2|25|3|TREATMENT|2020-08-12|25
e|TR|6ec23671-252e-4dc9-b919-88254fce68a5|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mL/g/h|FURTHER ENLARGEMENT|1|ug/m2/min|AGAR PROPORTION|Y||STUDY SUBJECT|RADIOLOGIST 1|N|3|Visit_3|40|5|FOLLOW-UP|2020-08-27|40
e|TR|6ec23671-252e-4dc9-b919-88254fce68a5|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|pmol|INCREASED|1|deg/mm|ELECTROCHEMILUMINESCENCE||Y|CAREGIVER|RADIOLOGIST 2|N|4|Visit_4|65|1|TREATMENT|2020-09-21|65
e|TR|6ec23671-252e-4dc9-b919-88254fce68a5|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|PACKET|PRESENT|1|mEq|COMPLEMENT FIXATION|Y||INTERVIEWER|RADIOLOGIST 2|Y|5|Visit_5|90|3|WASHOUT|2020-10-16|90
e|TR|db59e5e1-ccda-480b-8955-da5157e16c4a|1|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|kN/cm2|EQUIVOCAL|1|beats/min|ELECTROMYOGRAPHY|||FRIEND|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|2|FOLLOW-UP|2020-05-14|10
e|TR|db59e5e1-ccda-480b-8955-da5157e16c4a|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|uOsm|FOCALLY INCREASED|1|mL/(min*100mL)|X-RAY|Y||CHILD|PATHOLOGIST 1|NA|2|Visit_2|25|1|TREATMENT|2020-05-29|25
e|TR|db59e5e1-ccda-480b-8955-da5157e16c4a|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mCi|PALPABLE|1|h/wk|TARGETED GENOME SEQUENCING|Y||ADJUDICATOR|PHYSIOTHERAPIST|U|3|Visit_3|40|4|TREATMENT|2020-06-13|40
e|TR|db59e5e1-ccda-480b-8955-da5157e16c4a|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|pg/L|UNCHANGED|1|L/h/m2|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||PARENT|ADJUDICATOR 3|U|4|Visit_4|65|6|FOLLOW-UP|2020-07-08|65
e|TR|db59e5e1-ccda-480b-8955-da5157e16c4a|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|mmHg*min/L|PRESENT|1|IU|ICC|||PROXY|MICROSCOPIST 2|U|5|Visit_5|90|2|TREATMENT|2020-08-02|90
e|TR|1dce856e-b7cb-4899-b27f-87ab8d918df4|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|CFU/mL|NORMAL|1|cd*s/m2|NON-CONTACT SPECULAR MICROSCOPY|||CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|3|FOLLOW-UP|2020-09-12|10
e|TR|1dce856e-b7cb-4899-b27f-87ab8d918df4|2|[?]|LESSCIND|Lesion Success Indicator|[?]|SYRINGE|UNEQUIVOCAL|1|nmol/mL/min|WESTERN BLOT|Y|Y|PROXY|RADIOLOGIST 2|U|2|Visit_2|25|1|TREATMENT|2020-09-27|25
e|TR|1dce856e-b7cb-4899-b27f-87ab8d918df4|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|pmol/L|PATHOLOGICAL|1|mg/dL|WRIGHT-GIEMSA STAIN|Y||STUDY SUBJECT|READER|NA|3|Visit_3|40|4|SCREENING|2020-10-12|40
e|TR|1dce856e-b7cb-4899-b27f-87ab8d918df4|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|beats/min|INCREASED|1|mL/m2/h|SPIRAL CT|||DOMESTIC PARTNER|INTERNIST|Y|4|Visit_4|65|3|TREATMENT|2020-11-06|65
e|TR|1dce856e-b7cb-4899-b27f-87ab8d918df4|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|ug/kg/day|DECREASED|1|pt_br|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||SPOUSE|RADIOLOGIST 2|NA|5|Visit_5|90|5|WASHOUT|2020-12-01|90
e|TR|7449180b-e226-4e97-a059-8760f6523f77|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|km/h|PATHOLOGICAL|1|pkat|FLUORESCENT ENZYME IMMUNOASSAY|||INTERVIEWER|READER 3|N|1|Visit_1|10|1|SCREENING|2020-07-04|10
e|TR|7449180b-e226-4e97-a059-8760f6523f77|2|[?]|NEWCONF|New Tumor Confirmed|[?]|10^6/g|ENLARGEMENT FROM NADIR|1|uV*sec|WRIGHT STAIN|||VENDOR|ENDOCRINOLOGIST|N|2|Visit_2|25|2|TREATMENT|2020-07-19|25
e|TR|7449180b-e226-4e97-a059-8760f6523f77|3|[?]|ACHNAD|Absolute Change From Nadir|[?]|pmol/L/h|ENLARGEMENT FROM NADIR|1|g/m2|COMPLEMENT FIXATION||Y|INVESTIGATOR|READER|U|3|Visit_3|40|2|TREATMENT|2020-08-03|40
e|TR|7449180b-e226-4e97-a059-8760f6523f77|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|ug/L/h|FOCALLY INCREASED|1|VOXEL|FLOW MICROSCOPY|||CLINICAL RESEARCH ASSOCIATE|RATER 1|Y|4|Visit_4|65|4|FOLLOW-UP|2020-08-28|65
e|TR|7449180b-e226-4e97-a059-8760f6523f77|5|[?]|LPERP|Longest Perpendicular|[?]|gMFI|ENLARGEMENT|1|v/v|PH METER MEASUREMENT METHOD|Y|Y|DOMESTIC PARTNER|OPHTHALMOLOGIST|Y|5|Visit_5|90|5|FOLLOW-UP|2020-09-22|90
e|TR|f077c497-b0f0-4a20-b448-608b0cc6ab36|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|10^6 U|PATHOLOGICAL|1|cup eq|FLUORESCENCE ANGIOGRAPHY|||ADJUDICATOR|READER 3|NA|1|Visit_1|10|2|TREATMENT|2020-06-08|10
e|TR|f077c497-b0f0-4a20-b448-608b0cc6ab36|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mAnson U/mL|NONPALPABLE|1|psi|CALCOFLUOR WHITE STAIN|||CLINICAL RESEARCH ASSOCIATE|UROLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-06-23|25
e|TR|f077c497-b0f0-4a20-b448-608b0cc6ab36|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|genEq/mL|ENLARGEMENT|1|cm/s|NUCLEIC ACID AMPLIFICATION TEST||Y|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-07-08|40
e|TR|f077c497-b0f0-4a20-b448-608b0cc6ab36|4|[?]|PPD|Product of Perpendicular Diameters|[?]|rpm|NORMAL|1|STRIP|FLAME PHOTOMETRY||Y|INTERVIEWER|NEUROLOGIST 2|NA|4|Visit_4|65|2|TREATMENT|2020-08-02|65
e|TR|f077c497-b0f0-4a20-b448-608b0cc6ab36|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|uEq|FOCALLY INCREASED|1|PA|WESTERN BLOT|||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|U|5|Visit_5|90|4|WASHOUT|2020-08-27|90
e|TR|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|cL|EQUIVOCAL|1|kIU|RAJI CELL EIA|Y|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|U|1|Visit_1|10|3|WASHOUT|2020-06-12|10
e|TR|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|2|[?]|ACHNAD|Absolute Change From Nadir|[?]|PATCH|TUMOR MERGED|1|mV*min|SNP ARRAY|||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|2|Visit_2|25|3|TREATMENT|2020-06-27|25
e|TR|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|3|[?]|LNSTATE|Lymph Node State|[?]|TAMPON|PATHOLOGICAL|1|cycle/min|CARDIAC THERMODILUTION|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|Y|3|Visit_3|40|4|TREATMENT|2020-07-12|40
e|TR|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mg/dose|TUMOR MERGED|1|ng|FLOW CYTOMETRY|||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|4|Visit_4|65|7|FOLLOW-UP|2020-08-06|65
e|TR|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|nsec|FOCALLY INCREASED|1|10^3 DNA copies/mL|RADIAL IMMUNODIFFUSION||Y|PROXY|PHYSIOTHERAPIST|U|5|Visit_5|90|1|TREATMENT|2020-08-31|90
e|TR|3f7c46ac-fe30-4ef3-a581-99c064a85efa|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|Torr|NORMAL|1|anti-Xa IU/mL|POTENTIOMETRY|||CAREGIVER|UROLOGIST|NA|1|Visit_1|10|4|TREATMENT|2021-01-11|10
e|TR|3f7c46ac-fe30-4ef3-a581-99c064a85efa|2|[?]|PCHGBL|Percent Change From Baseline|[?]|10^4/L|FOCALLY INCREASED|1|IU/mL|ANTIBIOTIC AGAR SCREEN|||INTERVIEWER|READER 2|N|2|Visit_2|25|7|WASHOUT|2021-01-26|25
e|TR|3f7c46ac-fe30-4ef3-a581-99c064a85efa|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|mg/min|FURTHER ENLARGEMENT|1|hPa|KINETIC CHROMOGENIC ASSAY|||CHILD|RADIOLOGIST 1|N|3|Visit_3|40|5|TREATMENT|2021-02-10|40
e|TR|3f7c46ac-fe30-4ef3-a581-99c064a85efa|4|[?]|LESSCIND|Lesion Success Indicator|[?]|hr/day|NON-PATHOLOGICAL|1|MET*min|IMMUNO-PET SCAN|||INDEPENDENT ASSESSOR|RADIOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2021-03-07|65
e|TR|3f7c46ac-fe30-4ef3-a581-99c064a85efa|5|[?]|VDIAM|Viable Diameter|[?]|Ci/mg|PRESENT|1|ppb|NUCLEIC ACID HYBRIDIZATION|||CHILD|NEUROLOGIST 2|Y|5|Visit_5|90|3|FOLLOW-UP|2021-04-01|90
e|TR|8d944400-df75-4ec7-8fb4-239eb0f6de9d|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|SBE/mL|NON-PATHOLOGICAL|1|deg/mm|FLUORESCENT IMMUNOASSAY|||VENDOR|PATHOLOGIST 2|N|1|Visit_1|10|6|WASHOUT|2020-09-22|10
e|TR|8d944400-df75-4ec7-8fb4-239eb0f6de9d|2|[?]|BNLNUM|Number of Bone Lesions|[?]|/10^3|INCREASED|1|SYRINGE|NUCLEIC ACID HYBRIDIZATION|||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|U|2|Visit_2|25|6|TREATMENT|2020-10-07|25
e|TR|8d944400-df75-4ec7-8fb4-239eb0f6de9d|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mgEq|NON-PATHOLOGICAL|1|U/m2/h|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|6|TREATMENT|2020-10-22|40
e|TR|8d944400-df75-4ec7-8fb4-239eb0f6de9d|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mg/kg/min|ENLARGEMENT|1|mg/kg|DYNAMIC CONTRAST ENHANCED MRI|Y||NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|4|FOLLOW-UP|2020-11-16|65
e|TR|8d944400-df75-4ec7-8fb4-239eb0f6de9d|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|mOsm/kg|FURTHER ENLARGEMENT|1|POINT|WEBER GREEN STAIN|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|5|Visit_5|90|5|TREATMENT|2020-12-11|90
e|TR|7b201f93-bd8c-4507-a7b7-27a02e364647|1|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|EIA unit|PRESENT|1|nkat/L|AURAMINE STAIN|||PROXY|ONCOLOGIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-12-23|10
e|TR|7b201f93-bd8c-4507-a7b7-27a02e364647|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|RNA copies/mL|ENLARGEMENT|1|mmHg*min/L|EEG||Y|FRIEND|RADIOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2021-01-07|25
e|TR|7b201f93-bd8c-4507-a7b7-27a02e364647|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|LOZENGE|EQUIVOCAL|1|nkat/L|ENZYMATIC SPECTROPHOTOMETRY|||SPOUSE|ENDOCRINOLOGIST|NA|3|Visit_3|40|3|SCREENING|2021-01-22|40
e|TR|7b201f93-bd8c-4507-a7b7-27a02e364647|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|L/s/kPa|FOCALLY INCREASED|1|%(w/w)|NUCLEIC ACID SEQUENCING|Y||FAMILY MEMBER|CLINICAL PATHOLOGIST|U|4|Visit_4|65|5|FOLLOW-UP|2021-02-16|65
e|TR|7b201f93-bd8c-4507-a7b7-27a02e364647|5|[?]|PALPSTAT|Palpable State|[?]|mEq/g|NORMAL|1|VIRTUAL PIXEL|TOTAL BODY IRRADIATION|Y||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|2|TREATMENT|2021-03-13|90
e|TR|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|1|[?]|TUMSTATE|Tumor State|[?]|L|NONPALPABLE|1|10^12 IU/L|FORCED OSCILLATION TECHNIQUE|Y||FAMILY MEMBER|READER 1|N|1|Visit_1|10|3|FOLLOW-UP|2020-08-05|10
e|TR|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|10^6 RNA copies/mL|NORMAL|1|deg|SPIRAL CT|||CAREGIVER|ONCOLOGIST 2|NA|2|Visit_2|25|1|TREATMENT|2020-08-20|25
e|TR|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|3|[?]|LPERP|Longest Perpendicular|[?]|Ci/uL|DECREASED|1|ug/m2/day|WHOLE EXOME SEQUENCING|||STUDY SUBJECT|MICROSCOPIST 1|Y|3|Visit_3|40|1|SCREENING|2020-09-04|40
e|TR|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|Siemens|ENLARGEMENT FROM NADIR|1|/500 WBC|ELECTROMYOGRAPHY|||CHILD|RADIOLOGIST 1|U|4|Visit_4|65|6|FOLLOW-UP|2020-09-29|65
e|TR|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|5|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|cd/m2|EQUIVOCAL|1|Bq/uL|CONTRAST ENHANCED CT SCAN|||SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|5|Visit_5|90|2|WASHOUT|2020-10-24|90
e|TR|3611b798-9b3d-4173-b23e-3017939847e0|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|kg/mol|EQUIVOCAL|1|L/h/m2|HPLC|||SIBLING|MICROSCOPIST|N|1|Visit_1|10|4|TREATMENT|2020-08-03|10
e|TR|3611b798-9b3d-4173-b23e-3017939847e0|2|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|uL/dose|ENLARGEMENT FROM NADIR|1|10^7 PFU|JAEGER EYE CHART|Y||STUDY SUBJECT|UROLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-08-18|25
e|TR|3611b798-9b3d-4173-b23e-3017939847e0|3|[?]|DIAMETER|Diameter|[?]|10^6 copies/mL|DIFFUSELY INCREASED|1|log10 TCID 50/dose|POPULATION SEQUENCING|Y||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|3|TREATMENT|2020-09-02|40
e|TR|3611b798-9b3d-4173-b23e-3017939847e0|4|[?]|LPERP|Longest Perpendicular|[?]|AU/mL|INCREASED|1|ng/dL|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y|PARENT|ADJUDICATOR 2|U|4|Visit_4|65|4|FOLLOW-UP|2020-09-27|65
e|TR|3611b798-9b3d-4173-b23e-3017939847e0|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|U/m2/min|FOCALLY INCREASED|1|/500 WBC|IMMUNOBLOT||Y|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|N|5|Visit_5|90|2|TREATMENT|2020-10-22|90
e|TR|f651799b-9723-4c2c-88d1-de2f347e9a69|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|WEEKS|INCREASED|1|um/day|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y|Y|PARENT|READER|Y|1|Visit_1|10|6|TREATMENT|2020-06-24|10
e|TR|f651799b-9723-4c2c-88d1-de2f347e9a69|2|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mol/day|DIFFUSELY INCREASED|1|Absorbance U/mL|SPECULAR MICROSCOPY|Y||ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|7|TREATMENT|2020-07-09|25
e|TR|f651799b-9723-4c2c-88d1-de2f347e9a69|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|NEBULE|UNCHANGED|1|mmHg/sec|TURBIDIMETRY|Y||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|Y|3|Visit_3|40|1|TREATMENT|2020-07-24|40
e|TR|f651799b-9723-4c2c-88d1-de2f347e9a69|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|uCi|UNCHANGED|1|ug/mL/h|SINGLE-MOLECULE ARRAY|Y||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|4|Visit_4|65|4|TREATMENT|2020-08-18|65
e|TR|f651799b-9723-4c2c-88d1-de2f347e9a69|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|anti-Xa IU/mL|NONPALPABLE|1|log10 PFU/mL|WESTERN BLOT||Y|DOMESTIC PARTNER|READER|U|5|Visit_5|90|4|WASHOUT|2020-09-12|90
e|TR|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|deg2|EQUIVOCAL|1|/mm2|TRANSTHORACIC ECHOCARDIOGRAPHY|||INVESTIGATOR|NEUROLOGIST 1|Y|1|Visit_1|10|3|SCREENING|2020-10-19|10
e|TR|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|2|[?]|BNLNUM|Number of Bone Lesions|[?]|kat|NORMAL|1|bel|CALIPER MEASUREMENT METHOD|||INTERVIEWER|MICROSCOPIST 2|NA|2|Visit_2|25|4|TREATMENT|2020-11-03|25
e|TR|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|DRUM|NORMAL|1|10^3/L|MAMMOGRAPHY|Y|Y|ADJUDICATOR|ONCOLOGIST|U|3|Visit_3|40|5|FOLLOW-UP|2020-11-18|40
e|TR|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mmol/mol|ENLARGEMENT FROM NADIR|1|PNU/mL|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||Y|PARENT|PATHOLOGIST|U|4|Visit_4|65|4|TREATMENT|2020-12-13|65
e|TR|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|CIGARETTE|PATHOLOGICAL|1|titer|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||FRIEND|HEMATOLOGIST|U|5|Visit_5|90|4|FOLLOW-UP|2021-01-07|90
e|TR|29b16c31-df0e-493c-a777-46113b904879|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|g/cage/day|NON-PATHOLOGICAL|1|mkat|GC/FID|||CHILD|ADJUDICATOR 3|NA|1|Visit_1|10|6|TREATMENT|2020-06-07|10
e|TR|29b16c31-df0e-493c-a777-46113b904879|2|[?]|AREA|Area|[?]|mAnson U/mL|NORMAL|1|log10 TCID 50/dose|MAMMOGRAPHY|||VENDOR|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|5|SCREENING|2020-06-22|25
e|TR|29b16c31-df0e-493c-a777-46113b904879|3|[?]|CALCFIND|Calcification Indicator|[?]|lx|INCREASED|1|kUSP|LIQUID SCINTILLATION COUNTING|||PARENT|PHYSIOTHERAPIST|Y|3|Visit_3|40|4|TREATMENT|2020-07-07|40
e|TR|29b16c31-df0e-493c-a777-46113b904879|4|[?]|AREA|Area|[?]|ms/mmHg|PALPABLE|1|mCi/L|CONTRAST ENHANCED X-RAY|||HEALTH CARE PROFESSIONAL|INTERNIST|NA|4|Visit_4|65|5|TREATMENT|2020-08-01|65
e|TR|29b16c31-df0e-493c-a777-46113b904879|5|[?]|ORSTATE|Organ State|[?]|uL/dose|DECREASED|1|ug/m2|X-RAY|||INTERVIEWER|MICROSCOPIST 1|Y|5|Visit_5|90|5|TREATMENT|2020-08-26|90
e|TR|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|10^6 U|PALPABLE|1|Bq/kg|HEMATOXYLIN AND EOSIN STAIN|||GUARDIAN|OTOLARYNGOLOGIST|N|1|Visit_1|10|2|WASHOUT|2020-07-31|10
e|TR|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|IU/L|DIFFUSELY INCREASED|1|RING|ALCIAN BLUE STAIN|||PARENT|ONCOLOGIST 2|NA|2|Visit_2|25|7|FOLLOW-UP|2020-08-15|25
e|TR|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|3|[?]|VDIAM|Viable Diameter|[?]|g/cage/wk|TUMOR MERGED|1|POINT|CISH||Y|GUARDIAN|UROLOGIST|NA|3|Visit_3|40|4|WASHOUT|2020-08-30|40
e|TR|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|deg/mm|UNCHANGED|1|/wk|RADIATION DOSIMETRY|||CHILD|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|4|SCREENING|2020-09-24|65
e|TR|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|fmol/g|UNEQUIVOCAL|1|ug/mol|CLIP|||INVESTIGATOR|READER|Y|5|Visit_5|90|7|SCREENING|2020-10-19|90
e|TR|118914c8-9f6a-47c8-b427-296a99547756|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|Joule|ENLARGEMENT|1|Joule|POLYGRAPHY|||PARENT|CLINICAL PATHOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-10-25|10
e|TR|118914c8-9f6a-47c8-b427-296a99547756|2|[?]|CALCFIND|Calcification Indicator|[?]|umol/dL|EQUIVOCAL|1|Antibody Unit|DYNAMIC LIGHT SCATTERING|||STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-11-09|25
e|TR|118914c8-9f6a-47c8-b427-296a99547756|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|PACK|FOCALLY INCREASED|1|mEq/uL|THIN SMEAR|||SIBLING|INTERNIST|Y|3|Visit_3|40|7|SCREENING|2020-11-24|40
e|TR|118914c8-9f6a-47c8-b427-296a99547756|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|ug/m2|DIFFUSELY INCREASED|1|SYRINGE|ISHIHARA COLOR PLATES||Y|SIGNIFICANT OTHER|PATHOLOGIST 1|N|4|Visit_4|65|5|TREATMENT|2020-12-19|65
e|TR|118914c8-9f6a-47c8-b427-296a99547756|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|log10 TCID 50/dose|ENLARGEMENT|1|g/cage|ENZYMATIC SPECTROPHOTOMETRY|||CHILD|OPHTHALMOLOGIST|U|5|Visit_5|90|5|SCREENING|2021-01-13|90
e|TR|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|1|[?]|ORVERLN|Organ Vertical Length|[?]|10^4/L|DIFFUSELY INCREASED|1|mL/g/h|CISH|||SIBLING|ENDOCRINOLOGIST|N|1|Visit_1|10|3|TREATMENT|2020-12-09|10
e|TR|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|2|[?]|VDIAM|Viable Diameter|[?]|MONTHS|UNCHANGED|1|U/g/min|SINGLE-SLICE SPIRAL CT||Y|FRIEND|RADIOLOGIST 2|Y|2|Visit_2|25|2|WASHOUT|2020-12-24|25
e|TR|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|BEAM BREAKS|ENLARGEMENT|1|nCi|SINGLE-MOLECULE ARRAY|Y|Y|SIGNIFICANT OTHER|READER|Y|3|Visit_3|40|5|TREATMENT|2021-01-08|40
e|TR|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|fmol/L|FOCALLY INCREASED|1|uEq/L|WHOLE TRANSCRIPTOME SEQUENCING||Y|STUDY SUBJECT|READER|Y|4|Visit_4|65|5|TREATMENT|2021-02-02|65
e|TR|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|5|[?]|BNLNUM|Number of Bone Lesions|[?]|mL/day|PRESENT|1|10^7 TCID 50/dose|PELLI-ROBSON EYE CHART||Y|PROXY|RATER 1|N|5|Visit_5|90|2|FOLLOW-UP|2021-02-27|90
e|TR|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|WAFER|INCREASED|1|F|PALPATION|||GUARDIAN|MICROSCOPIST 1|Y|1|Visit_1|10|6|TREATMENT|2021-01-08|10
e|TR|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|log10 PFU/mL|DECREASED|1|umol/mg/min|X-RAY FLUORESCENCE SPECTROMETRY|||INVESTIGATOR|ONCOLOGIST 1|U|2|Visit_2|25|3|TREATMENT|2021-01-23|25
e|TR|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|dpm/100mg|PALPABLE|1|km|STRESS ECHOCARDIOGRAPHY|||FAMILY MEMBER|ADJUDICATOR 2|Y|3|Visit_3|40|5|SCREENING|2021-02-07|40
e|TR|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|4|[?]|SUMVOL|Sum of Volume|[?]|pg/dL|EQUIVOCAL|1|NEEDLE GAUGE|MAGNETIC RESONANCE ELASTOGRAPHY|||VENDOR|MICROSCOPIST 1|NA|4|Visit_4|65|4|TREATMENT|2021-03-04|65
e|TR|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|Hz|NORMAL|1|mL/day|INCISION-INDUCED BLEEDING METHOD||Y|STUDY SUBJECT|RATER 2|NA|5|Visit_5|90|6|FOLLOW-UP|2021-03-29|90
e|TR|7a5ae465-03b9-4006-a29e-94822ed857aa|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|g/kg|DIFFUSELY INCREASED|1|Joule|MICROARRAY|Y|Y|INTERVIEWER|UROLOGIST|NA|1|Visit_1|10|7|SCREENING|2020-07-02|10
e|TR|7a5ae465-03b9-4006-a29e-94822ed857aa|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|DNA copies/mL|ENLARGEMENT|1|cmHg|DUCTOGRAPHY|||ADJUDICATOR|RADIOLOGIST 1|NA|2|Visit_2|25|4|TREATMENT|2020-07-17|25
e|TR|7a5ae465-03b9-4006-a29e-94822ed857aa|3|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|ag|INCREASED|1|Hz/s|NUCLEIC ACID BASED METHOD|Y||GUARDIAN|MICROSCOPIST|Y|3|Visit_3|40|7|WASHOUT|2020-08-01|40
e|TR|7a5ae465-03b9-4006-a29e-94822ed857aa|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|cpm|FOCALLY INCREASED|1|mEq/g|FARNSWORTH-MUNSELL 100 HUE TEST|Y||PROXY|PATHOLOGIST 1|U|4|Visit_4|65|2|TREATMENT|2020-08-26|65
e|TR|7a5ae465-03b9-4006-a29e-94822ed857aa|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mol/g|NORMAL|1|%(w/v)|RADIAL IMMUNODIFFUSION|||SPOUSE|NEUROLOGIST|U|5|Visit_5|90|2|FOLLOW-UP|2020-09-20|90
e|TR|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|1|[?]|DIAMETER|Diameter|[?]|TUBE|NON-PATHOLOGICAL|1|dpm/mg|APPLANATION TONOMETRY|||STUDY SUBJECT|ONCOLOGIST 1|U|1|Visit_1|10|2|WASHOUT|2020-09-22|10
e|TR|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|2|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|Bq/uL|EQUIVOCAL|1|/month|EEG||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|NA|2|Visit_2|25|4|WASHOUT|2020-10-07|25
e|TR|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|3|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mg/animal|PALPABLE|1|mL/cage/day|JAFFE REACTION|||PARENT|ONCOLOGIST 2|Y|3|Visit_3|40|1|TREATMENT|2020-10-22|40
e|TR|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|4|[?]|PPD|Product of Perpendicular Diameters|[?]|CCID 50/dose|TUMOR MERGED|1|pmol/10^10 cells|THIN SMEAR||Y|SIBLING|OPHTHALMOLOGIST|U|4|Visit_4|65|7|FOLLOW-UP|2020-11-16|65
e|TR|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|LB|NORMAL|1|mmol/min/kPa/L|MICROARRAY|||INDEPENDENT ASSESSOR|MICROSCOPIST 1|N|5|Visit_5|90|4|WASHOUT|2020-12-11|90
e|TR|2e4cd860-734a-40b0-bde5-ca08297415a9|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|10^6 RNA copies/mL|PATHOLOGICAL|1|nkat/g Hb|ELECTRICAL IMPEDANCE MYOGRAPHY|||ADJUDICATOR|ONCOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-11-25|10
e|TR|2e4cd860-734a-40b0-bde5-ca08297415a9|2|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|KIT|NON-PATHOLOGICAL|1|g/U|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||PROXY|PATHOLOGIST|NA|2|Visit_2|25|7|FOLLOW-UP|2020-12-10|25
e|TR|2e4cd860-734a-40b0-bde5-ca08297415a9|3|[?]|ORSTATE|Organ State|[?]|MBq/uL|PATHOLOGICAL|1|foz_us|KNEMOMETRY|Y||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|Y|3|Visit_3|40|7|FOLLOW-UP|2020-12-25|40
e|TR|2e4cd860-734a-40b0-bde5-ca08297415a9|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|10^3/hpf|PALPABLE|1|km/h|DYNAMOMETRY||Y|VENDOR|READER 3|N|4|Visit_4|65|1|FOLLOW-UP|2021-01-19|65
e|TR|2e4cd860-734a-40b0-bde5-ca08297415a9|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|mL/sec/1.73m2|INCREASED|1|mg/L FEU|KNEMOMETRY|Y||INDEPENDENT ASSESSOR|ONCOLOGIST 2|Y|5|Visit_5|90|1|TREATMENT|2021-02-13|90
e|TR|3f1854fb-d14e-4699-888b-d5042fa9327c|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|foz_us|PALPABLE|1|Bq|HILLMEN COLOR CHART|||PARENT|READER 2|N|1|Visit_1|10|2|SCREENING|2020-08-04|10
e|TR|3f1854fb-d14e-4699-888b-d5042fa9327c|2|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|WEEKS|ENLARGEMENT|1|10^6/L|SNELLEN EYE CHART|Y||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|NA|2|Visit_2|25|3|FOLLOW-UP|2020-08-19|25
e|TR|3f1854fb-d14e-4699-888b-d5042fa9327c|3|[?]|ORVERLN|Organ Vertical Length|[?]|nmol/mol|EQUIVOCAL|1|genEq/mL|MICROBIAL CULTURE, SOLID|Y|Y|INVESTIGATOR|READER 3|NA|3|Visit_3|40|2|TREATMENT|2020-09-03|40
e|TR|3f1854fb-d14e-4699-888b-d5042fa9327c|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|yd|PALPABLE|1|ug/kg/day|NUCLEIC ACID HYBRIDIZATION|||FRIEND|CARDIOLOGIST|NA|4|Visit_4|65|3|FOLLOW-UP|2020-09-28|65
e|TR|3f1854fb-d14e-4699-888b-d5042fa9327c|5|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|FFU|ENLARGEMENT|1|keV|MUGA||Y|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-10-23|90
e|TR|f6e37eba-e224-47f3-baa0-59dfdfb47b70|1|[?]|NEWCONF|New Tumor Confirmed|[?]|mmol2/L2|INCREASED|1|U/g/h|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||FRIEND|CARDIOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-12-10|10
e|TR|f6e37eba-e224-47f3-baa0-59dfdfb47b70|2|[?]|BNLNUM|Number of Bone Lesions|[?]|PACKAGE|EQUIVOCAL|1|km|PET SCAN|Y||INVESTIGATOR|ONCOLOGIST|NA|2|Visit_2|25|3|FOLLOW-UP|2020-12-25|25
e|TR|f6e37eba-e224-47f3-baa0-59dfdfb47b70|3|[?]|VDIAM|Viable Diameter|[?]|min|UNEQUIVOCAL|1|fmol/L/sec|ELASTOGRAPHY|Y||PROXY|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|1|WASHOUT|2021-01-09|40
e|TR|f6e37eba-e224-47f3-baa0-59dfdfb47b70|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|g/kg|TUMOR MERGED|1|Ci/ug|SISH|||NON-HEALTH CARE PROFESSIONAL|READER 3|Y|4|Visit_4|65|5|WASHOUT|2021-02-03|65
e|TR|f6e37eba-e224-47f3-baa0-59dfdfb47b70|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|MBq/uL|PALPABLE|1|/LPF|PET/CT SCAN|||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|1|FOLLOW-UP|2021-02-28|90
e|TR|8298b45d-16ff-42ef-8404-0f3ce628f9e5|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|mmHg/sec|UNCHANGED|1|GPL U|TELLER ACUITY CARDS|Y||FRIEND|PATHOLOGIST|NA|1|Visit_1|10|7|WASHOUT|2020-07-31|10
e|TR|8298b45d-16ff-42ef-8404-0f3ce628f9e5|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|s/h|PALPABLE|1|Bq/kg|GC/MS/MS||Y|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|2|WASHOUT|2020-08-15|25
e|TR|8298b45d-16ff-42ef-8404-0f3ce628f9e5|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|JAR|PRESENT|1|uU/L|SPECT/CT SCAN||Y|SIBLING|RADIOLOGIST|U|3|Visit_3|40|2|WASHOUT|2020-08-30|40
e|TR|8298b45d-16ff-42ef-8404-0f3ce628f9e5|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|mm/2h|ABSENT|1|cmH2O*s2/mL|POTENTIOMETRY|||DOMESTIC PARTNER|READER 1|N|4|Visit_4|65|4|TREATMENT|2020-09-24|65
e|TR|8298b45d-16ff-42ef-8404-0f3ce628f9e5|5|[?]|LDIAM|Longest Diameter|[?]|mmol/mol|DECREASED|1|kUSP|IMMUNOCHROMATOGRAPHY|Y|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|5|Visit_5|90|5|TREATMENT|2020-10-19|90
e|TR|ee5c6623-5cb4-4f18-99b0-6373328abc1d|1|[?]|DIAMETER|Diameter|[?]|deg2|TUMOR MERGED|1|IU/kg/h|DOUBLE IMMUNODIFFUSION|||CAREGIVER|HEMATOLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-06-11|10
e|TR|ee5c6623-5cb4-4f18-99b0-6373328abc1d|2|[?]|PALPSTAT|Palpable State|[?]|L/s/kPa|FURTHER ENLARGEMENT FROM NADIR|1|nm|IMMUNE REPERTOIRE DEEP SEQUENCING|Y||FAMILY MEMBER|ONCOLOGIST 1|U|2|Visit_2|25|1|TREATMENT|2020-06-26|25
e|TR|ee5c6623-5cb4-4f18-99b0-6373328abc1d|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|deg|PALPABLE|1|ms/mmHg|WHOLE TRANSCRIPTOME SEQUENCING|||SIGNIFICANT OTHER|ONCOLOGIST 2|Y|3|Visit_3|40|5|TREATMENT|2020-07-11|40
e|TR|ee5c6623-5cb4-4f18-99b0-6373328abc1d|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|10^6/g|DIFFUSELY INCREASED|1|aMFI|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y||ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|4|Visit_4|65|5|TREATMENT|2020-08-05|65
e|TR|ee5c6623-5cb4-4f18-99b0-6373328abc1d|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|genEq|NONPALPABLE|1|log10 TCID 50/dose|WHOLE EXOME SEQUENCING|Y|Y|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|7|SCREENING|2020-08-30|90
e|TR|f8d6576b-b300-4c5f-8f5a-6bb35250d576|1|[?]|ACHNAD|Absolute Change From Nadir|[?]|mg/kg|UNCHANGED|1|ug/cm2|DIRECT SEQUENCING||Y|FAMILY MEMBER|PATHOLOGIST 1|Y|1|Visit_1|10|2|TREATMENT|2020-06-25|10
e|TR|f8d6576b-b300-4c5f-8f5a-6bb35250d576|2|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|uCi|FURTHER ENLARGEMENT FROM NADIR|1|Enzyme U/L|LANDOLT RING||Y|VENDOR|NEUROLOGIST|Y|2|Visit_2|25|7|TREATMENT|2020-07-10|25
e|TR|f8d6576b-b300-4c5f-8f5a-6bb35250d576|3|[?]|LPERP|Longest Perpendicular|[?]|mL/cage/wk|FOCALLY INCREASED|1|lx|INDIA INK STAIN|||GUARDIAN|INTERNIST|NA|3|Visit_3|40|2|WASHOUT|2020-07-25|40
e|TR|f8d6576b-b300-4c5f-8f5a-6bb35250d576|4|[?]|LPERP|Longest Perpendicular|[?]|breaths/30s|UNCHANGED|1|mL/100g/min|LC/MS|Y|Y|CAREGIVER|PHYSIOTHERAPIST|N|4|Visit_4|65|2|SCREENING|2020-08-19|65
e|TR|f8d6576b-b300-4c5f-8f5a-6bb35250d576|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|g/L|PATHOLOGICAL|1|ug/g/min|JAFFE REACTION|||FRIEND|OTOLARYNGOLOGIST|N|5|Visit_5|90|4|FOLLOW-UP|2020-09-13|90
e|TR|8635a6b3-d16e-432c-90bf-53f1494dbe5e|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|psi|NORMAL|1|v/v|DUKE INCISION METHOD|||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|1|Visit_1|10|6|WASHOUT|2020-10-26|10
e|TR|8635a6b3-d16e-432c-90bf-53f1494dbe5e|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|mL/dose|EQUIVOCAL|1|SPRAY|MICROPARTICLE ENZYME IMMUNOASSAY|Y||ADJUDICATION COMMITTEE|DERMATOLOGIST|Y|2|Visit_2|25|1|FOLLOW-UP|2020-11-10|25
e|TR|8635a6b3-d16e-432c-90bf-53f1494dbe5e|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|10^9 CFU|DIFFUSELY INCREASED|1|/100 WBC|ATOMIC ABSORPTION SPECTROMETRY||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|Y|3|Visit_3|40|7|TREATMENT|2020-11-25|40
e|TR|8635a6b3-d16e-432c-90bf-53f1494dbe5e|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|BAU|ENLARGEMENT FROM NADIR|1|uCi/kg|TRIPLE-PHASE SPIRAL CT SCAN|||FAMILY MEMBER|NEUROLOGIST|Y|4|Visit_4|65|5|WASHOUT|2020-12-20|65
e|TR|8635a6b3-d16e-432c-90bf-53f1494dbe5e|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|kDa|FURTHER ENLARGEMENT|1|10^8/L|GEL ELECTROPHORESIS|||FAMILY MEMBER|OTOLARYNGOLOGIST|Y|5|Visit_5|90|2|WASHOUT|2021-01-14|90
e|TR|2cda4297-410a-49e4-949c-deb3dc4c6656|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mmol|FURTHER ENLARGEMENT|1|Bq/ug|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||CAREGIVER|INTERNIST|Y|1|Visit_1|10|1|SCREENING|2020-06-20|10
e|TR|2cda4297-410a-49e4-949c-deb3dc4c6656|2|[?]|RADIODEN|Radiodensity|[?]|m3|DECREASED|1|PIPE|FUNDUS PHOTOGRAPHY|Y|Y|STUDY SUBJECT|RATER 2|U|2|Visit_2|25|3|TREATMENT|2020-07-05|25
e|TR|2cda4297-410a-49e4-949c-deb3dc4c6656|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|TRANSDUCING UNIT/mL|PATHOLOGICAL|1|mL/kg/h|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|Y|3|Visit_3|40|5|TREATMENT|2020-07-20|40
e|TR|2cda4297-410a-49e4-949c-deb3dc4c6656|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|Hounsfield Unit|FOCALLY INCREASED|1|mmol|NEPHELOMETRY|Y|Y|INVESTIGATOR|ONCOLOGIST 1|Y|4|Visit_4|65|1|WASHOUT|2020-08-14|65
e|TR|2cda4297-410a-49e4-949c-deb3dc4c6656|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|U/animal|EQUIVOCAL|1|Bq/kg|MRI WITHOUT CONTRAST|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|Y|5|Visit_5|90|5|TREATMENT|2020-09-08|90
e|TR|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|1|[?]|LPERP|Longest Perpendicular|[?]|days/wk|FURTHER ENLARGEMENT|1|ug/day|DOPPLER ULTRASOUND|||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|2|TREATMENT|2021-01-29|10
e|TR|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|FEU|ABSENT|1|cmH2O*s/mL|JAFFE REACTION|||SPOUSE|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|3|WASHOUT|2021-02-13|25
e|TR|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|mL/g/min|NONPALPABLE|1|umol/h/mmol|ENZYMATIC ULTRACENTRIFUGATION|||CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|6|WASHOUT|2021-02-28|40
e|TR|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|CYLINDER|NON-PATHOLOGICAL|1|pkat/L|HEMAGGLUTINATION ASSAY||Y|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|NA|4|Visit_4|65|7|TREATMENT|2021-03-25|65
e|TR|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|5|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|MPS U|FOCALLY INCREASED|1|IU/dL|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||PARENT|NEUROLOGIST|Y|5|Visit_5|90|4|TREATMENT|2021-04-19|90
e|TR|9e82141b-e2b9-42c7-b813-b79bda2bd216|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|umol/day|FURTHER ENLARGEMENT|1|10^3 CFU|TRANSCRIPTION-MEDIATED AMPLIFICATION|||CHILD|RADIOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-05-31|10
e|TR|9e82141b-e2b9-42c7-b813-b79bda2bd216|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|log10 copies/mL|EQUIVOCAL|1|C|SXA SCAN||Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|2|Visit_2|25|6|TREATMENT|2020-06-15|25
e|TR|9e82141b-e2b9-42c7-b813-b79bda2bd216|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|oz eq|PATHOLOGICAL|1|gtt|ULTRASOUND|||CLINICAL RESEARCH COORDINATOR|READER 2|U|3|Visit_3|40|3|TREATMENT|2020-06-30|40
e|TR|9e82141b-e2b9-42c7-b813-b79bda2bd216|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|/day|PRESENT|1|mL/g/day|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||FAMILY MEMBER|READER 1|U|4|Visit_4|65|5|TREATMENT|2020-07-25|65
e|TR|9e82141b-e2b9-42c7-b813-b79bda2bd216|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|EU|PATHOLOGICAL|1|Newton|DOUBLE IMMUNODIFFUSION|||CAREGIVER|DERMATOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-08-19|90
e|TR|4b432c61-c620-4c5e-8aad-411facc0f4db|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|vp/dose|FURTHER ENLARGEMENT FROM NADIR|1|nmol/kg/day|MICROPARTICLE ENZYME IMMUNOASSAY|||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|NA|1|Visit_1|10|2|TREATMENT|2020-09-14|10
e|TR|4b432c61-c620-4c5e-8aad-411facc0f4db|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|SBE/mL|ENLARGEMENT FROM NADIR|1|min|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||INTERVIEWER|RADIOLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-09-29|25
e|TR|4b432c61-c620-4c5e-8aad-411facc0f4db|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|BOX|DECREASED|1|ug/kg/h|CALCULATION|||PARENT|MICROSCOPIST 3|NA|3|Visit_3|40|3|WASHOUT|2020-10-14|40
e|TR|4b432c61-c620-4c5e-8aad-411facc0f4db|4|[?]|ORVERLN|Organ Vertical Length|[?]|Ejaculate U|FURTHER ENLARGEMENT FROM NADIR|1|Watt|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||NON-HEALTH CARE PROFESSIONAL|READER|Y|4|Visit_4|65|5|FOLLOW-UP|2020-11-08|65
e|TR|4b432c61-c620-4c5e-8aad-411facc0f4db|5|[?]|LDIAM|Longest Diameter|[?]|uIU/L|PRESENT|1|KIT|TRICHROME STAIN|||INTERVIEWER|RATER 1|N|5|Visit_5|90|2|SCREENING|2020-12-03|90
e|TR|1a1e6863-26da-4b5d-b82a-5703e3e9056e|1|[?]|VOLUME|Volume|[?]|SBE/mL|ENLARGEMENT|1|fmol|MANUAL CLOT DETECTION||Y|FRIEND|CARDIOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-12-26|10
e|TR|1a1e6863-26da-4b5d-b82a-5703e3e9056e|2|[?]|LNSTATE|Lymph Node State|[?]|pkat|EQUIVOCAL|1|10^6 organisms/mL|ULTRASONOGRAPHIC ELASTOGRAPHY|Y||STUDY SUBJECT|PHYSIOTHERAPIST|U|2|Visit_2|25|1|WASHOUT|2021-01-10|25
e|TR|1a1e6863-26da-4b5d-b82a-5703e3e9056e|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mg/mL/day|PALPABLE|1|DRUM|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|U|3|Visit_3|40|5|TREATMENT|2021-01-25|40
e|TR|1a1e6863-26da-4b5d-b82a-5703e3e9056e|4|[?]|VOLUME|Volume|[?]|ug/L FEU|UNEQUIVOCAL|1|mmHg/L/min|HIGH RESOLUTION CT|||FAMILY MEMBER|PHYSIOTHERAPIST|NA|4|Visit_4|65|7|TREATMENT|2021-02-19|65
e|TR|1a1e6863-26da-4b5d-b82a-5703e3e9056e|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|L/h/m2|EQUIVOCAL|1|ug/cm2|SPECT/CT SCAN|||CLINICAL STUDY SPONSOR|INTERNIST|U|5|Visit_5|90|6|TREATMENT|2021-03-16|90
e|TR|8c8053d1-adae-4d45-870e-cf4ad2475c74|1|[?]|ACHNAD|Absolute Change From Nadir|[?]|yd|FOCALLY INCREASED|1|sec|NUCLEIC ACID BASED METHOD|Y||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|1|Visit_1|10|2|SCREENING|2020-05-11|10
e|TR|8c8053d1-adae-4d45-870e-cf4ad2475c74|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|WAFER|NONPALPABLE|1|Log10 ELISA unit/dose|IRON HEMATOXYLIN STAIN|Y|Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|2|Visit_2|25|4|WASHOUT|2020-05-26|25
e|TR|8c8053d1-adae-4d45-870e-cf4ad2475c74|3|[?]|ORVERLN|Organ Vertical Length|[?]|mg/L|PATHOLOGICAL|1|DRINK|NUCLEIC ACID SEQUENCING|Y|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|3|Visit_3|40|6|WASHOUT|2020-06-10|40
e|TR|8c8053d1-adae-4d45-870e-cf4ad2475c74|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|pg/L|PALPABLE|1|/2000 RBC|CONTRAST ENHANCED CT SCAN|Y||SIBLING|CLINICAL PATHOLOGIST|N|4|Visit_4|65|7|WASHOUT|2020-07-05|65
e|TR|8c8053d1-adae-4d45-870e-cf4ad2475c74|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|V|UNCHANGED|1|mm/min|SCINTIGRAPHY|||PROXY|ONCOLOGIST 1|NA|5|Visit_5|90|1|SCREENING|2020-07-30|90
e|TR|c3b911a8-116e-4940-80a2-7128db004f4a|1|[?]|BNLNUM|Number of Bone Lesions|[?]|10^3 organisms|DECREASED|1|mEq/ug|FLOCCULATION, CHARCOAL ENHANCED|Y||VENDOR|CLINICAL PATHOLOGIST|N|1|Visit_1|10|2|SCREENING|2020-11-19|10
e|TR|c3b911a8-116e-4940-80a2-7128db004f4a|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|log10 CFU/mL|UNCHANGED|1|mL/m2/h|KLEIHAUER-BETKE|Y|Y|PROXY|UROLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-12-04|25
e|TR|c3b911a8-116e-4940-80a2-7128db004f4a|3|[?]|BNLNUM|Number of Bone Lesions|[?]|mm/min|PRESENT|1|g/kg|GC/MS/MS|||HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|3|Visit_3|40|3|SCREENING|2020-12-19|40
e|TR|c3b911a8-116e-4940-80a2-7128db004f4a|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|Log10 ELISA unit|FOCALLY INCREASED|1|HOURS|MANUAL COUNT|||CHILD|PATHOLOGIST 2|Y|4|Visit_4|65|4|TREATMENT|2021-01-13|65
e|TR|c3b911a8-116e-4940-80a2-7128db004f4a|5|[?]|BNLNUM|Number of Bone Lesions|[?]|mOsm/L|UNCHANGED|1|10^9 organisms/g|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||Y|FRIEND|UROLOGIST|Y|5|Visit_5|90|7|WASHOUT|2021-02-07|90
e|TR|401d66ba-bc00-4495-ba5d-796068dd1fd6|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|SACHET|DIFFUSELY INCREASED|1|mg/h|MICRO BROTH DILUTION||Y|FAMILY MEMBER|MICROSCOPIST|NA|1|Visit_1|10|7|TREATMENT|2020-06-11|10
e|TR|401d66ba-bc00-4495-ba5d-796068dd1fd6|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|uU/L|NONPALPABLE|1|/10^5|PALPATION||Y|STUDY SUBJECT|PATHOLOGIST|NA|2|Visit_2|25|1|WASHOUT|2020-06-26|25
e|TR|401d66ba-bc00-4495-ba5d-796068dd1fd6|3|[?]|LESSCIND|Lesion Success Indicator|[?]|nmol BCE/mmol|DECREASED|1|APL U|PET/MRI SCAN|||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|Y|3|Visit_3|40|4|TREATMENT|2020-07-11|40
e|TR|401d66ba-bc00-4495-ba5d-796068dd1fd6|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mm|DIFFUSELY INCREASED|1|CFU/g|ERGOSPIROMETRY|||NON-HEALTH CARE PROFESSIONAL|READER 3|NA|4|Visit_4|65|3|TREATMENT|2020-08-05|65
e|TR|401d66ba-bc00-4495-ba5d-796068dd1fd6|5|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|10^6 organisms/g|PATHOLOGICAL|1|vp/mL|ISHIHARA COLOR PLATES|||SIGNIFICANT OTHER|UROLOGIST|U|5|Visit_5|90|6|TREATMENT|2020-08-30|90
e|TR|f8113725-4deb-48a1-876a-ba168a6d2cee|1|[?]|ORSTATE|Organ State|[?]|DAgU|DECREASED|1|V|HIGH RESOLUTION CT|||CHILD|FORENSIC PATHOLOGIST|N|1|Visit_1|10|2|TREATMENT|2021-01-22|10
e|TR|f8113725-4deb-48a1-876a-ba168a6d2cee|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|mol|NON-PATHOLOGICAL|1|PIXELS/cm|INDIRECT IMMUNOFLUORESCENCE|Y||SIBLING|ONCOLOGIST 1|U|2|Visit_2|25|1|TREATMENT|2021-02-06|25
e|TR|f8113725-4deb-48a1-876a-ba168a6d2cee|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|BLOCKS|PALPABLE|1|U/g|ACID FAST STAIN|Y||SIBLING|PATHOLOGIST 1|U|3|Visit_3|40|7|TREATMENT|2021-02-21|40
e|TR|f8113725-4deb-48a1-876a-ba168a6d2cee|4|[?]|ORSTATE|Organ State|[?]|10^6 DNA copies/mL|FOCALLY INCREASED|1|mL/m2/min|OPTICAL MAPPING|Y|Y|VENDOR|PHYSIOTHERAPIST|NA|4|Visit_4|65|2|TREATMENT|2021-03-18|65
e|TR|f8113725-4deb-48a1-876a-ba168a6d2cee|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|ft|DECREASED|1|kIU|IMMUNOBLOT|||CAREGIVER|RADIOLOGIST 2|U|5|Visit_5|90|2|SCREENING|2021-04-12|90
e|TR|f056c174-b6da-4df6-bf95-2e31911939fb|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|mL/(min*100mL)|INCREASED|1|um2|HPLC|||PROXY|READER 2|U|1|Visit_1|10|1|TREATMENT|2020-12-16|10
e|TR|f056c174-b6da-4df6-bf95-2e31911939fb|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|uCi|TUMOR MERGED|1|10^11/L|TOTAL BODY RADIOGRAPHY|||VENDOR|PATHOLOGIST 2|N|2|Visit_2|25|6|TREATMENT|2020-12-31|25
e|TR|f056c174-b6da-4df6-bf95-2e31911939fb|3|[?]|SUMVOL|Sum of Volume|[?]|log10 PFU/mL|FOCALLY INCREASED|1|mm|GC/FID|||CLINICAL STUDY SPONSOR|READER|NA|3|Visit_3|40|1|WASHOUT|2021-01-15|40
e|TR|f056c174-b6da-4df6-bf95-2e31911939fb|4|[?]|VDIAM|Viable Diameter|[?]|m/sec|NON-PATHOLOGICAL|1|mL/breath|BALLPOINT PEN TECHNIQUE||Y|SPOUSE|PATHOLOGIST 2|U|4|Visit_4|65|4|WASHOUT|2021-02-09|65
e|TR|f056c174-b6da-4df6-bf95-2e31911939fb|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|nkat|PATHOLOGICAL|1|Newton|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|||SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|2|TREATMENT|2021-03-06|90
e|TR|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|U/m2/h|FOCALLY INCREASED|1|ft|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y||CLINICAL STUDY SPONSOR|ONCOLOGIST|U|1|Visit_1|10|6|WASHOUT|2020-09-16|10
e|TR|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|mg/animal|PRESENT|1|/2000 RBC|SEQUENCING|Y||SIGNIFICANT OTHER|RADIOLOGIST 2|U|2|Visit_2|25|5|TREATMENT|2020-10-01|25
e|TR|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|MdFI|PRESENT|1|USP U|REFLECTANCE SPECTROSCOPY|||FRIEND|ONCOLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-10-16|40
e|TR|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|4|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|MnFI|ENLARGEMENT FROM NADIR|1|U/m2/min|BALLPOINT PEN TECHNIQUE|Y||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|2|SCREENING|2020-11-10|65
e|TR|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|10^9 CFU/g|NORMAL|1|mm/h|AMSLER GRID|Y|Y|SIBLING|READER|U|5|Visit_5|90|3|WASHOUT|2020-12-05|90
e|TR|57b7f30f-5f2a-425d-8bf2-fd5915cac481|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|h/wk|FURTHER ENLARGEMENT FROM NADIR|1|s^-1(%O2)^-1|CELL BASED BIOASSAY|Y||INVESTIGATOR|RADIOLOGIST|NA|1|Visit_1|10|2|SCREENING|2021-01-18|10
e|TR|57b7f30f-5f2a-425d-8bf2-fd5915cac481|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|uL/mL|ABSENT|1|%/s|LINE PROBE ASSAY|||CHILD|ENDOCRINOLOGIST|U|2|Visit_2|25|5|TREATMENT|2021-02-02|25
e|TR|57b7f30f-5f2a-425d-8bf2-fd5915cac481|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mL/m2/day|FOCALLY INCREASED|1|ELISA unit|TEMPLATE INCISION METHOD|||GUARDIAN|OPHTHALMOLOGIST|Y|3|Visit_3|40|2|WASHOUT|2021-02-17|40
e|TR|57b7f30f-5f2a-425d-8bf2-fd5915cac481|4|[?]|NEWCONF|New Tumor Confirmed|[?]|TABLET|FURTHER ENLARGEMENT FROM NADIR|1|Bq/kg|NUCLEAR RADIOLOGY||Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|4|Visit_4|65|7|SCREENING|2021-03-14|65
e|TR|57b7f30f-5f2a-425d-8bf2-fd5915cac481|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|IU/kg|ENLARGEMENT|1|U/g/h|CALCULATION|||CLINICAL RESEARCH ASSOCIATE|INTERNIST|U|5|Visit_5|90|2|TREATMENT|2021-04-08|90
e|TR|02d9a74a-abc8-4b47-a4d4-a196d339f621|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mg/m2/min|NON-PATHOLOGICAL|1|U/cL|OLIGO ACGH|||FRIEND|PHYSIOTHERAPIST|NA|1|Visit_1|10|3|FOLLOW-UP|2020-09-14|10
e|TR|02d9a74a-abc8-4b47-a4d4-a196d339f621|2|[?]|VDIAM|Viable Diameter|[?]|Bq|PALPABLE|1|ug/h|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||INTERVIEWER|ONCOLOGIST 2|NA|2|Visit_2|25|6|TREATMENT|2020-09-29|25
e|TR|02d9a74a-abc8-4b47-a4d4-a196d339f621|3|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|deg/mm|PALPABLE|1|ngEq/L|AUTOMATED COUNT||Y|DOMESTIC PARTNER|INTERNIST|Y|3|Visit_3|40|2|FOLLOW-UP|2020-10-14|40
e|TR|02d9a74a-abc8-4b47-a4d4-a196d339f621|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|Anson U|EQUIVOCAL|1|APS U|POTENTIOMETRY|||HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|4|Visit_4|65|6|FOLLOW-UP|2020-11-08|65
e|TR|02d9a74a-abc8-4b47-a4d4-a196d339f621|5|[?]|RADIODEN|Radiodensity|[?]|uEq/L|EQUIVOCAL|1|SFC/10^6 PBMC|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||CHILD|ADJUDICATOR 3|N|5|Visit_5|90|7|TREATMENT|2020-12-03|90
e|TR|81480f83-206f-40c0-a5a4-f75b31cda363|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|oz eq|NONPALPABLE|1|EP U|AUDIOMETRY|||FRIEND|RATER|Y|1|Visit_1|10|4|FOLLOW-UP|2020-11-22|10
e|TR|81480f83-206f-40c0-a5a4-f75b31cda363|2|[?]|RADIODEN|Radiodensity|[?]|uV|UNEQUIVOCAL|1|kPa/L/sec|SPIRAL CT|||ADJUDICATOR|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|1|FOLLOW-UP|2020-12-07|25
e|TR|81480f83-206f-40c0-a5a4-f75b31cda363|3|[?]|SUMVOL|Sum of Volume|[?]|mmAL|ENLARGEMENT FROM NADIR|1|mg/h|SPECULAR MICROSCOPY|||STUDY SUBJECT|PHYSIOTHERAPIST|N|3|Visit_3|40|4|WASHOUT|2020-12-22|40
e|TR|81480f83-206f-40c0-a5a4-f75b31cda363|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|PNU/mL|DECREASED|1|nL|TWO-COLOR MICROARRAY|||PARENT|RATER 2|Y|4|Visit_4|65|7|TREATMENT|2021-01-16|65
e|TR|81480f83-206f-40c0-a5a4-f75b31cda363|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|PFU|UNEQUIVOCAL|1|Torr|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||PARENT|RATER 1|N|5|Visit_5|90|3|TREATMENT|2021-02-10|90
e|TR|2b183b69-3ed8-4356-b9e2-0988128de3f2|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mOsm/kg|PATHOLOGICAL|1|TRANSDUCING UNIT/mL|DOUBLE IMMUNODIFFUSION|Y||FAMILY MEMBER|PHYSIOTHERAPIST|U|1|Visit_1|10|6|FOLLOW-UP|2020-10-16|10
e|TR|2b183b69-3ed8-4356-b9e2-0988128de3f2|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|log10 CFU/mL|ENLARGEMENT FROM NADIR|1|ELISA unit|IHC|||SIGNIFICANT OTHER|RATER 1|U|2|Visit_2|25|5|SCREENING|2020-10-31|25
e|TR|2b183b69-3ed8-4356-b9e2-0988128de3f2|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|POUCH|NORMAL|1|Pa|PHOROPTER|||GUARDIAN|NEUROLOGIST|U|3|Visit_3|40|3|SCREENING|2020-11-15|40
e|TR|2b183b69-3ed8-4356-b9e2-0988128de3f2|4|[?]|ORVERLN|Organ Vertical Length|[?]|F|FOCALLY INCREASED|1|ug/g/h|DOUBLE IMMUNODIFFUSION|Y||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|Y|4|Visit_4|65|1|WASHOUT|2020-12-10|65
e|TR|2b183b69-3ed8-4356-b9e2-0988128de3f2|5|[?]|VOLUME|Volume|[?]|CFU/mL|FURTHER ENLARGEMENT FROM NADIR|1|mEq/ug|MALDI|||STUDY SUBJECT|MICROSCOPIST 2|NA|5|Visit_5|90|1|TREATMENT|2021-01-04|90
e|TR|6ed8a749-81c0-4998-817d-efc86cfaa091|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|anti-Xa IU/mL|NONPALPABLE|1|/LSQN|NEXT GENERATION SEQUENCING|Y||SIBLING|CLINICAL PATHOLOGIST|N|1|Visit_1|10|7|SCREENING|2020-06-05|10
e|TR|6ed8a749-81c0-4998-817d-efc86cfaa091|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|IU/day|FURTHER ENLARGEMENT|1|Gravitational Unit|OPTICAL DENSITY MEASUREMENT|||STUDY SUBJECT|RATER 2|U|2|Visit_2|25|4|WASHOUT|2020-06-20|25
e|TR|6ed8a749-81c0-4998-817d-efc86cfaa091|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mL/animal/wk|UNCHANGED|1|mg/min|RIA|||FRIEND|RATER 1|U|3|Visit_3|40|4|SCREENING|2020-07-05|40
e|TR|6ed8a749-81c0-4998-817d-efc86cfaa091|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|log10 CCID 50/dose|NONPALPABLE|1|umol/mol|FARNSWORTH-MUNSELL 100 HUE TEST||Y|STUDY SUBJECT|NEUROLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-07-30|65
e|TR|6ed8a749-81c0-4998-817d-efc86cfaa091|5|[?]|PCHGBL|Percent Change From Baseline|[?]|Gravitational Unit|UNCHANGED|1|Gauss|EEG|Y||PROXY|MICROSCOPIST|U|5|Visit_5|90|3|TREATMENT|2020-08-24|90
e|TR|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|1|[?]|VDIAM|Viable Diameter|[?]|Torr|TUMOR MERGED|1|MBP|LIGHT MICROSCOPY|||CAREGIVER|READER 3|N|1|Visit_1|10|5|TREATMENT|2021-01-18|10
e|TR|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|10^4 CFU|PATHOLOGICAL|1|10^4/hpf|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||ADJUDICATION COMMITTEE|MICROSCOPIST 3|NA|2|Visit_2|25|6|FOLLOW-UP|2021-02-02|25
e|TR|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|1/(s*kPa)|EQUIVOCAL|1|%/s|ELECTROGASTROGRAPHY|Y||INDEPENDENT ASSESSOR|ADJUDICATOR 3|N|3|Visit_3|40|7|TREATMENT|2021-02-17|40
e|TR|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mL/cage/day|FOCALLY INCREASED|1|L/min/m2|CLAUSS METHOD|Y|Y|DOMESTIC PARTNER|ADJUDICATOR 3|Y|4|Visit_4|65|1|SCREENING|2021-03-14|65
e|TR|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|5|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|10^6 RNA copies/mL|DECREASED|1|BLOCKS|INDIA INK STAIN|Y|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|NA|5|Visit_5|90|1|FOLLOW-UP|2021-04-08|90
e|TR|e6162980-e240-4924-a13a-dde28b2345cd|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|vg/kg|TUMOR MERGED|1|Bq/L|CONFOCAL MICROSCOPY|||ADJUDICATOR|RADIOLOGIST|NA|1|Visit_1|10|2|SCREENING|2020-08-11|10
e|TR|e6162980-e240-4924-a13a-dde28b2345cd|2|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|10^6 CFU/mL|DIFFUSELY INCREASED|1|cpm|PULSE OXIMETRY|Y||INDEPENDENT ASSESSOR|MICROSCOPIST|U|2|Visit_2|25|7|TREATMENT|2020-08-26|25
e|TR|e6162980-e240-4924-a13a-dde28b2345cd|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|P|TUMOR MERGED|1|nmol/kg/day|DIRECT SEQUENCING|||STUDY SUBJECT|RATER 2|Y|3|Visit_3|40|4|TREATMENT|2020-09-10|40
e|TR|e6162980-e240-4924-a13a-dde28b2345cd|4|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mL/beat|NON-PATHOLOGICAL|1|mV|RIA|||CHILD|MICROSCOPIST|NA|4|Visit_4|65|1|SCREENING|2020-10-05|65
e|TR|e6162980-e240-4924-a13a-dde28b2345cd|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|U/kg/min|DECREASED|1|BOWL|SNELLEN EYE CHART|||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|5|Visit_5|90|6|SCREENING|2020-10-30|90
e|TR|3dc9c666-8be3-4cfa-88d4-b18647e08d00|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|PNU/mL|ENLARGEMENT FROM NADIR|1|10^3 organisms/g|DYNAMOMETRY|Y||STUDY SUBJECT|NEUROLOGIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-06-13|10
e|TR|3dc9c666-8be3-4cfa-88d4-b18647e08d00|2|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|U/m2/day|EQUIVOCAL|1|PATCH|AGAR DILUTION|||DOMESTIC PARTNER|RATER 2|NA|2|Visit_2|25|3|WASHOUT|2020-06-28|25
e|TR|3dc9c666-8be3-4cfa-88d4-b18647e08d00|3|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|Henry|DECREASED|1|C|HPLC|||PROXY|RADIOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-07-13|40
e|TR|3dc9c666-8be3-4cfa-88d4-b18647e08d00|4|[?]|RADIODEN|Radiodensity|[?]|umol/L|PATHOLOGICAL|1|Bq/L|NON-INVASIVE DIELECTRIC SENSING||Y|INTERVIEWER|ONCOLOGIST 1|N|4|Visit_4|65|2|TREATMENT|2020-08-07|65
e|TR|3dc9c666-8be3-4cfa-88d4-b18647e08d00|5|[?]|LNSTATE|Lymph Node State|[?]|ag|PRESENT|1|kPa/L/sec|WEBER GREEN STAIN|||ADJUDICATOR|MICROSCOPIST 1|U|5|Visit_5|90|1|SCREENING|2020-09-01|90
e|TR|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|umol/L/sec|ENLARGEMENT FROM NADIR|1|mEq/g|SLOAN LETTER EYE CHART 100%||Y|INVESTIGATOR|ONCOLOGIST 1|Y|1|Visit_1|10|5|WASHOUT|2021-01-23|10
e|TR|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|2|[?]|ORVERLN|Organ Vertical Length|[?]|U/mg|PALPABLE|1|Roentgen|CYSTOMETRY||Y|FAMILY MEMBER|ADJUDICATOR 3|U|2|Visit_2|25|7|WASHOUT|2021-02-07|25
e|TR|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|log10 PFU|PATHOLOGICAL|1|10^3 DNA copies/mL|CYSTOMETRY|||CHILD|ONCOLOGIST 1|U|3|Visit_3|40|7|TREATMENT|2021-02-22|40
e|TR|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|NEEDLE GAUGE|PRESENT|1|MET*h|DUCTOGRAPHY|Y||CHILD|ADJUDICATOR 3|NA|4|Visit_4|65|6|TREATMENT|2021-03-19|65
e|TR|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|pmol/L/h|DECREASED|1|umol/dL|DUKE INCISION METHOD|||ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|5|Visit_5|90|6|SCREENING|2021-04-13|90
e|TR|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|Bq/mg|UNEQUIVOCAL|1|mL/100g/min|CORONARY ANGIOGRAPHY|||PROXY|MICROSCOPIST 2|Y|1|Visit_1|10|7|TREATMENT|2020-11-19|10
e|TR|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|ukat|DECREASED|1|cL|ELECTRONEUROGRAPHY||Y|GUARDIAN|MICROSCOPIST 1|N|2|Visit_2|25|4|SCREENING|2020-12-04|25
e|TR|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|dB|PALPABLE|1|kg/cm2|INDIRECT IMMUNOFLUORESCENCE|||ADJUDICATOR|PATHOLOGIST 1|Y|3|Visit_3|40|1|WASHOUT|2020-12-19|40
e|TR|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|4|[?]|LDIAM|Longest Diameter|[?]|ppth|FURTHER ENLARGEMENT FROM NADIR|1|m3|QUANTITATIVE ULTRASOUND|||SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|3|TREATMENT|2021-01-13|65
e|TR|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mL/breath|ENLARGEMENT FROM NADIR|1|log10 CCID 50/dose|IMMUNORADIOMETRIC ASSAY|Y|Y|CHILD|ADJUDICATOR 2|NA|5|Visit_5|90|3|FOLLOW-UP|2021-02-07|90
e|TR|2738b933-c71d-4239-a093-6b4aa7cc41df|1|[?]|RADIODEN|Radiodensity|[?]|g/animal|DIFFUSELY INCREASED|1|mL/(min*100mL)|REFRACTOMETRY||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|1|Visit_1|10|6|SCREENING|2020-05-28|10
e|TR|2738b933-c71d-4239-a093-6b4aa7cc41df|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|psec|EQUIVOCAL|1|VIAL|EPSILOMETER|Y||FRIEND|RADIOLOGIST|Y|2|Visit_2|25|1|FOLLOW-UP|2020-06-12|25
e|TR|2738b933-c71d-4239-a093-6b4aa7cc41df|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|PIXELS/in|UNCHANGED|1|/40 HPFs|FLOCCULATION|||VENDOR|PATHOLOGIST 2|N|3|Visit_3|40|5|TREATMENT|2020-06-27|40
e|TR|2738b933-c71d-4239-a093-6b4aa7cc41df|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|ag|NONPALPABLE|1|mEq/L|TEMPLATE INCISION METHOD|||FAMILY MEMBER|PATHOLOGIST 1|Y|4|Visit_4|65|2|TREATMENT|2020-07-22|65
e|TR|2738b933-c71d-4239-a093-6b4aa7cc41df|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|10^9 organisms|PALPABLE|1|mmol/L|SLIT LAMP PHOTOGRAPHY||Y|STUDY SUBJECT|OPHTHALMOLOGIST|U|5|Visit_5|90|4|SCREENING|2020-08-16|90
e|TR|68b9ff4e-9694-4545-a752-4d3ac0e89fda|1|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|usec|PALPABLE|1|BOLUS|ANGIOGRAPHY||Y|INVESTIGATOR|PATHOLOGIST 2|U|1|Visit_1|10|5|TREATMENT|2021-01-08|10
e|TR|68b9ff4e-9694-4545-a752-4d3ac0e89fda|2|[?]|ACHNAD|Absolute Change From Nadir|[?]|mm/2h|PATHOLOGICAL|1|U/kg/h|AGAR PROPORTION|||ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|NA|2|Visit_2|25|7|FOLLOW-UP|2021-01-23|25
e|TR|68b9ff4e-9694-4545-a752-4d3ac0e89fda|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|nkat|DECREASED|1|MBq/uL|CISH|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|NA|3|Visit_3|40|1|TREATMENT|2021-02-07|40
e|TR|68b9ff4e-9694-4545-a752-4d3ac0e89fda|4|[?]|LPERP|Longest Perpendicular|[?]|BAU|ENLARGEMENT|1|uL/mL|GEL ELECTROPHORESIS|||SIGNIFICANT OTHER|MICROSCOPIST 1|U|4|Visit_4|65|2|FOLLOW-UP|2021-03-04|65
e|TR|68b9ff4e-9694-4545-a752-4d3ac0e89fda|5|[?]|SUMDIAM|Sum of Diameter|[?]|uCi|NORMAL|1|CCID 50/dose|PAP STAIN|||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|5|Visit_5|90|1|TREATMENT|2021-03-29|90
e|TR|0f0ec179-5100-4a3d-9f93-54140aca7d30|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|mL/m2|FURTHER ENLARGEMENT|1|mg/min|PERCUSSION|||ADJUDICATOR|PATHOLOGIST 1|N|1|Visit_1|10|5|FOLLOW-UP|2020-08-25|10
e|TR|0f0ec179-5100-4a3d-9f93-54140aca7d30|2|[?]|PCHGBL|Percent Change From Baseline|[?]|Anson U|ENLARGEMENT|1|dpm/0.5 mL|AUSCULTATION|||DOMESTIC PARTNER|RATER|N|2|Visit_2|25|4|TREATMENT|2020-09-09|25
e|TR|0f0ec179-5100-4a3d-9f93-54140aca7d30|3|[?]|LNSTATE|Lymph Node State|[?]|PFU/dose|PRESENT|1|/40 HPFs|SANGER SEQUENCING|Y||HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|3|Visit_3|40|3|WASHOUT|2020-09-24|40
e|TR|0f0ec179-5100-4a3d-9f93-54140aca7d30|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|v/v|ENLARGEMENT|1|mL/mmHg/min/L|ENZYMATIC COLORIMETRY|Y||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|U|4|Visit_4|65|4|TREATMENT|2020-10-19|65
e|TR|0f0ec179-5100-4a3d-9f93-54140aca7d30|5|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|log10 IU/mL|UNEQUIVOCAL|1|nkat|LANDOLT RING||Y|CAREGIVER|ENDOCRINOLOGIST|N|5|Visit_5|90|3|FOLLOW-UP|2020-11-13|90
e|TR|6affe43d-e455-40af-8478-dc38019e89e1|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mAnson U/mL|PATHOLOGICAL|1|uL/kg/day|RAJI CELL EIA|Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|1|Visit_1|10|4|TREATMENT|2020-06-17|10
e|TR|6affe43d-e455-40af-8478-dc38019e89e1|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|usec|UNEQUIVOCAL|1|ng/L|EIA|||ADJUDICATION COMMITTEE|RATER|N|2|Visit_2|25|7|WASHOUT|2020-07-02|25
e|TR|6affe43d-e455-40af-8478-dc38019e89e1|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|BISCUIT|PALPABLE|1|mL/100g/min|IMPEDANCE CONDUCTIVITY|||SPOUSE|MICROSCOPIST|Y|3|Visit_3|40|5|SCREENING|2020-07-17|40
e|TR|6affe43d-e455-40af-8478-dc38019e89e1|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|10^3 organisms/g|PALPABLE|1|PIXELS/cm|MICRO BROTH DILUTION|Y|Y|PROXY|DERMATOLOGIST|U|4|Visit_4|65|2|TREATMENT|2020-08-11|65
e|TR|6affe43d-e455-40af-8478-dc38019e89e1|5|[?]|NEWCONF|New Tumor Confirmed|[?]|GBq/g|PRESENT|1|Joule|SURFACE PLASMON RESONANCE|||FAMILY MEMBER|RATER 2|U|5|Visit_5|90|5|TREATMENT|2020-09-05|90
e|TR|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|DIOPTER|PATHOLOGICAL|1|log10 CFU/g|CLOT DETECTION|||SIGNIFICANT OTHER|PATHOLOGIST 2|U|1|Visit_1|10|5|SCREENING|2020-06-07|10
e|TR|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|2|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|kHz|FOCALLY INCREASED|1|nmol/mL/min|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|Y|SPOUSE|DERMATOLOGIST|Y|2|Visit_2|25|5|WASHOUT|2020-06-22|25
e|TR|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|cycle/min|ENLARGEMENT|1|Pa|FLOW MICROSCOPY|||INTERVIEWER|RATER|N|3|Visit_3|40|4|TREATMENT|2020-07-07|40
e|TR|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|Gy/min|TUMOR MERGED|1|mg/g/min|DUKE INCISION METHOD||Y|SIGNIFICANT OTHER|ONCOLOGIST 2|U|4|Visit_4|65|5|TREATMENT|2020-08-01|65
e|TR|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|5|[?]|VOLUME|Volume|[?]|titer|NON-PATHOLOGICAL|1|uV|QUANTITATIVE ULTRASOUND||Y|FRIEND|OPHTHALMOLOGIST|Y|5|Visit_5|90|5|WASHOUT|2020-08-26|90
e|TR|e0258c95-7bcc-4b54-895c-f290a1364b5c|1|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|10^8/L|NORMAL|1|nkat/L|TOTAL BODY IRRADIATION||Y|CLINICAL RESEARCH ASSOCIATE|RATER 1|Y|1|Visit_1|10|2|FOLLOW-UP|2020-12-27|10
e|TR|e0258c95-7bcc-4b54-895c-f290a1364b5c|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|pg/cell|PRESENT|1|uCi/kg|MAGNETIC RESONANCE ANGIOGRAPHY|Y||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2021-01-11|25
e|TR|e0258c95-7bcc-4b54-895c-f290a1364b5c|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|ng/dL|FOCALLY INCREASED|1|FINGERTIP UNIT|CINEANGIOGRAPHY|Y||SIGNIFICANT OTHER|NEUROLOGIST 2|U|3|Visit_3|40|5|WASHOUT|2021-01-26|40
e|TR|e0258c95-7bcc-4b54-895c-f290a1364b5c|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|BISCUIT|NON-PATHOLOGICAL|1|U/mmol|REFLECTANCE SPECTROSCOPY|||NON-HEALTH CARE PROFESSIONAL|READER 1|N|4|Visit_4|65|4|SCREENING|2021-02-20|65
e|TR|e0258c95-7bcc-4b54-895c-f290a1364b5c|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mkat|DIFFUSELY INCREASED|1|AgU/mL|THICK SMEAR|||ADJUDICATOR|RATER|N|5|Visit_5|90|7|TREATMENT|2021-03-17|90
e|TR|7218f9ae-0119-4633-a8d3-7d98b2ae1671|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|MET*h|PALPABLE|1|nmol/L/min|CYSTOSCOPY||Y|SPOUSE|OPHTHALMOLOGIST|NA|1|Visit_1|10|2|SCREENING|2021-01-13|10
e|TR|7218f9ae-0119-4633-a8d3-7d98b2ae1671|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|DRINK|UNCHANGED|1|GLOBULE|BIOIMPEDANCE SPECTROSCOPY||Y|FAMILY MEMBER|NEUROLOGIST 1|U|2|Visit_2|25|1|FOLLOW-UP|2021-01-28|25
e|TR|7218f9ae-0119-4633-a8d3-7d98b2ae1671|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|fmol|NONPALPABLE|1|Enzyme U/m2|LANDOLT RING|||PARENT|RATER 2|N|3|Visit_3|40|1|TREATMENT|2021-02-12|40
e|TR|7218f9ae-0119-4633-a8d3-7d98b2ae1671|4|[?]|LPERP|Longest Perpendicular|[?]|BE/mL|PALPABLE|1|10^7/L|NON-INVASIVE DIELECTRIC SENSING|||PROXY|RADIOLOGIST 1|Y|4|Visit_4|65|7|FOLLOW-UP|2021-03-09|65
e|TR|7218f9ae-0119-4633-a8d3-7d98b2ae1671|5|[?]|LESSCIND|Lesion Success Indicator|[?]|mol/L|ABSENT|1|umol/min|KINYOUN STAIN|||PARENT|UROLOGIST|U|5|Visit_5|90|4|WASHOUT|2021-04-03|90
e|TR|f8c938ff-21c8-4d0b-9335-08d2865543ab|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|Farad|FURTHER ENLARGEMENT FROM NADIR|1|Ci/mg|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Y|Y|INVESTIGATOR|OPTOMETRIST|U|1|Visit_1|10|4|TREATMENT|2020-05-11|10
e|TR|f8c938ff-21c8-4d0b-9335-08d2865543ab|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|PRESSOR UNITS|ABSENT|1|Absorbance U/mL|POPULATION SEQUENCING|||STUDY SUBJECT|ADJUDICATOR|Y|2|Visit_2|25|4|FOLLOW-UP|2020-05-26|25
e|TR|f8c938ff-21c8-4d0b-9335-08d2865543ab|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|ks|FURTHER ENLARGEMENT|1|BAU|TRANSVAGINAL ULTRASOUND|Y||INTERVIEWER|ADJUDICATOR 1|NA|3|Visit_3|40|1|SCREENING|2020-06-10|40
e|TR|f8c938ff-21c8-4d0b-9335-08d2865543ab|4|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|mL/mmHg|UNEQUIVOCAL|1|hr/day|PANENDOSCOPY|||SIGNIFICANT OTHER|MICROSCOPIST 1|NA|4|Visit_4|65|7|TREATMENT|2020-07-05|65
e|TR|f8c938ff-21c8-4d0b-9335-08d2865543ab|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|usec|FURTHER ENLARGEMENT FROM NADIR|1|Absorbance U/min|DIGITAL PCR ARRAY|||PROXY|OPHTHALMOLOGIST|NA|5|Visit_5|90|3|FOLLOW-UP|2020-07-30|90
e|TR|7176f852-7392-4636-800f-3aad48e93065|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|vp/dose|NONPALPABLE|1|mmHg*min/L|LYMPHANGIOGRAPHY|||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|2|TREATMENT|2021-01-16|10
e|TR|7176f852-7392-4636-800f-3aad48e93065|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|JAR|DIFFUSELY INCREASED|1|h*%|CRYOSCOPY|||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2021-01-31|25
e|TR|7176f852-7392-4636-800f-3aad48e93065|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|Sv|TUMOR MERGED|1|mEq/mL|FLOW CYTOMETRY|||CHILD|ADJUDICATOR 1|NA|3|Visit_3|40|1|TREATMENT|2021-02-15|40
e|TR|7176f852-7392-4636-800f-3aad48e93065|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|Bq/L|TUMOR MERGED|1|mCi/L|SEQUENCING|Y||ADJUDICATOR|PHYSIOTHERAPIST|U|4|Visit_4|65|5|WASHOUT|2021-03-12|65
e|TR|7176f852-7392-4636-800f-3aad48e93065|5|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|fg|ENLARGEMENT|1|CAPSULE|MALDI||Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|5|Visit_5|90|7|TREATMENT|2021-04-06|90
e|TR|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|IU/dL|ABSENT|1|um2|STATIC PERIMETRY|||CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|7|FOLLOW-UP|2020-10-08|10
e|TR|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|2|[?]|LPERP|Longest Perpendicular|[?]|OI50|NON-PATHOLOGICAL|1|uV*sec|COLORIMETRY|||DOMESTIC PARTNER|PHYSIOTHERAPIST|NA|2|Visit_2|25|6|TREATMENT|2020-10-23|25
e|TR|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|3|[?]|LPERP|Longest Perpendicular|[?]|mmHg*min/L|FURTHER ENLARGEMENT FROM NADIR|1|g/m2/day|WEBER GREEN STAIN|||SIGNIFICANT OTHER|PATHOLOGIST 1|U|3|Visit_3|40|3|FOLLOW-UP|2020-11-07|40
e|TR|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|4|[?]|TUMSTATE|Tumor State|[?]|Bq/ug|PATHOLOGICAL|1|in2|CARDIAC THERMODILUTION|||STUDY SUBJECT|RATER|U|4|Visit_4|65|6|TREATMENT|2020-12-02|65
e|TR|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|5|[?]|BNLNUM|Number of Bone Lesions|[?]|ft|PRESENT|1|ug/kg/h|QUANTITATIVE CORONARY ANGIOGRAPHY|Y||GUARDIAN|OPTOMETRIST|Y|5|Visit_5|90|7|SCREENING|2020-12-27|90
e|TR|69e41d6b-57f7-48b0-be7a-29fca953f8d9|1|[?]|PPD|Product of Perpendicular Diameters|[?]|mEq/mmol|UNEQUIVOCAL|1|days/month|POLYMERASE CHAIN REACTION|||CHILD|PATHOLOGIST|NA|1|Visit_1|10|4|FOLLOW-UP|2020-10-28|10
e|TR|69e41d6b-57f7-48b0-be7a-29fca953f8d9|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|pmol/L/h|PATHOLOGICAL|1|kBq|NUCLEIC ACID SEQUENCING|||FAMILY MEMBER|MICROSCOPIST 1|N|2|Visit_2|25|5|WASHOUT|2020-11-12|25
e|TR|69e41d6b-57f7-48b0-be7a-29fca953f8d9|3|[?]|LPERP|Longest Perpendicular|[?]|um/s|NONPALPABLE|1|nCi|TOTAL BODY IRRADIATION|||SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|3|SCREENING|2020-11-27|40
e|TR|69e41d6b-57f7-48b0-be7a-29fca953f8d9|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|10^7 CFU/mL|TUMOR MERGED|1|mL/m2/day|LYMPHANGIOGRAPHY|||CAREGIVER|ONCOLOGIST 2|NA|4|Visit_4|65|4|SCREENING|2020-12-22|65
e|TR|69e41d6b-57f7-48b0-be7a-29fca953f8d9|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|P|TUMOR MERGED|1|VIAL|FLUORESCENT ENZYME IMMUNOASSAY||Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2021-01-16|90
e|TR|a38eb4fc-2422-4d4a-a435-58ae9bf42589|1|[?]|SUMVOL|Sum of Volume|[?]|CIGAR|DIFFUSELY INCREASED|1|cP|X-RAY FLUORESCENCE SPECTROMETRY||Y|SPOUSE|RATER 2|NA|1|Visit_1|10|5|WASHOUT|2020-11-23|10
e|TR|a38eb4fc-2422-4d4a-a435-58ae9bf42589|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|USP U|NORMAL|1|/ms|HIGH RESOLUTION CT|||CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-12-08|25
e|TR|a38eb4fc-2422-4d4a-a435-58ae9bf42589|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|10^4/L|TUMOR MERGED|1|tsp eq|MANUAL COUNT|Y||PARENT|ONCOLOGIST 2|U|3|Visit_3|40|1|WASHOUT|2020-12-23|40
e|TR|a38eb4fc-2422-4d4a-a435-58ae9bf42589|4|[?]|BNLNUM|Number of Bone Lesions|[?]|mL/sec/1.73m2|PATHOLOGICAL|1|BISCUIT|TEST STRIP|||SPOUSE|ADJUDICATOR 2|NA|4|Visit_4|65|5|WASHOUT|2021-01-17|65
e|TR|a38eb4fc-2422-4d4a-a435-58ae9bf42589|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|mEq/L|ENLARGEMENT FROM NADIR|1|TABLET|HPLC/IEX|||CHILD|ONCOLOGIST|N|5|Visit_5|90|3|TREATMENT|2021-02-11|90
e|TR|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|1|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|10^9 organisms/g|ABSENT|1|OD Unit|MALDI||Y|FRIEND|MICROSCOPIST|NA|1|Visit_1|10|2|TREATMENT|2020-09-26|10
e|TR|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|2|[?]|BNLNUM|Number of Bone Lesions|[?]|10^9/L|NONPALPABLE|1|IU/dL|ELISPOT|||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-10-11|25
e|TR|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|3|[?]|SUMVOL|Sum of Volume|[?]|C|NON-PATHOLOGICAL|1|Enzyme U/m2|ELISA|||SIBLING|MICROSCOPIST 3|N|3|Visit_3|40|6|TREATMENT|2020-10-26|40
e|TR|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|4|[?]|LDIAM|Longest Diameter|[?]|ng|DECREASED|1|U/kg|TONOMETRY|Y||NON-HEALTH CARE PROFESSIONAL|READER 3|U|4|Visit_4|65|7|WASHOUT|2020-11-20|65
e|TR|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|5|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|mg/kg/week|NONPALPABLE|1|ug|FISH||Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|Y|5|Visit_5|90|2|TREATMENT|2020-12-15|90
e|TR|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|10^6 DNA copies/mL|EQUIVOCAL|1|JAR|PET/CT SCAN WITHOUT CONTRAST|||VENDOR|READER|NA|1|Visit_1|10|6|WASHOUT|2021-01-01|10
e|TR|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|anti-Xa IU|PRESENT|1|nmol/L|HPLC-FL|||ADJUDICATION COMMITTEE|RATER 1|NA|2|Visit_2|25|1|TREATMENT|2021-01-16|25
e|TR|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|10^3 RNA copies/mL|PALPABLE|1|uL/kg/day|WHOLE TRANSCRIPTOME SEQUENCING|||PARENT|RADIOLOGIST 1|NA|3|Visit_3|40|1|TREATMENT|2021-01-31|40
e|TR|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|4|[?]|VOLUME|Volume|[?]|cg|NONPALPABLE|1|U/m2|LASER CAPTURE MICRODISSECTION|||FRIEND|MICROSCOPIST 2|N|4|Visit_4|65|6|WASHOUT|2021-02-25|65
e|TR|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|5|[?]|RADIODEN|Radiodensity|[?]|dL|PATHOLOGICAL|1|10^7 PFU|ELECTRICAL IMPEDANCE MYOGRAPHY|Y||SIGNIFICANT OTHER|OPHTHALMOLOGIST|U|5|Visit_5|90|3|FOLLOW-UP|2021-03-22|90
e|TR|dd518f55-0280-445d-a29f-10f09b21fd53|1|[?]|ORVERLN|Organ Vertical Length|[?]|L/kg|FURTHER ENLARGEMENT|1|kg/cm|COULOMETRIC TITRATION||Y|INVESTIGATOR|RATER|N|1|Visit_1|10|7|FOLLOW-UP|2020-05-18|10
e|TR|dd518f55-0280-445d-a29f-10f09b21fd53|2|[?]|LPERP|Longest Perpendicular|[?]|ug|EQUIVOCAL|1|umol/L/h|DROPLET DIGITAL PCR|||STUDY SUBJECT|RADIOLOGIST 2|U|2|Visit_2|25|6|FOLLOW-UP|2020-06-02|25
e|TR|dd518f55-0280-445d-a29f-10f09b21fd53|3|[?]|LDIAM|Longest Diameter|[?]|/100 HPFs|TUMOR MERGED|1|pmol/g|OLIGO ACGH|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|3|Visit_3|40|5|SCREENING|2020-06-17|40
e|TR|dd518f55-0280-445d-a29f-10f09b21fd53|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|BAR|FURTHER ENLARGEMENT|1|ug/dL|ELASTOGRAPHY|Y||STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|1|TREATMENT|2020-07-12|65
e|TR|dd518f55-0280-445d-a29f-10f09b21fd53|5|[?]|BNLNUM|Number of Bone Lesions|[?]|mg/kg/min|UNCHANGED|1|mL/animal|MRI|Y||INDEPENDENT ASSESSOR|READER 1|Y|5|Visit_5|90|2|TREATMENT|2020-08-06|90
e|TR|49a972da-dfad-438e-b5bc-26ee6b955a59|1|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mEq/kg|DIFFUSELY INCREASED|1|Ci/uL|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y||DOMESTIC PARTNER|RATER|NA|1|Visit_1|10|7|TREATMENT|2020-06-24|10
e|TR|49a972da-dfad-438e-b5bc-26ee6b955a59|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|10^3/hpf|NON-PATHOLOGICAL|1|mol/mg|IRON HEMATOXYLIN STAIN|||SPOUSE|RATER 2|U|2|Visit_2|25|2|FOLLOW-UP|2020-07-09|25
e|TR|49a972da-dfad-438e-b5bc-26ee6b955a59|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|g/cage/wk|PATHOLOGICAL|1|U/g/h|ICC|Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|Y|3|Visit_3|40|2|TREATMENT|2020-07-24|40
e|TR|49a972da-dfad-438e-b5bc-26ee6b955a59|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mL/s|TUMOR MERGED|1|cm H2O|FISH|||ADJUDICATION COMMITTEE|RATER|N|4|Visit_4|65|1|TREATMENT|2020-08-18|65
e|TR|49a972da-dfad-438e-b5bc-26ee6b955a59|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|mm/h|UNEQUIVOCAL|1|/500 WBC|CONGO RED STAIN|Y||SPOUSE|PHYSIOTHERAPIST|NA|5|Visit_5|90|4|TREATMENT|2020-09-12|90
e|TR|502a42a7-2ed6-46b9-9b10-728f849334b6|1|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|Shock Wave|EQUIVOCAL|1|amol|IMMUNOASSAY|||INVESTIGATOR|PATHOLOGIST|N|1|Visit_1|10|3|TREATMENT|2020-11-21|10
e|TR|502a42a7-2ed6-46b9-9b10-728f849334b6|2|[?]|LNSTATE|Lymph Node State|[?]|g/dL|DIFFUSELY INCREASED|1|mmol/mol|IMMUNOBLOT|Y|Y|FAMILY MEMBER|MICROSCOPIST|N|2|Visit_2|25|2|WASHOUT|2020-12-06|25
e|TR|502a42a7-2ed6-46b9-9b10-728f849334b6|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|kcal/day|PRESENT|1|OD Unit|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||CAREGIVER|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|7|WASHOUT|2020-12-21|40
e|TR|502a42a7-2ed6-46b9-9b10-728f849334b6|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mL/beat|PRESENT|1|Ci/uL|DOUBLE IMMUNODIFFUSION|Y||INDEPENDENT ASSESSOR|ADJUDICATOR|N|4|Visit_4|65|7|TREATMENT|2021-01-15|65
e|TR|502a42a7-2ed6-46b9-9b10-728f849334b6|5|[?]|SUMVOL|Sum of Volume|[?]|/HPF|PRESENT|1|uL|RADIOGRAPHY|||FRIEND|ADJUDICATOR 3|N|5|Visit_5|90|4|SCREENING|2021-02-09|90
e|TR|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|nL|FURTHER ENLARGEMENT FROM NADIR|1|kg|OPTICAL DENSITY MEASUREMENT|||CLINICAL STUDY SPONSOR|CARDIOLOGIST|Y|1|Visit_1|10|7|TREATMENT|2020-10-26|10
e|TR|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|2|[?]|BNLNUM|Number of Bone Lesions|[?]|CFU/g|ENLARGEMENT|1|uV|LC-FL|||SPOUSE|ADJUDICATOR 2|Y|2|Visit_2|25|6|TREATMENT|2020-11-10|25
e|TR|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|KIT|ENLARGEMENT|1|gpELISA unit/mL|AGAR DILUTION|||SIBLING|ADJUDICATOR 1|N|3|Visit_3|40|2|SCREENING|2020-11-25|40
e|TR|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|4|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|Torr|ABSENT|1|U/kg/day|IODINE STAIN|||SPOUSE|PHYSIOTHERAPIST|U|4|Visit_4|65|5|TREATMENT|2020-12-20|65
e|TR|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|U/g/min|DECREASED|1|ng/dL|ANALYTICAL ULTRACENTRIFUGATION|||ADJUDICATOR|OPHTHALMOLOGIST|NA|5|Visit_5|90|2|SCREENING|2021-01-14|90
e|TR|40c048ea-d637-426b-8afe-2da3a6961528|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|pmol/10^9 cells|NORMAL|1|mEq/L|DIFFUSION TENSOR MRI|||INTERVIEWER|READER 2|U|1|Visit_1|10|1|SCREENING|2020-07-13|10
e|TR|40c048ea-d637-426b-8afe-2da3a6961528|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|mph|DECREASED|1|log10 PFU/mL|INDIA INK STAIN|Y||PARENT|ENDOCRINOLOGIST|N|2|Visit_2|25|7|WASHOUT|2020-07-28|25
e|TR|40c048ea-d637-426b-8afe-2da3a6961528|3|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|Gy|PRESENT|1|PFU/mL|SPECT/CT SCAN|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-08-12|40
e|TR|40c048ea-d637-426b-8afe-2da3a6961528|4|[?]|ORSTATE|Organ State|[?]|10^3/hpf|INCREASED|1|mOsm/kg|PANENDOSCOPY||Y|PROXY|ADJUDICATOR 1|N|4|Visit_4|65|6|TREATMENT|2020-09-06|65
e|TR|40c048ea-d637-426b-8afe-2da3a6961528|5|[?]|PPD|Product of Perpendicular Diameters|[?]|gpELISA unit/mL|PATHOLOGICAL|1|umol/L|IMPEDANCE CONDUCTIVITY|Y||CLINICAL STUDY SPONSOR|MICROSCOPIST 1|Y|5|Visit_5|90|1|FOLLOW-UP|2020-10-01|90
e|TR|4d03b209-bd53-47f5-8251-f9fb2074bc38|1|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mL/kg|FURTHER ENLARGEMENT|1|pmol/L/h|LINE PROBE ASSAY|Y||SPOUSE|OPHTHALMOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2021-01-02|10
e|TR|4d03b209-bd53-47f5-8251-f9fb2074bc38|2|[?]|LPERP|Longest Perpendicular|[?]|mmol/day|PALPABLE|1|sec|MICROARRAY||Y|DOMESTIC PARTNER|PATHOLOGIST|NA|2|Visit_2|25|4|SCREENING|2021-01-17|25
e|TR|4d03b209-bd53-47f5-8251-f9fb2074bc38|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|Osm|TUMOR MERGED|1|deg/s|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|||ADJUDICATOR|PHYSIOTHERAPIST|Y|3|Visit_3|40|3|TREATMENT|2021-02-01|40
e|TR|4d03b209-bd53-47f5-8251-f9fb2074bc38|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|10^7 CFU/mL|DECREASED|1|mL/h|ECHOCARDIOGRAPHY|Y||INTERVIEWER|HEMATOLOGIST|N|4|Visit_4|65|2|WASHOUT|2021-02-26|65
e|TR|4d03b209-bd53-47f5-8251-f9fb2074bc38|5|[?]|PPD|Product of Perpendicular Diameters|[?]|FIU|DIFFUSELY INCREASED|1|NEBULE|MEDIASTINOSCOPY|||INTERVIEWER|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|6|SCREENING|2021-03-23|90
e|TR|35f01eda-1acb-4700-8285-c8cd4b69b524|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|ug/mol|FURTHER ENLARGEMENT FROM NADIR|1|mgEq|TRIPLE-PHASE MRI SCAN||Y|GUARDIAN|PHYSIOTHERAPIST|Y|1|Visit_1|10|3|TREATMENT|2020-09-30|10
e|TR|35f01eda-1acb-4700-8285-c8cd4b69b524|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|mmol2/L2|ENLARGEMENT FROM NADIR|1|dL|ELECTROPHORESIS|||SIGNIFICANT OTHER|OPHTHALMOLOGIST|N|2|Visit_2|25|1|FOLLOW-UP|2020-10-15|25
e|TR|35f01eda-1acb-4700-8285-c8cd4b69b524|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|U/kg/h|TUMOR MERGED|1|LOZENGE|HPLC/IEX|||PROXY|ONCOLOGIST 1|Y|3|Visit_3|40|3|TREATMENT|2020-10-30|40
e|TR|35f01eda-1acb-4700-8285-c8cd4b69b524|4|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|L/min|FURTHER ENLARGEMENT FROM NADIR|1|Ci/mg|OPHTHALMOSCOPY|||GUARDIAN|ADJUDICATOR|U|4|Visit_4|65|5|FOLLOW-UP|2020-11-24|65
e|TR|35f01eda-1acb-4700-8285-c8cd4b69b524|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|mEq/day|FOCALLY INCREASED|1|cmol/L|MICROBIAL CULTURE, SOLID|||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|N|5|Visit_5|90|2|TREATMENT|2020-12-19|90
e|TR|9df97277-7d07-4020-bae0-dfa982f21c8d|1|[?]|LDIAM|Longest Diameter|[?]|U/g Hb|NON-PATHOLOGICAL|1|nmol/mL/min|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y||SIBLING|READER 1|N|1|Visit_1|10|6|TREATMENT|2020-11-02|10
e|TR|9df97277-7d07-4020-bae0-dfa982f21c8d|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|uIU/dL|PALPABLE|1|mEq/L|WRIGHT-GIEMSA STAIN|||SIGNIFICANT OTHER|RATER 2|NA|2|Visit_2|25|3|TREATMENT|2020-11-17|25
e|TR|9df97277-7d07-4020-bae0-dfa982f21c8d|3|[?]|LNSTATE|Lymph Node State|[?]|ELISA unit|PATHOLOGICAL|1|BU/mL|INDIA INK STAIN|Y||SIGNIFICANT OTHER|MICROSCOPIST 2|N|3|Visit_3|40|2|WASHOUT|2020-12-02|40
e|TR|9df97277-7d07-4020-bae0-dfa982f21c8d|4|[?]|TUMSTATE|Tumor State|[?]|pkat|ENLARGEMENT|1|mg/m2/day|MICROBIAL CULTURE, SOLID|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|4|Visit_4|65|4|TREATMENT|2020-12-27|65
e|TR|9df97277-7d07-4020-bae0-dfa982f21c8d|5|[?]|ORVERLN|Organ Vertical Length|[?]|CAPSULE|UNCHANGED|1|kBq|PATHOLOGICAL EVALUATION|||PARENT|NEUROLOGIST 1|Y|5|Visit_5|90|3|FOLLOW-UP|2021-01-21|90
e|TR|d1b522d5-557a-4361-a9da-292aa601fbc3|1|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|/cmH2O|NON-PATHOLOGICAL|1|DAgU|KINYOUN STAIN||Y|INTERVIEWER|OTOLARYNGOLOGIST|NA|1|Visit_1|10|5|SCREENING|2020-10-09|10
e|TR|d1b522d5-557a-4361-a9da-292aa601fbc3|2|[?]|LPERP|Longest Perpendicular|[?]|Roentgen|NONPALPABLE|1|m2|CONFOCAL MICROSCOPY|||PARENT|HEMATOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-10-24|25
e|TR|d1b522d5-557a-4361-a9da-292aa601fbc3|3|[?]|BNLNUM|Number of Bone Lesions|[?]|TABLET|UNCHANGED|1|mL/100g/min|SNP ARRAY|Y||SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-11-08|40
e|TR|d1b522d5-557a-4361-a9da-292aa601fbc3|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|CCID 50/dose|INCREASED|1|kPa|CONFOCAL MICROSCOPY|||VENDOR|READER 2|N|4|Visit_4|65|6|FOLLOW-UP|2020-12-03|65
e|TR|d1b522d5-557a-4361-a9da-292aa601fbc3|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|10^6/L|TUMOR MERGED|1|/5x10^4 WBC|HEMAGGLUTINATION INHIBITION ASSAY|||SIGNIFICANT OTHER|RATER 2|N|5|Visit_5|90|3|TREATMENT|2020-12-28|90
e|TR|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|1|[?]|NEWCONF|New Tumor Confirmed|[?]|kg|ENLARGEMENT|1|10^3/hpf|TELLER ACUITY CARDS|Y|Y|INVESTIGATOR|NEUROLOGIST|U|1|Visit_1|10|4|FOLLOW-UP|2020-07-27|10
e|TR|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|2|[?]|LNSTATE|Lymph Node State|[?]|pkat/L|ENLARGEMENT|1|pt_br|MICROSCOPY|Y||CAREGIVER|MICROSCOPIST 1|Y|2|Visit_2|25|5|TREATMENT|2020-08-11|25
e|TR|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|BP|FURTHER ENLARGEMENT|1|IU/mL|WHOLE TRANSCRIPTOME SEQUENCING|||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-08-26|40
e|TR|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|4|[?]|SUMVOL|Sum of Volume|[?]|kN/cm2|NORMAL|1|umol/L|PULSE OXIMETRY|Y||SIBLING|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|4|SCREENING|2020-09-20|65
e|TR|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|5|[?]|DIAMETER|Diameter|[?]|L/s/kPa|NONPALPABLE|1|nmol/L|DISK DIFFUSION|||INDEPENDENT ASSESSOR|RADIOLOGIST|Y|5|Visit_5|90|2|TREATMENT|2020-10-15|90
e|TR|da2d0844-3608-4927-9103-cb7c52dd2c96|1|[?]|ORSTATE|Organ State|[?]|U/m2/min|ENLARGEMENT FROM NADIR|1|Absorbance U/min|TRANSMISSION ELECTRON MICROSCOPY|Y||PARENT|MICROSCOPIST 1|N|1|Visit_1|10|1|SCREENING|2021-01-26|10
e|TR|da2d0844-3608-4927-9103-cb7c52dd2c96|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|IU/mmol|NONPALPABLE|1|10^7 PFU|DOPPLER ULTRASOUND|||HEALTH CARE PROFESSIONAL|HEMATOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2021-02-10|25
e|TR|da2d0844-3608-4927-9103-cb7c52dd2c96|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|PFU/dose|TUMOR MERGED|1|uL/mL|NUCLEIC ACID BASED METHOD|||FRIEND|MICROSCOPIST|Y|3|Visit_3|40|6|TREATMENT|2021-02-25|40
e|TR|da2d0844-3608-4927-9103-cb7c52dd2c96|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|atm|TUMOR MERGED|1|mEq/mL|CONGO RED STAIN|Y||CAREGIVER|ADJUDICATOR 2|NA|4|Visit_4|65|1|TREATMENT|2021-03-22|65
e|TR|da2d0844-3608-4927-9103-cb7c52dd2c96|5|[?]|AREA|Area|[?]|mg/dose|ENLARGEMENT FROM NADIR|1|mL/cm3/min|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y||SIBLING|RATER|N|5|Visit_5|90|4|SCREENING|2021-04-16|90
e|TR|30b6f8a7-4512-462d-a162-45c3dad853e5|1|[?]|LESSCIND|Lesion Success Indicator|[?]|in|PATHOLOGICAL|1|AU/mL|PUPILLOMETRY||Y|STUDY SUBJECT|ADJUDICATOR|NA|1|Visit_1|10|1|TREATMENT|2020-12-02|10
e|TR|30b6f8a7-4512-462d-a162-45c3dad853e5|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|10^7 CFU|ABSENT|1|GBq/mg|MANUAL COUNT|||CAREGIVER|OPHTHALMOLOGIST|NA|2|Visit_2|25|2|FOLLOW-UP|2020-12-17|25
e|TR|30b6f8a7-4512-462d-a162-45c3dad853e5|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|umol/day|EQUIVOCAL|1|m3|BIOIMPEDANCE SPECTROSCOPY|Y||INTERVIEWER|READER 1|N|3|Visit_3|40|1|TREATMENT|2021-01-01|40
e|TR|30b6f8a7-4512-462d-a162-45c3dad853e5|4|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|Shock Wave|PALPABLE|1|copies/uL|PUPILLOMETRY|||DOMESTIC PARTNER|UROLOGIST|U|4|Visit_4|65|4|TREATMENT|2021-01-26|65
e|TR|30b6f8a7-4512-462d-a162-45c3dad853e5|5|[?]|ORSTATE|Organ State|[?]|umol/L|ABSENT|1|10^3 DNA copies/mL|DC SHEATH FLOW|||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|4|TREATMENT|2021-02-20|90
e|TR|1a3808b9-6004-4133-8f59-49905d04655e|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|psi|FURTHER ENLARGEMENT FROM NADIR|1|Hz/s|TWO-COLOR MICROARRAY|||GUARDIAN|PHYSIOTHERAPIST|Y|1|Visit_1|10|2|TREATMENT|2020-11-07|10
e|TR|1a3808b9-6004-4133-8f59-49905d04655e|2|[?]|AREA|Area|[?]|%/min|DECREASED|1|ug/m2/min|STRESS ECHOCARDIOGRAPHY|Y||CLINICAL STUDY SPONSOR|ONCOLOGIST|N|2|Visit_2|25|2|TREATMENT|2020-11-22|25
e|TR|1a3808b9-6004-4133-8f59-49905d04655e|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|MET*h|ABSENT|1|10^6 RNA copies/mL|SLIT LAMP PHOTOGRAPHY|||INVESTIGATOR|ONCOLOGIST|N|3|Visit_3|40|6|FOLLOW-UP|2020-12-07|40
e|TR|1a3808b9-6004-4133-8f59-49905d04655e|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|RNA copies/mL|FURTHER ENLARGEMENT|1|mg/dL|TRANSVAGINAL ULTRASOUND|||SPOUSE|READER 2|N|4|Visit_4|65|3|TREATMENT|2021-01-01|65
e|TR|1a3808b9-6004-4133-8f59-49905d04655e|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|g/cage/day|NONPALPABLE|1|Hounsfield Unit|MAPH|||SIBLING|NEUROLOGIST 1|U|5|Visit_5|90|7|TREATMENT|2021-01-26|90
e|TR|5c91894d-c756-4ade-9fc4-2a64d4acc53f|1|[?]|ORVERLN|Organ Vertical Length|[?]|ug/g/day|UNCHANGED|1|mN|RADIOIMMUNOPRECIPITATION ASSAY|||PARENT|DERMATOLOGIST|N|1|Visit_1|10|3|FOLLOW-UP|2021-01-19|10
e|TR|5c91894d-c756-4ade-9fc4-2a64d4acc53f|2|[?]|CALCFIND|Calcification Indicator|[?]|Gauss|PATHOLOGICAL|1|mEq/dL|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||VENDOR|RADIOLOGIST 1|Y|2|Visit_2|25|3|TREATMENT|2021-02-03|25
e|TR|5c91894d-c756-4ade-9fc4-2a64d4acc53f|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|g|PALPABLE|1|log10 PFU|MICROSCOPY|Y|Y|VENDOR|RADIOLOGIST|U|3|Visit_3|40|6|FOLLOW-UP|2021-02-18|40
e|TR|5c91894d-c756-4ade-9fc4-2a64d4acc53f|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|pg/cell|ENLARGEMENT FROM NADIR|1|mg/cm2|SPIRAL CT SCAN WITHOUT CONTRAST|||INDEPENDENT ASSESSOR|RATER 1|Y|4|Visit_4|65|3|SCREENING|2021-03-15|65
e|TR|5c91894d-c756-4ade-9fc4-2a64d4acc53f|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|aMFI|NON-PATHOLOGICAL|1|NEBULE|LC/MS|||SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|1|TREATMENT|2021-04-09|90
e|TR|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|U/g/h|FURTHER ENLARGEMENT FROM NADIR|1|umol/h/mmol|WHOLE GENOME SEQUENCING|Y||ADJUDICATOR|NEUROLOGIST|NA|1|Visit_1|10|6|FOLLOW-UP|2020-07-15|10
e|TR|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|kg|NONPALPABLE|1|CIGARETTE|SINGLE-SLICE SPIRAL CT||Y|FAMILY MEMBER|RATER 1|NA|2|Visit_2|25|4|TREATMENT|2020-07-30|25
e|TR|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|3|[?]|DIAMETER|Diameter|[?]|min*mg/mL|NORMAL|1|OD Unit|FLAME PHOTOMETRY|||INDEPENDENT ASSESSOR|MICROSCOPIST|N|3|Visit_3|40|7|TREATMENT|2020-08-14|40
e|TR|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|4|[?]|BNLNUM|Number of Bone Lesions|[?]|Gy/min|PATHOLOGICAL|1|SPRAY|GC/MS|||INVESTIGATOR|READER 1|Y|4|Visit_4|65|3|SCREENING|2020-09-08|65
e|TR|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|Sv|NONPALPABLE|1|kg/cm|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||FAMILY MEMBER|PATHOLOGIST 1|Y|5|Visit_5|90|1|FOLLOW-UP|2020-10-03|90
e|TR|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|1|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|EID 50/mL|UNCHANGED|1|mEq/L|HPLC/MS|||FAMILY MEMBER|NEUROLOGIST 1|Y|1|Visit_1|10|2|TREATMENT|2020-09-15|10
e|TR|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|ug/g/day|ABSENT|1|GBq/mg|MICROBIAL CULTURE, LIQUID|||FAMILY MEMBER|CLINICAL PATHOLOGIST|N|2|Visit_2|25|3|TREATMENT|2020-09-30|25
e|TR|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|AFU|PRESENT|1|mL/100g/min|SLOAN LETTER EYE CHART 100%|Y||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|3|Visit_3|40|5|SCREENING|2020-10-15|40
e|TR|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mol/mol|NONPALPABLE|1|DDU|AUSCULTATION||Y|STUDY SUBJECT|NEUROLOGIST|N|4|Visit_4|65|3|WASHOUT|2020-11-09|65
e|TR|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|5|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|ft|PALPABLE|1|Ci/g|MULTIPLE BREATH WASHOUT|||SPOUSE|READER 2|U|5|Visit_5|90|4|WASHOUT|2020-12-04|90
e|TR|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|1|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|Tesla|ENLARGEMENT FROM NADIR|1|mL/cm|SMEAR|||INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|4|TREATMENT|2020-06-10|10
e|TR|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|Enzyme U|FOCALLY INCREASED|1|pmol|CLAUSS METHOD|||SPOUSE|PATHOLOGIST 2|NA|2|Visit_2|25|1|TREATMENT|2020-06-25|25
e|TR|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|log10 TCID 50/dose|DECREASED|1|Ci/uL|WHOLE TRANSCRIPTOME SEQUENCING|||INVESTIGATOR|ONCOLOGIST 2|Y|3|Visit_3|40|7|TREATMENT|2020-07-10|40
e|TR|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|4|[?]|LESSCIND|Lesion Success Indicator|[?]|MPL U/mL|DIFFUSELY INCREASED|1|MBq/uL|RADIOIMMUNOPRECIPITATION ASSAY|||STUDY SUBJECT|READER 2|Y|4|Visit_4|65|2|TREATMENT|2020-08-04|65
e|TR|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mg/mL/day|ABSENT|1|nmol BCE/L|INDIRECT IMMUNOFLUORESCENCE|Y|Y|CLINICAL STUDY SPONSOR|RATER 1|NA|5|Visit_5|90|2|TREATMENT|2020-08-29|90
e|TR|37610314-f803-4ffa-a584-ebfe09267a0d|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|Bq/mL|EQUIVOCAL|1|/100 HPFs|ISHIHARA COLOR PLATES||Y|SPOUSE|NEUROLOGIST 1|U|1|Visit_1|10|3|TREATMENT|2020-06-30|10
e|TR|37610314-f803-4ffa-a584-ebfe09267a0d|2|[?]|LESSCIND|Lesion Success Indicator|[?]|km|PATHOLOGICAL|1|BOWL|HPLC/MS|Y|Y|NON-HEALTH CARE PROFESSIONAL|READER 2|U|2|Visit_2|25|6|TREATMENT|2020-07-15|25
e|TR|37610314-f803-4ffa-a584-ebfe09267a0d|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|ug/L|INCREASED|1|PHERESIS UNIT|RADIAL IMMUNODIFFUSION|||INVESTIGATOR|ADJUDICATOR 1|NA|3|Visit_3|40|5|TREATMENT|2020-07-30|40
e|TR|37610314-f803-4ffa-a584-ebfe09267a0d|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|Shock Wave|PRESENT|1|mEq/mmol|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||Y|SIGNIFICANT OTHER|DERMATOLOGIST|NA|4|Visit_4|65|5|FOLLOW-UP|2020-08-24|65
e|TR|37610314-f803-4ffa-a584-ebfe09267a0d|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|um|NORMAL|1|MAC50|DARK FIELD MICROSCOPY|Y||HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|5|Visit_5|90|4|TREATMENT|2020-09-18|90
e|TR|760ec5ce-3ae7-4268-9f76-b83085ad3754|1|[?]|LDIAM|Longest Diameter|[?]|MESF|PATHOLOGICAL|1|dyn|CONTRAST ENHANCED MRI|||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-09-24|10
e|TR|760ec5ce-3ae7-4268-9f76-b83085ad3754|2|[?]|LESSCIND|Lesion Success Indicator|[?]|ug/kg|UNEQUIVOCAL|1|OD Unit|MAGNETIC RESONANCE ELASTOGRAPHY|||SPOUSE|ADJUDICATOR|N|2|Visit_2|25|2|FOLLOW-UP|2020-10-09|25
e|TR|760ec5ce-3ae7-4268-9f76-b83085ad3754|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|PIPE|ENLARGEMENT FROM NADIR|1|10^6 U|FLUORESCENT IMMUNOASSAY|||INDEPENDENT ASSESSOR|CARDIOLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-10-24|40
e|TR|760ec5ce-3ae7-4268-9f76-b83085ad3754|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|DNA copies/mL|PRESENT|1|/kg|CAPILLARY ELECTROPHORESIS|||FAMILY MEMBER|READER|Y|4|Visit_4|65|2|FOLLOW-UP|2020-11-18|65
e|TR|760ec5ce-3ae7-4268-9f76-b83085ad3754|5|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|kIU|UNCHANGED|1|10^4 CFU/mL|DYNAMOMETRY|||ADJUDICATOR|PATHOLOGIST 2|N|5|Visit_5|90|4|SCREENING|2020-12-13|90
e|TR|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|1|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|PFU/dose|ENLARGEMENT FROM NADIR|1|L/s|CAPILLARY ELECTROPHORESIS||Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-06-15|10
e|TR|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mmol/kg|FOCALLY INCREASED|1|10^6 CFU/mL|SPIROMETRY|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|2|Visit_2|25|2|SCREENING|2020-06-30|25
e|TR|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|3|[?]|LESSCIND|Lesion Success Indicator|[?]|kIU|ENLARGEMENT|1|ug/kg/h|DOPPLER ULTRASOUND|||HEALTH CARE PROFESSIONAL|READER 3|U|3|Visit_3|40|6|TREATMENT|2020-07-15|40
e|TR|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|L/min/m2|PRESENT|1|Gy/h|DISK DIFFUSION|||CHILD|RATER 1|NA|4|Visit_4|65|6|WASHOUT|2020-08-09|65
e|TR|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|5|[?]|DIAMETER|Diameter|[?]|g/day|TUMOR MERGED|1|ng/dL|TONOMETRY||Y|INVESTIGATOR|CARDIOLOGIST|NA|5|Visit_5|90|5|SCREENING|2020-09-03|90
e|TR|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|dB|NORMAL|1|fraction of 1|DIGITAL PCR ARRAY|Y||PARENT|ADJUDICATOR 3|N|1|Visit_1|10|5|TREATMENT|2021-01-24|10
e|TR|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|Gy/h|FOCALLY INCREASED|1|U/m2/h|CENTRIFUGATION||Y|STUDY SUBJECT|READER|N|2|Visit_2|25|1|FOLLOW-UP|2021-02-08|25
e|TR|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|10^6 organisms/mg|ENLARGEMENT|1|PIXEL|FISH||Y|ADJUDICATION COMMITTEE|INTERNIST|U|3|Visit_3|40|7|FOLLOW-UP|2021-02-23|40
e|TR|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|PACK|EQUIVOCAL|1|Log10 ELISA unit|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y||CAREGIVER|READER 3|N|4|Visit_4|65|7|WASHOUT|2021-03-20|65
e|TR|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|10^12 IU/L|DIFFUSELY INCREASED|1|SFC/10^6 PBMC|ULTRASOUND||Y|PROXY|RATER 1|NA|5|Visit_5|90|7|FOLLOW-UP|2021-04-14|90
e|TR|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mU|UNCHANGED|1|L/kg|SINGLE-MOLECULE ARRAY|||PROXY|NEUROLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-11-13|10
e|TR|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|km/h|DIFFUSELY INCREASED|1|KALLIKREIN INHIBITOR UNIT|INCISION-INDUCED BLEEDING METHOD|Y|Y|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|2|Visit_2|25|1|WASHOUT|2020-11-28|25
e|TR|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|3|[?]|VOLUME|Volume|[?]|Gravitational Unit|PALPABLE|1|ug/animal|LASER CAPTURE MICRODISSECTION||Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|7|FOLLOW-UP|2020-12-13|40
e|TR|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mg/day|EQUIVOCAL|1|mg/day|IVY INCISION METHOD|||SIBLING|ENDOCRINOLOGIST|U|4|Visit_4|65|3|TREATMENT|2021-01-07|65
e|TR|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|5|[?]|NEWCONF|New Tumor Confirmed|[?]|BISCUIT|NONPALPABLE|1|TRANSDUCING UNIT/mL|RYAN BLUE STAIN|||ADJUDICATOR|RADIOLOGIST|U|5|Visit_5|90|3|FOLLOW-UP|2021-02-01|90
e|TR|d7b41e15-6725-4433-8a35-72629e342b47|1|[?]|ORSTATE|Organ State|[?]|10^5/hpf|FURTHER ENLARGEMENT FROM NADIR|1|uV*sec|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y||PROXY|OTOLARYNGOLOGIST|NA|1|Visit_1|10|6|WASHOUT|2020-09-14|10
e|TR|d7b41e15-6725-4433-8a35-72629e342b47|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|10^3 organisms/g|ENLARGEMENT FROM NADIR|1|mL/sec/1.73m2|CONTACT SPECULAR MICROSCOPY||Y|DOMESTIC PARTNER|CARDIOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-09-29|25
e|TR|d7b41e15-6725-4433-8a35-72629e342b47|3|[?]|LNSTATE|Lymph Node State|[?]|U/g/min|DIFFUSELY INCREASED|1|YEARS|RADIOIMMUNOPRECIPITATION ASSAY|||GUARDIAN|PATHOLOGIST 2|Y|3|Visit_3|40|4|TREATMENT|2020-10-14|40
e|TR|d7b41e15-6725-4433-8a35-72629e342b47|4|[?]|NEWCONF|New Tumor Confirmed|[?]|/40 HPFs|FURTHER ENLARGEMENT|1|umol/L/sec|ALCIAN BLUE STAIN|||NON-HEALTH CARE PROFESSIONAL|UROLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-11-08|65
e|TR|d7b41e15-6725-4433-8a35-72629e342b47|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|10^7 PFU|PATHOLOGICAL|1|days/month|THERMAL IONIZATION MASS SPECTROMETRY|||ADJUDICATION COMMITTEE|RATER|U|5|Visit_5|90|1|TREATMENT|2020-12-03|90
e|TR|aeddc1ed-545c-405e-b1f7-08131961f5ff|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|cmH2O*s2/mL|DIFFUSELY INCREASED|1|VIRTUAL PIXEL|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||SIGNIFICANT OTHER|RADIOLOGIST 2|U|1|Visit_1|10|6|SCREENING|2020-10-15|10
e|TR|aeddc1ed-545c-405e-b1f7-08131961f5ff|2|[?]|SUMVOL|Sum of Volume|[?]|Rad|EQUIVOCAL|1|mL/min/mmHg|FLOCCULATION||Y|CAREGIVER|CLINICAL PATHOLOGIST|N|2|Visit_2|25|1|TREATMENT|2020-10-30|25
e|TR|aeddc1ed-545c-405e-b1f7-08131961f5ff|3|[?]|LPERP|Longest Perpendicular|[?]|uL/kg/day|PATHOLOGICAL|1|mAnson U/mL|MRI WITHOUT CONTRAST|Y||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|NA|3|Visit_3|40|4|FOLLOW-UP|2020-11-14|40
e|TR|aeddc1ed-545c-405e-b1f7-08131961f5ff|4|[?]|DIAMETER|Diameter|[?]|mCi|DECREASED|1|AgU/mL|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||SIGNIFICANT OTHER|PHYSIOTHERAPIST|U|4|Visit_4|65|3|WASHOUT|2020-12-09|65
e|TR|aeddc1ed-545c-405e-b1f7-08131961f5ff|5|[?]|NEWCONF|New Tumor Confirmed|[?]|in|PRESENT|1|ug/dL|ATOMIC ABSORPTION SPECTROMETRY|||CLINICAL STUDY SPONSOR|READER 2|U|5|Visit_5|90|5|SCREENING|2021-01-03|90
e|TR|3effe272-6a68-4163-a4f3-bd269af6061c|1|[?]|VDIAM|Viable Diameter|[?]|mg/dL|ENLARGEMENT FROM NADIR|1|10^5/hpf|REFLECTANCE SPECTROSCOPY|||INVESTIGATOR|MICROSCOPIST|NA|1|Visit_1|10|6|TREATMENT|2021-01-15|10
e|TR|3effe272-6a68-4163-a4f3-bd269af6061c|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|10^6 CFU|NONPALPABLE|1|mm|OPTICAL COHERENCE TOMOGRAPHY|||ADJUDICATOR|HEMATOLOGIST|U|2|Visit_2|25|1|WASHOUT|2021-01-30|25
e|TR|3effe272-6a68-4163-a4f3-bd269af6061c|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|min*mg/mL|PRESENT|1|cmH2O*s/mL|LIGHT MICROSCOPY|||SIGNIFICANT OTHER|RATER 1|N|3|Visit_3|40|3|TREATMENT|2021-02-14|40
e|TR|3effe272-6a68-4163-a4f3-bd269af6061c|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mU|UNEQUIVOCAL|1|Absorbance U/mL|OPTICAL MAPPING|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|2|SCREENING|2021-03-11|65
e|TR|3effe272-6a68-4163-a4f3-bd269af6061c|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|mEq/L|ENLARGEMENT FROM NADIR|1|cg|FLUORESCEIN STAIN|Y||SPOUSE|MICROSCOPIST|Y|5|Visit_5|90|5|TREATMENT|2021-04-05|90
e|TR|8153c765-a92a-4b0f-9ef3-6ca925337f54|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|mU/L|ENLARGEMENT|1|Gauss|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|1|Visit_1|10|7|TREATMENT|2020-09-29|10
e|TR|8153c765-a92a-4b0f-9ef3-6ca925337f54|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|HEP|UNCHANGED|1|umol|GIEMSA STAIN|||VENDOR|ENDOCRINOLOGIST|U|2|Visit_2|25|5|SCREENING|2020-10-14|25
e|TR|8153c765-a92a-4b0f-9ef3-6ca925337f54|3|[?]|AREA|Area|[?]|mV/sec|PATHOLOGICAL|1|AFU|MICROBIAL CULTURE, SOLID|Y||CAREGIVER|RADIOLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-10-29|40
e|TR|8153c765-a92a-4b0f-9ef3-6ca925337f54|4|[?]|LPERP|Longest Perpendicular|[?]|g/animal|EQUIVOCAL|1|10^7 CFU/mL|KNEMOMETRY|Y|Y|DOMESTIC PARTNER|ADJUDICATOR 2|U|4|Visit_4|65|5|TREATMENT|2020-11-23|65
e|TR|8153c765-a92a-4b0f-9ef3-6ca925337f54|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mm/2h|NORMAL|1|/HPF|ICC|||SPOUSE|CARDIOLOGIST|U|5|Visit_5|90|5|WASHOUT|2020-12-18|90
e|TR|8d27cdcf-768e-4630-95b5-da554f6f3b56|1|[?]|PALPSTAT|Palpable State|[?]|EP U|UNEQUIVOCAL|1|IU/g|IMMUNOPRECIPITATION|||PROXY|READER 1|Y|1|Visit_1|10|6|WASHOUT|2020-10-30|10
e|TR|8d27cdcf-768e-4630-95b5-da554f6f3b56|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|cycle/min|PRESENT|1|mol/mL|TRANSMISSION ELECTRON MICROSCOPY|||INDEPENDENT ASSESSOR|RADIOLOGIST 2|U|2|Visit_2|25|5|TREATMENT|2020-11-14|25
e|TR|8d27cdcf-768e-4630-95b5-da554f6f3b56|3|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|/LSQN|PRESENT|1|U/kg/h|INFRARED SPECTROMETRY|||CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|N|3|Visit_3|40|6|FOLLOW-UP|2020-11-29|40
e|TR|8d27cdcf-768e-4630-95b5-da554f6f3b56|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|pL|ABSENT|1|10^3 organisms|HPLC/MS/MS|Y||FAMILY MEMBER|HEMATOLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-12-24|65
e|TR|8d27cdcf-768e-4630-95b5-da554f6f3b56|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|ppm|ABSENT|1|umol/L|HEMAGGLUTINATION ASSAY|||FRIEND|PATHOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2021-01-18|90
e|TR|5c2791ff-aaf6-413f-9827-6e97e2273388|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|mV/sec|FOCALLY INCREASED|1|mmol/s|SLOAN LETTER EYE CHART 100%|||INDEPENDENT ASSESSOR|NEUROLOGIST 1|NA|1|Visit_1|10|3|WASHOUT|2020-09-06|10
e|TR|5c2791ff-aaf6-413f-9827-6e97e2273388|2|[?]|CALCFIND|Calcification Indicator|[?]|CAN|UNCHANGED|1|cm/min|MANUAL COUNT||Y|ADJUDICATOR|RADIOLOGIST 2|Y|2|Visit_2|25|2|SCREENING|2020-09-21|25
e|TR|5c2791ff-aaf6-413f-9827-6e97e2273388|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|km/h|ENLARGEMENT|1|TCID 50/dose|RAJI CELL EIA|Y||PARENT|READER|Y|3|Visit_3|40|4|TREATMENT|2020-10-06|40
e|TR|5c2791ff-aaf6-413f-9827-6e97e2273388|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|vp/mL|EQUIVOCAL|1|pptr|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|Y||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|4|Visit_4|65|4|FOLLOW-UP|2020-10-31|65
e|TR|5c2791ff-aaf6-413f-9827-6e97e2273388|5|[?]|LESSCIND|Lesion Success Indicator|[?]|DAgU/mL|NON-PATHOLOGICAL|1|BOLUS|X-RAY FLUORESCENCE SPECTROMETRY|Y||INVESTIGATOR|READER 1|N|5|Visit_5|90|5|WASHOUT|2020-11-25|90
e|TR|b336d8c2-7bca-404e-aea3-5148d559ea99|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|kg/L|NORMAL|1|MESF|MRI|||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|1|Visit_1|10|4|SCREENING|2020-09-19|10
e|TR|b336d8c2-7bca-404e-aea3-5148d559ea99|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|genEq/mL|INCREASED|1|g/cage/day|PALPATION||Y|INDEPENDENT ASSESSOR|NEUROLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-10-04|25
e|TR|b336d8c2-7bca-404e-aea3-5148d559ea99|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|sec|NONPALPABLE|1|deg/s|FLUORESCENT IMMUNOASSAY|||CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|NA|3|Visit_3|40|2|SCREENING|2020-10-19|40
e|TR|b336d8c2-7bca-404e-aea3-5148d559ea99|4|[?]|AREA|Area|[?]|INHALATION|FOCALLY INCREASED|1|amol|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||FAMILY MEMBER|DERMATOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-11-13|65
e|TR|b336d8c2-7bca-404e-aea3-5148d559ea99|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|nkat/g Hb|PALPABLE|1|10^4/hpf|LC/MS|Y||VENDOR|UROLOGIST|NA|5|Visit_5|90|3|FOLLOW-UP|2020-12-08|90
e|TR|702b2f8f-63b9-44c1-a46d-1a41bc837c32|1|[?]|LPERP|Longest Perpendicular|[?]|mL/cage|DECREASED|1|10^9 organisms/g|MYELOPEROXIDASE STAIN|||CAREGIVER|PATHOLOGIST 2|NA|1|Visit_1|10|7|WASHOUT|2020-06-17|10
e|TR|702b2f8f-63b9-44c1-a46d-1a41bc837c32|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|cP|INCREASED|1|L/s/kPa|MACRO BROTH DILUTION|||VENDOR|READER 2|N|2|Visit_2|25|3|TREATMENT|2020-07-02|25
e|TR|702b2f8f-63b9-44c1-a46d-1a41bc837c32|3|[?]|DIAMETER|Diameter|[?]|/LPF|UNEQUIVOCAL|1|DIP|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||CHILD|MICROSCOPIST|NA|3|Visit_3|40|1|TREATMENT|2020-07-17|40
e|TR|702b2f8f-63b9-44c1-a46d-1a41bc837c32|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|cP|DECREASED|1|mg/kg/day|MICROBIAL CONCENTRATION|Y|Y|STUDY SUBJECT|RATER|N|4|Visit_4|65|2|TREATMENT|2020-08-11|65
e|TR|702b2f8f-63b9-44c1-a46d-1a41bc837c32|5|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|nmol BCE/L|TUMOR MERGED|1|mmol2/L2|FISH|||DOMESTIC PARTNER|MICROSCOPIST|U|5|Visit_5|90|2|TREATMENT|2020-09-05|90
e|TR|1261eee1-f073-4419-b0b7-28abd0ec1513|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|10^10/L|TUMOR MERGED|1|mAnson U/mL|FARNSWORTH-MUNSELL 100 HUE TEST|Y||SIGNIFICANT OTHER|PATHOLOGIST 1|U|1|Visit_1|10|7|WASHOUT|2020-10-01|10
e|TR|1261eee1-f073-4419-b0b7-28abd0ec1513|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|mL/m2/day|PATHOLOGICAL|1|%(v/v)|SCANNING ELECTRON MICROSCOPY||Y|CLINICAL STUDY SPONSOR|INTERNIST|N|2|Visit_2|25|6|WASHOUT|2020-10-16|25
e|TR|1261eee1-f073-4419-b0b7-28abd0ec1513|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|GLOBULE|PATHOLOGICAL|1|Gravitational Unit|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|3|Visit_3|40|2|FOLLOW-UP|2020-10-31|40
e|TR|1261eee1-f073-4419-b0b7-28abd0ec1513|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|copies/ug|DIFFUSELY INCREASED|1|aMFI|TURBIDIMETRY|||ADJUDICATOR|NEUROLOGIST 1|N|4|Visit_4|65|7|TREATMENT|2020-11-25|65
e|TR|1261eee1-f073-4419-b0b7-28abd0ec1513|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|DPM|FOCALLY INCREASED|1|mg/m2/day|MACRO BROTH DILUTION|||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|4|TREATMENT|2020-12-20|90
e|TR|46eefdf3-c314-4e61-963c-ce7f48c636e5|1|[?]|BNLNUM|Number of Bone Lesions|[?]|m|PATHOLOGICAL|1|aMFI|THICK SMEAR|Y||INVESTIGATOR|UROLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-12-29|10
e|TR|46eefdf3-c314-4e61-963c-ce7f48c636e5|2|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|g/kg/day|FURTHER ENLARGEMENT FROM NADIR|1|10^9 organisms|PULMONARY ANGIOGRAPHY|||NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|NA|2|Visit_2|25|7|WASHOUT|2021-01-13|25
e|TR|46eefdf3-c314-4e61-963c-ce7f48c636e5|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|mL/cage/wk|PALPABLE|1|10^4/hpf|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Y||CLINICAL RESEARCH COORDINATOR|READER 1|NA|3|Visit_3|40|6|TREATMENT|2021-01-28|40
e|TR|46eefdf3-c314-4e61-963c-ce7f48c636e5|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|10^10/L|TUMOR MERGED|1|mL/animal|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||INTERVIEWER|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|5|TREATMENT|2021-02-22|65
e|TR|46eefdf3-c314-4e61-963c-ce7f48c636e5|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|RNA copies/mL|NONPALPABLE|1|mmHg/sec|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||Y|SPOUSE|CLINICAL PATHOLOGIST|U|5|Visit_5|90|5|WASHOUT|2021-03-19|90
e|TR|f632159b-8c91-4f0d-81cb-e5b9195588c9|1|[?]|LPERP|Longest Perpendicular|[?]|m3|INCREASED|1|10^6 IU/mL|DIRECT SEQUENCING|Y||SPOUSE|OPTOMETRIST|N|1|Visit_1|10|5|SCREENING|2021-01-12|10
e|TR|f632159b-8c91-4f0d-81cb-e5b9195588c9|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|ug|FURTHER ENLARGEMENT FROM NADIR|1|g/kg/day|NEPHELOMETRY|||ADJUDICATION COMMITTEE|PATHOLOGIST 2|N|2|Visit_2|25|7|TREATMENT|2021-01-27|25
e|TR|f632159b-8c91-4f0d-81cb-e5b9195588c9|3|[?]|PPD|Product of Perpendicular Diameters|[?]|oz eq|FOCALLY INCREASED|1|BAG|AMSLER GRID|Y|Y|DOMESTIC PARTNER|MICROSCOPIST|Y|3|Visit_3|40|7|TREATMENT|2021-02-11|40
e|TR|f632159b-8c91-4f0d-81cb-e5b9195588c9|4|[?]|SUMDIAM|Sum of Diameter|[?]|vp/mL|UNEQUIVOCAL|1|cmHg|PELLI-ROBSON EYE CHART||Y|FRIEND|RATER 1|N|4|Visit_4|65|3|FOLLOW-UP|2021-03-08|65
e|TR|f632159b-8c91-4f0d-81cb-e5b9195588c9|5|[?]|LESSCIND|Lesion Success Indicator|[?]|10^7 TCID 50/dose|UNCHANGED|1|ug/animal|PANENDOSCOPY|Y||STUDY SUBJECT|UROLOGIST|NA|5|Visit_5|90|1|TREATMENT|2021-04-02|90
e|TR|898a9d2f-338b-41bf-8ac0-c4a025481349|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|pmol/L|FOCALLY INCREASED|1|nm|RADIOIMMUNOPRECIPITATION ASSAY|Y||FRIEND|HEMATOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-05-24|10
e|TR|898a9d2f-338b-41bf-8ac0-c4a025481349|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|PNU/mL|PALPABLE|1|BP|SINGLE-SLICE SPIRAL CT|||ADJUDICATION COMMITTEE|NEUROLOGIST 1|Y|2|Visit_2|25|1|SCREENING|2020-06-08|25
e|TR|898a9d2f-338b-41bf-8ac0-c4a025481349|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|ng/L|UNEQUIVOCAL|1|HEP|DOPPLER ULTRASOUND|||PARENT|READER 3|U|3|Visit_3|40|1|SCREENING|2020-06-23|40
e|TR|898a9d2f-338b-41bf-8ac0-c4a025481349|4|[?]|DIAMETER|Diameter|[?]|IU/day|INCREASED|1|log10 IU/mL|RIA|||INTERVIEWER|MICROSCOPIST 3|U|4|Visit_4|65|1|WASHOUT|2020-07-18|65
e|TR|898a9d2f-338b-41bf-8ac0-c4a025481349|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|WEEKS|FOCALLY INCREASED|1|10^6/hpf|ENZYMATIC ULTRACENTRIFUGATION|||INVESTIGATOR|READER 2|U|5|Visit_5|90|4|SCREENING|2020-08-12|90
e|TR|db3824aa-375d-4e40-a14b-af0e4460914e|1|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|/2500 WBC|INCREASED|1|10^4 CFU|ENZYMATIC SPECTROPHOTOMETRY|||ADJUDICATION COMMITTEE|MICROSCOPIST|Y|1|Visit_1|10|6|TREATMENT|2020-05-20|10
e|TR|db3824aa-375d-4e40-a14b-af0e4460914e|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|/100 HPFs|FURTHER ENLARGEMENT FROM NADIR|1|QUANTITY SUFFICIENT|OPTICAL COHERENCE TOMOGRAPHY|Y||INTERVIEWER|READER 2|N|2|Visit_2|25|7|TREATMENT|2020-06-04|25
e|TR|db3824aa-375d-4e40-a14b-af0e4460914e|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|Frames/s|NONPALPABLE|1|tsp eq|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||CHILD|CARDIOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-06-19|40
e|TR|db3824aa-375d-4e40-a14b-af0e4460914e|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|kV|INCREASED|1|/2000 RBC|PH METER MEASUREMENT METHOD||Y|ADJUDICATOR|MICROSCOPIST 1|U|4|Visit_4|65|2|TREATMENT|2020-07-14|65
e|TR|db3824aa-375d-4e40-a14b-af0e4460914e|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|uV2|UNEQUIVOCAL|1|mg/m2/h|RIA||Y|GUARDIAN|PATHOLOGIST 1|N|5|Visit_5|90|4|TREATMENT|2020-08-08|90
e|TR|0ea6be64-32f8-4e10-b993-687ea200e4e9|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|mm/h|EQUIVOCAL|1|FINGERTIP UNIT|BETA LACTAMASE|||FRIEND|INTERNIST|Y|1|Visit_1|10|7|TREATMENT|2021-01-28|10
e|TR|0ea6be64-32f8-4e10-b993-687ea200e4e9|2|[?]|ACHNAD|Absolute Change From Nadir|[?]|U/kg|UNCHANGED|1|cup eq|CRYOSCOPY|||STUDY SUBJECT|READER|Y|2|Visit_2|25|6|FOLLOW-UP|2021-02-12|25
e|TR|0ea6be64-32f8-4e10-b993-687ea200e4e9|3|[?]|VOLUME|Volume|[?]|dyn|TUMOR MERGED|1|beats/min|SEQUENCING|Y||NON-HEALTH CARE PROFESSIONAL|RATER|U|3|Visit_3|40|7|TREATMENT|2021-02-27|40
e|TR|0ea6be64-32f8-4e10-b993-687ea200e4e9|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|ppth|INCREASED|1|kPa/L/sec|IMMUNOFLUORESCENT STAIN||Y|GUARDIAN|PATHOLOGIST 1|NA|4|Visit_4|65|7|SCREENING|2021-03-24|65
e|TR|0ea6be64-32f8-4e10-b993-687ea200e4e9|5|[?]|LESSCIND|Lesion Success Indicator|[?]|SACHET|UNCHANGED|1|in|TOTAL BODY IRRADIATION|Y||FAMILY MEMBER|RATER|N|5|Visit_5|90|4|FOLLOW-UP|2021-04-18|90
e|TR|18504c4e-41c8-4c1a-a479-d179ccd318e3|1|[?]|LDIAM|Longest Diameter|[?]|pmol/day|EQUIVOCAL|1|BP|TRYPAN BLUE STAIN|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|Y|1|Visit_1|10|5|SCREENING|2020-06-22|10
e|TR|18504c4e-41c8-4c1a-a479-d179ccd318e3|2|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|nmol/L/h|PALPABLE|1|Arbitrary U|WESTERGREN|Y||STUDY SUBJECT|MICROSCOPIST 3|Y|2|Visit_2|25|7|TREATMENT|2020-07-07|25
e|TR|18504c4e-41c8-4c1a-a479-d179ccd318e3|3|[?]|SUMVOL|Sum of Volume|[?]|mg/dL|EQUIVOCAL|1|ms/mmHg|IMMUNOASSAY||Y|INVESTIGATOR|PATHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-07-22|40
e|TR|18504c4e-41c8-4c1a-a479-d179ccd318e3|4|[?]|DIAMETER|Diameter|[?]|V|PATHOLOGICAL|1|ag|KINETIC CHROMOGENIC ASSAY||Y|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|4|TREATMENT|2020-08-16|65
e|TR|18504c4e-41c8-4c1a-a479-d179ccd318e3|5|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|copies/uL|FOCALLY INCREASED|1|amp|NUCLEIC ACID SEQUENCING|||SPOUSE|RATER 2|N|5|Visit_5|90|5|TREATMENT|2020-09-10|90
e|TR|7f211d8a-7478-4082-8d95-4ace9ceee919|1|[?]|DIAMETER|Diameter|[?]|PACK|PATHOLOGICAL|1|GBq/mg|SISH|Y|Y|SIBLING|NEUROLOGIST|NA|1|Visit_1|10|4|FOLLOW-UP|2020-08-19|10
e|TR|7f211d8a-7478-4082-8d95-4ace9ceee919|2|[?]|PALPSTAT|Palpable State|[?]|ukat/L|NORMAL|1|mmol/day|IMMUNOPRECIPITATION|||FAMILY MEMBER|OPTOMETRIST|N|2|Visit_2|25|7|WASHOUT|2020-09-03|25
e|TR|7f211d8a-7478-4082-8d95-4ace9ceee919|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|JAR|FURTHER ENLARGEMENT|1|Joule|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|3|Visit_3|40|3|WASHOUT|2020-09-18|40
e|TR|7f211d8a-7478-4082-8d95-4ace9ceee919|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|SACHET|TUMOR MERGED|1|HOURS|IMMUNOCHEMILUMINOMETRIC ASSAY|Y|Y|FAMILY MEMBER|RATER 1|U|4|Visit_4|65|2|WASHOUT|2020-10-13|65
e|TR|7f211d8a-7478-4082-8d95-4ace9ceee919|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|Henry|PRESENT|1|Watt|TWO-COLOR MICROARRAY|||ADJUDICATOR|RATER 2|NA|5|Visit_5|90|6|TREATMENT|2020-11-07|90
e|TR|0739e140-bcac-4df9-9629-bd0748d1fdd6|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|cm2|FURTHER ENLARGEMENT FROM NADIR|1|U/g|GRAM STAIN|||ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|NA|1|Visit_1|10|6|TREATMENT|2020-10-09|10
e|TR|0739e140-bcac-4df9-9629-bd0748d1fdd6|2|[?]|ORSTATE|Organ State|[?]|10^7 TCID 50/dose|UNCHANGED|1|ug/kg/min|CALCULATION|Y||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|2|Visit_2|25|5|TREATMENT|2020-10-24|25
e|TR|0739e140-bcac-4df9-9629-bd0748d1fdd6|3|[?]|BNLNUM|Number of Bone Lesions|[?]|Log10 ELISA unit|FOCALLY INCREASED|1|mL/sec/1.73m2|DROPLET DIGITAL PCR|Y|Y|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|NA|3|Visit_3|40|7|SCREENING|2020-11-08|40
e|TR|0739e140-bcac-4df9-9629-bd0748d1fdd6|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|U/L|NON-PATHOLOGICAL|1|BOTTLE|CELLULOSE TAPE|||GUARDIAN|NEUROLOGIST|U|4|Visit_4|65|3|TREATMENT|2020-12-03|65
e|TR|0739e140-bcac-4df9-9629-bd0748d1fdd6|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|mol|DIFFUSELY INCREASED|1|uCi|IMMUNOPRECIPITATION|||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|U|5|Visit_5|90|1|TREATMENT|2020-12-28|90
e|TR|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|Anson U|EQUIVOCAL|1|10^9 organisms|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||INVESTIGATOR|PHYSIOTHERAPIST|Y|1|Visit_1|10|6|SCREENING|2020-12-21|10
e|TR|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|2|[?]|ACHNAD|Absolute Change From Nadir|[?]|WEEKS|UNEQUIVOCAL|1|ukat/10^12 RBC|ELISPOT|||ADJUDICATOR|OPTOMETRIST|U|2|Visit_2|25|2|FOLLOW-UP|2021-01-05|25
e|TR|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|3|[?]|DIAMETER|Diameter|[?]|PHERESIS UNIT|DIFFUSELY INCREASED|1|CCID 50/dose|HEMAGGLUTINATION ASSAY|||CHILD|MICROSCOPIST 2|Y|3|Visit_3|40|3|TREATMENT|2021-01-20|40
e|TR|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|cd|PATHOLOGICAL|1|10^6 organisms/mg|CELLULAR PROLIFERATION ASSAY|||ADJUDICATION COMMITTEE|CARDIOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2021-02-14|65
e|TR|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|mg/day|ABSENT|1|mg|NON-CONTACT SPECULAR MICROSCOPY|Y|Y|INTERVIEWER|PATHOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2021-03-11|90
e|TR|f24b931a-2cdd-4432-a1dd-69c7286f4690|1|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|%/s|INCREASED|1|pm|FLUORESCENCE ANGIOGRAPHY|Y||CLINICAL RESEARCH COORDINATOR|READER 1|U|1|Visit_1|10|7|TREATMENT|2020-05-15|10
e|TR|f24b931a-2cdd-4432-a1dd-69c7286f4690|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|10^5/hpf|PRESENT|1|mEq/ug|SLOAN LETTER EYE CHART 100%|||FAMILY MEMBER|INTERNIST|Y|2|Visit_2|25|1|TREATMENT|2020-05-30|25
e|TR|f24b931a-2cdd-4432-a1dd-69c7286f4690|3|[?]|VDIAM|Viable Diameter|[?]|genEq|TUMOR MERGED|1|10^7 CFU/mL|LC/MS|||SPOUSE|MICROSCOPIST|N|3|Visit_3|40|3|TREATMENT|2020-06-14|40
e|TR|f24b931a-2cdd-4432-a1dd-69c7286f4690|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|ug/g/min|ENLARGEMENT|1|/500 WBC|COULOMETRIC TITRATION|||CHILD|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|3|WASHOUT|2020-07-09|65
e|TR|f24b931a-2cdd-4432-a1dd-69c7286f4690|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|U/kg/day|NORMAL|1|mL/min/mmHg|PHASE CONTRAST MICROSCOPY|||GUARDIAN|ENDOCRINOLOGIST|N|5|Visit_5|90|5|SCREENING|2020-08-03|90
e|TR|d394120d-7630-4fcf-a336-482599d88296|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|ag|PATHOLOGICAL|1|U/m2|CLOT DETECTION|||CAREGIVER|ONCOLOGIST 1|NA|1|Visit_1|10|6|TREATMENT|2021-01-22|10
e|TR|d394120d-7630-4fcf-a336-482599d88296|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|100 IU/mL|DECREASED|1|Sv|DYNAMIC CONTRAST ENHANCED MRI||Y|SIGNIFICANT OTHER|RATER 1|N|2|Visit_2|25|6|TREATMENT|2021-02-06|25
e|TR|d394120d-7630-4fcf-a336-482599d88296|3|[?]|LPERP|Longest Perpendicular|[?]|aMFI|NON-PATHOLOGICAL|1|mg|FLOCCULATION|||SIBLING|MICROSCOPIST 2|Y|3|Visit_3|40|4|WASHOUT|2021-02-21|40
e|TR|d394120d-7630-4fcf-a336-482599d88296|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mCi/L|ABSENT|1|g/cage/day|URANYL ACETATE STAIN|||STUDY SUBJECT|NEUROLOGIST 2|N|4|Visit_4|65|2|FOLLOW-UP|2021-03-18|65
e|TR|d394120d-7630-4fcf-a336-482599d88296|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mg/animal|FOCALLY INCREASED|1|/100 WBC|MICROPARTICLE ENZYME IMMUNOASSAY|||VENDOR|MICROSCOPIST 3|Y|5|Visit_5|90|6|FOLLOW-UP|2021-04-12|90
e|TR|bcda1d95-58ed-4991-9395-0b98efc1d9a1|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|RATIO|ENLARGEMENT|1|ohm|CONTRAST ENHANCED PET/CT SCAN|||SIBLING|READER 2|NA|1|Visit_1|10|3|SCREENING|2020-10-21|10
e|TR|bcda1d95-58ed-4991-9395-0b98efc1d9a1|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|Ejaculate U|DIFFUSELY INCREASED|1|ug/L/h|SNP ARRAY|||DOMESTIC PARTNER|CARDIOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2020-11-05|25
e|TR|bcda1d95-58ed-4991-9395-0b98efc1d9a1|3|[?]|CALCFIND|Calcification Indicator|[?]|mL/kg/h|DECREASED|1|/7.5 mL|GRADIENT DIFFUSION|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|1|FOLLOW-UP|2020-11-20|40
e|TR|bcda1d95-58ed-4991-9395-0b98efc1d9a1|4|[?]|LESSCIND|Lesion Success Indicator|[?]|mL/kg/min|DIFFUSELY INCREASED|1|aMFI|SLOAN LETTER EYE CHART 1.25%|Y||DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|2|SCREENING|2020-12-15|65
e|TR|bcda1d95-58ed-4991-9395-0b98efc1d9a1|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|log10 TCID 50/uL|FURTHER ENLARGEMENT|1|mm/min|SLIT LAMP PHOTOGRAPHY|||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|5|Visit_5|90|5|FOLLOW-UP|2021-01-09|90
e|TR|6999bd5c-0790-42b8-a4ff-e538776b0fb0|1|[?]|VOLUME|Volume|[?]|mm|ENLARGEMENT FROM NADIR|1|cm/s|ENZYMATIC COLORIMETRY||Y|FAMILY MEMBER|READER 3|NA|1|Visit_1|10|4|FOLLOW-UP|2020-08-15|10
e|TR|6999bd5c-0790-42b8-a4ff-e538776b0fb0|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mL/m2|PALPABLE|1|10^3/hpf|PYROSEQUENCING||Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|Y|2|Visit_2|25|7|TREATMENT|2020-08-30|25
e|TR|6999bd5c-0790-42b8-a4ff-e538776b0fb0|3|[?]|TUMSTATE|Tumor State|[?]|dpm/mL|PALPABLE|1|KALLIKREIN INHIBITOR UNIT|AGAR PROPORTION|Y||DOMESTIC PARTNER|RADIOLOGIST 1|NA|3|Visit_3|40|3|TREATMENT|2020-09-14|40
e|TR|6999bd5c-0790-42b8-a4ff-e538776b0fb0|4|[?]|BNLNUM|Number of Bone Lesions|[?]|L/s/kPa|PATHOLOGICAL|1|SFC/10^6 PBMC|SPECT SCAN|||ADJUDICATOR|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|4|TREATMENT|2020-10-09|65
e|TR|6999bd5c-0790-42b8-a4ff-e538776b0fb0|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|mmol/s|FURTHER ENLARGEMENT|1|10^11/L|PLETHYSMOGRAPHY|Y||SIGNIFICANT OTHER|RADIOLOGIST 1|U|5|Visit_5|90|2|TREATMENT|2020-11-03|90
e|TR|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|1|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|10^6 organisms/g|FURTHER ENLARGEMENT|1|nU/cL|TRYPAN BLUE STAIN|||STUDY SUBJECT|ADJUDICATOR 3|Y|1|Visit_1|10|4|TREATMENT|2020-12-21|10
e|TR|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|POUCH|NON-PATHOLOGICAL|1|pmol/10^10 cells|NON-INVASIVE DIELECTRIC SENSING|||DOMESTIC PARTNER|READER|Y|2|Visit_2|25|1|SCREENING|2021-01-05|25
e|TR|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|3|[?]|TUMSTATE|Tumor State|[?]|Log10 ELISA unit/dose|INCREASED|1|NEEDLE GAUGE|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||SPOUSE|ADJUDICATOR 2|N|3|Visit_3|40|4|TREATMENT|2021-01-20|40
e|TR|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|4|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|cmHg|NONPALPABLE|1|pt_us|NUCLEIC ACID SEQUENCING|||ADJUDICATOR|RATER|NA|4|Visit_4|65|2|SCREENING|2021-02-14|65
e|TR|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|5|[?]|CALCFIND|Calcification Indicator|[?]|CAPLET|PALPABLE|1|mg/L|IMMUNOTURBIDIMETRY|||VENDOR|ADJUDICATOR 1|Y|5|Visit_5|90|2|WASHOUT|2021-03-11|90
e|TR|59b0fee3-2294-448e-9837-38bd6b5c794b|1|[?]|VDIAM|Viable Diameter|[?]|DIOPTER|DIFFUSELY INCREASED|1|10^3 organisms/g|AUTOMATED COUNT|||CAREGIVER|NEUROLOGIST 1|N|1|Visit_1|10|1|WASHOUT|2021-01-01|10
e|TR|59b0fee3-2294-448e-9837-38bd6b5c794b|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|amp|DECREASED|1|cd|COMPUTERIZED CORNEAL TOPOGRAPHY|Y||PARENT|OPTOMETRIST|U|2|Visit_2|25|6|TREATMENT|2021-01-16|25
e|TR|59b0fee3-2294-448e-9837-38bd6b5c794b|3|[?]|SUMVOL|Sum of Volume|[?]|VOXEL|NORMAL|1|mmHg/sec|NEXT GENERATION TARGETED SEQUENCING|Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|3|Visit_3|40|2|WASHOUT|2021-01-31|40
e|TR|59b0fee3-2294-448e-9837-38bd6b5c794b|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|WEEKS|ABSENT|1|mmol/mol|CLIP|Y||CAREGIVER|RADIOLOGIST 2|U|4|Visit_4|65|1|SCREENING|2021-02-25|65
e|TR|59b0fee3-2294-448e-9837-38bd6b5c794b|5|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|mV/sec|NORMAL|1|PA|RYAN BLUE STAIN|Y||ADJUDICATOR|RATER|N|5|Visit_5|90|5|WASHOUT|2021-03-22|90
e|TR|d9bdb1e3-4630-423f-be01-4873bce30422|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|mmHg/sec|FOCALLY INCREASED|1|fraction of 1|CHROMOGENIC ASSAY|||FRIEND|INTERNIST|NA|1|Visit_1|10|3|TREATMENT|2020-12-22|10
e|TR|d9bdb1e3-4630-423f-be01-4873bce30422|2|[?]|BNLNUM|Number of Bone Lesions|[?]|L/day|DIFFUSELY INCREASED|1|ohm|DISK DIFFUSION|||CAREGIVER|READER 1|U|2|Visit_2|25|7|TREATMENT|2021-01-06|25
e|TR|d9bdb1e3-4630-423f-be01-4873bce30422|3|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|fmol/L|PALPABLE|1|mU/g|MOUSE PROTECTION ASSAY|||ADJUDICATOR|READER|NA|3|Visit_3|40|6|TREATMENT|2021-01-21|40
e|TR|d9bdb1e3-4630-423f-be01-4873bce30422|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|IU/day|UNEQUIVOCAL|1|umol/day|HANSEL STAIN||Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|U|4|Visit_4|65|2|WASHOUT|2021-02-15|65
e|TR|d9bdb1e3-4630-423f-be01-4873bce30422|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|nmol/kg/day|ENLARGEMENT FROM NADIR|1|/kg|HANSEL STAIN|Y||SPOUSE|UROLOGIST|U|5|Visit_5|90|7|WASHOUT|2021-03-12|90
e|TR|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|1|[?]|VOLUME|Volume|[?]|tsp|NORMAL|1|nmol/L/min|PHYSICAL EXAMINATION|||FAMILY MEMBER|RADIOLOGIST 1|Y|1|Visit_1|10|7|WASHOUT|2020-06-25|10
e|TR|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|mV|INCREASED|1|V/sec|SLOAN LETTER EYE CHART 100%|Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|2|Visit_2|25|3|WASHOUT|2020-07-10|25
e|TR|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|atm|PRESENT|1|Gy|QUANTITATIVE ULTRASOUND|||CAREGIVER|UROLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-07-25|40
e|TR|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|MHz|UNEQUIVOCAL|1|mL*cmH2O|TARGETED TRANSCRIPTOME SEQUENCING||Y|DOMESTIC PARTNER|READER|Y|4|Visit_4|65|2|FOLLOW-UP|2020-08-19|65
e|TR|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|Bq/uL|FOCALLY INCREASED|1|10^6 DNA copies/mL|GC/MS-CI|||CHILD|MICROSCOPIST 3|N|5|Visit_5|90|4|WASHOUT|2020-09-13|90
e|TR|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|ng/L|TUMOR MERGED|1|mU/L|AUTOREFRACTION|||CHILD|HEMATOLOGIST|U|1|Visit_1|10|5|FOLLOW-UP|2020-08-04|10
e|TR|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|2|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|h*%|DECREASED|1|m|CONTRAST ENHANCED CT SCAN|||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|Y|2|Visit_2|25|1|TREATMENT|2020-08-19|25
e|TR|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|3|[?]|LNSTATE|Lymph Node State|[?]|PNU/mL|UNCHANGED|1|ft3|NUCLEIC ACID HYBRIDIZATION||Y|HEALTH CARE PROFESSIONAL|READER 1|Y|3|Visit_3|40|5|TREATMENT|2020-09-03|40
e|TR|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|L/s|ABSENT|1|g/kg/day|AGAR DILUTION||Y|VENDOR|OPTOMETRIST|U|4|Visit_4|65|7|FOLLOW-UP|2020-09-28|65
e|TR|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|5|[?]|RADIODEN|Radiodensity|[?]|mL/cage|PALPABLE|1|Gy|ANGIOGRAPHY|||INVESTIGATOR|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|7|FOLLOW-UP|2020-10-23|90
e|TR|933c3a61-59a0-4cfb-ae17-45bc48229323|1|[?]|ORVERLN|Organ Vertical Length|[?]|dyn|NON-PATHOLOGICAL|1|g/cm2|CORONARY ANGIOGRAPHY|Y||INDEPENDENT ASSESSOR|RADIOLOGIST 2|NA|1|Visit_1|10|5|TREATMENT|2020-09-09|10
e|TR|933c3a61-59a0-4cfb-ae17-45bc48229323|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|Hz|NON-PATHOLOGICAL|1|mL/mmHg|DIFFUSION WEIGHTED MRI|Y||PROXY|RADIOLOGIST 2|U|2|Visit_2|25|4|SCREENING|2020-09-24|25
e|TR|933c3a61-59a0-4cfb-ae17-45bc48229323|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|10^12/L|PRESENT|1|mEq/day|NO INFORMATION|||ADJUDICATOR|ADJUDICATOR 1|Y|3|Visit_3|40|7|TREATMENT|2020-10-09|40
e|TR|933c3a61-59a0-4cfb-ae17-45bc48229323|4|[?]|BNLNUM|Number of Bone Lesions|[?]|mV|ABSENT|1|Ci|RIA|||FAMILY MEMBER|ADJUDICATOR|U|4|Visit_4|65|3|SCREENING|2020-11-03|65
e|TR|933c3a61-59a0-4cfb-ae17-45bc48229323|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|g/U|NON-PATHOLOGICAL|1|10^6/Ejaculate U|TOTAL BODY RADIOGRAPHY|||GUARDIAN|ADJUDICATOR|Y|5|Visit_5|90|3|TREATMENT|2020-11-28|90
e|TR|58d871e3-ef99-48da-ab12-fdfdc2e01da6|1|[?]|LNSTATE|Lymph Node State|[?]|SYRINGE|FURTHER ENLARGEMENT|1|mL/m2|ELLA||Y|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|1|Visit_1|10|2|SCREENING|2020-10-26|10
e|TR|58d871e3-ef99-48da-ab12-fdfdc2e01da6|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|PELLET|EQUIVOCAL|1|mg/g/h|MULTIPLEXED BEAD BASED IMMUNOASSAY|||PROXY|ADJUDICATOR|U|2|Visit_2|25|1|TREATMENT|2020-11-10|25
e|TR|58d871e3-ef99-48da-ab12-fdfdc2e01da6|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|g/animal/wk|FOCALLY INCREASED|1|APL U|MRI WITHOUT CONTRAST|Y|Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|U|3|Visit_3|40|1|TREATMENT|2020-11-25|40
e|TR|58d871e3-ef99-48da-ab12-fdfdc2e01da6|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|Siemens|ENLARGEMENT|1|10^6 copies/mL|REFLECTANCE SPECTROSCOPY|||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|U|4|Visit_4|65|6|WASHOUT|2020-12-20|65
e|TR|58d871e3-ef99-48da-ab12-fdfdc2e01da6|5|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|IU/g|FURTHER ENLARGEMENT|1|Bq/g|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y|INDEPENDENT ASSESSOR|PATHOLOGIST 1|NA|5|Visit_5|90|5|TREATMENT|2021-01-14|90
e|TR|ac66129e-3244-4cd8-a235-43b4bfb7dace|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|Ci/uL|FOCALLY INCREASED|1|ag|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||ADJUDICATOR|HEMATOLOGIST|N|1|Visit_1|10|5|SCREENING|2020-10-29|10
e|TR|ac66129e-3244-4cd8-a235-43b4bfb7dace|2|[?]|ORSTATE|Organ State|[?]|10^6/g|UNEQUIVOCAL|1|ug/L/h|CORONARY ANGIOGRAPHY||Y|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2020-11-13|25
e|TR|ac66129e-3244-4cd8-a235-43b4bfb7dace|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|Bq/g|DIFFUSELY INCREASED|1|ELISA unit/dose|HANSEL STAIN|||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|U|3|Visit_3|40|6|WASHOUT|2020-11-28|40
e|TR|ac66129e-3244-4cd8-a235-43b4bfb7dace|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|GBq/mg|FURTHER ENLARGEMENT|1|g/animal/day|DIGITAL PCR|Y|Y|NON-HEALTH CARE PROFESSIONAL|READER 1|NA|4|Visit_4|65|3|FOLLOW-UP|2020-12-23|65
e|TR|ac66129e-3244-4cd8-a235-43b4bfb7dace|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mL/cm H2O|NORMAL|1|10^4 CFU|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||ADJUDICATOR|MICROSCOPIST 3|NA|5|Visit_5|90|7|SCREENING|2021-01-17|90
e|TR|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|1|[?]|SUMVOL|Sum of Volume|[?]|mL/g/min|PRESENT|1|m|NUCLEIC ACID HYBRIDIZATION|||ADJUDICATOR|FORENSIC PATHOLOGIST|N|1|Visit_1|10|1|WASHOUT|2020-09-02|10
e|TR|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|2|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|dpm/100mg|TUMOR MERGED|1|ppb|DOUBLE IMMUNODIFFUSION|||CHILD|MICROSCOPIST 2|N|2|Visit_2|25|4|SCREENING|2020-09-17|25
e|TR|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|3|[?]|PCHGBL|Percent Change From Baseline|[?]|gMFI|DECREASED|1|IMPLANT|CALCULATION|||SPOUSE|PHYSIOTHERAPIST|N|3|Visit_3|40|7|TREATMENT|2020-10-02|40
e|TR|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|dpm/mL|EQUIVOCAL|1|10^3 copies/mL|TRICHROME STAIN|||FRIEND|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|4|WASHOUT|2020-10-27|65
e|TR|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|5|[?]|DIAMETER|Diameter|[?]|IU/mmol|FURTHER ENLARGEMENT|1|nkat/L|TOTAL BODY RADIOGRAPHY|Y|Y|FRIEND|PEDIATRIC NEUROLOGIST|N|5|Visit_5|90|2|SCREENING|2020-11-21|90
e|TR|3d59a754-10bb-4847-93ea-433b43265a2f|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|ug/kg/h|ENLARGEMENT FROM NADIR|1|CFU/g|HEMAGGLUTINATION ASSAY|||ADJUDICATION COMMITTEE|MICROSCOPIST 2|U|1|Visit_1|10|5|TREATMENT|2020-10-24|10
e|TR|3d59a754-10bb-4847-93ea-433b43265a2f|2|[?]|VOLUME|Volume|[?]|SUPPOSITORY|UNEQUIVOCAL|1|BOX|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|CAREGIVER|MICROSCOPIST 3|N|2|Visit_2|25|3|WASHOUT|2020-11-08|25
e|TR|3d59a754-10bb-4847-93ea-433b43265a2f|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|breaths/min|PALPABLE|1|dL|FLUORESCENCE ANGIOGRAPHY|||ADJUDICATOR|READER 1|N|3|Visit_3|40|6|TREATMENT|2020-11-23|40
e|TR|3d59a754-10bb-4847-93ea-433b43265a2f|4|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|nCi|PATHOLOGICAL|1|MONTHS|INCISION-INDUCED BLEEDING METHOD|Y||SIBLING|ONCOLOGIST 2|Y|4|Visit_4|65|2|TREATMENT|2020-12-18|65
e|TR|3d59a754-10bb-4847-93ea-433b43265a2f|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|g|PALPABLE|1|nkat/L|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y||CHILD|READER 1|NA|5|Visit_5|90|5|TREATMENT|2021-01-12|90
e|TR|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|oz|FURTHER ENLARGEMENT FROM NADIR|1|h*%|TRIPLE-PHASE MRI SCAN||Y|INTERVIEWER|CLINICAL PATHOLOGIST|N|1|Visit_1|10|4|SCREENING|2021-01-20|10
e|TR|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|2|[?]|SUMDIAM|Sum of Diameter|[?]|U/kg/min|DIFFUSELY INCREASED|1|mL/animal|CELLULOSE TAPE|||CLINICAL RESEARCH COORDINATOR|RATER 2|Y|2|Visit_2|25|7|FOLLOW-UP|2021-02-04|25
e|TR|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|BOLUS|PALPABLE|1|mmHg/L/min|FLUORESCENT MICROSCOPY||Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|U|3|Visit_3|40|2|TREATMENT|2021-02-19|40
e|TR|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|4|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|/2000 RBC|DIFFUSELY INCREASED|1|/mm|CARDIAC THERMODILUTION|||HEALTH CARE PROFESSIONAL|INTERNIST|NA|4|Visit_4|65|5|TREATMENT|2021-03-16|65
e|TR|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|nmol/g|EQUIVOCAL|1|ug/kg/day|CONTRAST ENHANCED MRI||Y|INVESTIGATOR|NEUROLOGIST 1|N|5|Visit_5|90|7|WASHOUT|2021-04-10|90
e|TR|89209495-c485-4eb7-b858-8dc5490d2b64|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|DIP|NORMAL|1|vp/mL|SLIT LAMP|||CLINICAL RESEARCH COORDINATOR|RATER|U|1|Visit_1|10|7|TREATMENT|2020-09-07|10
e|TR|89209495-c485-4eb7-b858-8dc5490d2b64|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|PACKET|NORMAL|1|mmHg/sec|ETDRS EYE CHART|Y||HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|2|Visit_2|25|6|FOLLOW-UP|2020-09-22|25
e|TR|89209495-c485-4eb7-b858-8dc5490d2b64|3|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|ug/animal|FURTHER ENLARGEMENT FROM NADIR|1|log10 TCID 50/uL|CALCOFLUOR WHITE STAIN|||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|6|WASHOUT|2020-10-07|40
e|TR|89209495-c485-4eb7-b858-8dc5490d2b64|4|[?]|VDIAM|Viable Diameter|[?]|uIU/L|NONPALPABLE|1|ohm|SPECTROPHOTOMETRY||Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|4|Visit_4|65|1|TREATMENT|2020-11-01|65
e|TR|89209495-c485-4eb7-b858-8dc5490d2b64|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|MET|PALPABLE|1|GPL U/mL|ANTIMICROBIAL COMBINATION TESTING||Y|NON-HEALTH CARE PROFESSIONAL|RATER 2|N|5|Visit_5|90|2|FOLLOW-UP|2020-11-26|90
e|TR|d80522bb-f146-4270-a6e1-326fde50d9ca|1|[?]|CALCFIND|Calcification Indicator|[?]|ug/L|NON-PATHOLOGICAL|1|cmH2O*s/mL|WRIGHT-GIEMSA STAIN|||CHILD|RATER 1|NA|1|Visit_1|10|1|WASHOUT|2020-12-31|10
e|TR|d80522bb-f146-4270-a6e1-326fde50d9ca|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mL/s/m2|FURTHER ENLARGEMENT|1|MPS U|DIFFUSION WEIGHTED MRI|||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|U|2|Visit_2|25|6|FOLLOW-UP|2021-01-15|25
e|TR|d80522bb-f146-4270-a6e1-326fde50d9ca|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|cmH2O*s2/mL|PALPABLE|1|BEAM BREAKS|PUPILLOMETRY|Y||INTERVIEWER|RADIOLOGIST|N|3|Visit_3|40|5|TREATMENT|2021-01-30|40
e|TR|d80522bb-f146-4270-a6e1-326fde50d9ca|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|RNA copies/mL|FURTHER ENLARGEMENT|1|ug/cm2|PET SCAN|||PARENT|PHYSIOTHERAPIST|Y|4|Visit_4|65|1|FOLLOW-UP|2021-02-24|65
e|TR|d80522bb-f146-4270-a6e1-326fde50d9ca|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|mU/g|FURTHER ENLARGEMENT|1|Absorbance U|RULER MEASUREMENT METHOD|||ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|NA|5|Visit_5|90|5|SCREENING|2021-03-21|90
e|TR|3982a462-95f6-4e71-93e5-9df777770067|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|IU/g Hb|DIFFUSELY INCREASED|1|ppth|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||Y|SPOUSE|READER|Y|1|Visit_1|10|6|FOLLOW-UP|2020-12-25|10
e|TR|3982a462-95f6-4e71-93e5-9df777770067|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|Bq/kg|FURTHER ENLARGEMENT|1|CFU/mL|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|N|2|Visit_2|25|7|FOLLOW-UP|2021-01-09|25
e|TR|3982a462-95f6-4e71-93e5-9df777770067|3|[?]|ORSTATE|Organ State|[?]|Log10 ELISA unit|NON-PATHOLOGICAL|1|mMU/mL|TWO-COLOR MICROARRAY|||GUARDIAN|MICROSCOPIST|Y|3|Visit_3|40|7|WASHOUT|2021-01-24|40
e|TR|3982a462-95f6-4e71-93e5-9df777770067|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|CCID 50/dose|INCREASED|1|10^6 IU|CAPILLARY ELECTROPHORESIS|Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|4|Visit_4|65|5|WASHOUT|2021-02-18|65
e|TR|3982a462-95f6-4e71-93e5-9df777770067|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|QUANTITY SUFFICIENT|ABSENT|1|pkat|ERGOSPIROMETRY|||SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|6|TREATMENT|2021-03-15|90
e|TR|f3a3a6ca-2344-4cee-a6a5-59beee9304df|1|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|kg/mol|PATHOLOGICAL|1|FINGERTIP UNIT|AURAMINE STAIN|Y||CLINICAL STUDY SPONSOR|MICROSCOPIST 3|N|1|Visit_1|10|2|SCREENING|2020-11-09|10
e|TR|f3a3a6ca-2344-4cee-a6a5-59beee9304df|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|MBq|ENLARGEMENT|1|ukat/L|ELISA||Y|INTERVIEWER|ADJUDICATOR|Y|2|Visit_2|25|1|TREATMENT|2020-11-24|25
e|TR|f3a3a6ca-2344-4cee-a6a5-59beee9304df|3|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|EID 50/mL|INCREASED|1|ug/min|INDIRECT IMMUNOFLUORESCENCE|||SIGNIFICANT OTHER|READER 1|U|3|Visit_3|40|7|TREATMENT|2020-12-09|40
e|TR|f3a3a6ca-2344-4cee-a6a5-59beee9304df|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mV|DIFFUSELY INCREASED|1|ug/m2/day|KINETIC CHROMOGENIC ASSAY||Y|INTERVIEWER|READER 3|U|4|Visit_4|65|4|WASHOUT|2021-01-03|65
e|TR|f3a3a6ca-2344-4cee-a6a5-59beee9304df|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|titer|FOCALLY INCREASED|1|mm2|DOPPLER ULTRASOUND||Y|DOMESTIC PARTNER|RADIOLOGIST|N|5|Visit_5|90|1|WASHOUT|2021-01-28|90
e|TR|175cfd82-a6fe-463b-81e5-07ae9e1253db|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|/2000 RBC|FURTHER ENLARGEMENT FROM NADIR|1|AMPULE|FUNDUS PHOTOGRAPHY|||ADJUDICATOR|READER 1|Y|1|Visit_1|10|4|WASHOUT|2020-05-26|10
e|TR|175cfd82-a6fe-463b-81e5-07ae9e1253db|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|V/sec|FOCALLY INCREASED|1|mL/cage|BETA LACTAMASE|||PROXY|NEUROLOGIST 2|Y|2|Visit_2|25|7|SCREENING|2020-06-10|25
e|TR|175cfd82-a6fe-463b-81e5-07ae9e1253db|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|mol/mL|DIFFUSELY INCREASED|1|10^6 IU/mL|NUCLEIC ACID HYBRIDIZATION|||SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|6|TREATMENT|2020-06-25|40
e|TR|175cfd82-a6fe-463b-81e5-07ae9e1253db|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mmol/s|EQUIVOCAL|1|MPS U|MICROBIAL CULTURE|||INTERVIEWER|HEMATOLOGIST|Y|4|Visit_4|65|3|SCREENING|2020-07-20|65
e|TR|175cfd82-a6fe-463b-81e5-07ae9e1253db|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|DNA copies/ug|ABSENT|1|fg|URANYL ACETATE STAIN|||CHILD|NEUROLOGIST 1|NA|5|Visit_5|90|4|WASHOUT|2020-08-14|90
e|TR|e19b469c-40d5-4506-8233-a86bebde880d|1|[?]|ORSTATE|Organ State|[?]|pg/L|FURTHER ENLARGEMENT|1|PFU|DROPLET DIGITAL PCR|Y||PARENT|PATHOLOGIST 1|N|1|Visit_1|10|3|SCREENING|2021-01-22|10
e|TR|e19b469c-40d5-4506-8233-a86bebde880d|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|uL/kg/day|UNEQUIVOCAL|1|v/v|AUSCULTATION|||SPOUSE|ONCOLOGIST 2|Y|2|Visit_2|25|3|FOLLOW-UP|2021-02-06|25
e|TR|e19b469c-40d5-4506-8233-a86bebde880d|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|pg/dL|UNCHANGED|1|PACKET|NUCLEIC ACID BASED METHOD|Y|Y|INVESTIGATOR|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|3|TREATMENT|2021-02-21|40
e|TR|e19b469c-40d5-4506-8233-a86bebde880d|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|IU|INCREASED|1|mg/kg/dose|BAC ACGH||Y|STUDY SUBJECT|MICROSCOPIST 2|N|4|Visit_4|65|7|SCREENING|2021-03-18|65
e|TR|e19b469c-40d5-4506-8233-a86bebde880d|5|[?]|VDIAM|Viable Diameter|[?]|mg/mL/day|FURTHER ENLARGEMENT|1|nm|CORONARY ANGIOGRAPHY|||STUDY SUBJECT|ONCOLOGIST 2|NA|5|Visit_5|90|5|TREATMENT|2021-04-12|90
e|TR|f280a4a5-9826-4d77-adf1-992284cb3314|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mMU/mL|INCREASED|1|GBq/mg|HEMOCYTOMETRY|||DOMESTIC PARTNER|OTOLARYNGOLOGIST|U|1|Visit_1|10|1|FOLLOW-UP|2020-12-19|10
e|TR|f280a4a5-9826-4d77-adf1-992284cb3314|2|[?]|ORSTATE|Organ State|[?]|nmol/day|INCREASED|1|umol/h/mmol|TELLER ACUITY CARDS|Y||ADJUDICATOR|READER 2|U|2|Visit_2|25|1|TREATMENT|2021-01-03|25
e|TR|f280a4a5-9826-4d77-adf1-992284cb3314|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|WAFER|TUMOR MERGED|1|atm|AGAR DILUTION|||HEALTH CARE PROFESSIONAL|UROLOGIST|Y|3|Visit_3|40|3|TREATMENT|2021-01-18|40
e|TR|f280a4a5-9826-4d77-adf1-992284cb3314|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|IU/L|FURTHER ENLARGEMENT|1|ug/kg|FLUORIMETRY|||SIBLING|DERMATOLOGIST|U|4|Visit_4|65|6|TREATMENT|2021-02-12|65
e|TR|f280a4a5-9826-4d77-adf1-992284cb3314|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mmol/mol|FURTHER ENLARGEMENT|1|mol/g|DROPLET DIGITAL PCR|||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|5|Visit_5|90|2|FOLLOW-UP|2021-03-09|90
e|TR|82840929-7800-4254-b60a-8af4786664f6|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|AU/mL|NORMAL|1|Ci/uL|POTENTIOMETRY|||SPOUSE|MICROSCOPIST|N|1|Visit_1|10|5|TREATMENT|2020-06-04|10
e|TR|82840929-7800-4254-b60a-8af4786664f6|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|ppb|EQUIVOCAL|1|OI50|PELLI-ROBSON EYE CHART|||PROXY|RADIOLOGIST|Y|2|Visit_2|25|2|SCREENING|2020-06-19|25
e|TR|82840929-7800-4254-b60a-8af4786664f6|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|uL/dose|FURTHER ENLARGEMENT FROM NADIR|1|mg/m2/h|DYNAMOMETRY|Y||STUDY SUBJECT|CARDIOLOGIST|U|3|Visit_3|40|1|WASHOUT|2020-07-04|40
e|TR|82840929-7800-4254-b60a-8af4786664f6|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|cmol/L|INCREASED|1|U/g/min|FLUORESCEIN STAIN||Y|PROXY|MICROSCOPIST 1|N|4|Visit_4|65|1|TREATMENT|2020-07-29|65
e|TR|82840929-7800-4254-b60a-8af4786664f6|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|uCi/L|NON-PATHOLOGICAL|1|bel|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y|SPOUSE|RADIOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2020-08-23|90
e|TR|dae25bdb-38fd-4852-9a9a-7627368e9497|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|kcal/day|PRESENT|1|mm2|DYNAMIC LIGHT SCATTERING|Y||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|U|1|Visit_1|10|3|FOLLOW-UP|2020-09-02|10
e|TR|dae25bdb-38fd-4852-9a9a-7627368e9497|2|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|log10 CFU/g|FOCALLY INCREASED|1|pg/cell|CONTACT SPECULAR MICROSCOPY||Y|SPOUSE|ADJUDICATOR 1|NA|2|Visit_2|25|7|TREATMENT|2020-09-17|25
e|TR|dae25bdb-38fd-4852-9a9a-7627368e9497|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mCi/kg|UNCHANGED|1|g/animal/wk|DC SHEATH FLOW||Y|PARENT|READER 1|NA|3|Visit_3|40|6|FOLLOW-UP|2020-10-02|40
e|TR|dae25bdb-38fd-4852-9a9a-7627368e9497|4|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|DAgU/mL|UNCHANGED|1|kcal/day|HEMAGGLUTINATION ASSAY|||VENDOR|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|5|SCREENING|2020-10-27|65
e|TR|dae25bdb-38fd-4852-9a9a-7627368e9497|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|/min|ENLARGEMENT|1|PATCH|CYSTOMETRY|||STUDY SUBJECT|NEUROLOGIST 1|NA|5|Visit_5|90|7|TREATMENT|2020-11-21|90
e|TR|9e009737-cd77-4b96-a4af-e9731ef7e9d0|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|AgU/mL|INCREASED|1|mg/kg/day|ELASTOGRAPHY|||STUDY SUBJECT|PHYSIOTHERAPIST|N|1|Visit_1|10|5|TREATMENT|2020-10-05|10
e|TR|9e009737-cd77-4b96-a4af-e9731ef7e9d0|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|msec|DIFFUSELY INCREASED|1|10^7 PFU|AUSCULTATION|Y||PARENT|READER 1|U|2|Visit_2|25|7|TREATMENT|2020-10-20|25
e|TR|9e009737-cd77-4b96-a4af-e9731ef7e9d0|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|RING|UNEQUIVOCAL|1|POUCH|ECHOCARDIOGRAPHY|Y|Y|FAMILY MEMBER|MICROSCOPIST 3|N|3|Visit_3|40|1|TREATMENT|2020-11-04|40
e|TR|9e009737-cd77-4b96-a4af-e9731ef7e9d0|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|Log10 ELISA unit|PALPABLE|1|ppth|PHYSICAL EXAMINATION||Y|FRIEND|NEUROLOGIST 1|N|4|Visit_4|65|1|FOLLOW-UP|2020-11-29|65
e|TR|9e009737-cd77-4b96-a4af-e9731ef7e9d0|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mEq/kg|ENLARGEMENT FROM NADIR|1|GPL U/mL|TOTAL BODY IRRADIATION|||INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|U|5|Visit_5|90|2|FOLLOW-UP|2020-12-24|90
e|TR|e7468d01-71b3-47c4-9715-62fe143364cb|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|s*kPa|FURTHER ENLARGEMENT|1|CUP|EEG|||ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|U|1|Visit_1|10|2|TREATMENT|2020-10-15|10
e|TR|e7468d01-71b3-47c4-9715-62fe143364cb|2|[?]|LPERP|Longest Perpendicular|[?]|ppth|DECREASED|1|10^6 RNA copies/mL|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||PARENT|PHYSIOTHERAPIST|NA|2|Visit_2|25|4|FOLLOW-UP|2020-10-30|25
e|TR|e7468d01-71b3-47c4-9715-62fe143364cb|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|foz_us|PATHOLOGICAL|1|ug/g/h|KINETIC MICROPARTICLE IMMUNOASSAY||Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|1|TREATMENT|2020-11-14|40
e|TR|e7468d01-71b3-47c4-9715-62fe143364cb|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|U/g/h|FURTHER ENLARGEMENT FROM NADIR|1|GBq/g|MULTIPLEXED BEAD BASED IMMUNOASSAY|||INTERVIEWER|FORENSIC PATHOLOGIST|U|4|Visit_4|65|3|TREATMENT|2020-12-09|65
e|TR|e7468d01-71b3-47c4-9715-62fe143364cb|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|CCID 50/mL|ENLARGEMENT|1|SFC/10^6 PBMC|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||CLINICAL RESEARCH COORDINATOR|INTERNIST|N|5|Visit_5|90|5|SCREENING|2021-01-03|90
e|TR|6a021859-1b18-4eb5-9548-0e32c0c1edf7|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|min|DIFFUSELY INCREASED|1|lx|IODINE STAIN|||FRIEND|ADJUDICATOR 3|Y|1|Visit_1|10|7|SCREENING|2020-05-18|10
e|TR|6a021859-1b18-4eb5-9548-0e32c0c1edf7|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mg|PRESENT|1|PELLET|MRS||Y|INDEPENDENT ASSESSOR|NEUROLOGIST 1|N|2|Visit_2|25|3|TREATMENT|2020-06-02|25
e|TR|6a021859-1b18-4eb5-9548-0e32c0c1edf7|3|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|log10 PFU|PRESENT|1|V|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y||FRIEND|MICROSCOPIST 2|NA|3|Visit_3|40|2|TREATMENT|2020-06-17|40
e|TR|6a021859-1b18-4eb5-9548-0e32c0c1edf7|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|mL/cm H2O|FOCALLY INCREASED|1|dyn|ELECTRONEUROGRAPHY|||FAMILY MEMBER|RATER|NA|4|Visit_4|65|4|FOLLOW-UP|2020-07-12|65
e|TR|6a021859-1b18-4eb5-9548-0e32c0c1edf7|5|[?]|PALPSTAT|Palpable State|[?]|ng/dL|DIFFUSELY INCREASED|1|mCi/L|SPECULAR MICROSCOPY|||GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|Y|5|Visit_5|90|7|SCREENING|2020-08-06|90
e|TR|eb409ec5-4c02-41c8-a11f-03d990818c2a|1|[?]|VDIAM|Viable Diameter|[?]|log10 copies/mL|INCREASED|1|ug/m2/min|SLOAN LETTER EYE CHART 100%|||HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|1|Visit_1|10|6|TREATMENT|2020-12-09|10
e|TR|eb409ec5-4c02-41c8-a11f-03d990818c2a|2|[?]|VOLUME|Volume|[?]|foz_br|ABSENT|1|pg/cell|PYROSEQUENCING|Y||GUARDIAN|ONCOLOGIST 2|NA|2|Visit_2|25|5|TREATMENT|2020-12-24|25
e|TR|eb409ec5-4c02-41c8-a11f-03d990818c2a|3|[?]|PCHGBL|Percent Change From Baseline|[?]|GPL U/mL|PATHOLOGICAL|1|POUCH|TEST STRIP|Y|Y|GUARDIAN|ADJUDICATOR|NA|3|Visit_3|40|7|FOLLOW-UP|2021-01-08|40
e|TR|eb409ec5-4c02-41c8-a11f-03d990818c2a|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|ug/g/day|ENLARGEMENT FROM NADIR|1|Enzyme U/g Hb|ZIEHL NEELSEN ACID FAST STAIN||Y|ADJUDICATION COMMITTEE|PATHOLOGIST 2|U|4|Visit_4|65|7|WASHOUT|2021-02-02|65
e|TR|eb409ec5-4c02-41c8-a11f-03d990818c2a|5|[?]|PCHGBL|Percent Change From Baseline|[?]|L/min|PRESENT|1|/4.0 mL|MANUAL COUNT|||PROXY|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|7|FOLLOW-UP|2021-02-27|90
e|TR|2178f542-809d-4306-84e4-26d3b3b370b0|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|Gravitational Unit|NON-PATHOLOGICAL|1|mCi/kg|MODIFIED ACID FAST STAIN|Y||PROXY|ONCOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-11-06|10
e|TR|2178f542-809d-4306-84e4-26d3b3b370b0|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mm/h|PRESENT|1|U/m2/day|THICK SMEAR|||CHILD|MICROSCOPIST 2|N|2|Visit_2|25|1|FOLLOW-UP|2020-11-21|25
e|TR|2178f542-809d-4306-84e4-26d3b3b370b0|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|MET*min|UNCHANGED|1|Ci/ug|IMMUNOFLUORESCENT STAIN|||SIGNIFICANT OTHER|RATER|U|3|Visit_3|40|5|TREATMENT|2020-12-06|40
e|TR|2178f542-809d-4306-84e4-26d3b3b370b0|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|HEP|DECREASED|1|mEq/L|PHASE CONTRAST MICROSCOPY|||PARENT|ONCOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-12-31|65
e|TR|2178f542-809d-4306-84e4-26d3b3b370b0|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|mL/m2/day|ABSENT|1|IU/mg|MACRO BROTH DILUTION|||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|5|Visit_5|90|1|TREATMENT|2021-01-25|90
e|TR|da7423fb-461e-43a6-bcb9-aa87051bda0a|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|Gauss|PATHOLOGICAL|1|HOMEOPATHIC DILUTION|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||ADJUDICATOR|ONCOLOGIST|U|1|Visit_1|10|4|FOLLOW-UP|2020-10-04|10
e|TR|da7423fb-461e-43a6-bcb9-aa87051bda0a|2|[?]|LDIAM|Longest Diameter|[?]|genEq|PATHOLOGICAL|1|g/cage/day|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||CHILD|READER 3|N|2|Visit_2|25|6|FOLLOW-UP|2020-10-19|25
e|TR|da7423fb-461e-43a6-bcb9-aa87051bda0a|3|[?]|LPERP|Longest Perpendicular|[?]|GBq|FOCALLY INCREASED|1|Enzyme U/g Hb|MALDI-TOF|Y||INDEPENDENT ASSESSOR|RADIOLOGIST 1|U|3|Visit_3|40|7|TREATMENT|2020-11-03|40
e|TR|da7423fb-461e-43a6-bcb9-aa87051bda0a|4|[?]|VDIAM|Viable Diameter|[?]|m/sec2|INCREASED|1|log10 PFU/mL|IMPEDANCE CONDUCTIVITY|||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|NA|4|Visit_4|65|7|SCREENING|2020-11-28|65
e|TR|da7423fb-461e-43a6-bcb9-aa87051bda0a|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|L/L|PRESENT|1|U/kg/min|BIOPSY|||VENDOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|7|SCREENING|2020-12-23|90
e|TR|40e4c69f-6115-4f0e-8555-45b12b222801|1|[?]|CALCFIND|Calcification Indicator|[?]|mg/mol|DECREASED|1|ug/animal|COLORIMETRY|Y||FRIEND|HEMATOLOGIST|NA|1|Visit_1|10|3|SCREENING|2021-01-30|10
e|TR|40e4c69f-6115-4f0e-8555-45b12b222801|2|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|Ci/kg|ABSENT|1|dyn|VIRUS PLAQUE ASSAY||Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|Y|2|Visit_2|25|5|TREATMENT|2021-02-14|25
e|TR|40e4c69f-6115-4f0e-8555-45b12b222801|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|KALLIKREIN INHIBITOR UNIT|DECREASED|1|nmol/L|CALIPER MEASUREMENT METHOD|Y||GUARDIAN|RATER 1|U|3|Visit_3|40|6|TREATMENT|2021-03-01|40
e|TR|40e4c69f-6115-4f0e-8555-45b12b222801|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|pt_us|FURTHER ENLARGEMENT|1|ug/g/min|CALIPER MEASUREMENT METHOD|||PARENT|HEMATOLOGIST|N|4|Visit_4|65|4|TREATMENT|2021-03-26|65
e|TR|40e4c69f-6115-4f0e-8555-45b12b222801|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|dB|TUMOR MERGED|1|cs|ICC||Y|SPOUSE|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|2|TREATMENT|2021-04-20|90
e|TR|1307d7f6-acb6-4096-a907-08345548a82b|1|[?]|LPERP|Longest Perpendicular|[?]|DAgU/mL|NONPALPABLE|1|DPM|ECHOCARDIOGRAPHY|Y||GUARDIAN|PATHOLOGIST|N|1|Visit_1|10|5|SCREENING|2020-05-28|10
e|TR|1307d7f6-acb6-4096-a907-08345548a82b|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|cmol/L|INCREASED|1|mL/h|HPLC/IEX||Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|NA|2|Visit_2|25|4|WASHOUT|2020-06-12|25
e|TR|1307d7f6-acb6-4096-a907-08345548a82b|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mL/dose|ABSENT|1|copies/uL|DYNAMIC LIGHT SCATTERING||Y|INTERVIEWER|RATER|N|3|Visit_3|40|5|WASHOUT|2020-06-27|40
e|TR|1307d7f6-acb6-4096-a907-08345548a82b|4|[?]|PALPSTAT|Palpable State|[?]|kBq/uL|FOCALLY INCREASED|1|psi|CENTRIFUGATION|||HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|5|WASHOUT|2020-07-22|65
e|TR|1307d7f6-acb6-4096-a907-08345548a82b|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|g/g|ENLARGEMENT FROM NADIR|1|atm|PULMONARY ANGIOGRAPHY||Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|2|TREATMENT|2020-08-16|90
e|TR|bac23835-1120-43b2-9d99-694bef97f44b|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|kHz|DIFFUSELY INCREASED|1|genEq/mL|IVY INCISION METHOD|Y||SIBLING|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|7|TREATMENT|2020-05-21|10
e|TR|bac23835-1120-43b2-9d99-694bef97f44b|2|[?]|PALPSTAT|Palpable State|[?]|F|ABSENT|1|kN/cm2|PAP STAIN|||CLINICAL STUDY SPONSOR|RATER 1|N|2|Visit_2|25|4|TREATMENT|2020-06-05|25
e|TR|bac23835-1120-43b2-9d99-694bef97f44b|3|[?]|LNSTATE|Lymph Node State|[?]|cmH2O*s2/mL|ENLARGEMENT FROM NADIR|1|hPa|JAEGER EYE CHART|Y|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST|N|3|Visit_3|40|1|TREATMENT|2020-06-20|40
e|TR|bac23835-1120-43b2-9d99-694bef97f44b|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|Hounsfield Unit|PRESENT|1|P|AUSCULTATION|Y||INVESTIGATOR|READER 1|NA|4|Visit_4|65|7|TREATMENT|2020-07-15|65
e|TR|bac23835-1120-43b2-9d99-694bef97f44b|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|aMFI|NON-PATHOLOGICAL|1|m/sec|STRESS ECHOCARDIOGRAPHY|Y|Y|PARENT|READER 1|N|5|Visit_5|90|1|WASHOUT|2020-08-09|90
e|TR|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|1|[?]|LNSTATE|Lymph Node State|[?]|nmol BCE/L|PALPABLE|1|uEq|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||FAMILY MEMBER|ADJUDICATOR|U|1|Visit_1|10|2|TREATMENT|2020-09-24|10
e|TR|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|Absorbance U/min|TUMOR MERGED|1|NFIU|POPULATION SEQUENCING|||INDEPENDENT ASSESSOR|INTERNIST|NA|2|Visit_2|25|2|TREATMENT|2020-10-09|25
e|TR|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|Coulomb|FURTHER ENLARGEMENT|1|U/L|LEAD CITRATE STAIN|Y||PARENT|READER 1|U|3|Visit_3|40|6|WASHOUT|2020-10-24|40
e|TR|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|Coulomb|FOCALLY INCREASED|1|PFU/animal|NUCLEIC ACID AMPLIFICATION TEST|Y||CLINICAL STUDY SPONSOR|RATER|Y|4|Visit_4|65|2|SCREENING|2020-11-18|65
e|TR|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|5|[?]|LPERP|Longest Perpendicular|[?]|Hz/s|ENLARGEMENT FROM NADIR|1|nCi|CONTRAST ENHANCED PET/CT SCAN|||PARENT|RADIOLOGIST 1|N|5|Visit_5|90|7|TREATMENT|2020-12-13|90
e|TR|14cd64f5-f3c8-47a4-b40e-9c5090890870|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|cm/s|ABSENT|1|cmH2O/mL|CARDIAC THERMODILUTION|||ADJUDICATION COMMITTEE|ONCOLOGIST 1|N|1|Visit_1|10|3|TREATMENT|2020-09-24|10
e|TR|14cd64f5-f3c8-47a4-b40e-9c5090890870|2|[?]|PALPSTAT|Palpable State|[?]|log EID 50/dose|PRESENT|1|Bq/g|NON-INVASIVE DIELECTRIC SENSING||Y|CHILD|MICROSCOPIST|Y|2|Visit_2|25|7|TREATMENT|2020-10-09|25
e|TR|14cd64f5-f3c8-47a4-b40e-9c5090890870|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|CIGARETTE|NORMAL|1|uU/L|MICROARRAY|||INVESTIGATOR|ADJUDICATOR|Y|3|Visit_3|40|6|SCREENING|2020-10-24|40
e|TR|14cd64f5-f3c8-47a4-b40e-9c5090890870|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|ft|TUMOR MERGED|1|foz_br|FUNCTIONAL MRI|Y|Y|STUDY SUBJECT|OTOLARYNGOLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-11-18|65
e|TR|14cd64f5-f3c8-47a4-b40e-9c5090890870|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|FIU|TUMOR MERGED|1|U/g/h|CLIP|Y|Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|NA|5|Visit_5|90|4|TREATMENT|2020-12-13|90
e|TR|ca4a06be-5e6a-4220-9854-e5fe02b384af|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|U/cL|EQUIVOCAL|1|pm|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||SPOUSE|ADJUDICATOR|U|1|Visit_1|10|7|SCREENING|2020-10-03|10
e|TR|ca4a06be-5e6a-4220-9854-e5fe02b384af|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|AgU/mL|NORMAL|1|U/g Hb|PHASE CONTRAST MICROSCOPY|Y||INTERVIEWER|ADJUDICATOR 2|NA|2|Visit_2|25|1|TREATMENT|2020-10-18|25
e|TR|ca4a06be-5e6a-4220-9854-e5fe02b384af|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|uEq/L|PATHOLOGICAL|1|mmol/L|HPLC/IEX|Y|Y|INVESTIGATOR|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-11-02|40
e|TR|ca4a06be-5e6a-4220-9854-e5fe02b384af|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|10^7/L|FURTHER ENLARGEMENT FROM NADIR|1|DROP|DXA SCAN|Y||HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|4|Visit_4|65|3|WASHOUT|2020-11-27|65
e|TR|ca4a06be-5e6a-4220-9854-e5fe02b384af|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|GPS U|INCREASED|1|ug|LINE PROBE ASSAY|||CHILD|PATHOLOGIST 2|NA|5|Visit_5|90|7|TREATMENT|2020-12-22|90
e|TR|55504c69-a659-402b-a0cb-95ab4e08c086|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|pmol/dL|ENLARGEMENT|1|GBq|IMMUNOCHROMATOGRAPHY|Y||STUDY SUBJECT|MICROSCOPIST 1|NA|1|Visit_1|10|2|TREATMENT|2021-01-14|10
e|TR|55504c69-a659-402b-a0cb-95ab4e08c086|2|[?]|VDIAM|Viable Diameter|[?]|U/m2/h|DIFFUSELY INCREASED|1|kN/cm2|GRADIENT DIFFUSION|Y|Y|FAMILY MEMBER|READER|NA|2|Visit_2|25|6|TREATMENT|2021-01-29|25
e|TR|55504c69-a659-402b-a0cb-95ab4e08c086|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|BAR|ENLARGEMENT|1|ugEq|HEMAGGLUTINATION INHIBITION ASSAY||Y|FRIEND|RADIOLOGIST|N|3|Visit_3|40|6|WASHOUT|2021-02-13|40
e|TR|55504c69-a659-402b-a0cb-95ab4e08c086|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|cmol/L|FURTHER ENLARGEMENT|1|COAT|CONTRAST ENHANCED MRI|Y||SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2021-03-10|65
e|TR|55504c69-a659-402b-a0cb-95ab4e08c086|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|F|FURTHER ENLARGEMENT|1|in|GC/FID||Y|DOMESTIC PARTNER|CARDIOLOGIST|U|5|Visit_5|90|5|TREATMENT|2021-04-04|90
e|TR|bffa468a-a27b-4e87-a60d-b5787a03c6f6|1|[?]|AREA|Area|[?]|umol/mol|FURTHER ENLARGEMENT|1|mL/dose|INDIA INK STAIN||Y|SPOUSE|READER|N|1|Visit_1|10|1|WASHOUT|2020-11-30|10
e|TR|bffa468a-a27b-4e87-a60d-b5787a03c6f6|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mg/kg|NON-PATHOLOGICAL|1|g/cage/wk|OPTICAL MAPPING|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|NA|2|Visit_2|25|6|TREATMENT|2020-12-15|25
e|TR|bffa468a-a27b-4e87-a60d-b5787a03c6f6|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|OI50|FURTHER ENLARGEMENT FROM NADIR|1|IU/g Hb|TRIPLE-PHASE SPIRAL CT SCAN|||INDEPENDENT ASSESSOR|DERMATOLOGIST|U|3|Visit_3|40|2|SCREENING|2020-12-30|40
e|TR|bffa468a-a27b-4e87-a60d-b5787a03c6f6|4|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|TAMPON|EQUIVOCAL|1|Tesla|AMSLER GRID|||CHILD|DERMATOLOGIST|N|4|Visit_4|65|1|FOLLOW-UP|2021-01-24|65
e|TR|bffa468a-a27b-4e87-a60d-b5787a03c6f6|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mCi/kg|ABSENT|1|EP U|IMMUNO-PET SCAN|||INDEPENDENT ASSESSOR|DERMATOLOGIST|Y|5|Visit_5|90|2|WASHOUT|2021-02-18|90
e|TR|2e25aa76-914f-41e3-82ce-7c56ba2f6271|1|[?]|PCHGBL|Percent Change From Baseline|[?]|mV|DIFFUSELY INCREASED|1|g/U|GRAM STAIN||Y|INTERVIEWER|PATHOLOGIST|Y|1|Visit_1|10|2|FOLLOW-UP|2020-12-11|10
e|TR|2e25aa76-914f-41e3-82ce-7c56ba2f6271|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|POINT|NONPALPABLE|1|mgEq|GC/MS-CI|||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|U|2|Visit_2|25|1|TREATMENT|2020-12-26|25
e|TR|2e25aa76-914f-41e3-82ce-7c56ba2f6271|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|/day|FURTHER ENLARGEMENT FROM NADIR|1|U/animal|MRI|||CAREGIVER|OPHTHALMOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2021-01-10|40
e|TR|2e25aa76-914f-41e3-82ce-7c56ba2f6271|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|DISK|TUMOR MERGED|1|BOTTLE|PHASE CONTRAST MICROSCOPY|||FAMILY MEMBER|ONCOLOGIST|N|4|Visit_4|65|4|TREATMENT|2021-02-04|65
e|TR|2e25aa76-914f-41e3-82ce-7c56ba2f6271|5|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|L/kg|PRESENT|1|10^3/L|ELECTROPHORESIS|||FAMILY MEMBER|DERMATOLOGIST|N|5|Visit_5|90|2|WASHOUT|2021-03-01|90
e|TR|12c24fff-080b-4889-a455-ff55d5c0536c|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|/ms|FOCALLY INCREASED|1|mL/cm3/min|LEAD CITRATE STAIN||Y|SIBLING|RATER 2|N|1|Visit_1|10|7|TREATMENT|2021-01-27|10
e|TR|12c24fff-080b-4889-a455-ff55d5c0536c|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|TAMPON|EQUIVOCAL|1|POUCH|ELECTROGASTROGRAPHY|||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|4|WASHOUT|2021-02-11|25
e|TR|12c24fff-080b-4889-a455-ff55d5c0536c|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|VIRTUAL PIXEL|UNEQUIVOCAL|1|Absorbance U|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|Y||GUARDIAN|MICROSCOPIST 1|Y|3|Visit_3|40|1|TREATMENT|2021-02-26|40
e|TR|12c24fff-080b-4889-a455-ff55d5c0536c|4|[?]|TUMSTATE|Tumor State|[?]|Ci/uL|DIFFUSELY INCREASED|1|mmol/s|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|3|SCREENING|2021-03-23|65
e|TR|12c24fff-080b-4889-a455-ff55d5c0536c|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|scm|NON-PATHOLOGICAL|1|ng/dL|TWO-COLOR MICROARRAY|||SIGNIFICANT OTHER|NEUROLOGIST|U|5|Visit_5|90|3|TREATMENT|2021-04-17|90
e|TR|aecfe062-4e0d-4c91-8b67-1f304c5765ae|1|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|/100 HPFs|DECREASED|1|mg|NUCLEAR RADIOLOGY||Y|ADJUDICATOR|MICROSCOPIST 1|N|1|Visit_1|10|6|WASHOUT|2021-01-21|10
e|TR|aecfe062-4e0d-4c91-8b67-1f304c5765ae|2|[?]|ORSTATE|Organ State|[?]|mg/dL|FURTHER ENLARGEMENT|1|Bq/ug|TRANSMISSION ELECTRON MICROSCOPY||Y|SPOUSE|ADJUDICATOR 1|NA|2|Visit_2|25|3|FOLLOW-UP|2021-02-05|25
e|TR|aecfe062-4e0d-4c91-8b67-1f304c5765ae|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|uV2|FURTHER ENLARGEMENT FROM NADIR|1|fmol/L/sec|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||CAREGIVER|READER 2|Y|3|Visit_3|40|3|WASHOUT|2021-02-20|40
e|TR|aecfe062-4e0d-4c91-8b67-1f304c5765ae|4|[?]|PPD|Product of Perpendicular Diameters|[?]|mL/beat|PALPABLE|1|m2|ANTIBIOTIC AGAR SCREEN|Y||CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|6|FOLLOW-UP|2021-03-17|65
e|TR|aecfe062-4e0d-4c91-8b67-1f304c5765ae|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|um2|TUMOR MERGED|1|umol/mol|PLETHYSMOGRAPHY|Y||CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|NA|5|Visit_5|90|4|FOLLOW-UP|2021-04-11|90
e|TR|05a142dc-a779-44cb-ab2e-f961676a3940|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|fmol|NORMAL|1|mL/m2|PET/MRI SCAN|||CHILD|MICROSCOPIST 3|NA|1|Visit_1|10|7|TREATMENT|2020-11-18|10
e|TR|05a142dc-a779-44cb-ab2e-f961676a3940|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|pmol/day|UNEQUIVOCAL|1|kUSP|SPECT SCAN|Y||FRIEND|ADJUDICATOR|NA|2|Visit_2|25|4|WASHOUT|2020-12-03|25
e|TR|05a142dc-a779-44cb-ab2e-f961676a3940|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|g/L|FURTHER ENLARGEMENT FROM NADIR|1|uIU/dL|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y|PARENT|CARDIOLOGIST|U|3|Visit_3|40|3|TREATMENT|2020-12-18|40
e|TR|05a142dc-a779-44cb-ab2e-f961676a3940|4|[?]|VOLUME|Volume|[?]|mg/m2/min|ENLARGEMENT FROM NADIR|1|mg/m2/min|RADIOGRAPHY|||PARENT|PHYSIOTHERAPIST|U|4|Visit_4|65|4|TREATMENT|2021-01-12|65
e|TR|05a142dc-a779-44cb-ab2e-f961676a3940|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|ks|INCREASED|1|uIU/dL|PULMONARY ANGIOGRAPHY|Y||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|5|Visit_5|90|2|TREATMENT|2021-02-06|90
e|TR|498524c5-08c4-41a4-af81-876ab2452f64|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|in2|DIFFUSELY INCREASED|1|HOMEOPATHIC DILUTION|MICRONEUTRALIZATION ASSAY|Y||INTERVIEWER|DERMATOLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-12-09|10
e|TR|498524c5-08c4-41a4-af81-876ab2452f64|2|[?]|ORSTATE|Organ State|[?]|sec|UNCHANGED|1|10^9 CFU/g|MECHANICAL CLOT DETECTION|||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|Y|2|Visit_2|25|1|TREATMENT|2020-12-24|25
e|TR|498524c5-08c4-41a4-af81-876ab2452f64|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|mL/cage/wk|NON-PATHOLOGICAL|1|dyn|WHOLE GENOME SEQUENCING||Y|STUDY SUBJECT|MICROSCOPIST 1|N|3|Visit_3|40|5|WASHOUT|2021-01-08|40
e|TR|498524c5-08c4-41a4-af81-876ab2452f64|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mL/cm H2O|UNEQUIVOCAL|1|ukat/L|CONTRAST ENHANCED PET/CT SCAN|Y||NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|N|4|Visit_4|65|5|WASHOUT|2021-02-02|65
e|TR|498524c5-08c4-41a4-af81-876ab2452f64|5|[?]|NEWCONF|New Tumor Confirmed|[?]|ug/L DDU|NORMAL|1|mol/mg|HPLC|||INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|5|Visit_5|90|5|TREATMENT|2021-02-27|90
e|TR|93490930-01cd-470e-81a3-bcd7a140ccc1|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|%|PATHOLOGICAL|1|ukat/10^12 RBC|RADIOGRAPHY||Y|PARENT|NEUROLOGIST|Y|1|Visit_1|10|4|SCREENING|2020-11-17|10
e|TR|93490930-01cd-470e-81a3-bcd7a140ccc1|2|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|kcal/day|TUMOR MERGED|1|cmH2O*s/mL|TRICHROME STAIN|||PROXY|RATER|Y|2|Visit_2|25|2|SCREENING|2020-12-02|25
e|TR|93490930-01cd-470e-81a3-bcd7a140ccc1|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|hr/day|DECREASED|1|mL/mmHg|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|SPOUSE|ADJUDICATOR 1|U|3|Visit_3|40|1|TREATMENT|2020-12-17|40
e|TR|93490930-01cd-470e-81a3-bcd7a140ccc1|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mV|NON-PATHOLOGICAL|1|breaths/min|RADIOGRAPHY|Y||VENDOR|CARDIOLOGIST|N|4|Visit_4|65|5|TREATMENT|2021-01-11|65
e|TR|93490930-01cd-470e-81a3-bcd7a140ccc1|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|copies/uL|NORMAL|1|/HPF|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y|SPOUSE|PATHOLOGIST|Y|5|Visit_5|90|3|SCREENING|2021-02-05|90
e|TR|fd588c97-c57f-432f-81a0-a116a017c5dd|1|[?]|LDIAM|Longest Diameter|[?]|nL|FURTHER ENLARGEMENT FROM NADIR|1|CAPSULE|SURFACE PLASMON RESONANCE|||CHILD|PATHOLOGIST 2|N|1|Visit_1|10|1|TREATMENT|2020-06-03|10
e|TR|fd588c97-c57f-432f-81a0-a116a017c5dd|2|[?]|ACHNAD|Absolute Change From Nadir|[?]|BOWL|DIFFUSELY INCREASED|1|ug/g/day|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||SIBLING|PATHOLOGIST 1|NA|2|Visit_2|25|7|WASHOUT|2020-06-18|25
e|TR|fd588c97-c57f-432f-81a0-a116a017c5dd|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|% INHIBITION|ABSENT|1|foz_us|CHROMATOGRAPHY|||STUDY SUBJECT|NEUROLOGIST 2|NA|3|Visit_3|40|4|TREATMENT|2020-07-03|40
e|TR|fd588c97-c57f-432f-81a0-a116a017c5dd|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|umol/mol|PATHOLOGICAL|1|uU/dL|CINEANGIOGRAPHY|||FRIEND|READER|U|4|Visit_4|65|6|TREATMENT|2020-07-28|65
e|TR|fd588c97-c57f-432f-81a0-a116a017c5dd|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|CAPFUL|EQUIVOCAL|1|BE/mL|CARDIAC THERMODILUTION|||GUARDIAN|ENDOCRINOLOGIST|U|5|Visit_5|90|1|TREATMENT|2020-08-22|90
e|TR|18028efc-33b9-4741-a47a-8fdac0a90e6e|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|DRINK|NONPALPABLE|1|mmHg/L/min|DISK DIFFUSION|||INVESTIGATOR|ENDOCRINOLOGIST|Y|1|Visit_1|10|7|FOLLOW-UP|2020-12-22|10
e|TR|18028efc-33b9-4741-a47a-8fdac0a90e6e|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|dpm/mg|TUMOR MERGED|1|fmol/L|MYELOPEROXIDASE STAIN|||CLINICAL RESEARCH COORDINATOR|READER 3|N|2|Visit_2|25|3|TREATMENT|2021-01-06|25
e|TR|18028efc-33b9-4741-a47a-8fdac0a90e6e|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|IMPLANT|FOCALLY INCREASED|1|mL/beat|FLUORESCENT ENZYME IMMUNOASSAY|||PARENT|ADJUDICATOR 3|Y|3|Visit_3|40|2|WASHOUT|2021-01-21|40
e|TR|18028efc-33b9-4741-a47a-8fdac0a90e6e|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|BAU/mL|EQUIVOCAL|1|10^7 CFU/mL|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|Y||SIGNIFICANT OTHER|MICROSCOPIST 2|Y|4|Visit_4|65|7|WASHOUT|2021-02-15|65
e|TR|18028efc-33b9-4741-a47a-8fdac0a90e6e|5|[?]|PCHGBL|Percent Change From Baseline|[?]|log10 TCID 50/mL|FOCALLY INCREASED|1|L/L|ACID FAST STAIN|||VENDOR|NEUROLOGIST|N|5|Visit_5|90|1|SCREENING|2021-03-12|90
e|TR|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|APL U|ENLARGEMENT|1|pptr|HEMAGGLUTINATION INHIBITION ASSAY||Y|CLINICAL RESEARCH COORDINATOR|READER 2|U|1|Visit_1|10|7|TREATMENT|2020-06-04|10
e|TR|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|Hz/s|ABSENT|1|V/sec|MICROBIAL CULTURE||Y|SPOUSE|ENDOCRINOLOGIST|U|2|Visit_2|25|7|FOLLOW-UP|2020-06-19|25
e|TR|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|mm2|PATHOLOGICAL|1|uCi/L|ACID FAST STAIN|Y||ADJUDICATION COMMITTEE|ADJUDICATOR|Y|3|Visit_3|40|5|SCREENING|2020-07-04|40
e|TR|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|4|[?]|RADIODEN|Radiodensity|[?]|ugEq|PALPABLE|1|grain|PULMONARY ANGIOGRAPHY|Y||SIGNIFICANT OTHER|READER 2|Y|4|Visit_4|65|4|SCREENING|2020-07-29|65
e|TR|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|5|[?]|AREA|Area|[?]|BOX|DIFFUSELY INCREASED|1|g|FLUORESCEIN STAIN|||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-08-23|90
e|TR|08fccce4-64bf-431e-81b0-a96566e77df6|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|MdFI|FURTHER ENLARGEMENT|1|tuberculin unit|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||PROXY|READER 3|N|1|Visit_1|10|3|SCREENING|2021-01-20|10
e|TR|08fccce4-64bf-431e-81b0-a96566e77df6|2|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|nmol BCE/mmol|PALPABLE|1|deg|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||GUARDIAN|RADIOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2021-02-04|25
e|TR|08fccce4-64bf-431e-81b0-a96566e77df6|3|[?]|SUMVOL|Sum of Volume|[?]|nmol BCE/nmol|ABSENT|1|mL/m2/h|MS/MS|||PARENT|OPTOMETRIST|Y|3|Visit_3|40|6|SCREENING|2021-02-19|40
e|TR|08fccce4-64bf-431e-81b0-a96566e77df6|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|10^4 CFU|ABSENT|1|pmol/g|SCINTIGRAPHY|Y||PARENT|OPTOMETRIST|N|4|Visit_4|65|7|TREATMENT|2021-03-16|65
e|TR|08fccce4-64bf-431e-81b0-a96566e77df6|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|psi|PATHOLOGICAL|1|Bq/L|WHOLE GENOME SEQUENCING|||INVESTIGATOR|OPTOMETRIST|NA|5|Visit_5|90|3|FOLLOW-UP|2021-04-10|90
e|TR|0354fab5-5636-4504-8345-af060ad4c90c|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|mph|UNEQUIVOCAL|1|F|DOUBLE IMMUNODIFFUSION||Y|ADJUDICATOR|RADIOLOGIST|U|1|Visit_1|10|4|TREATMENT|2021-01-23|10
e|TR|0354fab5-5636-4504-8345-af060ad4c90c|2|[?]|PCHGBL|Percent Change From Baseline|[?]|titer|NORMAL|1|cmH2O*s2/mL|BAC ACGH|Y||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|N|2|Visit_2|25|7|TREATMENT|2021-02-07|25
e|TR|0354fab5-5636-4504-8345-af060ad4c90c|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|GBq/mg|NORMAL|1|uL|SLOAN LETTER EYE CHART 2.5%|Y|Y|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|3|Visit_3|40|5|FOLLOW-UP|2021-02-22|40
e|TR|0354fab5-5636-4504-8345-af060ad4c90c|4|[?]|VDIAM|Viable Diameter|[?]|DNA copies/mL|NORMAL|1|ug/h|FLOW MICROSCOPY||Y|CLINICAL RESEARCH ASSOCIATE|RATER 2|N|4|Visit_4|65|4|TREATMENT|2021-03-19|65
e|TR|0354fab5-5636-4504-8345-af060ad4c90c|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|v/v|ENLARGEMENT|1|/100 HPFs|CISH|||INTERVIEWER|OPTOMETRIST|NA|5|Visit_5|90|6|TREATMENT|2021-04-13|90
e|TR|f4f1a53a-d621-4f75-b44e-96b959aed03d|1|[?]|BNLNUM|Number of Bone Lesions|[?]|Frames/s|NONPALPABLE|1|pmol/dL|MICRODENSITOMETRY|||SIGNIFICANT OTHER|ONCOLOGIST|N|1|Visit_1|10|2|TREATMENT|2021-01-09|10
e|TR|f4f1a53a-d621-4f75-b44e-96b959aed03d|2|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|ng/dL|PALPABLE|1|CAN|WHOLE EXOME SEQUENCING|||STUDY SUBJECT|INTERNIST|Y|2|Visit_2|25|4|FOLLOW-UP|2021-01-24|25
e|TR|f4f1a53a-d621-4f75-b44e-96b959aed03d|3|[?]|NEWCONF|New Tumor Confirmed|[?]|mL/m2|TUMOR MERGED|1|fraction of 1|DYNAMIC LIGHT SCATTERING|||GUARDIAN|NEUROLOGIST 2|U|3|Visit_3|40|6|WASHOUT|2021-02-08|40
e|TR|f4f1a53a-d621-4f75-b44e-96b959aed03d|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|/10^3|FURTHER ENLARGEMENT|1|fmol/L|CELLULAR PROLIFERATION ASSAY|||STUDY SUBJECT|CARDIOLOGIST|N|4|Visit_4|65|6|WASHOUT|2021-03-05|65
e|TR|f4f1a53a-d621-4f75-b44e-96b959aed03d|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|fL|NON-PATHOLOGICAL|1|BAU/mL|HPLC/MS|Y|Y|INVESTIGATOR|CARDIOLOGIST|U|5|Visit_5|90|5|TREATMENT|2021-03-30|90
e|TR|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|1|[?]|TUMSTATE|Tumor State|[?]|Bq/L|PATHOLOGICAL|1|CAPSULE|RADIAL IMMUNODIFFUSION|||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-10-01|10
e|TR|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|CAPFUL|ABSENT|1|/h|DOPPLER ULTRASOUND|Y|Y|SIGNIFICANT OTHER|ADJUDICATOR|Y|2|Visit_2|25|6|FOLLOW-UP|2020-10-16|25
e|TR|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|umol/min|ABSENT|1|atm|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||INVESTIGATOR|ONCOLOGIST 1|Y|3|Visit_3|40|6|TREATMENT|2020-10-31|40
e|TR|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|nmol BCE/mmol|FOCALLY INCREASED|1|mol|PERIODIC ACID SCHIFF STAIN|||PARENT|MICROSCOPIST 1|NA|4|Visit_4|65|6|SCREENING|2020-11-25|65
e|TR|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|5|[?]|SUMDIAM|Sum of Diameter|[?]|LENS|PATHOLOGICAL|1|log10 IU/mL|URANYL ACETATE STAIN|||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|4|TREATMENT|2020-12-20|90
e|TR|679423a4-92cf-4a93-8277-282f9b43f2ed|1|[?]|CALCFIND|Calcification Indicator|[?]|10^6 organisms/mg|FOCALLY INCREASED|1|pg/L|SIZE EXCLUSION CHROMATOGRAPHY|||INTERVIEWER|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|2|FOLLOW-UP|2020-08-03|10
e|TR|679423a4-92cf-4a93-8277-282f9b43f2ed|2|[?]|VDIAM|Viable Diameter|[?]|GBq/ug|ABSENT|1|IU/g Hb|RADIOGRAPHY|Y|Y|CHILD|ENDOCRINOLOGIST|NA|2|Visit_2|25|3|WASHOUT|2020-08-18|25
e|TR|679423a4-92cf-4a93-8277-282f9b43f2ed|3|[?]|SUMDIAM|Sum of Diameter|[?]|log EID 50/dose|NORMAL|1|ELISA unit|IMMUNOCHEMILUMINOMETRIC ASSAY|Y||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|4|SCREENING|2020-09-02|40
e|TR|679423a4-92cf-4a93-8277-282f9b43f2ed|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|ug/g/min|NONPALPABLE|1|U/g/h|ANTIMICROBIAL COMBINATION TESTING|Y||PROXY|PATHOLOGIST|N|4|Visit_4|65|6|SCREENING|2020-09-27|65
e|TR|679423a4-92cf-4a93-8277-282f9b43f2ed|5|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|PIPE|NORMAL|1|pmol/10^9 cells|CONGO RED STAIN|Y|Y|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|NA|5|Visit_5|90|2|FOLLOW-UP|2020-10-22|90
e|TR|fb686cda-337b-46aa-b67b-790414201d9a|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|MESF|TUMOR MERGED|1|fg|SPECT SCAN|||INVESTIGATOR|RADIOLOGIST 1|N|1|Visit_1|10|3|TREATMENT|2020-05-26|10
e|TR|fb686cda-337b-46aa-b67b-790414201d9a|2|[?]|PALPSTAT|Palpable State|[?]|/100 WBC|NONPALPABLE|1|ukat|DIGITAL PCR ARRAY|Y||DOMESTIC PARTNER|READER|Y|2|Visit_2|25|5|FOLLOW-UP|2020-06-10|25
e|TR|fb686cda-337b-46aa-b67b-790414201d9a|3|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|umol/L/min|DECREASED|1|mL/h|CENTRIFUGATION|Y|Y|FRIEND|ADJUDICATOR|N|3|Visit_3|40|2|TREATMENT|2020-06-25|40
e|TR|fb686cda-337b-46aa-b67b-790414201d9a|4|[?]|AREA|Area|[?]|CONTAINER|FOCALLY INCREASED|1|kg|CONTRAST ENHANCED PET/CT SCAN||Y|INDEPENDENT ASSESSOR|INTERNIST|Y|4|Visit_4|65|3|WASHOUT|2020-07-20|65
e|TR|fb686cda-337b-46aa-b67b-790414201d9a|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|100 IU/mL|NORMAL|1|mL/kg/h|DYNAMOMETRY||Y|FAMILY MEMBER|ADJUDICATOR|U|5|Visit_5|90|3|FOLLOW-UP|2020-08-14|90
e|TR|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|min*mg/mL|TUMOR MERGED|1|CCID 50/mL|INDIA INK STAIN|||GUARDIAN|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|2|SCREENING|2020-10-05|10
e|TR|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|2|[?]|BNLNUM|Number of Bone Lesions|[?]|L/h/m2|FURTHER ENLARGEMENT FROM NADIR|1|TRANSDUCING UNIT|NON-INVASIVE DIELECTRIC SENSING|||CAREGIVER|PATHOLOGIST 1|U|2|Visit_2|25|1|TREATMENT|2020-10-20|25
e|TR|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|3|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|CIGARETTE|ENLARGEMENT|1|m/sec2|MICROBIAL CONCENTRATION|||FRIEND|UROLOGIST|N|3|Visit_3|40|1|SCREENING|2020-11-04|40
e|TR|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|4|[?]|LESSCIND|Lesion Success Indicator|[?]|v/v|ENLARGEMENT|1|DROP|IRON HEMATOXYLIN STAIN|Y||VENDOR|ONCOLOGIST 2|U|4|Visit_4|65|2|FOLLOW-UP|2020-11-29|65
e|TR|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|g/cage|UNEQUIVOCAL|1|mL/mmHg|PLETHYSMOGRAPHY|Y|Y|PROXY|ONCOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-12-24|90
e|TR|92d7a180-9353-41f8-93e2-ebcee32a1c63|1|[?]|TUMSTATE|Tumor State|[?]|IU/mmol|PALPABLE|1|pg/cell|PYROSEQUENCING|Y||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-12-06|10
e|TR|92d7a180-9353-41f8-93e2-ebcee32a1c63|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|EID 50/dose|NON-PATHOLOGICAL|1|um/s|MICROPARTICLE ENZYME IMMUNOASSAY|||CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|NA|2|Visit_2|25|1|TREATMENT|2020-12-21|25
e|TR|92d7a180-9353-41f8-93e2-ebcee32a1c63|3|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|U/m2/day|FOCALLY INCREASED|1|GBq/ug|VIRUS PLAQUE ASSAY|||SPOUSE|RATER|N|3|Visit_3|40|7|TREATMENT|2021-01-05|40
e|TR|92d7a180-9353-41f8-93e2-ebcee32a1c63|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|Gravitational Unit|DECREASED|1|umol/h/mmol|WHOLE TRANSCRIPTOME SEQUENCING|||NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2021-01-30|65
e|TR|92d7a180-9353-41f8-93e2-ebcee32a1c63|5|[?]|CALCFIND|Calcification Indicator|[?]|kN/cm2|ABSENT|1|cup eq|CARDIAC THERMODILUTION|Y|Y|PROXY|HEMATOLOGIST|N|5|Visit_5|90|3|WASHOUT|2021-02-24|90
e|TR|5da18fbc-1274-4cb3-bb6b-b57872b9815b|1|[?]|DIAMETER|Diameter|[?]|Absorbance U/min|INCREASED|1|pt_us|AUSCULTATION||Y|VENDOR|NEUROLOGIST 2|Y|1|Visit_1|10|7|TREATMENT|2020-10-17|10
e|TR|5da18fbc-1274-4cb3-bb6b-b57872b9815b|2|[?]|CALCFIND|Calcification Indicator|[?]|BU|EQUIVOCAL|1|PNU/mL|SPECT/CT SCAN|||CAREGIVER|RATER|N|2|Visit_2|25|7|TREATMENT|2020-11-01|25
e|TR|5da18fbc-1274-4cb3-bb6b-b57872b9815b|3|[?]|RADIODEN|Radiodensity|[?]|10^3 copies/mL|PALPABLE|1|PFU|ACCELERATOR MASS SPECTROMETRY||Y|SIBLING|PATHOLOGIST 1|Y|3|Visit_3|40|1|TREATMENT|2020-11-16|40
e|TR|5da18fbc-1274-4cb3-bb6b-b57872b9815b|4|[?]|ORVERLN|Organ Vertical Length|[?]|ugEq|PATHOLOGICAL|1|10^6 IU/mL|KLEIHAUER-BETKE||Y|ADJUDICATION COMMITTEE|MICROSCOPIST 2|NA|4|Visit_4|65|3|WASHOUT|2020-12-11|65
e|TR|5da18fbc-1274-4cb3-bb6b-b57872b9815b|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|umol/day|INCREASED|1|Gauss|ERGOSPIROMETRY|Y|Y|CLINICAL RESEARCH COORDINATOR|UROLOGIST|Y|5|Visit_5|90|7|TREATMENT|2021-01-05|90
e|TR|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|cm/s|PATHOLOGICAL|1|mL/cage|ZIEHL NEELSEN ACID FAST STAIN|||CHILD|RADIOLOGIST 1|N|1|Visit_1|10|4|SCREENING|2020-11-21|10
e|TR|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|2|[?]|RADIODEN|Radiodensity|[?]|CIGAR|DECREASED|1|amol|STRESS ECHOCARDIOGRAPHY|||CLINICAL RESEARCH COORDINATOR|INTERNIST|NA|2|Visit_2|25|7|TREATMENT|2020-12-06|25
e|TR|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|U|UNEQUIVOCAL|1|mL/cage/wk|AUSCULTATION|||SIBLING|HEMATOLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-12-21|40
e|TR|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|GPL U|FURTHER ENLARGEMENT FROM NADIR|1|ks|DYNAMIC LIGHT SCATTERING|||ADJUDICATOR|DERMATOLOGIST|NA|4|Visit_4|65|6|WASHOUT|2021-01-15|65
e|TR|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|5|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|fmol/L/sec|PALPABLE|1|mg/m2/min|ELECTROCHEMILUMINESCENCE||Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|N|5|Visit_5|90|2|TREATMENT|2021-02-09|90
e|TR|4a195822-d646-4b22-a3b9-f6642442474d|1|[?]|VDIAM|Viable Diameter|[?]|grain|FURTHER ENLARGEMENT|1|ug/kg|X-RAY|||SIGNIFICANT OTHER|NEUROLOGIST 2|N|1|Visit_1|10|1|TREATMENT|2020-07-25|10
e|TR|4a195822-d646-4b22-a3b9-f6642442474d|2|[?]|PALPSTAT|Palpable State|[?]|ug/g/day|NORMAL|1|dmol|OPHTHALMOSCOPY|Y||FRIEND|NEUROLOGIST 1|NA|2|Visit_2|25|2|FOLLOW-UP|2020-08-09|25
e|TR|4a195822-d646-4b22-a3b9-f6642442474d|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|kcal/day|NORMAL|1|mPa|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||INTERVIEWER|READER 1|Y|3|Visit_3|40|3|WASHOUT|2020-08-24|40
e|TR|4a195822-d646-4b22-a3b9-f6642442474d|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|L|FOCALLY INCREASED|1|uV*sec|CELLULAR PROLIFERATION ASSAY|||INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|4|Visit_4|65|3|SCREENING|2020-09-18|65
e|TR|4a195822-d646-4b22-a3b9-f6642442474d|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|PHERESIS UNIT|FURTHER ENLARGEMENT|1|ohm|NEXT GENERATION SEQUENCING||Y|SIGNIFICANT OTHER|MICROSCOPIST|U|5|Visit_5|90|4|SCREENING|2020-10-13|90
e|TR|515808c1-fda7-43bb-91dc-28e2d4e308cd|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|TRANSDUCING UNIT/mL|PALPABLE|1|umol/dL|PLETHYSMOGRAPHY|Y||FAMILY MEMBER|OPHTHALMOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-09-07|10
e|TR|515808c1-fda7-43bb-91dc-28e2d4e308cd|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|uL/mL|UNEQUIVOCAL|1|mJoule/cm2|LC/MS||Y|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|3|SCREENING|2020-09-22|25
e|TR|515808c1-fda7-43bb-91dc-28e2d4e308cd|3|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|KIT|UNCHANGED|1|fL|ELECTRICAL IMPEDANCE MYOGRAPHY|||SPOUSE|PATHOLOGIST 1|N|3|Visit_3|40|4|FOLLOW-UP|2020-10-07|40
e|TR|515808c1-fda7-43bb-91dc-28e2d4e308cd|4|[?]|LNSTATE|Lymph Node State|[?]|10^4 CFU|ENLARGEMENT|1|mL/min/mmHg|INTRAVASCULAR ULTRASOUND|Y|Y|GUARDIAN|RADIOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-11-01|65
e|TR|515808c1-fda7-43bb-91dc-28e2d4e308cd|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|mEq/mmol|PRESENT|1|/kg|ANTIBIOTIC AGAR SCREEN|||DOMESTIC PARTNER|MICROSCOPIST|N|5|Visit_5|90|3|TREATMENT|2020-11-26|90
e|TR|18461665-388d-403b-90e4-2b42fcb4a01a|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|usec|PALPABLE|1|POUCH|MRS|||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|1|FOLLOW-UP|2020-10-03|10
e|TR|18461665-388d-403b-90e4-2b42fcb4a01a|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|10^6 IU|ENLARGEMENT FROM NADIR|1|nmol/kg/day|TRANSVAGINAL ULTRASOUND|||CAREGIVER|PATHOLOGIST 2|N|2|Visit_2|25|5|TREATMENT|2020-10-18|25
e|TR|18461665-388d-403b-90e4-2b42fcb4a01a|3|[?]|VDIAM|Viable Diameter|[?]|mU/g|FURTHER ENLARGEMENT|1|HOURS|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||CLINICAL STUDY SPONSOR|RATER|U|3|Visit_3|40|4|TREATMENT|2020-11-02|40
e|TR|18461665-388d-403b-90e4-2b42fcb4a01a|4|[?]|SUMVOL|Sum of Volume|[?]|Bq/mL|EQUIVOCAL|1|vp/dose|TOTAL BODY RADIOGRAPHY|||ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|U|4|Visit_4|65|3|TREATMENT|2020-11-27|65
e|TR|18461665-388d-403b-90e4-2b42fcb4a01a|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|Absorbance U/min|NORMAL|1|U/m2/min|NO INFORMATION|||FAMILY MEMBER|RADIOLOGIST 2|NA|5|Visit_5|90|3|SCREENING|2020-12-22|90
e|TR|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|vg/kg|EQUIVOCAL|1|10^3 copies/mL|DOPPLER ULTRASOUND||Y|GUARDIAN|READER|U|1|Visit_1|10|5|TREATMENT|2020-08-14|10
e|TR|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|nU/cL|UNEQUIVOCAL|1|lx|MICRODENSITOMETRY|||HEALTH CARE PROFESSIONAL|RATER 2|Y|2|Visit_2|25|3|WASHOUT|2020-08-29|25
e|TR|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|3|[?]|PALPSTAT|Palpable State|[?]|PIPE|PRESENT|1|mOsm/L|HEMAGGLUTINATION ASSAY|||VENDOR|READER 2|U|3|Visit_3|40|6|TREATMENT|2020-09-13|40
e|TR|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|bel|DECREASED|1|CFU/mL|WHOLE GENOME SEQUENCING|Y||SIBLING|DERMATOLOGIST|U|4|Visit_4|65|4|FOLLOW-UP|2020-10-08|65
e|TR|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mol|PATHOLOGICAL|1|g/animal/day|FLUORESCENT IMMUNOASSAY|||INDEPENDENT ASSESSOR|ONCOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2020-11-02|90
e|TR|e3ce1661-1b72-4835-88d1-5a6d3655b674|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|PIXEL|ENLARGEMENT FROM NADIR|1|F|REVERSE TRANSCRIPTASE PCR|||SIGNIFICANT OTHER|MICROSCOPIST 3|N|1|Visit_1|10|1|FOLLOW-UP|2020-08-12|10
e|TR|e3ce1661-1b72-4835-88d1-5a6d3655b674|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mL/cage|PRESENT|1|cmH2O*s2/mL|HIGH RESOLUTION CT|||STUDY SUBJECT|ADJUDICATOR 2|NA|2|Visit_2|25|4|SCREENING|2020-08-27|25
e|TR|e3ce1661-1b72-4835-88d1-5a6d3655b674|3|[?]|PCHGBL|Percent Change From Baseline|[?]|10^3 organisms|TUMOR MERGED|1|%/min|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||SIBLING|FORENSIC PATHOLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-09-11|40
e|TR|e3ce1661-1b72-4835-88d1-5a6d3655b674|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|g/animal|FURTHER ENLARGEMENT|1|10^6/g|ULTRASOUND|Y||DOMESTIC PARTNER|CARDIOLOGIST|Y|4|Visit_4|65|7|SCREENING|2020-10-06|65
e|TR|e3ce1661-1b72-4835-88d1-5a6d3655b674|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|m/sec2|PALPABLE|1|cs|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|7|SCREENING|2020-10-31|90
e|TR|240844e9-3dda-438e-81b2-8f6aa4e0427e|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|DDU|EQUIVOCAL|1|mL/dL|MEDIASTINOSCOPY|||PROXY|RATER 2|U|1|Visit_1|10|4|TREATMENT|2020-12-09|10
e|TR|240844e9-3dda-438e-81b2-8f6aa4e0427e|2|[?]|LNSTATE|Lymph Node State|[?]|Enzyme U|NON-PATHOLOGICAL|1|kg/L|FLUORESCENT SPOT TEST|Y||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|4|FOLLOW-UP|2020-12-24|25
e|TR|240844e9-3dda-438e-81b2-8f6aa4e0427e|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|ug/h|NONPALPABLE|1|min|STATIC PERIMETRY|Y||GUARDIAN|NEUROLOGIST 1|NA|3|Visit_3|40|6|WASHOUT|2021-01-08|40
e|TR|240844e9-3dda-438e-81b2-8f6aa4e0427e|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|cd*s/m2|EQUIVOCAL|1|ng/mol|IMMUNE REPERTOIRE DEEP SEQUENCING|Y|Y|VENDOR|MICROSCOPIST 3|Y|4|Visit_4|65|7|WASHOUT|2021-02-02|65
e|TR|240844e9-3dda-438e-81b2-8f6aa4e0427e|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|anti-Xa IU|FURTHER ENLARGEMENT FROM NADIR|1|umol/dL|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||GUARDIAN|MICROSCOPIST|U|5|Visit_5|90|1|WASHOUT|2021-02-27|90
e|TR|fccf5c5d-deb6-4f13-a485-afcda3556578|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|/10^3|PRESENT|1|BU|DIRECT SEQUENCING|Y||FRIEND|ONCOLOGIST 1|NA|1|Visit_1|10|2|FOLLOW-UP|2020-08-04|10
e|TR|fccf5c5d-deb6-4f13-a485-afcda3556578|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|h/wk|FURTHER ENLARGEMENT|1|10^10/L|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||STUDY SUBJECT|NEUROLOGIST 1|NA|2|Visit_2|25|4|FOLLOW-UP|2020-08-19|25
e|TR|fccf5c5d-deb6-4f13-a485-afcda3556578|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|Hz|ENLARGEMENT|1|uV2|NO INFORMATION||Y|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|1|TREATMENT|2020-09-03|40
e|TR|fccf5c5d-deb6-4f13-a485-afcda3556578|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|cmHg|UNEQUIVOCAL|1|BAU/mL|IMMUNOFIXATION ELECTROPHORESIS|||CHILD|READER|U|4|Visit_4|65|4|SCREENING|2020-09-28|65
e|TR|fccf5c5d-deb6-4f13-a485-afcda3556578|5|[?]|LDIAM|Longest Diameter|[?]|10^6 CFU|ABSENT|1|U/mg|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||CHILD|READER 2|U|5|Visit_5|90|6|TREATMENT|2020-10-23|90
e|TR|94620ed0-1ae8-4fa5-a629-9210860b0be9|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|CAN|NORMAL|1|TABLET|HIGH RESOLUTION CT|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|NA|1|Visit_1|10|6|TREATMENT|2020-08-04|10
e|TR|94620ed0-1ae8-4fa5-a629-9210860b0be9|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|APL U|DECREASED|1|NEBULE|MAPH|||HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|2|Visit_2|25|2|TREATMENT|2020-08-19|25
e|TR|94620ed0-1ae8-4fa5-a629-9210860b0be9|3|[?]|CALCFIND|Calcification Indicator|[?]|PACK|UNCHANGED|1|Gy/h|DOPPLER ULTRASOUND|||GUARDIAN|RATER 2|NA|3|Visit_3|40|3|TREATMENT|2020-09-03|40
e|TR|94620ed0-1ae8-4fa5-a629-9210860b0be9|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|10^11/L|FURTHER ENLARGEMENT FROM NADIR|1|dB|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|NA|4|Visit_4|65|3|TREATMENT|2020-09-28|65
e|TR|94620ed0-1ae8-4fa5-a629-9210860b0be9|5|[?]|RADIODEN|Radiodensity|[?]|100 IU/mL|FURTHER ENLARGEMENT|1|10^8 PFU|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||FRIEND|READER 3|NA|5|Visit_5|90|3|TREATMENT|2020-10-23|90
e|TR|9c3b6912-19be-435c-87fc-781a08efb847|1|[?]|VOLUME|Volume|[?]|cycle/min|UNEQUIVOCAL|1|mol/g|FLUORESCENCE ANGIOGRAPHY|||CAREGIVER|ADJUDICATOR 3|NA|1|Visit_1|10|7|TREATMENT|2021-01-22|10
e|TR|9c3b6912-19be-435c-87fc-781a08efb847|2|[?]|DIAMETER|Diameter|[?]|FIU|ABSENT|1|U/m2/min|TRIPLE-PHASE MRI SCAN||Y|CAREGIVER|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|6|TREATMENT|2021-02-06|25
e|TR|9c3b6912-19be-435c-87fc-781a08efb847|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|10^3 DNA copies/mL|NORMAL|1|PIXELS/in|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||Y|PROXY|MICROSCOPIST 1|Y|3|Visit_3|40|4|TREATMENT|2021-02-21|40
e|TR|9c3b6912-19be-435c-87fc-781a08efb847|4|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|CAPSULE|DIFFUSELY INCREASED|1|mg/kg/min|HIGH RESOLUTION MELT ANALYSIS|||ADJUDICATOR|NEUROLOGIST 2|Y|4|Visit_4|65|3|FOLLOW-UP|2021-03-18|65
e|TR|9c3b6912-19be-435c-87fc-781a08efb847|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|GPL U|ABSENT|1|ug/m2/day|PULMONARY ANGIOGRAPHY|||ADJUDICATION COMMITTEE|RATER|U|5|Visit_5|90|5|TREATMENT|2021-04-12|90
e|TR|171a6d85-ba2e-45da-b31b-01651b26e890|1|[?]|CALCFIND|Calcification Indicator|[?]|mL/s/m2|FOCALLY INCREASED|1|pL|ELECTROCHEMILUMINESCENCE|Y||GUARDIAN|ADJUDICATOR|Y|1|Visit_1|10|4|SCREENING|2020-08-02|10
e|TR|171a6d85-ba2e-45da-b31b-01651b26e890|2|[?]|LPERP|Longest Perpendicular|[?]|10^4/L|PALPABLE|1|Joule|GIEMSA STAIN|||CLINICAL STUDY SPONSOR|READER 1|U|2|Visit_2|25|2|WASHOUT|2020-08-17|25
e|TR|171a6d85-ba2e-45da-b31b-01651b26e890|3|[?]|TUMSTATE|Tumor State|[?]|mL/cage|PATHOLOGICAL|1|CFU/g|ANTIMICROBIAL COMBINATION TESTING||Y|SIGNIFICANT OTHER|PATHOLOGIST 1|NA|3|Visit_3|40|5|TREATMENT|2020-09-01|40
e|TR|171a6d85-ba2e-45da-b31b-01651b26e890|4|[?]|BNLNUM|Number of Bone Lesions|[?]|gpELISA unit/mL|EQUIVOCAL|1|cycle/min|PULSE OXIMETRY|Y|Y|GUARDIAN|PATHOLOGIST|NA|4|Visit_4|65|5|WASHOUT|2020-09-26|65
e|TR|171a6d85-ba2e-45da-b31b-01651b26e890|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|IU/g Hb|FURTHER ENLARGEMENT|1|cycle/min|CELL OF ORIGIN ASSAY|||NON-HEALTH CARE PROFESSIONAL|READER 2|N|5|Visit_5|90|2|TREATMENT|2020-10-21|90
e|TR|a8338164-1bb5-4474-9432-4d5a81ab30d8|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|CONTAINER|DIFFUSELY INCREASED|1|s*kPa|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||CLINICAL STUDY SPONSOR|NEUROLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-12-10|10
e|TR|a8338164-1bb5-4474-9432-4d5a81ab30d8|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|U/g Hb|UNCHANGED|1|ng|AMSLER GRID|Y||FRIEND|HEMATOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-12-25|25
e|TR|a8338164-1bb5-4474-9432-4d5a81ab30d8|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|DPM|ENLARGEMENT|1|umol/min|PET/MRI SCAN||Y|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|2|SCREENING|2021-01-09|40
e|TR|a8338164-1bb5-4474-9432-4d5a81ab30d8|4|[?]|PCHGBL|Percent Change From Baseline|[?]|IU/day|UNCHANGED|1|DPM|MUGA|||SPOUSE|ONCOLOGIST|U|4|Visit_4|65|7|WASHOUT|2021-02-03|65
e|TR|a8338164-1bb5-4474-9432-4d5a81ab30d8|5|[?]|ORVERLN|Organ Vertical Length|[?]|OD Unit|TUMOR MERGED|1|nkat/L|EIA|||INVESTIGATOR|ADJUDICATOR 1|U|5|Visit_5|90|7|FOLLOW-UP|2021-02-28|90
e|TR|6d64077e-1f18-4bd6-ba86-53d90121f7a9|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|Anson U|NORMAL|1|tuberculin unit|X-RAY|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|1|Visit_1|10|4|TREATMENT|2020-06-17|10
e|TR|6d64077e-1f18-4bd6-ba86-53d90121f7a9|2|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mph|ENLARGEMENT|1|Bq/g|U-HPLC/MS/MS|||ADJUDICATOR|READER|N|2|Visit_2|25|1|WASHOUT|2020-07-02|25
e|TR|6d64077e-1f18-4bd6-ba86-53d90121f7a9|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|/7.5 mL|EQUIVOCAL|1|mL/kg/min|NUCLEAR RADIOLOGY|||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|3|Visit_3|40|4|SCREENING|2020-07-17|40
e|TR|6d64077e-1f18-4bd6-ba86-53d90121f7a9|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|cg|NON-PATHOLOGICAL|1|umol/L|DISK DIFFUSION||Y|PROXY|ENDOCRINOLOGIST|NA|4|Visit_4|65|2|FOLLOW-UP|2020-08-11|65
e|TR|6d64077e-1f18-4bd6-ba86-53d90121f7a9|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|PNU/mL|FURTHER ENLARGEMENT FROM NADIR|1|GLOBULE|IHC|Y||INVESTIGATOR|PATHOLOGIST 2|N|5|Visit_5|90|7|SCREENING|2020-09-05|90
e|TR|91d08486-3db7-4c71-a63f-fd060f4ae1a4|1|[?]|LPERP|Longest Perpendicular|[?]|mL/m2/day|NON-PATHOLOGICAL|1|Gy/min|TEST STRIP|||PARENT|OPTOMETRIST|U|1|Visit_1|10|4|TREATMENT|2020-12-25|10
e|TR|91d08486-3db7-4c71-a63f-fd060f4ae1a4|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|g/kg|ABSENT|1|Sv|SLOAN LETTER EYE CHART 100%||Y|ADJUDICATOR|OPTOMETRIST|U|2|Visit_2|25|5|TREATMENT|2021-01-09|25
e|TR|91d08486-3db7-4c71-a63f-fd060f4ae1a4|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|ug/L FEU|EQUIVOCAL|1|umol/kg/min|TWO-COLOR MICROARRAY|||DOMESTIC PARTNER|CARDIOLOGIST|N|3|Visit_3|40|7|TREATMENT|2021-01-24|40
e|TR|91d08486-3db7-4c71-a63f-fd060f4ae1a4|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mEq/ug|TUMOR MERGED|1|APL U|SPECTROPHOTOMETRY|||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|Y|4|Visit_4|65|7|FOLLOW-UP|2021-02-18|65
e|TR|91d08486-3db7-4c71-a63f-fd060f4ae1a4|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mL/m2/day|TUMOR MERGED|1|/5x10^4 WBC|DYNAMIC CONTRAST ENHANCED MRI|Y|Y|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|5|Visit_5|90|3|SCREENING|2021-03-15|90
e|TR|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|Joule|NONPALPABLE|1|kBq|CT SCAN WITHOUT CONTRAST|||CLINICAL STUDY SPONSOR|MICROSCOPIST 2|NA|1|Visit_1|10|2|SCREENING|2020-08-14|10
e|TR|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|10^7 TCID 50/dose|NORMAL|1|10^9 CFU/g|OSCILLOMETRY||Y|VENDOR|ADJUDICATOR|NA|2|Visit_2|25|7|SCREENING|2020-08-29|25
e|TR|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|3|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|NEBULE|ENLARGEMENT|1|mAnson U/mL|OPTICAL MAPPING|Y||FRIEND|NEUROLOGIST 2|NA|3|Visit_3|40|5|TREATMENT|2020-09-13|40
e|TR|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|LENS|NON-PATHOLOGICAL|1|mph|CISH|||GUARDIAN|FORENSIC PATHOLOGIST|N|4|Visit_4|65|4|TREATMENT|2020-10-08|65
e|TR|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|5|[?]|BNLNUM|Number of Bone Lesions|[?]|POUCH|NORMAL|1|cm/min|ENZYMATIC COLORIMETRY|||SIGNIFICANT OTHER|ENDOCRINOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-11-02|90
e|TR|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|mg/dL|FURTHER ENLARGEMENT FROM NADIR|1|pptr|SICKLE CELL SOLUBILITY TEST|||ADJUDICATION COMMITTEE|NEUROLOGIST|Y|1|Visit_1|10|7|FOLLOW-UP|2021-01-09|10
e|TR|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|ug/h|NONPALPABLE|1|ohm|CHROMATOGRAPHY|||SIBLING|RADIOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2021-01-24|25
e|TR|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|gMFI|UNEQUIVOCAL|1|mL/m2|THICK SMEAR|||VENDOR|ONCOLOGIST 1|NA|3|Visit_3|40|7|FOLLOW-UP|2021-02-08|40
e|TR|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|4|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|mg/animal|NORMAL|1|U/mL|SNP ARRAY|||INDEPENDENT ASSESSOR|ONCOLOGIST 1|N|4|Visit_4|65|1|FOLLOW-UP|2021-03-05|65
e|TR|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|Pa|PATHOLOGICAL|1|umol/mg/min|IMMUNO-PET SCAN||Y|ADJUDICATION COMMITTEE|INTERNIST|N|5|Visit_5|90|4|TREATMENT|2021-03-30|90
e|TR|87998e13-813a-464d-935c-d5513cd0db5e|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|kg/cm2|FURTHER ENLARGEMENT FROM NADIR|1|nmol/g|TRANSVAGINAL ULTRASOUND|Y||INVESTIGATOR|PHYSIOTHERAPIST|U|1|Visit_1|10|2|WASHOUT|2020-08-31|10
e|TR|87998e13-813a-464d-935c-d5513cd0db5e|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|umol/h/mmol|FURTHER ENLARGEMENT|1|ug/dL|CONTRAST ENHANCED PET SCAN||Y|NON-HEALTH CARE PROFESSIONAL|READER 3|NA|2|Visit_2|25|5|TREATMENT|2020-09-15|25
e|TR|87998e13-813a-464d-935c-d5513cd0db5e|3|[?]|LESSCIND|Lesion Success Indicator|[?]|10^6 IU|DECREASED|1|g/kg/day|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||PARENT|UROLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-09-30|40
e|TR|87998e13-813a-464d-935c-d5513cd0db5e|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|L|ENLARGEMENT FROM NADIR|1|ug/m2/min|SIZE EXCLUSION CHROMATOGRAPHY|||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|NA|4|Visit_4|65|6|TREATMENT|2020-10-25|65
e|TR|87998e13-813a-464d-935c-d5513cd0db5e|5|[?]|ORVERLN|Organ Vertical Length|[?]|uL/dose|NON-PATHOLOGICAL|1|10^9/g|HEMOCYTOMETRY|Y||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|Y|5|Visit_5|90|7|FOLLOW-UP|2020-11-19|90
e|TR|7812e96e-ea53-4eb0-8160-d4118c567c9d|1|[?]|LPERP|Longest Perpendicular|[?]|g/cage/day|ENLARGEMENT FROM NADIR|1|ug/g/h|SCANNING ELECTRON MICROSCOPY|||SIBLING|RADIOLOGIST 1|NA|1|Visit_1|10|3|WASHOUT|2021-01-27|10
e|TR|7812e96e-ea53-4eb0-8160-d4118c567c9d|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|foz_br|FURTHER ENLARGEMENT|1|Newton|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||INDEPENDENT ASSESSOR|MICROSCOPIST 2|U|2|Visit_2|25|6|TREATMENT|2021-02-11|25
e|TR|7812e96e-ea53-4eb0-8160-d4118c567c9d|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|nmol/L/h|PATHOLOGICAL|1|nmol/kg/day|NEPHELOMETRY|||PROXY|INTERNIST|NA|3|Visit_3|40|3|TREATMENT|2021-02-26|40
e|TR|7812e96e-ea53-4eb0-8160-d4118c567c9d|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mg/mol|PATHOLOGICAL|1|kg/cm2|NO INFORMATION|||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|2|TREATMENT|2021-03-23|65
e|TR|7812e96e-ea53-4eb0-8160-d4118c567c9d|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|MAC50|TUMOR MERGED|1|mU/g|RAJI CELL RIA||Y|ADJUDICATION COMMITTEE|ADJUDICATOR 1|U|5|Visit_5|90|7|TREATMENT|2021-04-17|90
e|TR|f9c6c448-0e3d-421f-a63f-be4aeb965256|1|[?]|TUMSTATE|Tumor State|[?]|mg/kg/min|DIFFUSELY INCREASED|1|IU/kg|ELECTROPHORESIS|||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|1|Visit_1|10|5|TREATMENT|2020-11-08|10
e|TR|f9c6c448-0e3d-421f-a63f-be4aeb965256|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|mmol/day|DECREASED|1|ug/m2/min|NUCLEIC ACID BASED METHOD|Y||CLINICAL STUDY SPONSOR|MICROSCOPIST|NA|2|Visit_2|25|3|TREATMENT|2020-11-23|25
e|TR|f9c6c448-0e3d-421f-a63f-be4aeb965256|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|dram|ENLARGEMENT|1|DIOPTER|GC/MS-CI||Y|FRIEND|MICROSCOPIST 3|U|3|Visit_3|40|3|TREATMENT|2020-12-08|40
e|TR|f9c6c448-0e3d-421f-a63f-be4aeb965256|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|titer|NON-PATHOLOGICAL|1|pm|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|||VENDOR|CARDIOLOGIST|U|4|Visit_4|65|6|TREATMENT|2021-01-02|65
e|TR|f9c6c448-0e3d-421f-a63f-be4aeb965256|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mmol/kg|PATHOLOGICAL|1|/LSQN|PULSE OXIMETRY|Y||DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|3|FOLLOW-UP|2021-01-27|90
e|TR|e8da815a-b53c-46f4-a546-e8553152719f|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|uOsm|PRESENT|1|cmol|TEST STRIP|||GUARDIAN|ONCOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-12-27|10
e|TR|e8da815a-b53c-46f4-a546-e8553152719f|2|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|MBq|UNEQUIVOCAL|1|mg/g/h|TOTAL BODY RADIOGRAPHY|Y|Y|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|1|TREATMENT|2021-01-11|25
e|TR|e8da815a-b53c-46f4-a546-e8553152719f|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mEq/mmol|TUMOR MERGED|1|K|ELLA|||SIBLING|PATHOLOGIST 2|N|3|Visit_3|40|6|TREATMENT|2021-01-26|40
e|TR|e8da815a-b53c-46f4-a546-e8553152719f|4|[?]|PALPSTAT|Palpable State|[?]|IU/dL|FOCALLY INCREASED|1|msec|X-RAY FLUORESCENCE SPECTROMETRY|Y||ADJUDICATION COMMITTEE|READER 2|NA|4|Visit_4|65|4|TREATMENT|2021-02-20|65
e|TR|e8da815a-b53c-46f4-a546-e8553152719f|5|[?]|SUMVOL|Sum of Volume|[?]|cycle/min|TUMOR MERGED|1|mmol/g|HIGH LEVEL AMINOGLYCOSIDE SCREEN||Y|CAREGIVER|ADJUDICATOR 2|NA|5|Visit_5|90|4|WASHOUT|2021-03-17|90
e|TR|701d794b-07b4-4394-a2a4-d31a9f5b743a|1|[?]|PCHGBL|Percent Change From Baseline|[?]|cmH2O*s2/mL|ABSENT|1|DAgU|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|Y||INDEPENDENT ASSESSOR|ONCOLOGIST 1|Y|1|Visit_1|10|2|FOLLOW-UP|2021-01-29|10
e|TR|701d794b-07b4-4394-a2a4-d31a9f5b743a|2|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|BP|FOCALLY INCREASED|1|/10^4|PULSE OXIMETRY||Y|PROXY|MICROSCOPIST|U|2|Visit_2|25|7|FOLLOW-UP|2021-02-13|25
e|TR|701d794b-07b4-4394-a2a4-d31a9f5b743a|3|[?]|VDIAM|Viable Diameter|[?]|MESF|ABSENT|1|PELLET|TOLUIDINE BLUE STAIN|Y|Y|NON-HEALTH CARE PROFESSIONAL|INTERNIST|NA|3|Visit_3|40|6|WASHOUT|2021-02-28|40
e|TR|701d794b-07b4-4394-a2a4-d31a9f5b743a|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|fL|NON-PATHOLOGICAL|1|mL/beat|SXA SCAN|||ADJUDICATION COMMITTEE|ONCOLOGIST|N|4|Visit_4|65|1|TREATMENT|2021-03-25|65
e|TR|701d794b-07b4-4394-a2a4-d31a9f5b743a|5|[?]|SUMDIAM|Sum of Diameter|[?]|L/h|FOCALLY INCREASED|1|IU/kg/h|HEMAGGLUTINATION INHIBITION ASSAY|||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|2|WASHOUT|2021-04-19|90
e|TR|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|1|[?]|VDIAM|Viable Diameter|[?]|EID 50/dose|DECREASED|1|mm/2h|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y||FRIEND|ADJUDICATOR|N|1|Visit_1|10|5|TREATMENT|2020-12-25|10
e|TR|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|2|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|cd|EQUIVOCAL|1|DIOPTER|DUCTOGRAPHY|||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|5|WASHOUT|2021-01-09|25
e|TR|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|3|[?]|LDIAM|Longest Diameter|[?]|ug/mL/h|ENLARGEMENT FROM NADIR|1|STEPS|MICROBIAL BIOCHEMICAL IDENTIFICATION|||INTERVIEWER|READER 1|N|3|Visit_3|40|5|WASHOUT|2021-01-24|40
e|TR|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|10^3/hpf|PRESENT|1|mL/cm H2O|HIGH RESOLUTION MELT ANALYSIS||Y|DOMESTIC PARTNER|PHYSIOTHERAPIST|Y|4|Visit_4|65|4|SCREENING|2021-02-18|65
e|TR|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|5|[?]|LDIAM|Longest Diameter|[?]|Enzyme U/g Hb|UNEQUIVOCAL|1|tsp eq|PATHOLOGICAL EVALUATION|Y|Y|FRIEND|ONCOLOGIST|U|5|Visit_5|90|7|SCREENING|2021-03-15|90
e|TR|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|MET*h|UNCHANGED|1|ohm|STRESS ECHOCARDIOGRAPHY|||SIGNIFICANT OTHER|ADJUDICATOR|NA|1|Visit_1|10|3|FOLLOW-UP|2020-08-10|10
e|TR|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|2|[?]|PPD|Product of Perpendicular Diameters|[?]|mm/2h|DIFFUSELY INCREASED|1|CFU/g|GC/MS||Y|GUARDIAN|DERMATOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-08-25|25
e|TR|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|/month|NORMAL|1|log10 PFU|MICRONEUTRALIZATION ASSAY|Y|Y|CAREGIVER|READER 1|NA|3|Visit_3|40|6|FOLLOW-UP|2020-09-09|40
e|TR|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|mU/L|FURTHER ENLARGEMENT|1|10^7 CFU/mL|FREEZING POINT DEPRESSION|||FAMILY MEMBER|ADJUDICATOR 3|NA|4|Visit_4|65|5|FOLLOW-UP|2020-10-04|65
e|TR|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|Ci/mL|FURTHER ENLARGEMENT FROM NADIR|1|DPM|HPLC|||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|Y|5|Visit_5|90|3|FOLLOW-UP|2020-10-29|90
e|TR|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|1|[?]|VDIAM|Viable Diameter|[?]|vg/dose|FURTHER ENLARGEMENT|1|Henry|OBSERVATION|||NON-HEALTH CARE PROFESSIONAL|READER 3|Y|1|Visit_1|10|1|TREATMENT|2021-01-02|10
e|TR|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|ug/mol|NORMAL|1|Ci/ug|JAEGER EYE CHART|||ADJUDICATOR|READER 1|N|2|Visit_2|25|1|TREATMENT|2021-01-17|25
e|TR|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|3|[?]|LNSTATE|Lymph Node State|[?]|uU/L|FURTHER ENLARGEMENT|1|uL/dose|ENDOSCOPY|Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|NA|3|Visit_3|40|1|SCREENING|2021-02-01|40
e|TR|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|PIXELS/cm|NONPALPABLE|1|damol/L|ELISPOT|Y||PROXY|ADJUDICATOR 1|N|4|Visit_4|65|4|TREATMENT|2021-02-26|65
e|TR|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|BAU/mL|DIFFUSELY INCREASED|1|ug/kg/day|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||GUARDIAN|NEUROLOGIST|NA|5|Visit_5|90|4|FOLLOW-UP|2021-03-23|90
e|TR|bb2487c3-cc05-48f8-9031-0e433c07e3d6|1|[?]|RADIODEN|Radiodensity|[?]|min*mg/mL|PRESENT|1|ugEq|CT SCAN|||VENDOR|READER|U|1|Visit_1|10|5|TREATMENT|2020-11-29|10
e|TR|bb2487c3-cc05-48f8-9031-0e433c07e3d6|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|pmol|PATHOLOGICAL|1|mg|AUTOMATED COUNT|||CLINICAL STUDY SPONSOR|MICROSCOPIST 1|N|2|Visit_2|25|3|FOLLOW-UP|2020-12-14|25
e|TR|bb2487c3-cc05-48f8-9031-0e433c07e3d6|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|mV2/Hz|PATHOLOGICAL|1|APS U|MICRONEUTRALIZATION ASSAY|||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-12-29|40
e|TR|bb2487c3-cc05-48f8-9031-0e433c07e3d6|4|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|fmol|NON-PATHOLOGICAL|1|TUBE|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|4|TREATMENT|2021-01-23|65
e|TR|bb2487c3-cc05-48f8-9031-0e433c07e3d6|5|[?]|SUMVOL|Sum of Volume|[?]|m|DIFFUSELY INCREASED|1|mL/cm|SLIT LAMP|||CLINICAL STUDY SPONSOR|NEUROLOGIST 1|N|5|Visit_5|90|5|TREATMENT|2021-02-17|90
e|TR|2661da18-b539-49d8-ac80-9da03c127d21|1|[?]|PPD|Product of Perpendicular Diameters|[?]|PNU/mL|FURTHER ENLARGEMENT FROM NADIR|1|ug/h|FLAME PHOTOMETRY|||FRIEND|ADJUDICATOR|Y|1|Visit_1|10|4|WASHOUT|2020-07-26|10
e|TR|2661da18-b539-49d8-ac80-9da03c127d21|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|DPM|PRESENT|1|nL|DNA MICROARRAY|||FRIEND|RADIOLOGIST 1|NA|2|Visit_2|25|4|TREATMENT|2020-08-10|25
e|TR|2661da18-b539-49d8-ac80-9da03c127d21|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mEq|NON-PATHOLOGICAL|1|cmH2O/mL|FUNCTIONAL MRI||Y|PROXY|NEUROLOGIST|NA|3|Visit_3|40|1|TREATMENT|2020-08-25|40
e|TR|2661da18-b539-49d8-ac80-9da03c127d21|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|NEEDLE GAUGE|ENLARGEMENT FROM NADIR|1|vp/dose|TARGETED GENOME SEQUENCING|||ADJUDICATION COMMITTEE|MICROSCOPIST|U|4|Visit_4|65|2|SCREENING|2020-09-19|65
e|TR|2661da18-b539-49d8-ac80-9da03c127d21|5|[?]|NEWCONF|New Tumor Confirmed|[?]|U|DIFFUSELY INCREASED|1|mmHg|NEURAMINIDASE INHIBITION ASSAY|||FAMILY MEMBER|READER 1|NA|5|Visit_5|90|4|FOLLOW-UP|2020-10-14|90
e|TR|f1835786-c567-4235-9bd1-f7ffcec12741|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|ft2|ENLARGEMENT FROM NADIR|1|vg/kg|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|||ADJUDICATION COMMITTEE|MICROSCOPIST 1|NA|1|Visit_1|10|5|TREATMENT|2020-08-06|10
e|TR|f1835786-c567-4235-9bd1-f7ffcec12741|2|[?]|TUMSTATE|Tumor State|[?]|PFU/mL|PALPABLE|1|10^9 CFU/mL|LASER CAPTURE MICRODISSECTION|||PROXY|DERMATOLOGIST|Y|2|Visit_2|25|3|WASHOUT|2020-08-21|25
e|TR|f1835786-c567-4235-9bd1-f7ffcec12741|3|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|mmHg|NORMAL|1|mkat|LC/MS||Y|PROXY|OTOLARYNGOLOGIST|U|3|Visit_3|40|5|WASHOUT|2020-09-05|40
e|TR|f1835786-c567-4235-9bd1-f7ffcec12741|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|/4.0 mL|TUMOR MERGED|1|BOX|PLETHYSMOGRAPHY|||SPOUSE|UROLOGIST|U|4|Visit_4|65|6|WASHOUT|2020-09-30|65
e|TR|f1835786-c567-4235-9bd1-f7ffcec12741|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mg/min|ABSENT|1|TRANSDUCING UNIT|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y||CLINICAL STUDY SPONSOR|RATER 2|U|5|Visit_5|90|1|WASHOUT|2020-10-25|90
e|TR|019eb415-1da3-40fa-b4ba-b1f381ec3cac|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|mL/dL|ENLARGEMENT FROM NADIR|1|SQU/mL|SPECULAR MICROSCOPY|Y||SIBLING|ONCOLOGIST 2|Y|1|Visit_1|10|7|TREATMENT|2020-07-10|10
e|TR|019eb415-1da3-40fa-b4ba-b1f381ec3cac|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|VIAL|INCREASED|1|pmol|SPIRAL CT SCAN WITHOUT CONTRAST||Y|CAREGIVER|DERMATOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-07-25|25
e|TR|019eb415-1da3-40fa-b4ba-b1f381ec3cac|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|log10 CFU/g|FURTHER ENLARGEMENT|1|pmol/g|FLUOROSCOPY|||FAMILY MEMBER|ONCOLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-08-09|40
e|TR|019eb415-1da3-40fa-b4ba-b1f381ec3cac|4|[?]|LNSTATE|Lymph Node State|[?]|WAFER|FURTHER ENLARGEMENT|1|mL/cage/wk|INFRARED SPECTROMETRY|||GUARDIAN|ADJUDICATOR 1|N|4|Visit_4|65|3|TREATMENT|2020-09-03|65
e|TR|019eb415-1da3-40fa-b4ba-b1f381ec3cac|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|mN|UNEQUIVOCAL|1|BU/mL|GC/MS-EI|||CLINICAL STUDY SPONSOR|RATER 1|N|5|Visit_5|90|7|TREATMENT|2020-09-28|90
e|TR|2506c6e2-018f-4300-b3b5-44ff8d6e13df|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|ukat/10^12 RBC|TUMOR MERGED|1|h/wk|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||PARENT|READER 1|NA|1|Visit_1|10|3|TREATMENT|2020-07-23|10
e|TR|2506c6e2-018f-4300-b3b5-44ff8d6e13df|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|Frames/s|FOCALLY INCREASED|1|log10 PFU/mL|ELECTROGASTROGRAPHY|||PROXY|ONCOLOGIST 1|Y|2|Visit_2|25|7|WASHOUT|2020-08-07|25
e|TR|2506c6e2-018f-4300-b3b5-44ff8d6e13df|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|/7.5 mL|PRESENT|1|fmol|SMEAR|Y||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|Y|3|Visit_3|40|7|TREATMENT|2020-08-22|40
e|TR|2506c6e2-018f-4300-b3b5-44ff8d6e13df|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|umol/h/mmol|UNEQUIVOCAL|1|mL/min|DUCTOGRAPHY|Y||ADJUDICATOR|MICROSCOPIST|Y|4|Visit_4|65|1|FOLLOW-UP|2020-09-16|65
e|TR|2506c6e2-018f-4300-b3b5-44ff8d6e13df|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|m/sec2|FOCALLY INCREASED|1|PACK|IVY INCISION METHOD||Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|5|Visit_5|90|2|TREATMENT|2020-10-11|90
e|TR|65c439f8-9658-4ac5-9eae-0837182a90fd|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|ug/L|FURTHER ENLARGEMENT|1|10^9 organisms|MODIFIED ACID FAST STAIN|||VENDOR|PATHOLOGIST 2|Y|1|Visit_1|10|7|TREATMENT|2020-06-04|10
e|TR|65c439f8-9658-4ac5-9eae-0837182a90fd|2|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|BU/mL|UNCHANGED|1|10^7 CFU|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||SIBLING|OPTOMETRIST|U|2|Visit_2|25|3|FOLLOW-UP|2020-06-19|25
e|TR|65c439f8-9658-4ac5-9eae-0837182a90fd|3|[?]|PCHGBL|Percent Change From Baseline|[?]|EVENTS|NON-PATHOLOGICAL|1|days/month|PET/SPECT SCAN|||HEALTH CARE PROFESSIONAL|HEMATOLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-07-04|40
e|TR|65c439f8-9658-4ac5-9eae-0837182a90fd|4|[?]|LDIAM|Longest Diameter|[?]|g/kg/day|ABSENT|1|mL/m2|COMPLEMENT FIXATION|Y||CLINICAL RESEARCH ASSOCIATE|READER|U|4|Visit_4|65|7|TREATMENT|2020-07-29|65
e|TR|65c439f8-9658-4ac5-9eae-0837182a90fd|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|GLOBULE|UNCHANGED|1|/10^4|EIA|Y||CHILD|OPTOMETRIST|U|5|Visit_5|90|3|SCREENING|2020-08-23|90
e|TR|5b73ad4c-bb28-47d1-a2f6-8508444059a5|1|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|Bq/ug|ABSENT|1|umol|SEQUENCING|||PARENT|ONCOLOGIST 2|U|1|Visit_1|10|2|FOLLOW-UP|2020-06-12|10
e|TR|5b73ad4c-bb28-47d1-a2f6-8508444059a5|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|%|PATHOLOGICAL|1|copies/mL|PERCUSSION|||ADJUDICATOR|RADIOLOGIST 1|U|2|Visit_2|25|6|TREATMENT|2020-06-27|25
e|TR|5b73ad4c-bb28-47d1-a2f6-8508444059a5|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|nmol/mol|PRESENT|1|AFU|MYELOPEROXIDASE STAIN|||PARENT|READER 1|Y|3|Visit_3|40|3|TREATMENT|2020-07-12|40
e|TR|5b73ad4c-bb28-47d1-a2f6-8508444059a5|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|mg/kg/week|INCREASED|1|m/sec|COMPUTERIZED CORNEAL TOPOGRAPHY||Y|SIBLING|RATER 2|NA|4|Visit_4|65|4|SCREENING|2020-08-06|65
e|TR|5b73ad4c-bb28-47d1-a2f6-8508444059a5|5|[?]|CALCFIND|Calcification Indicator|[?]|g/day|UNEQUIVOCAL|1|10^3 copies/mL|IN VITRO GENE EXPRESSION ASSAY|||FRIEND|READER 3|U|5|Visit_5|90|6|WASHOUT|2020-08-31|90
e|TR|16dcaefa-701c-4863-b010-8ac640aeb55a|1|[?]|SUMVOL|Sum of Volume|[?]|mL/100g/min|UNEQUIVOCAL|1|ELISA unit/mL|IMMUNOPRECIPITATION|||ADJUDICATION COMMITTEE|ONCOLOGIST 2|NA|1|Visit_1|10|5|TREATMENT|2020-06-17|10
e|TR|16dcaefa-701c-4863-b010-8ac640aeb55a|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|ug|ABSENT|1|mL*cmH2O|FLUORESCENT SPOT TEST||Y|CHILD|NEUROLOGIST|U|2|Visit_2|25|1|SCREENING|2020-07-02|25
e|TR|16dcaefa-701c-4863-b010-8ac640aeb55a|3|[?]|NEWCONF|New Tumor Confirmed|[?]|10^3 organisms/mL|PATHOLOGICAL|1|g/mol|BIOIMPEDANCE SPECTROSCOPY|||INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|5|WASHOUT|2020-07-17|40
e|TR|16dcaefa-701c-4863-b010-8ac640aeb55a|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|ug/kg/day|NONPALPABLE|1|10^3 organisms/g|MOUSE PROTECTION ASSAY||Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|4|Visit_4|65|7|TREATMENT|2020-08-11|65
e|TR|16dcaefa-701c-4863-b010-8ac640aeb55a|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|PLUG|PATHOLOGICAL|1|m/sec|IN VITRO GENE EXPRESSION ASSAY|||ADJUDICATOR|MICROSCOPIST 2|NA|5|Visit_5|90|7|TREATMENT|2020-09-05|90
e|TR|4c19e870-9195-41d8-9c8a-8a54bb428732|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|10^4/L|NORMAL|1|g/m2|FORCED OSCILLATION TECHNIQUE|||CLINICAL STUDY SPONSOR|NEUROLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-08-03|10
e|TR|4c19e870-9195-41d8-9c8a-8a54bb428732|2|[?]|RADIODEN|Radiodensity|[?]|ft|PALPABLE|1|cpm|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||INVESTIGATOR|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|5|WASHOUT|2020-08-18|25
e|TR|4c19e870-9195-41d8-9c8a-8a54bb428732|3|[?]|DIAMETER|Diameter|[?]|gMFI|ENLARGEMENT|1|10^6 U|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|NA|3|Visit_3|40|6|SCREENING|2020-09-02|40
e|TR|4c19e870-9195-41d8-9c8a-8a54bb428732|4|[?]|RADIODEN|Radiodensity|[?]|mL/cage/wk|NON-PATHOLOGICAL|1|10^3/hpf|WHOLE GENOME SEQUENCING|||FRIEND|NEUROLOGIST 2|Y|4|Visit_4|65|3|FOLLOW-UP|2020-09-27|65
e|TR|4c19e870-9195-41d8-9c8a-8a54bb428732|5|[?]|DIAMETER|Diameter|[?]|umol/L|PALPABLE|1|RFU|REBOUND TONOMETRY|||STUDY SUBJECT|ADJUDICATOR 2|N|5|Visit_5|90|2|FOLLOW-UP|2020-10-22|90
e|TR|7682184f-0801-4315-9c5f-116f7321a2b0|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|min|EQUIVOCAL|1|cal|PHOTOMETRIC CLOT DETECTION|||ADJUDICATOR|MICROSCOPIST 2|Y|1|Visit_1|10|4|TREATMENT|2020-12-22|10
e|TR|7682184f-0801-4315-9c5f-116f7321a2b0|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|Ci/uL|ABSENT|1|TABLET|LIQUID SCINTILLATION COUNTING|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|U|2|Visit_2|25|7|FOLLOW-UP|2021-01-06|25
e|TR|7682184f-0801-4315-9c5f-116f7321a2b0|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|kat|ENLARGEMENT FROM NADIR|1|CAPLET|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y||SIGNIFICANT OTHER|MICROSCOPIST|NA|3|Visit_3|40|7|TREATMENT|2021-01-21|40
e|TR|7682184f-0801-4315-9c5f-116f7321a2b0|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|U/m2/h|ABSENT|1|g/animal|ENDPOINT DILUTION ASSAY||Y|INDEPENDENT ASSESSOR|OPTOMETRIST|U|4|Visit_4|65|5|TREATMENT|2021-02-15|65
e|TR|7682184f-0801-4315-9c5f-116f7321a2b0|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|cmol|ENLARGEMENT FROM NADIR|1|U/cL|PHASE-CONTRAST MRI|||GUARDIAN|PATHOLOGIST|Y|5|Visit_5|90|1|TREATMENT|2021-03-12|90
e|TR|c40f9cb3-b597-4614-8ba5-d40849030ff9|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|RNA copies/mL|DIFFUSELY INCREASED|1|km/h|THIN SMEAR|||INVESTIGATOR|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|4|SCREENING|2020-12-12|10
e|TR|c40f9cb3-b597-4614-8ba5-d40849030ff9|2|[?]|SUMDIAM|Sum of Diameter|[?]|atm|FURTHER ENLARGEMENT FROM NADIR|1|U/mL|MS/MS|||CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-12-27|25
e|TR|c40f9cb3-b597-4614-8ba5-d40849030ff9|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|/wk|ABSENT|1|mL/g/min|DROPLET DIGITAL PCR|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|NA|3|Visit_3|40|1|TREATMENT|2021-01-11|40
e|TR|c40f9cb3-b597-4614-8ba5-d40849030ff9|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mg/kg|FOCALLY INCREASED|1|kN/cm2|TARGETED GENOME SEQUENCING|||SIGNIFICANT OTHER|PATHOLOGIST 2|N|4|Visit_4|65|2|TREATMENT|2021-02-05|65
e|TR|c40f9cb3-b597-4614-8ba5-d40849030ff9|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mEq|UNEQUIVOCAL|1|mJoule/cm2|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y||HEALTH CARE PROFESSIONAL|RATER|N|5|Visit_5|90|7|TREATMENT|2021-03-02|90
e|TR|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|1|[?]|ORVERLN|Organ Vertical Length|[?]|cg|FURTHER ENLARGEMENT|1|mL/beat|MALDI-TOF|||CAREGIVER|ENDOCRINOLOGIST|N|1|Visit_1|10|2|FOLLOW-UP|2020-09-09|10
e|TR|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|2|[?]|DIAMETER|Diameter|[?]|usec|UNEQUIVOCAL|1|g/animal/day|TONOMETRY|Y||VENDOR|RATER 2|U|2|Visit_2|25|6|FOLLOW-UP|2020-09-24|25
e|TR|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|3|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|10^6 CFU/g|NORMAL|1|10^3 CFU|FLUORESCENT MICROSCOPY|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|3|Visit_3|40|5|TREATMENT|2020-10-09|40
e|TR|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|nmol/L/min|DIFFUSELY INCREASED|1|U/animal|DYNAMIC LIGHT SCATTERING||Y|ADJUDICATOR|NEUROLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-11-03|65
e|TR|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|pg/dL|DECREASED|1|/5x10^4 WBC|APPLANATION TONOMETRY|||SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-11-28|90
e|TR|c9308aa7-f38f-4b54-a919-d3f893b18cd1|1|[?]|ORVERLN|Organ Vertical Length|[?]|IU/mL|DIFFUSELY INCREASED|1|um/s|DUCTOGRAPHY|||SIGNIFICANT OTHER|READER 3|NA|1|Visit_1|10|3|SCREENING|2020-11-07|10
e|TR|c9308aa7-f38f-4b54-a919-d3f893b18cd1|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|vp/mL|FOCALLY INCREASED|1|DROP|LIGHT MICROSCOPY|Y||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|N|2|Visit_2|25|3|TREATMENT|2020-11-22|25
e|TR|c9308aa7-f38f-4b54-a919-d3f893b18cd1|3|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|PRESSOR UNITS|PRESENT|1|IU/mg|ERGOSPIROMETRY||Y|INDEPENDENT ASSESSOR|NEUROLOGIST 1|U|3|Visit_3|40|3|SCREENING|2020-12-07|40
e|TR|c9308aa7-f38f-4b54-a919-d3f893b18cd1|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|g/kg/day|ABSENT|1|mol|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||FAMILY MEMBER|RATER 1|N|4|Visit_4|65|1|FOLLOW-UP|2021-01-01|65
e|TR|c9308aa7-f38f-4b54-a919-d3f893b18cd1|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|PFU/mL|NORMAL|1|U/mg|KNEMOMETRY||Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|4|FOLLOW-UP|2021-01-26|90
e|TR|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|1|[?]|RADIODEN|Radiodensity|[?]|mg/kg/min|PATHOLOGICAL|1|LB|CONFOCAL MICROSCOPY|||DOMESTIC PARTNER|RATER|U|1|Visit_1|10|2|TREATMENT|2020-08-22|10
e|TR|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|/2500 WBC|PALPABLE|1|Ci/mL|AURAMINE STAIN|||INDEPENDENT ASSESSOR|ONCOLOGIST 1|Y|2|Visit_2|25|2|SCREENING|2020-09-06|25
e|TR|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|APS U|ABSENT|1|psec|ISHIHARA COLOR PLATES|||STUDY SUBJECT|READER 3|Y|3|Visit_3|40|4|WASHOUT|2020-09-21|40
e|TR|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|Pack Year|FOCALLY INCREASED|1|mL/m2/day|IMMUNOPRECIPITATION|||FRIEND|CARDIOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-10-16|65
e|TR|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|ng|TUMOR MERGED|1|cs|CALCOFLUOR WHITE STAIN|Y||INVESTIGATOR|READER 1|N|5|Visit_5|90|7|TREATMENT|2020-11-10|90
e|TR|3da865e8-9680-4112-b6d3-1f5763cfdaae|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|steps/min|NORMAL|1|NEEDLE GAUGE|LAPAROSCOPY|Y||FAMILY MEMBER|FORENSIC PATHOLOGIST|N|1|Visit_1|10|5|SCREENING|2021-01-20|10
e|TR|3da865e8-9680-4112-b6d3-1f5763cfdaae|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|Gauss|ABSENT|1|ng/mol|RADIOIMMUNOPRECIPITATION ASSAY||Y|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|2|Visit_2|25|1|WASHOUT|2021-02-04|25
e|TR|3da865e8-9680-4112-b6d3-1f5763cfdaae|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|Mile|NON-PATHOLOGICAL|1|mL/g/day|AUSCULTATION|Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|3|Visit_3|40|3|WASHOUT|2021-02-19|40
e|TR|3da865e8-9680-4112-b6d3-1f5763cfdaae|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mg/kg/h|EQUIVOCAL|1|pmol/10^10 cells|LC/MS/MS|||VENDOR|RATER 2|Y|4|Visit_4|65|3|TREATMENT|2021-03-16|65
e|TR|3da865e8-9680-4112-b6d3-1f5763cfdaae|5|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|ugEq|DECREASED|1|Pa|MAMMOGRAPHY|||CAREGIVER|RADIOLOGIST 2|Y|5|Visit_5|90|6|TREATMENT|2021-04-10|90
e|TR|60afc3a3-56b7-4988-9006-e12f3bc1097c|1|[?]|VDIAM|Viable Diameter|[?]|AMPULE|ABSENT|1|mmol/min/kPa/L|REBOUND TONOMETRY|||CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|Y|1|Visit_1|10|3|TREATMENT|2020-08-16|10
e|TR|60afc3a3-56b7-4988-9006-e12f3bc1097c|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|STRIP|FURTHER ENLARGEMENT FROM NADIR|1|U/mL|SINGLE-MOLECULE ARRAY|||PROXY|NEUROLOGIST 2|U|2|Visit_2|25|6|FOLLOW-UP|2020-08-31|25
e|TR|60afc3a3-56b7-4988-9006-e12f3bc1097c|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|APPLICATION|ABSENT|1|mol/day|FLUORESCENCE ANGIOGRAPHY|Y||GUARDIAN|ADJUDICATOR 2|U|3|Visit_3|40|6|TREATMENT|2020-09-15|40
e|TR|60afc3a3-56b7-4988-9006-e12f3bc1097c|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|anti-Xa IU|ENLARGEMENT|1|kHz|X-RAY||Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|5|WASHOUT|2020-10-10|65
e|TR|60afc3a3-56b7-4988-9006-e12f3bc1097c|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|CUP|NON-PATHOLOGICAL|1|cL|CONTRAST ENHANCED CT SCAN|||DOMESTIC PARTNER|NEUROLOGIST|Y|5|Visit_5|90|1|WASHOUT|2020-11-04|90
e|TR|440119fb-ad46-4348-b236-8e2979c7bf2e|1|[?]|CALCFIND|Calcification Indicator|[?]|dB|TUMOR MERGED|1|cal|MULTI-SLICE SPIRAL CT|Y|Y|ADJUDICATION COMMITTEE|DERMATOLOGIST|Y|1|Visit_1|10|5|SCREENING|2020-12-16|10
e|TR|440119fb-ad46-4348-b236-8e2979c7bf2e|2|[?]|SUMVOL|Sum of Volume|[?]|ng/mol|FOCALLY INCREASED|1|F|DYNAMIC LIGHT SCATTERING|Y||SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|7|TREATMENT|2020-12-31|25
e|TR|440119fb-ad46-4348-b236-8e2979c7bf2e|3|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|MONTHS|EQUIVOCAL|1|10^3/L|ORCHIDOMETERY||Y|CAREGIVER|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|7|WASHOUT|2021-01-15|40
e|TR|440119fb-ad46-4348-b236-8e2979c7bf2e|4|[?]|AREA|Area|[?]|cd/m2|NORMAL|1|mV/sec|MICROBIAL CULTURE, SOLID||Y|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2021-02-09|65
e|TR|440119fb-ad46-4348-b236-8e2979c7bf2e|5|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|mL/cm|TUMOR MERGED|1|umol/h/mmol|KLEIHAUER-BETKE|Y||FRIEND|ADJUDICATOR 3|U|5|Visit_5|90|2|TREATMENT|2021-03-06|90
e|TR|af45a9de-c8aa-4602-8e3b-d16998740ebd|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|ug/min|FURTHER ENLARGEMENT FROM NADIR|1|Bq/kg|SLOAN LETTER EYE CHART 2.5%|||DOMESTIC PARTNER|PATHOLOGIST 1|N|1|Visit_1|10|6|WASHOUT|2020-06-15|10
e|TR|af45a9de-c8aa-4602-8e3b-d16998740ebd|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|uCi/kg|ENLARGEMENT|1|mL/g/min|REFLECTANCE SPECTROSCOPY|||INVESTIGATOR|RADIOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-06-30|25
e|TR|af45a9de-c8aa-4602-8e3b-d16998740ebd|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|mL/cm|EQUIVOCAL|1|fmol/L/sec|FLOW CYTOMETRY||Y|SIBLING|RATER 1|Y|3|Visit_3|40|6|TREATMENT|2020-07-15|40
e|TR|af45a9de-c8aa-4602-8e3b-d16998740ebd|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|F|NONPALPABLE|1|GBq/mg|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y|DOMESTIC PARTNER|MICROSCOPIST|NA|4|Visit_4|65|4|FOLLOW-UP|2020-08-09|65
e|TR|af45a9de-c8aa-4602-8e3b-d16998740ebd|5|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|IU/day|NONPALPABLE|1|umol/h/mmol|HEMOCYTOMETRY|||SIBLING|PATHOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-09-03|90
e|TR|23306866-3fcb-418d-861b-de3bd779260d|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mL/100g/min|NORMAL|1|mMU/mL|IMMUNOCHEMILUMINOMETRIC ASSAY|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|1|Visit_1|10|6|TREATMENT|2020-07-25|10
e|TR|23306866-3fcb-418d-861b-de3bd779260d|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|IU/mg|FOCALLY INCREASED|1|F|SLIT LAMP|||CHILD|ENDOCRINOLOGIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-08-09|25
e|TR|23306866-3fcb-418d-861b-de3bd779260d|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|s*kPa|INCREASED|1|10^6 organisms/mg|SLOAN LETTER EYE CHART 100%||Y|CHILD|UROLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-08-24|40
e|TR|23306866-3fcb-418d-861b-de3bd779260d|4|[?]|LNSTATE|Lymph Node State|[?]|uCi/L|ENLARGEMENT|1|Gy|TRANSTHORACIC ECHOCARDIOGRAPHY|||DOMESTIC PARTNER|NEUROLOGIST|N|4|Visit_4|65|5|SCREENING|2020-09-18|65
e|TR|23306866-3fcb-418d-861b-de3bd779260d|5|[?]|PCHGBL|Percent Change From Baseline|[?]|tsp|EQUIVOCAL|1|TCID 50/dose|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|U|5|Visit_5|90|6|WASHOUT|2020-10-13|90
e|TR|144d2eb9-d79a-4a61-91f5-6a807832d8ca|1|[?]|ACHNAD|Absolute Change From Nadir|[?]|/40 HPFs|TUMOR MERGED|1|Arbitrary U|POLYGRAPHY|||CHILD|NEUROLOGIST|Y|1|Visit_1|10|7|WASHOUT|2020-08-04|10
e|TR|144d2eb9-d79a-4a61-91f5-6a807832d8ca|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|Bq/kg|PATHOLOGICAL|1|nmol/kg/day|MS/MS|Y||INVESTIGATOR|PATHOLOGIST 1|Y|2|Visit_2|25|6|WASHOUT|2020-08-19|25
e|TR|144d2eb9-d79a-4a61-91f5-6a807832d8ca|3|[?]|DIAMETER|Diameter|[?]|v/v|NORMAL|1|ukat|REBOUND TONOMETRY|||VENDOR|PATHOLOGIST 2|N|3|Visit_3|40|6|TREATMENT|2020-09-03|40
e|TR|144d2eb9-d79a-4a61-91f5-6a807832d8ca|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|cmH2O/mL|FOCALLY INCREASED|1|uV|ENDOSCOPY|Y||INTERVIEWER|RADIOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-09-28|65
e|TR|144d2eb9-d79a-4a61-91f5-6a807832d8ca|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|days/wk|UNCHANGED|1|kcal|REFLECTANCE SPECTROSCOPY|Y||INVESTIGATOR|NEUROLOGIST 2|Y|5|Visit_5|90|5|SCREENING|2020-10-23|90
e|TR|92855d33-eee6-449f-a9e6-c06a1532571f|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|10^6 CFU/g|FURTHER ENLARGEMENT FROM NADIR|1|mmol/L|RULER MEASUREMENT METHOD|Y||SPOUSE|ONCOLOGIST|U|1|Visit_1|10|7|FOLLOW-UP|2020-11-29|10
e|TR|92855d33-eee6-449f-a9e6-c06a1532571f|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|U/mg|ENLARGEMENT|1|%/min|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y||PARENT|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|6|WASHOUT|2020-12-14|25
e|TR|92855d33-eee6-449f-a9e6-c06a1532571f|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|Ci/g|EQUIVOCAL|1|TRACE|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|3|Visit_3|40|1|FOLLOW-UP|2020-12-29|40
e|TR|92855d33-eee6-449f-a9e6-c06a1532571f|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|APPLICATION|ENLARGEMENT FROM NADIR|1|g/m2|PEAK FLOWMETRY|||SIGNIFICANT OTHER|PATHOLOGIST 1|N|4|Visit_4|65|5|TREATMENT|2021-01-23|65
e|TR|92855d33-eee6-449f-a9e6-c06a1532571f|5|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mL/animal/wk|DECREASED|1|Enzyme U|ANTIMICROBIAL COMBINATION TESTING|||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|N|5|Visit_5|90|1|SCREENING|2021-02-17|90
e|TR|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|deg/s|DIFFUSELY INCREASED|1|pt_us|SPECTROPHOTOMETRY|||PROXY|PHYSIOTHERAPIST|N|1|Visit_1|10|3|TREATMENT|2021-01-29|10
e|TR|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|2|[?]|SUMDIAM|Sum of Diameter|[?]|Ci/uL|UNEQUIVOCAL|1|SFC/10^6 PBMC|PH METER MEASUREMENT METHOD||Y|FAMILY MEMBER|NEUROLOGIST 1|Y|2|Visit_2|25|3|WASHOUT|2021-02-13|25
e|TR|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|BOTTLE|FURTHER ENLARGEMENT|1|/cmH2O|NON-CONTACT SPECULAR MICROSCOPY|||CLINICAL STUDY SPONSOR|RATER 2|N|3|Visit_3|40|3|WASHOUT|2021-02-28|40
e|TR|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mm/min|FURTHER ENLARGEMENT FROM NADIR|1|uU/dL|MANUAL CLOT DETECTION|||ADJUDICATION COMMITTEE|ONCOLOGIST 1|U|4|Visit_4|65|6|TREATMENT|2021-03-25|65
e|TR|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|uEq/L|ENLARGEMENT|1|10^9 CFU|X-RAY FLUORESCENCE SPECTROMETRY|||FRIEND|PHYSIOTHERAPIST|Y|5|Visit_5|90|4|TREATMENT|2021-04-19|90
e|TR|40cb9bc3-abec-4158-bdee-becdeceba727|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|U/m2/day|ENLARGEMENT FROM NADIR|1|mg/h|ULTRASONOGRAPHIC ELASTOGRAPHY|||FRIEND|ADJUDICATOR 3|U|1|Visit_1|10|3|SCREENING|2020-10-19|10
e|TR|40cb9bc3-abec-4158-bdee-becdeceba727|2|[?]|SUMVOL|Sum of Volume|[?]|SBE/mL|NON-PATHOLOGICAL|1|Henry|FLUORESCENT IMMUNOASSAY||Y|PARENT|INTERNIST|NA|2|Visit_2|25|2|TREATMENT|2020-11-03|25
e|TR|40cb9bc3-abec-4158-bdee-becdeceba727|3|[?]|VDIAM|Viable Diameter|[?]|HEP|NON-PATHOLOGICAL|1|ugEq/L|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||ADJUDICATOR|CARDIOLOGIST|NA|3|Visit_3|40|6|FOLLOW-UP|2020-11-18|40
e|TR|40cb9bc3-abec-4158-bdee-becdeceba727|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|ug/cm2|ABSENT|1|/2500 WBC|DOPPLER ULTRASOUND|||GUARDIAN|ADJUDICATOR 2|U|4|Visit_4|65|3|TREATMENT|2020-12-13|65
e|TR|40cb9bc3-abec-4158-bdee-becdeceba727|5|[?]|AREA|Area|[?]|cmH2O*s/mL|UNCHANGED|1|mCi|PHOTOGRAPHY|||CHILD|MICROSCOPIST 2|N|5|Visit_5|90|6|SCREENING|2021-01-07|90
e|TR|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|1|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mg|UNEQUIVOCAL|1|cycle/min|LIGHT SCATTERING SPECTROSCOPY|||HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|1|Visit_1|10|1|SCREENING|2020-10-17|10
e|TR|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|/10^5|PATHOLOGICAL|1|um/day|CYSTOMETRY|||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|1|WASHOUT|2020-11-01|25
e|TR|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|FFU|PALPABLE|1|mL/m2/day|MYELOPEROXIDASE STAIN|||CHILD|ENDOCRINOLOGIST|Y|3|Visit_3|40|6|FOLLOW-UP|2020-11-16|40
e|TR|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|KALLIKREIN INHIBITOR UNIT|UNEQUIVOCAL|1|kg/L|PHOTOMETRY||Y|SIBLING|ADJUDICATOR 2|Y|4|Visit_4|65|1|TREATMENT|2020-12-11|65
e|TR|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|5|[?]|RADIODEN|Radiodensity|[?]|g/cage/day|INCREASED|1|OD Unit|ELECTRICAL IMPEDANCE MYOGRAPHY|||INTERVIEWER|NEUROLOGIST|Y|5|Visit_5|90|7|FOLLOW-UP|2021-01-05|90
e|TR|616b284a-3fed-4009-bafe-7da10acd537e|1|[?]|NEWCONF|New Tumor Confirmed|[?]|SPRAY|INCREASED|1|kUSP|WESTERN BLOT|||PROXY|HEMATOLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-09-03|10
e|TR|616b284a-3fed-4009-bafe-7da10acd537e|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|um2|ENLARGEMENT FROM NADIR|1|AU/mL|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||INDEPENDENT ASSESSOR|READER 2|Y|2|Visit_2|25|1|TREATMENT|2020-09-18|25
e|TR|616b284a-3fed-4009-bafe-7da10acd537e|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|TUBE|FURTHER ENLARGEMENT FROM NADIR|1|mV*min|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||DOMESTIC PARTNER|READER 3|N|3|Visit_3|40|5|TREATMENT|2020-10-03|40
e|TR|616b284a-3fed-4009-bafe-7da10acd537e|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|PUFF|DECREASED|1|cmH2O*s2/mL|LEAD CITRATE STAIN|||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|2|TREATMENT|2020-10-28|65
e|TR|616b284a-3fed-4009-bafe-7da10acd537e|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|ELISA unit|PATHOLOGICAL|1|mg/kg/day|HEMATOXYLIN AND EOSIN STAIN||Y|SPOUSE|MICROSCOPIST 3|N|5|Visit_5|90|6|FOLLOW-UP|2020-11-22|90
e|TR|d39b53da-187f-4da6-9614-2bd301e9ad05|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mmol/min/kPa/L|UNEQUIVOCAL|1|cd/m2|OSCILLOMETRY|Y|Y|FAMILY MEMBER|INTERNIST|NA|1|Visit_1|10|2|TREATMENT|2020-10-02|10
e|TR|d39b53da-187f-4da6-9614-2bd301e9ad05|2|[?]|ORVERLN|Organ Vertical Length|[?]|ECL unit|ABSENT|1|uSiemens|TRANSTHORACIC ECHOCARDIOGRAPHY|Y|Y|ADJUDICATION COMMITTEE|RATER|U|2|Visit_2|25|2|TREATMENT|2020-10-17|25
e|TR|d39b53da-187f-4da6-9614-2bd301e9ad05|3|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|umol/mg/min|ENLARGEMENT FROM NADIR|1|ug/cm2|FLUORESCENT SPOT TEST|||CAREGIVER|MICROSCOPIST|NA|3|Visit_3|40|7|WASHOUT|2020-11-01|40
e|TR|d39b53da-187f-4da6-9614-2bd301e9ad05|4|[?]|LDIAM|Longest Diameter|[?]|ag|DECREASED|1|L/min|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||ADJUDICATOR|OTOLARYNGOLOGIST|Y|4|Visit_4|65|3|SCREENING|2020-11-26|65
e|TR|d39b53da-187f-4da6-9614-2bd301e9ad05|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|10^4/L|EQUIVOCAL|1|mg/L FEU|AURAMINE STAIN|||INVESTIGATOR|READER 1|N|5|Visit_5|90|7|WASHOUT|2020-12-21|90
e|TR|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|1|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|IU/mg|FURTHER ENLARGEMENT FROM NADIR|1|mmAL|LASER CAPTURE MICRODISSECTION|||FRIEND|PATHOLOGIST 1|Y|1|Visit_1|10|7|WASHOUT|2020-12-04|10
e|TR|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|2|[?]|DIAMETER|Diameter|[?]|U/10^12 RBC|ENLARGEMENT|1|cpm|DUCTOGRAPHY|Y||CHILD|PATHOLOGIST|N|2|Visit_2|25|4|FOLLOW-UP|2020-12-19|25
e|TR|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mV*min|FURTHER ENLARGEMENT|1|mg/g/h|KINETIC CHROMOGENIC ASSAY|||SPOUSE|PHYSIOTHERAPIST|Y|3|Visit_3|40|3|TREATMENT|2021-01-03|40
e|TR|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|lx|DECREASED|1|%/min|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y||PARENT|ADJUDICATOR 3|Y|4|Visit_4|65|1|FOLLOW-UP|2021-01-28|65
e|TR|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|5|[?]|ORSTATE|Organ State|[?]|ug|DIFFUSELY INCREASED|1|IU/kg|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||ADJUDICATOR|CLINICAL PATHOLOGIST|N|5|Visit_5|90|7|SCREENING|2021-02-22|90
e|TR|e51cf168-af89-44d9-9e56-14785071f6b0|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|Pa|PATHOLOGICAL|1|mL|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||Y|PARENT|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|3|SCREENING|2020-11-27|10
e|TR|e51cf168-af89-44d9-9e56-14785071f6b0|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mL/m2/h|ABSENT|1|nmol/g|PALM METHOD||Y|STUDY SUBJECT|ONCOLOGIST|N|2|Visit_2|25|5|FOLLOW-UP|2020-12-12|25
e|TR|e51cf168-af89-44d9-9e56-14785071f6b0|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|uL/mL|UNCHANGED|1|mEq/mmol|AUSCULTATION|||HEALTH CARE PROFESSIONAL|RATER 2|N|3|Visit_3|40|3|WASHOUT|2020-12-27|40
e|TR|e51cf168-af89-44d9-9e56-14785071f6b0|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|fraction of 1|ENLARGEMENT|1|umol/day|INDIRECT IMMUNOFLUORESCENCE|||INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|6|TREATMENT|2021-01-21|65
e|TR|e51cf168-af89-44d9-9e56-14785071f6b0|5|[?]|PPD|Product of Perpendicular Diameters|[?]|GPL U|FURTHER ENLARGEMENT FROM NADIR|1|log EID 50/dose|SURFACE PLASMON RESONANCE||Y|PARENT|RATER 1|Y|5|Visit_5|90|5|TREATMENT|2021-02-15|90
e|TR|8416f8c6-d0e4-43fc-9a66-6a916e853e87|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|ug/g/h|FURTHER ENLARGEMENT|1|mg/kg/min|THERMAL IONIZATION MASS SPECTROMETRY|Y||NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-06-13|10
e|TR|8416f8c6-d0e4-43fc-9a66-6a916e853e87|2|[?]|BNLNUM|Number of Bone Lesions|[?]|/5x10^4 WBC|FURTHER ENLARGEMENT FROM NADIR|1|10^6 organisms/mL|NEXT GENERATION SEQUENCING|||ADJUDICATION COMMITTEE|RADIOLOGIST 1|NA|2|Visit_2|25|5|TREATMENT|2020-06-28|25
e|TR|8416f8c6-d0e4-43fc-9a66-6a916e853e87|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|gMFI|UNCHANGED|1|cmH2O/mL|COMPUTERIZED CORNEAL TOPOGRAPHY|||STUDY SUBJECT|RATER|NA|3|Visit_3|40|6|WASHOUT|2020-07-13|40
e|TR|8416f8c6-d0e4-43fc-9a66-6a916e853e87|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|dpm/mL|FURTHER ENLARGEMENT FROM NADIR|1|MET*min|MALDI-TOF|||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|4|Visit_4|65|5|WASHOUT|2020-08-07|65
e|TR|8416f8c6-d0e4-43fc-9a66-6a916e853e87|5|[?]|VOLUME|Volume|[?]|mg/dose|PATHOLOGICAL|1|PLUG|NUCLEIC ACID BASED METHOD|||INTERVIEWER|READER 1|NA|5|Visit_5|90|7|TREATMENT|2020-09-01|90
e|TR|a110e924-90a1-4e84-b47a-410f800fa201|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|RNA copies/mL|PATHOLOGICAL|1|Gy|QUANTITATIVE CORONARY ANGIOGRAPHY|||SPOUSE|READER|Y|1|Visit_1|10|3|WASHOUT|2020-10-29|10
e|TR|a110e924-90a1-4e84-b47a-410f800fa201|2|[?]|AREA|Area|[?]|/LPF|TUMOR MERGED|1|umol/min|CONFOCAL MICROSCOPY||Y|CAREGIVER|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-11-13|25
e|TR|a110e924-90a1-4e84-b47a-410f800fa201|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mg/mL/min|DECREASED|1|mAmp|FLOCCULATION||Y|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-11-28|40
e|TR|a110e924-90a1-4e84-b47a-410f800fa201|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|kBq|NON-PATHOLOGICAL|1|DISK|LINE PROBE ASSAY|Y||VENDOR|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|3|SCREENING|2020-12-23|65
e|TR|a110e924-90a1-4e84-b47a-410f800fa201|5|[?]|TUMSTATE|Tumor State|[?]|LENS|ABSENT|1|10^4 CFU|OBSERVATION||Y|DOMESTIC PARTNER|CARDIOLOGIST|N|5|Visit_5|90|3|TREATMENT|2021-01-17|90
e|TR|40681cb8-5d49-4e1d-b893-f5fad62a0885|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|fraction of 1|PRESENT|1|10^3 CFU|ARTERIAL SPIN LABELING FUNCTIONAL MRI||Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|NA|1|Visit_1|10|4|WASHOUT|2020-08-08|10
e|TR|40681cb8-5d49-4e1d-b893-f5fad62a0885|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|nkat/L|FURTHER ENLARGEMENT FROM NADIR|1|Hounsfield Unit|PHOTOMETRIC CLOT DETECTION|||SIBLING|ONCOLOGIST|U|2|Visit_2|25|2|FOLLOW-UP|2020-08-23|25
e|TR|40681cb8-5d49-4e1d-b893-f5fad62a0885|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|JDF Unit|TUMOR MERGED|1|mV*min|ENZYMATIC COLORIMETRY|Y||STUDY SUBJECT|RADIOLOGIST 2|Y|3|Visit_3|40|6|TREATMENT|2020-09-07|40
e|TR|40681cb8-5d49-4e1d-b893-f5fad62a0885|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|deg|FOCALLY INCREASED|1|mEq/mL|CONGO RED STAIN|||PROXY|ONCOLOGIST 1|NA|4|Visit_4|65|2|FOLLOW-UP|2020-10-02|65
e|TR|40681cb8-5d49-4e1d-b893-f5fad62a0885|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|10^3 organisms/g|NORMAL|1|Tbsp|MAGNETIC RESONANCE ANGIOGRAPHY|Y|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|U|5|Visit_5|90|4|TREATMENT|2020-10-27|90
e|TR|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|/10^3|FURTHER ENLARGEMENT|1|PACKET|DUKE INCISION METHOD|||INTERVIEWER|UROLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-12-17|10
e|TR|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|mV2/Hz|INCREASED|1|GLOBULE|ELECTROCHEMILUMINESCENCE|||ADJUDICATOR|NEUROLOGIST 2|N|2|Visit_2|25|7|TREATMENT|2021-01-01|25
e|TR|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|U/g/h|PATHOLOGICAL|1|ukat/10^12 RBC|TRANSMISSION ELECTRON MICROSCOPY||Y|CHILD|ONCOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2021-01-16|40
e|TR|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|mIU/L|NON-PATHOLOGICAL|1|cd/m2|FLOW CYTOMETRY|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|4|Visit_4|65|7|TREATMENT|2021-02-10|65
e|TR|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|mL/animal/day|DIFFUSELY INCREASED|1|uOsm|PUPILLOMETRY||Y|INVESTIGATOR|PATHOLOGIST 2|NA|5|Visit_5|90|5|TREATMENT|2021-03-07|90
e|TR|96e65c5c-723c-42d9-8e88-0bcb600e9f88|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|TROCHE|PATHOLOGICAL|1|lm|EPSILOMETER|||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|4|TREATMENT|2020-09-10|10
e|TR|96e65c5c-723c-42d9-8e88-0bcb600e9f88|2|[?]|VDIAM|Viable Diameter|[?]|vp/dose|ABSENT|1|mmol/L|CONTRAST ENHANCED PET/CT SCAN|Y||VENDOR|PATHOLOGIST|U|2|Visit_2|25|5|TREATMENT|2020-09-25|25
e|TR|96e65c5c-723c-42d9-8e88-0bcb600e9f88|3|[?]|BNLNUM|Number of Bone Lesions|[?]|FIU|TUMOR MERGED|1|uOsm|ANALYTICAL ULTRACENTRIFUGATION|||ADJUDICATOR|PATHOLOGIST 2|N|3|Visit_3|40|7|WASHOUT|2020-10-10|40
e|TR|96e65c5c-723c-42d9-8e88-0bcb600e9f88|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|Bq/L|DECREASED|1|Henry|ICP-MS|||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|NA|4|Visit_4|65|2|TREATMENT|2020-11-04|65
e|TR|96e65c5c-723c-42d9-8e88-0bcb600e9f88|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|min|PATHOLOGICAL|1|yd|MANUAL CLOT DETECTION|Y||SPOUSE|RATER 1|Y|5|Visit_5|90|3|TREATMENT|2020-11-29|90
e|TR|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|1|[?]|ACHNAD|Absolute Change From Nadir|[?]|cmol/L|ABSENT|1|pm|TRIPLE-PHASE SPIRAL CT SCAN||Y|GUARDIAN|ONCOLOGIST 2|U|1|Visit_1|10|4|WASHOUT|2020-07-12|10
e|TR|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|IMPLANT|FURTHER ENLARGEMENT|1|dpm/mL|MRI WITHOUT CONTRAST|Y||INDEPENDENT ASSESSOR|RADIOLOGIST 2|U|2|Visit_2|25|5|FOLLOW-UP|2020-07-27|25
e|TR|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|JAR|ABSENT|1|COAT|ANGIOGRAPHY|||FRIEND|NEUROLOGIST|NA|3|Visit_3|40|5|FOLLOW-UP|2020-08-11|40
e|TR|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|4|[?]|DIAMETER|Diameter|[?]|/h|ENLARGEMENT|1|mJoule/cm2|ELLA||Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2020-09-05|65
e|TR|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|CAN|INCREASED|1|PFU/dose|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-09-30|90
e|TR|f81742a2-5250-43d7-a6e2-8fcb1625a114|1|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|ng/dL|FOCALLY INCREASED|1|amp|SMEAR||Y|INVESTIGATOR|ADJUDICATOR 2|N|1|Visit_1|10|3|TREATMENT|2020-05-30|10
e|TR|f81742a2-5250-43d7-a6e2-8fcb1625a114|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|SACHET|FURTHER ENLARGEMENT|1|Bq/kg|TRICHROME STAIN|Y|Y|PARENT|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|2|FOLLOW-UP|2020-06-14|25
e|TR|f81742a2-5250-43d7-a6e2-8fcb1625a114|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|cmH2O*s2/mL|TUMOR MERGED|1|Ci/mL|PEAK FLOWMETRY|Y|Y|PROXY|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-06-29|40
e|TR|f81742a2-5250-43d7-a6e2-8fcb1625a114|4|[?]|ORSTATE|Organ State|[?]|10^12/L|INCREASED|1|Ci/mg|HPLC-UV|Y||STUDY SUBJECT|RADIOLOGIST|U|4|Visit_4|65|6|FOLLOW-UP|2020-07-24|65
e|TR|f81742a2-5250-43d7-a6e2-8fcb1625a114|5|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mL/cm|TUMOR MERGED|1|Ci/g|PERFUSION MRI||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|5|Visit_5|90|6|SCREENING|2020-08-18|90
e|TR|c6bad1d0-3514-4f98-b229-d093a94dfbc4|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|10^6 organisms/mg|PALPABLE|1|PELLET|ENZYMATIC SPECTROPHOTOMETRY||Y|PROXY|ONCOLOGIST|U|1|Visit_1|10|2|SCREENING|2020-06-24|10
e|TR|c6bad1d0-3514-4f98-b229-d093a94dfbc4|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|U.CARR|EQUIVOCAL|1|CONTAINER|MICROBIAL CONCENTRATION|||GUARDIAN|ONCOLOGIST 2|Y|2|Visit_2|25|3|FOLLOW-UP|2020-07-09|25
e|TR|c6bad1d0-3514-4f98-b229-d093a94dfbc4|3|[?]|RADIODEN|Radiodensity|[?]|Ci/mg|FURTHER ENLARGEMENT FROM NADIR|1|MPL U/mL|MAGNETIC RESONANCE ANGIOGRAPHY|||STUDY SUBJECT|MICROSCOPIST|NA|3|Visit_3|40|1|TREATMENT|2020-07-24|40
e|TR|c6bad1d0-3514-4f98-b229-d093a94dfbc4|4|[?]|ORSTATE|Organ State|[?]|10^3 DNA copies/mL|NORMAL|1|/MBP|U-HPLC/MS/MS|||CLINICAL STUDY SPONSOR|MICROSCOPIST 2|NA|4|Visit_4|65|4|FOLLOW-UP|2020-08-18|65
e|TR|c6bad1d0-3514-4f98-b229-d093a94dfbc4|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|kcal|ENLARGEMENT FROM NADIR|1|pmol/L/h|CELL BASED BIOASSAY|Y||DOMESTIC PARTNER|NEUROLOGIST 1|NA|5|Visit_5|90|5|TREATMENT|2020-09-12|90
e|TR|84d68bcc-dc7a-4366-9630-40ce8885351d|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|ng/mol|ENLARGEMENT FROM NADIR|1|U/m2/min|NO INFORMATION|||INTERVIEWER|UROLOGIST|N|1|Visit_1|10|5|SCREENING|2020-06-16|10
e|TR|84d68bcc-dc7a-4366-9630-40ce8885351d|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mL/dose|FURTHER ENLARGEMENT FROM NADIR|1|BU/mL|NUCLEIC ACID AMPLIFICATION TEST|||FRIEND|READER|NA|2|Visit_2|25|4|TREATMENT|2020-07-01|25
e|TR|84d68bcc-dc7a-4366-9630-40ce8885351d|3|[?]|ORSTATE|Organ State|[?]|/10^4|PATHOLOGICAL|1|pg/cell|IMMUNE REPERTOIRE DEEP SEQUENCING|||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-07-16|40
e|TR|84d68bcc-dc7a-4366-9630-40ce8885351d|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|10^10/L|INCREASED|1|ug/m2/day|EPSILOMETER||Y|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|U|4|Visit_4|65|5|FOLLOW-UP|2020-08-10|65
e|TR|84d68bcc-dc7a-4366-9630-40ce8885351d|5|[?]|LNSTATE|Lymph Node State|[?]|/40 HPFs|PRESENT|1|APS U|QUANTITATIVE COMPUTED TOMOGRAPHY|||INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|7|SCREENING|2020-09-04|90
e|TR|517f3930-5202-4e0a-b3e1-85ed4bd7e117|1|[?]|PALPSTAT|Palpable State|[?]|10^12 IU/L|FURTHER ENLARGEMENT|1|mg/kg/h|REFLECTANCE SPECTROSCOPY|||FAMILY MEMBER|MICROSCOPIST 1|U|1|Visit_1|10|5|WASHOUT|2021-01-08|10
e|TR|517f3930-5202-4e0a-b3e1-85ed4bd7e117|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|mmHg/L/min|TUMOR MERGED|1|CAPLET|PHOROPTER||Y|GUARDIAN|DERMATOLOGIST|U|2|Visit_2|25|5|TREATMENT|2021-01-23|25
e|TR|517f3930-5202-4e0a-b3e1-85ed4bd7e117|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|PIXELS/in|PATHOLOGICAL|1|Linear ft*LB|CONTRAST ENHANCED CT SCAN||Y|ADJUDICATION COMMITTEE|NEUROLOGIST|N|3|Visit_3|40|5|SCREENING|2021-02-07|40
e|TR|517f3930-5202-4e0a-b3e1-85ed4bd7e117|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mg/kg/h|NON-PATHOLOGICAL|1|IU/dL|MICRODENSITOMETRY||Y|SIGNIFICANT OTHER|PATHOLOGIST|NA|4|Visit_4|65|6|SCREENING|2021-03-04|65
e|TR|517f3930-5202-4e0a-b3e1-85ed4bd7e117|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|L/min|PRESENT|1|L/min|VIRUS PLAQUE ASSAY|||NON-HEALTH CARE PROFESSIONAL|RATER 1|Y|5|Visit_5|90|6|SCREENING|2021-03-29|90
e|TR|edd73650-27bb-474f-bab7-d2c3d57b2dc4|1|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|Gy/h|NORMAL|1|mg/kg/dose|IMMUNOASSAY|||INVESTIGATOR|ONCOLOGIST 2|N|1|Visit_1|10|1|TREATMENT|2020-12-21|10
e|TR|edd73650-27bb-474f-bab7-d2c3d57b2dc4|2|[?]|SUMDIAM|Sum of Diameter|[?]|bel|TUMOR MERGED|1|pg/dL|FARNSWORTH-MUNSELL 100 HUE TEST|||STUDY SUBJECT|MICROSCOPIST|NA|2|Visit_2|25|2|SCREENING|2021-01-05|25
e|TR|edd73650-27bb-474f-bab7-d2c3d57b2dc4|3|[?]|LESSCIND|Lesion Success Indicator|[?]|ms/mmHg|ENLARGEMENT FROM NADIR|1|U/m2/h|SPIRAL CT SCAN WITHOUT CONTRAST|Y||CAREGIVER|MICROSCOPIST|U|3|Visit_3|40|4|TREATMENT|2021-01-20|40
e|TR|edd73650-27bb-474f-bab7-d2c3d57b2dc4|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|ug/mL/h|FURTHER ENLARGEMENT|1|CUP|COMPUTERIZED CORNEAL TOPOGRAPHY|||VENDOR|ONCOLOGIST 2|U|4|Visit_4|65|7|TREATMENT|2021-02-14|65
e|TR|edd73650-27bb-474f-bab7-d2c3d57b2dc4|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|um|FURTHER ENLARGEMENT FROM NADIR|1|Gy/min|APPLANATION TONOMETRY|||FAMILY MEMBER|NEUROLOGIST|Y|5|Visit_5|90|6|FOLLOW-UP|2021-03-11|90
e|TR|98737dfa-0058-4420-a515-38526f01f90d|1|[?]|PCHGBL|Percent Change From Baseline|[?]|DAgU|UNEQUIVOCAL|1|dram|TOLUIDINE BLUE STAIN||Y|ADJUDICATOR|PHYSIOTHERAPIST|U|1|Visit_1|10|4|TREATMENT|2020-09-09|10
e|TR|98737dfa-0058-4420-a515-38526f01f90d|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|g/g|FOCALLY INCREASED|1|MPS U|ELISPOT|||INVESTIGATOR|RADIOLOGIST 1|Y|2|Visit_2|25|7|SCREENING|2020-09-24|25
e|TR|98737dfa-0058-4420-a515-38526f01f90d|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|pmol/10^9 cells|NON-PATHOLOGICAL|1|deg|ELLA|Y||VENDOR|ADJUDICATOR 2|U|3|Visit_3|40|4|TREATMENT|2020-10-09|40
e|TR|98737dfa-0058-4420-a515-38526f01f90d|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|mEq/mL|DIFFUSELY INCREASED|1|pmol/L/h|FLUORESCEIN STAIN|||ADJUDICATION COMMITTEE|READER 3|N|4|Visit_4|65|6|TREATMENT|2020-11-03|65
e|TR|98737dfa-0058-4420-a515-38526f01f90d|5|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|EID 50/mL|ENLARGEMENT|1|10^6/g|WRIGHT-GIEMSA STAIN||Y|CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|5|Visit_5|90|4|SCREENING|2020-11-28|90
e|TR|e713c631-cdd8-428f-a3a6-0195f6fb80b4|1|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mgEq|FOCALLY INCREASED|1|log10 PFU/mL|ACID FAST STAIN|||FAMILY MEMBER|RATER 1|Y|1|Visit_1|10|5|SCREENING|2020-10-03|10
e|TR|e713c631-cdd8-428f-a3a6-0195f6fb80b4|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|10^7 CFU/mL|ABSENT|1|/2500 WBC|GC/MS-CI|||ADJUDICATION COMMITTEE|CARDIOLOGIST|U|2|Visit_2|25|3|WASHOUT|2020-10-18|25
e|TR|e713c631-cdd8-428f-a3a6-0195f6fb80b4|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|IMPLANT|PRESENT|1|JDF Unit|JAEGER EYE CHART|||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|3|Visit_3|40|2|TREATMENT|2020-11-02|40
e|TR|e713c631-cdd8-428f-a3a6-0195f6fb80b4|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|10^4/hpf|FURTHER ENLARGEMENT FROM NADIR|1|BLOCKS|ULTRASOUND|||INDEPENDENT ASSESSOR|READER|Y|4|Visit_4|65|5|TREATMENT|2020-11-27|65
e|TR|e713c631-cdd8-428f-a3a6-0195f6fb80b4|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|10^12 IU/L|NONPALPABLE|1|MPS U|ELECTRONEUROGRAPHY||Y|FRIEND|PATHOLOGIST 2|N|5|Visit_5|90|7|TREATMENT|2020-12-22|90
e|TR|a3964bed-1273-4bce-bbb4-b8d768b30aa3|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|10^3 RNA copies/mL|PALPABLE|1|mL*cmH2O|SCINTIGRAPHY||Y|FAMILY MEMBER|RATER 2|U|1|Visit_1|10|5|TREATMENT|2020-09-20|10
e|TR|a3964bed-1273-4bce-bbb4-b8d768b30aa3|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|ohm|INCREASED|1|deg/mm|DOUBLE IMMUNODIFFUSION|Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|2|Visit_2|25|1|TREATMENT|2020-10-05|25
e|TR|a3964bed-1273-4bce-bbb4-b8d768b30aa3|3|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|umol/L|INCREASED|1|U/L|APPLANATION TONOMETRY||Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|3|Visit_3|40|6|WASHOUT|2020-10-20|40
e|TR|a3964bed-1273-4bce-bbb4-b8d768b30aa3|4|[?]|RADIODEN|Radiodensity|[?]|kN/cm2|PATHOLOGICAL|1|GBq/mg|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y|INVESTIGATOR|ADJUDICATOR 2|Y|4|Visit_4|65|3|TREATMENT|2020-11-14|65
e|TR|a3964bed-1273-4bce-bbb4-b8d768b30aa3|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|fmol/g|EQUIVOCAL|1|pt_us|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||DOMESTIC PARTNER|OTOLARYNGOLOGIST|U|5|Visit_5|90|1|WASHOUT|2020-12-09|90
e|TR|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mg/L|FURTHER ENLARGEMENT|1|CCID 50/mL|TEMPLATE INCISION METHOD|||ADJUDICATOR|MICROSCOPIST|NA|1|Visit_1|10|6|WASHOUT|2020-12-21|10
e|TR|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|2|[?]|NEWCONF|New Tumor Confirmed|[?]|ug/kg/min|PATHOLOGICAL|1|U/g Hb|GC/MS|||VENDOR|MICROSCOPIST 3|N|2|Visit_2|25|6|FOLLOW-UP|2021-01-05|25
e|TR|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|IU/g Hb|EQUIVOCAL|1|s*kPa|PULMONARY ANGIOGRAPHY|||CAREGIVER|ONCOLOGIST 1|NA|3|Visit_3|40|3|SCREENING|2021-01-20|40
e|TR|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|4|[?]|PALPSTAT|Palpable State|[?]|cg|NONPALPABLE|1|L/day|PANENDOSCOPY||Y|FRIEND|ADJUDICATOR|N|4|Visit_4|65|2|TREATMENT|2021-02-14|65
e|TR|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|KIT|ABSENT|1|MnFI|ROMANOWSKY STAIN|||CHILD|ADJUDICATOR 3|N|5|Visit_5|90|1|TREATMENT|2021-03-11|90
e|TR|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|nmol/day|TUMOR MERGED|1|mL/min/mmHg|MALDI|||FAMILY MEMBER|PATHOLOGIST 2|N|1|Visit_1|10|5|SCREENING|2020-06-09|10
e|TR|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|2|[?]|AREA|Area|[?]|uV*sec|PALPABLE|1|10^6 copies/mL|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||ADJUDICATION COMMITTEE|PATHOLOGIST 1|U|2|Visit_2|25|3|TREATMENT|2020-06-24|25
e|TR|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|fL|NONPALPABLE|1|cpm|TEMPLATE INCISION METHOD|Y||PROXY|ADJUDICATOR 3|N|3|Visit_3|40|3|FOLLOW-UP|2020-07-09|40
e|TR|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|tsp eq|PRESENT|1|Ci/L|BIOPSY||Y|CLINICAL RESEARCH ASSOCIATE|READER|Y|4|Visit_4|65|1|TREATMENT|2020-08-03|65
e|TR|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|5|[?]|PPD|Product of Perpendicular Diameters|[?]|log EID 50/dose|PATHOLOGICAL|1|GBq|RYAN BLUE STAIN|||INVESTIGATOR|READER|U|5|Visit_5|90|6|TREATMENT|2020-08-28|90
e|TR|597ff319-c16e-4aae-a7d9-ed2bc25684dc|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|%(w/w)|TUMOR MERGED|1|CYLINDER|PHYSICAL EXAMINATION|||INVESTIGATOR|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|4|SCREENING|2020-05-28|10
e|TR|597ff319-c16e-4aae-a7d9-ed2bc25684dc|2|[?]|ORSTATE|Organ State|[?]|U/mmol|PATHOLOGICAL|1|/LPF|MUGA|Y||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|N|2|Visit_2|25|4|SCREENING|2020-06-12|25
e|TR|597ff319-c16e-4aae-a7d9-ed2bc25684dc|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mgEq|ABSENT|1|BU/mL|JAFFE REACTION|||SIBLING|INTERNIST|Y|3|Visit_3|40|3|WASHOUT|2020-06-27|40
e|TR|597ff319-c16e-4aae-a7d9-ed2bc25684dc|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|cal|PATHOLOGICAL|1|kat|BIOPSY|Y||INDEPENDENT ASSESSOR|RATER|N|4|Visit_4|65|7|TREATMENT|2020-07-22|65
e|TR|597ff319-c16e-4aae-a7d9-ed2bc25684dc|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|mEq/dL|TUMOR MERGED|1|nmol BCE/nmol|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|1|WASHOUT|2020-08-16|90
e|TR|7d845e3e-8bd1-4647-a3e8-352a52b585cb|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|10^9/L|TUMOR MERGED|1|Bq/L|RADIOGRAPHY|||HEALTH CARE PROFESSIONAL|READER|NA|1|Visit_1|10|3|TREATMENT|2020-11-08|10
e|TR|7d845e3e-8bd1-4647-a3e8-352a52b585cb|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|Bq/mg|FOCALLY INCREASED|1|VIAL|PEAK FLOWMETRY|Y||CLINICAL RESEARCH COORDINATOR|RATER|U|2|Visit_2|25|5|SCREENING|2020-11-23|25
e|TR|7d845e3e-8bd1-4647-a3e8-352a52b585cb|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|U/kg/min|FURTHER ENLARGEMENT|1|ka_u/dL|APPLANATION TONOMETRY|Y||CLINICAL STUDY SPONSOR|UROLOGIST|NA|3|Visit_3|40|4|SCREENING|2020-12-08|40
e|TR|7d845e3e-8bd1-4647-a3e8-352a52b585cb|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|mL|PATHOLOGICAL|1|mAmp|LIGHT SCATTERING SPECTROSCOPY|||FRIEND|ADJUDICATOR 2|NA|4|Visit_4|65|6|FOLLOW-UP|2021-01-02|65
e|TR|7d845e3e-8bd1-4647-a3e8-352a52b585cb|5|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|damol/L|ENLARGEMENT|1|umol/day|MICRONEUTRALIZATION ASSAY|Y||FAMILY MEMBER|OTOLARYNGOLOGIST|N|5|Visit_5|90|6|SCREENING|2021-01-27|90
e|TR|7e9f4283-f90b-4f74-939c-b42648e8373c|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|sec|FOCALLY INCREASED|1|ug/m2|ELECTROCHEMILUMINESCENCE|Y||INDEPENDENT ASSESSOR|RATER 2|N|1|Visit_1|10|6|SCREENING|2020-12-15|10
e|TR|7e9f4283-f90b-4f74-939c-b42648e8373c|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|Newton|EQUIVOCAL|1|mU/L|MRI||Y|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|3|SCREENING|2020-12-30|25
e|TR|7e9f4283-f90b-4f74-939c-b42648e8373c|3|[?]|SUMDIAM|Sum of Diameter|[?]|Bq/mL|UNCHANGED|1|mol/mL|ELECTROCHEMILUMINESCENCE|||DOMESTIC PARTNER|HEMATOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2021-01-14|40
e|TR|7e9f4283-f90b-4f74-939c-b42648e8373c|4|[?]|BNLNUM|Number of Bone Lesions|[?]|Tesla|NORMAL|1|10^8 PFU|FUNCTIONAL MRI|||CHILD|HEMATOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2021-02-08|65
e|TR|7e9f4283-f90b-4f74-939c-b42648e8373c|5|[?]|PALPSTAT|Palpable State|[?]|AMPULE|PALPABLE|1|um2|TWO-COLOR MICROARRAY|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|7|TREATMENT|2021-03-05|90
e|TR|20a637e6-83d2-4a86-9ecc-8ddb0523997f|1|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|breaths/30s|PATHOLOGICAL|1|Newton|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|N|1|Visit_1|10|5|TREATMENT|2020-10-31|10
e|TR|20a637e6-83d2-4a86-9ecc-8ddb0523997f|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|log10 copies/mL|ABSENT|1|10^3 organisms|GRADIENT DIFFUSION|Y|Y|FRIEND|ONCOLOGIST 1|Y|2|Visit_2|25|1|FOLLOW-UP|2020-11-15|25
e|TR|20a637e6-83d2-4a86-9ecc-8ddb0523997f|3|[?]|DIAMETER|Diameter|[?]|kN/cm2|NONPALPABLE|1|Ejaculate U|DUCTOGRAPHY|||CHILD|ONCOLOGIST|N|3|Visit_3|40|6|SCREENING|2020-11-30|40
e|TR|20a637e6-83d2-4a86-9ecc-8ddb0523997f|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|TABLET|UNCHANGED|1|beats/min|CONTRAST ENHANCED MRI|||PARENT|MICROSCOPIST 1|NA|4|Visit_4|65|1|TREATMENT|2020-12-25|65
e|TR|20a637e6-83d2-4a86-9ecc-8ddb0523997f|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|ppth|DECREASED|1|mU|MRI|||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|N|5|Visit_5|90|5|SCREENING|2021-01-19|90
e|TR|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|bel|NORMAL|1|Bq/kg|PERFUSION MRI|||PARENT|INTERNIST|N|1|Visit_1|10|7|WASHOUT|2020-05-16|10
e|TR|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|PACKAGE|UNEQUIVOCAL|1|mmol/g|POLYSOMNOGRAPHY|||FRIEND|OPHTHALMOLOGIST|U|2|Visit_2|25|7|WASHOUT|2020-05-31|25
e|TR|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|3|[?]|PALPSTAT|Palpable State|[?]|VIRTUAL PIXEL|PRESENT|1|log10 PFU/mL|PANENDOSCOPY||Y|FRIEND|ONCOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-06-15|40
e|TR|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|fL|NONPALPABLE|1|MBq/uL|KINETIC CHROMOGENIC ASSAY|||CHILD|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|4|TREATMENT|2020-07-10|65
e|TR|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|5|[?]|SUMDIAM|Sum of Diameter|[?]|AMPULE|TUMOR MERGED|1|nmol BCE/L|ELLA|||PARENT|MICROSCOPIST 2|NA|5|Visit_5|90|1|FOLLOW-UP|2020-08-04|90
e|TR|595aa95c-4378-47c1-96e9-5512d08fb653|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|Ejaculate U|ABSENT|1|mL/sec/1.73m2|GEL ELECTROPHORESIS|||CAREGIVER|RATER 2|N|1|Visit_1|10|4|TREATMENT|2020-08-23|10
e|TR|595aa95c-4378-47c1-96e9-5512d08fb653|2|[?]|RADIODEN|Radiodensity|[?]|mEq/mmol|DECREASED|1|usec|WRIGHT STAIN||Y|INDEPENDENT ASSESSOR|NEUROLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-09-07|25
e|TR|595aa95c-4378-47c1-96e9-5512d08fb653|3|[?]|SUMVOL|Sum of Volume|[?]|dL|FURTHER ENLARGEMENT FROM NADIR|1|cup eq|MULTIPLE BREATH WASHOUT|||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-09-22|40
e|TR|595aa95c-4378-47c1-96e9-5512d08fb653|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|L/min/m2|DIFFUSELY INCREASED|1|mg|PHASE-CONTRAST MRI|Y||STUDY SUBJECT|RATER|U|4|Visit_4|65|1|FOLLOW-UP|2020-10-17|65
e|TR|595aa95c-4378-47c1-96e9-5512d08fb653|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|titer|FURTHER ENLARGEMENT FROM NADIR|1|ng/L|STATIC PERIMETRY||Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|U|5|Visit_5|90|4|FOLLOW-UP|2020-11-11|90
e|TR|b528dc24-e791-41b1-95b3-fc0be18da47f|1|[?]|SUMVOL|Sum of Volume|[?]|Absorbance U|ENLARGEMENT FROM NADIR|1|log10 TCID 50/mL|PANENDOSCOPY|Y||GUARDIAN|ADJUDICATOR 1|Y|1|Visit_1|10|7|TREATMENT|2020-12-27|10
e|TR|b528dc24-e791-41b1-95b3-fc0be18da47f|2|[?]|PALPSTAT|Palpable State|[?]|km|UNCHANGED|1|nmol BCE/mmol|TRANSCRIPTION-MEDIATED AMPLIFICATION||Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2021-01-11|25
e|TR|b528dc24-e791-41b1-95b3-fc0be18da47f|3|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|EU|INCREASED|1|amol|MULTI-SLICE SPIRAL CT|||DOMESTIC PARTNER|READER 3|U|3|Visit_3|40|7|TREATMENT|2021-01-26|40
e|TR|b528dc24-e791-41b1-95b3-fc0be18da47f|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|%(w/w)|DECREASED|1|tsp|CLAUSS METHOD|||ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|7|TREATMENT|2021-02-20|65
e|TR|b528dc24-e791-41b1-95b3-fc0be18da47f|5|[?]|VOLUME|Volume|[?]|lm|PATHOLOGICAL|1|mL/kg|RADIOIMMUNOPRECIPITATION ASSAY|Y||SIGNIFICANT OTHER|RADIOLOGIST|N|5|Visit_5|90|1|WASHOUT|2021-03-17|90
e|TR|7a43c892-0e7f-4f33-9130-e175e475531f|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|SYRINGE|EQUIVOCAL|1|/wk|PERCUSSION||Y|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-05-17|10
e|TR|7a43c892-0e7f-4f33-9130-e175e475531f|2|[?]|LNSTATE|Lymph Node State|[?]|Mile|NON-PATHOLOGICAL|1|ug/kg/day|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||Y|DOMESTIC PARTNER|MICROSCOPIST 2|N|2|Visit_2|25|5|FOLLOW-UP|2020-06-01|25
e|TR|7a43c892-0e7f-4f33-9130-e175e475531f|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|uV*sec|FURTHER ENLARGEMENT FROM NADIR|1|HOURS|SLOAN LETTER EYE CHART 2.5%|||SIGNIFICANT OTHER|ONCOLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-06-16|40
e|TR|7a43c892-0e7f-4f33-9130-e175e475531f|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|mEq/kg|EQUIVOCAL|1|STRIP|WHOLE TRANSCRIPTOME SEQUENCING||Y|SIBLING|RATER 2|Y|4|Visit_4|65|5|TREATMENT|2020-07-11|65
e|TR|7a43c892-0e7f-4f33-9130-e175e475531f|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|10^6 IU|ENLARGEMENT|1|/LSQN|ENZYMATIC ULTRACENTRIFUGATION|||ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-08-05|90
e|TR|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|10^3 organisms/mL|UNCHANGED|1|K|ICP-MS|Y|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|1|Visit_1|10|7|WASHOUT|2020-12-10|10
e|TR|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mOsm/kg|FURTHER ENLARGEMENT|1|cal|HIGH RESOLUTION CT|||SIBLING|PHYSIOTHERAPIST|U|2|Visit_2|25|1|TREATMENT|2020-12-25|25
e|TR|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|3|[?]|PCHGBL|Percent Change From Baseline|[?]|IU/kg/h|TUMOR MERGED|1|10^4/hpf|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||Y|CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|N|3|Visit_3|40|3|SCREENING|2021-01-09|40
e|TR|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|4|[?]|VDIAM|Viable Diameter|[?]|BAU|ENLARGEMENT|1|GPL U|MICROBIAL BIOCHEMICAL IDENTIFICATION|||INVESTIGATOR|PATHOLOGIST 1|U|4|Visit_4|65|7|TREATMENT|2021-02-03|65
e|TR|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|5|[?]|SUMVOL|Sum of Volume|[?]|Log10 ELISA unit/dose|FOCALLY INCREASED|1|mg/mL/min|MICROSCOPY|||FRIEND|RADIOLOGIST 2|N|5|Visit_5|90|4|SCREENING|2021-02-28|90
e|TR|bde9096e-9ab9-45fe-8e96-1ec9762824a0|1|[?]|BNLNUM|Number of Bone Lesions|[?]|Watt|NORMAL|1|g/day|HILLMEN COLOR CHART|||HEALTH CARE PROFESSIONAL|RATER 1|U|1|Visit_1|10|7|TREATMENT|2020-08-27|10
e|TR|bde9096e-9ab9-45fe-8e96-1ec9762824a0|2|[?]|VSLFLIND|Vessel Failure Indicator|[?]|%(w/v)|NON-PATHOLOGICAL|1|PA|PET SCAN|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|NA|2|Visit_2|25|6|WASHOUT|2020-09-11|25
e|TR|bde9096e-9ab9-45fe-8e96-1ec9762824a0|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|msec|ENLARGEMENT FROM NADIR|1|mL/cage/wk|KNEMOMETRY|||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-09-26|40
e|TR|bde9096e-9ab9-45fe-8e96-1ec9762824a0|4|[?]|LDIAM|Longest Diameter|[?]|%(w/w)|INCREASED|1|10^3 copies/mL|PUPILLOMETRY|Y||INVESTIGATOR|RADIOLOGIST 1|NA|4|Visit_4|65|5|WASHOUT|2020-10-21|65
e|TR|bde9096e-9ab9-45fe-8e96-1ec9762824a0|5|[?]|LESSCIND|Lesion Success Indicator|[?]|pt_br|UNEQUIVOCAL|1|K|LAPAROSCOPY|Y||CLINICAL RESEARCH ASSOCIATE|RATER|NA|5|Visit_5|90|2|WASHOUT|2020-11-15|90
e|TR|ea7907aa-811e-48ec-9fc6-ab8affde8913|1|[?]|VDIAM|Viable Diameter|[?]|Osm|ENLARGEMENT|1|umol|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||GUARDIAN|PATHOLOGIST|Y|1|Visit_1|10|7|SCREENING|2020-06-28|10
e|TR|ea7907aa-811e-48ec-9fc6-ab8affde8913|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|min|NONPALPABLE|1|BLOCKS|INCISION-INDUCED BLEEDING METHOD|Y||VENDOR|PHYSIOTHERAPIST|U|2|Visit_2|25|1|FOLLOW-UP|2020-07-13|25
e|TR|ea7907aa-811e-48ec-9fc6-ab8affde8913|3|[?]|RADIODEN|Radiodensity|[?]|10^9 organisms/g|FURTHER ENLARGEMENT FROM NADIR|1|10^4/L|DOPPLER ULTRASOUND||Y|CAREGIVER|READER 2|N|3|Visit_3|40|7|TREATMENT|2020-07-28|40
e|TR|ea7907aa-811e-48ec-9fc6-ab8affde8913|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|ug/kg|UNCHANGED|1|GLOBULE|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||SPOUSE|NEUROLOGIST 2|Y|4|Visit_4|65|6|TREATMENT|2020-08-22|65
e|TR|ea7907aa-811e-48ec-9fc6-ab8affde8913|5|[?]|VOLUME|Volume|[?]|RFU|EQUIVOCAL|1|NFIU|COMPUTERIZED CORNEAL TOPOGRAPHY|||PROXY|READER|NA|5|Visit_5|90|6|TREATMENT|2020-09-16|90
e|TR|3aa9935c-943d-406a-bb6e-fc067fa8a487|1|[?]|LNSTATE|Lymph Node State|[?]|/LSQN|FURTHER ENLARGEMENT FROM NADIR|1|Gy/h|SLOAN LETTER EYE CHART 1.25%|Y||STUDY SUBJECT|ADJUDICATOR|NA|1|Visit_1|10|1|TREATMENT|2020-08-27|10
e|TR|3aa9935c-943d-406a-bb6e-fc067fa8a487|2|[?]|RADIODEN|Radiodensity|[?]|1/(s*kPa)|FOCALLY INCREASED|1|FINGERTIP UNIT|SURFACE PLASMON RESONANCE|||GUARDIAN|PHYSIOTHERAPIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-09-11|25
e|TR|3aa9935c-943d-406a-bb6e-fc067fa8a487|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|foz_us|ENLARGEMENT|1|ng/L|PHASE CONTRAST MICROSCOPY|Y||CHILD|PATHOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-09-26|40
e|TR|3aa9935c-943d-406a-bb6e-fc067fa8a487|4|[?]|SUMDIAM|Sum of Diameter|[?]|mol/L|ABSENT|1|m2|IN VITRO GENE EXPRESSION ASSAY||Y|GUARDIAN|PHYSIOTHERAPIST|Y|4|Visit_4|65|2|FOLLOW-UP|2020-10-21|65
e|TR|3aa9935c-943d-406a-bb6e-fc067fa8a487|5|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|IU/mmol|UNCHANGED|1|CARTRIDGE|THICK SMEAR|||STUDY SUBJECT|NEUROLOGIST 1|U|5|Visit_5|90|2|WASHOUT|2020-11-15|90
e|TR|0cac2007-ca12-45ba-9b1c-70f753232f05|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|JDF Unit|FURTHER ENLARGEMENT FROM NADIR|1|cd*s/m2|MAGNETIC RESONANCE ENTEROGRAPHY|||GUARDIAN|INTERNIST|Y|1|Visit_1|10|6|SCREENING|2020-12-01|10
e|TR|0cac2007-ca12-45ba-9b1c-70f753232f05|2|[?]|NEWCONF|New Tumor Confirmed|[?]|uCi|NONPALPABLE|1|s^-1(%O2)^-1|MUGA||Y|CAREGIVER|HEMATOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-12-16|25
e|TR|0cac2007-ca12-45ba-9b1c-70f753232f05|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|umol/dL|ENLARGEMENT|1|U/mg|DIGITAL PCR|||DOMESTIC PARTNER|READER 2|N|3|Visit_3|40|5|FOLLOW-UP|2020-12-31|40
e|TR|0cac2007-ca12-45ba-9b1c-70f753232f05|4|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|Torr|DECREASED|1|QUANTITY SUFFICIENT|FORCED OSCILLATION TECHNIQUE|||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|U|4|Visit_4|65|2|TREATMENT|2021-01-25|65
e|TR|0cac2007-ca12-45ba-9b1c-70f753232f05|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|cm|FOCALLY INCREASED|1|mL/m2/day|POLYMERASE CHAIN REACTION|||INVESTIGATOR|UROLOGIST|U|5|Visit_5|90|3|TREATMENT|2021-02-19|90
e|TR|2339e91a-b93e-426f-9b60-3d3b6969268d|1|[?]|BNLNUM|Number of Bone Lesions|[?]|mL/beat|DIFFUSELY INCREASED|1|L/h/m2|CELL BASED BIOASSAY|||STUDY SUBJECT|RATER|NA|1|Visit_1|10|1|TREATMENT|2020-07-07|10
e|TR|2339e91a-b93e-426f-9b60-3d3b6969268d|2|[?]|TUMSTATE|Tumor State|[?]|mL/kg/h|FURTHER ENLARGEMENT FROM NADIR|1|10^10/L|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y||SIGNIFICANT OTHER|HEMATOLOGIST|N|2|Visit_2|25|1|FOLLOW-UP|2020-07-22|25
e|TR|2339e91a-b93e-426f-9b60-3d3b6969268d|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|10^7 PFU|NORMAL|1|mEq|IN SITU HYBRIDIZATION|||CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|5|FOLLOW-UP|2020-08-06|40
e|TR|2339e91a-b93e-426f-9b60-3d3b6969268d|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|umol|DIFFUSELY INCREASED|1|atm|URANYL ACETATE STAIN||Y|CHILD|INTERNIST|N|4|Visit_4|65|5|TREATMENT|2020-08-31|65
e|TR|2339e91a-b93e-426f-9b60-3d3b6969268d|5|[?]|NEWCONF|New Tumor Confirmed|[?]|vg/mL|DECREASED|1|mL/animal/wk|FLUORESCENT SPOT TEST||Y|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-09-25|90
e|TR|0d09e35b-e864-4492-a341-21c71d92b551|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|COAT|PALPABLE|1|pL|AMSLER GRID|||SPOUSE|MICROSCOPIST 1|N|1|Visit_1|10|6|TREATMENT|2020-10-30|10
e|TR|0d09e35b-e864-4492-a341-21c71d92b551|2|[?]|AREA|Area|[?]|LOZENGE|DECREASED|1|kV|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||CHILD|MICROSCOPIST 1|Y|2|Visit_2|25|6|FOLLOW-UP|2020-11-14|25
e|TR|0d09e35b-e864-4492-a341-21c71d92b551|3|[?]|VOLUME|Volume|[?]|10^9/dose|FURTHER ENLARGEMENT FROM NADIR|1|EID 50/dose|POLYMERASE CHAIN REACTION||Y|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-11-29|40
e|TR|0d09e35b-e864-4492-a341-21c71d92b551|4|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|ug/mL/h|INCREASED|1|eq|ELECTROGASTROGRAPHY|||PARENT|PHYSIOTHERAPIST|U|4|Visit_4|65|4|SCREENING|2020-12-24|65
e|TR|0d09e35b-e864-4492-a341-21c71d92b551|5|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|mmol2/L2|NORMAL|1|10^6 RNA copies/mL|WHOLE TRANSCRIPTOME SEQUENCING|||NON-HEALTH CARE PROFESSIONAL|READER 2|Y|5|Visit_5|90|7|TREATMENT|2021-01-18|90
e|TR|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|1|[?]|ORVERLN|Organ Vertical Length|[?]|Pa|FOCALLY INCREASED|1|/month|WRIGHT-GIEMSA STAIN|Y||ADJUDICATION COMMITTEE|READER|NA|1|Visit_1|10|2|FOLLOW-UP|2020-06-05|10
e|TR|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|g/cm2|UNCHANGED|1|YEARS|BRDU CELLULAR PROLIFERATION ASSAY|||INDEPENDENT ASSESSOR|INTERNIST|N|2|Visit_2|25|3|SCREENING|2020-06-20|25
e|TR|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|3|[?]|LDIAM|Longest Diameter|[?]|%(w/v)|UNEQUIVOCAL|1|10^4 CFU/mL|CONTRAST ENHANCED SPIRAL CT SCAN|Y||NON-HEALTH CARE PROFESSIONAL|READER 2|NA|3|Visit_3|40|4|TREATMENT|2020-07-05|40
e|TR|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|PACKAGE|ENLARGEMENT FROM NADIR|1|DROP|RAJI CELL EIA|||INVESTIGATOR|MICROSCOPIST 2|Y|4|Visit_4|65|3|WASHOUT|2020-07-30|65
e|TR|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|5|[?]|ORVERLN|Organ Vertical Length|[?]|mm|FURTHER ENLARGEMENT|1|ug/kg/day|MAGNETIC RESONANCE ANGIOGRAPHY|||CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-08-24|90
e|TR|0a5b1036-cd00-4221-b218-ee2664e5a43e|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|kg/L|ENLARGEMENT|1|mL/cm|IMMUNORADIOMETRIC ASSAY|||DOMESTIC PARTNER|NEUROLOGIST|N|1|Visit_1|10|3|TREATMENT|2021-01-02|10
e|TR|0a5b1036-cd00-4221-b218-ee2664e5a43e|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|ug/mL/h|PRESENT|1|mg/g/h|ELLA|||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|2|Visit_2|25|2|FOLLOW-UP|2021-01-17|25
e|TR|0a5b1036-cd00-4221-b218-ee2664e5a43e|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|pmol/g|EQUIVOCAL|1|genEq/mL|ELECTROCHEMILUMINESCENCE|Y||INDEPENDENT ASSESSOR|READER|N|3|Visit_3|40|7|TREATMENT|2021-02-01|40
e|TR|0a5b1036-cd00-4221-b218-ee2664e5a43e|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|POUCH|PALPABLE|1|L|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||CHILD|RADIOLOGIST 1|N|4|Visit_4|65|6|TREATMENT|2021-02-26|65
e|TR|0a5b1036-cd00-4221-b218-ee2664e5a43e|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|ug/cm2|NON-PATHOLOGICAL|1|DDU|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|Y|5|Visit_5|90|2|WASHOUT|2021-03-23|90
e|TR|a4f74465-7abc-4cc2-a0be-25d1c802af8c|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|Enzyme U|EQUIVOCAL|1|PACK|FLUORESCENCE ANGIOGRAPHY|||CLINICAL STUDY SPONSOR|PATHOLOGIST 2|NA|1|Visit_1|10|3|TREATMENT|2020-09-30|10
e|TR|a4f74465-7abc-4cc2-a0be-25d1c802af8c|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|/100 HPFs|TUMOR MERGED|1|log10 PFU|JAEGER EYE CHART|Y||PARENT|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|1|SCREENING|2020-10-15|25
e|TR|a4f74465-7abc-4cc2-a0be-25d1c802af8c|3|[?]|TUMSTATE|Tumor State|[?]|10^9 CFU|EQUIVOCAL|1|pg/L|INFRARED SPECTROMETRY|Y||ADJUDICATOR|ONCOLOGIST 1|N|3|Visit_3|40|1|TREATMENT|2020-10-30|40
e|TR|a4f74465-7abc-4cc2-a0be-25d1c802af8c|4|[?]|DIAMETER|Diameter|[?]|GBq/ug|DECREASED|1|INHALATION|WESTERGREN||Y|VENDOR|UROLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-11-24|65
e|TR|a4f74465-7abc-4cc2-a0be-25d1c802af8c|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|oz eq|NORMAL|1|ppth|HPLC|||CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|5|Visit_5|90|1|FOLLOW-UP|2020-12-19|90
e|TR|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|ppb|TUMOR MERGED|1|g/L|EEG|||PROXY|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|6|WASHOUT|2020-11-12|10
e|TR|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|2|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|ug/kg|EQUIVOCAL|1|10^7 PFU|SIZE EXCLUSION CHROMATOGRAPHY|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|NA|2|Visit_2|25|2|WASHOUT|2020-11-27|25
e|TR|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|3|[?]|BNLNUM|Number of Bone Lesions|[?]|mEq/mmol|INCREASED|1|BEAM BREAKS|FLUORESCEIN STAIN|Y||SIBLING|ADJUDICATOR 1|N|3|Visit_3|40|3|TREATMENT|2020-12-12|40
e|TR|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|h*%|UNCHANGED|1|NEBULE|DYNAMIC CONTRAST ENHANCED MRI|||CAREGIVER|READER 3|NA|4|Visit_4|65|2|SCREENING|2021-01-06|65
e|TR|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|MASK|FURTHER ENLARGEMENT FROM NADIR|1|ug/L DDU|NEPHELOMETRY|||VENDOR|ADJUDICATOR 3|NA|5|Visit_5|90|3|TREATMENT|2021-01-31|90
e|TR|e7262592-01e8-4cb3-b967-ec1037505e81|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|pg/cell|PATHOLOGICAL|1|mL/min/1.73m2|THIN SMEAR|Y||CLINICAL RESEARCH COORDINATOR|READER 3|N|1|Visit_1|10|5|WASHOUT|2020-09-12|10
e|TR|e7262592-01e8-4cb3-b967-ec1037505e81|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|10^3 CFU/g|UNCHANGED|1|10^6 organisms/mL|NUCLEIC ACID HYBRIDIZATION|Y||CAREGIVER|READER 3|NA|2|Visit_2|25|6|WASHOUT|2020-09-27|25
e|TR|e7262592-01e8-4cb3-b967-ec1037505e81|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|FIU|NONPALPABLE|1|mL/mmHg|PHOROPTER|Y||ADJUDICATOR|ADJUDICATOR 1|U|3|Visit_3|40|5|FOLLOW-UP|2020-10-12|40
e|TR|e7262592-01e8-4cb3-b967-ec1037505e81|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|cy/cm|FOCALLY INCREASED|1|10^6 U|DIFFUSION WEIGHTED MRI||Y|ADJUDICATION COMMITTEE|ADJUDICATOR|U|4|Visit_4|65|1|SCREENING|2020-11-06|65
e|TR|e7262592-01e8-4cb3-b967-ec1037505e81|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|g/m2/day|INCREASED|1|mL/g/day|BETA LACTAMASE||Y|GUARDIAN|HEMATOLOGIST|Y|5|Visit_5|90|4|WASHOUT|2020-12-01|90
e|TR|bf150829-1b25-418a-9bc6-61716984387c|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|V/sec|NON-PATHOLOGICAL|1|mL/s/m2|PERCUSSION|Y||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|3|TREATMENT|2020-06-15|10
e|TR|bf150829-1b25-418a-9bc6-61716984387c|2|[?]|VSLFLIND|Vessel Failure Indicator|[?]|deg/s|EQUIVOCAL|1|mmHg/L/min|GC/MS-CI|Y||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|N|2|Visit_2|25|5|WASHOUT|2020-06-30|25
e|TR|bf150829-1b25-418a-9bc6-61716984387c|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|PIPE|FURTHER ENLARGEMENT FROM NADIR|1|uCi/L|DIGITAL PCR ARRAY||Y|CHILD|HEMATOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-07-15|40
e|TR|bf150829-1b25-418a-9bc6-61716984387c|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|pg/dL|NORMAL|1|mg/mL/min|WESTERN BLOT|Y||CHILD|PHYSIOTHERAPIST|NA|4|Visit_4|65|3|TREATMENT|2020-08-09|65
e|TR|bf150829-1b25-418a-9bc6-61716984387c|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mkat|DECREASED|1|pmol|PHYSICAL EXAMINATION|||INDEPENDENT ASSESSOR|RATER 2|NA|5|Visit_5|90|1|TREATMENT|2020-09-03|90
e|TR|5c1cc260-97a0-493c-bc11-57f31ffd7455|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|Enzyme U/m2|FURTHER ENLARGEMENT|1|mmol/g|MICROARRAY||Y|FAMILY MEMBER|MICROSCOPIST 1|N|1|Visit_1|10|4|TREATMENT|2020-09-06|10
e|TR|5c1cc260-97a0-493c-bc11-57f31ffd7455|2|[?]|TUMSTATE|Tumor State|[?]|dL|UNCHANGED|1|U/L|GEL ELECTROPHORESIS|||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|5|TREATMENT|2020-09-21|25
e|TR|5c1cc260-97a0-493c-bc11-57f31ffd7455|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|HOURS|FURTHER ENLARGEMENT FROM NADIR|1|fraction of 1|SCINTIGRAPHY|||SIGNIFICANT OTHER|RADIOLOGIST 1|U|3|Visit_3|40|5|TREATMENT|2020-10-06|40
e|TR|5c1cc260-97a0-493c-bc11-57f31ffd7455|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|ug/mol|UNEQUIVOCAL|1|PUFF|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||ADJUDICATOR|RADIOLOGIST|NA|4|Visit_4|65|4|WASHOUT|2020-10-31|65
e|TR|5c1cc260-97a0-493c-bc11-57f31ffd7455|5|[?]|LDIAM|Longest Diameter|[?]|/10^4|FURTHER ENLARGEMENT|1|10^6 IU/mL|SNELLEN EYE CHART|Y|Y|ADJUDICATOR|ADJUDICATOR 3|NA|5|Visit_5|90|7|WASHOUT|2020-11-25|90
e|TR|cca2835b-ca8d-4db6-89b4-9f2855968a8a|1|[?]|VDIAM|Viable Diameter|[?]|h*%|DECREASED|1|EID 50/dose|AURAMINE STAIN||Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|7|TREATMENT|2020-07-19|10
e|TR|cca2835b-ca8d-4db6-89b4-9f2855968a8a|2|[?]|VSLFLIND|Vessel Failure Indicator|[?]|pg/cell|NON-PATHOLOGICAL|1|mph|MALDI|||PARENT|RADIOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-08-03|25
e|TR|cca2835b-ca8d-4db6-89b4-9f2855968a8a|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|STEPS|NONPALPABLE|1|/10^5|CELLULAR PROLIFERATION ASSAY|||SPOUSE|CARDIOLOGIST|NA|3|Visit_3|40|7|FOLLOW-UP|2020-08-18|40
e|TR|cca2835b-ca8d-4db6-89b4-9f2855968a8a|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|MPL U|PRESENT|1|cL|AUTOMATED COUNT|||INDEPENDENT ASSESSOR|OPTOMETRIST|U|4|Visit_4|65|4|TREATMENT|2020-09-12|65
e|TR|cca2835b-ca8d-4db6-89b4-9f2855968a8a|5|[?]|LNSTATE|Lymph Node State|[?]|MET|FURTHER ENLARGEMENT FROM NADIR|1|cm/s|THICK SMEAR||Y|DOMESTIC PARTNER|INTERNIST|U|5|Visit_5|90|4|FOLLOW-UP|2020-10-07|90
e|TR|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mmol/g|NON-PATHOLOGICAL|1|PFU|WRIGHT STAIN|Y||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|U|1|Visit_1|10|1|SCREENING|2020-10-07|10
e|TR|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|2|[?]|SUMDIAM|Sum of Diameter|[?]|mg/mL/min|PRESENT|1|ft3|ENDOSCOPY|||VENDOR|NEUROLOGIST|N|2|Visit_2|25|7|TREATMENT|2020-10-22|25
e|TR|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|/cmH2O|FOCALLY INCREASED|1|Frames/s|NON-INVASIVE DIELECTRIC SENSING|Y||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|5|SCREENING|2020-11-06|40
e|TR|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|4|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|ug/L|PATHOLOGICAL|1|Log10 ELISA unit/dose|LC/MS|Y|Y|VENDOR|INTERNIST|NA|4|Visit_4|65|4|TREATMENT|2020-12-01|65
e|TR|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|5|[?]|CALCFIND|Calcification Indicator|[?]|10^6 CFU/mL|FURTHER ENLARGEMENT FROM NADIR|1|mEq/dL|QUANTITATIVE CORONARY ANGIOGRAPHY|Y||SIBLING|PATHOLOGIST 2|U|5|Visit_5|90|6|WASHOUT|2020-12-26|90
e|TR|74cd0a4f-f9fe-4df9-93b8-7832512d0828|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|uEq/L|PALPABLE|1|U/m2/day|MAPH|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|1|Visit_1|10|2|TREATMENT|2020-05-15|10
e|TR|74cd0a4f-f9fe-4df9-93b8-7832512d0828|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|in2|INCREASED|1|mL/day|X-RAY FLUORESCENCE SPECTROMETRY|||ADJUDICATION COMMITTEE|MICROSCOPIST 3|NA|2|Visit_2|25|3|TREATMENT|2020-05-30|25
e|TR|74cd0a4f-f9fe-4df9-93b8-7832512d0828|3|[?]|LDIAM|Longest Diameter|[?]|tuberculin unit|UNCHANGED|1|ugEq/L|SPECTROPHOTOMETRY||Y|SIGNIFICANT OTHER|INTERNIST|U|3|Visit_3|40|5|WASHOUT|2020-06-14|40
e|TR|74cd0a4f-f9fe-4df9-93b8-7832512d0828|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|Enzyme U/m2|INCREASED|1|STEPS|ANTIMICROBIAL COMBINATION TESTING||Y|PROXY|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-07-09|65
e|TR|74cd0a4f-f9fe-4df9-93b8-7832512d0828|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|mg/kg/min|NORMAL|1|dpm/mL|PYROSEQUENCING|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|N|5|Visit_5|90|1|TREATMENT|2020-08-03|90
e|TR|09238251-feaf-45a9-b295-dfed9a75fbb2|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|Mile|NORMAL|1|mCi/kg|DROPLET DIGITAL PCR||Y|INDEPENDENT ASSESSOR|PATHOLOGIST 1|Y|1|Visit_1|10|4|TREATMENT|2020-06-26|10
e|TR|09238251-feaf-45a9-b295-dfed9a75fbb2|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mL/m2/h|INCREASED|1|10^6/Ejaculate U|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||GUARDIAN|ONCOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-07-11|25
e|TR|09238251-feaf-45a9-b295-dfed9a75fbb2|3|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|MASK|FURTHER ENLARGEMENT|1|cmH2O*s2/mL|ICC||Y|GUARDIAN|OPTOMETRIST|Y|3|Visit_3|40|2|TREATMENT|2020-07-26|40
e|TR|09238251-feaf-45a9-b295-dfed9a75fbb2|4|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|mL/sec/1.73m2|PRESENT|1|mEq/kg|GIEMSA STAIN||Y|PARENT|RATER 1|NA|4|Visit_4|65|3|TREATMENT|2020-08-20|65
e|TR|09238251-feaf-45a9-b295-dfed9a75fbb2|5|[?]|LDIAM|Longest Diameter|[?]|AU/mL|FURTHER ENLARGEMENT|1|mol/day|HEMAGGLUTINATION INHIBITION ASSAY|||INTERVIEWER|PEDIATRIC NEUROLOGIST|N|5|Visit_5|90|5|SCREENING|2020-09-14|90
e|TR|3e896568-85dc-4a14-ba41-eb3575940a9d|1|[?]|PALPSTAT|Palpable State|[?]|ug/kg/h|ENLARGEMENT|1|mAmp|EIA|||STUDY SUBJECT|OPTOMETRIST|N|1|Visit_1|10|5|TREATMENT|2021-01-26|10
e|TR|3e896568-85dc-4a14-ba41-eb3575940a9d|2|[?]|LESSCIND|Lesion Success Indicator|[?]|10^7 TCID 50/dose|FURTHER ENLARGEMENT FROM NADIR|1|mg/day|IMMUNOPRECIPITATION|Y||SIGNIFICANT OTHER|RATER|U|2|Visit_2|25|1|WASHOUT|2021-02-10|25
e|TR|3e896568-85dc-4a14-ba41-eb3575940a9d|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mmHg|FURTHER ENLARGEMENT FROM NADIR|1|mL/kg/h|WRIGHT-GIEMSA STAIN|||FAMILY MEMBER|OPTOMETRIST|N|3|Visit_3|40|4|SCREENING|2021-02-25|40
e|TR|3e896568-85dc-4a14-ba41-eb3575940a9d|4|[?]|PALPSTAT|Palpable State|[?]|Joule|PRESENT|1|ngEq/L|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||SIBLING|OPTOMETRIST|Y|4|Visit_4|65|6|WASHOUT|2021-03-22|65
e|TR|3e896568-85dc-4a14-ba41-eb3575940a9d|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mL/g/day|PRESENT|1|mmAL|HPLC/IEX|||PARENT|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|1|SCREENING|2021-04-16|90
e|TR|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mol/mL|FURTHER ENLARGEMENT FROM NADIR|1|10^9 CFU|MICROBIAL CULTURE, SOLID|||INDEPENDENT ASSESSOR|NEUROLOGIST|NA|1|Visit_1|10|4|WASHOUT|2020-10-22|10
e|TR|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|2|[?]|LNSTATE|Lymph Node State|[?]|ks|NON-PATHOLOGICAL|1|log10 TCID 50/mL|HPLC/IEX|||INTERVIEWER|UROLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-11-06|25
e|TR|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|Tbsp|NON-PATHOLOGICAL|1|PNU/mL|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||INDEPENDENT ASSESSOR|ADJUDICATOR 1|NA|3|Visit_3|40|6|FOLLOW-UP|2020-11-21|40
e|TR|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|cmH2O*s2/mL|UNEQUIVOCAL|1|mU/g|WEBER GREEN STAIN|||DOMESTIC PARTNER|READER 1|Y|4|Visit_4|65|5|TREATMENT|2020-12-16|65
e|TR|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|keV|NORMAL|1|log EID 50/dose|AUTOREFRACTION|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|5|Visit_5|90|3|TREATMENT|2021-01-10|90
e|TR|725c5a91-72b0-4b2c-a51a-d1006303373e|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|uL/dose|DIFFUSELY INCREASED|1|mg/mol|ANTIBIOTIC AGAR SCREEN|||INVESTIGATOR|PATHOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-11-23|10
e|TR|725c5a91-72b0-4b2c-a51a-d1006303373e|2|[?]|LNSTATE|Lymph Node State|[?]|mL/g/h|UNCHANGED|1|aMFI|FLUORIMETRY|||GUARDIAN|RADIOLOGIST 1|Y|2|Visit_2|25|3|FOLLOW-UP|2020-12-08|25
e|TR|725c5a91-72b0-4b2c-a51a-d1006303373e|3|[?]|AREA|Area|[?]|uU/dL|UNCHANGED|1|ug/m2/min|REVERSE TRANSCRIPTASE PCR||Y|CAREGIVER|UROLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-12-23|40
e|TR|725c5a91-72b0-4b2c-a51a-d1006303373e|4|[?]|VDIAM|Viable Diameter|[?]|PNU/mL|UNCHANGED|1|10^12 IU/L|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||FAMILY MEMBER|OPTOMETRIST|U|4|Visit_4|65|6|TREATMENT|2021-01-17|65
e|TR|725c5a91-72b0-4b2c-a51a-d1006303373e|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|kBq/uL|ABSENT|1|Shock Wave|TRANSCRIPTION-MEDIATED AMPLIFICATION|||SPOUSE|RADIOLOGIST 1|NA|5|Visit_5|90|3|FOLLOW-UP|2021-02-11|90
e|TR|5bf5b31d-a59d-46b7-8f8f-97919d449565|1|[?]|SUMDIAM|Sum of Diameter|[?]|um/day|INCREASED|1|/100 WBC|IMMUNOFIXATION ELECTROPHORESIS|||INVESTIGATOR|INTERNIST|Y|1|Visit_1|10|1|TREATMENT|2021-01-01|10
e|TR|5bf5b31d-a59d-46b7-8f8f-97919d449565|2|[?]|PPD|Product of Perpendicular Diameters|[?]|APS U|UNCHANGED|1|10^7 CFU/mL|MULTIPLE BREATH WASHOUT|Y||DOMESTIC PARTNER|ONCOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2021-01-16|25
e|TR|5bf5b31d-a59d-46b7-8f8f-97919d449565|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|gpELISA unit/mL|INCREASED|1|10^6 organisms/mg|REVERSE TRANSCRIPTASE PCR|||FRIEND|CARDIOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2021-01-31|40
e|TR|5bf5b31d-a59d-46b7-8f8f-97919d449565|4|[?]|CALCFIND|Calcification Indicator|[?]|10^6/Ejaculate U|PATHOLOGICAL|1|PA|JAEGER EYE CHART|||FRIEND|ONCOLOGIST 2|NA|4|Visit_4|65|7|TREATMENT|2021-02-25|65
e|TR|5bf5b31d-a59d-46b7-8f8f-97919d449565|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|10^3 organisms/g|NON-PATHOLOGICAL|1|fmol/L|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||VENDOR|RATER|NA|5|Visit_5|90|6|TREATMENT|2021-03-22|90
e|TR|7fc35880-1672-4e64-ba3b-aa3f1e42764b|1|[?]|LDIAM|Longest Diameter|[?]|mL/cm|ABSENT|1|nCi|RAJI CELL RIA|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|1|Visit_1|10|4|SCREENING|2020-05-26|10
e|TR|7fc35880-1672-4e64-ba3b-aa3f1e42764b|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|PIPE|FOCALLY INCREASED|1|mg/m2/min|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y||PARENT|OTOLARYNGOLOGIST|Y|2|Visit_2|25|1|FOLLOW-UP|2020-06-10|25
e|TR|7fc35880-1672-4e64-ba3b-aa3f1e42764b|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|g/g/day|NON-PATHOLOGICAL|1|mg2/dL2|SLIT LAMP PHOTOGRAPHY|Y||STUDY SUBJECT|NEUROLOGIST 1|NA|3|Visit_3|40|1|SCREENING|2020-06-25|40
e|TR|7fc35880-1672-4e64-ba3b-aa3f1e42764b|4|[?]|TUMSTATE|Tumor State|[?]|APL U/mL|FOCALLY INCREASED|1|10^12 IU/L|THICK SMEAR||Y|PROXY|ADJUDICATOR|Y|4|Visit_4|65|6|SCREENING|2020-07-20|65
e|TR|7fc35880-1672-4e64-ba3b-aa3f1e42764b|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|cal|EQUIVOCAL|1|Gauss|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||Y|ADJUDICATOR|MICROSCOPIST 2|Y|5|Visit_5|90|5|TREATMENT|2020-08-14|90
e|TR|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|Torr|UNEQUIVOCAL|1|nmol|MODIFIED ACID FAST STAIN|||INVESTIGATOR|PATHOLOGIST|N|1|Visit_1|10|2|SCREENING|2020-10-14|10
e|TR|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|2|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|umol/mg/min|INCREASED|1|MONTHS|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||SPOUSE|READER 3|NA|2|Visit_2|25|1|SCREENING|2020-10-29|25
e|TR|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|3|[?]|LDIAM|Longest Diameter|[?]|mL/min/1.73m2|TUMOR MERGED|1|/min|CISH|||FAMILY MEMBER|RADIOLOGIST 2|U|3|Visit_3|40|7|TREATMENT|2020-11-13|40
e|TR|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|CCID 50/mL|FURTHER ENLARGEMENT|1|kg/L|FLUORESCEIN STAIN|Y||PROXY|DERMATOLOGIST|N|4|Visit_4|65|6|FOLLOW-UP|2020-12-08|65
e|TR|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|cal|UNEQUIVOCAL|1|ng|MALDI|||SIBLING|MICROSCOPIST 3|U|5|Visit_5|90|3|WASHOUT|2021-01-02|90
e|TR|f8878ffd-67af-414c-b346-596dbec640cf|1|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mol/day|UNCHANGED|1|/10^5|HPLC/MS||Y|INDEPENDENT ASSESSOR|ADJUDICATOR 2|NA|1|Visit_1|10|2|TREATMENT|2021-01-04|10
e|TR|f8878ffd-67af-414c-b346-596dbec640cf|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|mU/L|EQUIVOCAL|1|mL/kg/day|IHC|||DOMESTIC PARTNER|RADIOLOGIST|NA|2|Visit_2|25|4|FOLLOW-UP|2021-01-19|25
e|TR|f8878ffd-67af-414c-b346-596dbec640cf|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|nmol|ABSENT|1|DRUM|FARR ASSAY|||FAMILY MEMBER|CLINICAL PATHOLOGIST|U|3|Visit_3|40|2|SCREENING|2021-02-03|40
e|TR|f8878ffd-67af-414c-b346-596dbec640cf|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|mCi|UNCHANGED|1|10^6 RNA copies/mL|CONFOCAL MICROSCOPY|||INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|4|Visit_4|65|7|TREATMENT|2021-02-28|65
e|TR|f8878ffd-67af-414c-b346-596dbec640cf|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|kg/cm|PALPABLE|1|cL|ICC|||INVESTIGATOR|READER 3|U|5|Visit_5|90|7|SCREENING|2021-03-25|90
e|TR|d8212248-cd8c-4404-8ad8-2c89c05bee9e|1|[?]|RADIODEN|Radiodensity|[?]|kN/cm2|PRESENT|1|CIGARETTE|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||CLINICAL RESEARCH ASSOCIATE|RATER|Y|1|Visit_1|10|3|WASHOUT|2020-05-11|10
e|TR|d8212248-cd8c-4404-8ad8-2c89c05bee9e|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|umol/L|ABSENT|1|Bq|IMMUNORADIOMETRIC ASSAY|Y|Y|STUDY SUBJECT|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|5|FOLLOW-UP|2020-05-26|25
e|TR|d8212248-cd8c-4404-8ad8-2c89c05bee9e|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|nmol BCE/nmol|NONPALPABLE|1|mL/m2|CONTRAST ENHANCED PET SCAN|||STUDY SUBJECT|INTERNIST|N|3|Visit_3|40|4|SCREENING|2020-06-10|40
e|TR|d8212248-cd8c-4404-8ad8-2c89c05bee9e|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|BISCUIT|NON-PATHOLOGICAL|1|Ci/g|KLEIHAUER-BETKE|||INVESTIGATOR|RADIOLOGIST 2|U|4|Visit_4|65|1|WASHOUT|2020-07-05|65
e|TR|d8212248-cd8c-4404-8ad8-2c89c05bee9e|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|pt_us|FOCALLY INCREASED|1|scm|PALM METHOD|||CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|NA|5|Visit_5|90|5|TREATMENT|2020-07-30|90
e|TR|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|1|[?]|VOLUME|Volume|[?]|vp/dose|TUMOR MERGED|1|mCi/kg|DYNAMOMETRY||Y|SIGNIFICANT OTHER|OPHTHALMOLOGIST|N|1|Visit_1|10|1|FOLLOW-UP|2020-07-02|10
e|TR|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mkat|UNEQUIVOCAL|1|/VF|HIGH LEVEL AMINOGLYCOSIDE SCREEN||Y|NON-HEALTH CARE PROFESSIONAL|READER 3|NA|2|Visit_2|25|7|TREATMENT|2020-07-17|25
e|TR|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|3|[?]|SUMVOL|Sum of Volume|[?]|umol/L/h|PALPABLE|1|g/dL|THERMAL IONIZATION MASS SPECTROMETRY|||VENDOR|PATHOLOGIST 2|N|3|Visit_3|40|7|TREATMENT|2020-08-01|40
e|TR|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|EVENTS|DECREASED|1|gtt|APPLANATION TONOMETRY|||CAREGIVER|READER 2|U|4|Visit_4|65|6|TREATMENT|2020-08-26|65
e|TR|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|5|[?]|LDIAM|Longest Diameter|[?]|g/cm2|NORMAL|1|Gauss|ELECTROPHORESIS||Y|CHILD|OTOLARYNGOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2020-09-20|90
e|TR|b832144e-88c4-4ad6-b173-abac7802a36c|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|SACHET|PRESENT|1|mU|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|Y|1|Visit_1|10|4|TREATMENT|2021-01-14|10
e|TR|b832144e-88c4-4ad6-b173-abac7802a36c|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|mL/kg/day|FURTHER ENLARGEMENT FROM NADIR|1|cd/m2|LISSAMINE GREEN STAIN|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|NA|2|Visit_2|25|7|WASHOUT|2021-01-29|25
e|TR|b832144e-88c4-4ad6-b173-abac7802a36c|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|log10 copies/mL|FURTHER ENLARGEMENT|1|log10 copies/mL|NON-CONTACT SPECULAR MICROSCOPY|Y||CLINICAL STUDY SPONSOR|READER 2|N|3|Visit_3|40|1|TREATMENT|2021-02-13|40
e|TR|b832144e-88c4-4ad6-b173-abac7802a36c|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|PFU/animal|DIFFUSELY INCREASED|1|lm|SMEAR|||VENDOR|CLINICAL PATHOLOGIST|N|4|Visit_4|65|7|TREATMENT|2021-03-10|65
e|TR|b832144e-88c4-4ad6-b173-abac7802a36c|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|10^9 CFU/g|ENLARGEMENT FROM NADIR|1|uL/dose|SCANNING ELECTRON MICROSCOPY|Y||DOMESTIC PARTNER|NEUROLOGIST 2|NA|5|Visit_5|90|2|FOLLOW-UP|2021-04-04|90
e|TR|6acacd87-c487-401c-8888-76ccf97b640d|1|[?]|CALCFIND|Calcification Indicator|[?]|MESF|EQUIVOCAL|1|steps/min|MULTIPLE BREATH WASHOUT|||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|N|1|Visit_1|10|2|SCREENING|2020-05-25|10
e|TR|6acacd87-c487-401c-8888-76ccf97b640d|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|Pack Year|FURTHER ENLARGEMENT FROM NADIR|1|mV*min|ERGOSPIROMETRY|||ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|1|WASHOUT|2020-06-09|25
e|TR|6acacd87-c487-401c-8888-76ccf97b640d|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|IU/L|DECREASED|1|kPa/L/sec|MAGNETIC RESONANCE ANGIOGRAPHY||Y|DOMESTIC PARTNER|READER 3|NA|3|Visit_3|40|4|FOLLOW-UP|2020-06-24|40
e|TR|6acacd87-c487-401c-8888-76ccf97b640d|4|[?]|LESSCIND|Lesion Success Indicator|[?]|MET*h|ENLARGEMENT FROM NADIR|1|U/g/min|FLUORESCENT SPOT TEST|||CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|NA|4|Visit_4|65|5|FOLLOW-UP|2020-07-19|65
e|TR|6acacd87-c487-401c-8888-76ccf97b640d|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|MnFI|FURTHER ENLARGEMENT|1|g|TOLUIDINE BLUE STAIN||Y|ADJUDICATION COMMITTEE|READER|Y|5|Visit_5|90|7|TREATMENT|2020-08-13|90
e|TR|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|cGy|FURTHER ENLARGEMENT|1|IU/dL|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|1|Visit_1|10|6|TREATMENT|2020-07-16|10
e|TR|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|2|[?]|LNSTATE|Lymph Node State|[?]|mL/m2/day|FURTHER ENLARGEMENT|1|DNA copies/mL|AUDIOMETRY|||INTERVIEWER|NEUROLOGIST 1|NA|2|Visit_2|25|6|TREATMENT|2020-07-31|25
e|TR|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|3|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|genEq/mL|INCREASED|1|CUP|LISSAMINE GREEN STAIN|Y||VENDOR|RADIOLOGIST|NA|3|Visit_3|40|4|WASHOUT|2020-08-15|40
e|TR|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|DAgU/mL|ENLARGEMENT|1|mL/(min*100mL)|COLORIMETRY|Y||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|4|Visit_4|65|4|TREATMENT|2020-09-09|65
e|TR|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|5|[?]|LESSCIND|Lesion Success Indicator|[?]|100 IU/mL|ENLARGEMENT|1|10^3 CFU/g|BALLPOINT PEN TECHNIQUE||Y|HEALTH CARE PROFESSIONAL|READER 1|U|5|Visit_5|90|5|TREATMENT|2020-10-04|90
e|TR|73988e01-56c0-4b31-84e2-c23ce0bac5ac|1|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|mU/g|EQUIVOCAL|1|10^9/g|POTENTIOMETRY|||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|N|1|Visit_1|10|4|WASHOUT|2021-01-03|10
e|TR|73988e01-56c0-4b31-84e2-c23ce0bac5ac|2|[?]|PCHGBL|Percent Change From Baseline|[?]|log10 TCID 50/mL|INCREASED|1|MPL U/mL|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|U|2|Visit_2|25|4|TREATMENT|2021-01-18|25
e|TR|73988e01-56c0-4b31-84e2-c23ce0bac5ac|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|g/cage|FURTHER ENLARGEMENT|1|min|PEAK FLOWMETRY|||SPOUSE|ADJUDICATOR 1|U|3|Visit_3|40|6|TREATMENT|2021-02-02|40
e|TR|73988e01-56c0-4b31-84e2-c23ce0bac5ac|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|Ci/L|PRESENT|1|/10^5|PET/CT SCAN|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|N|4|Visit_4|65|2|WASHOUT|2021-02-27|65
e|TR|73988e01-56c0-4b31-84e2-c23ce0bac5ac|5|[?]|CALCFIND|Calcification Indicator|[?]|/mm|NONPALPABLE|1|ag|AGAR PROPORTION|||SIBLING|PHYSIOTHERAPIST|U|5|Visit_5|90|2|TREATMENT|2021-03-24|90
e|TR|0670f6a3-18c9-4027-91c1-56f5555589a8|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|cm/s|ENLARGEMENT FROM NADIR|1|Farad|ANGIOGRAPHY|Y||PARENT|MICROSCOPIST|N|1|Visit_1|10|4|TREATMENT|2020-05-13|10
e|TR|0670f6a3-18c9-4027-91c1-56f5555589a8|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mU|FURTHER ENLARGEMENT FROM NADIR|1|dpm/0.5 mL|ENDOSCOPY|||CAREGIVER|READER 2|N|2|Visit_2|25|4|SCREENING|2020-05-28|25
e|TR|0670f6a3-18c9-4027-91c1-56f5555589a8|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|tuberculin unit|ABSENT|1|SPRAY|IMMUNOCHROMATOGRAPHY|||FRIEND|UROLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-06-12|40
e|TR|0670f6a3-18c9-4027-91c1-56f5555589a8|4|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|oz eq|PALPABLE|1|mm|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y||INDEPENDENT ASSESSOR|READER 2|NA|4|Visit_4|65|3|TREATMENT|2020-07-07|65
e|TR|0670f6a3-18c9-4027-91c1-56f5555589a8|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|10^9 CFU/g|NORMAL|1|mU/g|PET/CT SCAN WITHOUT CONTRAST||Y|GUARDIAN|OPHTHALMOLOGIST|Y|5|Visit_5|90|7|FOLLOW-UP|2020-08-01|90
e|TR|59179734-8784-4a88-aa6b-51b6082ffc1b|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|genEq|FOCALLY INCREASED|1|TRANSDUCING UNIT/mL|FLAME PHOTOMETRY|||PROXY|NEUROLOGIST 1|Y|1|Visit_1|10|1|TREATMENT|2020-08-11|10
e|TR|59179734-8784-4a88-aa6b-51b6082ffc1b|2|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|Ci/uL|FURTHER ENLARGEMENT FROM NADIR|1|MAC50|MICROBIAL CONCENTRATION|||INTERVIEWER|READER|Y|2|Visit_2|25|2|FOLLOW-UP|2020-08-26|25
e|TR|59179734-8784-4a88-aa6b-51b6082ffc1b|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|/wk|NONPALPABLE|1|GBq/ug|TRANSCRIPTION-MEDIATED AMPLIFICATION||Y|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|N|3|Visit_3|40|3|FOLLOW-UP|2020-09-10|40
e|TR|59179734-8784-4a88-aa6b-51b6082ffc1b|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|IU/kg|FOCALLY INCREASED|1|damol/L|AURAMINE STAIN|Y||PARENT|RATER|Y|4|Visit_4|65|1|TREATMENT|2020-10-05|65
e|TR|59179734-8784-4a88-aa6b-51b6082ffc1b|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|SUPPOSITORY|UNEQUIVOCAL|1|L/s|MAPH|||STUDY SUBJECT|ADJUDICATOR 3|Y|5|Visit_5|90|1|TREATMENT|2020-10-30|90
e|TR|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|1|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|ukat/10^12 RBC|ENLARGEMENT|1|Gy/min|DXA SCAN|||CHILD|NEUROLOGIST 1|N|1|Visit_1|10|4|FOLLOW-UP|2020-08-22|10
e|TR|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|mU/g|TUMOR MERGED|1|MET*min|ELISPOT|||VENDOR|PATHOLOGIST 2|U|2|Visit_2|25|2|TREATMENT|2020-09-06|25
e|TR|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|pg/cell|PALPABLE|1|mEq/mmol|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||HEALTH CARE PROFESSIONAL|UROLOGIST|N|3|Visit_3|40|4|SCREENING|2020-09-21|40
e|TR|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|g/animal/day|DECREASED|1|U/kg/min|ETDRS EYE CHART|||PARENT|OTOLARYNGOLOGIST|N|4|Visit_4|65|3|TREATMENT|2020-10-16|65
e|TR|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|10^7 CFU/mL|NONPALPABLE|1|g/m2/day|IMMUNOASSAY||Y|CLINICAL STUDY SPONSOR|NEUROLOGIST|Y|5|Visit_5|90|1|TREATMENT|2020-11-10|90
e|TR|01c642f8-48ef-4375-aa2b-d0940b74e580|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|cmol|EQUIVOCAL|1|GBq/mg|TOLUIDINE BLUE STAIN|Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|1|Visit_1|10|2|TREATMENT|2020-09-19|10
e|TR|01c642f8-48ef-4375-aa2b-d0940b74e580|2|[?]|DIAMETER|Diameter|[?]|Roentgen|PRESENT|1|titer|ORCHIDOMETERY|||CAREGIVER|RATER 1|Y|2|Visit_2|25|3|SCREENING|2020-10-04|25
e|TR|01c642f8-48ef-4375-aa2b-d0940b74e580|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|mCi/kg|PALPABLE|1|Newton|ELECTRONEUROGRAPHY||Y|STUDY SUBJECT|RATER 1|Y|3|Visit_3|40|4|WASHOUT|2020-10-19|40
e|TR|01c642f8-48ef-4375-aa2b-d0940b74e580|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|kcal/day|PRESENT|1|mol/mg|SLOAN LETTER EYE CHART 100%|||PROXY|MICROSCOPIST|Y|4|Visit_4|65|2|WASHOUT|2020-11-13|65
e|TR|01c642f8-48ef-4375-aa2b-d0940b74e580|5|[?]|LDIAM|Longest Diameter|[?]|BAU/mL|UNCHANGED|1|pg|GIEMSA STAIN|Y|Y|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|5|Visit_5|90|7|FOLLOW-UP|2020-12-08|90
e|TR|c0e7028c-6f5c-410a-afde-e56af2177983|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|10^10/L|PRESENT|1|CAN|MEDIASTINOSCOPY|||SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-07-06|10
e|TR|c0e7028c-6f5c-410a-afde-e56af2177983|2|[?]|BNLNUM|Number of Bone Lesions|[?]|DIOPTER|ENLARGEMENT FROM NADIR|1|mm/sec|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|Y|Y|PARENT|MICROSCOPIST 2|N|2|Visit_2|25|2|FOLLOW-UP|2020-07-21|25
e|TR|c0e7028c-6f5c-410a-afde-e56af2177983|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|/40 HPFs|PATHOLOGICAL|1|Absorbance U/min|TRYPAN BLUE STAIN|Y||ADJUDICATION COMMITTEE|RADIOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-08-05|40
e|TR|c0e7028c-6f5c-410a-afde-e56af2177983|4|[?]|LNSTATE|Lymph Node State|[?]|log10 CFU/mL|ABSENT|1|cm/s|ANALYTICAL ULTRACENTRIFUGATION||Y|INTERVIEWER|RADIOLOGIST 2|NA|4|Visit_4|65|3|WASHOUT|2020-08-30|65
e|TR|c0e7028c-6f5c-410a-afde-e56af2177983|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|BAU|UNEQUIVOCAL|1|/VF|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||SPOUSE|PATHOLOGIST 1|Y|5|Visit_5|90|5|WASHOUT|2020-09-24|90
e|TR|eba928ed-9434-4e75-b49d-169298f966e1|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|GBq/mg|PATHOLOGICAL|1|MBq/uL|FLOW MICROSCOPY|Y|Y|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|3|TREATMENT|2020-08-12|10
e|TR|eba928ed-9434-4e75-b49d-169298f966e1|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|DAgU|ABSENT|1|cGy|NEPHELOMETRY|||VENDOR|MICROSCOPIST 3|N|2|Visit_2|25|3|TREATMENT|2020-08-27|25
e|TR|eba928ed-9434-4e75-b49d-169298f966e1|3|[?]|CALCFIND|Calcification Indicator|[?]|fraction of 1|DECREASED|1|mmol|MS/MS|||GUARDIAN|RADIOLOGIST|NA|3|Visit_3|40|1|TREATMENT|2020-09-11|40
e|TR|eba928ed-9434-4e75-b49d-169298f966e1|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|g/g|PRESENT|1|grain|GC/MS-EI||Y|CLINICAL RESEARCH ASSOCIATE|RATER 1|Y|4|Visit_4|65|4|TREATMENT|2020-10-06|65
e|TR|eba928ed-9434-4e75-b49d-169298f966e1|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|mm3/mm2/year|UNEQUIVOCAL|1|Ci/mL|ELECTROMYOGRAPHY||Y|NON-HEALTH CARE PROFESSIONAL|RATER 2|U|5|Visit_5|90|7|TREATMENT|2020-10-31|90
e|TR|4772aa80-2097-4867-a549-b6f9b140f141|1|[?]|PPD|Product of Perpendicular Diameters|[?]|g/L|FURTHER ENLARGEMENT|1|GPS U|FLOW CYTOMETRY||Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|1|Visit_1|10|3|TREATMENT|2020-07-12|10
e|TR|4772aa80-2097-4867-a549-b6f9b140f141|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|/10^4|DECREASED|1|sec|IMMUNOBLOT|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|N|2|Visit_2|25|4|TREATMENT|2020-07-27|25
e|TR|4772aa80-2097-4867-a549-b6f9b140f141|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|10^7 CFU/mL|DECREASED|1|10^6 IU|PERIPHERAL ANGIOGRAPHY|||NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-08-11|40
e|TR|4772aa80-2097-4867-a549-b6f9b140f141|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|USP U|PALPABLE|1|mL/m2/min|ENDPOINT DILUTION ASSAY|||PROXY|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2020-09-05|65
e|TR|4772aa80-2097-4867-a549-b6f9b140f141|5|[?]|BNLNUM|Number of Bone Lesions|[?]|CCID 50/mL|DECREASED|1|10^6 organisms/mg|MAPH|||PARENT|RADIOLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-09-30|90
e|TR|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mL/m2/min|UNEQUIVOCAL|1|CAN|DIGITAL PCR|Y|Y|SIBLING|ONCOLOGIST 2|N|1|Visit_1|10|6|TREATMENT|2020-06-07|10
e|TR|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|ug/g/min|FURTHER ENLARGEMENT FROM NADIR|1|mm2|TOTAL BODY IRRADIATION|||PROXY|INTERNIST|NA|2|Visit_2|25|3|TREATMENT|2020-06-22|25
e|TR|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|3|[?]|SUMVOL|Sum of Volume|[?]|nkat/g Hb|ENLARGEMENT|1|ug/L FEU|THIN SMEAR|Y||NON-HEALTH CARE PROFESSIONAL|UROLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-07-07|40
e|TR|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|g/m2|INCREASED|1|10^6 organisms|MRS|Y||SIGNIFICANT OTHER|CARDIOLOGIST|Y|4|Visit_4|65|3|FOLLOW-UP|2020-08-01|65
e|TR|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|5|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|yd|ENLARGEMENT FROM NADIR|1|mJoule/cm2|THERMAL IONIZATION MASS SPECTROMETRY||Y|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|5|TREATMENT|2020-08-26|90
e|TR|4d8dd0d0-407d-4374-8345-c11f30603273|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|RATIO|NORMAL|1|10^4/hpf|ETDRS EYE CHART|||FAMILY MEMBER|ADJUDICATOR 2|NA|1|Visit_1|10|5|SCREENING|2021-01-01|10
e|TR|4d8dd0d0-407d-4374-8345-c11f30603273|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|pmol/g|EQUIVOCAL|1|CCID 50/dose|ACRIDINE ORANGE STAIN|||PARENT|PATHOLOGIST 2|U|2|Visit_2|25|2|FOLLOW-UP|2021-01-16|25
e|TR|4d8dd0d0-407d-4374-8345-c11f30603273|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|U/kg|DIFFUSELY INCREASED|1|/10^4|MOUSE PROTECTION ASSAY|||FAMILY MEMBER|OPHTHALMOLOGIST|N|3|Visit_3|40|3|WASHOUT|2021-01-31|40
e|TR|4d8dd0d0-407d-4374-8345-c11f30603273|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|Ci/mL|PATHOLOGICAL|1|vp/mL|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y|INTERVIEWER|READER 2|Y|4|Visit_4|65|5|FOLLOW-UP|2021-02-25|65
e|TR|4d8dd0d0-407d-4374-8345-c11f30603273|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|g/day|FURTHER ENLARGEMENT FROM NADIR|1|F|AUTOMATED COUNT|||INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|5|Visit_5|90|4|WASHOUT|2021-03-22|90
e|TR|6996077b-556a-47b9-bbff-20c1b4df35ea|1|[?]|LDIAM|Longest Diameter|[?]|mEq/L|EQUIVOCAL|1|beats/min|JAFFE REACTION|||FRIEND|OTOLARYNGOLOGIST|Y|1|Visit_1|10|1|FOLLOW-UP|2020-06-08|10
e|TR|6996077b-556a-47b9-bbff-20c1b4df35ea|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|min/day|PALPABLE|1|mmol/L|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||INDEPENDENT ASSESSOR|MICROSCOPIST 2|NA|2|Visit_2|25|1|FOLLOW-UP|2020-06-23|25
e|TR|6996077b-556a-47b9-bbff-20c1b4df35ea|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|IU/day|PRESENT|1|grain|GC/MS/MS|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|U|3|Visit_3|40|2|TREATMENT|2020-07-08|40
e|TR|6996077b-556a-47b9-bbff-20c1b4df35ea|4|[?]|SUMDIAM|Sum of Diameter|[?]|g/g/day|UNCHANGED|1|vg/kg|LIQUID SCINTILLATION COUNTING|Y|Y|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|4|Visit_4|65|4|TREATMENT|2020-08-02|65
e|TR|6996077b-556a-47b9-bbff-20c1b4df35ea|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|PELLET|FURTHER ENLARGEMENT FROM NADIR|1|mL/cm H2O|SURFACE PLASMON RESONANCE|Y||GUARDIAN|INTERNIST|N|5|Visit_5|90|4|TREATMENT|2020-08-27|90
e|TR|d79d31c5-d51a-46a7-b22c-20d6d483f46e|1|[?]|NEWCONF|New Tumor Confirmed|[?]|Bq/ug|DIFFUSELY INCREASED|1|kcal|AMSLER GRID|Y||NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-10-23|10
e|TR|d79d31c5-d51a-46a7-b22c-20d6d483f46e|2|[?]|LDIAM|Longest Diameter|[?]|cm/min|FURTHER ENLARGEMENT|1|g/m2/day|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||VENDOR|ADJUDICATOR 1|U|2|Visit_2|25|6|SCREENING|2020-11-07|25
e|TR|d79d31c5-d51a-46a7-b22c-20d6d483f46e|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|ng/mol|DIFFUSELY INCREASED|1|Joule|SLOAN LETTER EYE CHART 1.25%|||STUDY SUBJECT|MICROSCOPIST 1|Y|3|Visit_3|40|6|FOLLOW-UP|2020-11-22|40
e|TR|d79d31c5-d51a-46a7-b22c-20d6d483f46e|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|kcal/day|PALPABLE|1|nU/cL|MICRONEUTRALIZATION ASSAY|||VENDOR|RATER 2|U|4|Visit_4|65|4|TREATMENT|2020-12-17|65
e|TR|d79d31c5-d51a-46a7-b22c-20d6d483f46e|5|[?]|PCHGBL|Percent Change From Baseline|[?]|mL/kg|TUMOR MERGED|1|pmol/dL|DIFFUSION TENSOR MRI|Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|N|5|Visit_5|90|7|TREATMENT|2021-01-11|90
e|TR|738d539e-a810-4207-8904-fc6a5d055424|1|[?]|SUMDIAM|Sum of Diameter|[?]|U/g|TUMOR MERGED|1|nmol BCE/mmol|ANTIMICROBIAL COMBINATION TESTING|Y|Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|N|1|Visit_1|10|7|TREATMENT|2021-01-08|10
e|TR|738d539e-a810-4207-8904-fc6a5d055424|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|100 IU/mL|DECREASED|1|mL/cm H2O|SINGLE-MOLECULE ARRAY|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|U|2|Visit_2|25|1|TREATMENT|2021-01-23|25
e|TR|738d539e-a810-4207-8904-fc6a5d055424|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mmAL|NORMAL|1|MBP|INDIA INK STAIN|||PROXY|READER 2|NA|3|Visit_3|40|5|WASHOUT|2021-02-07|40
e|TR|738d539e-a810-4207-8904-fc6a5d055424|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|ukat/10^12 RBC|DIFFUSELY INCREASED|1|U/m2|CONTRAST ENHANCED X-RAY||Y|INVESTIGATOR|PATHOLOGIST 2|Y|4|Visit_4|65|1|FOLLOW-UP|2021-03-04|65
e|TR|738d539e-a810-4207-8904-fc6a5d055424|5|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|GBq/mg|TUMOR MERGED|1|ug/L DDU|TOTAL BODY RADIOGRAPHY|Y||PROXY|ONCOLOGIST 1|U|5|Visit_5|90|3|WASHOUT|2021-03-29|90
e|TR|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|nmol/day|PATHOLOGICAL|1|nmol|HEMATOXYLIN AND EOSIN STAIN|||FRIEND|PHYSIOTHERAPIST|Y|1|Visit_1|10|7|TREATMENT|2020-08-11|10
e|TR|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|2|[?]|RADIODEN|Radiodensity|[?]|PIXEL|UNEQUIVOCAL|1|scm|HPLC|||FAMILY MEMBER|DERMATOLOGIST|U|2|Visit_2|25|1|FOLLOW-UP|2020-08-26|25
e|TR|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|3|[?]|DIAMETER|Diameter|[?]|Joule|INCREASED|1|mL|CRYOSCOPY|Y||SIBLING|DERMATOLOGIST|NA|3|Visit_3|40|1|TREATMENT|2020-09-10|40
e|TR|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|ug/m2/min|INCREASED|1|lm|CELLULOSE TAPE|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|6|WASHOUT|2020-10-05|65
e|TR|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|5|[?]|SUMVOL|Sum of Volume|[?]|TAMPON|DIFFUSELY INCREASED|1|ppm|ELISPOT|||ADJUDICATOR|ONCOLOGIST 2|U|5|Visit_5|90|7|TREATMENT|2020-10-30|90
e|TR|20841d37-0444-4d1d-b934-1e805cdacdaf|1|[?]|DIAMETER|Diameter|[?]|mmol2/L2|TUMOR MERGED|1|/VF|CALIPER MEASUREMENT METHOD|Y||FRIEND|RATER 2|U|1|Visit_1|10|4|FOLLOW-UP|2020-11-22|10
e|TR|20841d37-0444-4d1d-b934-1e805cdacdaf|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|ug/mol|ENLARGEMENT FROM NADIR|1|NEEDLE GAUGE|URANYL ACETATE STAIN||Y|STUDY SUBJECT|ONCOLOGIST 2|Y|2|Visit_2|25|2|TREATMENT|2020-12-07|25
e|TR|20841d37-0444-4d1d-b934-1e805cdacdaf|3|[?]|ORVERLN|Organ Vertical Length|[?]|mEq/ug|NONPALPABLE|1|log10 CFU/g|POTENTIOMETRY|Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|N|3|Visit_3|40|2|SCREENING|2020-12-22|40
e|TR|20841d37-0444-4d1d-b934-1e805cdacdaf|4|[?]|NEWCONF|New Tumor Confirmed|[?]|L/min/m2|FURTHER ENLARGEMENT FROM NADIR|1|Sv|MRS|Y||PARENT|PATHOLOGIST 2|U|4|Visit_4|65|1|TREATMENT|2021-01-16|65
e|TR|20841d37-0444-4d1d-b934-1e805cdacdaf|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|m3|NON-PATHOLOGICAL|1|DIP|PERIPHERAL ANGIOGRAPHY|||SPOUSE|OPHTHALMOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2021-02-10|90
e|TR|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|mEq/g|NONPALPABLE|1|/day|OPTICAL DENSITY MEASUREMENT|||CAREGIVER|RADIOLOGIST|NA|1|Visit_1|10|6|FOLLOW-UP|2020-11-01|10
e|TR|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|10^5/hpf|FOCALLY INCREASED|1|Linear ft*LB|MALDI|||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|7|WASHOUT|2020-11-16|25
e|TR|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|10^9 organisms/g|DECREASED|1|kat|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||SIGNIFICANT OTHER|ADJUDICATOR|U|3|Visit_3|40|3|TREATMENT|2020-12-01|40
e|TR|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|um|PATHOLOGICAL|1|U/g|MICROSCOPY|||STUDY SUBJECT|OTOLARYNGOLOGIST|Y|4|Visit_4|65|4|TREATMENT|2020-12-26|65
e|TR|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|ug/cm2|FURTHER ENLARGEMENT|1|PNU/mL|IMMUNO-PET SCAN|Y||GUARDIAN|PEDIATRIC NEUROLOGIST|N|5|Visit_5|90|2|WASHOUT|2021-01-20|90
e|TR|d74682f1-824e-449d-bdf1-db517d8fdf2e|1|[?]|RADIODEN|Radiodensity|[?]|MASK|PALPABLE|1|10^4/hpf|CONTRAST ENHANCED PET/CT SCAN||Y|SPOUSE|UROLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-08-08|10
e|TR|d74682f1-824e-449d-bdf1-db517d8fdf2e|2|[?]|BNLNUM|Number of Bone Lesions|[?]|Bq/mL|ABSENT|1|RATIO|CISH|||SIBLING|PATHOLOGIST 1|U|2|Visit_2|25|1|TREATMENT|2020-08-23|25
e|TR|d74682f1-824e-449d-bdf1-db517d8fdf2e|3|[?]|SUMVOL|Sum of Volume|[?]|cmHg|ABSENT|1|QUANTITY SUFFICIENT|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|3|Visit_3|40|2|TREATMENT|2020-09-07|40
e|TR|d74682f1-824e-449d-bdf1-db517d8fdf2e|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|V/sec|ABSENT|1|amol|BALLPOINT PEN TECHNIQUE|||CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-10-02|65
e|TR|d74682f1-824e-449d-bdf1-db517d8fdf2e|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|log10 CFU/g|FURTHER ENLARGEMENT FROM NADIR|1|nmol/L|APPLANATION TONOMETRY|||PARENT|OTOLARYNGOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2020-10-27|90
e|TR|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|/month|NONPALPABLE|1|days/month|ANTIBIOTIC AGAR SCREEN|||PROXY|DERMATOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-12-07|10
e|TR|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|DNA copies/mL|DECREASED|1|mL/cage/wk|WESTERGREN|||INDEPENDENT ASSESSOR|ONCOLOGIST 1|U|2|Visit_2|25|3|SCREENING|2020-12-22|25
e|TR|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|RATIO|PRESENT|1|fmol/L/sec|ELASTOGRAPHY|||PROXY|READER 1|N|3|Visit_3|40|6|WASHOUT|2021-01-06|40
e|TR|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|EID 50/mL|ABSENT|1|umol/kg/min|TRICHROME STAIN|Y|Y|FRIEND|ADJUDICATOR|U|4|Visit_4|65|5|SCREENING|2021-01-31|65
e|TR|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|aMFI|TUMOR MERGED|1|CIGARETTE|DARK FIELD MICROSCOPY|||CAREGIVER|NEUROLOGIST|Y|5|Visit_5|90|4|SCREENING|2021-02-25|90
e|TR|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|1|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|log10 TCID 50/uL|FOCALLY INCREASED|1|mL/g/min|ENDOSCOPY||Y|INTERVIEWER|ONCOLOGIST 2|NA|1|Visit_1|10|7|FOLLOW-UP|2020-07-02|10
e|TR|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|Enzyme U/g Hb|UNEQUIVOCAL|1|mg/g/h|MANUAL COUNT|||ADJUDICATOR|ADJUDICATOR 3|Y|2|Visit_2|25|3|SCREENING|2020-07-17|25
e|TR|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|KALLIKREIN INHIBITOR UNIT|ENLARGEMENT|1|LENS|HPLC-UV|Y||CLINICAL STUDY SPONSOR|DERMATOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-08-01|40
e|TR|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|4|[?]|PPD|Product of Perpendicular Diameters|[?]|mg/m2|FURTHER ENLARGEMENT|1|GLOBULE|GRADIENT DIFFUSION||Y|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|7|WASHOUT|2020-08-26|65
e|TR|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|10^9 CFU/mL|UNEQUIVOCAL|1|DROP|TRANSTHORACIC ECHOCARDIOGRAPHY|Y||DOMESTIC PARTNER|INTERNIST|U|5|Visit_5|90|7|TREATMENT|2020-09-20|90
e|TR|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|1|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|U/kg/min|ABSENT|1|BISCUIT|PAP STAIN|||GUARDIAN|RADIOLOGIST|Y|1|Visit_1|10|1|SCREENING|2020-11-17|10
e|TR|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|2|[?]|VOLUME|Volume|[?]|IU/mg|PALPABLE|1|nmol/g|ELASTOGRAPHY|Y||SIBLING|RADIOLOGIST 1|U|2|Visit_2|25|1|WASHOUT|2020-12-02|25
e|TR|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|kPa/L/sec|INCREASED|1|kg/cm|MAPH|||INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|3|WASHOUT|2020-12-17|40
e|TR|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|4|[?]|ORSTATE|Organ State|[?]|BAR|ENLARGEMENT FROM NADIR|1|U/g Hb|WESTERN BLOT||Y|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|4|Visit_4|65|6|WASHOUT|2021-01-11|65
e|TR|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|5|[?]|SUMDIAM|Sum of Diameter|[?]|mg/kg|ABSENT|1|WEEKS|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y|CAREGIVER|ONCOLOGIST 2|Y|5|Visit_5|90|5|TREATMENT|2021-02-05|90
e|TR|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|umol/min|DIFFUSELY INCREASED|1|cs|INCISION-INDUCED BLEEDING METHOD|||PROXY|PATHOLOGIST 2|U|1|Visit_1|10|7|FOLLOW-UP|2020-10-27|10
e|TR|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|2|[?]|RADIODEN|Radiodensity|[?]|log10 PFU|FURTHER ENLARGEMENT|1|mg/g/min|CONTRAST ENHANCED PET/CT SCAN|||CAREGIVER|PATHOLOGIST 2|N|2|Visit_2|25|6|TREATMENT|2020-11-11|25
e|TR|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|BOLUS|NONPALPABLE|1|nmol/kg/day|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-11-26|40
e|TR|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|POINT|UNEQUIVOCAL|1|kPa/L/sec|TARGETED GENOME SEQUENCING|Y|Y|STUDY SUBJECT|ONCOLOGIST 1|U|4|Visit_4|65|1|FOLLOW-UP|2020-12-21|65
e|TR|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|5|[?]|ORSTATE|Organ State|[?]|DDU|FURTHER ENLARGEMENT FROM NADIR|1|pg/L|MICRODENSITOMETRY|||DOMESTIC PARTNER|READER 3|N|5|Visit_5|90|5|WASHOUT|2021-01-15|90
e|TR|b5644705-65e9-4d9b-9f5c-f8f62d26e257|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|HEP|ENLARGEMENT|1|10^6 organisms/mL|SCINTIGRAPHY|||ADJUDICATOR|ADJUDICATOR|NA|1|Visit_1|10|1|TREATMENT|2020-12-24|10
e|TR|b5644705-65e9-4d9b-9f5c-f8f62d26e257|2|[?]|VDIAM|Viable Diameter|[?]|10^7/L|EQUIVOCAL|1|QUANTITY SUFFICIENT|CELLULAR PROLIFERATION ASSAY||Y|CHILD|READER 1|Y|2|Visit_2|25|3|TREATMENT|2021-01-08|25
e|TR|b5644705-65e9-4d9b-9f5c-f8f62d26e257|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|m3|INCREASED|1|10^6 CFU/g|AUDIOMETRY|Y||STUDY SUBJECT|CARDIOLOGIST|Y|3|Visit_3|40|5|SCREENING|2021-01-23|40
e|TR|b5644705-65e9-4d9b-9f5c-f8f62d26e257|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|Hounsfield Unit|DIFFUSELY INCREASED|1|Gauss|PYROSEQUENCING|||HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|4|Visit_4|65|5|TREATMENT|2021-02-17|65
e|TR|b5644705-65e9-4d9b-9f5c-f8f62d26e257|5|[?]|BNLNUM|Number of Bone Lesions|[?]|mL/breath|FURTHER ENLARGEMENT|1|10^6 CFU/mL|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||INTERVIEWER|ONCOLOGIST 1|NA|5|Visit_5|90|7|FOLLOW-UP|2021-03-14|90
e|TR|ec82f59b-197a-4ccc-b5e5-d91627a86a27|1|[?]|PPD|Product of Perpendicular Diameters|[?]|ng/L|ENLARGEMENT|1|PIXELS/cm|TWO-COLOR MICROARRAY|||CLINICAL STUDY SPONSOR|ADJUDICATOR|U|1|Visit_1|10|6|SCREENING|2020-05-16|10
e|TR|ec82f59b-197a-4ccc-b5e5-d91627a86a27|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|cd|ENLARGEMENT|1|tuberculin unit/mL|FLUORESCENT SPOT TEST|Y||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-05-31|25
e|TR|ec82f59b-197a-4ccc-b5e5-d91627a86a27|3|[?]|LNSTATE|Lymph Node State|[?]|Weber|UNCHANGED|1|U/cL|PELLI-ROBSON EYE CHART|Y||ADJUDICATOR|PATHOLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-06-15|40
e|TR|ec82f59b-197a-4ccc-b5e5-d91627a86a27|4|[?]|PALPSTAT|Palpable State|[?]|BAU/mL|UNCHANGED|1|PNU/mL|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||ADJUDICATION COMMITTEE|ONCOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-07-10|65
e|TR|ec82f59b-197a-4ccc-b5e5-d91627a86a27|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|mOsm/kg|DIFFUSELY INCREASED|1|uL/kg/day|SANGER SEQUENCING|||CLINICAL STUDY SPONSOR|READER 3|NA|5|Visit_5|90|1|TREATMENT|2020-08-04|90
e|TR|527fd604-110f-47b1-bd8b-b1de2f5b0d29|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|pmol/dL|TUMOR MERGED|1|g/cm2|TRICHROME STAIN|Y||STUDY SUBJECT|READER 2|Y|1|Visit_1|10|3|WASHOUT|2020-11-29|10
e|TR|527fd604-110f-47b1-bd8b-b1de2f5b0d29|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|U/kg/min|UNEQUIVOCAL|1|Tbsp|DARK FIELD MICROSCOPY|||STUDY SUBJECT|OPHTHALMOLOGIST|N|2|Visit_2|25|5|WASHOUT|2020-12-14|25
e|TR|527fd604-110f-47b1-bd8b-b1de2f5b0d29|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|kg/cm2|DECREASED|1|g/m2/day|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||INTERVIEWER|MICROSCOPIST 1|Y|3|Visit_3|40|4|FOLLOW-UP|2020-12-29|40
e|TR|527fd604-110f-47b1-bd8b-b1de2f5b0d29|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|g/dL|PALPABLE|1|KIT|FLUORESCENT MICROSCOPY|||PROXY|INTERNIST|U|4|Visit_4|65|2|TREATMENT|2021-01-23|65
e|TR|527fd604-110f-47b1-bd8b-b1de2f5b0d29|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mol/L|TUMOR MERGED|1|ft2|AUSCULTATION||Y|DOMESTIC PARTNER|OPHTHALMOLOGIST|NA|5|Visit_5|90|1|TREATMENT|2021-02-17|90
e|TR|1e1de453-920a-4132-b2f7-6335ee81ec83|1|[?]|DIAMETER|Diameter|[?]|%/min|FURTHER ENLARGEMENT FROM NADIR|1|vg/dose|CONTRAST ENHANCED PET/CT SCAN||Y|STUDY SUBJECT|PATHOLOGIST 1|N|1|Visit_1|10|3|TREATMENT|2020-10-22|10
e|TR|1e1de453-920a-4132-b2f7-6335ee81ec83|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|DRINK|FURTHER ENLARGEMENT|1|10^6 IU/mL|LIGHT MICROSCOPY|||GUARDIAN|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|5|TREATMENT|2020-11-06|25
e|TR|1e1de453-920a-4132-b2f7-6335ee81ec83|3|[?]|DIAMETER|Diameter|[?]|VIRTUAL PIXEL|ENLARGEMENT FROM NADIR|1|BAR|PLAQUE REDUCTION NEUTRALIZATION ASSAY||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|3|Visit_3|40|7|WASHOUT|2020-11-21|40
e|TR|1e1de453-920a-4132-b2f7-6335ee81ec83|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|10^6 copies/mL|ENLARGEMENT|1|mV2/Hz|PLETHYSMOGRAPHY||Y|CLINICAL STUDY SPONSOR|RATER|N|4|Visit_4|65|7|SCREENING|2020-12-16|65
e|TR|1e1de453-920a-4132-b2f7-6335ee81ec83|5|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|amp|ENLARGEMENT FROM NADIR|1|days/month|REVERSE TRANSCRIPTASE PCR|Y|Y|ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|Y|5|Visit_5|90|6|TREATMENT|2021-01-10|90
e|TR|e553ad8e-96f4-4cb0-a005-51e9b64513b7|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|VIRTUAL PIXEL|FURTHER ENLARGEMENT|1|g/mol|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||CAREGIVER|PATHOLOGIST 1|N|1|Visit_1|10|4|FOLLOW-UP|2020-06-29|10
e|TR|e553ad8e-96f4-4cb0-a005-51e9b64513b7|2|[?]|VOLUME|Volume|[?]|km/h|UNCHANGED|1|PIPE|PEAK FLOWMETRY||Y|CAREGIVER|RADIOLOGIST 1|Y|2|Visit_2|25|2|TREATMENT|2020-07-14|25
e|TR|e553ad8e-96f4-4cb0-a005-51e9b64513b7|3|[?]|LPERP|Longest Perpendicular|[?]|ug/L|FOCALLY INCREASED|1|TRANSDUCING UNIT|NEPHELOMETRY|Y||ADJUDICATION COMMITTEE|ADJUDICATOR|Y|3|Visit_3|40|3|WASHOUT|2020-07-29|40
e|TR|e553ad8e-96f4-4cb0-a005-51e9b64513b7|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|RATIO|FURTHER ENLARGEMENT FROM NADIR|1|10^3 CFU/g|SCINTIGRAPHY|Y|Y|PROXY|MICROSCOPIST|N|4|Visit_4|65|4|WASHOUT|2020-08-23|65
e|TR|e553ad8e-96f4-4cb0-a005-51e9b64513b7|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|uV2|UNEQUIVOCAL|1|nmol/g|WRIGHT STAIN|||INVESTIGATOR|RADIOLOGIST 1|NA|5|Visit_5|90|5|WASHOUT|2020-09-17|90
e|TR|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|m|EQUIVOCAL|1|pmol/L|MEDIASTINOSCOPY|||FRIEND|OTOLARYNGOLOGIST|U|1|Visit_1|10|3|FOLLOW-UP|2020-12-16|10
e|TR|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|2|[?]|NEWCONF|New Tumor Confirmed|[?]|km|EQUIVOCAL|1|Ci|QUANTITATIVE CORONARY ANGIOGRAPHY||Y|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-12-31|25
e|TR|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|g/g|FOCALLY INCREASED|1|mL/cm|ELASTOGRAPHY||Y|SIBLING|RATER 1|Y|3|Visit_3|40|5|TREATMENT|2021-01-15|40
e|TR|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|TUBE|FURTHER ENLARGEMENT|1|C|ELECTRICAL IMPEDANCE MYOGRAPHY|||FAMILY MEMBER|UROLOGIST|Y|4|Visit_4|65|6|FOLLOW-UP|2021-02-09|65
e|TR|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|5|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mEq/L|NONPALPABLE|1|scm|AUTOMATED COUNT|||DOMESTIC PARTNER|READER 3|U|5|Visit_5|90|4|WASHOUT|2021-03-06|90
e|TR|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|COAT|PATHOLOGICAL|1|uV*sec|VENTILATION PERFUSION LUNG SCAN|Y||NON-HEALTH CARE PROFESSIONAL|RATER|NA|1|Visit_1|10|6|SCREENING|2020-06-09|10
e|TR|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|10^9 CFU/g|FURTHER ENLARGEMENT|1|Ci/g|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||PARENT|RATER 1|U|2|Visit_2|25|7|TREATMENT|2020-06-24|25
e|TR|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|ug/g/min|FURTHER ENLARGEMENT FROM NADIR|1|g/cage/wk|BRDU CELLULAR PROLIFERATION ASSAY|||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|2|TREATMENT|2020-07-09|40
e|TR|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|pptr|NON-PATHOLOGICAL|1|tsp|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||GUARDIAN|PATHOLOGIST|U|4|Visit_4|65|1|SCREENING|2020-08-03|65
e|TR|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|MASK|PRESENT|1|IMPLANT|DXA SCAN|Y||PROXY|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|6|WASHOUT|2020-08-28|90
e|TR|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|GBq|ENLARGEMENT FROM NADIR|1|ug/m2/h|ECHOCARDIOGRAPHY||Y|DOMESTIC PARTNER|DERMATOLOGIST|U|1|Visit_1|10|7|SCREENING|2020-10-29|10
e|TR|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|log10 CCID 50/dose|PATHOLOGICAL|1|IU/g|TRIPLE-PHASE SPIRAL CT SCAN||Y|VENDOR|NEUROLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-11-13|25
e|TR|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|CONTAINER|PRESENT|1|mmHg*min/L|ZIEHL NEELSEN ACID FAST STAIN|||VENDOR|MICROSCOPIST 1|NA|3|Visit_3|40|6|FOLLOW-UP|2020-11-28|40
e|TR|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|4|[?]|ORVERLN|Organ Vertical Length|[?]|F|NONPALPABLE|1|umol/mol|MAGNETIC RESONANCE ANGIOGRAPHY|||ADJUDICATOR|NEUROLOGIST 1|NA|4|Visit_4|65|3|WASHOUT|2020-12-23|65
e|TR|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|sec|NON-PATHOLOGICAL|1|mol/L|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||SPOUSE|ADJUDICATOR 2|U|5|Visit_5|90|2|WASHOUT|2021-01-17|90
e|TR|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|1|[?]|ORSTATE|Organ State|[?]|L/min/m2|DIFFUSELY INCREASED|1|V/sec|CONTRAST ENHANCED X-RAY|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-12-24|10
e|TR|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|uL/kg/day|NORMAL|1|ukat|ICP-MS|Y||PROXY|OPTOMETRIST|Y|2|Visit_2|25|7|TREATMENT|2021-01-08|25
e|TR|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|fg|NONPALPABLE|1|SYRINGE|ELECTROPHORESIS|||SIGNIFICANT OTHER|PATHOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2021-01-23|40
e|TR|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|Shock Wave|UNEQUIVOCAL|1|IU/g Hb|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||CLINICAL STUDY SPONSOR|RATER 2|N|4|Visit_4|65|3|TREATMENT|2021-02-17|65
e|TR|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|5|[?]|ORVERLN|Organ Vertical Length|[?]|Ci/L|FOCALLY INCREASED|1|U/m2/day|U-HPLC/MS/MS|Y|Y|SPOUSE|RADIOLOGIST|NA|5|Visit_5|90|5|SCREENING|2021-03-14|90
e|TR|ad04ec90-9fd5-49f2-ae23-264273eb0a24|1|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|cmH2O/mL|DIFFUSELY INCREASED|1|U/m2|PYROSEQUENCING|||ADJUDICATION COMMITTEE|PATHOLOGIST 2|U|1|Visit_1|10|6|WASHOUT|2020-10-17|10
e|TR|ad04ec90-9fd5-49f2-ae23-264273eb0a24|2|[?]|PALPSTAT|Palpable State|[?]|APS U|FOCALLY INCREASED|1|U/g/day|ULTRASOUND|||HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|2|Visit_2|25|7|SCREENING|2020-11-01|25
e|TR|ad04ec90-9fd5-49f2-ae23-264273eb0a24|3|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|TRACE|FURTHER ENLARGEMENT|1|/kg|FARR ASSAY||Y|INVESTIGATOR|MICROSCOPIST 3|N|3|Visit_3|40|7|WASHOUT|2020-11-16|40
e|TR|ad04ec90-9fd5-49f2-ae23-264273eb0a24|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|/4.0 mL|NORMAL|1|10^6 U|ANGIOGRAPHY||Y|ADJUDICATION COMMITTEE|ONCOLOGIST 2|Y|4|Visit_4|65|3|FOLLOW-UP|2020-12-11|65
e|TR|ad04ec90-9fd5-49f2-ae23-264273eb0a24|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|SFC/10^6 PBMC|PATHOLOGICAL|1|umol/L/h|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|U|5|Visit_5|90|4|TREATMENT|2021-01-05|90
e|TR|a1d203ef-7ee1-4373-988a-370532bae2b1|1|[?]|AREA|Area|[?]|Gauss|UNCHANGED|1|10^9 CFU/g|HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y||INTERVIEWER|PATHOLOGIST 2|N|1|Visit_1|10|7|TREATMENT|2021-01-28|10
e|TR|a1d203ef-7ee1-4373-988a-370532bae2b1|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mEq/g|FURTHER ENLARGEMENT FROM NADIR|1|nU/cL|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y|GUARDIAN|NEUROLOGIST|Y|2|Visit_2|25|1|WASHOUT|2021-02-12|25
e|TR|a1d203ef-7ee1-4373-988a-370532bae2b1|3|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mU/L|ENLARGEMENT FROM NADIR|1|dL|FLUOROSCOPY|||PROXY|PATHOLOGIST 1|Y|3|Visit_3|40|3|FOLLOW-UP|2021-02-27|40
e|TR|a1d203ef-7ee1-4373-988a-370532bae2b1|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|10^6 copies/mL|NON-PATHOLOGICAL|1|U/mg|SNP ARRAY|||ADJUDICATION COMMITTEE|OPTOMETRIST|N|4|Visit_4|65|1|TREATMENT|2021-03-24|65
e|TR|a1d203ef-7ee1-4373-988a-370532bae2b1|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|ug|NON-PATHOLOGICAL|1|Siemens|MANUAL CLOT DETECTION|||CHILD|OTOLARYNGOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2021-04-18|90
e|TR|4389d158-cb51-4779-b19a-f38dbef0806a|1|[?]|LDIAM|Longest Diameter|[?]|cmHg|NORMAL|1|amu|AUTOMATED COUNT||Y|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-06-22|10
e|TR|4389d158-cb51-4779-b19a-f38dbef0806a|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|BU|EQUIVOCAL|1|PACKET|TELLER ACUITY CARDS|Y||FRIEND|ONCOLOGIST 2|U|2|Visit_2|25|2|TREATMENT|2020-07-07|25
e|TR|4389d158-cb51-4779-b19a-f38dbef0806a|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|IU/dL|NONPALPABLE|1|uV|PET/MRI SCAN|||CLINICAL STUDY SPONSOR|RATER 2|U|3|Visit_3|40|6|TREATMENT|2020-07-22|40
e|TR|4389d158-cb51-4779-b19a-f38dbef0806a|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|Coulomb|NON-PATHOLOGICAL|1|ng/mol|FLUORIMETRY|Y||ADJUDICATOR|OPHTHALMOLOGIST|U|4|Visit_4|65|5|SCREENING|2020-08-16|65
e|TR|4389d158-cb51-4779-b19a-f38dbef0806a|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|V/sec|PATHOLOGICAL|1|uCi/kg|MALDI-TOF|||CLINICAL STUDY SPONSOR|DERMATOLOGIST|NA|5|Visit_5|90|5|TREATMENT|2020-09-10|90
e|TR|3a973b7a-3583-4383-b59e-3dab51b511bd|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|log10 CFU/g|INCREASED|1|IMPLANT|FORCED OSCILLATION TECHNIQUE|||CHILD|RADIOLOGIST 2|Y|1|Visit_1|10|1|TREATMENT|2021-01-19|10
e|TR|3a973b7a-3583-4383-b59e-3dab51b511bd|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|vg/dose|UNEQUIVOCAL|1|/min|IODINE STAIN|||CAREGIVER|ADJUDICATOR 2|Y|2|Visit_2|25|1|TREATMENT|2021-02-03|25
e|TR|3a973b7a-3583-4383-b59e-3dab51b511bd|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|mV*min|UNEQUIVOCAL|1|umol/min|POPULATION SEQUENCING||Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|3|Visit_3|40|7|WASHOUT|2021-02-18|40
e|TR|3a973b7a-3583-4383-b59e-3dab51b511bd|4|[?]|LPERP|Longest Perpendicular|[?]|pptr|FURTHER ENLARGEMENT|1|kcal|CELL BASED BIOASSAY|Y||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2021-03-15|65
e|TR|3a973b7a-3583-4383-b59e-3dab51b511bd|5|[?]|PPD|Product of Perpendicular Diameters|[?]|mg/kg/dose|DECREASED|1|mL/kg|MUGA|||INVESTIGATOR|OPTOMETRIST|N|5|Visit_5|90|6|TREATMENT|2021-04-09|90
e|TR|d283591c-2085-459e-94f2-d3eb6b81aea7|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|nmol BCE/nmol|PATHOLOGICAL|1|GPS U|LC/MS|Y|Y|CLINICAL RESEARCH ASSOCIATE|READER 1|Y|1|Visit_1|10|2|FOLLOW-UP|2020-09-28|10
e|TR|d283591c-2085-459e-94f2-d3eb6b81aea7|2|[?]|ORVERLN|Organ Vertical Length|[?]|umol/kg/min|ENLARGEMENT FROM NADIR|1|RING|NUCLEAR RADIOLOGY|||CAREGIVER|RATER 1|NA|2|Visit_2|25|2|TREATMENT|2020-10-13|25
e|TR|d283591c-2085-459e-94f2-d3eb6b81aea7|3|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|ugEq|UNEQUIVOCAL|1|breaths/min|KINYOUN STAIN|||PARENT|READER|U|3|Visit_3|40|1|TREATMENT|2020-10-28|40
e|TR|d283591c-2085-459e-94f2-d3eb6b81aea7|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|foz_us|TUMOR MERGED|1|ug/day|TRANSCRIPTION-MEDIATED AMPLIFICATION||Y|PARENT|MICROSCOPIST 1|NA|4|Visit_4|65|7|TREATMENT|2020-11-22|65
e|TR|d283591c-2085-459e-94f2-d3eb6b81aea7|5|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|Ci/mL|DIFFUSELY INCREASED|1|IU/L|LIGHT SCATTERING SPECTROSCOPY|||PARENT|DERMATOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-12-17|90
e|TR|da31f695-9f6a-46b2-8002-5c1c21b55cf3|1|[?]|PPD|Product of Perpendicular Diameters|[?]|mg/cm2|FURTHER ENLARGEMENT|1|mg/dose|HPLC/MS|||STUDY SUBJECT|RATER|NA|1|Visit_1|10|7|SCREENING|2020-10-01|10
e|TR|da31f695-9f6a-46b2-8002-5c1c21b55cf3|2|[?]|BNLNUM|Number of Bone Lesions|[?]|ka_u/dL|PALPABLE|1|oz|VIRUS PLAQUE ASSAY|Y||FAMILY MEMBER|MICROSCOPIST 2|Y|2|Visit_2|25|1|TREATMENT|2020-10-16|25
e|TR|da31f695-9f6a-46b2-8002-5c1c21b55cf3|3|[?]|ORSTATE|Organ State|[?]|uL/kg/day|UNCHANGED|1|GBq/ug|IMMUNORADIOMETRIC ASSAY||Y|DOMESTIC PARTNER|MICROSCOPIST 2|N|3|Visit_3|40|3|WASHOUT|2020-10-31|40
e|TR|da31f695-9f6a-46b2-8002-5c1c21b55cf3|4|[?]|BNLNUM|Number of Bone Lesions|[?]|SUPPOSITORY|ENLARGEMENT FROM NADIR|1|cy/cm|ELISA|||CLINICAL STUDY SPONSOR|MICROSCOPIST|Y|4|Visit_4|65|1|SCREENING|2020-11-25|65
e|TR|da31f695-9f6a-46b2-8002-5c1c21b55cf3|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|MET|EQUIVOCAL|1|CAPLET|MICROBIAL CONCENTRATION|Y||CLINICAL STUDY SPONSOR|DERMATOLOGIST|U|5|Visit_5|90|1|TREATMENT|2020-12-20|90
e|TR|4cd63e56-3d93-403a-8011-3b4fcf26e445|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|10^12 IU/L|NON-PATHOLOGICAL|1|%|DUKE INCISION METHOD|||INTERVIEWER|READER 2|N|1|Visit_1|10|6|FOLLOW-UP|2020-12-27|10
e|TR|4cd63e56-3d93-403a-8011-3b4fcf26e445|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|P|NONPALPABLE|1|IU/dL|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y|SIBLING|ADJUDICATOR 3|U|2|Visit_2|25|1|SCREENING|2021-01-11|25
e|TR|4cd63e56-3d93-403a-8011-3b4fcf26e445|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|pmol|UNEQUIVOCAL|1|cd/m2|IMMUNOCHROMATOGRAPHY||Y|SIGNIFICANT OTHER|PATHOLOGIST|U|3|Visit_3|40|6|TREATMENT|2021-01-26|40
e|TR|4cd63e56-3d93-403a-8011-3b4fcf26e445|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mL/cage/wk|PALPABLE|1|kg/mol|KLEIHAUER-BETKE||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|NA|4|Visit_4|65|4|TREATMENT|2021-02-20|65
e|TR|4cd63e56-3d93-403a-8011-3b4fcf26e445|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|DIOPTER|UNEQUIVOCAL|1|Bq/mg|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||INVESTIGATOR|INTERNIST|U|5|Visit_5|90|2|TREATMENT|2021-03-17|90
e|TR|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|1|[?]|PPD|Product of Perpendicular Diameters|[?]|Gravitational Unit|UNCHANGED|1|mg/mol|RADIOIMMUNOPRECIPITATION ASSAY|Y||INVESTIGATOR|READER 3|N|1|Visit_1|10|2|TREATMENT|2020-05-23|10
e|TR|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|DROP|ABSENT|1|mL/g/min|IMMUNE REPERTOIRE DEEP SEQUENCING||Y|INVESTIGATOR|ONCOLOGIST 1|N|2|Visit_2|25|2|TREATMENT|2020-06-07|25
e|TR|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|yd|DIFFUSELY INCREASED|1|hPa|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|N|3|Visit_3|40|5|WASHOUT|2020-06-22|40
e|TR|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mCi/L|DIFFUSELY INCREASED|1|cm|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y||INDEPENDENT ASSESSOR|PATHOLOGIST 1|Y|4|Visit_4|65|1|WASHOUT|2020-07-17|65
e|TR|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|5|[?]|VDIAM|Viable Diameter|[?]|pg|UNCHANGED|1|um/day|FLUORESCENT SPOT TEST|||DOMESTIC PARTNER|OPHTHALMOLOGIST|NA|5|Visit_5|90|1|WASHOUT|2020-08-11|90
e|TR|f31bab3b-3624-44a5-a62f-f8cf9055eec4|1|[?]|LESSCIND|Lesion Success Indicator|[?]|mL/animal/wk|NONPALPABLE|1|fmol/L/sec|TARGETED GENOME SEQUENCING|||SIGNIFICANT OTHER|PHYSIOTHERAPIST|U|1|Visit_1|10|5|TREATMENT|2020-08-09|10
e|TR|f31bab3b-3624-44a5-a62f-f8cf9055eec4|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|pmol/10^9 cells|ENLARGEMENT FROM NADIR|1|/mm2|TEST STRIP|||ADJUDICATION COMMITTEE|PATHOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-08-24|25
e|TR|f31bab3b-3624-44a5-a62f-f8cf9055eec4|3|[?]|ACHNAD|Absolute Change From Nadir|[?]|mmAL|DIFFUSELY INCREASED|1|uU/dL|RAJI CELL EIA|Y|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|NA|3|Visit_3|40|3|SCREENING|2020-09-08|40
e|TR|f31bab3b-3624-44a5-a62f-f8cf9055eec4|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|BU|NONPALPABLE|1|m2|SPECT SCAN||Y|CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|U|4|Visit_4|65|1|TREATMENT|2020-10-03|65
e|TR|f31bab3b-3624-44a5-a62f-f8cf9055eec4|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|m2|UNCHANGED|1|g/cage|CORONARY ANGIOGRAPHY|Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|5|Visit_5|90|7|TREATMENT|2020-10-28|90
e|TR|0b5675aa-4ec0-4548-9a0b-a13f8de89883|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|U/g/day|INCREASED|1|TUBE|CINEANGIOGRAPHY|||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|Y|1|Visit_1|10|1|TREATMENT|2020-06-28|10
e|TR|0b5675aa-4ec0-4548-9a0b-a13f8de89883|2|[?]|TUMSTATE|Tumor State|[?]|LB|DIFFUSELY INCREASED|1|PFU|DC SHEATH FLOW|Y|Y|INVESTIGATOR|NEUROLOGIST|U|2|Visit_2|25|7|WASHOUT|2020-07-13|25
e|TR|0b5675aa-4ec0-4548-9a0b-a13f8de89883|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|umol/mg/min|ABSENT|1|BAR|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y|FRIEND|RADIOLOGIST|Y|3|Visit_3|40|6|FOLLOW-UP|2020-07-28|40
e|TR|0b5675aa-4ec0-4548-9a0b-a13f8de89883|4|[?]|DIAMETER|Diameter|[?]|g/animal/day|DIFFUSELY INCREASED|1|kN/cm2|COMPUTERIZED CORNEAL TOPOGRAPHY|||ADJUDICATION COMMITTEE|ONCOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-08-22|65
e|TR|0b5675aa-4ec0-4548-9a0b-a13f8de89883|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|Pack Year|PALPABLE|1|kg|ORCHIDOMETERY|||STUDY SUBJECT|PHYSIOTHERAPIST|Y|5|Visit_5|90|3|TREATMENT|2020-09-16|90
e|TR|9bdf9856-3b2a-43db-b369-3e13868ef413|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|g/cage/day|DECREASED|1|mol/day|CORONARY ANGIOGRAPHY|||VENDOR|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|7|WASHOUT|2021-01-23|10
e|TR|9bdf9856-3b2a-43db-b369-3e13868ef413|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|PA|ENLARGEMENT|1|pkat/L|TOTAL BODY IRRADIATION|||GUARDIAN|MICROSCOPIST 1|N|2|Visit_2|25|6|WASHOUT|2021-02-07|25
e|TR|9bdf9856-3b2a-43db-b369-3e13868ef413|3|[?]|TUMSTATE|Tumor State|[?]|DNA copies/mL|PALPABLE|1|kN/cm2|PULSE OXIMETRY|||CAREGIVER|INTERNIST|N|3|Visit_3|40|5|WASHOUT|2021-02-22|40
e|TR|9bdf9856-3b2a-43db-b369-3e13868ef413|4|[?]|VDIAM|Viable Diameter|[?]|tsp eq|FURTHER ENLARGEMENT|1|pmol/L|PUPILLOMETRY|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|4|Visit_4|65|2|WASHOUT|2021-03-19|65
e|TR|9bdf9856-3b2a-43db-b369-3e13868ef413|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|vp/mL|ENLARGEMENT FROM NADIR|1|ug/kg|PET/MRI SCAN|||INDEPENDENT ASSESSOR|NEUROLOGIST 1|Y|5|Visit_5|90|5|TREATMENT|2021-04-13|90
e|TR|5cc53922-60c0-4bce-8d4a-bc59e9203d63|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|dram|DIFFUSELY INCREASED|1|IU/g|FARNSWORTH-MUNSELL 100 HUE TEST||Y|ADJUDICATOR|RADIOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-12-28|10
e|TR|5cc53922-60c0-4bce-8d4a-bc59e9203d63|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|ft3|NON-PATHOLOGICAL|1|TRANSDUCING UNIT|HPLC/MS/MS|Y||CHILD|OTOLARYNGOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2021-01-12|25
e|TR|5cc53922-60c0-4bce-8d4a-bc59e9203d63|3|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|psec|NONPALPABLE|1|kHz|IMMUNOBLOT||Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|3|Visit_3|40|7|SCREENING|2021-01-27|40
e|TR|5cc53922-60c0-4bce-8d4a-bc59e9203d63|4|[?]|LDIAM|Longest Diameter|[?]|TRANSDUCING UNIT/mL|ENLARGEMENT FROM NADIR|1|mCi|HPLC/MS|||CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|N|4|Visit_4|65|6|TREATMENT|2021-02-21|65
e|TR|5cc53922-60c0-4bce-8d4a-bc59e9203d63|5|[?]|LNSTATE|Lymph Node State|[?]|10^6/Ejaculate U|PALPABLE|1|mg/L FEU|AUDIOMETRY|||CHILD|ONCOLOGIST 1|N|5|Visit_5|90|3|FOLLOW-UP|2021-03-18|90
e|TR|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|1|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|CCID 50/dose|NONPALPABLE|1|cmol/L|MIGET|Y||SPOUSE|NEUROLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-12-29|10
e|TR|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|L/L|NORMAL|1|LOZENGE|IN SITU HYBRIDIZATION|Y|Y|GUARDIAN|MICROSCOPIST|N|2|Visit_2|25|4|TREATMENT|2021-01-13|25
e|TR|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|3|[?]|LDIAM|Longest Diameter|[?]|DROP|PRESENT|1|mEq/day|ICP-MS|||FRIEND|PATHOLOGIST|NA|3|Visit_3|40|4|FOLLOW-UP|2021-01-28|40
e|TR|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|cm2|PALPABLE|1|ng/day|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Y||FAMILY MEMBER|ENDOCRINOLOGIST|N|4|Visit_4|65|1|TREATMENT|2021-02-22|65
e|TR|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|m/sec|UNCHANGED|1|RFU|COMPLEMENT FIXATION|||ADJUDICATION COMMITTEE|NEUROLOGIST 2|U|5|Visit_5|90|4|TREATMENT|2021-03-19|90
e|TR|066281d3-27b8-439f-8340-f59115f646ef|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|L/s/kPa|NORMAL|1|ag|ISHIHARA COLOR PLATES||Y|SIGNIFICANT OTHER|UROLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-10-21|10
e|TR|066281d3-27b8-439f-8340-f59115f646ef|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|/ms|PRESENT|1|pg/dL|ENZYMATIC ULTRACENTRIFUGATION|||PARENT|NEUROLOGIST|Y|2|Visit_2|25|3|FOLLOW-UP|2020-11-05|25
e|TR|066281d3-27b8-439f-8340-f59115f646ef|3|[?]|TUMSTATE|Tumor State|[?]|BOWL|FURTHER ENLARGEMENT|1|L/L|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|||SIGNIFICANT OTHER|RADIOLOGIST|N|3|Visit_3|40|4|WASHOUT|2020-11-20|40
e|TR|066281d3-27b8-439f-8340-f59115f646ef|4|[?]|BNLNUM|Number of Bone Lesions|[?]|kg/cm|DECREASED|1|umol/L/sec|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||PARENT|INTERNIST|N|4|Visit_4|65|5|TREATMENT|2020-12-15|65
e|TR|066281d3-27b8-439f-8340-f59115f646ef|5|[?]|ORSTATE|Organ State|[?]|log10 TCID 50/uL|DECREASED|1|TUBE|FLUORESCENT IMMUNOASSAY|Y||INDEPENDENT ASSESSOR|RADIOLOGIST 2|N|5|Visit_5|90|7|TREATMENT|2021-01-09|90
e|TR|d23cc47e-da96-4042-a69f-60097beaef0e|1|[?]|DIAMETER|Diameter|[?]|PFU/animal|FURTHER ENLARGEMENT|1|DROP|THIN SMEAR||Y|CHILD|RADIOLOGIST|NA|1|Visit_1|10|4|FOLLOW-UP|2021-01-21|10
e|TR|d23cc47e-da96-4042-a69f-60097beaef0e|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|mL/animal/wk|INCREASED|1|mmol|CONTRAST ENHANCED MRI|||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|7|SCREENING|2021-02-05|25
e|TR|d23cc47e-da96-4042-a69f-60097beaef0e|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|C|ENLARGEMENT FROM NADIR|1|BAR|SCINTIGRAPHY|Y||INVESTIGATOR|RADIOLOGIST 2|U|3|Visit_3|40|2|FOLLOW-UP|2021-02-20|40
e|TR|d23cc47e-da96-4042-a69f-60097beaef0e|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mol/day|NONPALPABLE|1|mm/sec|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||INTERVIEWER|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|2|TREATMENT|2021-03-17|65
e|TR|d23cc47e-da96-4042-a69f-60097beaef0e|5|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|BAR|ABSENT|1|mL/kg/h|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y|SIGNIFICANT OTHER|READER|N|5|Visit_5|90|6|WASHOUT|2021-04-11|90
e|TR|b896c679-87d0-4e29-ad27-3944cf09b3ec|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|g/cage/wk|INCREASED|1|U/m2/day|PERFUSION MRI|||CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2021-01-02|10
e|TR|b896c679-87d0-4e29-ad27-3944cf09b3ec|2|[?]|SUMVOL|Sum of Volume|[?]|tsp|FURTHER ENLARGEMENT FROM NADIR|1|Rad|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||Y|GUARDIAN|PATHOLOGIST|Y|2|Visit_2|25|5|WASHOUT|2021-01-17|25
e|TR|b896c679-87d0-4e29-ad27-3944cf09b3ec|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|ugEq|UNCHANGED|1|mL/breath|DXA SCAN|Y|Y|STUDY SUBJECT|READER|N|3|Visit_3|40|3|TREATMENT|2021-02-01|40
e|TR|b896c679-87d0-4e29-ad27-3944cf09b3ec|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|mEq/mmol|NON-PATHOLOGICAL|1|10^12/L|RADIOGRAPHY|||GUARDIAN|ONCOLOGIST 2|N|4|Visit_4|65|4|SCREENING|2021-02-26|65
e|TR|b896c679-87d0-4e29-ad27-3944cf09b3ec|5|[?]|NEWCONF|New Tumor Confirmed|[?]|Linear ft*LB|NORMAL|1|Hz/s|CARDIAC THERMODILUTION|||CLINICAL RESEARCH COORDINATOR|READER 3|U|5|Visit_5|90|1|WASHOUT|2021-03-23|90
e|TR|6d0ec221-6eb6-4fed-806e-2bc700968333|1|[?]|VDIAM|Viable Diameter|[?]|Bq/g|FURTHER ENLARGEMENT FROM NADIR|1|cm|ORCHIDOMETERY|||SPOUSE|PHYSIOTHERAPIST|Y|1|Visit_1|10|7|TREATMENT|2020-07-27|10
e|TR|6d0ec221-6eb6-4fed-806e-2bc700968333|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|APL U|PALPABLE|1|gpELISA unit/mL|SPECULAR MICROSCOPY|||INTERVIEWER|ONCOLOGIST 1|U|2|Visit_2|25|7|FOLLOW-UP|2020-08-11|25
e|TR|6d0ec221-6eb6-4fed-806e-2bc700968333|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|DPM|PRESENT|1|%/s|MALDI-TOF|||CAREGIVER|NEUROLOGIST 2|U|3|Visit_3|40|1|WASHOUT|2020-08-26|40
e|TR|6d0ec221-6eb6-4fed-806e-2bc700968333|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|10^10/L|UNEQUIVOCAL|1|s^-1(%O2)^-1|BETA LACTAMASE|||CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|N|4|Visit_4|65|7|TREATMENT|2020-09-20|65
e|TR|6d0ec221-6eb6-4fed-806e-2bc700968333|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|BU|TUMOR MERGED|1|mV|SIZE EXCLUSION CHROMATOGRAPHY|Y||INTERVIEWER|UROLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-10-15|90
e|TR|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|1|[?]|VOLUME|Volume|[?]|Pa|INCREASED|1|/LPF|ELISA|||VENDOR|DERMATOLOGIST|NA|1|Visit_1|10|4|FOLLOW-UP|2020-10-03|10
e|TR|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|2|[?]|VSLFLIND|Vessel Failure Indicator|[?]|log10 CFU/g|FURTHER ENLARGEMENT|1|10^5/L|TWO-COLOR MICROARRAY|||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-10-18|25
e|TR|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|amu|NORMAL|1|SUPPOSITORY|SPECULAR MICROSCOPY|Y|Y|NON-HEALTH CARE PROFESSIONAL|RATER 1|U|3|Visit_3|40|4|FOLLOW-UP|2020-11-02|40
e|TR|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|U/g|PALPABLE|1|mL/m2/min|PLETHYSMOGRAPHY|||PARENT|ADJUDICATOR|N|4|Visit_4|65|5|FOLLOW-UP|2020-11-27|65
e|TR|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|vp/mL|FOCALLY INCREASED|1|pt_us|TRANSTHORACIC ECHOCARDIOGRAPHY|Y||SPOUSE|READER 2|NA|5|Visit_5|90|2|FOLLOW-UP|2020-12-22|90
e|TR|15e5e7ca-b832-450c-a20c-b21585086328|1|[?]|ORSTATE|Organ State|[?]|pmol/10^10 cells|NORMAL|1|mL/s/m2|NUCLEAR RADIOLOGY|||INTERVIEWER|READER 3|N|1|Visit_1|10|3|SCREENING|2021-01-05|10
e|TR|15e5e7ca-b832-450c-a20c-b21585086328|2|[?]|PPD|Product of Perpendicular Diameters|[?]|RATIO|UNEQUIVOCAL|1|mg/L|DOUBLE IMMUNODIFFUSION|||FRIEND|OPTOMETRIST|Y|2|Visit_2|25|7|FOLLOW-UP|2021-01-20|25
e|TR|15e5e7ca-b832-450c-a20c-b21585086328|3|[?]|ACHNAD|Absolute Change From Nadir|[?]|Bq/mg|UNEQUIVOCAL|1|uL/mL|LISSAMINE GREEN STAIN|||INDEPENDENT ASSESSOR|ADJUDICATOR 1|N|3|Visit_3|40|4|FOLLOW-UP|2021-02-04|40
e|TR|15e5e7ca-b832-450c-a20c-b21585086328|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|Hz/s|PALPABLE|1|cmH2O*s2/mL|PUPILLOMETRY|||GUARDIAN|ONCOLOGIST 2|N|4|Visit_4|65|5|TREATMENT|2021-03-01|65
e|TR|15e5e7ca-b832-450c-a20c-b21585086328|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|uIU/dL|NON-PATHOLOGICAL|1|Henry|FLUORESCEIN STAIN|||CLINICAL RESEARCH COORDINATOR|READER|U|5|Visit_5|90|4|WASHOUT|2021-03-26|90
e|TR|b46ff3a2-f257-4803-8064-e29bd1114bfc|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|/5x10^4 WBC|DIFFUSELY INCREASED|1|Absorbance U|MICROBIAL CULTURE||Y|FAMILY MEMBER|NEUROLOGIST 1|N|1|Visit_1|10|7|TREATMENT|2020-10-13|10
e|TR|b46ff3a2-f257-4803-8064-e29bd1114bfc|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|days/month|ENLARGEMENT|1|KIT|DIGITAL PCR|||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|2|Visit_2|25|5|SCREENING|2020-10-28|25
e|TR|b46ff3a2-f257-4803-8064-e29bd1114bfc|3|[?]|ACHNAD|Absolute Change From Nadir|[?]|pm|NORMAL|1|10^9 organisms/mg|AUTOREFRACTION||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|NA|3|Visit_3|40|4|TREATMENT|2020-11-12|40
e|TR|b46ff3a2-f257-4803-8064-e29bd1114bfc|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|DIP|ENLARGEMENT|1|U/g/min|SPECULAR MICROSCOPY|||ADJUDICATION COMMITTEE|PATHOLOGIST 2|N|4|Visit_4|65|1|SCREENING|2020-12-07|65
e|TR|b46ff3a2-f257-4803-8064-e29bd1114bfc|5|[?]|LPERP|Longest Perpendicular|[?]|AgU/mL|PATHOLOGICAL|1|L/s/kPa|SIZE EXCLUSION CHROMATOGRAPHY|||CLINICAL STUDY SPONSOR|READER 1|Y|5|Visit_5|90|7|FOLLOW-UP|2021-01-01|90
e|TR|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|1|[?]|NEWCONF|New Tumor Confirmed|[?]|kg/cm2|PRESENT|1|h/wk|RADIAL IMMUNODIFFUSION|||STUDY SUBJECT|ADJUDICATOR|NA|1|Visit_1|10|1|SCREENING|2020-12-06|10
e|TR|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|2|[?]|SUMVOL|Sum of Volume|[?]|DRINK|UNEQUIVOCAL|1|ug/mL/h|EIA|||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|Y|2|Visit_2|25|2|FOLLOW-UP|2020-12-21|25
e|TR|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|BP|NONPALPABLE|1|vp/mL|LANDOLT RING|Y||DOMESTIC PARTNER|RATER|Y|3|Visit_3|40|2|TREATMENT|2021-01-05|40
e|TR|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|uEq|NORMAL|1|PIXELS/in|TWO-COLOR MICROARRAY|||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|Y|4|Visit_4|65|1|TREATMENT|2021-01-30|65
e|TR|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|5|[?]|LPERP|Longest Perpendicular|[?]|DROP|PALPABLE|1|Absorbance U/mL|IMMUNOBLOT|||CHILD|READER 1|U|5|Visit_5|90|3|WASHOUT|2021-02-24|90
e|TR|a5c667d1-d2ac-49f7-ad44-bf9a44762025|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|tuberculin unit|NON-PATHOLOGICAL|1|bel|WRIGHT STAIN|||DOMESTIC PARTNER|ADJUDICATOR 3|NA|1|Visit_1|10|7|TREATMENT|2020-10-06|10
e|TR|a5c667d1-d2ac-49f7-ad44-bf9a44762025|2|[?]|LPERP|Longest Perpendicular|[?]|10^6 CFU|PALPABLE|1|pg/cell|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||CAREGIVER|RADIOLOGIST|N|2|Visit_2|25|2|SCREENING|2020-10-21|25
e|TR|a5c667d1-d2ac-49f7-ad44-bf9a44762025|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mMU/mL|FURTHER ENLARGEMENT FROM NADIR|1|EID 50/mL|ELLA|||FRIEND|ONCOLOGIST 1|Y|3|Visit_3|40|4|TREATMENT|2020-11-05|40
e|TR|a5c667d1-d2ac-49f7-ad44-bf9a44762025|4|[?]|TUMSTATE|Tumor State|[?]|mmHg/sec|PALPABLE|1|mol|SPECT/CT SCAN|Y|Y|VENDOR|ONCOLOGIST|U|4|Visit_4|65|4|TREATMENT|2020-11-30|65
e|TR|a5c667d1-d2ac-49f7-ad44-bf9a44762025|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|CFU/g|ABSENT|1|fL|REFRACTOMETRY|||GUARDIAN|OTOLARYNGOLOGIST|N|5|Visit_5|90|3|SCREENING|2020-12-25|90
e|TR|944a2627-13f1-4ecf-9545-8819a1327138|1|[?]|CALCFIND|Calcification Indicator|[?]|MASK|ENLARGEMENT|1|lx|INCISION-INDUCED BLEEDING METHOD|||INTERVIEWER|ONCOLOGIST 2|Y|1|Visit_1|10|7|FOLLOW-UP|2021-01-17|10
e|TR|944a2627-13f1-4ecf-9545-8819a1327138|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|aMFI|UNEQUIVOCAL|1|mL/cm3/min|JAEGER EYE CHART||Y|VENDOR|ADJUDICATOR 1|U|2|Visit_2|25|6|TREATMENT|2021-02-01|25
e|TR|944a2627-13f1-4ecf-9545-8819a1327138|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|10^8/L|PRESENT|1|mm3/mm2/year|CALCOFLUOR WHITE STAIN|||INVESTIGATOR|READER 3|U|3|Visit_3|40|5|SCREENING|2021-02-16|40
e|TR|944a2627-13f1-4ecf-9545-8819a1327138|4|[?]|NEWCONF|New Tumor Confirmed|[?]|DNA copies/ug|UNEQUIVOCAL|1|ug/m2|MICROBIAL CULTURE, SOLID|||STUDY SUBJECT|ADJUDICATOR|NA|4|Visit_4|65|5|TREATMENT|2021-03-13|65
e|TR|944a2627-13f1-4ecf-9545-8819a1327138|5|[?]|PPD|Product of Perpendicular Diameters|[?]|ms2|FOCALLY INCREASED|1|mmHg/sec|ELISPOT|||PARENT|RADIOLOGIST 1|NA|5|Visit_5|90|2|TREATMENT|2021-04-07|90
e|TR|7902955a-6336-45e5-a15d-7c368a28ac4f|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|/LPF|UNEQUIVOCAL|1|mg/m2/min|SNELLEN EYE CHART|Y||PROXY|INTERNIST|U|1|Visit_1|10|3|TREATMENT|2020-06-01|10
e|TR|7902955a-6336-45e5-a15d-7c368a28ac4f|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|cycle/min|UNEQUIVOCAL|1|Watt|MULTIPLE BREATH WASHOUT||Y|INDEPENDENT ASSESSOR|READER|NA|2|Visit_2|25|7|WASHOUT|2020-06-16|25
e|TR|7902955a-6336-45e5-a15d-7c368a28ac4f|3|[?]|RADIODEN|Radiodensity|[?]|BOLUS|ENLARGEMENT|1|cy/cm|ECHOCARDIOGRAPHY|||GUARDIAN|ONCOLOGIST 2|N|3|Visit_3|40|5|WASHOUT|2020-07-01|40
e|TR|7902955a-6336-45e5-a15d-7c368a28ac4f|4|[?]|LPERP|Longest Perpendicular|[?]|grain|NON-PATHOLOGICAL|1|10^7 CFU/mL|LIQUID SCINTILLATION COUNTING|||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|NA|4|Visit_4|65|3|SCREENING|2020-07-26|65
e|TR|7902955a-6336-45e5-a15d-7c368a28ac4f|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|ug/cm2|UNEQUIVOCAL|1|uL/mL|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|Y||VENDOR|ONCOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-08-20|90
e|TR|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|1|[?]|TUMSTATE|Tumor State|[?]|fL|TUMOR MERGED|1|Henry|ANTIBIOTIC AGAR SCREEN||Y|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-12-20|10
e|TR|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mEq/mL|ENLARGEMENT|1|Watt|FLOCCULATION, CHARCOAL ENHANCED|||SIBLING|ADJUDICATOR 2|U|2|Visit_2|25|3|SCREENING|2021-01-04|25
e|TR|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|3|[?]|LPERP|Longest Perpendicular|[?]|10^3 copies/mL|UNEQUIVOCAL|1|breaths/30s|COMPUTERIZED CORNEAL TOPOGRAPHY|||INTERVIEWER|INTERNIST|N|3|Visit_3|40|1|TREATMENT|2021-01-19|40
e|TR|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|deg|ABSENT|1|MPS U|BIOPSY|||STUDY SUBJECT|NEUROLOGIST|N|4|Visit_4|65|5|FOLLOW-UP|2021-02-13|65
e|TR|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|5|[?]|TUMSTATE|Tumor State|[?]|kg/m2|INCREASED|1|mEq/ug|THERMAL IONIZATION MASS SPECTROMETRY|||CLINICAL RESEARCH ASSOCIATE|INTERNIST|N|5|Visit_5|90|4|SCREENING|2021-03-10|90
e|TR|6071d81f-2f38-414f-90ca-4ad80c971054|1|[?]|DIAMETER|Diameter|[?]|cm H2O|ENLARGEMENT|1|hr/day|AGAR DILUTION|||SIGNIFICANT OTHER|MICROSCOPIST|NA|1|Visit_1|10|7|TREATMENT|2020-09-07|10
e|TR|6071d81f-2f38-414f-90ca-4ad80c971054|2|[?]|NEWCONF|New Tumor Confirmed|[?]|BU|NON-PATHOLOGICAL|1|dpm/0.5 mL|INTERRUPTER TECHNIQUE|||PARENT|ADJUDICATOR 3|U|2|Visit_2|25|2|TREATMENT|2020-09-22|25
e|TR|6071d81f-2f38-414f-90ca-4ad80c971054|3|[?]|SUMDIAM|Sum of Diameter|[?]|Sv|NONPALPABLE|1|mL/cage|NEXT GENERATION SEQUENCING|||DOMESTIC PARTNER|RADIOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-10-07|40
e|TR|6071d81f-2f38-414f-90ca-4ad80c971054|4|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|U/g/min|NON-PATHOLOGICAL|1|rpm|CONTRAST ENHANCED PET/CT SCAN|||GUARDIAN|MICROSCOPIST|Y|4|Visit_4|65|2|WASHOUT|2020-11-01|65
e|TR|6071d81f-2f38-414f-90ca-4ad80c971054|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|SPRAY|FURTHER ENLARGEMENT|1|U/mmol|DC SHEATH FLOW|Y||PARENT|OPTOMETRIST|Y|5|Visit_5|90|4|WASHOUT|2020-11-26|90
e|TR|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|1|[?]|PALPSTAT|Palpable State|[?]|umol/day|NORMAL|1|PRESSOR UNITS|SCINTIGRAPHY||Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|1|Visit_1|10|7|WASHOUT|2020-09-28|10
e|TR|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mEq/mL|ABSENT|1|scm|ERGOSPIROMETRY|Y||SPOUSE|PATHOLOGIST 2|Y|2|Visit_2|25|4|TREATMENT|2020-10-13|25
e|TR|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|uSiemens|DIFFUSELY INCREASED|1|10^8/L|CONTRAST ENHANCED MRI|||SIGNIFICANT OTHER|ADJUDICATOR 2|N|3|Visit_3|40|2|TREATMENT|2020-10-28|40
e|TR|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|s*kPa|EQUIVOCAL|1|mL/mmHg|RAJI CELL RIA|||FAMILY MEMBER|OPTOMETRIST|U|4|Visit_4|65|6|FOLLOW-UP|2020-11-22|65
e|TR|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|5|[?]|CALCFIND|Calcification Indicator|[?]|ELISA unit|INCREASED|1|ug/kg/min|IRON HEMATOXYLIN STAIN|||INVESTIGATOR|HEMATOLOGIST|Y|5|Visit_5|90|2|TREATMENT|2020-12-17|90
e|TR|a046d48d-b1fa-4d46-902e-3984aed00ec7|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|mmol/min/kPa|PALPABLE|1|uIU/L|PHOTOMETRY|Y|Y|SIBLING|ONCOLOGIST 1|N|1|Visit_1|10|4|TREATMENT|2020-08-01|10
e|TR|a046d48d-b1fa-4d46-902e-3984aed00ec7|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|COAT|ABSENT|1|APL U/mL|IMMUNOFLUORESCENT STAIN||Y|INVESTIGATOR|PHYSIOTHERAPIST|NA|2|Visit_2|25|7|TREATMENT|2020-08-16|25
e|TR|a046d48d-b1fa-4d46-902e-3984aed00ec7|3|[?]|VDIAM|Viable Diameter|[?]|/4.0 mL|INCREASED|1|kg|SLIT LAMP||Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-08-31|40
e|TR|a046d48d-b1fa-4d46-902e-3984aed00ec7|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|U/m2|NON-PATHOLOGICAL|1|g/dL|ELISPOT|||CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2020-09-25|65
e|TR|a046d48d-b1fa-4d46-902e-3984aed00ec7|5|[?]|PCHGBL|Percent Change From Baseline|[?]|km|EQUIVOCAL|1|10^9 organisms/mL|MICROBIAL CULTURE, SOLID||Y|FAMILY MEMBER|FORENSIC PATHOLOGIST|N|5|Visit_5|90|3|WASHOUT|2020-10-20|90
e|TR|8b60e1b0-2cd9-419d-b345-9006af042932|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|ppth|INCREASED|1|mL/m2/h|DISK DIFFUSION|||SPOUSE|RADIOLOGIST 2|NA|1|Visit_1|10|6|TREATMENT|2020-12-16|10
e|TR|8b60e1b0-2cd9-419d-b345-9006af042932|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mmHg|ENLARGEMENT FROM NADIR|1|APL U|CONTRAST ENHANCED MRI|Y||GUARDIAN|OTOLARYNGOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-12-31|25
e|TR|8b60e1b0-2cd9-419d-b345-9006af042932|3|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|/7.5 mL|FURTHER ENLARGEMENT FROM NADIR|1|RING|MICROBIAL CULTURE, SOLID||Y|INVESTIGATOR|ADJUDICATOR 2|U|3|Visit_3|40|1|FOLLOW-UP|2021-01-15|40
e|TR|8b60e1b0-2cd9-419d-b345-9006af042932|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|kcal/day|UNCHANGED|1|DRINK|MAGNETIC RESONANCE ELASTOGRAPHY|||INTERVIEWER|UROLOGIST|N|4|Visit_4|65|5|TREATMENT|2021-02-09|65
e|TR|8b60e1b0-2cd9-419d-b345-9006af042932|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|nmol BCE/nmol|DIFFUSELY INCREASED|1|sec|ERGOSPIROMETRY||Y|HEALTH CARE PROFESSIONAL|INTERNIST|Y|5|Visit_5|90|6|TREATMENT|2021-03-06|90
e|TR|712029bc-471a-4e3d-9123-e38b3c38bc6c|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|umol/mg/min|ENLARGEMENT|1|uCi|MALDI-TOF||Y|INTERVIEWER|MICROSCOPIST 1|Y|1|Visit_1|10|1|SCREENING|2021-01-24|10
e|TR|712029bc-471a-4e3d-9123-e38b3c38bc6c|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|copies/ug|UNCHANGED|1|mAnson U/mL|HPLC-FL||Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2021-02-08|25
e|TR|712029bc-471a-4e3d-9123-e38b3c38bc6c|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|TAMPON|TUMOR MERGED|1|mIU/L|OSCILLOMETRY||Y|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|4|TREATMENT|2021-02-23|40
e|TR|712029bc-471a-4e3d-9123-e38b3c38bc6c|4|[?]|DIAMETER|Diameter|[?]|U/g/day|PATHOLOGICAL|1|EID 50/dose|DIFFUSION WEIGHTED MRI|Y||PROXY|FORENSIC PATHOLOGIST|N|4|Visit_4|65|1|TREATMENT|2021-03-20|65
e|TR|712029bc-471a-4e3d-9123-e38b3c38bc6c|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|CIGAR|ENLARGEMENT FROM NADIR|1|uEq|ELECTRONEUROGRAPHY|||VENDOR|READER|N|5|Visit_5|90|3|FOLLOW-UP|2021-04-14|90
e|TR|92c0183d-5704-45ad-9aec-e24bc5777b80|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|L/min|DECREASED|1|ng/day|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||Y|SIGNIFICANT OTHER|MICROSCOPIST 3|NA|1|Visit_1|10|7|TREATMENT|2021-01-20|10
e|TR|92c0183d-5704-45ad-9aec-e24bc5777b80|2|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|Newton|DIFFUSELY INCREASED|1|BAU/mL|FARR ASSAY||Y|GUARDIAN|NEUROLOGIST 2|NA|2|Visit_2|25|2|SCREENING|2021-02-04|25
e|TR|92c0183d-5704-45ad-9aec-e24bc5777b80|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|Tesla|DIFFUSELY INCREASED|1|days/wk|PHOROPTER|Y|Y|PARENT|OTOLARYNGOLOGIST|Y|3|Visit_3|40|1|FOLLOW-UP|2021-02-19|40
e|TR|92c0183d-5704-45ad-9aec-e24bc5777b80|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|Bq/mL|NORMAL|1|CIGAR|PET/CT SCAN|||CHILD|ADJUDICATOR 1|NA|4|Visit_4|65|7|TREATMENT|2021-03-16|65
e|TR|92c0183d-5704-45ad-9aec-e24bc5777b80|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|log10 IU/mL|NONPALPABLE|1|mL/s|SLOAN LETTER EYE CHART 1.25%|||CHILD|RATER 1|Y|5|Visit_5|90|1|TREATMENT|2021-04-10|90
e|TR|52ce3b1f-9500-4323-861d-73c8b96f59de|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|Log10 ELISA unit/dose|UNEQUIVOCAL|1|s*kPa|GC/MS-CI||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|1|Visit_1|10|3|FOLLOW-UP|2020-10-26|10
e|TR|52ce3b1f-9500-4323-861d-73c8b96f59de|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mAmp|PALPABLE|1|BEAM BREAKS|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||CAREGIVER|ADJUDICATOR 2|Y|2|Visit_2|25|2|SCREENING|2020-11-10|25
e|TR|52ce3b1f-9500-4323-861d-73c8b96f59de|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|fmol/L/sec|NON-PATHOLOGICAL|1|Sv|IMMUNODIFFUSION|||FRIEND|READER 2|NA|3|Visit_3|40|3|WASHOUT|2020-11-25|40
e|TR|52ce3b1f-9500-4323-861d-73c8b96f59de|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|MBq|ABSENT|1|uL/kg/day|LINE PROBE ASSAY||Y|INTERVIEWER|ENDOCRINOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2020-12-20|65
e|TR|52ce3b1f-9500-4323-861d-73c8b96f59de|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|Gauss|ENLARGEMENT|1|mL/g/h|TRANSVAGINAL ULTRASOUND|Y||SIBLING|UROLOGIST|U|5|Visit_5|90|6|SCREENING|2021-01-14|90
e|TR|3655d198-2e7e-419e-8337-d7eea7d795ca|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|m2|PRESENT|1|FFU|KINETIC MICROPARTICLE IMMUNOASSAY|Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|N|1|Visit_1|10|2|TREATMENT|2020-11-23|10
e|TR|3655d198-2e7e-419e-8337-d7eea7d795ca|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|IU/L|FURTHER ENLARGEMENT FROM NADIR|1|pmol/L/h|CONTRAST ENHANCED MRI|||SPOUSE|PATHOLOGIST 1|NA|2|Visit_2|25|3|TREATMENT|2020-12-08|25
e|TR|3655d198-2e7e-419e-8337-d7eea7d795ca|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|dram|FURTHER ENLARGEMENT FROM NADIR|1|mEq/g|URANYL ACETATE STAIN|Y||SIGNIFICANT OTHER|ONCOLOGIST|N|3|Visit_3|40|7|TREATMENT|2020-12-23|40
e|TR|3655d198-2e7e-419e-8337-d7eea7d795ca|4|[?]|SUMVOL|Sum of Volume|[?]|BLOCKS|ENLARGEMENT|1|mEq/g|MEDIASTINOSCOPY|||GUARDIAN|CARDIOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2021-01-17|65
e|TR|3655d198-2e7e-419e-8337-d7eea7d795ca|5|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|v/v|ABSENT|1|mg/mL/min|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||CLINICAL RESEARCH COORDINATOR|UROLOGIST|NA|5|Visit_5|90|4|TREATMENT|2021-02-11|90
e|TR|d47da6bf-8abf-4b62-8bb8-797155981158|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|PA|ABSENT|1|mg/m2|CELLULOSE TAPE|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-09-10|10
e|TR|d47da6bf-8abf-4b62-8bb8-797155981158|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|Tesla|ENLARGEMENT FROM NADIR|1|10^9/g|ENDOSCOPY||Y|FRIEND|ONCOLOGIST 1|NA|2|Visit_2|25|3|TREATMENT|2020-09-25|25
e|TR|d47da6bf-8abf-4b62-8bb8-797155981158|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|CAPFUL|NON-PATHOLOGICAL|1|dyn|ACRIDINE ORANGE STAIN|||INDEPENDENT ASSESSOR|ADJUDICATOR 3|Y|3|Visit_3|40|3|TREATMENT|2020-10-10|40
e|TR|d47da6bf-8abf-4b62-8bb8-797155981158|4|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|GPL U/mL|PRESENT|1|FFU|MICROBIAL CONCENTRATION|||INTERVIEWER|ONCOLOGIST 2|U|4|Visit_4|65|4|TREATMENT|2020-11-04|65
e|TR|d47da6bf-8abf-4b62-8bb8-797155981158|5|[?]|SUMVOL|Sum of Volume|[?]|10^6 IU/mL|INCREASED|1|kPa/L/sec|TRANSTHORACIC ECHOCARDIOGRAPHY|||VENDOR|PATHOLOGIST 1|NA|5|Visit_5|90|7|FOLLOW-UP|2020-11-29|90
e|TR|25e81c81-8c23-4c9e-be79-35247384dd1f|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|g/m2|FOCALLY INCREASED|1|mL/kg|IHC|||CLINICAL STUDY SPONSOR|NEUROLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-08-08|10
e|TR|25e81c81-8c23-4c9e-be79-35247384dd1f|2|[?]|DIAMETER|Diameter|[?]|lx|FURTHER ENLARGEMENT|1|GLOBULE|FLAME PHOTOMETRY|Y||CHILD|CARDIOLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-08-23|25
e|TR|25e81c81-8c23-4c9e-be79-35247384dd1f|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|usec|PATHOLOGICAL|1|mL*cmH2O|MYELOPEROXIDASE STAIN|||CAREGIVER|ADJUDICATOR 2|NA|3|Visit_3|40|7|TREATMENT|2020-09-07|40
e|TR|25e81c81-8c23-4c9e-be79-35247384dd1f|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|mg/mL/day|ABSENT|1|TROCHE|MOUSE PROTECTION ASSAY|Y|Y|CAREGIVER|MICROSCOPIST 3|NA|4|Visit_4|65|5|SCREENING|2020-10-02|65
e|TR|25e81c81-8c23-4c9e-be79-35247384dd1f|5|[?]|VDIAM|Viable Diameter|[?]|days/month|TUMOR MERGED|1|mL/day|RIA|Y||CHILD|MICROSCOPIST|Y|5|Visit_5|90|2|TREATMENT|2020-10-27|90
e|TR|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|1|[?]|ORVERLN|Organ Vertical Length|[?]|g/animal/wk|PATHOLOGICAL|1|MET*min|LASER CAPTURE MICRODISSECTION|||PARENT|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|4|WASHOUT|2020-07-27|10
e|TR|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|kg/cm|NONPALPABLE|1|10^9/g|ACID FAST STAIN|Y||SIBLING|RADIOLOGIST|N|2|Visit_2|25|2|WASHOUT|2020-08-11|25
e|TR|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|U.CARR|DECREASED|1|h/wk|IN SITU HYBRIDIZATION|||ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-08-26|40
e|TR|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|steps/min|FURTHER ENLARGEMENT FROM NADIR|1|Gy|REVERSE TRANSCRIPTASE PCR||Y|FAMILY MEMBER|INTERNIST|NA|4|Visit_4|65|4|TREATMENT|2020-09-20|65
e|TR|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|5|[?]|AREA|Area|[?]|U/mL|UNEQUIVOCAL|1|breaths/min|OPTICAL DENSITY MEASUREMENT|||STUDY SUBJECT|MICROSCOPIST 1|N|5|Visit_5|90|5|SCREENING|2020-10-15|90
e|TR|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|ug|DECREASED|1|mg/g/h|DC SHEATH FLOW|||DOMESTIC PARTNER|READER 2|U|1|Visit_1|10|2|SCREENING|2020-11-12|10
e|TR|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|copies/ug|ENLARGEMENT FROM NADIR|1|ug/dL|LISSAMINE GREEN STAIN|Y||PROXY|ADJUDICATOR|N|2|Visit_2|25|4|TREATMENT|2020-11-27|25
e|TR|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|nmol|FURTHER ENLARGEMENT|1|ohm|PHOTOGRAPHY||Y|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|3|TREATMENT|2020-12-12|40
e|TR|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|4|[?]|LDIAM|Longest Diameter|[?]|ng/dL|NORMAL|1|Osm|POTENTIOMETRY|Y||STUDY SUBJECT|INTERNIST|N|4|Visit_4|65|2|FOLLOW-UP|2021-01-06|65
e|TR|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|5|[?]|ORSTATE|Organ State|[?]|anti-Xa IU|EQUIVOCAL|1|10^9 CFU/g|ENZYMATIC COLORIMETRY|Y|Y|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|N|5|Visit_5|90|7|TREATMENT|2021-01-31|90
e|TR|5ba70148-c29b-47af-9280-10d1a942380a|1|[?]|DIAMETER|Diameter|[?]|BOX|PATHOLOGICAL|1|nkat|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||Y|ADJUDICATION COMMITTEE|RATER|Y|1|Visit_1|10|7|SCREENING|2020-11-28|10
e|TR|5ba70148-c29b-47af-9280-10d1a942380a|2|[?]|DIAMETER|Diameter|[?]|ug/h|NORMAL|1|mmol/min/kPa/L|NON-INVASIVE DIELECTRIC SENSING||Y|FAMILY MEMBER|READER|NA|2|Visit_2|25|2|TREATMENT|2020-12-13|25
e|TR|5ba70148-c29b-47af-9280-10d1a942380a|3|[?]|ORSTATE|Organ State|[?]|DDU|FURTHER ENLARGEMENT FROM NADIR|1|/cmH2O|FLUORESCENCE ANGIOGRAPHY|||DOMESTIC PARTNER|MICROSCOPIST 3|NA|3|Visit_3|40|5|TREATMENT|2020-12-28|40
e|TR|5ba70148-c29b-47af-9280-10d1a942380a|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|/sec|TUMOR MERGED|1|10^3 organisms/mL|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||Y|CAREGIVER|MICROSCOPIST 2|U|4|Visit_4|65|4|SCREENING|2021-01-22|65
e|TR|5ba70148-c29b-47af-9280-10d1a942380a|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|V|FURTHER ENLARGEMENT FROM NADIR|1|PATCH|HPLC/MS|Y||CAREGIVER|NEUROLOGIST 2|Y|5|Visit_5|90|1|WASHOUT|2021-02-16|90
e|TR|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|vp/mL|ENLARGEMENT FROM NADIR|1|tuberculin unit/mL|SLIT LAMP PHOTOGRAPHY|||CAREGIVER|OPTOMETRIST|NA|1|Visit_1|10|4|TREATMENT|2020-05-27|10
e|TR|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|ohm|FURTHER ENLARGEMENT FROM NADIR|1|mL/cage/wk|TRIPLE-PHASE MRI SCAN|||INVESTIGATOR|READER 2|NA|2|Visit_2|25|4|TREATMENT|2020-06-11|25
e|TR|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mg|TUMOR MERGED|1|ppb|TRANSVAGINAL ULTRASOUND|||GUARDIAN|INTERNIST|N|3|Visit_3|40|7|TREATMENT|2020-06-26|40
e|TR|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|PACK|NONPALPABLE|1|Ci/mL|MALDI-TOF|||INVESTIGATOR|READER 3|Y|4|Visit_4|65|6|TREATMENT|2020-07-21|65
e|TR|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mg/dose|UNCHANGED|1|pmol|MS/MS||Y|ADJUDICATOR|MICROSCOPIST|U|5|Visit_5|90|5|WASHOUT|2020-08-15|90
e|TR|2d8f8b1e-7914-400b-afc5-8dc23a626d76|1|[?]|BNLNUM|Number of Bone Lesions|[?]|g/day|EQUIVOCAL|1|ft3|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|Y||FAMILY MEMBER|RATER 1|NA|1|Visit_1|10|2|SCREENING|2020-06-19|10
e|TR|2d8f8b1e-7914-400b-afc5-8dc23a626d76|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|uL|FOCALLY INCREASED|1|ug/L|WHOLE EXOME SEQUENCING|Y||ADJUDICATION COMMITTEE|ADJUDICATOR|Y|2|Visit_2|25|2|FOLLOW-UP|2020-07-04|25
e|TR|2d8f8b1e-7914-400b-afc5-8dc23a626d76|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|log10 TCID 50/uL|ENLARGEMENT|1|Gy|U-HPLC/MS/MS||Y|PROXY|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-07-19|40
e|TR|2d8f8b1e-7914-400b-afc5-8dc23a626d76|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mmAL|INCREASED|1|U.CARR|IMMUNOPRECIPITATION||Y|VENDOR|MICROSCOPIST 3|Y|4|Visit_4|65|6|TREATMENT|2020-08-13|65
e|TR|2d8f8b1e-7914-400b-afc5-8dc23a626d76|5|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|QUANTITY SUFFICIENT|DECREASED|1|Anson U|INCISION-INDUCED BLEEDING METHOD|||PROXY|PHYSIOTHERAPIST|Y|5|Visit_5|90|2|TREATMENT|2020-09-07|90
e|TR|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|tuberculin unit|TUMOR MERGED|1|tuberculin unit/mL|QUANTITATIVE COMPUTED TOMOGRAPHY|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|N|1|Visit_1|10|1|SCREENING|2020-08-20|10
e|TR|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|min/day|EQUIVOCAL|1|Osm|THIN SMEAR|Y||SIGNIFICANT OTHER|ONCOLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-09-04|25
e|TR|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|mmHg/sec|DIFFUSELY INCREASED|1|ppth|RADIOGRAPHY|||PROXY|ONCOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-09-19|40
e|TR|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|cm H2O|ENLARGEMENT FROM NADIR|1|CAN|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||STUDY SUBJECT|READER|NA|4|Visit_4|65|6|TREATMENT|2020-10-14|65
e|TR|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mEq/day|FOCALLY INCREASED|1|mL/cage|FORCED OSCILLATION TECHNIQUE||Y|GUARDIAN|ONCOLOGIST 2|N|5|Visit_5|90|3|SCREENING|2020-11-08|90
e|TR|a73142e4-e34b-4144-b95f-7a5562574c1b|1|[?]|CALCFIND|Calcification Indicator|[?]|Weber|UNCHANGED|1|PUFF|TARGETED GENOME SEQUENCING|Y|Y|INDEPENDENT ASSESSOR|READER|Y|1|Visit_1|10|6|TREATMENT|2020-08-08|10
e|TR|a73142e4-e34b-4144-b95f-7a5562574c1b|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|cm|TUMOR MERGED|1|/sec|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||PROXY|READER|NA|2|Visit_2|25|1|TREATMENT|2020-08-23|25
e|TR|a73142e4-e34b-4144-b95f-7a5562574c1b|3|[?]|PPD|Product of Perpendicular Diameters|[?]|mEq/dL|UNEQUIVOCAL|1|mg/m2/day|DC SHEATH FLOW|||STUDY SUBJECT|FORENSIC PATHOLOGIST|N|3|Visit_3|40|5|WASHOUT|2020-09-07|40
e|TR|a73142e4-e34b-4144-b95f-7a5562574c1b|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mL/s/m2|NONPALPABLE|1|aMFI|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||Y|PROXY|RATER 1|NA|4|Visit_4|65|1|TREATMENT|2020-10-02|65
e|TR|a73142e4-e34b-4144-b95f-7a5562574c1b|5|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|U/L|EQUIVOCAL|1|CIGAR|PELLI-ROBSON EYE CHART|||ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|Y|5|Visit_5|90|1|FOLLOW-UP|2020-10-27|90
e|TR|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|genEq|NON-PATHOLOGICAL|1|mL/s/m2|FLUOROSCOPY|||INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|2|SCREENING|2020-06-03|10
e|TR|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|U/animal|NONPALPABLE|1|TRANSDUCING UNIT|SPECT SCAN|Y|Y|SPOUSE|ADJUDICATOR|N|2|Visit_2|25|5|WASHOUT|2020-06-18|25
e|TR|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|3|[?]|RADIODEN|Radiodensity|[?]|DIOPTER|PRESENT|1|mmHg/sec|ENZYMATIC SPECTROPHOTOMETRY|Y||NON-HEALTH CARE PROFESSIONAL|UROLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-07-03|40
e|TR|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|kN/cm2|EQUIVOCAL|1|Hz|MICROBIAL CONCENTRATION|||SPOUSE|ONCOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-07-28|65
e|TR|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|5|[?]|CALCFIND|Calcification Indicator|[?]|IMPLANT|FOCALLY INCREASED|1|mmHg/sec|U-HPLC/MS/MS||Y|ADJUDICATOR|ENDOCRINOLOGIST|U|5|Visit_5|90|1|TREATMENT|2020-08-22|90
e|TR|0f682806-b63c-4c3f-9fda-1e59befbd3a3|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|RING|FOCALLY INCREASED|1|fmol/L|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|Y|Y|CHILD|DERMATOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-05-29|10
e|TR|0f682806-b63c-4c3f-9fda-1e59befbd3a3|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|10^9 organisms|ENLARGEMENT|1|mg/kg/day|RADIOGRAPHY|||HEALTH CARE PROFESSIONAL|READER 1|NA|2|Visit_2|25|6|FOLLOW-UP|2020-06-13|25
e|TR|0f682806-b63c-4c3f-9fda-1e59befbd3a3|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|EID 50/mL|DIFFUSELY INCREASED|1|mL/cage|COULOMETRIC TITRATION|||FRIEND|RADIOLOGIST 2|Y|3|Visit_3|40|1|WASHOUT|2020-06-28|40
e|TR|0f682806-b63c-4c3f-9fda-1e59befbd3a3|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|amol|NONPALPABLE|1|10^8/L|COLORIMETRY|||HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|4|Visit_4|65|7|TREATMENT|2020-07-23|65
e|TR|0f682806-b63c-4c3f-9fda-1e59befbd3a3|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|mm/min|ENLARGEMENT FROM NADIR|1|ug|LINE PROBE ASSAY|Y|Y|HEALTH CARE PROFESSIONAL|READER 1|NA|5|Visit_5|90|1|SCREENING|2020-08-17|90
e|TR|1d8aba56-f62e-4116-b447-899dedd3d4df|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|DDU|NONPALPABLE|1|U/m2/h|TONOMETRY|||PARENT|CLINICAL PATHOLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-09-29|10
e|TR|1d8aba56-f62e-4116-b447-899dedd3d4df|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|Log10 ELISA unit|NONPALPABLE|1|gtt|HIGH RESOLUTION MELT ANALYSIS|||PROXY|READER|NA|2|Visit_2|25|7|FOLLOW-UP|2020-10-14|25
e|TR|1d8aba56-f62e-4116-b447-899dedd3d4df|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|min|PATHOLOGICAL|1|/4.0 mL|LYMPHANGIOGRAPHY||Y|VENDOR|NEUROLOGIST 1|NA|3|Visit_3|40|1|TREATMENT|2020-10-29|40
e|TR|1d8aba56-f62e-4116-b447-899dedd3d4df|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|BOLUS|ABSENT|1|nL|HEMAGGLUTINATION INHIBITION ASSAY||Y|SIBLING|RATER 2|NA|4|Visit_4|65|7|TREATMENT|2020-11-23|65
e|TR|1d8aba56-f62e-4116-b447-899dedd3d4df|5|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|/mm|FURTHER ENLARGEMENT FROM NADIR|1|cm/s|IMPULSE OSCILLOMETRY|||ADJUDICATION COMMITTEE|RATER 1|Y|5|Visit_5|90|1|WASHOUT|2020-12-18|90
e|TR|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|umol|ABSENT|1|NEBULE|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||CLINICAL RESEARCH ASSOCIATE|UROLOGIST|Y|1|Visit_1|10|1|SCREENING|2020-08-14|10
e|TR|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|ELISA unit|FURTHER ENLARGEMENT FROM NADIR|1|%/s|DISK DIFFUSION||Y|PARENT|RATER|N|2|Visit_2|25|2|FOLLOW-UP|2020-08-29|25
e|TR|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|3|[?]|BNLNUM|Number of Bone Lesions|[?]|dB|DIFFUSELY INCREASED|1|L/h|FLOW MICROSCOPY|Y||HEALTH CARE PROFESSIONAL|UROLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-09-13|40
e|TR|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|dpm/mL|DECREASED|1|rpm|QUANTITATIVE CORONARY ANGIOGRAPHY|Y||VENDOR|READER 1|Y|4|Visit_4|65|2|TREATMENT|2020-10-08|65
e|TR|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|5|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|cs|NON-PATHOLOGICAL|1|mL/animal/wk|PUPILLOMETRY||Y|ADJUDICATOR|ENDOCRINOLOGIST|Y|5|Visit_5|90|5|SCREENING|2020-11-02|90
e|TR|383d3f30-14b7-48c3-b1a8-0f481ef37a50|1|[?]|NEWCONF|New Tumor Confirmed|[?]|ug/min|UNEQUIVOCAL|1|mMU/mL|SNELLEN EYE CHART|||INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|7|SCREENING|2020-06-07|10
e|TR|383d3f30-14b7-48c3-b1a8-0f481ef37a50|2|[?]|SUMDIAM|Sum of Diameter|[?]|cm|PRESENT|1|eq|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|Y|INVESTIGATOR|RATER|N|2|Visit_2|25|5|SCREENING|2020-06-22|25
e|TR|383d3f30-14b7-48c3-b1a8-0f481ef37a50|3|[?]|BNLNUM|Number of Bone Lesions|[?]|deg/s|FURTHER ENLARGEMENT FROM NADIR|1|dB|MICRODENSITOMETRY|||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-07-07|40
e|TR|383d3f30-14b7-48c3-b1a8-0f481ef37a50|4|[?]|LNSTATE|Lymph Node State|[?]|kg/cm2|TUMOR MERGED|1|Hounsfield Unit|FREEZING POINT DEPRESSION|||SIBLING|MICROSCOPIST 1|Y|4|Visit_4|65|2|SCREENING|2020-08-01|65
e|TR|383d3f30-14b7-48c3-b1a8-0f481ef37a50|5|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|EP U|UNCHANGED|1|JDF Unit|PULMONARY ANGIOGRAPHY|Y||ADJUDICATOR|PATHOLOGIST 2|Y|5|Visit_5|90|2|SCREENING|2020-08-26|90
e|TR|b4f81b74-fee9-4544-9404-206d931ed8e5|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|kg/cm|PATHOLOGICAL|1|mmHg*min/L|QUANTITATIVE CORONARY ANGIOGRAPHY|||CHILD|OTOLARYNGOLOGIST|N|1|Visit_1|10|1|WASHOUT|2020-10-18|10
e|TR|b4f81b74-fee9-4544-9404-206d931ed8e5|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|mol/L|PALPABLE|1|km/h|PEAK FLOWMETRY|||INVESTIGATOR|ONCOLOGIST 1|U|2|Visit_2|25|2|WASHOUT|2020-11-02|25
e|TR|b4f81b74-fee9-4544-9404-206d931ed8e5|3|[?]|NEWCONF|New Tumor Confirmed|[?]|10^6 RNA copies/mL|DIFFUSELY INCREASED|1|nmol/day|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||Y|INTERVIEWER|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|4|FOLLOW-UP|2020-11-17|40
e|TR|b4f81b74-fee9-4544-9404-206d931ed8e5|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|AgU/mL|PATHOLOGICAL|1|LB|CELL BASED BIOASSAY|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|4|Visit_4|65|7|TREATMENT|2020-12-12|65
e|TR|b4f81b74-fee9-4544-9404-206d931ed8e5|5|[?]|DIAMETER|Diameter|[?]|hPa|NORMAL|1|AMPULE|LIGHT MICROSCOPY|||STUDY SUBJECT|READER 1|NA|5|Visit_5|90|6|TREATMENT|2021-01-06|90
e|TR|9e69b457-20db-45e5-a535-0cd8ac102fea|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|CONTAINER|ABSENT|1|dpm/mg|KNEMOMETRY|Y|Y|STUDY SUBJECT|NEUROLOGIST 2|Y|1|Visit_1|10|1|TREATMENT|2020-06-07|10
e|TR|9e69b457-20db-45e5-a535-0cd8ac102fea|2|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|g/animal|FURTHER ENLARGEMENT|1|mg/g/h|CORONARY ANGIOGRAPHY|||ADJUDICATOR|READER 1|N|2|Visit_2|25|6|TREATMENT|2020-06-22|25
e|TR|9e69b457-20db-45e5-a535-0cd8ac102fea|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|DRINK|UNCHANGED|1|IU/day|MANUAL COUNT|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-07-07|40
e|TR|9e69b457-20db-45e5-a535-0cd8ac102fea|4|[?]|PCHGBL|Percent Change From Baseline|[?]|g/cm2|NON-PATHOLOGICAL|1|EVENTS|ULTRASONOGRAPHIC ELASTOGRAPHY|Y|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|N|4|Visit_4|65|2|FOLLOW-UP|2020-08-01|65
e|TR|9e69b457-20db-45e5-a535-0cd8ac102fea|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|MONTHS|FOCALLY INCREASED|1|mg/m2|MAGNETIC RESONANCE ANGIOGRAPHY|Y||DOMESTIC PARTNER|ENDOCRINOLOGIST|U|5|Visit_5|90|4|TREATMENT|2020-08-26|90
e|TR|14211798-ddf6-47c8-bd9d-056d95bad8ff|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|foz_br|UNCHANGED|1|MESF|RAJI CELL RIA|||FRIEND|MICROSCOPIST|U|1|Visit_1|10|5|WASHOUT|2020-09-26|10
e|TR|14211798-ddf6-47c8-bd9d-056d95bad8ff|2|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|/ms|INCREASED|1|mL/m2/day|JAFFE REACTION||Y|CHILD|ONCOLOGIST 2|NA|2|Visit_2|25|2|TREATMENT|2020-10-11|25
e|TR|14211798-ddf6-47c8-bd9d-056d95bad8ff|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|SQU/mL|FURTHER ENLARGEMENT|1|pt_br|VIRUS PLAQUE ASSAY|Y||SIBLING|RADIOLOGIST 2|U|3|Visit_3|40|7|WASHOUT|2020-10-26|40
e|TR|14211798-ddf6-47c8-bd9d-056d95bad8ff|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|ng/dL|ENLARGEMENT FROM NADIR|1|/5x10^4 WBC|TARGETED GENOME SEQUENCING||Y|STUDY SUBJECT|NEUROLOGIST|Y|4|Visit_4|65|4|WASHOUT|2020-11-20|65
e|TR|14211798-ddf6-47c8-bd9d-056d95bad8ff|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|DRUM|PATHOLOGICAL|1|EU|CINEANGIOGRAPHY|Y||SIBLING|READER 1|N|5|Visit_5|90|7|SCREENING|2020-12-15|90
e|TR|63f3194e-9b88-491a-9a68-19109ed86e2b|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|dram|ENLARGEMENT FROM NADIR|1|ug/L/h|POLYSOMNOGRAPHY|||SIBLING|ADJUDICATOR|N|1|Visit_1|10|1|FOLLOW-UP|2020-06-10|10
e|TR|63f3194e-9b88-491a-9a68-19109ed86e2b|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|DRINK|PALPABLE|1|APS U|PULMONARY ANGIOGRAPHY|||PARENT|NEUROLOGIST 2|U|2|Visit_2|25|1|SCREENING|2020-06-25|25
e|TR|63f3194e-9b88-491a-9a68-19109ed86e2b|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|mg/kg/min|FURTHER ENLARGEMENT FROM NADIR|1|mEq/mL|IMMUNOFLUORESCENT STAIN|Y||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|3|Visit_3|40|1|WASHOUT|2020-07-10|40
e|TR|63f3194e-9b88-491a-9a68-19109ed86e2b|4|[?]|BNLNUM|Number of Bone Lesions|[?]|mm3/mm2/year|NORMAL|1|ELISA unit/dose|TOTAL BODY RADIOGRAPHY|||INDEPENDENT ASSESSOR|NEUROLOGIST|Y|4|Visit_4|65|4|FOLLOW-UP|2020-08-04|65
e|TR|63f3194e-9b88-491a-9a68-19109ed86e2b|5|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|uL|UNEQUIVOCAL|1|copies/ug|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||PROXY|PATHOLOGIST 2|N|5|Visit_5|90|2|TREATMENT|2020-08-29|90
e|TR|b6208258-d7c2-4dde-addf-4677946ab165|1|[?]|RADIODEN|Radiodensity|[?]|m3|FURTHER ENLARGEMENT|1|ohm|AGAR DILUTION|Y||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|1|Visit_1|10|6|TREATMENT|2020-09-20|10
e|TR|b6208258-d7c2-4dde-addf-4677946ab165|2|[?]|LDIAM|Longest Diameter|[?]|breaths/30s|FURTHER ENLARGEMENT FROM NADIR|1|QUANTITY SUFFICIENT|OBSERVATION|||GUARDIAN|NEUROLOGIST 1|N|2|Visit_2|25|4|TREATMENT|2020-10-05|25
e|TR|b6208258-d7c2-4dde-addf-4677946ab165|3|[?]|VOLUME|Volume|[?]|mV|NON-PATHOLOGICAL|1|/cmH2O|NEURAMINIDASE INHIBITION ASSAY||Y|CLINICAL RESEARCH ASSOCIATE|READER|N|3|Visit_3|40|6|TREATMENT|2020-10-20|40
e|TR|b6208258-d7c2-4dde-addf-4677946ab165|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|10^9 organisms|FURTHER ENLARGEMENT|1|mL/cm|NUCLEIC ACID AMPLIFICATION TEST|||INTERVIEWER|MICROSCOPIST 3|U|4|Visit_4|65|4|FOLLOW-UP|2020-11-14|65
e|TR|b6208258-d7c2-4dde-addf-4677946ab165|5|[?]|NEWCONF|New Tumor Confirmed|[?]|TCID 50/dose|FURTHER ENLARGEMENT|1|U/kg|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||ADJUDICATOR|NEUROLOGIST 1|U|5|Visit_5|90|3|WASHOUT|2020-12-09|90
e|TR|a669a7b9-2034-4bca-aa80-0371c5fb46d3|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|Osm|INCREASED|1|ohm|DIFFUSION TENSOR MRI|Y||DOMESTIC PARTNER|UROLOGIST|U|1|Visit_1|10|7|FOLLOW-UP|2021-01-26|10
e|TR|a669a7b9-2034-4bca-aa80-0371c5fb46d3|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|10^10/L|ENLARGEMENT FROM NADIR|1|HEP|ELECTROGASTROGRAPHY|||PROXY|MICROSCOPIST 3|Y|2|Visit_2|25|3|TREATMENT|2021-02-10|25
e|TR|a669a7b9-2034-4bca-aa80-0371c5fb46d3|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|nmol/L|UNEQUIVOCAL|1|ug/L DDU|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|6|TREATMENT|2021-02-25|40
e|TR|a669a7b9-2034-4bca-aa80-0371c5fb46d3|4|[?]|VOLUME|Volume|[?]|EID 50/mL|FURTHER ENLARGEMENT|1|ms2|PELLI-ROBSON EYE CHART|||DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|7|SCREENING|2021-03-22|65
e|TR|a669a7b9-2034-4bca-aa80-0371c5fb46d3|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|cP|INCREASED|1|mL/min/mmHg|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y||SPOUSE|ONCOLOGIST|NA|5|Visit_5|90|5|SCREENING|2021-04-16|90
e|TR|e148c13d-ee41-4503-a7e5-397dd6155f04|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|mmol/day|NONPALPABLE|1|mkat|ELISA|Y||PROXY|READER 3|Y|1|Visit_1|10|4|TREATMENT|2020-07-18|10
e|TR|e148c13d-ee41-4503-a7e5-397dd6155f04|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|ug/kg/day|ENLARGEMENT|1|L/min|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||VENDOR|ONCOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-08-02|25
e|TR|e148c13d-ee41-4503-a7e5-397dd6155f04|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|/month|PALPABLE|1|MBq/uL|AUSCULTATION||Y|GUARDIAN|PATHOLOGIST|N|3|Visit_3|40|4|WASHOUT|2020-08-17|40
e|TR|e148c13d-ee41-4503-a7e5-397dd6155f04|4|[?]|NEWCONF|New Tumor Confirmed|[?]|mOsm/L|PRESENT|1|Gy|ULTRASOUND|||INTERVIEWER|RATER 1|Y|4|Visit_4|65|7|TREATMENT|2020-09-11|65
e|TR|e148c13d-ee41-4503-a7e5-397dd6155f04|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|pmol/L/h|DECREASED|1|10^6 organisms/mg|IODINE STAIN|||PARENT|MICROSCOPIST 3|Y|5|Visit_5|90|3|TREATMENT|2020-10-06|90
e|TR|815de94a-f259-41ee-8951-8df150184a25|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|Coulomb|NONPALPABLE|1|mEq/g|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||HEALTH CARE PROFESSIONAL|READER 1|Y|1|Visit_1|10|7|TREATMENT|2020-07-07|10
e|TR|815de94a-f259-41ee-8951-8df150184a25|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|mL/breath|FURTHER ENLARGEMENT FROM NADIR|1|fg|FLOW CYTOMETRY||Y|INVESTIGATOR|NEUROLOGIST|Y|2|Visit_2|25|5|SCREENING|2020-07-22|25
e|TR|815de94a-f259-41ee-8951-8df150184a25|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|L/min|PALPABLE|1|umol/day|DARK FIELD MICROSCOPY|||ADJUDICATOR|PATHOLOGIST|NA|3|Visit_3|40|2|WASHOUT|2020-08-06|40
e|TR|815de94a-f259-41ee-8951-8df150184a25|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|amol|TUMOR MERGED|1|10^7 TCID 50/dose|HPLC/IEX|||ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|7|TREATMENT|2020-08-31|65
e|TR|815de94a-f259-41ee-8951-8df150184a25|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|PELLET|FOCALLY INCREASED|1|pmol/day|MICROARRAY|||PARENT|RATER 2|NA|5|Visit_5|90|2|TREATMENT|2020-09-25|90
e|TR|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|RFU|INCREASED|1|mEq/uL|NUCLEIC ACID BASED METHOD|||STUDY SUBJECT|READER 3|N|1|Visit_1|10|4|TREATMENT|2020-05-16|10
e|TR|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|2|[?]|ORSTATE|Organ State|[?]|uU/L|UNCHANGED|1|keV|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y||VENDOR|NEUROLOGIST 2|N|2|Visit_2|25|7|TREATMENT|2020-05-31|25
e|TR|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|g/animal|PATHOLOGICAL|1|fmol/L|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y||INTERVIEWER|DERMATOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-06-15|40
e|TR|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|rpm|TUMOR MERGED|1|ELISA unit/dose|CONTACT SPECULAR MICROSCOPY||Y|SIGNIFICANT OTHER|DERMATOLOGIST|N|4|Visit_4|65|2|SCREENING|2020-07-10|65
e|TR|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|5|[?]|PALPSTAT|Palpable State|[?]|VIAL|DIFFUSELY INCREASED|1|/min|AUTOMATED COUNT|||ADJUDICATOR|ONCOLOGIST 1|U|5|Visit_5|90|5|SCREENING|2020-08-04|90
e|TR|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|AgU/mL|FURTHER ENLARGEMENT FROM NADIR|1|titer|IRON HEMATOXYLIN STAIN|||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|U|1|Visit_1|10|2|SCREENING|2021-01-25|10
e|TR|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|2|[?]|PALPSTAT|Palpable State|[?]|Hz|DIFFUSELY INCREASED|1|deg2|MACRO BROTH DILUTION||Y|SIBLING|RADIOLOGIST 2|NA|2|Visit_2|25|3|TREATMENT|2021-02-09|25
e|TR|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|g/cm2|ABSENT|1|mL/100g/min|MIGET|||PROXY|ADJUDICATOR 3|U|3|Visit_3|40|4|SCREENING|2021-02-24|40
e|TR|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|mEq/uL|DIFFUSELY INCREASED|1|g/kg|PATHOLOGICAL EVALUATION|||STUDY SUBJECT|RATER 2|N|4|Visit_4|65|2|TREATMENT|2021-03-21|65
e|TR|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|5|[?]|SUMVOL|Sum of Volume|[?]|log10 IU/mL|TUMOR MERGED|1|Ci/kg|GC/MS-CI|Y|Y|SIBLING|HEMATOLOGIST|N|5|Visit_5|90|5|SCREENING|2021-04-15|90
e|TR|a616ef00-05d6-459a-8474-06ab3eb493b1|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|breaths/min|PATHOLOGICAL|1|ag|PET/CT SCAN||Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|1|Visit_1|10|3|TREATMENT|2020-09-25|10
e|TR|a616ef00-05d6-459a-8474-06ab3eb493b1|2|[?]|LDIAM|Longest Diameter|[?]|IU/dL|PALPABLE|1|nmol/g|CONTRAST ENHANCED PET/CT SCAN|||DOMESTIC PARTNER|MICROSCOPIST 3|NA|2|Visit_2|25|5|TREATMENT|2020-10-10|25
e|TR|a616ef00-05d6-459a-8474-06ab3eb493b1|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|MET|INCREASED|1|%/min|IMMUNORADIOMETRIC ASSAY|Y||DOMESTIC PARTNER|ONCOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-10-25|40
e|TR|a616ef00-05d6-459a-8474-06ab3eb493b1|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|pg/L|NONPALPABLE|1|ug/kg|PHOTOMETRIC CLOT DETECTION||Y|CAREGIVER|ADJUDICATOR 1|N|4|Visit_4|65|3|FOLLOW-UP|2020-11-19|65
e|TR|a616ef00-05d6-459a-8474-06ab3eb493b1|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mU/L|FURTHER ENLARGEMENT FROM NADIR|1|DNA copies/mL|DNA MICROARRAY|||SIGNIFICANT OTHER|UROLOGIST|NA|5|Visit_5|90|3|FOLLOW-UP|2020-12-14|90
e|TR|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|1|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|DROP|EQUIVOCAL|1|mol/mol|ANGIOGRAPHY|||CAREGIVER|ONCOLOGIST|N|1|Visit_1|10|3|SCREENING|2020-08-20|10
e|TR|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|EVENTS|FURTHER ENLARGEMENT FROM NADIR|1|DIP|GC/MS-CI|||FAMILY MEMBER|OPTOMETRIST|U|2|Visit_2|25|4|TREATMENT|2020-09-04|25
e|TR|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|mL/100g/min|ABSENT|1|ug/L FEU|TOTAL BODY IRRADIATION|Y||INTERVIEWER|RATER|N|3|Visit_3|40|3|WASHOUT|2020-09-19|40
e|TR|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|VIRTUAL PIXEL|UNCHANGED|1|Osm|HEMATOXYLIN AND EOSIN STAIN|||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|N|4|Visit_4|65|5|TREATMENT|2020-10-14|65
e|TR|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|5|[?]|PPD|Product of Perpendicular Diameters|[?]|nmol/mL/min|TUMOR MERGED|1|MPL U/mL|WHOLE EXOME SEQUENCING|||SIGNIFICANT OTHER|RATER 2|NA|5|Visit_5|90|3|TREATMENT|2020-11-08|90
e|TR|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|sec|FURTHER ENLARGEMENT|1|L/day|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||NON-HEALTH CARE PROFESSIONAL|READER 2|U|1|Visit_1|10|6|TREATMENT|2020-10-21|10
e|TR|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|ug/dose|ABSENT|1|MET*h|PHASE CONTRAST MICROSCOPY|Y||GUARDIAN|ENDOCRINOLOGIST|NA|2|Visit_2|25|7|SCREENING|2020-11-05|25
e|TR|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mL/mmHg|FURTHER ENLARGEMENT|1|EIA unit|FLOW MICROSCOPY||Y|STUDY SUBJECT|MICROSCOPIST|N|3|Visit_3|40|6|FOLLOW-UP|2020-11-20|40
e|TR|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|NEEDLE GAUGE|ENLARGEMENT FROM NADIR|1|ft|IMMUNOFIXATION ELECTROPHORESIS|||CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|NA|4|Visit_4|65|7|SCREENING|2020-12-15|65
e|TR|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|APL U|NORMAL|1|nmol/day|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||VENDOR|READER 1|N|5|Visit_5|90|1|TREATMENT|2021-01-09|90
e|TR|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|ug/min|ENLARGEMENT|1|10^4 CFU|STATIC PERIMETRY|||VENDOR|READER|Y|1|Visit_1|10|1|TREATMENT|2020-07-04|10
e|TR|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|2|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mL/min/mmHg|NONPALPABLE|1|fmol/g|SPECT/CT SCAN|||CAREGIVER|OPHTHALMOLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-07-19|25
e|TR|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|mol/g|UNCHANGED|1|CONTAINER|FLOW MICROSCOPY|Y||CHILD|CLINICAL PATHOLOGIST|N|3|Visit_3|40|2|WASHOUT|2020-08-03|40
e|TR|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mol/mol|DIFFUSELY INCREASED|1|FEU|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y|PROXY|RADIOLOGIST 2|NA|4|Visit_4|65|1|FOLLOW-UP|2020-08-28|65
e|TR|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|5|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|mEq|FOCALLY INCREASED|1|cGy|ETDRS EYE CHART|Y||SIGNIFICANT OTHER|OPHTHALMOLOGIST|U|5|Visit_5|90|4|WASHOUT|2020-09-22|90
e|TR|2014bcd0-1430-4096-87f5-650a01dae626|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|COAT|UNEQUIVOCAL|1|ELISA unit|SNELLEN EYE CHART||Y|CHILD|READER|NA|1|Visit_1|10|6|TREATMENT|2020-05-31|10
e|TR|2014bcd0-1430-4096-87f5-650a01dae626|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|cmol|FURTHER ENLARGEMENT FROM NADIR|1|mg/kg/dose|HPLC/IEX|Y||HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|2|Visit_2|25|6|TREATMENT|2020-06-15|25
e|TR|2014bcd0-1430-4096-87f5-650a01dae626|3|[?]|VDIAM|Viable Diameter|[?]|nmol BCE/mmol|DECREASED|1|10^7/L|MICROBIAL BIOCHEMICAL IDENTIFICATION|Y|Y|CAREGIVER|CARDIOLOGIST|NA|3|Visit_3|40|5|FOLLOW-UP|2020-06-30|40
e|TR|2014bcd0-1430-4096-87f5-650a01dae626|4|[?]|LPERP|Longest Perpendicular|[?]|ug/mL/h|ABSENT|1|APL U/mL|RULER MEASUREMENT METHOD|||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|NA|4|Visit_4|65|1|TREATMENT|2020-07-25|65
e|TR|2014bcd0-1430-4096-87f5-650a01dae626|5|[?]|NEWCONF|New Tumor Confirmed|[?]|mg/day|NONPALPABLE|1|RFU|CLAUSS METHOD|||INDEPENDENT ASSESSOR|READER 1|Y|5|Visit_5|90|4|TREATMENT|2020-08-19|90
e|TR|e043f1b3-6b65-45c0-bdae-eb783406c263|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|mm2|DIFFUSELY INCREASED|1|MHz|IVY INCISION METHOD|Y|Y|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-11-11|10
e|TR|e043f1b3-6b65-45c0-bdae-eb783406c263|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|mL/m2/day|FURTHER ENLARGEMENT|1|mg/kg/day|QUANTITATIVE ULTRASOUND||Y|INDEPENDENT ASSESSOR|PATHOLOGIST 1|NA|2|Visit_2|25|1|TREATMENT|2020-11-26|25
e|TR|e043f1b3-6b65-45c0-bdae-eb783406c263|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|P|ENLARGEMENT|1|Absorbance U/mL|AUDIOMETRY|Y|Y|VENDOR|MICROSCOPIST 3|N|3|Visit_3|40|7|TREATMENT|2020-12-11|40
e|TR|e043f1b3-6b65-45c0-bdae-eb783406c263|4|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mg/dose|PALPABLE|1|mAmp|HILLMEN COLOR CHART|||SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|6|TREATMENT|2021-01-05|65
e|TR|e043f1b3-6b65-45c0-bdae-eb783406c263|5|[?]|LESSCIND|Lesion Success Indicator|[?]|mU/L|FURTHER ENLARGEMENT FROM NADIR|1|nmol/day|NEPHELOMETRY|||PROXY|RATER 1|NA|5|Visit_5|90|6|TREATMENT|2021-01-30|90
e|TR|45623c39-86de-4b2f-bf2d-998d0e941e92|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|PFU|TUMOR MERGED|1|usec|AMSLER GRID|||DOMESTIC PARTNER|READER 3|NA|1|Visit_1|10|5|SCREENING|2020-07-22|10
e|TR|45623c39-86de-4b2f-bf2d-998d0e941e92|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|10^7 PFU|FURTHER ENLARGEMENT|1|BU|PET SCAN|||ADJUDICATION COMMITTEE|NEUROLOGIST|Y|2|Visit_2|25|1|WASHOUT|2020-08-06|25
e|TR|45623c39-86de-4b2f-bf2d-998d0e941e92|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|g/animal/wk|NORMAL|1|10^9 CFU/mL|DYNAMOMETRY||Y|SIBLING|UROLOGIST|NA|3|Visit_3|40|1|SCREENING|2020-08-21|40
e|TR|45623c39-86de-4b2f-bf2d-998d0e941e92|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|lx|ENLARGEMENT|1|days/wk|TRANSMISSION ELECTRON MICROSCOPY|||FRIEND|READER 3|NA|4|Visit_4|65|1|TREATMENT|2020-09-15|65
e|TR|45623c39-86de-4b2f-bf2d-998d0e941e92|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|U/m2/min|ABSENT|1|pg/dL|ELISA|Y||CAREGIVER|ONCOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-10-10|90
e|TR|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mL/kg/min|DECREASED|1|copies/ug|KINETIC MICROPARTICLE IMMUNOASSAY|||HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|1|Visit_1|10|1|FOLLOW-UP|2020-10-18|10
e|TR|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|2|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|Coulomb|FURTHER ENLARGEMENT|1|10^6 organisms/mg|NUCLEIC ACID HYBRIDIZATION|||INVESTIGATOR|RATER|N|2|Visit_2|25|3|TREATMENT|2020-11-02|25
e|TR|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mL|FURTHER ENLARGEMENT FROM NADIR|1|mEq/kg|QUANTITATIVE COMPUTED TOMOGRAPHY|||FAMILY MEMBER|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|6|SCREENING|2020-11-17|40
e|TR|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mL/m2|PALPABLE|1|nmol/mL/min|NUCLEIC ACID SEQUENCING|||CHILD|HEMATOLOGIST|N|4|Visit_4|65|1|TREATMENT|2020-12-12|65
e|TR|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|fmol/L|PRESENT|1|vg/kg|OLIGO ACGH|Y||DOMESTIC PARTNER|MICROSCOPIST 3|U|5|Visit_5|90|7|TREATMENT|2021-01-06|90
e|TR|e5a105f7-38ac-4f19-aace-4149ed9b1100|1|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mEq/uL|PRESENT|1|U/g/h|ATOMIC ABSORPTION SPECTROMETRY|||CLINICAL STUDY SPONSOR|MICROSCOPIST 3|N|1|Visit_1|10|1|TREATMENT|2020-09-03|10
e|TR|e5a105f7-38ac-4f19-aace-4149ed9b1100|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mm/h|INCREASED|1|mg/mL/day|CYSTOSCOPY|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|Y|2|Visit_2|25|4|TREATMENT|2020-09-18|25
e|TR|e5a105f7-38ac-4f19-aace-4149ed9b1100|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mg/kg|UNEQUIVOCAL|1|NEBULE|CLOT DETECTION|||ADJUDICATOR|ENDOCRINOLOGIST|Y|3|Visit_3|40|3|SCREENING|2020-10-03|40
e|TR|e5a105f7-38ac-4f19-aace-4149ed9b1100|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|U/L|FURTHER ENLARGEMENT FROM NADIR|1|nkat|SLOAN LETTER EYE CHART 100%|||CAREGIVER|READER 2|Y|4|Visit_4|65|2|SCREENING|2020-10-28|65
e|TR|e5a105f7-38ac-4f19-aace-4149ed9b1100|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|CFU/mL|ABSENT|1|FIU|BAC ACGH|||INVESTIGATOR|CARDIOLOGIST|U|5|Visit_5|90|1|WASHOUT|2020-11-22|90
e|TR|c568ab93-8e7f-4e4e-9685-f0c13f293606|1|[?]|LDIAM|Longest Diameter|[?]|uCi|TUMOR MERGED|1|fmol/g|SURFACE PLASMON RESONANCE|||INTERVIEWER|RATER|Y|1|Visit_1|10|5|SCREENING|2021-01-14|10
e|TR|c568ab93-8e7f-4e4e-9685-f0c13f293606|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|Log10 ELISA unit/dose|FURTHER ENLARGEMENT|1|Gy|COLORIMETRY||Y|SIBLING|ADJUDICATOR 1|NA|2|Visit_2|25|4|TREATMENT|2021-01-29|25
e|TR|c568ab93-8e7f-4e4e-9685-f0c13f293606|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|EP U|ABSENT|1|nmol/L/h|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y||INTERVIEWER|ADJUDICATOR 3|Y|3|Visit_3|40|1|SCREENING|2021-02-13|40
e|TR|c568ab93-8e7f-4e4e-9685-f0c13f293606|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|cL|PATHOLOGICAL|1|RFU|THICK SMEAR|||SIBLING|READER 3|Y|4|Visit_4|65|5|WASHOUT|2021-03-10|65
e|TR|c568ab93-8e7f-4e4e-9685-f0c13f293606|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|copies/ug|ENLARGEMENT|1|Ci/g|MANUAL CLOT DETECTION||Y|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2021-04-04|90
e|TR|bccd8af0-2ecf-4091-92e4-681597b57ca4|1|[?]|ORSTATE|Organ State|[?]|mkat|EQUIVOCAL|1|mg/m2|PET/CT SCAN WITHOUT CONTRAST||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|1|Visit_1|10|1|SCREENING|2020-09-30|10
e|TR|bccd8af0-2ecf-4091-92e4-681597b57ca4|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|Shock Wave|DECREASED|1|fmol/g|FLUORESCENCE ANGIOGRAPHY||Y|PARENT|ADJUDICATOR 3|N|2|Visit_2|25|3|WASHOUT|2020-10-15|25
e|TR|bccd8af0-2ecf-4091-92e4-681597b57ca4|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|FEU|NORMAL|1|Siemens|IMPULSE OSCILLOMETRY|Y|Y|INTERVIEWER|HEMATOLOGIST|Y|3|Visit_3|40|2|FOLLOW-UP|2020-10-30|40
e|TR|bccd8af0-2ecf-4091-92e4-681597b57ca4|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|pm|DIFFUSELY INCREASED|1|Ci/g|DYNAMOMETRY|||VENDOR|ADJUDICATOR 1|U|4|Visit_4|65|1|FOLLOW-UP|2020-11-24|65
e|TR|bccd8af0-2ecf-4091-92e4-681597b57ca4|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|DPM|PATHOLOGICAL|1|RATIO|COULOMETRIC TITRATION|||PROXY|NEUROLOGIST 1|U|5|Visit_5|90|7|SCREENING|2020-12-19|90
e|TR|bf069a02-03a6-4013-b16d-d7c954a6cc3d|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mgEq|UNEQUIVOCAL|1|LENS|WHOLE TRANSCRIPTOME SEQUENCING|||SIBLING|RATER 1|NA|1|Visit_1|10|3|TREATMENT|2020-08-06|10
e|TR|bf069a02-03a6-4013-b16d-d7c954a6cc3d|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|10^9/g|ENLARGEMENT FROM NADIR|1|IU/mmol|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||CLINICAL RESEARCH COORDINATOR|READER|N|2|Visit_2|25|1|WASHOUT|2020-08-21|25
e|TR|bf069a02-03a6-4013-b16d-d7c954a6cc3d|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|BOX|FOCALLY INCREASED|1|TUBE|MUGA|Y||SPOUSE|PATHOLOGIST 1|U|3|Visit_3|40|1|WASHOUT|2020-09-05|40
e|TR|bf069a02-03a6-4013-b16d-d7c954a6cc3d|4|[?]|NEWCONF|New Tumor Confirmed|[?]|pmol/g|FURTHER ENLARGEMENT|1|cmHg|POLYGRAPHY||Y|CAREGIVER|NEUROLOGIST 2|Y|4|Visit_4|65|1|WASHOUT|2020-09-30|65
e|TR|bf069a02-03a6-4013-b16d-d7c954a6cc3d|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|10^6 CFU/g|ENLARGEMENT|1|kBq|IMMUNO-PET SCAN|Y|Y|GUARDIAN|MICROSCOPIST 3|U|5|Visit_5|90|6|TREATMENT|2020-10-25|90
e|TR|c40fc52b-2668-4fab-b051-5b258da72f2c|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|um/day|FURTHER ENLARGEMENT|1|ug/L FEU|IHC|Y||GUARDIAN|MICROSCOPIST 3|Y|1|Visit_1|10|1|TREATMENT|2020-10-11|10
e|TR|c40fc52b-2668-4fab-b051-5b258da72f2c|2|[?]|LPERP|Longest Perpendicular|[?]|hr/day|DECREASED|1|CCID 50/dose|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|Y|2|Visit_2|25|5|FOLLOW-UP|2020-10-26|25
e|TR|c40fc52b-2668-4fab-b051-5b258da72f2c|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|EVENTS|FURTHER ENLARGEMENT|1|foz_br|ELLA|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-11-10|40
e|TR|c40fc52b-2668-4fab-b051-5b258da72f2c|4|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|%|ENLARGEMENT FROM NADIR|1|10^6 IU/mL|INFRARED SPECTROMETRY|Y||FRIEND|HEMATOLOGIST|NA|4|Visit_4|65|4|WASHOUT|2020-12-05|65
e|TR|c40fc52b-2668-4fab-b051-5b258da72f2c|5|[?]|LDIAM|Longest Diameter|[?]|g/cage/wk|NON-PATHOLOGICAL|1|mm/sec|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y|Y|ADJUDICATOR|INTERNIST|N|5|Visit_5|90|7|TREATMENT|2020-12-30|90
e|TR|d7c792d8-fc98-41ab-8a9e-59de1e186a06|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|gMFI|PATHOLOGICAL|1|dpm/mg|LIQUID SCINTILLATION COUNTING|||INTERVIEWER|READER 3|U|1|Visit_1|10|1|TREATMENT|2020-07-28|10
e|TR|d7c792d8-fc98-41ab-8a9e-59de1e186a06|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|U/m2/day|NON-PATHOLOGICAL|1|umol/min|HEMAGGLUTINATION INHIBITION ASSAY|||CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|7|SCREENING|2020-08-12|25
e|TR|d7c792d8-fc98-41ab-8a9e-59de1e186a06|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|IU/g Hb|INCREASED|1|mL*cmH2O|IMMUNO-PET SCAN|||CAREGIVER|OTOLARYNGOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-08-27|40
e|TR|d7c792d8-fc98-41ab-8a9e-59de1e186a06|4|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|dyn|ENLARGEMENT|1|Gravitational Unit|ACRIDINE ORANGE STAIN|||ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|4|TREATMENT|2020-09-21|65
e|TR|d7c792d8-fc98-41ab-8a9e-59de1e186a06|5|[?]|LESSCIND|Lesion Success Indicator|[?]|ug/dL|FURTHER ENLARGEMENT|1|10^9/dose|FLUORESCENCE ANGIOGRAPHY||Y|DOMESTIC PARTNER|ADJUDICATOR|N|5|Visit_5|90|3|FOLLOW-UP|2020-10-16|90
e|TR|f7773659-f207-4b29-8389-3aa766a6337a|1|[?]|LNSTATE|Lymph Node State|[?]|MnFI|ENLARGEMENT|1|10^4/hpf|IMMUNE REPERTOIRE DEEP SEQUENCING|||SPOUSE|RADIOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-10-19|10
e|TR|f7773659-f207-4b29-8389-3aa766a6337a|2|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mm/2h|ENLARGEMENT|1|nCi|ERGOSPIROMETRY|||ADJUDICATION COMMITTEE|INTERNIST|U|2|Visit_2|25|6|WASHOUT|2020-11-03|25
e|TR|f7773659-f207-4b29-8389-3aa766a6337a|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|pg/cell|ENLARGEMENT|1|cm|MAGNETIC RESONANCE ENTEROGRAPHY|||ADJUDICATOR|PHYSIOTHERAPIST|Y|3|Visit_3|40|4|SCREENING|2020-11-18|40
e|TR|f7773659-f207-4b29-8389-3aa766a6337a|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|L/L|INCREASED|1|ukat|IMMUNOASSAY|Y|Y|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|Y|4|Visit_4|65|2|TREATMENT|2020-12-13|65
e|TR|f7773659-f207-4b29-8389-3aa766a6337a|5|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|log10 PFU|UNEQUIVOCAL|1|atm|ERGOSPIROMETRY||Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|N|5|Visit_5|90|4|TREATMENT|2021-01-07|90
e|TR|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|USP U|UNCHANGED|1|usec|BRDU CELLULAR PROLIFERATION ASSAY|Y||INDEPENDENT ASSESSOR|NEUROLOGIST 2|NA|1|Visit_1|10|4|WASHOUT|2021-01-07|10
e|TR|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|/LSQN|DECREASED|1|%(w/w)|PANENDOSCOPY|Y||CHILD|PATHOLOGIST 1|NA|2|Visit_2|25|5|SCREENING|2021-01-22|25
e|TR|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|oz|NORMAL|1|PACKET|MULTIPLE BREATH WASHOUT|Y||FAMILY MEMBER|ADJUDICATOR 3|U|3|Visit_3|40|1|SCREENING|2021-02-06|40
e|TR|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|pmol/10^9 cells|INCREASED|1|min*mg/mL|PET/CT SCAN|||SPOUSE|ONCOLOGIST|N|4|Visit_4|65|2|FOLLOW-UP|2021-03-03|65
e|TR|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|5|[?]|PALPSTAT|Palpable State|[?]|usec|UNEQUIVOCAL|1|PIXEL|HIGH RESOLUTION MELT ANALYSIS|||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|NA|5|Visit_5|90|4|TREATMENT|2021-03-28|90
e|TR|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|Absorbance U|ABSENT|1|mmol/L|GC/MS-EI|||CLINICAL RESEARCH ASSOCIATE|RATER|Y|1|Visit_1|10|7|TREATMENT|2021-01-26|10
e|TR|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|2|[?]|AREA|Area|[?]|log10 CFU/g|ABSENT|1|/2000 RBC|FARNSWORTH-MUNSELL 100 HUE TEST|Y|Y|ADJUDICATION COMMITTEE|OPTOMETRIST|NA|2|Visit_2|25|1|SCREENING|2021-02-10|25
e|TR|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|OD Unit|PALPABLE|1|Tbsp|DC SHEATH FLOW|||FRIEND|ADJUDICATOR|N|3|Visit_3|40|5|WASHOUT|2021-02-25|40
e|TR|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|uV*sec|PALPABLE|1|QUANTITY SUFFICIENT|FLUORESCENT MICROSCOPY||Y|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|U|4|Visit_4|65|1|TREATMENT|2021-03-22|65
e|TR|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|days/wk|TUMOR MERGED|1|10^8 PFU|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|NA|5|Visit_5|90|7|SCREENING|2021-04-16|90
e|TR|700049a2-ef66-466b-b1d8-f0800bcfde43|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|nsec|ENLARGEMENT|1|Pa|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||PROXY|RADIOLOGIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-06-27|10
e|TR|700049a2-ef66-466b-b1d8-f0800bcfde43|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mEq/day|UNCHANGED|1|mL/kg/min|ELECTROGASTROGRAPHY|||PARENT|ONCOLOGIST 1|Y|2|Visit_2|25|1|TREATMENT|2020-07-12|25
e|TR|700049a2-ef66-466b-b1d8-f0800bcfde43|3|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|ug/h|PALPABLE|1|pmol/day|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||STUDY SUBJECT|RATER 1|U|3|Visit_3|40|7|SCREENING|2020-07-27|40
e|TR|700049a2-ef66-466b-b1d8-f0800bcfde43|4|[?]|PALPSTAT|Palpable State|[?]|gMFI|NONPALPABLE|1|RING|PELLI-ROBSON EYE CHART|||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|Y|4|Visit_4|65|4|TREATMENT|2020-08-21|65
e|TR|700049a2-ef66-466b-b1d8-f0800bcfde43|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|Coulomb|NORMAL|1|BOWL|NON-INVASIVE DIELECTRIC SENSING||Y|SPOUSE|MICROSCOPIST 2|Y|5|Visit_5|90|1|SCREENING|2020-09-15|90
e|TR|00d906a6-2d14-4199-aff9-524388c5117f|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|nkat/g Hb|ABSENT|1|h/wk|DIRECT SEQUENCING|Y||SIBLING|INTERNIST|Y|1|Visit_1|10|7|TREATMENT|2020-11-24|10
e|TR|00d906a6-2d14-4199-aff9-524388c5117f|2|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|cm/s|PALPABLE|1|STRIP|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||CAREGIVER|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|4|FOLLOW-UP|2020-12-09|25
e|TR|00d906a6-2d14-4199-aff9-524388c5117f|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|Bq/g|FURTHER ENLARGEMENT|1|CARTRIDGE|RADIAL IMMUNODIFFUSION|Y||CAREGIVER|RADIOLOGIST 1|NA|3|Visit_3|40|5|FOLLOW-UP|2020-12-24|40
e|TR|00d906a6-2d14-4199-aff9-524388c5117f|4|[?]|VOLUME|Volume|[?]|mg/kg/min|NONPALPABLE|1|Henry|CELLULOSE TAPE|||INDEPENDENT ASSESSOR|ONCOLOGIST 2|N|4|Visit_4|65|4|SCREENING|2021-01-18|65
e|TR|00d906a6-2d14-4199-aff9-524388c5117f|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|umol/mg/min|PALPABLE|1|MHz|ORCHIDOMETERY|||CAREGIVER|PHYSIOTHERAPIST|Y|5|Visit_5|90|5|SCREENING|2021-02-12|90
e|TR|2fcc5910-bce0-4510-b17e-3925850d6d32|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mV/sec|EQUIVOCAL|1|tuberculin unit|CONTRAST ENHANCED SPIRAL CT SCAN|||SPOUSE|OPTOMETRIST|Y|1|Visit_1|10|6|SCREENING|2020-12-16|10
e|TR|2fcc5910-bce0-4510-b17e-3925850d6d32|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|pg/L|NORMAL|1|cd*s/m2|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||INTERVIEWER|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-12-31|25
e|TR|2fcc5910-bce0-4510-b17e-3925850d6d32|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|L/s|PALPABLE|1|%(v/v)|NUCLEIC ACID BASED METHOD|Y||CLINICAL STUDY SPONSOR|MICROSCOPIST 2|Y|3|Visit_3|40|1|TREATMENT|2021-01-15|40
e|TR|2fcc5910-bce0-4510-b17e-3925850d6d32|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|C|NON-PATHOLOGICAL|1|Gy/h|SLIT LAMP PHOTOGRAPHY|||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|6|TREATMENT|2021-02-09|65
e|TR|2fcc5910-bce0-4510-b17e-3925850d6d32|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mm/sec|UNEQUIVOCAL|1|ug/kg/min|SANGER SEQUENCING|Y||DOMESTIC PARTNER|PHYSIOTHERAPIST|N|5|Visit_5|90|7|TREATMENT|2021-03-06|90
e|TR|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|1|[?]|VDIAM|Viable Diameter|[?]|GBq/mg|PALPABLE|1|mg|GC/MS-CI|||CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|N|1|Visit_1|10|3|WASHOUT|2020-08-31|10
e|TR|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|uL/mL|DECREASED|1|pmol/L|AMSLER GRID|||CAREGIVER|MICROSCOPIST 1|Y|2|Visit_2|25|6|WASHOUT|2020-09-15|25
e|TR|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|Siemens|ENLARGEMENT|1|kat|CONFOCAL MICROSCOPY|||STUDY SUBJECT|RADIOLOGIST 1|N|3|Visit_3|40|1|TREATMENT|2020-09-30|40
e|TR|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|10^9 organisms/mL|FOCALLY INCREASED|1|mV2/Hz|VIRUS PLAQUE ASSAY|||FRIEND|MICROSCOPIST 1|NA|4|Visit_4|65|1|FOLLOW-UP|2020-10-25|65
e|TR|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|GBq/mg|DECREASED|1|GLOBULE|SLOAN LETTER EYE CHART 1.25%|||ADJUDICATION COMMITTEE|OPTOMETRIST|NA|5|Visit_5|90|1|WASHOUT|2020-11-19|90
e|TR|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|1|[?]|NEWCONF|New Tumor Confirmed|[?]|JAR|DECREASED|1|mL/kg/h|ERGOSPIROMETRY|||SIGNIFICANT OTHER|RADIOLOGIST 1|N|1|Visit_1|10|1|TREATMENT|2020-07-26|10
e|TR|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|2|[?]|VOLUME|Volume|[?]|gpELISA unit/mL|FURTHER ENLARGEMENT|1|umol/h/mmol|NUCLEIC ACID HYBRIDIZATION||Y|DOMESTIC PARTNER|DERMATOLOGIST|Y|2|Visit_2|25|1|SCREENING|2020-08-10|25
e|TR|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|3|[?]|DIAMETER|Diameter|[?]|tuberculin unit/mL|NONPALPABLE|1|ug/m2/min|DYNAMOMETRY|||ADJUDICATION COMMITTEE|READER 1|NA|3|Visit_3|40|3|SCREENING|2020-08-25|40
e|TR|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|4|[?]|PPD|Product of Perpendicular Diameters|[?]|FFU|FOCALLY INCREASED|1|gMFI|FARR ASSAY|Y|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-09-19|65
e|TR|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|LENS|FOCALLY INCREASED|1|cg|AGAR PROPORTION|Y||CAREGIVER|HEMATOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-10-14|90
e|TR|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|1|[?]|PPD|Product of Perpendicular Diameters|[?]|ka_u/dL|ENLARGEMENT|1|Bq/g|FLUORESCENT ENZYME IMMUNOASSAY|Y||CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|N|1|Visit_1|10|5|TREATMENT|2020-10-28|10
e|TR|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|in2|DECREASED|1|ug/L FEU|KARYOTYPING|||FRIEND|HEMATOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-11-12|25
e|TR|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|3|[?]|DIAMETER|Diameter|[?]|mg/mL/day|ABSENT|1|nmol/L|MICROARRAY||Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|NA|3|Visit_3|40|2|SCREENING|2020-11-27|40
e|TR|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|um2|UNEQUIVOCAL|1|kPa/L/sec|PHOTOMETRY|||PARENT|ONCOLOGIST 1|NA|4|Visit_4|65|5|FOLLOW-UP|2020-12-22|65
e|TR|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|5|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mEq/L|ENLARGEMENT|1|pmol/10^10 cells|KARYOTYPING|||CLINICAL STUDY SPONSOR|READER 1|NA|5|Visit_5|90|6|TREATMENT|2021-01-16|90
e|TR|ff163542-abec-4260-b257-f15a11e580ee|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|days/month|EQUIVOCAL|1|mg/h|AGAR PROPORTION|||SIGNIFICANT OTHER|RATER 2|NA|1|Visit_1|10|6|TREATMENT|2020-08-16|10
e|TR|ff163542-abec-4260-b257-f15a11e580ee|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|Ci/ug|PRESENT|1|Bq/mL|CONTRAST ENHANCED SPIRAL CT SCAN|||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|2|Visit_2|25|1|TREATMENT|2020-08-31|25
e|TR|ff163542-abec-4260-b257-f15a11e580ee|3|[?]|LNSTATE|Lymph Node State|[?]|mL/m2|NONPALPABLE|1|CUP|AUTOREFRACTION|||PARENT|PHYSIOTHERAPIST|N|3|Visit_3|40|5|TREATMENT|2020-09-15|40
e|TR|ff163542-abec-4260-b257-f15a11e580ee|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|kV|PRESENT|1|FEU|ATOMIC ABSORPTION SPECTROMETRY|||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|6|WASHOUT|2020-10-10|65
e|TR|ff163542-abec-4260-b257-f15a11e580ee|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|mg/kg/week|NONPALPABLE|1|10^3 organisms|CONTRAST ENHANCED CT SCAN|Y||INDEPENDENT ASSESSOR|CARDIOLOGIST|NA|5|Visit_5|90|5|TREATMENT|2020-11-04|90
e|TR|bb73f732-a52f-4013-9ae6-60ff23b9c224|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mL/cm3/min|ENLARGEMENT FROM NADIR|1|nmol/day|DXA SCAN|||HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|1|Visit_1|10|7|TREATMENT|2020-08-05|10
e|TR|bb73f732-a52f-4013-9ae6-60ff23b9c224|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|mL/m2/h|EQUIVOCAL|1|Ci/kg|CHROMOGENIC ASSAY|||SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|6|SCREENING|2020-08-20|25
e|TR|bb73f732-a52f-4013-9ae6-60ff23b9c224|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|g/U|NONPALPABLE|1|/cmH2O|SNP ARRAY|Y||SPOUSE|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-09-04|40
e|TR|bb73f732-a52f-4013-9ae6-60ff23b9c224|4|[?]|ORSTATE|Organ State|[?]|DDU|UNCHANGED|1|10^6 U|QUANTITATIVE CORONARY ANGIOGRAPHY|||SPOUSE|MICROSCOPIST 1|U|4|Visit_4|65|5|WASHOUT|2020-09-29|65
e|TR|bb73f732-a52f-4013-9ae6-60ff23b9c224|5|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mm/min|DIFFUSELY INCREASED|1|cm H2O|WHOLE EXOME SEQUENCING||Y|VENDOR|CLINICAL PATHOLOGIST|U|5|Visit_5|90|1|WASHOUT|2020-10-24|90
e|TR|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|m|PATHOLOGICAL|1|ug/m2|TWO-COLOR MICROARRAY|||SIGNIFICANT OTHER|RATER|Y|1|Visit_1|10|1|TREATMENT|2020-07-21|10
e|TR|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|2|[?]|VDIAM|Viable Diameter|[?]|10^9 organisms/mg|DIFFUSELY INCREASED|1|ug/kg/day|DYNAMOMETRY|Y||DOMESTIC PARTNER|RADIOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-08-05|25
e|TR|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|3|[?]|VDIAM|Viable Diameter|[?]|mg/kg/week|FOCALLY INCREASED|1|nmol/L|ACCELERATOR MASS SPECTROMETRY|||CHILD|DERMATOLOGIST|Y|3|Visit_3|40|2|SCREENING|2020-08-20|40
e|TR|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|4|[?]|SUMVOL|Sum of Volume|[?]|/kg|NONPALPABLE|1|mg/m2/min|GRADIENT DIFFUSION|||INDEPENDENT ASSESSOR|READER 3|N|4|Visit_4|65|1|SCREENING|2020-09-14|65
e|TR|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|10^3/hpf|TUMOR MERGED|1|dL|OLIGO ACGH|Y|Y|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|6|SCREENING|2020-10-09|90
e|TR|8e056558-ffd2-4c43-bbfa-40914b38af34|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|uU/dL|UNCHANGED|1|mL/s/m2|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|1|Visit_1|10|5|TREATMENT|2021-01-29|10
e|TR|8e056558-ffd2-4c43-bbfa-40914b38af34|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|CUP|EQUIVOCAL|1|mm/h|FLUORESCENT MICROSCOPY|Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|Y|2|Visit_2|25|1|TREATMENT|2021-02-13|25
e|TR|8e056558-ffd2-4c43-bbfa-40914b38af34|3|[?]|SUMDIAM|Sum of Diameter|[?]|U/mL|PATHOLOGICAL|1|mg/g/min|DYNAMOMETRY|Y|Y|FRIEND|OPTOMETRIST|N|3|Visit_3|40|7|FOLLOW-UP|2021-02-28|40
e|TR|8e056558-ffd2-4c43-bbfa-40914b38af34|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|cg|DIFFUSELY INCREASED|1|ug/m2/h|DOUBLE IMMUNODIFFUSION||Y|CAREGIVER|RADIOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2021-03-25|65
e|TR|8e056558-ffd2-4c43-bbfa-40914b38af34|5|[?]|VOLUME|Volume|[?]|ug/animal|FURTHER ENLARGEMENT|1|mg/kg/dose|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY||Y|CAREGIVER|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|4|FOLLOW-UP|2021-04-19|90
e|TR|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|CAPFUL|FOCALLY INCREASED|1|10^3 CFU/mL|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||Y|HEALTH CARE PROFESSIONAL|RATER 2|U|1|Visit_1|10|7|TREATMENT|2020-05-29|10
e|TR|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|um2|NORMAL|1|CIGARETTE|MANUAL COUNT|||INTERVIEWER|ENDOCRINOLOGIST|N|2|Visit_2|25|4|FOLLOW-UP|2020-06-13|25
e|TR|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|3|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|Ejaculate U|PATHOLOGICAL|1|mL/min/mmHg|DIGITAL PCR||Y|DOMESTIC PARTNER|OPTOMETRIST|NA|3|Visit_3|40|6|SCREENING|2020-06-28|40
e|TR|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|IU/kg/h|PRESENT|1|CYLINDER|CT SCAN WITHOUT CONTRAST|Y||INTERVIEWER|MICROSCOPIST 3|Y|4|Visit_4|65|6|SCREENING|2020-07-23|65
e|TR|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|5|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|cmH2O*s2/mL|ABSENT|1|10^4/L|CELL OF ORIGIN ASSAY|||CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|U|5|Visit_5|90|4|SCREENING|2020-08-17|90
e|TR|624c1353-347a-417d-9aab-7f1e7077ba7f|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|days/month|PRESENT|1|foz_us|HPLC-UV|||STUDY SUBJECT|RADIOLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-08-28|10
e|TR|624c1353-347a-417d-9aab-7f1e7077ba7f|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|mg/L FEU|EQUIVOCAL|1|tsp eq|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|U|2|Visit_2|25|5|TREATMENT|2020-09-12|25
e|TR|624c1353-347a-417d-9aab-7f1e7077ba7f|3|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mg/mol|EQUIVOCAL|1|10^3 DNA copies/mL|PET/CT SCAN|Y||PROXY|PHYSIOTHERAPIST|Y|3|Visit_3|40|4|WASHOUT|2020-09-27|40
e|TR|624c1353-347a-417d-9aab-7f1e7077ba7f|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|/100 WBC|DIFFUSELY INCREASED|1|mg/day|POLYMERASE CHAIN REACTION|||PARENT|NEUROLOGIST|U|4|Visit_4|65|1|FOLLOW-UP|2020-10-22|65
e|TR|624c1353-347a-417d-9aab-7f1e7077ba7f|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|kPa/L/sec|NON-PATHOLOGICAL|1|10^6 RNA copies/mL|ENDOSCOPY|||PROXY|READER 1|N|5|Visit_5|90|7|SCREENING|2020-11-16|90
e|TR|ef1cddb8-f4ce-45c4-8671-32fe95f00993|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|GLOBULE|DIFFUSELY INCREASED|1|uCi/L|REVERSE TRANSCRIPTASE PCR|||SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|1|FOLLOW-UP|2020-08-02|10
e|TR|ef1cddb8-f4ce-45c4-8671-32fe95f00993|2|[?]|LPERP|Longest Perpendicular|[?]|days/month|UNCHANGED|1|L/day|HPLC/MS/MS|||CAREGIVER|MICROSCOPIST 3|Y|2|Visit_2|25|5|TREATMENT|2020-08-17|25
e|TR|ef1cddb8-f4ce-45c4-8671-32fe95f00993|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|pkat|NON-PATHOLOGICAL|1|U/m2|TRANSVAGINAL ULTRASOUND|||GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|4|WASHOUT|2020-09-01|40
e|TR|ef1cddb8-f4ce-45c4-8671-32fe95f00993|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|CYLINDER|INCREASED|1|mL/mmHg/min/L|CELLULAR PROLIFERATION ASSAY|Y||CLINICAL STUDY SPONSOR|HEMATOLOGIST|NA|4|Visit_4|65|5|WASHOUT|2020-09-26|65
e|TR|ef1cddb8-f4ce-45c4-8671-32fe95f00993|5|[?]|SUMDIAM|Sum of Diameter|[?]|ng/mol|DIFFUSELY INCREASED|1|U/mg|CYSTOMETRY|||CLINICAL RESEARCH COORDINATOR|READER|NA|5|Visit_5|90|6|TREATMENT|2020-10-21|90
e|TR|da6294b5-de91-4bf7-b160-55d22fefcb07|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mg/mL/day|DIFFUSELY INCREASED|1|PATCH|SIZE EXCLUSION CHROMATOGRAPHY|||STUDY SUBJECT|RATER 2|NA|1|Visit_1|10|5|TREATMENT|2020-06-28|10
e|TR|da6294b5-de91-4bf7-b160-55d22fefcb07|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|mU/L|UNEQUIVOCAL|1|genEq/mL|NUCLEIC ACID AMPLIFICATION TEST|||CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-07-13|25
e|TR|da6294b5-de91-4bf7-b160-55d22fefcb07|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|ng/L|FOCALLY INCREASED|1|U/mL|VENTILATION PERFUSION LUNG SCAN|Y||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|U|3|Visit_3|40|5|SCREENING|2020-07-28|40
e|TR|da6294b5-de91-4bf7-b160-55d22fefcb07|4|[?]|LDIAM|Longest Diameter|[?]|pt_us|ENLARGEMENT FROM NADIR|1|ug/L FEU|HEMATOXYLIN AND EOSIN STAIN||Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|Y|4|Visit_4|65|3|WASHOUT|2020-08-22|65
e|TR|da6294b5-de91-4bf7-b160-55d22fefcb07|5|[?]|NEWCONF|New Tumor Confirmed|[?]|grain|NON-PATHOLOGICAL|1|fmol|U-HPLC/MS/MS|||CAREGIVER|RATER|U|5|Visit_5|90|6|WASHOUT|2020-09-16|90
e|TR|c01c16d4-7a37-421d-9191-1874eba6a1e3|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|U/kg/min|EQUIVOCAL|1|Ci/uL|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y||CAREGIVER|ONCOLOGIST 1|U|1|Visit_1|10|3|TREATMENT|2020-10-09|10
e|TR|c01c16d4-7a37-421d-9191-1874eba6a1e3|2|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mmol|EQUIVOCAL|1|Torr|AUSCULTATION|||FAMILY MEMBER|NEUROLOGIST 1|N|2|Visit_2|25|4|FOLLOW-UP|2020-10-24|25
e|TR|c01c16d4-7a37-421d-9191-1874eba6a1e3|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|Osm|DIFFUSELY INCREASED|1|DAYS|RIA|Y|Y|FAMILY MEMBER|MICROSCOPIST|NA|3|Visit_3|40|1|TREATMENT|2020-11-08|40
e|TR|c01c16d4-7a37-421d-9191-1874eba6a1e3|4|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|Farad|EQUIVOCAL|1|10^6/g|PH METER MEASUREMENT METHOD|||INVESTIGATOR|ONCOLOGIST|NA|4|Visit_4|65|7|TREATMENT|2020-12-03|65
e|TR|c01c16d4-7a37-421d-9191-1874eba6a1e3|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|U/cL|FOCALLY INCREASED|1|ug/g/min|RADIATION DOSIMETRY||Y|SPOUSE|READER|U|5|Visit_5|90|5|TREATMENT|2020-12-28|90
e|TR|6036407d-5ac8-400d-91f7-afd63f3cab88|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|pmol/g|ABSENT|1|beats/min|TARGETED GENOME SEQUENCING|||PROXY|NEUROLOGIST 1|Y|1|Visit_1|10|1|FOLLOW-UP|2020-06-22|10
e|TR|6036407d-5ac8-400d-91f7-afd63f3cab88|2|[?]|LNSTATE|Lymph Node State|[?]|copies/uL|FOCALLY INCREASED|1|lx|DISK DIFFUSION||Y|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-07-07|25
e|TR|6036407d-5ac8-400d-91f7-afd63f3cab88|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|dpm/100mg|NONPALPABLE|1|U/kg|THICK SMEAR|||CHILD|ONCOLOGIST 1|NA|3|Visit_3|40|6|WASHOUT|2020-07-22|40
e|TR|6036407d-5ac8-400d-91f7-afd63f3cab88|4|[?]|LESSCIND|Lesion Success Indicator|[?]|Farad|NONPALPABLE|1|pkat|ISHIHARA COLOR PLATES|||VENDOR|CARDIOLOGIST|Y|4|Visit_4|65|5|SCREENING|2020-08-16|65
e|TR|6036407d-5ac8-400d-91f7-afd63f3cab88|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|lm|INCREASED|1|cm2|DROPLET DIGITAL PCR|||VENDOR|HEMATOLOGIST|N|5|Visit_5|90|6|FOLLOW-UP|2020-09-10|90
e|TR|69cf0c4b-13f6-4955-8046-72a333059d6e|1|[?]|BNLNUM|Number of Bone Lesions|[?]|kBq|UNEQUIVOCAL|1|log10 TCID 50/uL|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y|INTERVIEWER|NEUROLOGIST 1|N|1|Visit_1|10|7|TREATMENT|2020-12-16|10
e|TR|69cf0c4b-13f6-4955-8046-72a333059d6e|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|SBE/mL|UNEQUIVOCAL|1|Coulomb|MANUAL COUNT||Y|INVESTIGATOR|ONCOLOGIST 2|Y|2|Visit_2|25|7|TREATMENT|2020-12-31|25
e|TR|69cf0c4b-13f6-4955-8046-72a333059d6e|3|[?]|DIAMETER|Diameter|[?]|BEAM BREAKS|NORMAL|1|ms/mmHg|SLIT LAMP PHOTOGRAPHY|||SIBLING|RADIOLOGIST|N|3|Visit_3|40|5|TREATMENT|2021-01-15|40
e|TR|69cf0c4b-13f6-4955-8046-72a333059d6e|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mL/animal/wk|EQUIVOCAL|1|mL/dose|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||SPOUSE|OTOLARYNGOLOGIST|U|4|Visit_4|65|3|FOLLOW-UP|2021-02-09|65
e|TR|69cf0c4b-13f6-4955-8046-72a333059d6e|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mL/cage/wk|PRESENT|1|/100 HPFs|MAGNETIC RESONANCE ELASTOGRAPHY|||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|U|5|Visit_5|90|7|TREATMENT|2021-03-06|90
e|TR|19829028-595c-4811-90e3-0ca696a04ba3|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|CAPSULE|UNCHANGED|1|ng/L|CLINICAL EVALUATION|Y||INDEPENDENT ASSESSOR|ONCOLOGIST 1|U|1|Visit_1|10|2|SCREENING|2020-07-15|10
e|TR|19829028-595c-4811-90e3-0ca696a04ba3|2|[?]|PCHGBL|Percent Change From Baseline|[?]|%/s|UNEQUIVOCAL|1|U/g|ELECTRONEUROGRAPHY|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|U|2|Visit_2|25|7|TREATMENT|2020-07-30|25
e|TR|19829028-595c-4811-90e3-0ca696a04ba3|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|anti-Xa IU/mL|PALPABLE|1|IU|ATOMIC ABSORPTION SPECTROMETRY|||SPOUSE|READER 2|Y|3|Visit_3|40|4|TREATMENT|2020-08-14|40
e|TR|19829028-595c-4811-90e3-0ca696a04ba3|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|uEq/L|NON-PATHOLOGICAL|1|10^12 IU/L|SCINTIGRAPHY|||FAMILY MEMBER|READER 1|U|4|Visit_4|65|3|TREATMENT|2020-09-08|65
e|TR|19829028-595c-4811-90e3-0ca696a04ba3|5|[?]|RADIODEN|Radiodensity|[?]|IU/mL|ABSENT|1|days/wk|MRI WITHOUT CONTRAST|||PROXY|NEUROLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-10-03|90
e|TR|562a8182-8e9b-4a68-9b95-bc52df58ed46|1|[?]|VOLUME|Volume|[?]|cs|ENLARGEMENT FROM NADIR|1|ug/m2/day|TEST STRIP|||STUDY SUBJECT|OTOLARYNGOLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-09-05|10
e|TR|562a8182-8e9b-4a68-9b95-bc52df58ed46|2|[?]|PPD|Product of Perpendicular Diameters|[?]|dL|ENLARGEMENT|1|TCID 50/dose|PULSE OXIMETRY||Y|CLINICAL RESEARCH COORDINATOR|RATER 2|NA|2|Visit_2|25|5|FOLLOW-UP|2020-09-20|25
e|TR|562a8182-8e9b-4a68-9b95-bc52df58ed46|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|keV|DECREASED|1|log10 TCID 50/uL|SLOAN LETTER EYE CHART 2.5%|Y||FRIEND|ADJUDICATOR 3|Y|3|Visit_3|40|4|TREATMENT|2020-10-05|40
e|TR|562a8182-8e9b-4a68-9b95-bc52df58ed46|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|uL/dose|UNCHANGED|1|pg/cell|PULSE OXIMETRY|||PROXY|ENDOCRINOLOGIST|Y|4|Visit_4|65|4|TREATMENT|2020-10-30|65
e|TR|562a8182-8e9b-4a68-9b95-bc52df58ed46|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|uU/L|ABSENT|1|ukat/10^12 RBC|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|Y|ADJUDICATOR|NEUROLOGIST 1|Y|5|Visit_5|90|6|TREATMENT|2020-11-24|90
e|TR|b29e6912-42f4-471b-ad90-1ec446f89ac0|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|ppb|PALPABLE|1|nmol/L|CONFOCAL MICROSCOPY|||CAREGIVER|MICROSCOPIST 3|U|1|Visit_1|10|1|FOLLOW-UP|2021-01-19|10
e|TR|b29e6912-42f4-471b-ad90-1ec446f89ac0|2|[?]|SUMVOL|Sum of Volume|[?]|Absorbance U|FURTHER ENLARGEMENT|1|10^6 CFU/mL|ENDOSCOPY|Y||VENDOR|READER 1|NA|2|Visit_2|25|5|WASHOUT|2021-02-03|25
e|TR|b29e6912-42f4-471b-ad90-1ec446f89ac0|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|10^9 organisms|ENLARGEMENT|1|km/h|LANDOLT RING|||INVESTIGATOR|ONCOLOGIST 1|NA|3|Visit_3|40|2|FOLLOW-UP|2021-02-18|40
e|TR|b29e6912-42f4-471b-ad90-1ec446f89ac0|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|SACHET|PATHOLOGICAL|1|cs|GIEMSA STAIN|||STUDY SUBJECT|READER 3|Y|4|Visit_4|65|7|SCREENING|2021-03-15|65
e|TR|b29e6912-42f4-471b-ad90-1ec446f89ac0|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|mL/kg|INCREASED|1|U/10^12 RBC|DYNAMOMETRY||Y|ADJUDICATOR|RADIOLOGIST 2|N|5|Visit_5|90|7|TREATMENT|2021-04-09|90
e|TR|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|1|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|g/kg/day|ENLARGEMENT|1|mOsm|ENZYMATIC COLORIMETRY|||GUARDIAN|ONCOLOGIST|Y|1|Visit_1|10|3|TREATMENT|2020-06-09|10
e|TR|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|2|[?]|PPD|Product of Perpendicular Diameters|[?]|U|DIFFUSELY INCREASED|1|kat|AUDIOMETRY|||FRIEND|MICROSCOPIST 3|U|2|Visit_2|25|5|TREATMENT|2020-06-24|25
e|TR|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|3|[?]|LDIAM|Longest Diameter|[?]|cm/s|UNEQUIVOCAL|1|AMPULE|IMPEDANCE CONDUCTIVITY||Y|CAREGIVER|RADIOLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-07-09|40
e|TR|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|MBP|PATHOLOGICAL|1|ug/day|SLOAN LETTER EYE CHART 1.25%||Y|ADJUDICATOR|INTERNIST|NA|4|Visit_4|65|3|TREATMENT|2020-08-03|65
e|TR|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|10^3 CFU/g|ABSENT|1|U|KINETIC MICROPARTICLE IMMUNOASSAY|Y||PARENT|NEUROLOGIST 2|Y|5|Visit_5|90|7|FOLLOW-UP|2020-08-28|90
e|TR|396295ba-9f4c-4689-88c2-f80cb28b567a|1|[?]|VOLUME|Volume|[?]|PIXEL|EQUIVOCAL|1|/5x10^4 WBC|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|||PARENT|READER 2|NA|1|Visit_1|10|6|TREATMENT|2020-12-31|10
e|TR|396295ba-9f4c-4689-88c2-f80cb28b567a|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mg/h|NONPALPABLE|1|TRANSDUCING UNIT|CONFOCAL MICROSCOPY|||ADJUDICATION COMMITTEE|MICROSCOPIST 2|U|2|Visit_2|25|5|WASHOUT|2021-01-15|25
e|TR|396295ba-9f4c-4689-88c2-f80cb28b567a|3|[?]|VOLUME|Volume|[?]|mL/cm3/min|DIFFUSELY INCREASED|1|10^9 organisms|HILLMEN COLOR CHART|Y|Y|CLINICAL STUDY SPONSOR|CARDIOLOGIST|NA|3|Visit_3|40|3|SCREENING|2021-01-30|40
e|TR|396295ba-9f4c-4689-88c2-f80cb28b567a|4|[?]|VOLUME|Volume|[?]|kg/L|ABSENT|1|mL*cmH2O|ACRIDINE ORANGE STAIN|||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|4|Visit_4|65|3|TREATMENT|2021-02-24|65
e|TR|396295ba-9f4c-4689-88c2-f80cb28b567a|5|[?]|LDIAM|Longest Diameter|[?]|DIOPTER|NORMAL|1|Tbsp|ULTRASOUND|||SIGNIFICANT OTHER|UROLOGIST|NA|5|Visit_5|90|5|SCREENING|2021-03-21|90
e|TR|56072c44-67c3-4c93-8db7-2d1570b2bbbc|1|[?]|LDIAM|Longest Diameter|[?]|grain|UNEQUIVOCAL|1|pptr|GC/MS|Y||SIBLING|ADJUDICATOR 1|NA|1|Visit_1|10|3|TREATMENT|2020-08-26|10
e|TR|56072c44-67c3-4c93-8db7-2d1570b2bbbc|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|uL/dose|ENLARGEMENT FROM NADIR|1|AU/mL|HEMATOXYLIN AND EOSIN STAIN|Y||SIBLING|RATER 2|N|2|Visit_2|25|1|TREATMENT|2020-09-10|25
e|TR|56072c44-67c3-4c93-8db7-2d1570b2bbbc|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|L/day|NORMAL|1|DIOPTER|PALPATION||Y|CAREGIVER|PHYSIOTHERAPIST|Y|3|Visit_3|40|4|WASHOUT|2020-09-25|40
e|TR|56072c44-67c3-4c93-8db7-2d1570b2bbbc|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|TCID 50/dose|UNEQUIVOCAL|1|Frames/s|WRIGHT STAIN|Y||CAREGIVER|ONCOLOGIST 2|Y|4|Visit_4|65|5|TREATMENT|2020-10-20|65
e|TR|56072c44-67c3-4c93-8db7-2d1570b2bbbc|5|[?]|ORVERLN|Organ Vertical Length|[?]|fg|ENLARGEMENT|1|Gy/min|PET/SPECT SCAN|||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|7|FOLLOW-UP|2020-11-14|90
e|TR|55b23180-01f2-498e-a0af-cb9cd7d81750|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|GPL U/mL|ENLARGEMENT|1|pmol/L|ANTIMICROBIAL COMBINATION TESTING|||CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|NA|1|Visit_1|10|4|SCREENING|2020-07-01|10
e|TR|55b23180-01f2-498e-a0af-cb9cd7d81750|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|ELISA unit/mL|ABSENT|1|BOX|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|NA|2|Visit_2|25|5|FOLLOW-UP|2020-07-16|25
e|TR|55b23180-01f2-498e-a0af-cb9cd7d81750|3|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|in|FURTHER ENLARGEMENT FROM NADIR|1|damol/L|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y||INTERVIEWER|ENDOCRINOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-07-31|40
e|TR|55b23180-01f2-498e-a0af-cb9cd7d81750|4|[?]|PPD|Product of Perpendicular Diameters|[?]|vg/kg|NORMAL|1|fmol|IN SITU HYBRIDIZATION|||PROXY|RATER|NA|4|Visit_4|65|6|FOLLOW-UP|2020-08-25|65
e|TR|55b23180-01f2-498e-a0af-cb9cd7d81750|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mN|EQUIVOCAL|1|nmol/mL/min|PH METER MEASUREMENT METHOD|Y||FRIEND|NEUROLOGIST 1|NA|5|Visit_5|90|7|TREATMENT|2020-09-19|90
e|TR|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|1|[?]|VDIAM|Viable Diameter|[?]|mIU/L|ENLARGEMENT|1|PHERESIS UNIT|OPTICAL DENSITY MEASUREMENT|Y||FAMILY MEMBER|READER 1|U|1|Visit_1|10|6|SCREENING|2020-11-09|10
e|TR|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|kg/cm2|NON-PATHOLOGICAL|1|s/h|DROPLET DIGITAL PCR|Y||SIBLING|CARDIOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-11-24|25
e|TR|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|10^6 IU/mL|PRESENT|1|/2000 RBC|CT SCAN|||SIBLING|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-12-09|40
e|TR|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|um|PATHOLOGICAL|1|/cmH2O|FLOW MICROSCOPY|Y||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|NA|4|Visit_4|65|4|TREATMENT|2021-01-03|65
e|TR|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|5|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|IU/dL|TUMOR MERGED|1|PFU/animal|NEXT GENERATION SEQUENCING|Y|Y|INVESTIGATOR|ONCOLOGIST 2|NA|5|Visit_5|90|3|FOLLOW-UP|2021-01-28|90
e|TR|940e4aef-5648-46b3-9c3e-7c40f7930030|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mL/g/h|DECREASED|1|steps/min|GC/FID|||INVESTIGATOR|RATER 1|N|1|Visit_1|10|2|TREATMENT|2020-11-15|10
e|TR|940e4aef-5648-46b3-9c3e-7c40f7930030|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|log10 CCID 50/dose|PATHOLOGICAL|1|/LPF|QUANTITATIVE COMPUTED TOMOGRAPHY|Y||SIBLING|READER 1|NA|2|Visit_2|25|5|TREATMENT|2020-11-30|25
e|TR|940e4aef-5648-46b3-9c3e-7c40f7930030|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|uU/L|UNCHANGED|1|Siemens|DNA MICROARRAY|||FRIEND|RATER|Y|3|Visit_3|40|3|TREATMENT|2020-12-15|40
e|TR|940e4aef-5648-46b3-9c3e-7c40f7930030|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|Absorbance U|FURTHER ENLARGEMENT|1|ELISA unit|ELECTRONEUROGRAPHY|||SPOUSE|READER 2|Y|4|Visit_4|65|4|TREATMENT|2021-01-09|65
e|TR|940e4aef-5648-46b3-9c3e-7c40f7930030|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|beats/min|FURTHER ENLARGEMENT|1|GBq/mg|RAJI CELL EIA||Y|SIBLING|ENDOCRINOLOGIST|NA|5|Visit_5|90|5|TREATMENT|2021-02-03|90
e|TR|e4bece1e-6672-4b55-824f-56aa923e60f9|1|[?]|PPD|Product of Perpendicular Diameters|[?]|uV*sec|ENLARGEMENT|1|AMPULE|MIGET|||HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|1|Visit_1|10|4|TREATMENT|2020-06-22|10
e|TR|e4bece1e-6672-4b55-824f-56aa923e60f9|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|ug/mL/h|EQUIVOCAL|1|kg|SICKLE CELL SOLUBILITY TEST|||DOMESTIC PARTNER|MICROSCOPIST|Y|2|Visit_2|25|1|TREATMENT|2020-07-07|25
e|TR|e4bece1e-6672-4b55-824f-56aa923e60f9|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|mL/animal|NON-PATHOLOGICAL|1|10^7 TCID 50/dose|OSCILLOMETRY|Y||PARENT|HEMATOLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-07-22|40
e|TR|e4bece1e-6672-4b55-824f-56aa923e60f9|4|[?]|DIAMETER|Diameter|[?]|U/g|PRESENT|1|MBP|MAGNETIC RESONANCE ENTEROGRAPHY|Y||CHILD|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|2|TREATMENT|2020-08-16|65
e|TR|e4bece1e-6672-4b55-824f-56aa923e60f9|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|nmol/L/min|NON-PATHOLOGICAL|1|100 IU/mL|IODINE STAIN|||CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|1|TREATMENT|2020-09-10|90
e|TR|12e607da-f53c-4078-9742-23a111db6f54|1|[?]|LESSCIND|Lesion Success Indicator|[?]|umol/kg/min|PRESENT|1|nmol/L|CHROMOGENIC ASSAY|||FAMILY MEMBER|ONCOLOGIST 1|NA|1|Visit_1|10|6|FOLLOW-UP|2020-10-03|10
e|TR|12e607da-f53c-4078-9742-23a111db6f54|2|[?]|CALCFIND|Calcification Indicator|[?]|dpm/mL|NORMAL|1|mL/cage/wk|PAP STAIN|Y|Y|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-10-18|25
e|TR|12e607da-f53c-4078-9742-23a111db6f54|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|FFU|NONPALPABLE|1|yd|IMPEDANCE CONDUCTIVITY|||INVESTIGATOR|CARDIOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2020-11-02|40
e|TR|12e607da-f53c-4078-9742-23a111db6f54|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mm/h|FURTHER ENLARGEMENT FROM NADIR|1|uV*sec|HEMAGGLUTINATION ASSAY|||CAREGIVER|NEUROLOGIST 2|Y|4|Visit_4|65|4|FOLLOW-UP|2020-11-27|65
e|TR|12e607da-f53c-4078-9742-23a111db6f54|5|[?]|VDIAM|Viable Diameter|[?]|uEq/L|FURTHER ENLARGEMENT|1|gpELISA unit/mL|PULSE OXIMETRY|Y||SIBLING|READER 2|U|5|Visit_5|90|5|FOLLOW-UP|2020-12-22|90
e|TR|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|1|[?]|PPD|Product of Perpendicular Diameters|[?]|10^5/hpf|DECREASED|1|Enzyme U/L|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|2|FOLLOW-UP|2021-01-26|10
e|TR|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mg/cm2|PATHOLOGICAL|1|PRESSOR UNITS|FLUORESCENT ENZYME IMMUNOASSAY||Y|INTERVIEWER|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|4|FOLLOW-UP|2021-02-10|25
e|TR|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|L/min/m2|UNCHANGED|1|mm/min|SLOAN LETTER EYE CHART 1.25%|Y||VENDOR|ONCOLOGIST 2|N|3|Visit_3|40|5|TREATMENT|2021-02-25|40
e|TR|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|ug/L DDU|TUMOR MERGED|1|grain|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||CHILD|OPTOMETRIST|U|4|Visit_4|65|7|TREATMENT|2021-03-22|65
e|TR|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|ng/mol|EQUIVOCAL|1|mV/sec|LIGHT SCATTERING SPECTROSCOPY|||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|U|5|Visit_5|90|2|TREATMENT|2021-04-16|90
e|TR|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|1|[?]|DIAMETER|Diameter|[?]|log10 IU/mL|TUMOR MERGED|1|mg/animal|TOTAL BODY RADIOGRAPHY|Y||GUARDIAN|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|7|WASHOUT|2020-07-16|10
e|TR|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|uV*sec|FURTHER ENLARGEMENT|1|MET*h|FLUORESCEIN STAIN|||DOMESTIC PARTNER|ADJUDICATOR 2|U|2|Visit_2|25|4|TREATMENT|2020-07-31|25
e|TR|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|3|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|cm H2O|NON-PATHOLOGICAL|1|DAgU/mL|VIRUS PLAQUE ASSAY|||PARENT|RADIOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-08-15|40
e|TR|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|4|[?]|NEWCONF|New Tumor Confirmed|[?]|10^11/L|FURTHER ENLARGEMENT FROM NADIR|1|GBq/ug|ECHOCARDIOGRAPHY|||SIBLING|ONCOLOGIST|NA|4|Visit_4|65|7|WASHOUT|2020-09-09|65
e|TR|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|Ci/ug|TUMOR MERGED|1|uU/dL|CELLULOSE TAPE|Y||FAMILY MEMBER|NEUROLOGIST 1|U|5|Visit_5|90|2|SCREENING|2020-10-04|90
e|TR|3260122d-3bf4-45ff-a026-2379158721d0|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|nmol/L/h|INCREASED|1|DDU|PEAK FLOWMETRY|||PARENT|MICROSCOPIST|U|1|Visit_1|10|2|SCREENING|2020-06-04|10
e|TR|3260122d-3bf4-45ff-a026-2379158721d0|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|L/min/m2|NONPALPABLE|1|mmHg/sec|OPTICAL MAPPING|||HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|N|2|Visit_2|25|7|WASHOUT|2020-06-19|25
e|TR|3260122d-3bf4-45ff-a026-2379158721d0|3|[?]|PPD|Product of Perpendicular Diameters|[?]|amol|UNCHANGED|1|pmol/10^10 cells|PHASE-CONTRAST MRI||Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|N|3|Visit_3|40|2|FOLLOW-UP|2020-07-04|40
e|TR|3260122d-3bf4-45ff-a026-2379158721d0|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|%/min|TUMOR MERGED|1|/sec|ANTIBIOTIC AGAR SCREEN|||GUARDIAN|ADJUDICATOR 1|N|4|Visit_4|65|3|WASHOUT|2020-07-29|65
e|TR|3260122d-3bf4-45ff-a026-2379158721d0|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|DAgU|PALPABLE|1|Siemens|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||SPOUSE|RATER|Y|5|Visit_5|90|1|TREATMENT|2020-08-23|90
e|TR|05eb4e29-887e-4cdb-8854-49939a8a13d1|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|Gravitational Unit|PATHOLOGICAL|1|U/g/h|MAMMOGRAPHY|||INDEPENDENT ASSESSOR|RATER|U|1|Visit_1|10|5|SCREENING|2020-11-05|10
e|TR|05eb4e29-887e-4cdb-8854-49939a8a13d1|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|SYRINGE|PALPABLE|1|copies/ug|MANUAL CLOT DETECTION|||SIBLING|OTOLARYNGOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-11-20|25
e|TR|05eb4e29-887e-4cdb-8854-49939a8a13d1|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|ug/g/h|NORMAL|1|ug/dose|SLOAN LETTER EYE CHART 1.25%|Y||PARENT|UROLOGIST|N|3|Visit_3|40|3|FOLLOW-UP|2020-12-05|40
e|TR|05eb4e29-887e-4cdb-8854-49939a8a13d1|4|[?]|LPERP|Longest Perpendicular|[?]|cmH2O*s/mL|DECREASED|1|log10 CFU/g|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y||GUARDIAN|NEUROLOGIST 2|U|4|Visit_4|65|6|TREATMENT|2020-12-30|65
e|TR|05eb4e29-887e-4cdb-8854-49939a8a13d1|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mg/kg/day|ABSENT|1|Tesla|DUKE INCISION METHOD|||PROXY|MICROSCOPIST 3|NA|5|Visit_5|90|7|FOLLOW-UP|2021-01-24|90
e|TR|c8390c70-766d-4252-9356-39591651bcdf|1|[?]|BNLNUM|Number of Bone Lesions|[?]|dpm/0.5 mL|NONPALPABLE|1|IU/mg|RIA|||INDEPENDENT ASSESSOR|INTERNIST|U|1|Visit_1|10|1|SCREENING|2020-08-11|10
e|TR|c8390c70-766d-4252-9356-39591651bcdf|2|[?]|DIAMETER|Diameter|[?]|mg/kg/dose|DECREASED|1|mg/dose|DUCTOGRAPHY||Y|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-08-26|25
e|TR|c8390c70-766d-4252-9356-39591651bcdf|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|uIU/L|INCREASED|1|IMPLANT|GC/MS/MS||Y|INTERVIEWER|PATHOLOGIST 2|U|3|Visit_3|40|3|SCREENING|2020-09-10|40
e|TR|c8390c70-766d-4252-9356-39591651bcdf|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|g/cage/day|DIFFUSELY INCREASED|1|ug/dose|QUANTITATIVE COMPUTED TOMOGRAPHY|||INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2020-10-05|65
e|TR|c8390c70-766d-4252-9356-39591651bcdf|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mm/min|FURTHER ENLARGEMENT|1|/kg|SLOAN LETTER EYE CHART 2.5%|||PROXY|HEMATOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-10-30|90
e|TR|a40bf877-c070-40b3-89df-d566b942246e|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|FIU|FURTHER ENLARGEMENT|1|log10 PFU|NEPHELOMETRY||Y|INDEPENDENT ASSESSOR|OPTOMETRIST|Y|1|Visit_1|10|7|TREATMENT|2020-06-16|10
e|TR|a40bf877-c070-40b3-89df-d566b942246e|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|mmol2/L2|PALPABLE|1|ukat/10^12 RBC|NO INFORMATION||Y|FRIEND|PATHOLOGIST 1|U|2|Visit_2|25|6|SCREENING|2020-07-01|25
e|TR|a40bf877-c070-40b3-89df-d566b942246e|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|uL|DECREASED|1|10^6/g|NUCLEIC ACID BASED METHOD|||VENDOR|UROLOGIST|NA|3|Visit_3|40|6|WASHOUT|2020-07-16|40
e|TR|a40bf877-c070-40b3-89df-d566b942246e|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|Weber|ABSENT|1|days/month|CONTACT SPECULAR MICROSCOPY|Y||ADJUDICATION COMMITTEE|NEUROLOGIST|NA|4|Visit_4|65|1|TREATMENT|2020-08-10|65
e|TR|a40bf877-c070-40b3-89df-d566b942246e|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|U/10^12 RBC|NON-PATHOLOGICAL|1|amol|FLUORESCEIN STAIN||Y|VENDOR|RATER 1|NA|5|Visit_5|90|3|WASHOUT|2020-09-04|90
e|TR|e9633621-3d08-4b47-b394-5bd3fa47c07f|1|[?]|LESSCIND|Lesion Success Indicator|[?]|L/s|UNEQUIVOCAL|1|fraction of 1|IMMUNOFIXATION ELECTROPHORESIS|||FAMILY MEMBER|RADIOLOGIST|U|1|Visit_1|10|5|SCREENING|2021-01-16|10
e|TR|e9633621-3d08-4b47-b394-5bd3fa47c07f|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mmAL|INCREASED|1|10^9 organisms/mg|IODINE STAIN|Y||HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2021-01-31|25
e|TR|e9633621-3d08-4b47-b394-5bd3fa47c07f|3|[?]|ORVERLN|Organ Vertical Length|[?]|mMU/mL|NORMAL|1|kat|MECHANICAL CLOT DETECTION|Y||CLINICAL STUDY SPONSOR|RADIOLOGIST|N|3|Visit_3|40|5|TREATMENT|2021-02-15|40
e|TR|e9633621-3d08-4b47-b394-5bd3fa47c07f|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|m/sec|ABSENT|1|nmol/L/h|HPLC/MS|Y||CHILD|UROLOGIST|NA|4|Visit_4|65|7|TREATMENT|2021-03-12|65
e|TR|e9633621-3d08-4b47-b394-5bd3fa47c07f|5|[?]|LNSTATE|Lymph Node State|[?]|psec|UNEQUIVOCAL|1|mmol/mol|KNEMOMETRY|Y||INTERVIEWER|PATHOLOGIST 2|NA|5|Visit_5|90|3|TREATMENT|2021-04-06|90
e|TR|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|CAPSULE|NON-PATHOLOGICAL|1|min|DIFFUSION TENSOR MRI|||VENDOR|PATHOLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-06-08|10
e|TR|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|Bq/ug|NONPALPABLE|1|pt_us|TEST STRIP|||VENDOR|RATER 2|Y|2|Visit_2|25|6|WASHOUT|2020-06-23|25
e|TR|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|MESF|PALPABLE|1|nL|IMMUNE REPERTOIRE DEEP SEQUENCING|Y||ADJUDICATION COMMITTEE|NEUROLOGIST 2|NA|3|Visit_3|40|4|SCREENING|2020-07-08|40
e|TR|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|g/cage/wk|TUMOR MERGED|1|/mm2|HPLC-UV|||INDEPENDENT ASSESSOR|NEUROLOGIST 2|U|4|Visit_4|65|6|TREATMENT|2020-08-02|65
e|TR|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|5|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|10^9 organisms|DIFFUSELY INCREASED|1|mL/g/h|GRADIENT DIFFUSION|Y||FRIEND|OTOLARYNGOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-08-27|90
e|TR|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|1|[?]|CALCFIND|Calcification Indicator|[?]|pmol/L|NONPALPABLE|1|uU/dL|ELECTRONEUROGRAPHY|||GUARDIAN|HEMATOLOGIST|N|1|Visit_1|10|4|FOLLOW-UP|2020-07-16|10
e|TR|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|2|[?]|ORVERLN|Organ Vertical Length|[?]|kHz|PALPABLE|1|FFU|IMPEDANCE CONDUCTIVITY|||FRIEND|PATHOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-07-31|25
e|TR|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|SBE/mL|TUMOR MERGED|1|Gy/min|CONTRAST ENHANCED MRI|||CLINICAL STUDY SPONSOR|OPTOMETRIST|NA|3|Visit_3|40|5|TREATMENT|2020-08-15|40
e|TR|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|BISCUIT|NONPALPABLE|1|BOX|IMMUNOCHROMATOGRAPHY|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|4|Visit_4|65|3|WASHOUT|2020-09-09|65
e|TR|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|RATIO|PRESENT|1|umol/L|PHYSICAL EXAMINATION|||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|N|5|Visit_5|90|7|TREATMENT|2020-10-04|90
e|TR|63f43990-e56e-440c-a445-76e7d114cf26|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|umol/L/min|TUMOR MERGED|1|s*kPa|INCISION-INDUCED BLEEDING METHOD|||DOMESTIC PARTNER|RATER|Y|1|Visit_1|10|5|WASHOUT|2020-10-02|10
e|TR|63f43990-e56e-440c-a445-76e7d114cf26|2|[?]|LESSCIND|Lesion Success Indicator|[?]|CARTRIDGE|FURTHER ENLARGEMENT FROM NADIR|1|MONTHS|DROPLET DIGITAL PCR||Y|INTERVIEWER|CLINICAL PATHOLOGIST|U|2|Visit_2|25|3|SCREENING|2020-10-17|25
e|TR|63f43990-e56e-440c-a445-76e7d114cf26|3|[?]|NEWCONF|New Tumor Confirmed|[?]|dmol|NON-PATHOLOGICAL|1|MPS U|ETDRS EYE CHART|||ADJUDICATOR|RADIOLOGIST 1|NA|3|Visit_3|40|5|WASHOUT|2020-11-01|40
e|TR|63f43990-e56e-440c-a445-76e7d114cf26|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mg/mL/min|EQUIVOCAL|1|log10 CFU/mL|THICK SMEAR|Y|Y|STUDY SUBJECT|READER|Y|4|Visit_4|65|2|TREATMENT|2020-11-26|65
e|TR|63f43990-e56e-440c-a445-76e7d114cf26|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|Gauss|NON-PATHOLOGICAL|1|vg/dose|HPLC-FL|||SIBLING|RADIOLOGIST 1|U|5|Visit_5|90|6|TREATMENT|2020-12-21|90
e|TR|380c89f4-2650-4a54-92f5-5e1278b9a91e|1|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mg/L|ENLARGEMENT FROM NADIR|1|/4.0 mL|CLINICAL EVALUATION|Y|Y|GUARDIAN|ONCOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-10-22|10
e|TR|380c89f4-2650-4a54-92f5-5e1278b9a91e|2|[?]|PALPSTAT|Palpable State|[?]|pmol/L/h|NORMAL|1|cmH2O/mL|PEAK FLOWMETRY|||INTERVIEWER|OTOLARYNGOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-11-06|25
e|TR|380c89f4-2650-4a54-92f5-5e1278b9a91e|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|Bq/ug|UNCHANGED|1|ng/mol|GEL ELECTROPHORESIS|||CHILD|READER 2|N|3|Visit_3|40|5|FOLLOW-UP|2020-11-21|40
e|TR|380c89f4-2650-4a54-92f5-5e1278b9a91e|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|APS U|EQUIVOCAL|1|Enzyme U/L|OBSERVATION|||SPOUSE|NEUROLOGIST 1|N|4|Visit_4|65|6|TREATMENT|2020-12-16|65
e|TR|380c89f4-2650-4a54-92f5-5e1278b9a91e|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|cmH2O*s/mL|ENLARGEMENT|1|vg/dose|REBOUND TONOMETRY|||STUDY SUBJECT|RATER 1|NA|5|Visit_5|90|4|TREATMENT|2021-01-10|90
e|TR|84c1f5f4-6415-49d8-b854-22e7529d65b6|1|[?]|ORVERLN|Organ Vertical Length|[?]|Arbitrary U|ENLARGEMENT|1|HEP|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|1|Visit_1|10|5|SCREENING|2020-12-05|10
e|TR|84c1f5f4-6415-49d8-b854-22e7529d65b6|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|L|NORMAL|1|kPa|KLEIHAUER-BETKE|||INTERVIEWER|RATER|N|2|Visit_2|25|5|TREATMENT|2020-12-20|25
e|TR|84c1f5f4-6415-49d8-b854-22e7529d65b6|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|L/day|PATHOLOGICAL|1|10^9 organisms/mL|U-HPLC/MS/MS|||FRIEND|RADIOLOGIST|N|3|Visit_3|40|6|TREATMENT|2021-01-04|40
e|TR|84c1f5f4-6415-49d8-b854-22e7529d65b6|4|[?]|ORVERLN|Organ Vertical Length|[?]|g/animal/wk|NORMAL|1|cmH2O*s2/mL|PERIPHERAL ANGIOGRAPHY|Y||CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|N|4|Visit_4|65|1|TREATMENT|2021-01-29|65
e|TR|84c1f5f4-6415-49d8-b854-22e7529d65b6|5|[?]|TUMSTATE|Tumor State|[?]|PNU/mL|DIFFUSELY INCREASED|1|MONTHS|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y|VENDOR|PHYSIOTHERAPIST|Y|5|Visit_5|90|2|TREATMENT|2021-02-23|90
e|TR|77c26a0c-0c84-44d7-8351-a50f3236e59a|1|[?]|SUMVOL|Sum of Volume|[?]|APL U|DIFFUSELY INCREASED|1|mAmp|OBSERVATION|||CHILD|ADJUDICATOR 1|Y|1|Visit_1|10|3|FOLLOW-UP|2020-05-14|10
e|TR|77c26a0c-0c84-44d7-8351-a50f3236e59a|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mol/mg|NON-PATHOLOGICAL|1|dL|CELLULOSE TAPE|||CHILD|ADJUDICATOR 1|Y|2|Visit_2|25|6|SCREENING|2020-05-29|25
e|TR|77c26a0c-0c84-44d7-8351-a50f3236e59a|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|pkat|NON-PATHOLOGICAL|1|mg/kg|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y||INTERVIEWER|PATHOLOGIST 2|N|3|Visit_3|40|1|TREATMENT|2020-06-13|40
e|TR|77c26a0c-0c84-44d7-8351-a50f3236e59a|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mmol|EQUIVOCAL|1|kg/cm2|HEMAGGLUTINATION ASSAY|||FRIEND|ENDOCRINOLOGIST|U|4|Visit_4|65|5|SCREENING|2020-07-08|65
e|TR|77c26a0c-0c84-44d7-8351-a50f3236e59a|5|[?]|ORVERLN|Organ Vertical Length|[?]|amu|ENLARGEMENT FROM NADIR|1|mL/dL|TRICHROME STAIN|Y||DOMESTIC PARTNER|ADJUDICATOR|N|5|Visit_5|90|5|FOLLOW-UP|2020-08-02|90
e|TR|a201c78a-e826-4f42-a997-7c6a019e2c91|1|[?]|ORSTATE|Organ State|[?]|log10 TCID 50/mL|FURTHER ENLARGEMENT|1|Enzyme U/L|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||CHILD|RADIOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-08-03|10
e|TR|a201c78a-e826-4f42-a997-7c6a019e2c91|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|mL/min/mmHg|DIFFUSELY INCREASED|1|kBq/uL|LYMPHANGIOGRAPHY||Y|NON-HEALTH CARE PROFESSIONAL|READER 3|NA|2|Visit_2|25|7|WASHOUT|2020-08-18|25
e|TR|a201c78a-e826-4f42-a997-7c6a019e2c91|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|APPLICATION|NONPALPABLE|1|deg/mm|MALDI|||INTERVIEWER|ONCOLOGIST|U|3|Visit_3|40|5|SCREENING|2020-09-02|40
e|TR|a201c78a-e826-4f42-a997-7c6a019e2c91|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|SUPPOSITORY|TUMOR MERGED|1|DNA copies/ug|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||Y|VENDOR|HEMATOLOGIST|U|4|Visit_4|65|4|SCREENING|2020-09-27|65
e|TR|a201c78a-e826-4f42-a997-7c6a019e2c91|5|[?]|NEWCONF|New Tumor Confirmed|[?]|nmol|FOCALLY INCREASED|1|IU/g Hb|CELL BASED BIOASSAY|||FRIEND|RATER|NA|5|Visit_5|90|6|TREATMENT|2020-10-22|90
e|TR|c41880bd-1e29-4961-b74d-bb0d979ab00f|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mL/cm H2O|DIFFUSELY INCREASED|1|ug/kg/min|AMSLER GRID|||INVESTIGATOR|NEUROLOGIST 1|Y|1|Visit_1|10|1|WASHOUT|2020-09-11|10
e|TR|c41880bd-1e29-4961-b74d-bb0d979ab00f|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|ppb|NON-PATHOLOGICAL|1|g/U|VENTILATION PERFUSION LUNG SCAN|Y||SPOUSE|RATER|N|2|Visit_2|25|6|TREATMENT|2020-09-26|25
e|TR|c41880bd-1e29-4961-b74d-bb0d979ab00f|3|[?]|PCHGBL|Percent Change From Baseline|[?]|L/min|UNEQUIVOCAL|1|KIT|HPLC/MS|||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|2|TREATMENT|2020-10-11|40
e|TR|c41880bd-1e29-4961-b74d-bb0d979ab00f|4|[?]|VOLUME|Volume|[?]|mmol|PATHOLOGICAL|1|CIGARETTE|POLYGRAPHY|||CHILD|ONCOLOGIST 1|N|4|Visit_4|65|6|WASHOUT|2020-11-05|65
e|TR|c41880bd-1e29-4961-b74d-bb0d979ab00f|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|s^-1(%O2)^-1|NORMAL|1|10^12 IU/L|PERFUSION MRI|||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|6|SCREENING|2020-11-30|90
e|TR|7de60015-fa9d-4a39-bd19-51c718a624e6|1|[?]|AREA|Area|[?]|U/mL|NON-PATHOLOGICAL|1|g/animal/wk|OSCILLOMETRY|Y|Y|SIGNIFICANT OTHER|ADJUDICATOR 1|U|1|Visit_1|10|5|FOLLOW-UP|2020-10-24|10
e|TR|7de60015-fa9d-4a39-bd19-51c718a624e6|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|KALLIKREIN INHIBITOR UNIT|PATHOLOGICAL|1|Gy|SPECT/CT SCAN|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|U|2|Visit_2|25|6|TREATMENT|2020-11-08|25
e|TR|7de60015-fa9d-4a39-bd19-51c718a624e6|3|[?]|BNLNUM|Number of Bone Lesions|[?]|BU|NON-PATHOLOGICAL|1|uL/dose|MICRODENSITOMETRY|||DOMESTIC PARTNER|MICROSCOPIST 2|N|3|Visit_3|40|5|TREATMENT|2020-11-23|40
e|TR|7de60015-fa9d-4a39-bd19-51c718a624e6|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|mL/cage/wk|FURTHER ENLARGEMENT FROM NADIR|1|RATIO|GIEMSA STAIN|||ADJUDICATOR|RATER 1|N|4|Visit_4|65|2|TREATMENT|2020-12-18|65
e|TR|7de60015-fa9d-4a39-bd19-51c718a624e6|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|umol/L/sec|DIFFUSELY INCREASED|1|MESF|LINE PROBE ASSAY|Y|Y|VENDOR|RATER 1|U|5|Visit_5|90|5|WASHOUT|2021-01-12|90
e|TR|34d03f58-155a-4908-bba3-aa979be84610|1|[?]|TUMSTATE|Tumor State|[?]|U/dL|UNCHANGED|1|IU/g|TRYPAN BLUE STAIN||Y|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|U|1|Visit_1|10|4|SCREENING|2020-06-29|10
e|TR|34d03f58-155a-4908-bba3-aa979be84610|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|10^8 PFU|INCREASED|1|BOLUS|TRIPLE-PHASE MRI SCAN|||INTERVIEWER|ADJUDICATOR 3|Y|2|Visit_2|25|7|TREATMENT|2020-07-14|25
e|TR|34d03f58-155a-4908-bba3-aa979be84610|3|[?]|RADIODEN|Radiodensity|[?]|mmol/min/kPa|TUMOR MERGED|1|EU|WESTERN BLOT|Y||PARENT|ADJUDICATOR 3|NA|3|Visit_3|40|3|TREATMENT|2020-07-29|40
e|TR|34d03f58-155a-4908-bba3-aa979be84610|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|ug/m2/min|DECREASED|1|U/g|ELECTRONEUROGRAPHY|||INVESTIGATOR|HEMATOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-08-23|65
e|TR|34d03f58-155a-4908-bba3-aa979be84610|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|Tesla|INCREASED|1|umol/dL|LAPAROSCOPY|Y||CAREGIVER|PATHOLOGIST 1|Y|5|Visit_5|90|6|TREATMENT|2020-09-17|90
e|TR|3818424f-cbc9-4e79-94b8-7edbc706bdbc|1|[?]|ORVERLN|Organ Vertical Length|[?]|g/mol|ENLARGEMENT|1|g/animal/wk|CELL BASED BIOASSAY|||ADJUDICATOR|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-08-23|10
e|TR|3818424f-cbc9-4e79-94b8-7edbc706bdbc|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|cmol/L|TUMOR MERGED|1|PRESSOR UNITS|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y|INTERVIEWER|HEMATOLOGIST|U|2|Visit_2|25|5|SCREENING|2020-09-07|25
e|TR|3818424f-cbc9-4e79-94b8-7edbc706bdbc|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|LB|UNEQUIVOCAL|1|mU/L|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||INDEPENDENT ASSESSOR|PATHOLOGIST 2|Y|3|Visit_3|40|3|SCREENING|2020-09-22|40
e|TR|3818424f-cbc9-4e79-94b8-7edbc706bdbc|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|OD Unit|PALPABLE|1|Absorbance U/mL|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||PARENT|RADIOLOGIST|N|4|Visit_4|65|1|SCREENING|2020-10-17|65
e|TR|3818424f-cbc9-4e79-94b8-7edbc706bdbc|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|/200 HPFs|DIFFUSELY INCREASED|1|pg/L|TRIPLE-PHASE MRI SCAN|||SIGNIFICANT OTHER|CARDIOLOGIST|N|5|Visit_5|90|3|WASHOUT|2020-11-11|90
e|TR|4191788e-b2dc-4885-87d8-da9feb6deea5|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|vp/mL|ENLARGEMENT|1|BEAM BREAKS|ULTRASOUND|||SIGNIFICANT OTHER|OPHTHALMOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-09-11|10
e|TR|4191788e-b2dc-4885-87d8-da9feb6deea5|2|[?]|SUMVOL|Sum of Volume|[?]|pg/dL|NORMAL|1|nmol/L|HEMAGGLUTINATION INHIBITION ASSAY||Y|ADJUDICATOR|OPTOMETRIST|NA|2|Visit_2|25|5|TREATMENT|2020-09-26|25
e|TR|4191788e-b2dc-4885-87d8-da9feb6deea5|3|[?]|LDIAM|Longest Diameter|[?]|mL/cage/wk|PATHOLOGICAL|1|mg/day|MAMMOGRAPHY|||FAMILY MEMBER|DERMATOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-10-11|40
e|TR|4191788e-b2dc-4885-87d8-da9feb6deea5|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|Ci/L|FOCALLY INCREASED|1|mL/cage|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y|VENDOR|PHYSIOTHERAPIST|NA|4|Visit_4|65|2|TREATMENT|2020-11-05|65
e|TR|4191788e-b2dc-4885-87d8-da9feb6deea5|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|ug/animal|ENLARGEMENT FROM NADIR|1|ELISA unit/mL|NON-INVASIVE DIELECTRIC SENSING||Y|FAMILY MEMBER|MICROSCOPIST 3|U|5|Visit_5|90|7|TREATMENT|2020-11-30|90
e|TR|8572a9c4-eb87-4745-81b9-8316bc8de69e|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|uIU/dL|DIFFUSELY INCREASED|1|Coulomb|FUNCTIONAL MRI|Y||PARENT|RATER|Y|1|Visit_1|10|3|WASHOUT|2020-12-24|10
e|TR|8572a9c4-eb87-4745-81b9-8316bc8de69e|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|genEq/mL|ABSENT|1|10^7 CFU/mL|LIGHT SCATTERING SPECTROSCOPY|Y|Y|ADJUDICATION COMMITTEE|RATER|NA|2|Visit_2|25|6|SCREENING|2021-01-08|25
e|TR|8572a9c4-eb87-4745-81b9-8316bc8de69e|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mJoule/cm2|TUMOR MERGED|1|RATIO|SPIRAL CT||Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|U|3|Visit_3|40|2|TREATMENT|2021-01-23|40
e|TR|8572a9c4-eb87-4745-81b9-8316bc8de69e|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|mIU/L|UNEQUIVOCAL|1|DRUM|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Y||CHILD|RADIOLOGIST 1|NA|4|Visit_4|65|2|WASHOUT|2021-02-17|65
e|TR|8572a9c4-eb87-4745-81b9-8316bc8de69e|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|umol/day|TUMOR MERGED|1|MdFI|SPECT SCAN||Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|Y|5|Visit_5|90|6|SCREENING|2021-03-14|90
e|TR|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|1|[?]|BNLNUM|Number of Bone Lesions|[?]|Pa|FURTHER ENLARGEMENT|1|SACHET|PLETHYSMOGRAPHY|||CHILD|PHYSIOTHERAPIST|N|1|Visit_1|10|2|WASHOUT|2020-11-26|10
e|TR|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|kPa/L/sec|FOCALLY INCREASED|1|IU/kg|THICK SMEAR|||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-12-11|25
e|TR|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|3|[?]|ORSTATE|Organ State|[?]|amu|FURTHER ENLARGEMENT|1|WEEKS|CLINICAL EVALUATION|||PARENT|FORENSIC PATHOLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-12-26|40
e|TR|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|4|[?]|LESSCIND|Lesion Success Indicator|[?]|NEEDLE GAUGE|EQUIVOCAL|1|atm|ELECTRICAL IMPEDANCE MYOGRAPHY|||INTERVIEWER|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|4|TREATMENT|2021-01-20|65
e|TR|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|OI50|NORMAL|1|uCi/kg|PELLI-ROBSON EYE CHART|||VENDOR|MICROSCOPIST|U|5|Visit_5|90|4|SCREENING|2021-02-14|90
e|TR|3eceae61-a4a0-49fd-964b-9f142e0da067|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|nm|DECREASED|1|Log10 ELISA unit/dose|LC/MS|||NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|1|Visit_1|10|3|WASHOUT|2020-08-28|10
e|TR|3eceae61-a4a0-49fd-964b-9f142e0da067|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|MET|INCREASED|1|kDa|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-09-12|25
e|TR|3eceae61-a4a0-49fd-964b-9f142e0da067|3|[?]|LNSTATE|Lymph Node State|[?]|kg/L|EQUIVOCAL|1|/100 WBC|PANENDOSCOPY||Y|CLINICAL STUDY SPONSOR|DERMATOLOGIST|Y|3|Visit_3|40|2|FOLLOW-UP|2020-09-27|40
e|TR|3eceae61-a4a0-49fd-964b-9f142e0da067|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|pL|NONPALPABLE|1|ukat/10^12 RBC|ELECTROMYOGRAPHY||Y|ADJUDICATOR|DERMATOLOGIST|U|4|Visit_4|65|5|SCREENING|2020-10-22|65
e|TR|3eceae61-a4a0-49fd-964b-9f142e0da067|5|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|amu|PALPABLE|1|PACKET|AURAMINE STAIN|||ADJUDICATOR|PATHOLOGIST 1|NA|5|Visit_5|90|2|TREATMENT|2020-11-16|90
e|TR|fe7ad71c-601d-4909-b56a-401c9a10f00c|1|[?]|NEWCONF|New Tumor Confirmed|[?]|Ejaculate U|DECREASED|1|days/wk|AGAR PROPORTION|||NON-HEALTH CARE PROFESSIONAL|RATER 1|Y|1|Visit_1|10|3|TREATMENT|2020-05-21|10
e|TR|fe7ad71c-601d-4909-b56a-401c9a10f00c|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|cg|PRESENT|1|10^3 DNA copies/mL|ELLA|||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|4|SCREENING|2020-06-05|25
e|TR|fe7ad71c-601d-4909-b56a-401c9a10f00c|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|IU|DIFFUSELY INCREASED|1|nU/cL|CARDIAC THERMODILUTION|Y|Y|ADJUDICATION COMMITTEE|OPTOMETRIST|Y|3|Visit_3|40|3|TREATMENT|2020-06-20|40
e|TR|fe7ad71c-601d-4909-b56a-401c9a10f00c|4|[?]|VDIAM|Viable Diameter|[?]|genEq/mL|NON-PATHOLOGICAL|1|ukat/L|ICC|Y||DOMESTIC PARTNER|INTERNIST|NA|4|Visit_4|65|4|SCREENING|2020-07-15|65
e|TR|fe7ad71c-601d-4909-b56a-401c9a10f00c|5|[?]|LPERP|Longest Perpendicular|[?]|cmH2O/mL|PATHOLOGICAL|1|mmol/day|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||INVESTIGATOR|OPTOMETRIST|N|5|Visit_5|90|7|TREATMENT|2020-08-09|90
e|TR|cc52d895-5819-46c0-b8e6-b948f1cd2408|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|mmol/day|PALPABLE|1|lm|RADIAL IMMUNODIFFUSION||Y|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-07-06|10
e|TR|cc52d895-5819-46c0-b8e6-b948f1cd2408|2|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|mm/min|DIFFUSELY INCREASED|1|kg/cm|FLUORESCEIN STAIN|||HEALTH CARE PROFESSIONAL|INTERNIST|N|2|Visit_2|25|2|WASHOUT|2020-07-21|25
e|TR|cc52d895-5819-46c0-b8e6-b948f1cd2408|3|[?]|PCHGBL|Percent Change From Baseline|[?]|ELISA unit/mL|NORMAL|1|MdFI|MAPH||Y|PARENT|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|5|FOLLOW-UP|2020-08-05|40
e|TR|cc52d895-5819-46c0-b8e6-b948f1cd2408|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|kcal/day|DIFFUSELY INCREASED|1|mg/g/min|TARGETED GENOME SEQUENCING|Y||SPOUSE|PATHOLOGIST|U|4|Visit_4|65|6|TREATMENT|2020-08-30|65
e|TR|cc52d895-5819-46c0-b8e6-b948f1cd2408|5|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|10^3 CFU/g|ABSENT|1|TRANSDUCING UNIT/mL|PHOTOMETRIC CLOT DETECTION|Y|Y|VENDOR|CARDIOLOGIST|U|5|Visit_5|90|7|TREATMENT|2020-09-24|90
e|TR|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|1|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|L/day|ENLARGEMENT FROM NADIR|1|mm2|PULMONARY ANGIOGRAPHY||Y|DOMESTIC PARTNER|MICROSCOPIST 2|NA|1|Visit_1|10|1|TREATMENT|2021-01-29|10
e|TR|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|U/g/min|NONPALPABLE|1|ug/cm2|PEAK FLOWMETRY|||PARENT|RADIOLOGIST|Y|2|Visit_2|25|4|SCREENING|2021-02-13|25
e|TR|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|3|[?]|ACHNAD|Absolute Change From Nadir|[?]|mL/m2|DIFFUSELY INCREASED|1|mgEq|NON-CONTACT SPECULAR MICROSCOPY|||VENDOR|PATHOLOGIST 2|N|3|Visit_3|40|4|FOLLOW-UP|2021-02-28|40
e|TR|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|nCi|FURTHER ENLARGEMENT FROM NADIR|1|Gy/min|ELISA|Y||HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|4|Visit_4|65|3|SCREENING|2021-03-25|65
e|TR|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|5|[?]|LDIAM|Longest Diameter|[?]|pmol/L|ABSENT|1|IU/g Hb|MIGET|||CAREGIVER|HEMATOLOGIST|N|5|Visit_5|90|1|FOLLOW-UP|2021-04-19|90
e|TR|1409edea-a372-4938-889b-df6ee93b8543|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mL/s/m2|INCREASED|1|lx|PERCUSSION|||ADJUDICATION COMMITTEE|INTERNIST|N|1|Visit_1|10|7|WASHOUT|2020-08-27|10
e|TR|1409edea-a372-4938-889b-df6ee93b8543|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|10^6/Ejaculate U|PATHOLOGICAL|1|FEU|ETDRS EYE CHART|||FRIEND|OPHTHALMOLOGIST|NA|2|Visit_2|25|5|FOLLOW-UP|2020-09-11|25
e|TR|1409edea-a372-4938-889b-df6ee93b8543|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|BOWL|INCREASED|1|BAR|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y||INVESTIGATOR|ENDOCRINOLOGIST|U|3|Visit_3|40|5|FOLLOW-UP|2020-09-26|40
e|TR|1409edea-a372-4938-889b-df6ee93b8543|4|[?]|NEWCONF|New Tumor Confirmed|[?]|CAPLET|UNCHANGED|1|10^11/L|WRIGHT-GIEMSA STAIN|||VENDOR|ADJUDICATOR 2|N|4|Visit_4|65|5|TREATMENT|2020-10-21|65
e|TR|1409edea-a372-4938-889b-df6ee93b8543|5|[?]|LDIAM|Longest Diameter|[?]|psec|NON-PATHOLOGICAL|1|Rad|HEMAGGLUTINATION INHIBITION ASSAY|||CLINICAL RESEARCH COORDINATOR|RATER 2|N|5|Visit_5|90|5|FOLLOW-UP|2020-11-15|90
e|TR|3dc16ad2-d49d-4fad-9823-d0197fb57a42|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|nm|PRESENT|1|IU/mg|IN VITRO GENE EXPRESSION ASSAY|||HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|1|Visit_1|10|1|TREATMENT|2020-09-04|10
e|TR|3dc16ad2-d49d-4fad-9823-d0197fb57a42|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|Arbitrary U|FURTHER ENLARGEMENT|1|mL/kg|GC/MS-CI|||ADJUDICATOR|MICROSCOPIST 2|Y|2|Visit_2|25|7|TREATMENT|2020-09-19|25
e|TR|3dc16ad2-d49d-4fad-9823-d0197fb57a42|3|[?]|BNLNUM|Number of Bone Lesions|[?]|nCi|DIFFUSELY INCREASED|1|fg|IMMUNOBLOT||Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|Y|3|Visit_3|40|5|WASHOUT|2020-10-04|40
e|TR|3dc16ad2-d49d-4fad-9823-d0197fb57a42|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|ka_u/dL|ENLARGEMENT FROM NADIR|1|PELLET|IVY INCISION METHOD|||CAREGIVER|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|7|TREATMENT|2020-10-29|65
e|TR|3dc16ad2-d49d-4fad-9823-d0197fb57a42|5|[?]|PPD|Product of Perpendicular Diameters|[?]|mg/g/h|DECREASED|1|mL/g/day|SPECULAR MICROSCOPY|||DOMESTIC PARTNER|RATER 1|Y|5|Visit_5|90|3|WASHOUT|2020-11-23|90
e|TR|7c244128-0508-422f-88ba-ecce68cec054|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|mV2/Hz|UNCHANGED|1|mgEq|ECHOCARDIOGRAPHY|||ADJUDICATION COMMITTEE|ONCOLOGIST 2|Y|1|Visit_1|10|6|SCREENING|2020-08-05|10
e|TR|7c244128-0508-422f-88ba-ecce68cec054|2|[?]|SUMVOL|Sum of Volume|[?]|s^-1(%O2)^-1|TUMOR MERGED|1|yd|KNEMOMETRY|Y||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|N|2|Visit_2|25|2|SCREENING|2020-08-20|25
e|TR|7c244128-0508-422f-88ba-ecce68cec054|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|mOsm/L|ABSENT|1|yd|PELLI-ROBSON EYE CHART|Y||INDEPENDENT ASSESSOR|ADJUDICATOR|N|3|Visit_3|40|4|WASHOUT|2020-09-04|40
e|TR|7c244128-0508-422f-88ba-ecce68cec054|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|U/cL|EQUIVOCAL|1|mL*cmH2O|SPIRAL CT|||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|4|Visit_4|65|1|FOLLOW-UP|2020-09-29|65
e|TR|7c244128-0508-422f-88ba-ecce68cec054|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mL/cm|ENLARGEMENT FROM NADIR|1|mg/kg/h|FLUORESCENT SPOT TEST||Y|SIGNIFICANT OTHER|ADJUDICATOR 2|NA|5|Visit_5|90|2|SCREENING|2020-10-24|90
e|TR|247814c7-9fb3-43f2-9e0a-db70b27b3d95|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|Arbitrary U|INCREASED|1|kg/m2|GC/MS/MS|||INTERVIEWER|OPHTHALMOLOGIST|NA|1|Visit_1|10|5|SCREENING|2020-12-16|10
e|TR|247814c7-9fb3-43f2-9e0a-db70b27b3d95|2|[?]|SUMDIAM|Sum of Diameter|[?]|mL|NONPALPABLE|1|copies/ug|GC/MS-EI|Y||INTERVIEWER|NEUROLOGIST|N|2|Visit_2|25|2|FOLLOW-UP|2020-12-31|25
e|TR|247814c7-9fb3-43f2-9e0a-db70b27b3d95|3|[?]|VDIAM|Viable Diameter|[?]|kPa|ENLARGEMENT FROM NADIR|1|g/m2/day|ZIEHL NEELSEN ACID FAST STAIN|Y||INTERVIEWER|READER 3|NA|3|Visit_3|40|1|TREATMENT|2021-01-15|40
e|TR|247814c7-9fb3-43f2-9e0a-db70b27b3d95|4|[?]|PCHGBL|Percent Change From Baseline|[?]|10^9 CFU|ABSENT|1|10^11/L|MICROPARTICLE ENZYME IMMUNOASSAY|||INVESTIGATOR|RADIOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2021-02-09|65
e|TR|247814c7-9fb3-43f2-9e0a-db70b27b3d95|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|cd|UNEQUIVOCAL|1|log10 CFU/g|MYELOPEROXIDASE STAIN|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|5|Visit_5|90|7|TREATMENT|2021-03-06|90
e|TR|e870fe2f-b08c-41d9-a672-07da09fe2b99|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|g/cm2|FURTHER ENLARGEMENT|1|PHERESIS UNIT|AUDIOMETRY|||ADJUDICATOR|READER|Y|1|Visit_1|10|7|TREATMENT|2020-08-12|10
e|TR|e870fe2f-b08c-41d9-a672-07da09fe2b99|2|[?]|ORVERLN|Organ Vertical Length|[?]|L/kg|PATHOLOGICAL|1|10^3 copies/mL|SLOAN LETTER EYE CHART 100%|||SPOUSE|RATER 1|NA|2|Visit_2|25|4|TREATMENT|2020-08-27|25
e|TR|e870fe2f-b08c-41d9-a672-07da09fe2b99|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mm2|NON-PATHOLOGICAL|1|U/m2/min|IMMUNOCHROMATOGRAPHY|||FAMILY MEMBER|INTERNIST|U|3|Visit_3|40|5|TREATMENT|2020-09-11|40
e|TR|e870fe2f-b08c-41d9-a672-07da09fe2b99|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|GBq|ABSENT|1|mL*cmH2O|APPLANATION TONOMETRY|Y||VENDOR|NEUROLOGIST 1|NA|4|Visit_4|65|4|TREATMENT|2020-10-06|65
e|TR|e870fe2f-b08c-41d9-a672-07da09fe2b99|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|kg/L|DIFFUSELY INCREASED|1|m3|ULTRASONOGRAPHIC ELASTOGRAPHY|Y||FAMILY MEMBER|ADJUDICATOR|N|5|Visit_5|90|5|TREATMENT|2020-10-31|90
e|TR|32979638-fb88-4cbb-a110-a4d2016e9bc5|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|BU/mL|FOCALLY INCREASED|1|ug/kg/day|NUCLEIC ACID BASED METHOD|||VENDOR|READER|Y|1|Visit_1|10|4|FOLLOW-UP|2020-07-15|10
e|TR|32979638-fb88-4cbb-a110-a4d2016e9bc5|2|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|MONTHS|EQUIVOCAL|1|mL/m2/min|SPECT/CT SCAN|||CAREGIVER|ADJUDICATOR|U|2|Visit_2|25|2|TREATMENT|2020-07-30|25
e|TR|32979638-fb88-4cbb-a110-a4d2016e9bc5|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|L/s|TUMOR MERGED|1|ag|PYROSEQUENCING|Y||CAREGIVER|READER 1|NA|3|Visit_3|40|4|TREATMENT|2020-08-14|40
e|TR|32979638-fb88-4cbb-a110-a4d2016e9bc5|4|[?]|PPD|Product of Perpendicular Diameters|[?]|MONTHS|FURTHER ENLARGEMENT|1|Newton|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|5|FOLLOW-UP|2020-09-08|65
e|TR|32979638-fb88-4cbb-a110-a4d2016e9bc5|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|U/mmol|ENLARGEMENT FROM NADIR|1|cmH2O*s/mL|IMMUNORADIOMETRIC ASSAY|Y|Y|HEALTH CARE PROFESSIONAL|UROLOGIST|U|5|Visit_5|90|7|SCREENING|2020-10-03|90
e|TR|39b8db88-810b-4402-9ca3-c2bab1939c1c|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mEq/g|NON-PATHOLOGICAL|1|/sec|ETDRS EYE CHART|||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|3|FOLLOW-UP|2020-11-15|10
e|TR|39b8db88-810b-4402-9ca3-c2bab1939c1c|2|[?]|LNSTATE|Lymph Node State|[?]|APPLICATION|UNEQUIVOCAL|1|ugEq/L|IMMUNOTURBIDIMETRY|Y||STUDY SUBJECT|NEUROLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-11-30|25
e|TR|39b8db88-810b-4402-9ca3-c2bab1939c1c|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mg/kg/week|UNCHANGED|1|mgEq|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|INVESTIGATOR|PHYSIOTHERAPIST|N|3|Visit_3|40|6|WASHOUT|2020-12-15|40
e|TR|39b8db88-810b-4402-9ca3-c2bab1939c1c|4|[?]|LPERP|Longest Perpendicular|[?]|OI50|FOCALLY INCREASED|1|10^6/L|MYELOPEROXIDASE STAIN|||PROXY|RATER 2|N|4|Visit_4|65|4|TREATMENT|2021-01-09|65
e|TR|39b8db88-810b-4402-9ca3-c2bab1939c1c|5|[?]|LESSCIND|Lesion Success Indicator|[?]|psec|ENLARGEMENT FROM NADIR|1|mmol/min/kPa|KLEIHAUER-BETKE|||ADJUDICATOR|NEUROLOGIST 1|U|5|Visit_5|90|7|TREATMENT|2021-02-03|90
e|TR|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|1|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|U/dL|NORMAL|1|mg/m2/min|WEBER GREEN STAIN|Y||CHILD|OPTOMETRIST|U|1|Visit_1|10|1|TREATMENT|2020-07-27|10
e|TR|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|/h|NORMAL|1|TROCHE|TRANSMISSION ELECTRON MICROSCOPY|Y||PROXY|PHYSIOTHERAPIST|NA|2|Visit_2|25|4|SCREENING|2020-08-11|25
e|TR|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|3|[?]|ORSTATE|Organ State|[?]|EU|PATHOLOGICAL|1|mIU/L|ENZYMATIC SPECTROPHOTOMETRY|||PROXY|NEUROLOGIST|NA|3|Visit_3|40|1|TREATMENT|2020-08-26|40
e|TR|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|mOsm/kg|FURTHER ENLARGEMENT|1|ug/m2/day|MIGET|Y||STUDY SUBJECT|ONCOLOGIST 2|Y|4|Visit_4|65|3|SCREENING|2020-09-20|65
e|TR|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|5|[?]|SUMDIAM|Sum of Diameter|[?]|GPL U/mL|DIFFUSELY INCREASED|1|Log10 ELISA unit|MIGET||Y|CHILD|READER 3|Y|5|Visit_5|90|5|TREATMENT|2020-10-15|90
e|TR|bca1f50d-04e6-46f5-afb3-e48aaea1069d|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|Ci/mL|NORMAL|1|mL/h|THERMAL IONIZATION MASS SPECTROMETRY||Y|CAREGIVER|MICROSCOPIST 1|U|1|Visit_1|10|3|SCREENING|2020-11-03|10
e|TR|bca1f50d-04e6-46f5-afb3-e48aaea1069d|2|[?]|TUMSTATE|Tumor State|[?]|mL/g/min|DIFFUSELY INCREASED|1|/mm|SURFACE PLASMON RESONANCE|||INDEPENDENT ASSESSOR|MICROSCOPIST 2|Y|2|Visit_2|25|7|TREATMENT|2020-11-18|25
e|TR|bca1f50d-04e6-46f5-afb3-e48aaea1069d|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|ft|FURTHER ENLARGEMENT FROM NADIR|1|10^7 CFU|SINGLE-MOLECULE ARRAY||Y|GUARDIAN|RADIOLOGIST 2|N|3|Visit_3|40|1|FOLLOW-UP|2020-12-03|40
e|TR|bca1f50d-04e6-46f5-afb3-e48aaea1069d|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|ukat/L|PATHOLOGICAL|1|POINT|CHROMOGENIC ASSAY|||FRIEND|READER 1|NA|4|Visit_4|65|7|FOLLOW-UP|2020-12-28|65
e|TR|bca1f50d-04e6-46f5-afb3-e48aaea1069d|5|[?]|LPERP|Longest Perpendicular|[?]|cmH2O/mL|FURTHER ENLARGEMENT|1|ug/dose|GRAM STAIN|||SIGNIFICANT OTHER|NEUROLOGIST|N|5|Visit_5|90|2|SCREENING|2021-01-22|90
e|TR|6bddadef-13fb-4fab-b281-aa33aa97aa8f|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|10^3 copies/mL|NORMAL|1|mOsm|PYROSEQUENCING|||DOMESTIC PARTNER|RADIOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-05-24|10
e|TR|6bddadef-13fb-4fab-b281-aa33aa97aa8f|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|CAPFUL|ENLARGEMENT|1|10^3/L|HEMAGGLUTINATION INHIBITION ASSAY||Y|PARENT|ONCOLOGIST 1|U|2|Visit_2|25|7|FOLLOW-UP|2020-06-08|25
e|TR|6bddadef-13fb-4fab-b281-aa33aa97aa8f|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|Frames/s|UNEQUIVOCAL|1|usec|RAJI CELL RIA|||INVESTIGATOR|OPTOMETRIST|Y|3|Visit_3|40|2|TREATMENT|2020-06-23|40
e|TR|6bddadef-13fb-4fab-b281-aa33aa97aa8f|4|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|KALLIKREIN INHIBITOR UNIT|UNEQUIVOCAL|1|copies/uL|SPECULAR MICROSCOPY||Y|SIBLING|NEUROLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-07-18|65
e|TR|6bddadef-13fb-4fab-b281-aa33aa97aa8f|5|[?]|CALCFIND|Calcification Indicator|[?]|POINT|NONPALPABLE|1|/LSQN|MULTI-SLICE SPIRAL CT|||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|5|Visit_5|90|1|TREATMENT|2020-08-12|90
e|TR|6edb7414-d8f4-44da-8483-504b93a7e705|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|JAR|NORMAL|1|pkat|CONGO RED STAIN|||SPOUSE|READER 3|U|1|Visit_1|10|2|SCREENING|2020-06-07|10
e|TR|6edb7414-d8f4-44da-8483-504b93a7e705|2|[?]|VDIAM|Viable Diameter|[?]|U/mmol|DECREASED|1|pt_br|BALLPOINT PEN TECHNIQUE|||SPOUSE|RADIOLOGIST 1|Y|2|Visit_2|25|4|WASHOUT|2020-06-22|25
e|TR|6edb7414-d8f4-44da-8483-504b93a7e705|3|[?]|LDIAM|Longest Diameter|[?]|kHz|ENLARGEMENT|1|um2|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||NON-HEALTH CARE PROFESSIONAL|READER 1|N|3|Visit_3|40|1|WASHOUT|2020-07-07|40
e|TR|6edb7414-d8f4-44da-8483-504b93a7e705|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|L/s/kPa|EQUIVOCAL|1|mOsm|ELASTOGRAPHY||Y|PROXY|READER 3|Y|4|Visit_4|65|7|SCREENING|2020-08-01|65
e|TR|6edb7414-d8f4-44da-8483-504b93a7e705|5|[?]|LNSTATE|Lymph Node State|[?]|L/h/m2|INCREASED|1|nmol/L|NEXT GENERATION SEQUENCING|Y||ADJUDICATOR|ENDOCRINOLOGIST|Y|5|Visit_5|90|7|WASHOUT|2020-08-26|90
e|TR|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|1|[?]|VDIAM|Viable Diameter|[?]|mmol/day|ENLARGEMENT FROM NADIR|1|Enzyme U/g Hb|LAPAROSCOPY|||ADJUDICATOR|ADJUDICATOR 3|Y|1|Visit_1|10|4|FOLLOW-UP|2020-05-16|10
e|TR|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|2|[?]|ORVERLN|Organ Vertical Length|[?]|CAPLET|ABSENT|1|ug/m2/min|ALCIAN BLUE STAIN|||INVESTIGATOR|RADIOLOGIST 1|Y|2|Visit_2|25|5|FOLLOW-UP|2020-05-31|25
e|TR|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|3|[?]|PCHGBL|Percent Change From Baseline|[?]|dram|FOCALLY INCREASED|1|mEq/dL|LISSAMINE GREEN STAIN|||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|7|SCREENING|2020-06-15|40
e|TR|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|EP U|ABSENT|1|10^10/L|SXA SCAN|||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|U|4|Visit_4|65|3|TREATMENT|2020-07-10|65
e|TR|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|BAG|NON-PATHOLOGICAL|1|dyn|ACID FAST STAIN|Y||INTERVIEWER|RATER 1|U|5|Visit_5|90|3|TREATMENT|2020-08-04|90
e|TR|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|uEq|ABSENT|1|fmol|DISK DIFFUSION|||CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|1|SCREENING|2020-05-18|10
e|TR|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|kDa|UNCHANGED|1|ug/L DDU|ISHIHARA COLOR PLATES|||INDEPENDENT ASSESSOR|NEUROLOGIST 2|N|2|Visit_2|25|6|SCREENING|2020-06-02|25
e|TR|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|3|[?]|SUMVOL|Sum of Volume|[?]|msec|DECREASED|1|mL/h|PLETHYSMOGRAPHY|Y||CAREGIVER|ADJUDICATOR 1|Y|3|Visit_3|40|2|TREATMENT|2020-06-17|40
e|TR|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|cd*s/m2|ENLARGEMENT FROM NADIR|1|dpm/100mg|SLOAN LETTER EYE CHART 100%|||FAMILY MEMBER|RADIOLOGIST 2|Y|4|Visit_4|65|1|TREATMENT|2020-07-12|65
e|TR|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mL*cmH2O|DIFFUSELY INCREASED|1|cal|ELISA|||GUARDIAN|NEUROLOGIST|U|5|Visit_5|90|3|FOLLOW-UP|2020-08-06|90
e|TR|47d55e87-e559-424d-a6ad-d533a0d77f39|1|[?]|PPD|Product of Perpendicular Diameters|[?]|mOsm/L|FURTHER ENLARGEMENT FROM NADIR|1|uCi|DNA MICROARRAY||Y|INTERVIEWER|PATHOLOGIST 1|Y|1|Visit_1|10|1|FOLLOW-UP|2021-01-12|10
e|TR|47d55e87-e559-424d-a6ad-d533a0d77f39|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|FINGERTIP UNIT|ENLARGEMENT FROM NADIR|1|mmol/s|MICROBIAL CONCENTRATION|||INVESTIGATOR|OPTOMETRIST|U|2|Visit_2|25|6|SCREENING|2021-01-27|25
e|TR|47d55e87-e559-424d-a6ad-d533a0d77f39|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|ug/L/h|UNEQUIVOCAL|1|uL|SLOAN LETTER EYE CHART 1.25%||Y|CAREGIVER|FORENSIC PATHOLOGIST|U|3|Visit_3|40|3|SCREENING|2021-02-11|40
e|TR|47d55e87-e559-424d-a6ad-d533a0d77f39|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|MdFI|NONPALPABLE|1|10^6 DNA copies/mL|LIGHT SCATTERING SPECTROSCOPY|||INVESTIGATOR|PATHOLOGIST 2|NA|4|Visit_4|65|5|TREATMENT|2021-03-08|65
e|TR|47d55e87-e559-424d-a6ad-d533a0d77f39|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|ugEq|ENLARGEMENT|1|pg/cell|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||FAMILY MEMBER|READER 2|N|5|Visit_5|90|3|TREATMENT|2021-04-02|90
e|TR|f89c08df-2e24-4c97-a451-1980cecebf14|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|uCi|FURTHER ENLARGEMENT FROM NADIR|1|uOsm|ACRIDINE ORANGE STAIN|||ADJUDICATOR|PEDIATRIC NEUROLOGIST|NA|1|Visit_1|10|4|SCREENING|2020-12-18|10
e|TR|f89c08df-2e24-4c97-a451-1980cecebf14|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|pkat/L|INCREASED|1|dB|MRI WITHOUT CONTRAST|||INTERVIEWER|OTOLARYNGOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2021-01-02|25
e|TR|f89c08df-2e24-4c97-a451-1980cecebf14|3|[?]|AREA|Area|[?]|Rad|INCREASED|1|ELISA unit|BAC ACGH|||CAREGIVER|ADJUDICATOR 1|N|3|Visit_3|40|2|TREATMENT|2021-01-17|40
e|TR|f89c08df-2e24-4c97-a451-1980cecebf14|4|[?]|ORSTATE|Organ State|[?]|/100 HPFs|NORMAL|1|APPLICATION|REBOUND TONOMETRY|||ADJUDICATION COMMITTEE|NEUROLOGIST|NA|4|Visit_4|65|6|SCREENING|2021-02-11|65
e|TR|f89c08df-2e24-4c97-a451-1980cecebf14|5|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|ug/min|NON-PATHOLOGICAL|1|/ms|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||CAREGIVER|READER 2|Y|5|Visit_5|90|3|SCREENING|2021-03-08|90
e|TR|dbb225ed-e322-4946-a60a-0fafd7e22953|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|cpm|ABSENT|1|cy/cm|REFLECTANCE SPECTROSCOPY|||CLINICAL RESEARCH COORDINATOR|RATER 1|NA|1|Visit_1|10|3|TREATMENT|2021-01-24|10
e|TR|dbb225ed-e322-4946-a60a-0fafd7e22953|2|[?]|LESSCIND|Lesion Success Indicator|[?]|Enzyme U/g Hb|NORMAL|1|ECL unit|CHROMOGENIC ASSAY|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|U|2|Visit_2|25|1|TREATMENT|2021-02-08|25
e|TR|dbb225ed-e322-4946-a60a-0fafd7e22953|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|Arbitrary U|NON-PATHOLOGICAL|1|%/s|WRIGHT-GIEMSA STAIN|||CHILD|PATHOLOGIST 2|Y|3|Visit_3|40|1|FOLLOW-UP|2021-02-23|40
e|TR|dbb225ed-e322-4946-a60a-0fafd7e22953|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|uSiemens|DIFFUSELY INCREASED|1|10^3 DNA copies/mL|PYROSEQUENCING|||INDEPENDENT ASSESSOR|RATER|N|4|Visit_4|65|7|WASHOUT|2021-03-20|65
e|TR|dbb225ed-e322-4946-a60a-0fafd7e22953|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|uIU/dL|FOCALLY INCREASED|1|dmol|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|6|WASHOUT|2021-04-14|90
e|TR|95e61698-43f7-4cc5-aafa-06dac7870743|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|ug/dL|FURTHER ENLARGEMENT FROM NADIR|1|mm2|SMEAR|||SIGNIFICANT OTHER|ADJUDICATOR 1|Y|1|Visit_1|10|6|TREATMENT|2020-12-25|10
e|TR|95e61698-43f7-4cc5-aafa-06dac7870743|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|Anson U|DIFFUSELY INCREASED|1|SPRAY|ETDRS EYE CHART|||INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|Y|2|Visit_2|25|4|TREATMENT|2021-01-09|25
e|TR|95e61698-43f7-4cc5-aafa-06dac7870743|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|L/h/m2|ABSENT|1|umol|HPLC/IEX|Y|Y|VENDOR|ADJUDICATOR 2|U|3|Visit_3|40|2|TREATMENT|2021-01-24|40
e|TR|95e61698-43f7-4cc5-aafa-06dac7870743|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|dram|FOCALLY INCREASED|1|AgU/mL|SLIT LAMP PHOTOGRAPHY|||SIBLING|FORENSIC PATHOLOGIST|N|4|Visit_4|65|3|WASHOUT|2021-02-18|65
e|TR|95e61698-43f7-4cc5-aafa-06dac7870743|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|CCID 50/mL|DECREASED|1|10^9 organisms|FLUORESCENCE ANGIOGRAPHY|Y||SIGNIFICANT OTHER|PHYSIOTHERAPIST|U|5|Visit_5|90|6|TREATMENT|2021-03-15|90
e|TR|151308c7-03aa-4a0b-b13f-9838edb218ef|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|PIXEL|ENLARGEMENT FROM NADIR|1|HOURS|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||Y|VENDOR|PATHOLOGIST|U|1|Visit_1|10|2|SCREENING|2020-09-13|10
e|TR|151308c7-03aa-4a0b-b13f-9838edb218ef|2|[?]|LPERP|Longest Perpendicular|[?]|BLOCKS|NONPALPABLE|1|IMPLANT|CALCOFLUOR WHITE STAIN|Y||SIGNIFICANT OTHER|ADJUDICATOR 1|Y|2|Visit_2|25|5|TREATMENT|2020-09-28|25
e|TR|151308c7-03aa-4a0b-b13f-9838edb218ef|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|/10^5|FURTHER ENLARGEMENT FROM NADIR|1|g/animal/wk|GRADIENT DIFFUSION|||PROXY|INTERNIST|N|3|Visit_3|40|3|TREATMENT|2020-10-13|40
e|TR|151308c7-03aa-4a0b-b13f-9838edb218ef|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|TRANSDUCING UNIT/mL|FOCALLY INCREASED|1|mm/sec|BIOPSY||Y|GUARDIAN|HEMATOLOGIST|NA|4|Visit_4|65|6|WASHOUT|2020-11-07|65
e|TR|151308c7-03aa-4a0b-b13f-9838edb218ef|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|mmAL|NONPALPABLE|1|DROP|FLUOROSCOPY||Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|N|5|Visit_5|90|7|WASHOUT|2020-12-02|90
e|TR|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mMU/mL|ABSENT|1|Ci/mg|MULTI-SLICE SPIRAL CT|Y|Y|CLINICAL RESEARCH COORDINATOR|READER 3|Y|1|Visit_1|10|6|TREATMENT|2020-06-15|10
e|TR|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|mL/min/mmHg|INCREASED|1|mAmp|ATOMIC ABSORPTION SPECTROMETRY||Y|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|U|2|Visit_2|25|4|TREATMENT|2020-06-30|25
e|TR|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|MBP|NORMAL|1|amp|PET/MRI SCAN|||CAREGIVER|ADJUDICATOR 2|NA|3|Visit_3|40|3|FOLLOW-UP|2020-07-15|40
e|TR|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|U/g|NONPALPABLE|1|pg/L|ELECTROGASTROGRAPHY||Y|VENDOR|RADIOLOGIST 2|Y|4|Visit_4|65|3|TREATMENT|2020-08-09|65
e|TR|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|5|[?]|DIAMETER|Diameter|[?]|uV*sec|INCREASED|1|mU|LIGHT MICROSCOPY|Y|Y|INDEPENDENT ASSESSOR|ONCOLOGIST|Y|5|Visit_5|90|1|TREATMENT|2020-09-03|90
e|TR|23605586-1b30-4f05-bb15-417dd3a79994|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|10^8 PFU|ENLARGEMENT FROM NADIR|1|mPa|MIGET|||ADJUDICATOR|ADJUDICATOR|N|1|Visit_1|10|2|TREATMENT|2020-10-31|10
e|TR|23605586-1b30-4f05-bb15-417dd3a79994|2|[?]|SUMDIAM|Sum of Diameter|[?]|mol/day|NON-PATHOLOGICAL|1|kcal/day|PERCUSSION|||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|U|2|Visit_2|25|6|FOLLOW-UP|2020-11-15|25
e|TR|23605586-1b30-4f05-bb15-417dd3a79994|3|[?]|ACHNAD|Absolute Change From Nadir|[?]|Bq/mL|NORMAL|1|g/cm2|SURFACE PLASMON RESONANCE|||INVESTIGATOR|DERMATOLOGIST|NA|3|Visit_3|40|3|WASHOUT|2020-11-30|40
e|TR|23605586-1b30-4f05-bb15-417dd3a79994|4|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|U/L|FURTHER ENLARGEMENT|1|PIPE|SLIT LAMP||Y|SPOUSE|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2020-12-25|65
e|TR|23605586-1b30-4f05-bb15-417dd3a79994|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|Arbitrary U|PALPABLE|1|umol/L|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y|SIBLING|MICROSCOPIST 1|U|5|Visit_5|90|3|WASHOUT|2021-01-19|90
e|TR|57d15ac0-06a6-40e0-9201-4d947651c9b0|1|[?]|SUMDIAM|Sum of Diameter|[?]|F|EQUIVOCAL|1|mJoule/cm2|MICROBIAL CULTURE, SOLID||Y|INVESTIGATOR|ENDOCRINOLOGIST|Y|1|Visit_1|10|2|FOLLOW-UP|2020-08-28|10
e|TR|57d15ac0-06a6-40e0-9201-4d947651c9b0|2|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|10^9 organisms/g|DIFFUSELY INCREASED|1|anti-Xa IU|VENTILATION PERFUSION LUNG SCAN|Y||CLINICAL STUDY SPONSOR|HEMATOLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-09-12|25
e|TR|57d15ac0-06a6-40e0-9201-4d947651c9b0|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|10^9 organisms/mg|NON-PATHOLOGICAL|1|ft2|GEL ELECTROPHORESIS|Y||CHILD|READER|U|3|Visit_3|40|2|TREATMENT|2020-09-27|40
e|TR|57d15ac0-06a6-40e0-9201-4d947651c9b0|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|MPL U/mL|FOCALLY INCREASED|1|ug/g/h|FLUORIMETRY|||SIGNIFICANT OTHER|RADIOLOGIST|N|4|Visit_4|65|3|WASHOUT|2020-10-22|65
e|TR|57d15ac0-06a6-40e0-9201-4d947651c9b0|5|[?]|LESSCIND|Lesion Success Indicator|[?]|10^3/L|NORMAL|1|cd|ALCIAN BLUE STAIN||Y|SPOUSE|ADJUDICATOR|N|5|Visit_5|90|4|SCREENING|2020-11-16|90
e|TR|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|1|[?]|SUMVOL|Sum of Volume|[?]|cmHg|DECREASED|1|ug/dL|ECHOCARDIOGRAPHY|||INVESTIGATOR|OPHTHALMOLOGIST|NA|1|Visit_1|10|6|WASHOUT|2020-08-12|10
e|TR|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|ukat/10^12 RBC|UNEQUIVOCAL|1|kBq/uL|HIGH RESOLUTION MELT ANALYSIS|||SPOUSE|ADJUDICATOR 3|NA|2|Visit_2|25|3|SCREENING|2020-08-27|25
e|TR|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|3|[?]|ORVERLN|Organ Vertical Length|[?]|PHERESIS UNIT|DIFFUSELY INCREASED|1|mg/kg/day|HEMAGGLUTINATION ASSAY||Y|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|U|3|Visit_3|40|3|WASHOUT|2020-09-11|40
e|TR|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|YEARS|PRESENT|1|umol/min|MEDIASTINOSCOPY||Y|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|Y|4|Visit_4|65|2|SCREENING|2020-10-06|65
e|TR|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|WAFER|UNEQUIVOCAL|1|mg/L|FLUOROSCOPY|||DOMESTIC PARTNER|READER|NA|5|Visit_5|90|5|TREATMENT|2020-10-31|90
e|TR|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|TABLET|FOCALLY INCREASED|1|Frames/s|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||DOMESTIC PARTNER|NEUROLOGIST|NA|1|Visit_1|10|3|FOLLOW-UP|2020-08-31|10
e|TR|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|IU/g|ENLARGEMENT|1|10^9 organisms/mL|MRS|||SPOUSE|RATER 1|NA|2|Visit_2|25|1|SCREENING|2020-09-15|25
e|TR|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|Gy/min|TUMOR MERGED|1|Absorbance U/mL|IRON HEMATOXYLIN STAIN|||DOMESTIC PARTNER|UROLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-09-30|40
e|TR|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mL/cm3/min|PATHOLOGICAL|1|Pack Year|SLOAN LETTER EYE CHART 1.25%|||SIGNIFICANT OTHER|MICROSCOPIST 2|NA|4|Visit_4|65|7|WASHOUT|2020-10-25|65
e|TR|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|GLOBULE|NON-PATHOLOGICAL|1|mL/mmHg/min/L|SPECULAR MICROSCOPY|||CAREGIVER|ADJUDICATOR 2|NA|5|Visit_5|90|6|WASHOUT|2020-11-19|90
e|TR|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|1|[?]|SUMVOL|Sum of Volume|[?]|ohm|DIFFUSELY INCREASED|1|STRIP|SPECTROPHOTOMETRY|Y||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|4|TREATMENT|2020-12-24|10
e|TR|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|2|[?]|CALCFIND|Calcification Indicator|[?]|LB|FURTHER ENLARGEMENT FROM NADIR|1|10^3 RNA copies/mL|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||GUARDIAN|CARDIOLOGIST|U|2|Visit_2|25|4|FOLLOW-UP|2021-01-08|25
e|TR|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|3|[?]|PCHGBL|Percent Change From Baseline|[?]|NEBULE|ABSENT|1|fraction of 1|HEMAGGLUTINATION ASSAY|||FRIEND|RADIOLOGIST 2|U|3|Visit_3|40|5|TREATMENT|2021-01-23|40
e|TR|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|/7.5 mL|PATHOLOGICAL|1|mCi/kg|RYAN BLUE STAIN|||VENDOR|MICROSCOPIST 3|N|4|Visit_4|65|2|TREATMENT|2021-02-17|65
e|TR|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|10^9 organisms|DIFFUSELY INCREASED|1|GBq/g|MECHANICAL CLOT DETECTION|||INVESTIGATOR|ADJUDICATOR|Y|5|Visit_5|90|1|TREATMENT|2021-03-14|90
e|TR|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|1|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|cP|DECREASED|1|atm|TRANSMISSION ELECTRON MICROSCOPY|||CAREGIVER|INTERNIST|N|1|Visit_1|10|4|TREATMENT|2020-07-02|10
e|TR|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|2|[?]|LNSTATE|Lymph Node State|[?]|breaths/30s|DECREASED|1|tsp|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|Y||ADJUDICATOR|RADIOLOGIST 2|NA|2|Visit_2|25|7|TREATMENT|2020-07-17|25
e|TR|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|10^6 CFU/g|NORMAL|1|Ci/kg|TOLUIDINE BLUE STAIN||Y|ADJUDICATOR|MICROSCOPIST 3|Y|3|Visit_3|40|6|FOLLOW-UP|2020-08-01|40
e|TR|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|4|[?]|CALCFIND|Calcification Indicator|[?]|10^6 CFU/mL|TUMOR MERGED|1|grain|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||INTERVIEWER|OPHTHALMOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-08-26|65
e|TR|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|Ci|UNCHANGED|1|10^9/L|MUGA|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|5|Visit_5|90|4|TREATMENT|2020-09-20|90
e|TR|81f62132-123e-4888-abbe-8e289599e965|1|[?]|LPERP|Longest Perpendicular|[?]|GBq/g|FURTHER ENLARGEMENT FROM NADIR|1|Enzyme U|CYSTOMETRY|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|Y|1|Visit_1|10|7|TREATMENT|2020-12-04|10
e|TR|81f62132-123e-4888-abbe-8e289599e965|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|deg2|PRESENT|1|kPa|KINETIC CHROMOGENIC ASSAY|||INTERVIEWER|PHYSIOTHERAPIST|NA|2|Visit_2|25|3|TREATMENT|2020-12-19|25
e|TR|81f62132-123e-4888-abbe-8e289599e965|3|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|m/sec2|TUMOR MERGED|1|uEq|LASER CAPTURE MICRODISSECTION|||PARENT|DERMATOLOGIST|U|3|Visit_3|40|3|FOLLOW-UP|2021-01-03|40
e|TR|81f62132-123e-4888-abbe-8e289599e965|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|BE/mL|TUMOR MERGED|1|g/mol|URANYL ACETATE STAIN|||INDEPENDENT ASSESSOR|READER|Y|4|Visit_4|65|6|WASHOUT|2021-01-28|65
e|TR|81f62132-123e-4888-abbe-8e289599e965|5|[?]|DIAMETER|Diameter|[?]|Gy|DIFFUSELY INCREASED|1|U/10^12 RBC|KINYOUN STAIN|||NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|5|Visit_5|90|1|SCREENING|2021-02-22|90
e|TR|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|1|[?]|VDIAM|Viable Diameter|[?]|mL/breath|NONPALPABLE|1|/h|FLUORESCENT SPOT TEST|Y||SIGNIFICANT OTHER|RADIOLOGIST 2|NA|1|Visit_1|10|3|FOLLOW-UP|2020-05-16|10
e|TR|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|10^6 IU|PALPABLE|1|10^9 CFU/mL|MICRONEUTRALIZATION ASSAY|||CHILD|PATHOLOGIST 1|U|2|Visit_2|25|4|FOLLOW-UP|2020-05-31|25
e|TR|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|CAPSULE|TUMOR MERGED|1|%|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||SIBLING|RATER 1|U|3|Visit_3|40|4|FOLLOW-UP|2020-06-15|40
e|TR|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|nmol/g|PRESENT|1|ug|REFRACTOMETRY|||VENDOR|PATHOLOGIST 1|NA|4|Visit_4|65|3|TREATMENT|2020-07-10|65
e|TR|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|5|[?]|SUMDIAM|Sum of Diameter|[?]|mL/s|UNCHANGED|1|cmH2O*s2/mL|EEG||Y|INTERVIEWER|ONCOLOGIST 1|Y|5|Visit_5|90|6|TREATMENT|2020-08-04|90
e|TR|49282406-97ec-4108-adf9-e01c18ce59c6|1|[?]|PPD|Product of Perpendicular Diameters|[?]|MnFI|DIFFUSELY INCREASED|1|V/sec|GC/MS-CI|||SIBLING|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|1|FOLLOW-UP|2020-05-17|10
e|TR|49282406-97ec-4108-adf9-e01c18ce59c6|2|[?]|CALCFIND|Calcification Indicator|[?]|RNA copies/mL|DECREASED|1|IU|TRANSTHORACIC ECHOCARDIOGRAPHY|||INTERVIEWER|PATHOLOGIST 1|N|2|Visit_2|25|3|SCREENING|2020-06-01|25
e|TR|49282406-97ec-4108-adf9-e01c18ce59c6|3|[?]|ACHNAD|Absolute Change From Nadir|[?]|FEU|FURTHER ENLARGEMENT|1|Antibody Unit|FORCED OSCILLATION TECHNIQUE|||CLINICAL RESEARCH COORDINATOR|READER|NA|3|Visit_3|40|6|SCREENING|2020-06-16|40
e|TR|49282406-97ec-4108-adf9-e01c18ce59c6|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|mL/min/1.73m2|NON-PATHOLOGICAL|1|yd|OSCILLOMETRY|Y||ADJUDICATION COMMITTEE|PATHOLOGIST 2|NA|4|Visit_4|65|2|SCREENING|2020-07-11|65
e|TR|49282406-97ec-4108-adf9-e01c18ce59c6|5|[?]|SUMDIAM|Sum of Diameter|[?]|PFU|NORMAL|1|IMPLANT|FUNDUS PHOTOGRAPHY|Y||PROXY|READER 1|N|5|Visit_5|90|6|TREATMENT|2020-08-05|90
e|TR|310936c8-7d24-4eea-9892-1cd8bb675421|1|[?]|LDIAM|Longest Diameter|[?]|cycle/min|PRESENT|1|10^3 organisms|SNP ARRAY|||FAMILY MEMBER|PATHOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-07-06|10
e|TR|310936c8-7d24-4eea-9892-1cd8bb675421|2|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|CCID 50/mL|INCREASED|1|um/day|HPLC/MS/MS|||STUDY SUBJECT|READER|U|2|Visit_2|25|7|TREATMENT|2020-07-21|25
e|TR|310936c8-7d24-4eea-9892-1cd8bb675421|3|[?]|TUMSTATE|Tumor State|[?]|Weber|TUMOR MERGED|1|MET*h|SPIRAL CT||Y|CAREGIVER|READER 1|NA|3|Visit_3|40|5|TREATMENT|2020-08-05|40
e|TR|310936c8-7d24-4eea-9892-1cd8bb675421|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|10^9 CFU|DECREASED|1|DNA copies/ug|KINYOUN STAIN|||INTERVIEWER|OPTOMETRIST|NA|4|Visit_4|65|7|TREATMENT|2020-08-30|65
e|TR|310936c8-7d24-4eea-9892-1cd8bb675421|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|h*%|NONPALPABLE|1|Hounsfield Unit|MAMMOGRAPHY|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|U|5|Visit_5|90|6|FOLLOW-UP|2020-09-24|90
e|TR|034e303b-5675-4188-bcea-fc2e53b155d6|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|kBq|FURTHER ENLARGEMENT FROM NADIR|1|mJoule/cm2|PATHOLOGICAL EVALUATION|||HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-06-01|10
e|TR|034e303b-5675-4188-bcea-fc2e53b155d6|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mL/cm3/min|FOCALLY INCREASED|1|L/h/m2|X-RAY FLUORESCENCE SPECTROMETRY|Y||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|N|2|Visit_2|25|3|WASHOUT|2020-06-16|25
e|TR|034e303b-5675-4188-bcea-fc2e53b155d6|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|10^7 CFU/mL|DIFFUSELY INCREASED|1|mg/h|OPTICAL COHERENCE TOMOGRAPHY||Y|SPOUSE|OPTOMETRIST|U|3|Visit_3|40|3|TREATMENT|2020-07-01|40
e|TR|034e303b-5675-4188-bcea-fc2e53b155d6|4|[?]|PPD|Product of Perpendicular Diameters|[?]|10^8 PFU|NON-PATHOLOGICAL|1|Absorbance U/mL|TRANSCRIPTION-MEDIATED AMPLIFICATION|||VENDOR|INTERNIST|U|4|Visit_4|65|3|SCREENING|2020-07-26|65
e|TR|034e303b-5675-4188-bcea-fc2e53b155d6|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|cmH2O*s2/mL|EQUIVOCAL|1|dL|GC/MS-CI|Y||SIGNIFICANT OTHER|PATHOLOGIST 2|U|5|Visit_5|90|3|WASHOUT|2020-08-20|90
e|TR|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|1|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|Ci/uL|ENLARGEMENT FROM NADIR|1|nmol/mol|MULTI-SLICE SPIRAL CT|||PROXY|PATHOLOGIST|NA|1|Visit_1|10|4|FOLLOW-UP|2020-07-07|10
e|TR|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|2|[?]|DIAMETER|Diameter|[?]|MPL U|PRESENT|1|mol/L|DIGITAL PCR|||PROXY|RADIOLOGIST|N|2|Visit_2|25|3|FOLLOW-UP|2020-07-22|25
e|TR|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|/LSQN|ENLARGEMENT|1|BOX|MIGET|Y||GUARDIAN|OPHTHALMOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-08-06|40
e|TR|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|uV2|ABSENT|1|Enzyme U/g Hb|HEMAGGLUTINATION ASSAY|||PROXY|RADIOLOGIST 2|Y|4|Visit_4|65|5|TREATMENT|2020-08-31|65
e|TR|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|U/kg/day|FURTHER ENLARGEMENT|1|IU/day|OLIGO ACGH||Y|CAREGIVER|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|4|FOLLOW-UP|2020-09-25|90
e|TR|c912affb-cbc2-4919-81b4-ecaa03908261|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|mL/g/min|TUMOR MERGED|1|mEq/uL|CLIP|||ADJUDICATION COMMITTEE|RATER 1|U|1|Visit_1|10|2|FOLLOW-UP|2020-07-12|10
e|TR|c912affb-cbc2-4919-81b4-ecaa03908261|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|HOMEOPATHIC DILUTION|FURTHER ENLARGEMENT|1|mmHg*min/L|CONTRAST ENHANCED CT SCAN|Y||INTERVIEWER|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-07-27|25
e|TR|c912affb-cbc2-4919-81b4-ecaa03908261|3|[?]|VOLUME|Volume|[?]|kUSP|PATHOLOGICAL|1|%|EIA|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|NA|3|Visit_3|40|6|TREATMENT|2020-08-11|40
e|TR|c912affb-cbc2-4919-81b4-ecaa03908261|4|[?]|LPERP|Longest Perpendicular|[?]|nmol/mL/min|PATHOLOGICAL|1|MBP|CONTRAST ENHANCED SPIRAL CT SCAN|Y||INVESTIGATOR|OPHTHALMOLOGIST|N|4|Visit_4|65|4|WASHOUT|2020-09-05|65
e|TR|c912affb-cbc2-4919-81b4-ecaa03908261|5|[?]|DIAMETER|Diameter|[?]|mg/m2/h|FURTHER ENLARGEMENT FROM NADIR|1|nsec|HEMAGGLUTINATION ASSAY|Y||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|6|SCREENING|2020-09-30|90
e|TR|5af817f0-5dfb-4046-ac7c-4bae16a90036|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|mL/animal/wk|FURTHER ENLARGEMENT FROM NADIR|1|CCID 50/mL|CALCOFLUOR WHITE STAIN||Y|CAREGIVER|ADJUDICATOR 3|N|1|Visit_1|10|3|TREATMENT|2020-07-06|10
e|TR|5af817f0-5dfb-4046-ac7c-4bae16a90036|2|[?]|LESSCIND|Lesion Success Indicator|[?]|mL/g/day|EQUIVOCAL|1|10^6 copies/mL|DIFFUSION TENSOR MRI|||CAREGIVER|RADIOLOGIST 1|Y|2|Visit_2|25|5|WASHOUT|2020-07-21|25
e|TR|5af817f0-5dfb-4046-ac7c-4bae16a90036|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|VOXEL|DECREASED|1|lm|LIGHT MICROSCOPY|Y||CAREGIVER|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-08-05|40
e|TR|5af817f0-5dfb-4046-ac7c-4bae16a90036|4|[?]|VOLUME|Volume|[?]|mm/h|FURTHER ENLARGEMENT FROM NADIR|1|uOsm|TONOMETRY|||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|NA|4|Visit_4|65|3|SCREENING|2020-08-30|65
e|TR|5af817f0-5dfb-4046-ac7c-4bae16a90036|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|U/mL|ENLARGEMENT|1|KALLIKREIN INHIBITOR UNIT|TARGETED TRANSCRIPTOME SEQUENCING|||ADJUDICATION COMMITTEE|READER 2|NA|5|Visit_5|90|7|TREATMENT|2020-09-24|90
e|TR|dcefd656-a59a-4b71-9260-efcbcecd2132|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|umol/L/min|ABSENT|1|m/sec2|PAP STAIN|||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|N|1|Visit_1|10|5|TREATMENT|2020-06-04|10
e|TR|dcefd656-a59a-4b71-9260-efcbcecd2132|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|GBq/g|INCREASED|1|ug/m2/day|NEURAMINIDASE INHIBITION ASSAY|||CLINICAL RESEARCH COORDINATOR|READER 1|N|2|Visit_2|25|7|SCREENING|2020-06-19|25
e|TR|dcefd656-a59a-4b71-9260-efcbcecd2132|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|SPRAY|FURTHER ENLARGEMENT|1|VIAL|IMPEDANCE CONDUCTIVITY|Y||STUDY SUBJECT|ADJUDICATOR 2|U|3|Visit_3|40|7|TREATMENT|2020-07-04|40
e|TR|dcefd656-a59a-4b71-9260-efcbcecd2132|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|nmol BCE/nmol|ENLARGEMENT|1|COAT|PAP STAIN||Y|SPOUSE|RADIOLOGIST|N|4|Visit_4|65|7|TREATMENT|2020-07-29|65
e|TR|dcefd656-a59a-4b71-9260-efcbcecd2132|5|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|ms2|FOCALLY INCREASED|1|hr/day|ECHOCARDIOGRAPHY|||GUARDIAN|PATHOLOGIST 2|U|5|Visit_5|90|1|WASHOUT|2020-08-23|90
e|TR|641c8067-941a-4f1a-a7b1-4eea0242f1d7|1|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|mL/100g/min|UNEQUIVOCAL|1|/10^3|POLYMERASE CHAIN REACTION|||INVESTIGATOR|READER 2|N|1|Visit_1|10|6|TREATMENT|2020-12-22|10
e|TR|641c8067-941a-4f1a-a7b1-4eea0242f1d7|2|[?]|AREA|Area|[?]|Frames/s|DECREASED|1|fraction of 1|LINE PROBE ASSAY|||INVESTIGATOR|ONCOLOGIST 2|N|2|Visit_2|25|6|SCREENING|2021-01-06|25
e|TR|641c8067-941a-4f1a-a7b1-4eea0242f1d7|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|Bq/uL|EQUIVOCAL|1|U/mmol|DOPPLER ULTRASOUND|Y||GUARDIAN|RADIOLOGIST 1|Y|3|Visit_3|40|2|TREATMENT|2021-01-21|40
e|TR|641c8067-941a-4f1a-a7b1-4eea0242f1d7|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|ELISA unit/mL|INCREASED|1|WAFER|ECHOCARDIOGRAPHY|||SIBLING|MICROSCOPIST|NA|4|Visit_4|65|7|TREATMENT|2021-02-15|65
e|TR|641c8067-941a-4f1a-a7b1-4eea0242f1d7|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|Antibody Unit|ABSENT|1|mm/h|NON-INVASIVE DIELECTRIC SENSING|||SPOUSE|ADJUDICATOR 1|N|5|Visit_5|90|5|FOLLOW-UP|2021-03-12|90
e|TR|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|1|[?]|PALPSTAT|Palpable State|[?]|PACKET|UNEQUIVOCAL|1|nmol/L|PH METER MEASUREMENT METHOD|||SPOUSE|MICROSCOPIST 2|U|1|Visit_1|10|7|TREATMENT|2020-09-24|10
e|TR|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|EP U|DECREASED|1|mL/kg/h|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||SIGNIFICANT OTHER|RATER|N|2|Visit_2|25|7|SCREENING|2020-10-09|25
e|TR|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|3|[?]|ORVERLN|Organ Vertical Length|[?]|log10 TCID 50/uL|DIFFUSELY INCREASED|1|NEBULE|IMMUNOCHEMILUMINOMETRIC ASSAY|||SPOUSE|RADIOLOGIST 2|Y|3|Visit_3|40|5|TREATMENT|2020-10-24|40
e|TR|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|IU/mmol|PALPABLE|1|L/kg|FARR ASSAY|||CAREGIVER|ADJUDICATOR|N|4|Visit_4|65|3|TREATMENT|2020-11-18|65
e|TR|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|5|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|m2|DECREASED|1|mU|HPLC/MS|||INTERVIEWER|READER 1|NA|5|Visit_5|90|4|SCREENING|2020-12-13|90
e|TR|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|/5x10^4 WBC|NON-PATHOLOGICAL|1|10^7 CFU/mL|ELLA|Y||INVESTIGATOR|ADJUDICATOR 3|Y|1|Visit_1|10|1|TREATMENT|2020-10-31|10
e|TR|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|ppm|UNCHANGED|1|ng/dL|ULTRASOUND|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|2|Visit_2|25|7|TREATMENT|2020-11-15|25
e|TR|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mg/m2/h|ABSENT|1|%(w/w)|INDIA INK STAIN|||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|5|SCREENING|2020-11-30|40
e|TR|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|PNU/mL|ENLARGEMENT FROM NADIR|1|mol/mL|MULTIPLE BREATH WASHOUT|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|NA|4|Visit_4|65|5|TREATMENT|2020-12-25|65
e|TR|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mmHg*min/L|ENLARGEMENT FROM NADIR|1|nU/cL|REBOUND TONOMETRY|Y||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|5|Visit_5|90|5|TREATMENT|2021-01-19|90
e|TR|46304edd-0b05-4819-8fcb-35cf9c02764d|1|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|IU/mg|ENLARGEMENT FROM NADIR|1|QUANTITY SUFFICIENT|AGAR PROPORTION|Y|Y|SIGNIFICANT OTHER|MICROSCOPIST 1|N|1|Visit_1|10|2|FOLLOW-UP|2020-12-03|10
e|TR|46304edd-0b05-4819-8fcb-35cf9c02764d|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|DAgU/mL|DECREASED|1|Weber|DIFFUSION WEIGHTED MRI|||CAREGIVER|FORENSIC PATHOLOGIST|U|2|Visit_2|25|5|TREATMENT|2020-12-18|25
e|TR|46304edd-0b05-4819-8fcb-35cf9c02764d|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|ukat|ENLARGEMENT FROM NADIR|1|IU/kg|ELECTROCHEMILUMINESCENCE|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|N|3|Visit_3|40|4|TREATMENT|2021-01-02|40
e|TR|46304edd-0b05-4819-8fcb-35cf9c02764d|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|10^6/g|NON-PATHOLOGICAL|1|h*%|ECHOCARDIOGRAPHY|Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|NA|4|Visit_4|65|5|SCREENING|2021-01-27|65
e|TR|46304edd-0b05-4819-8fcb-35cf9c02764d|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|L/h/m2|DIFFUSELY INCREASED|1|nsec|EEG|Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|5|Visit_5|90|2|WASHOUT|2021-02-21|90
e|TR|3fd6dab2-b35f-4cc5-88dd-b507583d9539|1|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|km/h|UNCHANGED|1|mL/breath|BIOPSY|||PARENT|ADJUDICATOR 1|N|1|Visit_1|10|5|TREATMENT|2020-05-26|10
e|TR|3fd6dab2-b35f-4cc5-88dd-b507583d9539|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|Anson U|FOCALLY INCREASED|1|vg/mL|RADIOIMMUNOPRECIPITATION ASSAY|||SIBLING|READER 1|U|2|Visit_2|25|4|WASHOUT|2020-06-10|25
e|TR|3fd6dab2-b35f-4cc5-88dd-b507583d9539|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|rpm|FURTHER ENLARGEMENT FROM NADIR|1|APL U|RADIOIMMUNOPRECIPITATION ASSAY||Y|GUARDIAN|CARDIOLOGIST|N|3|Visit_3|40|1|FOLLOW-UP|2020-06-25|40
e|TR|3fd6dab2-b35f-4cc5-88dd-b507583d9539|4|[?]|SUMVOL|Sum of Volume|[?]|mL/kg/min|ABSENT|1|mol|PATHOLOGICAL EVALUATION|Y||SIGNIFICANT OTHER|INTERNIST|N|4|Visit_4|65|1|TREATMENT|2020-07-20|65
e|TR|3fd6dab2-b35f-4cc5-88dd-b507583d9539|5|[?]|VDIAM|Viable Diameter|[?]|um2|EQUIVOCAL|1|U/g Hb|PEAK FLOWMETRY|Y|Y|INTERVIEWER|NEUROLOGIST 2|Y|5|Visit_5|90|5|TREATMENT|2020-08-14|90
e|TR|daa3b89e-637a-43de-86c1-d0db93f00430|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|BEAM BREAKS|DIFFUSELY INCREASED|1|dpm/mL|QUANTITATIVE ULTRASOUND|Y||GUARDIAN|RADIOLOGIST|U|1|Visit_1|10|6|WASHOUT|2020-10-11|10
e|TR|daa3b89e-637a-43de-86c1-d0db93f00430|2|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mmHg/L/min|PALPABLE|1|EID 50/mL|PHOTOMETRIC CLOT DETECTION|||PROXY|MICROSCOPIST 3|Y|2|Visit_2|25|2|WASHOUT|2020-10-26|25
e|TR|daa3b89e-637a-43de-86c1-d0db93f00430|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|Bq/uL|NON-PATHOLOGICAL|1|nmol BCE/L|SNELLEN EYE CHART|||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-11-10|40
e|TR|daa3b89e-637a-43de-86c1-d0db93f00430|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mm/sec|NORMAL|1|mEq/L|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||SPOUSE|PATHOLOGIST 2|U|4|Visit_4|65|2|FOLLOW-UP|2020-12-05|65
e|TR|daa3b89e-637a-43de-86c1-d0db93f00430|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|mm2|FURTHER ENLARGEMENT|1|IU/day|HIGH LEVEL AMINOGLYCOSIDE SCREEN||Y|VENDOR|HEMATOLOGIST|U|5|Visit_5|90|1|TREATMENT|2020-12-30|90
e|TR|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|kHz|FURTHER ENLARGEMENT|1|ft2|ELECTROPHORESIS|Y|Y|INDEPENDENT ASSESSOR|OPTOMETRIST|N|1|Visit_1|10|7|WASHOUT|2020-07-04|10
e|TR|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|2|[?]|RADIODEN|Radiodensity|[?]|mol/mg|PRESENT|1|grain|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y|Y|CLINICAL STUDY SPONSOR|READER|NA|2|Visit_2|25|5|FOLLOW-UP|2020-07-19|25
e|TR|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|3|[?]|VDIAM|Viable Diameter|[?]|U/g/day|NONPALPABLE|1|Gy/min|TRYPAN BLUE STAIN|Y||FAMILY MEMBER|MICROSCOPIST 2|U|3|Visit_3|40|3|TREATMENT|2020-08-03|40
e|TR|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|4|[?]|LPERP|Longest Perpendicular|[?]|cGy|ENLARGEMENT|1|V|PERCUSSION|Y||INTERVIEWER|RADIOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2020-08-28|65
e|TR|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|5|[?]|LDIAM|Longest Diameter|[?]|copies/mL|TUMOR MERGED|1|mg/mL/day|MICRO BROTH DILUTION||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|N|5|Visit_5|90|7|SCREENING|2020-09-22|90
e|TR|c22014f2-2d7b-4897-8ad5-e46785e51837|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|umol|FOCALLY INCREASED|1|FEU|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|Y||HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-08-13|10
e|TR|c22014f2-2d7b-4897-8ad5-e46785e51837|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|MET|PRESENT|1|NFIU|AUTOREFRACTION||Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-08-28|25
e|TR|c22014f2-2d7b-4897-8ad5-e46785e51837|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mol/L|NONPALPABLE|1|mEq/kg|PLETHYSMOGRAPHY|Y||PARENT|PHYSIOTHERAPIST|Y|3|Visit_3|40|1|TREATMENT|2020-09-12|40
e|TR|c22014f2-2d7b-4897-8ad5-e46785e51837|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|ELISA unit|NONPALPABLE|1|Tesla|SINGLE-SLICE SPIRAL CT|Y|Y|INTERVIEWER|CLINICAL PATHOLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-10-07|65
e|TR|c22014f2-2d7b-4897-8ad5-e46785e51837|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|m/sec2|NONPALPABLE|1|cP|MACRO BROTH DILUTION|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|5|Visit_5|90|6|TREATMENT|2020-11-01|90
e|TR|987102b2-fe2f-4d72-b8dc-14a71bf034b5|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|RATIO|NONPALPABLE|1|mmAL|WHOLE GENOME SEQUENCING|||HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|U|1|Visit_1|10|4|FOLLOW-UP|2020-10-11|10
e|TR|987102b2-fe2f-4d72-b8dc-14a71bf034b5|2|[?]|NEWCONF|New Tumor Confirmed|[?]|ug/L DDU|ENLARGEMENT FROM NADIR|1|L/h|CONTRAST ENHANCED PET/CT SCAN|Y||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|7|TREATMENT|2020-10-26|25
e|TR|987102b2-fe2f-4d72-b8dc-14a71bf034b5|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|/ms|FURTHER ENLARGEMENT FROM NADIR|1|Log10 ELISA unit/dose|CLIP|||SIBLING|NEUROLOGIST|Y|3|Visit_3|40|7|FOLLOW-UP|2020-11-10|40
e|TR|987102b2-fe2f-4d72-b8dc-14a71bf034b5|4|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|%(w/v)|NON-PATHOLOGICAL|1|SPRAY|PEAK FLOWMETRY|Y||SIBLING|MICROSCOPIST 2|Y|4|Visit_4|65|5|TREATMENT|2020-12-05|65
e|TR|987102b2-fe2f-4d72-b8dc-14a71bf034b5|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|umol/L/h|ENLARGEMENT FROM NADIR|1|POINT|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|1|TREATMENT|2020-12-30|90
e|TR|24ce0c77-1921-4b87-91da-3627e2afd399|1|[?]|BNLNUM|Number of Bone Lesions|[?]|SACHET|ENLARGEMENT FROM NADIR|1|grain|STRESS ECHOCARDIOGRAPHY|||INTERVIEWER|HEMATOLOGIST|NA|1|Visit_1|10|2|WASHOUT|2021-01-29|10
e|TR|24ce0c77-1921-4b87-91da-3627e2afd399|2|[?]|TUMSTATE|Tumor State|[?]|pt_br|FURTHER ENLARGEMENT FROM NADIR|1|log10 CFU/g|CALCOFLUOR WHITE STAIN|||STUDY SUBJECT|NEUROLOGIST 2|NA|2|Visit_2|25|1|TREATMENT|2021-02-13|25
e|TR|24ce0c77-1921-4b87-91da-3627e2afd399|3|[?]|CALCFIND|Calcification Indicator|[?]|MnFI|ENLARGEMENT FROM NADIR|1|/MBP|SPIRAL CT||Y|DOMESTIC PARTNER|HEMATOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2021-02-28|40
e|TR|24ce0c77-1921-4b87-91da-3627e2afd399|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|log10 PFU/mL|UNEQUIVOCAL|1|HOMEOPATHIC DILUTION|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|Y|4|Visit_4|65|7|WASHOUT|2021-03-25|65
e|TR|24ce0c77-1921-4b87-91da-3627e2afd399|5|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|EP U|ENLARGEMENT|1|g|HIGH RESOLUTION MELT ANALYSIS||Y|CAREGIVER|ADJUDICATOR|NA|5|Visit_5|90|2|TREATMENT|2021-04-19|90
e|TR|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|kBq|PATHOLOGICAL|1|U/g|IMMUNOCHEMILUMINOMETRIC ASSAY||Y|VENDOR|PATHOLOGIST 2|U|1|Visit_1|10|4|FOLLOW-UP|2020-08-20|10
e|TR|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|2|[?]|PCHGBL|Percent Change From Baseline|[?]|PELLET|NONPALPABLE|1|msec|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y||CAREGIVER|READER 1|NA|2|Visit_2|25|4|TREATMENT|2020-09-04|25
e|TR|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|Henry|ENLARGEMENT|1|PFU/mL|PHYSICAL EXAMINATION|||HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|3|Visit_3|40|6|SCREENING|2020-09-19|40
e|TR|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|4|[?]|PCHGBL|Percent Change From Baseline|[?]|mol/L|EQUIVOCAL|1|Gy/h|MRI WITHOUT CONTRAST|Y||PROXY|RATER 1|Y|4|Visit_4|65|2|TREATMENT|2020-10-14|65
e|TR|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|L/s/kPa|PRESENT|1|STEPS|HANSEL STAIN|||FAMILY MEMBER|PHYSIOTHERAPIST|Y|5|Visit_5|90|7|TREATMENT|2020-11-08|90
e|TR|f4b83a72-7cde-4e02-8883-05e789c617a8|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|10^6 CFU/mL|TUMOR MERGED|1|P|CINEANGIOGRAPHY|Y||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|N|1|Visit_1|10|1|TREATMENT|2020-12-25|10
e|TR|f4b83a72-7cde-4e02-8883-05e789c617a8|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|/200 HPFs|NORMAL|1|g/cage/wk|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y||STUDY SUBJECT|DERMATOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2021-01-09|25
e|TR|f4b83a72-7cde-4e02-8883-05e789c617a8|3|[?]|RADIODEN|Radiodensity|[?]|10^4/L|FURTHER ENLARGEMENT|1|kg/L|FLAME PHOTOMETRY|||GUARDIAN|NEUROLOGIST|NA|3|Visit_3|40|7|WASHOUT|2021-01-24|40
e|TR|f4b83a72-7cde-4e02-8883-05e789c617a8|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|mV*min|NON-PATHOLOGICAL|1|mmol2/L2|KNEMOMETRY|||DOMESTIC PARTNER|DERMATOLOGIST|U|4|Visit_4|65|2|TREATMENT|2021-02-18|65
e|TR|f4b83a72-7cde-4e02-8883-05e789c617a8|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mEq/day|DECREASED|1|Absorbance U/mL|PERIPHERAL ANGIOGRAPHY|Y||CLINICAL STUDY SPONSOR|RATER 2|Y|5|Visit_5|90|2|TREATMENT|2021-03-15|90
e|TR|c4087538-422a-4bcf-af25-ed4aab36ed4b|1|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|g/m2|INCREASED|1|Watt|ULTRASONOGRAPHIC ELASTOGRAPHY|||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|4|TREATMENT|2021-01-09|10
e|TR|c4087538-422a-4bcf-af25-ed4aab36ed4b|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|/min|UNCHANGED|1|um|FLUORESCENT ENZYME IMMUNOASSAY|Y|Y|CAREGIVER|OPTOMETRIST|N|2|Visit_2|25|4|TREATMENT|2021-01-24|25
e|TR|c4087538-422a-4bcf-af25-ed4aab36ed4b|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|vp/mL|UNEQUIVOCAL|1|umol/h/mmol|IHC|Y||VENDOR|OPTOMETRIST|NA|3|Visit_3|40|2|FOLLOW-UP|2021-02-08|40
e|TR|c4087538-422a-4bcf-af25-ed4aab36ed4b|4|[?]|LPERP|Longest Perpendicular|[?]|ug/min|PRESENT|1|ks|SINGLE-MOLECULE ARRAY|||HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|4|Visit_4|65|4|SCREENING|2021-03-05|65
e|TR|c4087538-422a-4bcf-af25-ed4aab36ed4b|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|g/dL|EQUIVOCAL|1|ng/day|LANDOLT RING|Y||INTERVIEWER|MICROSCOPIST|Y|5|Visit_5|90|4|WASHOUT|2021-03-30|90
e|TR|947aefaf-20c7-47fc-ac56-140f9b6f38f3|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|U/m2|ABSENT|1|10^6 RNA copies/mL|PHYSICAL EXAMINATION||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|NA|1|Visit_1|10|5|TREATMENT|2020-11-06|10
e|TR|947aefaf-20c7-47fc-ac56-140f9b6f38f3|2|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|10^9 organisms/mL|ENLARGEMENT|1|mg/kg/week|DISK DIFFUSION|Y||ADJUDICATOR|ADJUDICATOR 3|N|2|Visit_2|25|2|WASHOUT|2020-11-21|25
e|TR|947aefaf-20c7-47fc-ac56-140f9b6f38f3|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|APS U|UNEQUIVOCAL|1|10^4 CFU/mL|ATOMIC ABSORPTION SPECTROMETRY|Y|Y|CHILD|READER|N|3|Visit_3|40|5|TREATMENT|2020-12-06|40
e|TR|947aefaf-20c7-47fc-ac56-140f9b6f38f3|4|[?]|PPD|Product of Perpendicular Diameters|[?]|Ci/uL|PRESENT|1|mEq/kg|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y||INTERVIEWER|ADJUDICATOR 3|N|4|Visit_4|65|4|TREATMENT|2020-12-31|65
e|TR|947aefaf-20c7-47fc-ac56-140f9b6f38f3|5|[?]|VDIAM|Viable Diameter|[?]|uL/dose|ABSENT|1|ugEq/L|FISH|Y|Y|DOMESTIC PARTNER|RADIOLOGIST|U|5|Visit_5|90|6|WASHOUT|2021-01-25|90
e|TR|3a0c00eb-5614-4053-844d-6bdb71efb1cd|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|ng|PRESENT|1|cm|DUCTOGRAPHY|||SIBLING|MICROSCOPIST 1|N|1|Visit_1|10|1|TREATMENT|2020-08-11|10
e|TR|3a0c00eb-5614-4053-844d-6bdb71efb1cd|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|ug/kg/min|NON-PATHOLOGICAL|1|mm/2h|HANSEL STAIN|||STUDY SUBJECT|ADJUDICATOR 3|NA|2|Visit_2|25|3|SCREENING|2020-08-26|25
e|TR|3a0c00eb-5614-4053-844d-6bdb71efb1cd|3|[?]|LPERP|Longest Perpendicular|[?]|in|UNCHANGED|1|/VF|AUTOREFRACTION|||SPOUSE|ONCOLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-09-10|40
e|TR|3a0c00eb-5614-4053-844d-6bdb71efb1cd|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|log10 IU/mL|NONPALPABLE|1|10^6/g|LIQUID SCINTILLATION COUNTING|||PROXY|READER|Y|4|Visit_4|65|1|TREATMENT|2020-10-05|65
e|TR|3a0c00eb-5614-4053-844d-6bdb71efb1cd|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|breaths/min|EQUIVOCAL|1|lm|IN SITU HYBRIDIZATION|||DOMESTIC PARTNER|ADJUDICATOR|U|5|Visit_5|90|3|WASHOUT|2020-10-30|90
e|TR|dc3ce247-24dd-4255-85a8-ec7a58d30c86|1|[?]|PPD|Product of Perpendicular Diameters|[?]|TABLET|FOCALLY INCREASED|1|mol|IMPEDANCE CONDUCTIVITY|||INVESTIGATOR|OTOLARYNGOLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-10-11|10
e|TR|dc3ce247-24dd-4255-85a8-ec7a58d30c86|2|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|uCi|PRESENT|1|MBq|BAC ACGH|Y||ADJUDICATION COMMITTEE|ONCOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-10-26|25
e|TR|dc3ce247-24dd-4255-85a8-ec7a58d30c86|3|[?]|AREA|Area|[?]|mmol/mol|NON-PATHOLOGICAL|1|lm|CONTRAST ENHANCED PET/CT SCAN|||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|3|Visit_3|40|2|FOLLOW-UP|2020-11-10|40
e|TR|dc3ce247-24dd-4255-85a8-ec7a58d30c86|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|nmol/g|ENLARGEMENT|1|SPRAY|CALCOFLUOR WHITE STAIN|||PARENT|OPHTHALMOLOGIST|U|4|Visit_4|65|1|WASHOUT|2020-12-05|65
e|TR|dc3ce247-24dd-4255-85a8-ec7a58d30c86|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|vg/kg|UNEQUIVOCAL|1|ug/m2/min|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||GUARDIAN|RADIOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2020-12-30|90
e|TR|61c19f94-bdfc-456d-ba7a-c9097ca1c645|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|copies/mL|INCREASED|1|nm|DNA MICROARRAY|||GUARDIAN|FORENSIC PATHOLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-07-04|10
e|TR|61c19f94-bdfc-456d-ba7a-c9097ca1c645|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|oz eq|EQUIVOCAL|1|cmol|NUCLEIC ACID SEQUENCING|||FRIEND|FORENSIC PATHOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-07-19|25
e|TR|61c19f94-bdfc-456d-ba7a-c9097ca1c645|3|[?]|PALPSTAT|Palpable State|[?]|PIXEL|DIFFUSELY INCREASED|1|nsec|LIGHT SCATTERING SPECTROSCOPY||Y|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|4|TREATMENT|2020-08-03|40
e|TR|61c19f94-bdfc-456d-ba7a-c9097ca1c645|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|IU/g Hb|NON-PATHOLOGICAL|1|g/cm2|CONFOCAL MICROSCOPY||Y|GUARDIAN|PATHOLOGIST|NA|4|Visit_4|65|7|SCREENING|2020-08-28|65
e|TR|61c19f94-bdfc-456d-ba7a-c9097ca1c645|5|[?]|PPD|Product of Perpendicular Diameters|[?]|cmH2O*s2/mL|NONPALPABLE|1|mmol/L|INFRARED SPECTROMETRY|||CLINICAL RESEARCH COORDINATOR|READER 3|N|5|Visit_5|90|5|TREATMENT|2020-09-22|90
e|TR|1e577f2d-2c45-477d-b74f-af24b81d6d20|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mg/mL/day|ENLARGEMENT FROM NADIR|1|mg/dose|MAMMOGRAPHY|||INDEPENDENT ASSESSOR|READER 1|Y|1|Visit_1|10|1|WASHOUT|2020-09-23|10
e|TR|1e577f2d-2c45-477d-b74f-af24b81d6d20|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mOsm/kg|NORMAL|1|L/L|NON-CONTACT SPECULAR MICROSCOPY||Y|FAMILY MEMBER|READER 1|N|2|Visit_2|25|1|WASHOUT|2020-10-08|25
e|TR|1e577f2d-2c45-477d-b74f-af24b81d6d20|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|mmHg*min/L|ENLARGEMENT|1|EVENTS|INTRAVASCULAR ULTRASOUND|Y||FAMILY MEMBER|ADJUDICATOR 1|Y|3|Visit_3|40|2|WASHOUT|2020-10-23|40
e|TR|1e577f2d-2c45-477d-b74f-af24b81d6d20|4|[?]|NEWCONF|New Tumor Confirmed|[?]|10^8 PFU|ABSENT|1|uEq/L|MYELOPEROXIDASE STAIN|Y||DOMESTIC PARTNER|PHYSIOTHERAPIST|NA|4|Visit_4|65|3|TREATMENT|2020-11-17|65
e|TR|1e577f2d-2c45-477d-b74f-af24b81d6d20|5|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|mL/m2/day|FOCALLY INCREASED|1|NFIU|DROPLET DIGITAL PCR|||CLINICAL RESEARCH COORDINATOR|READER|N|5|Visit_5|90|5|SCREENING|2020-12-12|90
e|TR|f845101e-c057-4f84-94b3-6043afb42ac7|1|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|damol/L|INCREASED|1|/5x10^4 WBC|POLYGRAPHY|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|N|1|Visit_1|10|7|TREATMENT|2020-10-27|10
e|TR|f845101e-c057-4f84-94b3-6043afb42ac7|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|AgU/mL|PRESENT|1|tuberculin unit/mL|MICROPARTICLE ENZYME IMMUNOASSAY||Y|FRIEND|OPTOMETRIST|Y|2|Visit_2|25|4|TREATMENT|2020-11-11|25
e|TR|f845101e-c057-4f84-94b3-6043afb42ac7|3|[?]|PALPSTAT|Palpable State|[?]|V/sec|PRESENT|1|cd*s/m2|EEG|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|3|Visit_3|40|7|WASHOUT|2020-11-26|40
e|TR|f845101e-c057-4f84-94b3-6043afb42ac7|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|SPRAY|NON-PATHOLOGICAL|1|ug/m2/min|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||CHILD|READER|Y|4|Visit_4|65|6|WASHOUT|2020-12-21|65
e|TR|f845101e-c057-4f84-94b3-6043afb42ac7|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|10^4/hpf|FURTHER ENLARGEMENT|1|mmol/g|TRANSVAGINAL ULTRASOUND|||HEALTH CARE PROFESSIONAL|RATER 1|U|5|Visit_5|90|1|TREATMENT|2021-01-15|90
e|TR|4ddb2076-6837-4028-81bc-3e8057475977|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|uCi/L|DECREASED|1|log10 TCID 50/dose|RAJI CELL RIA||Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|1|Visit_1|10|2|TREATMENT|2020-12-27|10
e|TR|4ddb2076-6837-4028-81bc-3e8057475977|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|BAU|FOCALLY INCREASED|1|kcal|POTENTIOMETRY|||FAMILY MEMBER|MICROSCOPIST 3|Y|2|Visit_2|25|1|FOLLOW-UP|2021-01-11|25
e|TR|4ddb2076-6837-4028-81bc-3e8057475977|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|/sec|NONPALPABLE|1|yd|TRANSCRIPTION-MEDIATED AMPLIFICATION|||INDEPENDENT ASSESSOR|UROLOGIST|NA|3|Visit_3|40|2|TREATMENT|2021-01-26|40
e|TR|4ddb2076-6837-4028-81bc-3e8057475977|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|mm/2h|TUMOR MERGED|1|min*mg/mL|SMEAR|||PROXY|ENDOCRINOLOGIST|Y|4|Visit_4|65|6|WASHOUT|2021-02-20|65
e|TR|4ddb2076-6837-4028-81bc-3e8057475977|5|[?]|CALCFIND|Calcification Indicator|[?]|U/g/min|ABSENT|1|v/v|FLUORESCENT SPOT TEST|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|U|5|Visit_5|90|3|WASHOUT|2021-03-17|90
e|TR|c165c69c-2ab2-495c-a190-e32d1204bc4e|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|TROCHE|PATHOLOGICAL|1|CIGARETTE|QUANTITATIVE CORONARY ANGIOGRAPHY|||GUARDIAN|READER 1|NA|1|Visit_1|10|4|TREATMENT|2021-01-01|10
e|TR|c165c69c-2ab2-495c-a190-e32d1204bc4e|2|[?]|ACHNAD|Absolute Change From Nadir|[?]|10^6/L|FURTHER ENLARGEMENT FROM NADIR|1|MPS U|CAPILLARY ELECTROPHORESIS|||DOMESTIC PARTNER|RADIOLOGIST 1|Y|2|Visit_2|25|5|SCREENING|2021-01-16|25
e|TR|c165c69c-2ab2-495c-a190-e32d1204bc4e|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|dpm/0.5 mL|PATHOLOGICAL|1|ag|STRESS ECHOCARDIOGRAPHY|||SIBLING|INTERNIST|Y|3|Visit_3|40|6|TREATMENT|2021-01-31|40
e|TR|c165c69c-2ab2-495c-a190-e32d1204bc4e|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|LENS|PATHOLOGICAL|1|TRANSDUCING UNIT/mL|PHOROPTER|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|U|4|Visit_4|65|3|TREATMENT|2021-02-25|65
e|TR|c165c69c-2ab2-495c-a190-e32d1204bc4e|5|[?]|SUMDIAM|Sum of Diameter|[?]|cm/min|ABSENT|1|mL/min/mmHg|QUANTITATIVE ULTRASOUND||Y|SIBLING|RADIOLOGIST|Y|5|Visit_5|90|2|TREATMENT|2021-03-22|90
e|TR|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|1|[?]|LPERP|Longest Perpendicular|[?]|mg/kg/min|PATHOLOGICAL|1|tsp eq|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||INTERVIEWER|ONCOLOGIST 1|Y|1|Visit_1|10|6|TREATMENT|2020-12-29|10
e|TR|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|2|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mph|PALPABLE|1|ft3|MALDI|Y||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|7|TREATMENT|2021-01-13|25
e|TR|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|m|ENLARGEMENT|1|cpm|GIEMSA STAIN|Y|Y|SPOUSE|MICROSCOPIST 1|NA|3|Visit_3|40|4|SCREENING|2021-01-28|40
e|TR|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|log10 PFU/mL|UNCHANGED|1|APS U|WRIGHT STAIN|||SPOUSE|DERMATOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2021-02-22|65
e|TR|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|5|[?]|LPERP|Longest Perpendicular|[?]|pptr|UNEQUIVOCAL|1|IU/day|DUKE INCISION METHOD||Y|ADJUDICATION COMMITTEE|ADJUDICATOR 2|Y|5|Visit_5|90|7|TREATMENT|2021-03-19|90
e|TR|024a9f6d-4ff1-4673-8617-3790f831fce7|1|[?]|PPD|Product of Perpendicular Diameters|[?]|10^6 U|PALPABLE|1|cd|CYSTOSCOPY|Y||INDEPENDENT ASSESSOR|OPTOMETRIST|U|1|Visit_1|10|3|WASHOUT|2020-06-13|10
e|TR|024a9f6d-4ff1-4673-8617-3790f831fce7|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mg/mL/min|PRESENT|1|/40 HPFs|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|Y|2|Visit_2|25|1|TREATMENT|2020-06-28|25
e|TR|024a9f6d-4ff1-4673-8617-3790f831fce7|3|[?]|AREA|Area|[?]|F|DIFFUSELY INCREASED|1|PACK|HPLC/MS/MS|||ADJUDICATION COMMITTEE|NEUROLOGIST 2|U|3|Visit_3|40|1|FOLLOW-UP|2020-07-13|40
e|TR|024a9f6d-4ff1-4673-8617-3790f831fce7|4|[?]|RADIODEN|Radiodensity|[?]|/MBP|PRESENT|1|10^6 copies/mL|CONTRAST ENHANCED X-RAY||Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|4|Visit_4|65|2|FOLLOW-UP|2020-08-07|65
e|TR|024a9f6d-4ff1-4673-8617-3790f831fce7|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|umol/L/sec|ABSENT|1|10^3 RNA copies/mL|DC SHEATH FLOW|Y|Y|GUARDIAN|ADJUDICATOR 2|NA|5|Visit_5|90|2|TREATMENT|2020-09-01|90
e|TR|40936fc6-251d-4a17-ae9d-3bd1150f8d20|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|BP|UNCHANGED|1|pmol/10^10 cells|ENDPOINT DILUTION ASSAY|||ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-11-18|10
e|TR|40936fc6-251d-4a17-ae9d-3bd1150f8d20|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|GPL U|PATHOLOGICAL|1|PATCH|MANUAL CLOT DETECTION|||PARENT|MICROSCOPIST 3|N|2|Visit_2|25|4|FOLLOW-UP|2020-12-03|25
e|TR|40936fc6-251d-4a17-ae9d-3bd1150f8d20|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|g/g|DECREASED|1|log10 PFU/mL|AUTOREFRACTION|Y||GUARDIAN|ADJUDICATOR 1|N|3|Visit_3|40|7|TREATMENT|2020-12-18|40
e|TR|40936fc6-251d-4a17-ae9d-3bd1150f8d20|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|Ci/mL|INCREASED|1|U/animal|KINETIC MICROPARTICLE IMMUNOASSAY|||PROXY|RADIOLOGIST 1|N|4|Visit_4|65|6|SCREENING|2021-01-12|65
e|TR|40936fc6-251d-4a17-ae9d-3bd1150f8d20|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|GPL U/mL|ENLARGEMENT FROM NADIR|1|/10^3|CALCOFLUOR WHITE STAIN|Y||CAREGIVER|NEUROLOGIST 2|NA|5|Visit_5|90|4|WASHOUT|2021-02-06|90
e|TR|17b9fa7a-f15d-423a-9671-99cd0cbbd362|1|[?]|VDIAM|Viable Diameter|[?]|gMFI|FOCALLY INCREASED|1|mV2/Hz|WESTERN BLOT|||SIBLING|UROLOGIST|NA|1|Visit_1|10|7|FOLLOW-UP|2020-11-11|10
e|TR|17b9fa7a-f15d-423a-9671-99cd0cbbd362|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|ppm|DIFFUSELY INCREASED|1|Hz/s|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||DOMESTIC PARTNER|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|3|FOLLOW-UP|2020-11-26|25
e|TR|17b9fa7a-f15d-423a-9671-99cd0cbbd362|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|PIPE|DIFFUSELY INCREASED|1|ugEq|SINGLE-MOLECULE ARRAY|||HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|3|Visit_3|40|2|SCREENING|2020-12-11|40
e|TR|17b9fa7a-f15d-423a-9671-99cd0cbbd362|4|[?]|SUMDIAM|Sum of Diameter|[?]|g/animal|DECREASED|1|P|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y|GUARDIAN|READER|U|4|Visit_4|65|3|TREATMENT|2021-01-05|65
e|TR|17b9fa7a-f15d-423a-9671-99cd0cbbd362|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|L/L|ENLARGEMENT|1|oz eq|SURFACE PLASMON RESONANCE|||SPOUSE|READER 2|N|5|Visit_5|90|5|TREATMENT|2021-01-30|90
e|TR|95c4465b-162a-433d-83c9-6d67dd729c9e|1|[?]|ORSTATE|Organ State|[?]|mm|UNEQUIVOCAL|1|copies/uL|ORCHIDOMETERY|Y|Y|FAMILY MEMBER|PATHOLOGIST 2|N|1|Visit_1|10|2|SCREENING|2020-10-22|10
e|TR|95c4465b-162a-433d-83c9-6d67dd729c9e|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|nm|NON-PATHOLOGICAL|1|mg/L|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||SIBLING|PATHOLOGIST 1|Y|2|Visit_2|25|5|TREATMENT|2020-11-06|25
e|TR|95c4465b-162a-433d-83c9-6d67dd729c9e|3|[?]|CALCFIND|Calcification Indicator|[?]|/mm2|ABSENT|1|uOsm|AUSCULTATION|||VENDOR|INTERNIST|Y|3|Visit_3|40|1|TREATMENT|2020-11-21|40
e|TR|95c4465b-162a-433d-83c9-6d67dd729c9e|4|[?]|SUMVOL|Sum of Volume|[?]|pkat|PALPABLE|1|cmHg|WEBER GREEN STAIN|||INTERVIEWER|ADJUDICATOR 1|NA|4|Visit_4|65|3|FOLLOW-UP|2020-12-16|65
e|TR|95c4465b-162a-433d-83c9-6d67dd729c9e|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|PFU|EQUIVOCAL|1|cL|IN VITRO GENE EXPRESSION ASSAY||Y|FRIEND|READER 3|Y|5|Visit_5|90|6|TREATMENT|2021-01-10|90
e|TR|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|1|[?]|DIAMETER|Diameter|[?]|breaths/min|FURTHER ENLARGEMENT|1|TABLET|SPECTROPHOTOMETRY||Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|Y|1|Visit_1|10|3|TREATMENT|2020-06-27|10
e|TR|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|Pack Year|DECREASED|1|10^3/L|QUANTITATIVE CORONARY ANGIOGRAPHY|||GUARDIAN|READER|NA|2|Visit_2|25|7|SCREENING|2020-07-12|25
e|TR|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|NEEDLE GAUGE|DECREASED|1|dram|TOTAL BODY RADIOGRAPHY|||INVESTIGATOR|READER 3|U|3|Visit_3|40|6|TREATMENT|2020-07-27|40
e|TR|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|pmol/day|NONPALPABLE|1|/2500 WBC|MALDI|||CHILD|READER 1|N|4|Visit_4|65|5|TREATMENT|2020-08-21|65
e|TR|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|5|[?]|RADIODEN|Radiodensity|[?]|NEBULE|FOCALLY INCREASED|1|vp/mL|RYAN BLUE STAIN|||PROXY|ADJUDICATOR|NA|5|Visit_5|90|5|TREATMENT|2020-09-15|90
e|TR|beb6b1ab-1264-456a-bf2b-81e28493301d|1|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|BAG|ENLARGEMENT FROM NADIR|1|PFU/mL|CHROMATOGRAPHY||Y|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|N|1|Visit_1|10|5|TREATMENT|2020-06-10|10
e|TR|beb6b1ab-1264-456a-bf2b-81e28493301d|2|[?]|VOLUME|Volume|[?]|mAnson U/mL|FURTHER ENLARGEMENT FROM NADIR|1|pL|ENZYMATIC COLORIMETRY|Y||HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|2|Visit_2|25|4|FOLLOW-UP|2020-06-25|25
e|TR|beb6b1ab-1264-456a-bf2b-81e28493301d|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|10^5/L|TUMOR MERGED|1|ug/day|CALIPER MEASUREMENT METHOD|||ADJUDICATION COMMITTEE|ADJUDICATOR|Y|3|Visit_3|40|1|SCREENING|2020-07-10|40
e|TR|beb6b1ab-1264-456a-bf2b-81e28493301d|4|[?]|VDIAM|Viable Diameter|[?]|RNA copies/mL|DIFFUSELY INCREASED|1|mol/mg|CELLULOSE TAPE|||FRIEND|ADJUDICATOR 1|Y|4|Visit_4|65|5|TREATMENT|2020-08-04|65
e|TR|beb6b1ab-1264-456a-bf2b-81e28493301d|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|anti-Xa IU|ABSENT|1|FEU|RAJI CELL EIA|Y||ADJUDICATOR|PHYSIOTHERAPIST|U|5|Visit_5|90|7|WASHOUT|2020-08-29|90
e|TR|4292c06d-044e-4dff-aea0-830178a6e220|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|DAgU|NORMAL|1|m/sec2|IMMUNOBLOT||Y|INVESTIGATOR|CLINICAL PATHOLOGIST|U|1|Visit_1|10|3|WASHOUT|2020-12-02|10
e|TR|4292c06d-044e-4dff-aea0-830178a6e220|2|[?]|RADIODEN|Radiodensity|[?]|L|ENLARGEMENT|1|Bq/mL|PATHOLOGICAL EVALUATION||Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-12-17|25
e|TR|4292c06d-044e-4dff-aea0-830178a6e220|3|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mL/(min*100mL)|PALPABLE|1|um|DROPLET DIGITAL PCR|||CHILD|ONCOLOGIST|NA|3|Visit_3|40|7|WASHOUT|2021-01-01|40
e|TR|4292c06d-044e-4dff-aea0-830178a6e220|4|[?]|PALPSTAT|Palpable State|[?]|mL/m2/day|NON-PATHOLOGICAL|1|um|AMSLER GRID||Y|PROXY|PHYSIOTHERAPIST|NA|4|Visit_4|65|1|WASHOUT|2021-01-26|65
e|TR|4292c06d-044e-4dff-aea0-830178a6e220|5|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mmol/s|ABSENT|1|%/min|IMMUNOPRECIPITATION|||CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|U|5|Visit_5|90|5|TREATMENT|2021-02-20|90
e|TR|050c12d2-cf9f-402b-9332-d6a9771ed115|1|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mg/m2/h|PATHOLOGICAL|1|Joule|MIGET||Y|GUARDIAN|INTERNIST|NA|1|Visit_1|10|2|SCREENING|2020-08-18|10
e|TR|050c12d2-cf9f-402b-9332-d6a9771ed115|2|[?]|PCHGBL|Percent Change From Baseline|[?]|m3|PALPABLE|1|cd*s/m2|LIQUID SCINTILLATION COUNTING|||PARENT|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-09-02|25
e|TR|050c12d2-cf9f-402b-9332-d6a9771ed115|3|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|kcal/day|UNCHANGED|1|mol/mg|ENDPOINT DILUTION ASSAY|||SIBLING|ENDOCRINOLOGIST|U|3|Visit_3|40|7|FOLLOW-UP|2020-09-17|40
e|TR|050c12d2-cf9f-402b-9332-d6a9771ed115|4|[?]|ORVERLN|Organ Vertical Length|[?]|m2|UNCHANGED|1|ug|CLOT DETECTION|||CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|Y|4|Visit_4|65|3|FOLLOW-UP|2020-10-12|65
e|TR|050c12d2-cf9f-402b-9332-d6a9771ed115|5|[?]|LPERP|Longest Perpendicular|[?]|hPa|DECREASED|1|scm|DIFFUSION WEIGHTED MRI||Y|INVESTIGATOR|READER|N|5|Visit_5|90|6|FOLLOW-UP|2020-11-06|90
e|TR|2f1073e4-607f-423f-a5de-f531b828e2d3|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|m/sec2|ABSENT|1|mkat|CRYOSCOPY|||INTERVIEWER|PATHOLOGIST 2|Y|1|Visit_1|10|6|FOLLOW-UP|2020-10-15|10
e|TR|2f1073e4-607f-423f-a5de-f531b828e2d3|2|[?]|LDIAM|Longest Diameter|[?]|/500 WBC|EQUIVOCAL|1|pt_br|MYELOPEROXIDASE STAIN||Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-10-30|25
e|TR|2f1073e4-607f-423f-a5de-f531b828e2d3|3|[?]|LPERP|Longest Perpendicular|[?]|mEq/L|UNCHANGED|1|mgEq|MECHANICAL CLOT DETECTION|||CAREGIVER|NEUROLOGIST 1|NA|3|Visit_3|40|4|WASHOUT|2020-11-14|40
e|TR|2f1073e4-607f-423f-a5de-f531b828e2d3|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|AU/mL|UNEQUIVOCAL|1|MnFI|WHOLE EXOME SEQUENCING|||SPOUSE|RATER|NA|4|Visit_4|65|4|TREATMENT|2020-12-09|65
e|TR|2f1073e4-607f-423f-a5de-f531b828e2d3|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|nkat/g Hb|NONPALPABLE|1|vg/mL|DYNAMOMETRY||Y|ADJUDICATOR|READER 3|N|5|Visit_5|90|6|WASHOUT|2021-01-03|90
e|TR|df466903-3212-4e73-bff0-a183447c7408|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|pmol/g|NONPALPABLE|1|log10 TCID 50/uL|BAC ACGH|||INDEPENDENT ASSESSOR|NEUROLOGIST|N|1|Visit_1|10|4|WASHOUT|2020-11-01|10
e|TR|df466903-3212-4e73-bff0-a183447c7408|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|OI50|NORMAL|1|CFU/mL|FLUORESCENT IMMUNOASSAY||Y|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|2|Visit_2|25|7|SCREENING|2020-11-16|25
e|TR|df466903-3212-4e73-bff0-a183447c7408|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|km/h|DECREASED|1|U/g/h|MICROBIAL BIOCHEMICAL IDENTIFICATION|||CHILD|NEUROLOGIST 1|NA|3|Visit_3|40|2|TREATMENT|2020-12-01|40
e|TR|df466903-3212-4e73-bff0-a183447c7408|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|U/L|ENLARGEMENT|1|BU/mL|LC/MS|||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|4|Visit_4|65|5|SCREENING|2020-12-26|65
e|TR|df466903-3212-4e73-bff0-a183447c7408|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|sec|TUMOR MERGED|1|Hz/s|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||FAMILY MEMBER|PATHOLOGIST 1|Y|5|Visit_5|90|5|FOLLOW-UP|2021-01-20|90
e|TR|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|uL/kg/day|PRESENT|1|kPa|PHASE-CONTRAST MRI|||ADJUDICATOR|ONCOLOGIST 1|U|1|Visit_1|10|7|TREATMENT|2020-07-13|10
e|TR|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|Bq|ENLARGEMENT FROM NADIR|1|dram|ALCIAN BLUE STAIN|||INTERVIEWER|FORENSIC PATHOLOGIST|U|2|Visit_2|25|1|SCREENING|2020-07-28|25
e|TR|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|3|[?]|SUMDIAM|Sum of Diameter|[?]|mmol/s|DIFFUSELY INCREASED|1|MPS U|CELLULOSE TAPE|||SIBLING|MICROSCOPIST 1|N|3|Visit_3|40|7|FOLLOW-UP|2020-08-12|40
e|TR|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|amp|ABSENT|1|kBq/uL|HPLC/MS|Y||FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|6|SCREENING|2020-09-06|65
e|TR|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|mV/sec|NONPALPABLE|1|10^6 copies/mL|LIGHT MICROSCOPY|||CLINICAL STUDY SPONSOR|NEUROLOGIST|U|5|Visit_5|90|1|SCREENING|2020-10-01|90
e|TR|c37df2f6-be8a-4709-b97d-061ab9754e0d|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|fL|TUMOR MERGED|1|mg/h|CLOT DETECTION||Y|FAMILY MEMBER|NEUROLOGIST 2|Y|1|Visit_1|10|7|TREATMENT|2020-08-01|10
e|TR|c37df2f6-be8a-4709-b97d-061ab9754e0d|2|[?]|VOLUME|Volume|[?]|m2|PATHOLOGICAL|1|/10^3|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||SIGNIFICANT OTHER|READER|U|2|Visit_2|25|2|TREATMENT|2020-08-16|25
e|TR|c37df2f6-be8a-4709-b97d-061ab9754e0d|3|[?]|BNLNUM|Number of Bone Lesions|[?]|sec|FURTHER ENLARGEMENT|1|EID 50/dose|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||Y|CAREGIVER|MICROSCOPIST 2|U|3|Visit_3|40|7|SCREENING|2020-08-31|40
e|TR|c37df2f6-be8a-4709-b97d-061ab9754e0d|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|CAN|ENLARGEMENT FROM NADIR|1|log10 copies/mL|MODIFIED ACID FAST STAIN|||HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-09-25|65
e|TR|c37df2f6-be8a-4709-b97d-061ab9754e0d|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|/HPF|FOCALLY INCREASED|1|DRINK|RYAN BLUE STAIN|||INVESTIGATOR|PATHOLOGIST 2|N|5|Visit_5|90|2|TREATMENT|2020-10-20|90
e|TR|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|1|[?]|AREA|Area|[?]|BLOCKS|TUMOR MERGED|1|ug|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||INTERVIEWER|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-05-13|10
e|TR|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|mV*min|PRESENT|1|pmol/10^9 cells|SLIT LAMP||Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|N|2|Visit_2|25|1|WASHOUT|2020-05-28|25
e|TR|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mL/g/h|DIFFUSELY INCREASED|1|ukat/L|MECHANICAL CLOT DETECTION|||FRIEND|READER 1|Y|3|Visit_3|40|6|TREATMENT|2020-06-12|40
e|TR|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|4|[?]|VDIAM|Viable Diameter|[?]|Watt|DIFFUSELY INCREASED|1|ug/mol|MALDI|Y||FAMILY MEMBER|MICROSCOPIST 2|U|4|Visit_4|65|2|FOLLOW-UP|2020-07-07|65
e|TR|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|5|[?]|ORVERLN|Organ Vertical Length|[?]|GPL U/mL|ENLARGEMENT|1|ug/L FEU|ICC|Y|Y|VENDOR|NEUROLOGIST 2|NA|5|Visit_5|90|1|TREATMENT|2020-08-01|90
e|TR|cec9e0ce-4d09-470c-9c26-df661d316a69|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|BU|FOCALLY INCREASED|1|mg/day|ENZYMATIC ULTRACENTRIFUGATION|||PARENT|ONCOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2021-01-05|10
e|TR|cec9e0ce-4d09-470c-9c26-df661d316a69|2|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|Gy/h|PATHOLOGICAL|1|IU/kg|NEXT GENERATION TARGETED SEQUENCING|Y||SIGNIFICANT OTHER|ADJUDICATOR|Y|2|Visit_2|25|3|TREATMENT|2021-01-20|25
e|TR|cec9e0ce-4d09-470c-9c26-df661d316a69|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|TUBE|ENLARGEMENT|1|pL|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||INDEPENDENT ASSESSOR|ADJUDICATOR|NA|3|Visit_3|40|5|TREATMENT|2021-02-04|40
e|TR|cec9e0ce-4d09-470c-9c26-df661d316a69|4|[?]|ORSTATE|Organ State|[?]|/MBP|DECREASED|1|mL/m2/h|ELECTROCHEMILUMINESCENCE|||CHILD|READER|Y|4|Visit_4|65|3|TREATMENT|2021-03-01|65
e|TR|cec9e0ce-4d09-470c-9c26-df661d316a69|5|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|10^6 IU/mL|NON-PATHOLOGICAL|1|Henry|DNA MICROARRAY|||FAMILY MEMBER|ENDOCRINOLOGIST|U|5|Visit_5|90|6|TREATMENT|2021-03-26|90
e|TR|b98b4e19-51ac-40cc-80d5-cb6d8000c112|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|WAFER|NORMAL|1|mV/sec|LC/MS/MS|Y||ADJUDICATOR|ENDOCRINOLOGIST|N|1|Visit_1|10|4|SCREENING|2021-01-17|10
e|TR|b98b4e19-51ac-40cc-80d5-cb6d8000c112|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|L/kg|DIFFUSELY INCREASED|1|mmol/min/kPa|CONFOCAL MICROSCOPY||Y|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2021-02-01|25
e|TR|b98b4e19-51ac-40cc-80d5-cb6d8000c112|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mEq/ug|NON-PATHOLOGICAL|1|TABLET|SCANNING ELECTRON MICROSCOPY|Y||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|3|Visit_3|40|6|WASHOUT|2021-02-16|40
e|TR|b98b4e19-51ac-40cc-80d5-cb6d8000c112|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|Hz/s|ENLARGEMENT FROM NADIR|1|uEq|WRIGHT-GIEMSA STAIN||Y|INTERVIEWER|RADIOLOGIST 2|N|4|Visit_4|65|4|TREATMENT|2021-03-13|65
e|TR|b98b4e19-51ac-40cc-80d5-cb6d8000c112|5|[?]|PALPSTAT|Palpable State|[?]|USP U|NON-PATHOLOGICAL|1|uL/mL|CLIP SEQUENCING|||INTERVIEWER|RADIOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2021-04-07|90
e|TR|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mg|FURTHER ENLARGEMENT FROM NADIR|1|10^3 CFU/mL|RADIATION DOSIMETRY|||HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|1|Visit_1|10|4|WASHOUT|2020-07-07|10
e|TR|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|grain|DIFFUSELY INCREASED|1|mU/g|ELISPOT||Y|HEALTH CARE PROFESSIONAL|INTERNIST|N|2|Visit_2|25|3|WASHOUT|2020-07-22|25
e|TR|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|U/cL|UNEQUIVOCAL|1|mph|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|Y|SIGNIFICANT OTHER|ONCOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2020-08-06|40
e|TR|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|10^7 PFU|DECREASED|1|%(w/w)|THICK SMEAR|||SPOUSE|CLINICAL PATHOLOGIST|U|4|Visit_4|65|1|SCREENING|2020-08-31|65
e|TR|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|IU/L|NORMAL|1|kg/L|IMMUNOBLOT|Y||HEALTH CARE PROFESSIONAL|READER 1|NA|5|Visit_5|90|6|TREATMENT|2020-09-25|90
e|TR|4bc30b18-c8d8-41a3-91d5-33b8b064087b|1|[?]|ORSTATE|Organ State|[?]|IU/mg|TUMOR MERGED|1|s/h|ANTIMICROBIAL COMBINATION TESTING|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|NA|1|Visit_1|10|7|TREATMENT|2020-07-12|10
e|TR|4bc30b18-c8d8-41a3-91d5-33b8b064087b|2|[?]|NEWCONF|New Tumor Confirmed|[?]|g/L|PATHOLOGICAL|1|CAPSULE|FLOCCULATION|Y||FRIEND|READER 3|NA|2|Visit_2|25|4|WASHOUT|2020-07-27|25
e|TR|4bc30b18-c8d8-41a3-91d5-33b8b064087b|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|Watt|FURTHER ENLARGEMENT FROM NADIR|1|PIPE|FORCED OSCILLATION TECHNIQUE|Y||CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|Y|3|Visit_3|40|3|SCREENING|2020-08-11|40
e|TR|4bc30b18-c8d8-41a3-91d5-33b8b064087b|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|in|ENLARGEMENT FROM NADIR|1|uEq/L|MICRO BROTH DILUTION||Y|CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|4|Visit_4|65|7|SCREENING|2020-09-05|65
e|TR|4bc30b18-c8d8-41a3-91d5-33b8b064087b|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|U/mL|PALPABLE|1|uV|MICROSCOPY|Y||INTERVIEWER|ONCOLOGIST 2|N|5|Visit_5|90|2|SCREENING|2020-09-30|90
e|TR|7ff27a70-0472-4cc1-b057-6b161ab29568|1|[?]|LPERP|Longest Perpendicular|[?]|VIRTUAL PIXEL|FURTHER ENLARGEMENT|1|%/s|CINEANGIOGRAPHY|||FRIEND|NEUROLOGIST 1|N|1|Visit_1|10|4|FOLLOW-UP|2020-11-19|10
e|TR|7ff27a70-0472-4cc1-b057-6b161ab29568|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|FEU|UNCHANGED|1|mL/mmHg/min/L|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||INDEPENDENT ASSESSOR|MICROSCOPIST 2|Y|2|Visit_2|25|6|TREATMENT|2020-12-04|25
e|TR|7ff27a70-0472-4cc1-b057-6b161ab29568|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|EVENTS|FOCALLY INCREASED|1|kV|MICROARRAY|||STUDY SUBJECT|NEUROLOGIST|N|3|Visit_3|40|6|SCREENING|2020-12-19|40
e|TR|7ff27a70-0472-4cc1-b057-6b161ab29568|4|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mg/dL|DIFFUSELY INCREASED|1|g/U|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||Y|NON-HEALTH CARE PROFESSIONAL|RATER 2|N|4|Visit_4|65|3|TREATMENT|2021-01-13|65
e|TR|7ff27a70-0472-4cc1-b057-6b161ab29568|5|[?]|AREA|Area|[?]|umol/dL|NON-PATHOLOGICAL|1|mm/sec|DISK DIFFUSION|||CHILD|ONCOLOGIST 1|NA|5|Visit_5|90|4|SCREENING|2021-02-07|90
e|TR|40529b01-9a80-4ada-a8df-96eec0e65043|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|anti-Xa IU/mL|PRESENT|1|L/min/m2|RADIOGRAPHY|||INVESTIGATOR|NEUROLOGIST 2|N|1|Visit_1|10|7|FOLLOW-UP|2020-06-17|10
e|TR|40529b01-9a80-4ada-a8df-96eec0e65043|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|10^9 organisms/mg|ABSENT|1|SUPPOSITORY|FARR ASSAY||Y|FRIEND|ADJUDICATOR 2|U|2|Visit_2|25|7|WASHOUT|2020-07-02|25
e|TR|40529b01-9a80-4ada-a8df-96eec0e65043|3|[?]|ORSTATE|Organ State|[?]|cmH2O/mL|FURTHER ENLARGEMENT|1|ug/min|JAFFE REACTION|||INTERVIEWER|ONCOLOGIST 2|NA|3|Visit_3|40|1|FOLLOW-UP|2020-07-17|40
e|TR|40529b01-9a80-4ada-a8df-96eec0e65043|4|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|1/(s*kPa)|ENLARGEMENT FROM NADIR|1|Bq/L|CELLULOSE TAPE|Y||CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|U|4|Visit_4|65|6|TREATMENT|2020-08-11|65
e|TR|40529b01-9a80-4ada-a8df-96eec0e65043|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mol|FOCALLY INCREASED|1|mol/day|HIGH RESOLUTION CT||Y|STUDY SUBJECT|RADIOLOGIST|N|5|Visit_5|90|1|TREATMENT|2020-09-05|90
e|TR|f3e22efc-0948-4c6e-9173-8e284d342d33|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|10^9 CFU|NON-PATHOLOGICAL|1|ug/kg|CONTACT SPECULAR MICROSCOPY|||CAREGIVER|RADIOLOGIST 2|N|1|Visit_1|10|4|WASHOUT|2020-12-06|10
e|TR|f3e22efc-0948-4c6e-9173-8e284d342d33|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|log10 PFU|PATHOLOGICAL|1|CCID 50/dose|PEAK FLOWMETRY|||CHILD|MICROSCOPIST 3|Y|2|Visit_2|25|5|FOLLOW-UP|2020-12-21|25
e|TR|f3e22efc-0948-4c6e-9173-8e284d342d33|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|PFU|ABSENT|1|Bq/L|IMMUNO-PET SCAN|||CHILD|PATHOLOGIST|N|3|Visit_3|40|5|FOLLOW-UP|2021-01-05|40
e|TR|f3e22efc-0948-4c6e-9173-8e284d342d33|4|[?]|ORSTATE|Organ State|[?]|/min|UNCHANGED|1|g/cage/day|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||SIBLING|INTERNIST|NA|4|Visit_4|65|4|TREATMENT|2021-01-30|65
e|TR|f3e22efc-0948-4c6e-9173-8e284d342d33|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|log10 CFU/g|FOCALLY INCREASED|1|min*mg/mL|EIA|||STUDY SUBJECT|RATER|N|5|Visit_5|90|4|WASHOUT|2021-02-24|90
e|TR|919eb5b4-a3df-41c6-86f7-c78501bb4335|1|[?]|PCHGBL|Percent Change From Baseline|[?]|nL|ENLARGEMENT FROM NADIR|1|ug/animal|GC/MS-CI|Y||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|1|FOLLOW-UP|2020-10-01|10
e|TR|919eb5b4-a3df-41c6-86f7-c78501bb4335|2|[?]|VOLUME|Volume|[?]|FFU|EQUIVOCAL|1|DRINK|POLYGRAPHY||Y|CHILD|RADIOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-10-16|25
e|TR|919eb5b4-a3df-41c6-86f7-c78501bb4335|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|/sec|FOCALLY INCREASED|1|mOsm/kg|CINEANGIOGRAPHY|||ADJUDICATOR|RATER|U|3|Visit_3|40|2|TREATMENT|2020-10-31|40
e|TR|919eb5b4-a3df-41c6-86f7-c78501bb4335|4|[?]|PPD|Product of Perpendicular Diameters|[?]|10^6 CFU/g|NON-PATHOLOGICAL|1|uEq|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||ADJUDICATOR|PATHOLOGIST|NA|4|Visit_4|65|7|SCREENING|2020-11-25|65
e|TR|919eb5b4-a3df-41c6-86f7-c78501bb4335|5|[?]|CALCFIND|Calcification Indicator|[?]|mEq/mL|NON-PATHOLOGICAL|1|h*%|NEURAMINIDASE INHIBITION ASSAY|||SIBLING|ADJUDICATOR 3|N|5|Visit_5|90|5|WASHOUT|2020-12-20|90
e|TR|f918d6e0-6fc2-4303-b323-521c5d531773|1|[?]|VOLUME|Volume|[?]|Log10 ELISA unit|PALPABLE|1|10^6/hpf|WEBER GREEN STAIN||Y|SIBLING|CARDIOLOGIST|Y|1|Visit_1|10|6|WASHOUT|2020-07-31|10
e|TR|f918d6e0-6fc2-4303-b323-521c5d531773|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mV2/Hz|PALPABLE|1|10^9 organisms/mL|POLYSOMNOGRAPHY|||PARENT|ADJUDICATOR 1|Y|2|Visit_2|25|1|TREATMENT|2020-08-15|25
e|TR|f918d6e0-6fc2-4303-b323-521c5d531773|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|QUANTITY SUFFICIENT|PALPABLE|1|um/s|KLEIHAUER-BETKE||Y|SIBLING|ONCOLOGIST|NA|3|Visit_3|40|6|FOLLOW-UP|2020-08-30|40
e|TR|f918d6e0-6fc2-4303-b323-521c5d531773|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mCi/kg|UNCHANGED|1|Pack Year|THICK SMEAR|Y||CHILD|MICROSCOPIST 1|Y|4|Visit_4|65|7|TREATMENT|2020-09-24|65
e|TR|f918d6e0-6fc2-4303-b323-521c5d531773|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mg/g/min|FURTHER ENLARGEMENT|1|log10 TCID 50/mL|NUCLEIC ACID BASED METHOD|Y||PARENT|ENDOCRINOLOGIST|NA|5|Visit_5|90|2|SCREENING|2020-10-19|90
e|TR|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|1|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|umol/dL|FURTHER ENLARGEMENT|1|g/day|IN SITU HYBRIDIZATION||Y|PROXY|INTERNIST|NA|1|Visit_1|10|2|FOLLOW-UP|2020-11-24|10
e|TR|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|PRESSOR UNITS|ABSENT|1|U/cL|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||INTERVIEWER|READER 2|U|2|Visit_2|25|1|TREATMENT|2020-12-09|25
e|TR|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|3|[?]|LESSCIND|Lesion Success Indicator|[?]|IMPLANT|UNEQUIVOCAL|1|Roentgen|IMMUNO-PET SCAN||Y|INVESTIGATOR|OPTOMETRIST|N|3|Visit_3|40|6|WASHOUT|2020-12-24|40
e|TR|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|%/s|INCREASED|1|nmol BCE/mmol|PALPATION|||INDEPENDENT ASSESSOR|UROLOGIST|N|4|Visit_4|65|7|TREATMENT|2021-01-18|65
e|TR|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|5|[?]|CALCFIND|Calcification Indicator|[?]|bel|PATHOLOGICAL|1|Enzyme U/g Hb|WHOLE TRANSCRIPTOME SEQUENCING|||CLINICAL RESEARCH COORDINATOR|READER 1|Y|5|Visit_5|90|2|TREATMENT|2021-02-12|90
e|TR|4b1e011f-a16d-4ff6-902d-451d5d13ee97|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|HOMEOPATHIC DILUTION|PALPABLE|1|U/kg/min|HEMAGGLUTINATION INHIBITION ASSAY|||PROXY|PATHOLOGIST 2|N|1|Visit_1|10|4|FOLLOW-UP|2020-06-21|10
e|TR|4b1e011f-a16d-4ff6-902d-451d5d13ee97|2|[?]|AREA|Area|[?]|mmol/min/kPa/L|UNEQUIVOCAL|1|DAgU/mL|ICC||Y|GUARDIAN|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|1|FOLLOW-UP|2020-07-06|25
e|TR|4b1e011f-a16d-4ff6-902d-451d5d13ee97|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|ug/g/day|NONPALPABLE|1|AMPULE|CYSTOMETRY|Y|Y|INVESTIGATOR|RADIOLOGIST 2|NA|3|Visit_3|40|3|TREATMENT|2020-07-21|40
e|TR|4b1e011f-a16d-4ff6-902d-451d5d13ee97|4|[?]|CALCFIND|Calcification Indicator|[?]|U/kg/min|FOCALLY INCREASED|1|Rad|PALPATION|||SPOUSE|OPHTHALMOLOGIST|U|4|Visit_4|65|5|WASHOUT|2020-08-15|65
e|TR|4b1e011f-a16d-4ff6-902d-451d5d13ee97|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|pmol/L/h|NONPALPABLE|1|nL|TRANSVAGINAL ULTRASOUND|||SIGNIFICANT OTHER|ADJUDICATOR|U|5|Visit_5|90|7|TREATMENT|2020-09-09|90
e|TR|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|U/mg|FURTHER ENLARGEMENT|1|BU/mL|FLAME PHOTOMETRY||Y|ADJUDICATION COMMITTEE|PATHOLOGIST 1|U|1|Visit_1|10|4|WASHOUT|2020-07-19|10
e|TR|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|pmol|ENLARGEMENT|1|U|CYSTOSCOPY||Y|STUDY SUBJECT|RADIOLOGIST 1|Y|2|Visit_2|25|4|FOLLOW-UP|2020-08-03|25
e|TR|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|g/cage/wk|UNCHANGED|1|g/cage/day|SANGER SEQUENCING||Y|FAMILY MEMBER|PATHOLOGIST 2|N|3|Visit_3|40|1|SCREENING|2020-08-18|40
e|TR|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|4|[?]|TUMSTATE|Tumor State|[?]|10^6 U|FURTHER ENLARGEMENT FROM NADIR|1|mg/dL|TRYPAN BLUE STAIN|||INTERVIEWER|ONCOLOGIST|U|4|Visit_4|65|1|TREATMENT|2020-09-12|65
e|TR|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|5|[?]|ORVERLN|Organ Vertical Length|[?]|ug|NON-PATHOLOGICAL|1|ppm|WHOLE EXOME SEQUENCING||Y|DOMESTIC PARTNER|RADIOLOGIST|NA|5|Visit_5|90|6|WASHOUT|2020-10-07|90
e|TR|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|1|[?]|AREA|Area|[?]|GBq/mg|NORMAL|1|g/m2/day|X-RAY FLUORESCENCE SPECTROMETRY|Y||STUDY SUBJECT|RATER 1|U|1|Visit_1|10|4|TREATMENT|2020-11-27|10
e|TR|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|g/animal|PATHOLOGICAL|1|BISCUIT|NUCLEAR RADIOLOGY|||ADJUDICATOR|READER 2|N|2|Visit_2|25|3|SCREENING|2020-12-12|25
e|TR|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|3|[?]|DIAMETER|Diameter|[?]|mEq/g|ENLARGEMENT FROM NADIR|1|BP|LIQUID SCINTILLATION COUNTING|||NON-HEALTH CARE PROFESSIONAL|RATER 1|N|3|Visit_3|40|2|FOLLOW-UP|2020-12-27|40
e|TR|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|4|[?]|DIAMETER|Diameter|[?]|DPM|NORMAL|1|/500 WBC|SANGER SEQUENCING||Y|FAMILY MEMBER|RATER|Y|4|Visit_4|65|3|TREATMENT|2021-01-21|65
e|TR|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|5|[?]|ORVERLN|Organ Vertical Length|[?]|MESF|PRESENT|1|U/m2/day|SINGLE-SLICE SPIRAL CT|Y||INVESTIGATOR|PATHOLOGIST|U|5|Visit_5|90|1|SCREENING|2021-02-15|90
e|TR|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|1|[?]|BNLNUM|Number of Bone Lesions|[?]|BEAM BREAKS|DIFFUSELY INCREASED|1|NFIU|CONTRAST ENHANCED CT SCAN|||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|N|1|Visit_1|10|4|SCREENING|2020-12-09|10
e|TR|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|2|[?]|SUMDIAM|Sum of Diameter|[?]|V/sec|NON-PATHOLOGICAL|1|Torr|KARYOTYPING|||PROXY|ONCOLOGIST 1|Y|2|Visit_2|25|7|TREATMENT|2020-12-24|25
e|TR|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|DAYS|ENLARGEMENT FROM NADIR|1|GPS U|SPIRAL CT|||INVESTIGATOR|ONCOLOGIST 1|N|3|Visit_3|40|7|SCREENING|2021-01-08|40
e|TR|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|4|[?]|RADIODEN|Radiodensity|[?]|ukat/L|UNCHANGED|1|mEq/g|RADIOIMMUNOPRECIPITATION ASSAY|||CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|5|TREATMENT|2021-02-02|65
e|TR|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|U/g|NON-PATHOLOGICAL|1|umol/L/h|HEMATOXYLIN AND EOSIN STAIN|||ADJUDICATION COMMITTEE|CARDIOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2021-02-27|90
e|TR|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|COAT|PALPABLE|1|HOURS|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|U|1|Visit_1|10|5|SCREENING|2020-07-06|10
e|TR|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|mg/kg/dose|UNEQUIVOCAL|1|Joule|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||ADJUDICATOR|ENDOCRINOLOGIST|U|2|Visit_2|25|7|FOLLOW-UP|2020-07-21|25
e|TR|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|umol/dL|PALPABLE|1|QUANTITY SUFFICIENT|SPIROMETRY|||INDEPENDENT ASSESSOR|PATHOLOGIST 2|N|3|Visit_3|40|3|FOLLOW-UP|2020-08-05|40
e|TR|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|4|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|g/g/day|TUMOR MERGED|1|LB|MANUAL CLOT DETECTION|||PROXY|ADJUDICATOR 3|Y|4|Visit_4|65|3|TREATMENT|2020-08-30|65
e|TR|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|L/L|NORMAL|1|ngEq/L|MAMMOGRAPHY|Y|Y|CLINICAL RESEARCH COORDINATOR|RATER|NA|5|Visit_5|90|3|SCREENING|2020-09-24|90
e|TR|7f1e0661-ebbd-4abd-9031-cb6b424977e2|1|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mOsm/kg|DIFFUSELY INCREASED|1|EIA unit|ELASTOGRAPHY|Y||STUDY SUBJECT|READER 2|Y|1|Visit_1|10|1|TREATMENT|2020-12-13|10
e|TR|7f1e0661-ebbd-4abd-9031-cb6b424977e2|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|cmol|NON-PATHOLOGICAL|1|mCi|TRIPLE-PHASE MRI SCAN||Y|SPOUSE|NEUROLOGIST 1|Y|2|Visit_2|25|5|SCREENING|2020-12-28|25
e|TR|7f1e0661-ebbd-4abd-9031-cb6b424977e2|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mg/L|ENLARGEMENT|1|U/g/min|DYNAMIC CONTRAST ENHANCED MRI|||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|3|TREATMENT|2021-01-12|40
e|TR|7f1e0661-ebbd-4abd-9031-cb6b424977e2|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|ft|INCREASED|1|V|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y|SIBLING|DERMATOLOGIST|U|4|Visit_4|65|1|SCREENING|2021-02-06|65
e|TR|7f1e0661-ebbd-4abd-9031-cb6b424977e2|5|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mL/animal/wk|NONPALPABLE|1|kg/L|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||INDEPENDENT ASSESSOR|RATER 2|Y|5|Visit_5|90|1|FOLLOW-UP|2021-03-03|90
e|TR|324a2c67-4802-4806-aff2-04fb9c7394d4|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|MBP|ABSENT|1|log10 TCID 50/uL|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|U|1|Visit_1|10|2|FOLLOW-UP|2020-05-27|10
e|TR|324a2c67-4802-4806-aff2-04fb9c7394d4|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|MASK|PRESENT|1|mm/sec|CONGO RED STAIN|||ADJUDICATOR|MICROSCOPIST|N|2|Visit_2|25|3|WASHOUT|2020-06-11|25
e|TR|324a2c67-4802-4806-aff2-04fb9c7394d4|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mL/cage|UNEQUIVOCAL|1|VIAL|HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y||ADJUDICATION COMMITTEE|RADIOLOGIST 2|N|3|Visit_3|40|5|FOLLOW-UP|2020-06-26|40
e|TR|324a2c67-4802-4806-aff2-04fb9c7394d4|4|[?]|CALCFIND|Calcification Indicator|[?]|Ci/kg|FURTHER ENLARGEMENT FROM NADIR|1|beats/min|LIGHT SCATTERING SPECTROSCOPY|||PARENT|ADJUDICATOR 1|Y|4|Visit_4|65|2|TREATMENT|2020-07-21|65
e|TR|324a2c67-4802-4806-aff2-04fb9c7394d4|5|[?]|NEWCONF|New Tumor Confirmed|[?]|g/m2/day|FURTHER ENLARGEMENT FROM NADIR|1|nmol/mol|AMSLER GRID|||SIGNIFICANT OTHER|HEMATOLOGIST|N|5|Visit_5|90|5|WASHOUT|2020-08-15|90
e|TR|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|mol/mg|DECREASED|1|cycle/min|TURBIDIMETRY|||VENDOR|RADIOLOGIST 2|N|1|Visit_1|10|3|FOLLOW-UP|2020-12-19|10
e|TR|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|2|[?]|LDIAM|Longest Diameter|[?]|MAC50|FOCALLY INCREASED|1|Enzyme U/L|MAGNETIC RESONANCE ELASTOGRAPHY|||DOMESTIC PARTNER|PATHOLOGIST|U|2|Visit_2|25|3|FOLLOW-UP|2021-01-03|25
e|TR|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|10^6/Ejaculate U|UNEQUIVOCAL|1|APL U/mL|ELASTOGRAPHY|||CLINICAL RESEARCH ASSOCIATE|RATER 1|N|3|Visit_3|40|6|WASHOUT|2021-01-18|40
e|TR|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|uIU/dL|NORMAL|1|nmol/kg/day|QUANTITATIVE CORONARY ANGIOGRAPHY||Y|CLINICAL RESEARCH COORDINATOR|RATER 2|U|4|Visit_4|65|4|SCREENING|2021-02-12|65
e|TR|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|deg2|DECREASED|1|FFU|RULER MEASUREMENT METHOD|||INDEPENDENT ASSESSOR|INTERNIST|N|5|Visit_5|90|6|TREATMENT|2021-03-09|90
e|TR|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|kg|NON-PATHOLOGICAL|1|10^3/hpf|BETA LACTAMASE|Y||SIGNIFICANT OTHER|PATHOLOGIST 1|Y|1|Visit_1|10|1|TREATMENT|2020-08-24|10
e|TR|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mL/day|NON-PATHOLOGICAL|1|mEq|NEPHELOMETRY|||HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|2|Visit_2|25|4|FOLLOW-UP|2020-09-08|25
e|TR|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|3|[?]|LDIAM|Longest Diameter|[?]|10^8/L|NONPALPABLE|1|/100 HPFs|PET SCAN|||CAREGIVER|READER 2|N|3|Visit_3|40|5|TREATMENT|2020-09-23|40
e|TR|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|4|[?]|LNSTATE|Lymph Node State|[?]|umol/mol|UNCHANGED|1|vg/mL|OPTICAL COHERENCE TOMOGRAPHY|||CLINICAL RESEARCH ASSOCIATE|READER 2|Y|4|Visit_4|65|5|WASHOUT|2020-10-18|65
e|TR|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mg/kg/day|NON-PATHOLOGICAL|1|mEq/day|INCISION-INDUCED BLEEDING METHOD|||CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-11-12|90
e|TR|911dc297-91cb-42b1-8a26-18f6c83c32a6|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|PRESSOR UNITS|INCREASED|1|L/s/kPa|GC/MS/MS|Y|Y|ADJUDICATION COMMITTEE|ONCOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-12-01|10
e|TR|911dc297-91cb-42b1-8a26-18f6c83c32a6|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|deg|TUMOR MERGED|1|10^3 RNA copies/mL|HILLMEN COLOR CHART|||SPOUSE|PHYSIOTHERAPIST|Y|2|Visit_2|25|5|TREATMENT|2020-12-16|25
e|TR|911dc297-91cb-42b1-8a26-18f6c83c32a6|3|[?]|PCHGBL|Percent Change From Baseline|[?]|mmHg|DIFFUSELY INCREASED|1|PELLET|ANTIBIOTIC AGAR SCREEN||Y|INTERVIEWER|MICROSCOPIST 3|N|3|Visit_3|40|3|TREATMENT|2020-12-31|40
e|TR|911dc297-91cb-42b1-8a26-18f6c83c32a6|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|/200 HPFs|INCREASED|1|Gauss|IMMUNORADIOMETRIC ASSAY|||FRIEND|MICROSCOPIST 3|Y|4|Visit_4|65|2|TREATMENT|2021-01-25|65
e|TR|911dc297-91cb-42b1-8a26-18f6c83c32a6|5|[?]|BNLNUM|Number of Bone Lesions|[?]|TABLET|TUMOR MERGED|1|Tbsp|FISH||Y|INTERVIEWER|ONCOLOGIST|N|5|Visit_5|90|4|WASHOUT|2021-02-19|90
e|TR|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|1|[?]|RADIODEN|Radiodensity|[?]|mL/g/day|UNEQUIVOCAL|1|10^9 CFU/mL|BIOIMPEDANCE SPECTROSCOPY|||INVESTIGATOR|MICROSCOPIST 1|U|1|Visit_1|10|4|TREATMENT|2020-11-25|10
e|TR|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|uEq|NONPALPABLE|1|CAPSULE|THERMAL IONIZATION MASS SPECTROMETRY|||CHILD|MICROSCOPIST|Y|2|Visit_2|25|4|FOLLOW-UP|2020-12-10|25
e|TR|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|3|[?]|BNLNUM|Number of Bone Lesions|[?]|Bq/mL|ENLARGEMENT|1|g/g|SLIT LAMP|Y||CHILD|PHYSIOTHERAPIST|N|3|Visit_3|40|7|TREATMENT|2020-12-25|40
e|TR|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|CAPFUL|FURTHER ENLARGEMENT|1|km/h|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|N|4|Visit_4|65|1|SCREENING|2021-01-19|65
e|TR|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|mL/animal/day|ABSENT|1|ukat/L|SLIT LAMP||Y|PARENT|PATHOLOGIST 2|U|5|Visit_5|90|5|WASHOUT|2021-02-13|90
e|TR|9bfcd733-2233-4e54-a6cd-641a59fc8a01|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|cm/s|UNEQUIVOCAL|1|dmol|CALCOFLUOR WHITE STAIN|||CHILD|RADIOLOGIST 1|Y|1|Visit_1|10|2|TREATMENT|2020-08-15|10
e|TR|9bfcd733-2233-4e54-a6cd-641a59fc8a01|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|deg/mm|PATHOLOGICAL|1|ppth|TOLUIDINE BLUE STAIN||Y|DOMESTIC PARTNER|INTERNIST|NA|2|Visit_2|25|6|TREATMENT|2020-08-30|25
e|TR|9bfcd733-2233-4e54-a6cd-641a59fc8a01|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|10^3 CFU/mL|NONPALPABLE|1|uL/dose|OPTICAL MAPPING||Y|GUARDIAN|READER|N|3|Visit_3|40|4|TREATMENT|2020-09-14|40
e|TR|9bfcd733-2233-4e54-a6cd-641a59fc8a01|4|[?]|LNSTATE|Lymph Node State|[?]|mL/g/h|NON-PATHOLOGICAL|1|/10^3|ELASTOGRAPHY|||CLINICAL STUDY SPONSOR|CARDIOLOGIST|N|4|Visit_4|65|1|TREATMENT|2020-10-09|65
e|TR|9bfcd733-2233-4e54-a6cd-641a59fc8a01|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|10^7/L|TUMOR MERGED|1|breaths/min|OSCILLOMETRY||Y|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|NA|5|Visit_5|90|5|TREATMENT|2020-11-03|90
e|TR|7eb97152-173c-4923-8604-5dad3140cc25|1|[?]|BNLNUM|Number of Bone Lesions|[?]|10^9/L|NONPALPABLE|1|ug/min|JAFFE REACTION|Y||PROXY|RATER 1|NA|1|Visit_1|10|3|SCREENING|2020-09-05|10
e|TR|7eb97152-173c-4923-8604-5dad3140cc25|2|[?]|SUMVOL|Sum of Volume|[?]|mU|PATHOLOGICAL|1|POINT|THERMAL IONIZATION MASS SPECTROMETRY|||ADJUDICATOR|ENDOCRINOLOGIST|NA|2|Visit_2|25|5|WASHOUT|2020-09-20|25
e|TR|7eb97152-173c-4923-8604-5dad3140cc25|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|BAR|UNEQUIVOCAL|1|U/10^12 RBC|PATHOLOGICAL EVALUATION|Y||SIGNIFICANT OTHER|READER 1|Y|3|Visit_3|40|1|SCREENING|2020-10-05|40
e|TR|7eb97152-173c-4923-8604-5dad3140cc25|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|log10 IU/mL|ENLARGEMENT FROM NADIR|1|ug/h|MASS SPECTROMETRY|||INVESTIGATOR|NEUROLOGIST|NA|4|Visit_4|65|5|TREATMENT|2020-10-30|65
e|TR|7eb97152-173c-4923-8604-5dad3140cc25|5|[?]|AREA|Area|[?]|/40 HPFs|NON-PATHOLOGICAL|1|mL/m2/day|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2020-11-24|90
e|TR|0b2104d0-e1e3-4516-8c4b-de5d42f82784|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|ug/m2/h|ENLARGEMENT|1|umol/L/h|FLOCCULATION, CHARCOAL ENHANCED|||INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|1|Visit_1|10|2|TREATMENT|2020-08-08|10
e|TR|0b2104d0-e1e3-4516-8c4b-de5d42f82784|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mEq/dL|ENLARGEMENT|1|dpm/mL|LISSAMINE GREEN STAIN|||INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|2|Visit_2|25|5|WASHOUT|2020-08-23|25
e|TR|0b2104d0-e1e3-4516-8c4b-de5d42f82784|3|[?]|LDIAM|Longest Diameter|[?]|uEq/L|PRESENT|1|MHz|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|U|3|Visit_3|40|7|TREATMENT|2020-09-07|40
e|TR|0b2104d0-e1e3-4516-8c4b-de5d42f82784|4|[?]|PPD|Product of Perpendicular Diameters|[?]|uL/mL|UNCHANGED|1|cd|FLUORESCENT SPOT TEST|Y|Y|SIBLING|MICROSCOPIST 1|Y|4|Visit_4|65|7|SCREENING|2020-10-02|65
e|TR|0b2104d0-e1e3-4516-8c4b-de5d42f82784|5|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|PFU/animal|UNCHANGED|1|10^6/hpf|CONTRAST ENHANCED MRI|||ADJUDICATION COMMITTEE|READER 1|U|5|Visit_5|90|3|TREATMENT|2020-10-27|90
e|TR|96f68979-6869-403b-a8bd-78c8f965f98a|1|[?]|CALCFIND|Calcification Indicator|[?]|nmol/day|NORMAL|1|CAPFUL|HEMAGGLUTINATION INHIBITION ASSAY|||FRIEND|ADJUDICATOR 2|Y|1|Visit_1|10|1|SCREENING|2020-05-26|10
e|TR|96f68979-6869-403b-a8bd-78c8f965f98a|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|mg/g/min|PATHOLOGICAL|1|nmol/day|OPHTHALMOSCOPY|||HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|2|Visit_2|25|4|SCREENING|2020-06-10|25
e|TR|96f68979-6869-403b-a8bd-78c8f965f98a|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|g/g/day|ENLARGEMENT|1|nmol/kg/day|BIOPSY|Y||FRIEND|NEUROLOGIST 2|Y|3|Visit_3|40|7|SCREENING|2020-06-25|40
e|TR|96f68979-6869-403b-a8bd-78c8f965f98a|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|CFU/mL|NORMAL|1|pm|CAPILLARY ELECTROPHORESIS|||STUDY SUBJECT|RADIOLOGIST 2|Y|4|Visit_4|65|3|WASHOUT|2020-07-20|65
e|TR|96f68979-6869-403b-a8bd-78c8f965f98a|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|mL/cage/wk|PALPABLE|1|pmol/day|ULTRASOUND|||FAMILY MEMBER|OPHTHALMOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-08-14|90
e|TR|e0f67610-b86a-4f5a-88eb-905b1e0aa609|1|[?]|SUMVOL|Sum of Volume|[?]|U/kg|INCREASED|1|mg/m2/min|MUGA|||ADJUDICATOR|RATER 1|U|1|Visit_1|10|1|TREATMENT|2020-10-16|10
e|TR|e0f67610-b86a-4f5a-88eb-905b1e0aa609|2|[?]|ORVERLN|Organ Vertical Length|[?]|mIU/L|TUMOR MERGED|1|vp/mL|PEAK FLOWMETRY|||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|N|2|Visit_2|25|2|TREATMENT|2020-10-31|25
e|TR|e0f67610-b86a-4f5a-88eb-905b1e0aa609|3|[?]|ORVERLN|Organ Vertical Length|[?]|IU/dL|PALPABLE|1|U/m2|SINGLE-MOLECULE ARRAY|||DOMESTIC PARTNER|ADJUDICATOR 2|N|3|Visit_3|40|6|TREATMENT|2020-11-15|40
e|TR|e0f67610-b86a-4f5a-88eb-905b1e0aa609|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|nmol BCE/nmol|UNCHANGED|1|FEU|QUANTITATIVE CORONARY ANGIOGRAPHY|||GUARDIAN|RADIOLOGIST 2|NA|4|Visit_4|65|1|SCREENING|2020-12-10|65
e|TR|e0f67610-b86a-4f5a-88eb-905b1e0aa609|5|[?]|NEWCONF|New Tumor Confirmed|[?]|mmol/L|FURTHER ENLARGEMENT FROM NADIR|1|SYRINGE|ALCIAN BLUE STAIN|||STUDY SUBJECT|OPTOMETRIST|U|5|Visit_5|90|1|WASHOUT|2021-01-04|90
e|TR|d62dc655-8865-4592-af0b-744524d9a24c|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mmHg/L/min|UNCHANGED|1|Frames/s|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||PARENT|RADIOLOGIST 1|U|1|Visit_1|10|4|TREATMENT|2020-09-29|10
e|TR|d62dc655-8865-4592-af0b-744524d9a24c|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|SYRINGE|ENLARGEMENT FROM NADIR|1|IU/dL|RADIATION DOSIMETRY|||SIGNIFICANT OTHER|ONCOLOGIST 2|Y|2|Visit_2|25|6|FOLLOW-UP|2020-10-14|25
e|TR|d62dc655-8865-4592-af0b-744524d9a24c|3|[?]|NEWCONF|New Tumor Confirmed|[?]|pkat/L|DIFFUSELY INCREASED|1|DIOPTER|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||CLINICAL RESEARCH ASSOCIATE|READER 3|NA|3|Visit_3|40|6|FOLLOW-UP|2020-10-29|40
e|TR|d62dc655-8865-4592-af0b-744524d9a24c|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|ug/mol|NORMAL|1|mCi/L|HEMATOXYLIN AND EOSIN STAIN|||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|4|Visit_4|65|6|TREATMENT|2020-11-23|65
e|TR|d62dc655-8865-4592-af0b-744524d9a24c|5|[?]|LDIAM|Longest Diameter|[?]|mOsm/L|ENLARGEMENT|1|usec|ACID FAST STAIN|||CAREGIVER|READER|Y|5|Visit_5|90|4|FOLLOW-UP|2020-12-18|90
e|TR|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|foz_br|DIFFUSELY INCREASED|1|uCi/L|DARK FIELD MICROSCOPY||Y|GUARDIAN|ONCOLOGIST 2|N|1|Visit_1|10|2|TREATMENT|2021-01-08|10
e|TR|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|2|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|DROP|NONPALPABLE|1|ug/kg|FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y||PROXY|RADIOLOGIST|NA|2|Visit_2|25|4|SCREENING|2021-01-23|25
e|TR|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|3|[?]|DIAMETER|Diameter|[?]|mL/s/m2|NORMAL|1|10^6/L|IN VITRO GENE EXPRESSION ASSAY|||DOMESTIC PARTNER|RADIOLOGIST 1|NA|3|Visit_3|40|4|TREATMENT|2021-02-07|40
e|TR|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|4|[?]|ORSTATE|Organ State|[?]|mm/min|NORMAL|1|APS U|LANDOLT RING|Y|Y|INTERVIEWER|ONCOLOGIST 1|U|4|Visit_4|65|2|TREATMENT|2021-03-04|65
e|TR|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|BISCUIT|UNEQUIVOCAL|1|pL|FLUORIMETRY|||ADJUDICATOR|PATHOLOGIST|Y|5|Visit_5|90|3|SCREENING|2021-03-29|90
e|TR|8005bd56-3bd6-477a-a466-b9a3bd189770|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|mkat|PATHOLOGICAL|1|g/dL|ZIEHL NEELSEN ACID FAST STAIN|Y||ADJUDICATOR|PATHOLOGIST 2|N|1|Visit_1|10|2|TREATMENT|2020-12-23|10
e|TR|8005bd56-3bd6-477a-a466-b9a3bd189770|2|[?]|DIAMETER|Diameter|[?]|Bq/kg|UNEQUIVOCAL|1|BAU|LC/MS|||SIBLING|ONCOLOGIST 1|NA|2|Visit_2|25|5|WASHOUT|2021-01-07|25
e|TR|8005bd56-3bd6-477a-a466-b9a3bd189770|3|[?]|ORVERLN|Organ Vertical Length|[?]|MnFI|UNCHANGED|1|ukat/L|SURFACE PLASMON RESONANCE|Y||INVESTIGATOR|RATER 2|U|3|Visit_3|40|7|SCREENING|2021-01-22|40
e|TR|8005bd56-3bd6-477a-a466-b9a3bd189770|4|[?]|SUMVOL|Sum of Volume|[?]|GLOBULE|UNCHANGED|1|uEq/L|ANTIMICROBIAL COMBINATION TESTING|||FRIEND|ONCOLOGIST 2|Y|4|Visit_4|65|7|TREATMENT|2021-02-16|65
e|TR|8005bd56-3bd6-477a-a466-b9a3bd189770|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|Enzyme U/g Hb|ENLARGEMENT|1|BEAM BREAKS|ELLA|||ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|NA|5|Visit_5|90|6|FOLLOW-UP|2021-03-13|90
e|TR|078ea33d-4114-4320-9116-740b8385a94e|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|WAFER|NON-PATHOLOGICAL|1|nmol/g|PERFUSION MRI||Y|FRIEND|READER 2|Y|1|Visit_1|10|5|TREATMENT|2020-07-26|10
e|TR|078ea33d-4114-4320-9116-740b8385a94e|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|SPRAY|FURTHER ENLARGEMENT FROM NADIR|1|mOsm|IMMUNOFIXATION ELECTROPHORESIS|Y||SIBLING|RATER 1|N|2|Visit_2|25|1|SCREENING|2020-08-10|25
e|TR|078ea33d-4114-4320-9116-740b8385a94e|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|amol|DECREASED|1|ukat/L|VIRUS PLAQUE ASSAY|||STUDY SUBJECT|ADJUDICATOR 1|NA|3|Visit_3|40|7|TREATMENT|2020-08-25|40
e|TR|078ea33d-4114-4320-9116-740b8385a94e|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|amu|TUMOR MERGED|1|CAPLET|CLIP SEQUENCING|Y||PARENT|READER 1|NA|4|Visit_4|65|2|TREATMENT|2020-09-19|65
e|TR|078ea33d-4114-4320-9116-740b8385a94e|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|TAMPON|DECREASED|1|10^3 CFU/mL|CENTRIFUGATION|||STUDY SUBJECT|UROLOGIST|NA|5|Visit_5|90|6|FOLLOW-UP|2020-10-14|90
e|TR|1ca91975-9a42-4f4d-9c55-53f7561d82fa|1|[?]|AREA|Area|[?]|ug|FURTHER ENLARGEMENT FROM NADIR|1|10^9/g|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||Y|PARENT|FORENSIC PATHOLOGIST|U|1|Visit_1|10|2|TREATMENT|2020-06-03|10
e|TR|1ca91975-9a42-4f4d-9c55-53f7561d82fa|2|[?]|SUMDIAM|Sum of Diameter|[?]|kIU|TUMOR MERGED|1|ug/animal|ALCIAN BLUE STAIN|Y||SIBLING|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2020-06-18|25
e|TR|1ca91975-9a42-4f4d-9c55-53f7561d82fa|3|[?]|CALCFIND|Calcification Indicator|[?]|U/g/min|ENLARGEMENT FROM NADIR|1|CUP|FLOW CYTOMETRY|||SPOUSE|DERMATOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-07-03|40
e|TR|1ca91975-9a42-4f4d-9c55-53f7561d82fa|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mm|DIFFUSELY INCREASED|1|mL/m2/day|DUCTOGRAPHY|Y||ADJUDICATION COMMITTEE|PATHOLOGIST 1|Y|4|Visit_4|65|6|TREATMENT|2020-07-28|65
e|TR|1ca91975-9a42-4f4d-9c55-53f7561d82fa|5|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|FINGERTIP UNIT|ENLARGEMENT|1|fL|SPECTROPHOTOMETRY|||FRIEND|NEUROLOGIST|U|5|Visit_5|90|6|TREATMENT|2020-08-22|90
e|TR|c5f292ad-1729-402b-820f-83ecd29ba00d|1|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|dmol|EQUIVOCAL|1|/mm|MOUSE PROTECTION ASSAY|||SIBLING|RATER 2|NA|1|Visit_1|10|6|TREATMENT|2020-06-08|10
e|TR|c5f292ad-1729-402b-820f-83ecd29ba00d|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|g/kg|DIFFUSELY INCREASED|1|kPa/L/sec|MICRO BROTH DILUTION|||CLINICAL STUDY SPONSOR|UROLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-06-23|25
e|TR|c5f292ad-1729-402b-820f-83ecd29ba00d|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|WAFER|PALPABLE|1|mL/kg/day|SMEAR|Y||CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-07-08|40
e|TR|c5f292ad-1729-402b-820f-83ecd29ba00d|4|[?]|VOLUME|Volume|[?]|10^11/L|PATHOLOGICAL|1|kg/cm2|SPIROMETRY|||HEALTH CARE PROFESSIONAL|RATER 2|Y|4|Visit_4|65|5|TREATMENT|2020-08-02|65
e|TR|c5f292ad-1729-402b-820f-83ecd29ba00d|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|uL/kg/day|UNCHANGED|1|SYRINGE|TEMPLATE INCISION METHOD|||FAMILY MEMBER|ONCOLOGIST 2|U|5|Visit_5|90|4|TREATMENT|2020-08-27|90
e|TR|a746aefb-16c8-43db-a0c4-8e9a4efdb244|1|[?]|DIAMETER|Diameter|[?]|/month|FOCALLY INCREASED|1|Weber|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y||PARENT|ENDOCRINOLOGIST|U|1|Visit_1|10|6|WASHOUT|2020-06-27|10
e|TR|a746aefb-16c8-43db-a0c4-8e9a4efdb244|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|cmol|DECREASED|1|mg/mL/min|ENZYMATIC ULTRACENTRIFUGATION|Y||CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|U|2|Visit_2|25|3|SCREENING|2020-07-12|25
e|TR|a746aefb-16c8-43db-a0c4-8e9a4efdb244|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|10^3 CFU/mL|DECREASED|1|pkat/L|PELLI-ROBSON EYE CHART|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|N|3|Visit_3|40|5|TREATMENT|2020-07-27|40
e|TR|a746aefb-16c8-43db-a0c4-8e9a4efdb244|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|Enzyme U/L|FURTHER ENLARGEMENT|1|cycle/min|FREEZING POINT DEPRESSION||Y|PARENT|CLINICAL PATHOLOGIST|U|4|Visit_4|65|2|TREATMENT|2020-08-21|65
e|TR|a746aefb-16c8-43db-a0c4-8e9a4efdb244|5|[?]|RADIODEN|Radiodensity|[?]|ppth|NON-PATHOLOGICAL|1|Frames/s|FREEZING POINT DEPRESSION|Y||CHILD|RATER|U|5|Visit_5|90|1|TREATMENT|2020-09-15|90
e|TR|7f95b9c0-3b77-4c60-8890-ecc955f97122|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mIU/L|NONPALPABLE|1|U/m2/day|BIOPSY||Y|PARENT|ONCOLOGIST|NA|1|Visit_1|10|6|TREATMENT|2020-09-25|10
e|TR|7f95b9c0-3b77-4c60-8890-ecc955f97122|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|pmol/day|NON-PATHOLOGICAL|1|LENS|PET/CT SCAN|||PARENT|ONCOLOGIST|U|2|Visit_2|25|1|SCREENING|2020-10-10|25
e|TR|7f95b9c0-3b77-4c60-8890-ecc955f97122|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|nmol/day|PRESENT|1|kg/L|OPTICAL DENSITY MEASUREMENT|||FRIEND|PATHOLOGIST 2|Y|3|Visit_3|40|3|TREATMENT|2020-10-25|40
e|TR|7f95b9c0-3b77-4c60-8890-ecc955f97122|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|GBq/g|INCREASED|1|kg/L|POPULATION SEQUENCING|||FAMILY MEMBER|ADJUDICATOR|N|4|Visit_4|65|4|WASHOUT|2020-11-19|65
e|TR|7f95b9c0-3b77-4c60-8890-ecc955f97122|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|DISK|NON-PATHOLOGICAL|1|AMPULE|PHOTOMETRIC CLOT DETECTION||Y|FAMILY MEMBER|RADIOLOGIST|Y|5|Visit_5|90|6|WASHOUT|2020-12-14|90
e|TR|2be43c56-83f3-4148-9cb1-97c6d191d20e|1|[?]|LESSCIND|Lesion Success Indicator|[?]|nm|FOCALLY INCREASED|1|deg|MICROARRAY|||INTERVIEWER|MICROSCOPIST 2|NA|1|Visit_1|10|6|TREATMENT|2020-10-03|10
e|TR|2be43c56-83f3-4148-9cb1-97c6d191d20e|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|Absorbance U/mL|TUMOR MERGED|1|um2|PERIPHERAL ANGIOGRAPHY||Y|FAMILY MEMBER|NEUROLOGIST 2|Y|2|Visit_2|25|4|WASHOUT|2020-10-18|25
e|TR|2be43c56-83f3-4148-9cb1-97c6d191d20e|3|[?]|ORVERLN|Organ Vertical Length|[?]|dpm/0.5 mL|DECREASED|1|APL U/mL|JAFFE REACTION|||SPOUSE|INTERNIST|N|3|Visit_3|40|4|WASHOUT|2020-11-02|40
e|TR|2be43c56-83f3-4148-9cb1-97c6d191d20e|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|BAU|ENLARGEMENT FROM NADIR|1|/100 WBC|TOTAL BODY IRRADIATION|||CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|5|WASHOUT|2020-11-27|65
e|TR|2be43c56-83f3-4148-9cb1-97c6d191d20e|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|/min|ENLARGEMENT|1|10^6 U|CLIP SEQUENCING||Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|1|TREATMENT|2020-12-22|90
e|TR|e27e0325-5fbe-46c0-8264-982d83124203|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|STRIP|PATHOLOGICAL|1|mIU/L|ELECTROCHEMILUMINESCENCE|||INDEPENDENT ASSESSOR|RATER 2|Y|1|Visit_1|10|7|TREATMENT|2020-07-07|10
e|TR|e27e0325-5fbe-46c0-8264-982d83124203|2|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|nmol/mol|NON-PATHOLOGICAL|1|/5x10^4 WBC|STRESS ECHOCARDIOGRAPHY|Y||CLINICAL RESEARCH ASSOCIATE|RATER|Y|2|Visit_2|25|3|TREATMENT|2020-07-22|25
e|TR|e27e0325-5fbe-46c0-8264-982d83124203|3|[?]|VOLUME|Volume|[?]|log EID 50/dose|EQUIVOCAL|1|mgEq|GC/MS|||CAREGIVER|RADIOLOGIST 2|N|3|Visit_3|40|2|TREATMENT|2020-08-06|40
e|TR|e27e0325-5fbe-46c0-8264-982d83124203|4|[?]|DIAMETER|Diameter|[?]|BOLUS|INCREASED|1|NEEDLE GAUGE|POLYMERASE CHAIN REACTION|||GUARDIAN|ENDOCRINOLOGIST|U|4|Visit_4|65|4|TREATMENT|2020-08-31|65
e|TR|e27e0325-5fbe-46c0-8264-982d83124203|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|Absorbance U/mL|ABSENT|1|nmol/day|SPIRAL CT|||CAREGIVER|RADIOLOGIST 2|Y|5|Visit_5|90|5|SCREENING|2020-09-25|90
e|TR|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|1|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|APPLICATION|PATHOLOGICAL|1|umol/L|PULSE OXIMETRY|Y||CAREGIVER|ONCOLOGIST 1|N|1|Visit_1|10|3|TREATMENT|2020-12-19|10
e|TR|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|2|[?]|RADIODEN|Radiodensity|[?]|mL/s|NONPALPABLE|1|cm2|CARDIAC THERMODILUTION||Y|SPOUSE|DERMATOLOGIST|N|2|Visit_2|25|3|FOLLOW-UP|2021-01-03|25
e|TR|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|cmHg|FOCALLY INCREASED|1|PA|BAC ACGH|Y|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|Y|3|Visit_3|40|7|FOLLOW-UP|2021-01-18|40
e|TR|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|PFU|ENLARGEMENT|1|mg/m2|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|U|4|Visit_4|65|1|FOLLOW-UP|2021-02-12|65
e|TR|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|U/kg/min|EQUIVOCAL|1|IU/mg|DYNAMIC CONTRAST ENHANCED MRI|||DOMESTIC PARTNER|PATHOLOGIST 1|N|5|Visit_5|90|3|TREATMENT|2021-03-09|90
e|TR|29e08650-9eae-461f-981e-f2a20d8d4492|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|/day|ENLARGEMENT FROM NADIR|1|min*mg/mL|ELECTRICAL IMPEDANCE MYOGRAPHY|Y||CLINICAL STUDY SPONSOR|ONCOLOGIST|Y|1|Visit_1|10|3|TREATMENT|2020-11-17|10
e|TR|29e08650-9eae-461f-981e-f2a20d8d4492|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|CAPLET|NON-PATHOLOGICAL|1|mol/mg|SICKLE CELL SOLUBILITY TEST|Y||SPOUSE|PHYSIOTHERAPIST|U|2|Visit_2|25|4|TREATMENT|2020-12-02|25
e|TR|29e08650-9eae-461f-981e-f2a20d8d4492|3|[?]|NEWCONF|New Tumor Confirmed|[?]|kHz|UNCHANGED|1|Log10 ELISA unit|CT SCAN WITHOUT CONTRAST|Y||SPOUSE|INTERNIST|Y|3|Visit_3|40|7|TREATMENT|2020-12-17|40
e|TR|29e08650-9eae-461f-981e-f2a20d8d4492|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|/cmH2O|EQUIVOCAL|1|U/mg|TRANSCRIPTION-MEDIATED AMPLIFICATION|Y||SIBLING|PATHOLOGIST 2|U|4|Visit_4|65|3|TREATMENT|2021-01-11|65
e|TR|29e08650-9eae-461f-981e-f2a20d8d4492|5|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|deg2|TUMOR MERGED|1|ug/m2/day|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||PROXY|READER 2|N|5|Visit_5|90|1|SCREENING|2021-02-05|90
e|TR|2b944a62-10bc-475e-a90d-da3f07a2c4df|1|[?]|LNSTATE|Lymph Node State|[?]|mg/dose|FURTHER ENLARGEMENT|1|pmol/day|ELECTROPHORESIS|Y|Y|CLINICAL STUDY SPONSOR|INTERNIST|Y|1|Visit_1|10|4|TREATMENT|2020-09-01|10
e|TR|2b944a62-10bc-475e-a90d-da3f07a2c4df|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|APS U|DIFFUSELY INCREASED|1|CAPFUL|AURAMINE STAIN|||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|Y|2|Visit_2|25|4|TREATMENT|2020-09-16|25
e|TR|2b944a62-10bc-475e-a90d-da3f07a2c4df|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|10^3 CFU/g|NORMAL|1|dpm/mg|SNELLEN EYE CHART|Y||STUDY SUBJECT|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2020-10-01|40
e|TR|2b944a62-10bc-475e-a90d-da3f07a2c4df|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|FFU|UNCHANGED|1|kBq/uL|CONFOCAL MICROSCOPY|||VENDOR|ONCOLOGIST|U|4|Visit_4|65|6|SCREENING|2020-10-26|65
e|TR|2b944a62-10bc-475e-a90d-da3f07a2c4df|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|mmol2/L2|UNCHANGED|1|ft2|TRYPAN BLUE STAIN|||INVESTIGATOR|RADIOLOGIST 2|N|5|Visit_5|90|1|WASHOUT|2020-11-20|90
e|TR|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|/min|TUMOR MERGED|1|L/min/m2|ANTIMICROBIAL COMBINATION TESTING|||NON-HEALTH CARE PROFESSIONAL|READER 2|U|1|Visit_1|10|7|TREATMENT|2020-09-09|10
e|TR|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mg/cm2|INCREASED|1|km|COMPUTERIZED CORNEAL TOPOGRAPHY|Y||INTERVIEWER|OPHTHALMOLOGIST|Y|2|Visit_2|25|6|WASHOUT|2020-09-24|25
e|TR|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|Ci/mL|FOCALLY INCREASED|1|copies/ug|PAP STAIN|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|N|3|Visit_3|40|1|TREATMENT|2020-10-09|40
e|TR|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|10^5/hpf|PRESENT|1|Hz/s|CONFOCAL MICROSCOPY|Y||PARENT|HEMATOLOGIST|Y|4|Visit_4|65|2|SCREENING|2020-11-03|65
e|TR|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|ft3|FURTHER ENLARGEMENT|1|Bq|MICRODENSITOMETRY||Y|CHILD|NEUROLOGIST 1|NA|5|Visit_5|90|5|SCREENING|2020-11-28|90
e|TR|8aa77db3-b078-4073-a7f3-9b9a7fb14570|1|[?]|TUMSTATE|Tumor State|[?]|10^6 CFU/mL|ENLARGEMENT|1|tsp|HPLC|||ADJUDICATOR|RADIOLOGIST 2|N|1|Visit_1|10|7|WASHOUT|2020-11-12|10
e|TR|8aa77db3-b078-4073-a7f3-9b9a7fb14570|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|CCID 50/dose|ENLARGEMENT FROM NADIR|1|cP|IMMUNOBLOT|Y|Y|PARENT|OTOLARYNGOLOGIST|N|2|Visit_2|25|1|SCREENING|2020-11-27|25
e|TR|8aa77db3-b078-4073-a7f3-9b9a7fb14570|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|uV|PATHOLOGICAL|1|breaths/30s|FLUORESCENT ENZYME IMMUNOASSAY|||CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-12-12|40
e|TR|8aa77db3-b078-4073-a7f3-9b9a7fb14570|4|[?]|BNLNUM|Number of Bone Lesions|[?]|%(v/v)|ENLARGEMENT|1|mmol/g|CYSTOMETRY|Y|Y|FRIEND|NEUROLOGIST|NA|4|Visit_4|65|4|TREATMENT|2021-01-06|65
e|TR|8aa77db3-b078-4073-a7f3-9b9a7fb14570|5|[?]|PCHGBL|Percent Change From Baseline|[?]|mL/kg/day|UNEQUIVOCAL|1|10^4 CFU|CHROMATOGRAPHY||Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2021-01-31|90
e|TR|1fce031b-680b-414f-9b74-d6383e10091d|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|BOX|UNCHANGED|1|g/animal|FLUORESCENT SPOT TEST|||VENDOR|NEUROLOGIST 1|U|1|Visit_1|10|1|TREATMENT|2020-05-31|10
e|TR|1fce031b-680b-414f-9b74-d6383e10091d|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|ng/mol|NONPALPABLE|1|dram|DYNAMOMETRY|||SIBLING|MICROSCOPIST|NA|2|Visit_2|25|3|SCREENING|2020-06-15|25
e|TR|1fce031b-680b-414f-9b74-d6383e10091d|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mL/(min*100mL)|NON-PATHOLOGICAL|1|mg/kg/week|SIZE EXCLUSION CHROMATOGRAPHY|||FAMILY MEMBER|RADIOLOGIST 1|Y|3|Visit_3|40|4|TREATMENT|2020-06-30|40
e|TR|1fce031b-680b-414f-9b74-d6383e10091d|4|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|IU/g Hb|FOCALLY INCREASED|1|kcal/day|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||INVESTIGATOR|NEUROLOGIST 1|Y|4|Visit_4|65|7|FOLLOW-UP|2020-07-25|65
e|TR|1fce031b-680b-414f-9b74-d6383e10091d|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|Bq/mL|DIFFUSELY INCREASED|1|mg2/dL2|DISK DIFFUSION|Y|Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|6|TREATMENT|2020-08-19|90
e|TR|dcc67696-e91a-4cef-81dd-f2d2711363ae|1|[?]|SUMVOL|Sum of Volume|[?]|IU/dL|NON-PATHOLOGICAL|1|log10 TCID 50/dose|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y|DOMESTIC PARTNER|ONCOLOGIST|U|1|Visit_1|10|7|FOLLOW-UP|2020-12-28|10
e|TR|dcc67696-e91a-4cef-81dd-f2d2711363ae|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|APS U|DECREASED|1|copies/uL|MS/MS|Y||CLINICAL STUDY SPONSOR|MICROSCOPIST|U|2|Visit_2|25|7|FOLLOW-UP|2021-01-12|25
e|TR|dcc67696-e91a-4cef-81dd-f2d2711363ae|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mg/min|PATHOLOGICAL|1|L/day|MANUAL COUNT||Y|SPOUSE|PHYSIOTHERAPIST|U|3|Visit_3|40|5|SCREENING|2021-01-27|40
e|TR|dcc67696-e91a-4cef-81dd-f2d2711363ae|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|days/month|PRESENT|1|AgU/mL|NUCLEIC ACID BASED METHOD|Y||DOMESTIC PARTNER|HEMATOLOGIST|NA|4|Visit_4|65|5|WASHOUT|2021-02-21|65
e|TR|dcc67696-e91a-4cef-81dd-f2d2711363ae|5|[?]|PALPSTAT|Palpable State|[?]|m|INCREASED|1|ug/min|MICRODENSITOMETRY||Y|PROXY|ONCOLOGIST 2|NA|5|Visit_5|90|1|WASHOUT|2021-03-18|90
e|TR|91e83d7a-186a-4fed-8750-af796d77d356|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|TUBE|DIFFUSELY INCREASED|1|foz_us|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||GUARDIAN|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|6|FOLLOW-UP|2020-06-02|10
e|TR|91e83d7a-186a-4fed-8750-af796d77d356|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|Enzyme U|ENLARGEMENT FROM NADIR|1|RATIO|AUTOMATED COUNT|Y||HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|2|Visit_2|25|7|TREATMENT|2020-06-17|25
e|TR|91e83d7a-186a-4fed-8750-af796d77d356|3|[?]|LNSTATE|Lymph Node State|[?]|MET*min|DECREASED|1|EVENTS|MAPH|Y||CAREGIVER|DERMATOLOGIST|Y|3|Visit_3|40|3|FOLLOW-UP|2020-07-02|40
e|TR|91e83d7a-186a-4fed-8750-af796d77d356|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|rpm|PATHOLOGICAL|1|DNA copies/mL|BRDU CELLULAR PROLIFERATION ASSAY|Y|Y|CAREGIVER|MICROSCOPIST 2|U|4|Visit_4|65|4|SCREENING|2020-07-27|65
e|TR|91e83d7a-186a-4fed-8750-af796d77d356|5|[?]|CALCFIND|Calcification Indicator|[?]|cs|DECREASED|1|Bq/mL|MICRO BROTH DILUTION|||CLINICAL RESEARCH COORDINATOR|RATER|NA|5|Visit_5|90|5|TREATMENT|2020-08-21|90
e|TR|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|ug/m2|PRESENT|1|mol/day|THICK SMEAR|||INDEPENDENT ASSESSOR|RATER|Y|1|Visit_1|10|3|TREATMENT|2020-05-13|10
e|TR|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|10^9 organisms/mg|FURTHER ENLARGEMENT|1|PFU/animal|AUSCULTATION|||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|N|2|Visit_2|25|1|TREATMENT|2020-05-28|25
e|TR|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|3|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|Gy/min|NORMAL|1|mL/min/mmHg|WRIGHT-GIEMSA STAIN||Y|SIGNIFICANT OTHER|RADIOLOGIST 2|N|3|Visit_3|40|3|TREATMENT|2020-06-12|40
e|TR|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|hr/day|FURTHER ENLARGEMENT|1|fL|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y|Y|ADJUDICATION COMMITTEE|READER|N|4|Visit_4|65|4|SCREENING|2020-07-07|65
e|TR|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|5|[?]|VDIAM|Viable Diameter|[?]|10^11/L|UNCHANGED|1|Farad|IMMUNOCHROMATOGRAPHY|Y|Y|INTERVIEWER|READER 1|N|5|Visit_5|90|3|SCREENING|2020-08-01|90
e|TR|0145dfac-a107-4368-b358-bcd136e1ecb3|1|[?]|VDIAM|Viable Diameter|[?]|STEPS|PALPABLE|1|uU/dL|ELISA|Y||VENDOR|MICROSCOPIST 2|NA|1|Visit_1|10|2|TREATMENT|2021-01-08|10
e|TR|0145dfac-a107-4368-b358-bcd136e1ecb3|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|CAPLET|NON-PATHOLOGICAL|1|umol/mg/min|GRAM STAIN|Y||PROXY|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|3|TREATMENT|2021-01-23|25
e|TR|0145dfac-a107-4368-b358-bcd136e1ecb3|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mL/m2/min|INCREASED|1|Gy/h|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|1|TREATMENT|2021-02-07|40
e|TR|0145dfac-a107-4368-b358-bcd136e1ecb3|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mmol/mol|PALPABLE|1|umol/L|ATOMIC ABSORPTION SPECTROMETRY|||CAREGIVER|RATER 2|Y|4|Visit_4|65|3|FOLLOW-UP|2021-03-04|65
e|TR|0145dfac-a107-4368-b358-bcd136e1ecb3|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|umol/mg/min|PATHOLOGICAL|1|mg/g/h|ENDPOINT DILUTION ASSAY|||GUARDIAN|UROLOGIST|Y|5|Visit_5|90|2|WASHOUT|2021-03-29|90
e|TR|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|1|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mg/m2|EQUIVOCAL|1|10^3 organisms/mL|NUCLEIC ACID SEQUENCING||Y|CAREGIVER|RATER 2|Y|1|Visit_1|10|5|SCREENING|2020-12-29|10
e|TR|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|2|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|tuberculin unit/mL|UNEQUIVOCAL|1|log10 PFU/mL|DIRECT SEQUENCING|Y||INDEPENDENT ASSESSOR|DERMATOLOGIST|NA|2|Visit_2|25|1|FOLLOW-UP|2021-01-13|25
e|TR|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|3|[?]|ORSTATE|Organ State|[?]|APS U|FURTHER ENLARGEMENT|1|kDa|MICROBIAL CULTURE, SOLID|||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|4|FOLLOW-UP|2021-01-28|40
e|TR|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|Farad|PRESENT|1|mU/g|IMMUNORADIOMETRIC ASSAY|||INVESTIGATOR|ADJUDICATOR 1|NA|4|Visit_4|65|1|TREATMENT|2021-02-22|65
e|TR|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|5|[?]|TUMSTATE|Tumor State|[?]|mmol/kg|PATHOLOGICAL|1|log10 copies/mL|DUKE INCISION METHOD|Y||CHILD|RATER 2|NA|5|Visit_5|90|7|TREATMENT|2021-03-19|90
e|TR|d4d79f6a-ba90-4503-934b-8a86286d83d3|1|[?]|VOLUME|Volume|[?]|EID 50/dose|INCREASED|1|sec|IMMUNOTURBIDIMETRY|Y||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-11-17|10
e|TR|d4d79f6a-ba90-4503-934b-8a86286d83d3|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|nm|NORMAL|1|msec|HIGH RESOLUTION MELT ANALYSIS|Y||SIBLING|MICROSCOPIST|Y|2|Visit_2|25|7|WASHOUT|2020-12-02|25
e|TR|d4d79f6a-ba90-4503-934b-8a86286d83d3|3|[?]|NEWCONF|New Tumor Confirmed|[?]|mg/mL/min|UNEQUIVOCAL|1|mAmp|MICROBIAL CULTURE, LIQUID|||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|U|3|Visit_3|40|2|WASHOUT|2020-12-17|40
e|TR|d4d79f6a-ba90-4503-934b-8a86286d83d3|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|/10^3|ENLARGEMENT|1|/LSQN|DIFFUSION TENSOR MRI|||PROXY|READER 2|Y|4|Visit_4|65|6|SCREENING|2021-01-11|65
e|TR|d4d79f6a-ba90-4503-934b-8a86286d83d3|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|FINGERTIP UNIT|NORMAL|1|MBq|PHOROPTER|||FRIEND|OPTOMETRIST|U|5|Visit_5|90|7|WASHOUT|2021-02-05|90
e|TR|a329c350-49e2-415d-ba3c-e1ee929aec86|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|10^6 organisms/g|NON-PATHOLOGICAL|1|ug/min|MICROARRAY|||SIGNIFICANT OTHER|READER 1|N|1|Visit_1|10|7|FOLLOW-UP|2020-08-15|10
e|TR|a329c350-49e2-415d-ba3c-e1ee929aec86|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mMU/mL|NONPALPABLE|1|/wk|CLIP SEQUENCING|||INVESTIGATOR|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|6|WASHOUT|2020-08-30|25
e|TR|a329c350-49e2-415d-ba3c-e1ee929aec86|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|pmol/g|DIFFUSELY INCREASED|1|mU/g|HEMOCYTOMETRY||Y|SPOUSE|ADJUDICATOR 1|U|3|Visit_3|40|1|SCREENING|2020-09-14|40
e|TR|a329c350-49e2-415d-ba3c-e1ee929aec86|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|OI50|UNEQUIVOCAL|1|kg|CYSTOSCOPY|||INTERVIEWER|HEMATOLOGIST|U|4|Visit_4|65|7|SCREENING|2020-10-09|65
e|TR|a329c350-49e2-415d-ba3c-e1ee929aec86|5|[?]|LNSTATE|Lymph Node State|[?]|mMU/mL|FOCALLY INCREASED|1|sec|HPLC/IEX||Y|SIBLING|PHYSIOTHERAPIST|NA|5|Visit_5|90|5|TREATMENT|2020-11-03|90
e|TR|ff0e3543-c1f3-47f8-987f-7b00a4a33704|1|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mJoule/cm2|NONPALPABLE|1|fmol|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||CAREGIVER|DERMATOLOGIST|N|1|Visit_1|10|5|TREATMENT|2020-10-01|10
e|TR|ff0e3543-c1f3-47f8-987f-7b00a4a33704|2|[?]|BNLNUM|Number of Bone Lesions|[?]|DDU|NON-PATHOLOGICAL|1|g/U|REVERSE TRANSCRIPTASE PCR|||DOMESTIC PARTNER|RATER 1|NA|2|Visit_2|25|4|TREATMENT|2020-10-16|25
e|TR|ff0e3543-c1f3-47f8-987f-7b00a4a33704|3|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|RFU|FURTHER ENLARGEMENT FROM NADIR|1|kIU|GC/MS/MS||Y|ADJUDICATOR|MICROSCOPIST|U|3|Visit_3|40|1|FOLLOW-UP|2020-10-31|40
e|TR|ff0e3543-c1f3-47f8-987f-7b00a4a33704|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|ug/kg/min|DIFFUSELY INCREASED|1|10^9 CFU/mL|ANTIBIOTIC AGAR SCREEN|Y||PARENT|OPHTHALMOLOGIST|NA|4|Visit_4|65|3|WASHOUT|2020-11-25|65
e|TR|ff0e3543-c1f3-47f8-987f-7b00a4a33704|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|Weber|PALPABLE|1|pt_us|SPIRAL CT|Y||FRIEND|RATER 1|Y|5|Visit_5|90|1|TREATMENT|2020-12-20|90
e|TR|128153ce-7bee-4f8d-bb60-fb1776370b6d|1|[?]|LESSCIND|Lesion Success Indicator|[?]|10^5/hpf|FURTHER ENLARGEMENT FROM NADIR|1|cpm|CHROMATOGRAPHY||Y|STUDY SUBJECT|PATHOLOGIST|U|1|Visit_1|10|1|SCREENING|2021-01-11|10
e|TR|128153ce-7bee-4f8d-bb60-fb1776370b6d|2|[?]|BNLNUM|Number of Bone Lesions|[?]|mAnson U/mL|UNCHANGED|1|EU|PHOTOMETRIC CLOT DETECTION|||SIBLING|PATHOLOGIST 1|N|2|Visit_2|25|4|WASHOUT|2021-01-26|25
e|TR|128153ce-7bee-4f8d-bb60-fb1776370b6d|3|[?]|PPD|Product of Perpendicular Diameters|[?]|POUCH|PALPABLE|1|mol/day|MICROPARTICLE ENZYME IMMUNOASSAY|||CHILD|ONCOLOGIST 2|U|3|Visit_3|40|3|SCREENING|2021-02-10|40
e|TR|128153ce-7bee-4f8d-bb60-fb1776370b6d|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|ug/kg|INCREASED|1|10^9/g|OPTICAL DENSITY MEASUREMENT|||SIGNIFICANT OTHER|RATER|Y|4|Visit_4|65|6|TREATMENT|2021-03-07|65
e|TR|128153ce-7bee-4f8d-bb60-fb1776370b6d|5|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|ug|FURTHER ENLARGEMENT|1|mCi/kg|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||SPOUSE|READER 2|N|5|Visit_5|90|6|TREATMENT|2021-04-01|90
e|TR|22ee2f20-4a66-458f-a153-9d7e871e1db2|1|[?]|ORVERLN|Organ Vertical Length|[?]|U/m2/min|PATHOLOGICAL|1|mL/cm3/min|HEMOCYTOMETRY||Y|PARENT|NEUROLOGIST 1|N|1|Visit_1|10|1|WASHOUT|2020-06-17|10
e|TR|22ee2f20-4a66-458f-a153-9d7e871e1db2|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|10^9/g|ENLARGEMENT FROM NADIR|1|NEBULE|CLINICAL EVALUATION||Y|DOMESTIC PARTNER|DERMATOLOGIST|NA|2|Visit_2|25|4|FOLLOW-UP|2020-07-02|25
e|TR|22ee2f20-4a66-458f-a153-9d7e871e1db2|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mL/min/1.73m2|UNCHANGED|1|fmol/L|OSCILLOMETRY|||ADJUDICATOR|PHYSIOTHERAPIST|Y|3|Visit_3|40|7|FOLLOW-UP|2020-07-17|40
e|TR|22ee2f20-4a66-458f-a153-9d7e871e1db2|4|[?]|PALPSTAT|Palpable State|[?]|kg|TUMOR MERGED|1|cup eq|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-08-11|65
e|TR|22ee2f20-4a66-458f-a153-9d7e871e1db2|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|mL/m2/day|TUMOR MERGED|1|mV|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||Y|FAMILY MEMBER|NEUROLOGIST|NA|5|Visit_5|90|3|SCREENING|2020-09-05|90
e|TR|b7caaa04-bcc7-4350-ad98-85670a19778f|1|[?]|BNLNUM|Number of Bone Lesions|[?]|100 IU/mL|PATHOLOGICAL|1|U/10^12 RBC|CYSTOSCOPY|||ADJUDICATION COMMITTEE|READER|N|1|Visit_1|10|1|FOLLOW-UP|2020-07-06|10
e|TR|b7caaa04-bcc7-4350-ad98-85670a19778f|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|SUPPOSITORY|EQUIVOCAL|1|DRINK|RADIOIMMUNOPRECIPITATION ASSAY|||STUDY SUBJECT|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-07-21|25
e|TR|b7caaa04-bcc7-4350-ad98-85670a19778f|3|[?]|RADIODEN|Radiodensity|[?]|10^7 CFU/mL|PALPABLE|1|DISK|COMPUTERIZED CORNEAL TOPOGRAPHY|||INVESTIGATOR|CARDIOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-08-05|40
e|TR|b7caaa04-bcc7-4350-ad98-85670a19778f|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|PACKAGE|PATHOLOGICAL|1|breaths/30s|TRICHROME STAIN|||PARENT|RATER|N|4|Visit_4|65|4|SCREENING|2020-08-30|65
e|TR|b7caaa04-bcc7-4350-ad98-85670a19778f|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|kg/cm2|ENLARGEMENT|1|10^10/L|SLOAN LETTER EYE CHART 2.5%|Y||SIBLING|ENDOCRINOLOGIST|NA|5|Visit_5|90|1|SCREENING|2020-09-24|90
e|TR|2b58d5fd-3ec8-415b-bb53-a252049f228a|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|APPLICATION|NORMAL|1|mmHg/sec|SMEAR|||DOMESTIC PARTNER|CLINICAL PATHOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-12-17|10
e|TR|2b58d5fd-3ec8-415b-bb53-a252049f228a|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|CCID 50/mL|EQUIVOCAL|1|PNU/mL|MANUAL CLOT DETECTION|||STUDY SUBJECT|DERMATOLOGIST|Y|2|Visit_2|25|1|FOLLOW-UP|2021-01-01|25
e|TR|2b58d5fd-3ec8-415b-bb53-a252049f228a|3|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|HEP|NONPALPABLE|1|GLOBULE|PLETHYSMOGRAPHY|||FRIEND|MICROSCOPIST|U|3|Visit_3|40|2|WASHOUT|2021-01-16|40
e|TR|2b58d5fd-3ec8-415b-bb53-a252049f228a|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|log10 TCID 50/uL|PATHOLOGICAL|1|mmol/s|CONFOCAL MICROSCOPY||Y|FAMILY MEMBER|DERMATOLOGIST|N|4|Visit_4|65|4|TREATMENT|2021-02-10|65
e|TR|2b58d5fd-3ec8-415b-bb53-a252049f228a|5|[?]|SUMDIAM|Sum of Diameter|[?]|PRESSOR UNITS|FURTHER ENLARGEMENT|1|mL/(min*100mL)|IMMUNO-PET SCAN|||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|2|TREATMENT|2021-03-07|90
e|TR|60b23345-43f6-42eb-9225-5a674456c9b9|1|[?]|DIAMETER|Diameter|[?]|kDa|FURTHER ENLARGEMENT|1|umol/L/sec|MAGNETIC RESONANCE ANGIOGRAPHY|||VENDOR|NEUROLOGIST|U|1|Visit_1|10|2|FOLLOW-UP|2021-01-15|10
e|TR|60b23345-43f6-42eb-9225-5a674456c9b9|2|[?]|NEWCONF|New Tumor Confirmed|[?]|PIXELS/in|ENLARGEMENT FROM NADIR|1|pmol/L|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||Y|FAMILY MEMBER|ENDOCRINOLOGIST|N|2|Visit_2|25|5|TREATMENT|2021-01-30|25
e|TR|60b23345-43f6-42eb-9225-5a674456c9b9|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|ug/g/h|DIFFUSELY INCREASED|1|/10^4|MECHANICAL CLOT DETECTION|||SIBLING|ENDOCRINOLOGIST|U|3|Visit_3|40|5|FOLLOW-UP|2021-02-14|40
e|TR|60b23345-43f6-42eb-9225-5a674456c9b9|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|cup eq|NON-PATHOLOGICAL|1|vp/dose|STATIC PERIMETRY|Y||DOMESTIC PARTNER|CLINICAL PATHOLOGIST|U|4|Visit_4|65|3|TREATMENT|2021-03-11|65
e|TR|60b23345-43f6-42eb-9225-5a674456c9b9|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|BAG|DIFFUSELY INCREASED|1|EID 50/mL|DISK DIFFUSION|||VENDOR|NEUROLOGIST 1|N|5|Visit_5|90|1|TREATMENT|2021-04-05|90
e|TR|7979239e-2a6b-48e3-9d11-41c97b33d229|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|Bq/uL|INCREASED|1|uU/dL|PHOROPTER|||VENDOR|READER 2|Y|1|Visit_1|10|3|WASHOUT|2021-01-15|10
e|TR|7979239e-2a6b-48e3-9d11-41c97b33d229|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|USP U|DIFFUSELY INCREASED|1|mL/s/m2|WHOLE EXOME SEQUENCING|||PROXY|PATHOLOGIST|U|2|Visit_2|25|5|WASHOUT|2021-01-30|25
e|TR|7979239e-2a6b-48e3-9d11-41c97b33d229|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|pkat|NORMAL|1|U/10^12 RBC|CYSTOSCOPY|||FAMILY MEMBER|PATHOLOGIST 1|Y|3|Visit_3|40|5|WASHOUT|2021-02-14|40
e|TR|7979239e-2a6b-48e3-9d11-41c97b33d229|4|[?]|LDIAM|Longest Diameter|[?]|U/g/h|NONPALPABLE|1|MASK|CELL OF ORIGIN ASSAY|Y||SPOUSE|ADJUDICATOR|Y|4|Visit_4|65|3|TREATMENT|2021-03-11|65
e|TR|7979239e-2a6b-48e3-9d11-41c97b33d229|5|[?]|ORVERLN|Organ Vertical Length|[?]|10^3 CFU/g|TUMOR MERGED|1|pkat/L|ERGOSPIROMETRY|||NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|5|Visit_5|90|3|TREATMENT|2021-04-05|90
e|TR|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|1|[?]|DIAMETER|Diameter|[?]|mmAL|UNCHANGED|1|/100 WBC|PANENDOSCOPY|Y||SIGNIFICANT OTHER|RADIOLOGIST 2|U|1|Visit_1|10|3|FOLLOW-UP|2020-08-06|10
e|TR|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|2|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|ukat|PALPABLE|1|amol|GC/MS|||GUARDIAN|OTOLARYNGOLOGIST|Y|2|Visit_2|25|4|WASHOUT|2020-08-21|25
e|TR|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|3|[?]|ORVERLN|Organ Vertical Length|[?]|TAMPON|TUMOR MERGED|1|mg/min|DARK FIELD MICROSCOPY|||PROXY|ADJUDICATOR|N|3|Visit_3|40|2|SCREENING|2020-09-05|40
e|TR|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|PIXEL|FURTHER ENLARGEMENT|1|10^4 CFU/mL|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||DOMESTIC PARTNER|HEMATOLOGIST|NA|4|Visit_4|65|6|SCREENING|2020-09-30|65
e|TR|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|fmol|PRESENT|1|10^12/L|FLUORESCENT SPOT TEST||Y|NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|5|Visit_5|90|1|SCREENING|2020-10-25|90
e|TR|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|VIAL|PATHOLOGICAL|1|umol/L/h|HPLC-FL|||ADJUDICATION COMMITTEE|READER 2|NA|1|Visit_1|10|3|FOLLOW-UP|2021-01-05|10
e|TR|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|cd/m2|UNEQUIVOCAL|1|U/kg|FUNDUS PHOTOGRAPHY|||SPOUSE|MICROSCOPIST 2|Y|2|Visit_2|25|7|TREATMENT|2021-01-20|25
e|TR|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|nmol/L|NON-PATHOLOGICAL|1|10^9/dose|ELASTOGRAPHY|||CLINICAL STUDY SPONSOR|ONCOLOGIST|U|3|Visit_3|40|7|TREATMENT|2021-02-04|40
e|TR|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|4|[?]|CALCFIND|Calcification Indicator|[?]|mm/2h|EQUIVOCAL|1|h/wk|ECHOCARDIOGRAPHY|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|2|TREATMENT|2021-03-01|65
e|TR|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|5|[?]|PALPSTAT|Palpable State|[?]|CYLINDER|PRESENT|1|U/m2|MICROBIAL CONCENTRATION|||CLINICAL STUDY SPONSOR|MICROSCOPIST 2|Y|5|Visit_5|90|6|FOLLOW-UP|2021-03-26|90
e|TR|da35fc01-4258-4e4d-99d9-4172e84c46e8|1|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|GLOBULE|UNCHANGED|1|mEq/ug|URANYL ACETATE STAIN||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|1|Visit_1|10|4|TREATMENT|2020-07-22|10
e|TR|da35fc01-4258-4e4d-99d9-4172e84c46e8|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|kg/mol|ENLARGEMENT|1|msec|AURAMINE STAIN|||INTERVIEWER|CARDIOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2020-08-06|25
e|TR|da35fc01-4258-4e4d-99d9-4172e84c46e8|3|[?]|SUMDIAM|Sum of Diameter|[?]|OI50|DECREASED|1|g/cm2|PUPILLOMETRY|||SPOUSE|INTERNIST|Y|3|Visit_3|40|6|TREATMENT|2020-08-21|40
e|TR|da35fc01-4258-4e4d-99d9-4172e84c46e8|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|U/10^12 RBC|ABSENT|1|cup eq|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||ADJUDICATOR|FORENSIC PATHOLOGIST|U|4|Visit_4|65|6|FOLLOW-UP|2020-09-15|65
e|TR|da35fc01-4258-4e4d-99d9-4172e84c46e8|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|INHALATION|ENLARGEMENT|1|SYRINGE|DUCTOGRAPHY||Y|SIBLING|MICROSCOPIST 3|Y|5|Visit_5|90|3|TREATMENT|2020-10-10|90
e|TR|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|1|[?]|LESSCIND|Lesion Success Indicator|[?]|vg/kg|ABSENT|1|PFU|LASER CAPTURE MICRODISSECTION|||INTERVIEWER|OTOLARYNGOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-08-04|10
e|TR|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|2|[?]|LPERP|Longest Perpendicular|[?]|ECL unit|ENLARGEMENT FROM NADIR|1|ECL unit|MICRODENSITOMETRY|Y||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|NA|2|Visit_2|25|7|SCREENING|2020-08-19|25
e|TR|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|3|[?]|LESSCIND|Lesion Success Indicator|[?]|BAU/mL|PRESENT|1|min|DROPLET DIGITAL PCR|||SIGNIFICANT OTHER|DERMATOLOGIST|U|3|Visit_3|40|4|FOLLOW-UP|2020-09-03|40
e|TR|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|L/day|ABSENT|1|CFU/mL|SPECT/CT SCAN|||INVESTIGATOR|ONCOLOGIST 2|N|4|Visit_4|65|2|FOLLOW-UP|2020-09-28|65
e|TR|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|5|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|CUP|NORMAL|1|PFU/dose|HPLC|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|U|5|Visit_5|90|4|FOLLOW-UP|2020-10-23|90
e|TR|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mg/kg|FOCALLY INCREASED|1|h/wk|SCANNING ELECTRON MICROSCOPY|||FAMILY MEMBER|NEUROLOGIST 2|NA|1|Visit_1|10|3|FOLLOW-UP|2020-12-14|10
e|TR|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|2|[?]|ORSTATE|Organ State|[?]|mAnson U/mL|INCREASED|1|mL/cage/day|HIGH LEVEL AMINOGLYCOSIDE SCREEN||Y|PARENT|PATHOLOGIST 2|NA|2|Visit_2|25|7|WASHOUT|2020-12-29|25
e|TR|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|3|[?]|DIAMETER|Diameter|[?]|mL/cage|FURTHER ENLARGEMENT FROM NADIR|1|/4.0 mL|MANUAL COUNT|||CLINICAL RESEARCH ASSOCIATE|READER 2|N|3|Visit_3|40|3|TREATMENT|2021-01-13|40
e|TR|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|4|[?]|NEWCONF|New Tumor Confirmed|[?]|kg|ENLARGEMENT|1|foz_br|IODINE STAIN|||ADJUDICATION COMMITTEE|RADIOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2021-02-07|65
e|TR|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|5|[?]|PALPSTAT|Palpable State|[?]|SPRAY|DIFFUSELY INCREASED|1|mg/m2/h|SCANNING ELECTRON MICROSCOPY||Y|PARENT|CARDIOLOGIST|N|5|Visit_5|90|5|TREATMENT|2021-03-04|90
e|TR|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|1|[?]|CALCFIND|Calcification Indicator|[?]|Mile|ENLARGEMENT|1|mIU/L|CELL BASED BIOASSAY||Y|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-06-09|10
e|TR|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|ukat|DECREASED|1|mV*min|MANUAL CLOT DETECTION|Y||GUARDIAN|MICROSCOPIST 3|N|2|Visit_2|25|3|TREATMENT|2020-06-24|25
e|TR|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|HEP|FURTHER ENLARGEMENT|1|cmH2O/mL|BALLPOINT PEN TECHNIQUE|Y||INTERVIEWER|RADIOLOGIST 1|Y|3|Visit_3|40|7|WASHOUT|2020-07-09|40
e|TR|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|4|[?]|RADIODEN|Radiodensity|[?]|foz_us|DECREASED|1|/ms|PERCUSSION|||CLINICAL STUDY SPONSOR|RATER 1|Y|4|Visit_4|65|3|TREATMENT|2020-08-03|65
e|TR|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|L/kg|PALPABLE|1|EID 50/mL|LISSAMINE GREEN STAIN|||INDEPENDENT ASSESSOR|ADJUDICATOR 1|U|5|Visit_5|90|5|TREATMENT|2020-08-28|90
e|TR|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|gMFI|PATHOLOGICAL|1|cy/cm|IRON HEMATOXYLIN STAIN|||SIGNIFICANT OTHER|PATHOLOGIST 1|Y|1|Visit_1|10|1|FOLLOW-UP|2020-05-24|10
e|TR|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|10^6 CFU/mL|PATHOLOGICAL|1|dpm/mL|TRANSVAGINAL ULTRASOUND|||SPOUSE|OPTOMETRIST|U|2|Visit_2|25|4|WASHOUT|2020-06-08|25
e|TR|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|3|[?]|ORSTATE|Organ State|[?]|mCi/kg|ENLARGEMENT FROM NADIR|1|mL/breath|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y||VENDOR|ADJUDICATOR 1|N|3|Visit_3|40|2|TREATMENT|2020-06-23|40
e|TR|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mm/min|TUMOR MERGED|1|/4.0 mL|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y||CLINICAL STUDY SPONSOR|HEMATOLOGIST|N|4|Visit_4|65|2|SCREENING|2020-07-18|65
e|TR|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|umol/dL|ENLARGEMENT|1|L/h|LINE PROBE ASSAY|||ADJUDICATION COMMITTEE|RATER 2|Y|5|Visit_5|90|2|TREATMENT|2020-08-12|90
e|TR|136d59c6-9645-447a-a047-68d33dbb708e|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|%(v/v)|FURTHER ENLARGEMENT|1|STEPS|DROPLET DIGITAL PCR|Y||ADJUDICATION COMMITTEE|OPTOMETRIST|Y|1|Visit_1|10|3|SCREENING|2020-09-24|10
e|TR|136d59c6-9645-447a-a047-68d33dbb708e|2|[?]|ORVERLN|Organ Vertical Length|[?]|breaths/30s|PRESENT|1|um2|EIA|Y||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|Y|2|Visit_2|25|7|SCREENING|2020-10-09|25
e|TR|136d59c6-9645-447a-a047-68d33dbb708e|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|U/10^12 RBC|EQUIVOCAL|1|cg|LASER CAPTURE MICRODISSECTION|||GUARDIAN|NEUROLOGIST 2|Y|3|Visit_3|40|6|WASHOUT|2020-10-24|40
e|TR|136d59c6-9645-447a-a047-68d33dbb708e|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|deg/mm|NON-PATHOLOGICAL|1|mg/mL/day|RIA||Y|INTERVIEWER|PATHOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2020-11-18|65
e|TR|136d59c6-9645-447a-a047-68d33dbb708e|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|g/cm2|FOCALLY INCREASED|1|HOURS|DROPLET DIGITAL PCR|||INTERVIEWER|DERMATOLOGIST|U|5|Visit_5|90|7|WASHOUT|2020-12-13|90
e|TR|2e393b90-213c-4661-ad55-cabb2008bf14|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|ug/day|INCREASED|1|/4.0 mL|DIGITAL PCR ARRAY|Y||ADJUDICATOR|NEUROLOGIST 2|U|1|Visit_1|10|1|TREATMENT|2020-06-26|10
e|TR|2e393b90-213c-4661-ad55-cabb2008bf14|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|ohm|UNEQUIVOCAL|1|PA|GC/MS/MS|||HEALTH CARE PROFESSIONAL|RATER 2|NA|2|Visit_2|25|4|SCREENING|2020-07-11|25
e|TR|2e393b90-213c-4661-ad55-cabb2008bf14|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|/100 HPFs|PALPABLE|1|ug/m2|DXA SCAN|Y||PROXY|ADJUDICATOR 2|NA|3|Visit_3|40|4|TREATMENT|2020-07-26|40
e|TR|2e393b90-213c-4661-ad55-cabb2008bf14|4|[?]|TUMSTATE|Tumor State|[?]|NFIU|DIFFUSELY INCREASED|1|L/kg|TARGETED TRANSCRIPTOME SEQUENCING|||INVESTIGATOR|INTERNIST|N|4|Visit_4|65|4|WASHOUT|2020-08-20|65
e|TR|2e393b90-213c-4661-ad55-cabb2008bf14|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|sec|FURTHER ENLARGEMENT FROM NADIR|1|mmAL|ACID FAST STAIN|Y|Y|SPOUSE|READER 1|NA|5|Visit_5|90|2|SCREENING|2020-09-14|90
e|TR|f72002d8-262b-49da-84a4-42e6011286f0|1|[?]|ORVERLN|Organ Vertical Length|[?]|LOZENGE|NON-PATHOLOGICAL|1|mV|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||ADJUDICATOR|MICROSCOPIST|Y|1|Visit_1|10|4|TREATMENT|2020-10-14|10
e|TR|f72002d8-262b-49da-84a4-42e6011286f0|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|MdFI|ABSENT|1|10^3/hpf|ELECTRONEUROGRAPHY|||GUARDIAN|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|5|SCREENING|2020-10-29|25
e|TR|f72002d8-262b-49da-84a4-42e6011286f0|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|EID 50/mL|PATHOLOGICAL|1|min/day|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||VENDOR|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|2|WASHOUT|2020-11-13|40
e|TR|f72002d8-262b-49da-84a4-42e6011286f0|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|mg/g/h|FURTHER ENLARGEMENT FROM NADIR|1|nsec|LIGHT SCATTERING SPECTROSCOPY|||INVESTIGATOR|RATER 1|U|4|Visit_4|65|7|FOLLOW-UP|2020-12-08|65
e|TR|f72002d8-262b-49da-84a4-42e6011286f0|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mm/min|NONPALPABLE|1|beats/min|MICROARRAY||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|5|Visit_5|90|2|SCREENING|2021-01-02|90
e|TR|68869dda-531d-4218-b2b0-4f5f46825569|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|NEBULE|EQUIVOCAL|1|nmol/g|PET/SPECT SCAN|||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-12-08|10
e|TR|68869dda-531d-4218-b2b0-4f5f46825569|2|[?]|SUMVOL|Sum of Volume|[?]|mL/min/mmHg|NON-PATHOLOGICAL|1|/LSQN|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Y||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|N|2|Visit_2|25|2|FOLLOW-UP|2020-12-23|25
e|TR|68869dda-531d-4218-b2b0-4f5f46825569|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|USP U|PRESENT|1|ukat/L|SURFACE PLASMON RESONANCE|Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|3|Visit_3|40|5|SCREENING|2021-01-07|40
e|TR|68869dda-531d-4218-b2b0-4f5f46825569|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mL/g/min|DECREASED|1|fraction of 1|ETDRS EYE CHART|||SIGNIFICANT OTHER|NEUROLOGIST 2|NA|4|Visit_4|65|7|FOLLOW-UP|2021-02-01|65
e|TR|68869dda-531d-4218-b2b0-4f5f46825569|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|IU/L|ENLARGEMENT|1|ug/L FEU|EEG|||FAMILY MEMBER|RADIOLOGIST 2|NA|5|Visit_5|90|5|WASHOUT|2021-02-26|90
e|TR|68888445-1819-4f4c-bd0c-a445906476fb|1|[?]|PALPSTAT|Palpable State|[?]|mol|ENLARGEMENT FROM NADIR|1|mCi/L|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y|NON-HEALTH CARE PROFESSIONAL|INTERNIST|NA|1|Visit_1|10|5|FOLLOW-UP|2021-01-14|10
e|TR|68888445-1819-4f4c-bd0c-a445906476fb|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|/10^4|PRESENT|1|L/min|BAC ACGH||Y|SIGNIFICANT OTHER|UROLOGIST|U|2|Visit_2|25|7|TREATMENT|2021-01-29|25
e|TR|68888445-1819-4f4c-bd0c-a445906476fb|3|[?]|PPD|Product of Perpendicular Diameters|[?]|ug/dL|TUMOR MERGED|1|U/g/day|NUCLEIC ACID SEQUENCING|||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2021-02-13|40
e|TR|68888445-1819-4f4c-bd0c-a445906476fb|4|[?]|LPERP|Longest Perpendicular|[?]|10^3 CFU|DIFFUSELY INCREASED|1|anti-Xa IU|BIOIMPEDANCE SPECTROSCOPY|||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2021-03-10|65
e|TR|68888445-1819-4f4c-bd0c-a445906476fb|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mEq/ug|DIFFUSELY INCREASED|1|umol/L|LANDOLT RING|||VENDOR|ONCOLOGIST 1|NA|5|Visit_5|90|4|SCREENING|2021-04-04|90
e|TR|b2ce31a0-513a-449a-aa2c-7c9668fde275|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|umol/L|NORMAL|1|DNA copies/mL|WHOLE TRANSCRIPTOME SEQUENCING|||SPOUSE|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|5|FOLLOW-UP|2020-06-24|10
e|TR|b2ce31a0-513a-449a-aa2c-7c9668fde275|2|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|uCi/L|UNEQUIVOCAL|1|mN|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||INVESTIGATOR|UROLOGIST|U|2|Visit_2|25|5|TREATMENT|2020-07-09|25
e|TR|b2ce31a0-513a-449a-aa2c-7c9668fde275|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mg/m2|INCREASED|1|STEPS|AURAMINE STAIN|Y|Y|FAMILY MEMBER|ADJUDICATOR 3|Y|3|Visit_3|40|3|TREATMENT|2020-07-24|40
e|TR|b2ce31a0-513a-449a-aa2c-7c9668fde275|4|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mL/dL|NORMAL|1|ug/min|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|4|Visit_4|65|6|TREATMENT|2020-08-18|65
e|TR|b2ce31a0-513a-449a-aa2c-7c9668fde275|5|[?]|RADIODEN|Radiodensity|[?]|/min|PALPABLE|1|m|X-RAY||Y|STUDY SUBJECT|MICROSCOPIST 1|Y|5|Visit_5|90|3|FOLLOW-UP|2020-09-12|90
e|TR|6c1d481b-985a-4be0-97ca-ecd06a81b456|1|[?]|PCHGBL|Percent Change From Baseline|[?]|mg/animal|UNCHANGED|1|10^3 organisms/g|STATIC PERIMETRY|Y||CHILD|PATHOLOGIST 1|U|1|Visit_1|10|7|FOLLOW-UP|2020-10-05|10
e|TR|6c1d481b-985a-4be0-97ca-ecd06a81b456|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|ag|ENLARGEMENT FROM NADIR|1|msec|HPLC|||INVESTIGATOR|PATHOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-10-20|25
e|TR|6c1d481b-985a-4be0-97ca-ecd06a81b456|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|pmol/L/h|FOCALLY INCREASED|1|mL/g/min|FUNDUS PHOTOGRAPHY|||SIBLING|RATER|NA|3|Visit_3|40|1|TREATMENT|2020-11-04|40
e|TR|6c1d481b-985a-4be0-97ca-ecd06a81b456|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|10^6 U|NORMAL|1|/100 WBC|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y||CHILD|UROLOGIST|Y|4|Visit_4|65|4|WASHOUT|2020-11-29|65
e|TR|6c1d481b-985a-4be0-97ca-ecd06a81b456|5|[?]|DIAMETER|Diameter|[?]|g|INCREASED|1|ug/h|PH METER MEASUREMENT METHOD|Y||CHILD|OPTOMETRIST|U|5|Visit_5|90|1|TREATMENT|2020-12-24|90
e|TR|645a9247-efcb-4641-9514-58d6e28560e0|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|NFIU|UNEQUIVOCAL|1|10^7 TCID 50/dose|IMMUNOCHROMATOGRAPHY|||FRIEND|ONCOLOGIST 2|Y|1|Visit_1|10|2|TREATMENT|2020-12-21|10
e|TR|645a9247-efcb-4641-9514-58d6e28560e0|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|HEP|ABSENT|1|PHERESIS UNIT|IMMUNOFIXATION ELECTROPHORESIS|||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|2|Visit_2|25|7|FOLLOW-UP|2021-01-05|25
e|TR|645a9247-efcb-4641-9514-58d6e28560e0|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|log10 copies/mL|PRESENT|1|Rad|PHASE-CONTRAST MRI|||STUDY SUBJECT|PHYSIOTHERAPIST|NA|3|Visit_3|40|1|TREATMENT|2021-01-20|40
e|TR|645a9247-efcb-4641-9514-58d6e28560e0|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mL/kg/min|FURTHER ENLARGEMENT|1|IU|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||SIGNIFICANT OTHER|PATHOLOGIST 2|Y|4|Visit_4|65|6|FOLLOW-UP|2021-02-14|65
e|TR|645a9247-efcb-4641-9514-58d6e28560e0|5|[?]|RADIODEN|Radiodensity|[?]|uCi/L|FURTHER ENLARGEMENT|1|kg/mol|CLIP SEQUENCING||Y|FAMILY MEMBER|ADJUDICATOR|U|5|Visit_5|90|6|SCREENING|2021-03-11|90
e|TR|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|mN|NORMAL|1|Coulomb|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||SIGNIFICANT OTHER|ENDOCRINOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-09-15|10
e|TR|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|BOTTLE|DECREASED|1|MPL U/mL|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y||INTERVIEWER|ADJUDICATOR 1|N|2|Visit_2|25|6|TREATMENT|2020-09-30|25
e|TR|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|nmol/mL/min|ENLARGEMENT|1|VIRTUAL PIXEL|DIGITAL PCR|Y|Y|GUARDIAN|PHYSIOTHERAPIST|N|3|Visit_3|40|1|FOLLOW-UP|2020-10-15|40
e|TR|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|4|[?]|PALPSTAT|Palpable State|[?]|U/L|NORMAL|1|nmol BCE/nmol|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||SPOUSE|ENDOCRINOLOGIST|U|4|Visit_4|65|1|TREATMENT|2020-11-09|65
e|TR|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|5|[?]|PCHGBL|Percent Change From Baseline|[?]|U/mg|TUMOR MERGED|1|mL/mmHg|CELL OF ORIGIN ASSAY|||PARENT|MICROSCOPIST 1|Y|5|Visit_5|90|6|WASHOUT|2020-12-04|90
e|TR|05b05951-b1ba-4c51-b50f-9c842532bc4e|1|[?]|ORSTATE|Organ State|[?]|ug/mol|INCREASED|1|aMFI|CLIP|Y||INTERVIEWER|MICROSCOPIST 3|U|1|Visit_1|10|4|FOLLOW-UP|2020-07-28|10
e|TR|05b05951-b1ba-4c51-b50f-9c842532bc4e|2|[?]|LNSTATE|Lymph Node State|[?]|DRINK|ABSENT|1|mEq/kg|INDIRECT IMMUNOFLUORESCENCE|||CHILD|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-08-12|25
e|TR|05b05951-b1ba-4c51-b50f-9c842532bc4e|3|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|MASK|INCREASED|1|EID 50/mL|FLUORESCENCE ANGIOGRAPHY|Y||CAREGIVER|FORENSIC PATHOLOGIST|NA|3|Visit_3|40|4|FOLLOW-UP|2020-08-27|40
e|TR|05b05951-b1ba-4c51-b50f-9c842532bc4e|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|ft3|UNCHANGED|1|PIXEL|PALM METHOD|||ADJUDICATION COMMITTEE|RATER 1|NA|4|Visit_4|65|4|TREATMENT|2020-09-21|65
e|TR|05b05951-b1ba-4c51-b50f-9c842532bc4e|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|10^3 organisms|PALPABLE|1|BOWL|REFRACTOMETRY|Y|Y|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-10-16|90
e|TR|ab38e976-8c2b-48ff-bdba-5a056637ecdd|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|Tesla|ABSENT|1|ug/mol|CONTRAST ENHANCED PET SCAN|||PROXY|ADJUDICATOR 2|U|1|Visit_1|10|6|WASHOUT|2020-10-23|10
e|TR|ab38e976-8c2b-48ff-bdba-5a056637ecdd|2|[?]|AREA|Area|[?]|mL/m2/day|UNCHANGED|1|APL U|ANGIOGRAPHY|||INVESTIGATOR|MICROSCOPIST 1|N|2|Visit_2|25|6|TREATMENT|2020-11-07|25
e|TR|ab38e976-8c2b-48ff-bdba-5a056637ecdd|3|[?]|SUMDIAM|Sum of Diameter|[?]|mm3/mm2/year|EQUIVOCAL|1|Gy/min|DYNAMOMETRY|||DOMESTIC PARTNER|PHYSIOTHERAPIST|U|3|Visit_3|40|1|TREATMENT|2020-11-22|40
e|TR|ab38e976-8c2b-48ff-bdba-5a056637ecdd|4|[?]|PALPSTAT|Palpable State|[?]|tsp eq|EQUIVOCAL|1|g/cm2|PERCUSSION|Y||INDEPENDENT ASSESSOR|ADJUDICATOR 2|Y|4|Visit_4|65|6|FOLLOW-UP|2020-12-17|65
e|TR|ab38e976-8c2b-48ff-bdba-5a056637ecdd|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mm/sec|ABSENT|1|fmol/g|ZIEHL NEELSEN ACID FAST STAIN||Y|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|5|Visit_5|90|6|WASHOUT|2021-01-11|90
e|TR|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|1|[?]|VDIAM|Viable Diameter|[?]|mU/g|INCREASED|1|mg/mL/min|MULTI-SLICE SPIRAL CT|||PARENT|MICROSCOPIST|Y|1|Visit_1|10|6|FOLLOW-UP|2020-08-31|10
e|TR|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|ag|EQUIVOCAL|1|nmol BCE/nmol|NO INFORMATION|||STUDY SUBJECT|ADJUDICATOR|U|2|Visit_2|25|5|SCREENING|2020-09-15|25
e|TR|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|BP|DIFFUSELY INCREASED|1|mEq/L|IN SITU HYBRIDIZATION|||CLINICAL RESEARCH ASSOCIATE|READER 2|NA|3|Visit_3|40|3|TREATMENT|2020-09-30|40
e|TR|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|h/wk|PALPABLE|1|mL|CLINICAL EVALUATION|||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|N|4|Visit_4|65|5|TREATMENT|2020-10-25|65
e|TR|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mEq/day|FURTHER ENLARGEMENT|1|L/min/m2|QUANTITATIVE COMPUTED TOMOGRAPHY|||ADJUDICATOR|ONCOLOGIST 2|NA|5|Visit_5|90|3|TREATMENT|2020-11-19|90
e|TR|51a49847-6405-4842-b549-0e2ab99f61b2|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mg/L FEU|DECREASED|1|mCi/kg|COMPLEMENT FIXATION||Y|CAREGIVER|READER 1|Y|1|Visit_1|10|2|SCREENING|2021-01-16|10
e|TR|51a49847-6405-4842-b549-0e2ab99f61b2|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|DRUM|TUMOR MERGED|1|Farad|OLIGO ACGH|||CAREGIVER|ADJUDICATOR 2|Y|2|Visit_2|25|5|SCREENING|2021-01-31|25
e|TR|51a49847-6405-4842-b549-0e2ab99f61b2|3|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|mIU/L|PALPABLE|1|GBq|DNA MICROARRAY||Y|STUDY SUBJECT|MICROSCOPIST|U|3|Visit_3|40|7|TREATMENT|2021-02-15|40
e|TR|51a49847-6405-4842-b549-0e2ab99f61b2|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|BE/mL|ENLARGEMENT FROM NADIR|1|JAR|RADIATION DOSIMETRY|||CAREGIVER|ADJUDICATOR|Y|4|Visit_4|65|6|WASHOUT|2021-03-12|65
e|TR|51a49847-6405-4842-b549-0e2ab99f61b2|5|[?]|NEWCONF|New Tumor Confirmed|[?]|uL/mL|ENLARGEMENT|1|TABLET|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||CAREGIVER|ADJUDICATOR 3|U|5|Visit_5|90|3|SCREENING|2021-04-06|90
e|TR|44dcfb9a-c590-4826-a28c-b5e9f83129d5|1|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|uIU/dL|PRESENT|1|10^9/g|PELLI-ROBSON EYE CHART|||CAREGIVER|MICROSCOPIST 1|N|1|Visit_1|10|1|TREATMENT|2020-05-21|10
e|TR|44dcfb9a-c590-4826-a28c-b5e9f83129d5|2|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mL*cmH2O|NORMAL|1|nmol BCE/L|PATHOLOGICAL EVALUATION|Y||PROXY|RATER 1|NA|2|Visit_2|25|1|TREATMENT|2020-06-05|25
e|TR|44dcfb9a-c590-4826-a28c-b5e9f83129d5|3|[?]|ORSTATE|Organ State|[?]|nmol/g|ENLARGEMENT FROM NADIR|1|pt_br|ISHIHARA COLOR PLATES||Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|3|Visit_3|40|3|TREATMENT|2020-06-20|40
e|TR|44dcfb9a-c590-4826-a28c-b5e9f83129d5|4|[?]|TUMSTATE|Tumor State|[?]|min|PRESENT|1|kIU|BIOIMPEDANCE SPECTROSCOPY|Y|Y|HEALTH CARE PROFESSIONAL|UROLOGIST|NA|4|Visit_4|65|1|WASHOUT|2020-07-15|65
e|TR|44dcfb9a-c590-4826-a28c-b5e9f83129d5|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|ug/L FEU|DECREASED|1|APL U|ELASTOGRAPHY|Y||CAREGIVER|ONCOLOGIST|U|5|Visit_5|90|7|TREATMENT|2020-08-09|90
e|TR|98166d74-caa7-4693-a817-b2cbae947ff8|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mg/kg/day|NONPALPABLE|1|Rad|MANUAL COUNT||Y|SIBLING|OPHTHALMOLOGIST|N|1|Visit_1|10|5|SCREENING|2021-01-11|10
e|TR|98166d74-caa7-4693-a817-b2cbae947ff8|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|umol/mol|UNCHANGED|1|HOMEOPATHIC DILUTION|AURAMINE STAIN|Y||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|6|FOLLOW-UP|2021-01-26|25
e|TR|98166d74-caa7-4693-a817-b2cbae947ff8|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|%/s|ENLARGEMENT|1|mJoule/cm2|COMPUTERIZED CORNEAL TOPOGRAPHY|||INTERVIEWER|PATHOLOGIST 2|N|3|Visit_3|40|6|TREATMENT|2021-02-10|40
e|TR|98166d74-caa7-4693-a817-b2cbae947ff8|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|Ci/ug|NONPALPABLE|1|F|LIQUID SCINTILLATION COUNTING|Y||CLINICAL STUDY SPONSOR|OPTOMETRIST|NA|4|Visit_4|65|1|TREATMENT|2021-03-07|65
e|TR|98166d74-caa7-4693-a817-b2cbae947ff8|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|min|PALPABLE|1|mol/mL|HPLC-UV|||PROXY|ADJUDICATOR|U|5|Visit_5|90|1|TREATMENT|2021-04-01|90
e|TR|cb07675a-2042-44da-a1f9-8b7783347e88|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mL/kg/day|PATHOLOGICAL|1|cm/min|MICRONEUTRALIZATION ASSAY|||ADJUDICATOR|ADJUDICATOR 3|U|1|Visit_1|10|2|FOLLOW-UP|2020-12-05|10
e|TR|cb07675a-2042-44da-a1f9-8b7783347e88|2|[?]|VSLFLIND|Vessel Failure Indicator|[?]|PFU/dose|UNCHANGED|1|mL/g/min|RAJI CELL RIA|||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|6|FOLLOW-UP|2020-12-20|25
e|TR|cb07675a-2042-44da-a1f9-8b7783347e88|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|mmAL|PALPABLE|1|yd|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||INVESTIGATOR|CLINICAL PATHOLOGIST|N|3|Visit_3|40|2|TREATMENT|2021-01-04|40
e|TR|cb07675a-2042-44da-a1f9-8b7783347e88|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|ug/g/day|NORMAL|1|pm|SMEAR|||STUDY SUBJECT|NEUROLOGIST|Y|4|Visit_4|65|3|WASHOUT|2021-01-29|65
e|TR|cb07675a-2042-44da-a1f9-8b7783347e88|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|V|FOCALLY INCREASED|1|Siemens|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|Y|SPOUSE|PATHOLOGIST 1|Y|5|Visit_5|90|3|WASHOUT|2021-02-23|90
e|TR|a8a14aa1-4484-4bbc-86bf-c44257146a26|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|BE/mL|DECREASED|1|v/v|LC-FL|Y||CAREGIVER|MICROSCOPIST|NA|1|Visit_1|10|7|SCREENING|2020-07-01|10
e|TR|a8a14aa1-4484-4bbc-86bf-c44257146a26|2|[?]|ORVERLN|Organ Vertical Length|[?]|ukat/10^12 RBC|NON-PATHOLOGICAL|1|copies/uL|AGAR PROPORTION||Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|2|Visit_2|25|4|TREATMENT|2020-07-16|25
e|TR|a8a14aa1-4484-4bbc-86bf-c44257146a26|3|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|uL|PRESENT|1|10^6/g|DIGITAL PCR ARRAY|||PARENT|PATHOLOGIST 2|NA|3|Visit_3|40|5|SCREENING|2020-07-31|40
e|TR|a8a14aa1-4484-4bbc-86bf-c44257146a26|4|[?]|LPERP|Longest Perpendicular|[?]|10^6 CFU/mL|UNCHANGED|1|um2|TOTAL BODY RADIOGRAPHY|||SIGNIFICANT OTHER|MICROSCOPIST 1|Y|4|Visit_4|65|1|SCREENING|2020-08-25|65
e|TR|a8a14aa1-4484-4bbc-86bf-c44257146a26|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|10^9 organisms/mL|PALPABLE|1|cycle/min|IMMUNOFIXATION ELECTROPHORESIS|Y||FRIEND|ADJUDICATOR 3|U|5|Visit_5|90|4|WASHOUT|2020-09-19|90
e|TR|dfa4c661-9317-4bec-b307-a31eeadcaba6|1|[?]|LDIAM|Longest Diameter|[?]|Coulomb|UNEQUIVOCAL|1|mL/m2/day|TRANSVAGINAL ULTRASOUND|||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-06-04|10
e|TR|dfa4c661-9317-4bec-b307-a31eeadcaba6|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|/HPF|EQUIVOCAL|1|nmol/day|CAPILLARY ELECTROPHORESIS|||INVESTIGATOR|MICROSCOPIST|N|2|Visit_2|25|7|TREATMENT|2020-06-19|25
e|TR|dfa4c661-9317-4bec-b307-a31eeadcaba6|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|MET*min|INCREASED|1|nmol/day|SLOAN LETTER EYE CHART 1.25%|||FAMILY MEMBER|ADJUDICATOR 1|NA|3|Visit_3|40|6|FOLLOW-UP|2020-07-04|40
e|TR|dfa4c661-9317-4bec-b307-a31eeadcaba6|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|mm/2h|PATHOLOGICAL|1|cm/s|NUCLEIC ACID SEQUENCING|||SPOUSE|ONCOLOGIST 1|Y|4|Visit_4|65|2|SCREENING|2020-07-29|65
e|TR|dfa4c661-9317-4bec-b307-a31eeadcaba6|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|uU/dL|FOCALLY INCREASED|1|Bq/kg|INCISION-INDUCED BLEEDING METHOD||Y|SPOUSE|NEUROLOGIST 1|N|5|Visit_5|90|1|TREATMENT|2020-08-23|90
e|TR|9ed984a9-c153-4729-9dc9-3bb3d9059919|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|vg/kg|PRESENT|1|U/kg/h|TRICHROME STAIN|||INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|U|1|Visit_1|10|1|SCREENING|2020-09-01|10
e|TR|9ed984a9-c153-4729-9dc9-3bb3d9059919|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|LB|PRESENT|1|mMU/mL|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y||CAREGIVER|MICROSCOPIST 1|NA|2|Visit_2|25|5|FOLLOW-UP|2020-09-16|25
e|TR|9ed984a9-c153-4729-9dc9-3bb3d9059919|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|CUP|NONPALPABLE|1|ELISA unit|GC/MS|||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|3|Visit_3|40|4|SCREENING|2020-10-01|40
e|TR|9ed984a9-c153-4729-9dc9-3bb3d9059919|4|[?]|LPERP|Longest Perpendicular|[?]|10^7 CFU/mL|PATHOLOGICAL|1|log10 PFU/mL|FLUOROSCOPY|||PROXY|MICROSCOPIST 2|Y|4|Visit_4|65|4|WASHOUT|2020-10-26|65
e|TR|9ed984a9-c153-4729-9dc9-3bb3d9059919|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|mJoule/cm2|UNCHANGED|1|PACKAGE|PERCUSSION|||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|5|Visit_5|90|3|TREATMENT|2020-11-20|90
e|TR|fb234b67-3c81-4d55-bc63-2389a23d67b2|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|mol/mg|FURTHER ENLARGEMENT FROM NADIR|1|MPL U/mL|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2021-01-11|10
e|TR|fb234b67-3c81-4d55-bc63-2389a23d67b2|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|mL/animal/day|TUMOR MERGED|1|ug/cm2|CYSTOMETRY|||ADJUDICATOR|ADJUDICATOR|N|2|Visit_2|25|4|TREATMENT|2021-01-26|25
e|TR|fb234b67-3c81-4d55-bc63-2389a23d67b2|3|[?]|VOLUME|Volume|[?]|mg/m2|FURTHER ENLARGEMENT|1|U/m2/day|POPULATION SEQUENCING|||INVESTIGATOR|READER|U|3|Visit_3|40|2|WASHOUT|2021-02-10|40
e|TR|fb234b67-3c81-4d55-bc63-2389a23d67b2|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|kg/cm2|EQUIVOCAL|1|Gauss|FARNSWORTH-MUNSELL 100 HUE TEST|||SIBLING|READER 1|NA|4|Visit_4|65|7|SCREENING|2021-03-07|65
e|TR|fb234b67-3c81-4d55-bc63-2389a23d67b2|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|bel|PATHOLOGICAL|1|dpm/0.5 mL|CONTRAST ENHANCED CT SCAN|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|U|5|Visit_5|90|4|TREATMENT|2021-04-01|90
e|TR|84d7ff44-cbe2-446f-b667-5bc539de519b|1|[?]|ACHNAD|Absolute Change From Nadir|[?]|/100 HPFs|PRESENT|1|psec|INFRARED SPECTROMETRY|||SIBLING|RATER 2|U|1|Visit_1|10|6|TREATMENT|2020-07-06|10
e|TR|84d7ff44-cbe2-446f-b667-5bc539de519b|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|Log10 ELISA unit/dose|ABSENT|1|mEq/L|PERIPHERAL ANGIOGRAPHY|||GUARDIAN|RATER 1|NA|2|Visit_2|25|6|TREATMENT|2020-07-21|25
e|TR|84d7ff44-cbe2-446f-b667-5bc539de519b|3|[?]|VOLUME|Volume|[?]|mg/mol|PATHOLOGICAL|1|mL/m2/min|MICRONEUTRALIZATION ASSAY|Y|Y|SPOUSE|MICROSCOPIST 2|U|3|Visit_3|40|5|WASHOUT|2020-08-05|40
e|TR|84d7ff44-cbe2-446f-b667-5bc539de519b|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|mg/mL/day|NORMAL|1|PNU/mL|ETDRS EYE CHART|||VENDOR|OTOLARYNGOLOGIST|U|4|Visit_4|65|4|WASHOUT|2020-08-30|65
e|TR|84d7ff44-cbe2-446f-b667-5bc539de519b|5|[?]|ORVERLN|Organ Vertical Length|[?]|dpm/mL|ENLARGEMENT|1|mg/L FEU|NUCLEIC ACID BASED METHOD||Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|7|WASHOUT|2020-09-24|90
e|TR|c96e4485-4aff-4c18-9c65-5f1a800cc6db|1|[?]|BNLNUM|Number of Bone Lesions|[?]|AgU/mL|PRESENT|1|FINGERTIP UNIT|BRDU CELLULAR PROLIFERATION ASSAY|||CAREGIVER|PATHOLOGIST|Y|1|Visit_1|10|3|FOLLOW-UP|2020-09-24|10
e|TR|c96e4485-4aff-4c18-9c65-5f1a800cc6db|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|/h|INCREASED|1|mAnson U/mL|MIGET||Y|VENDOR|MICROSCOPIST 1|N|2|Visit_2|25|4|TREATMENT|2020-10-09|25
e|TR|c96e4485-4aff-4c18-9c65-5f1a800cc6db|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mL/min/mmHg|EQUIVOCAL|1|QUANTITY SUFFICIENT|IMMUNODIFFUSION|||INDEPENDENT ASSESSOR|HEMATOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-10-24|40
e|TR|c96e4485-4aff-4c18-9c65-5f1a800cc6db|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|IU/kg/h|NORMAL|1|BAR|SNP ARRAY|Y|Y|FAMILY MEMBER|ONCOLOGIST|U|4|Visit_4|65|5|FOLLOW-UP|2020-11-18|65
e|TR|c96e4485-4aff-4c18-9c65-5f1a800cc6db|5|[?]|DIAMETER|Diameter|[?]|uU/L|UNEQUIVOCAL|1|cm/min|WESTERN BLOT|Y||INDEPENDENT ASSESSOR|ONCOLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-12-13|90
e|TR|955188f1-b434-40ab-94c8-0c0fb7f23e84|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|kHz|ENLARGEMENT|1|10^6 U|GC/MS-EI|||INVESTIGATOR|ADJUDICATOR 1|NA|1|Visit_1|10|1|WASHOUT|2020-12-14|10
e|TR|955188f1-b434-40ab-94c8-0c0fb7f23e84|2|[?]|VDIAM|Viable Diameter|[?]|um2|FURTHER ENLARGEMENT FROM NADIR|1|mg/kg|LEAD CITRATE STAIN|Y||PARENT|READER 2|NA|2|Visit_2|25|6|TREATMENT|2020-12-29|25
e|TR|955188f1-b434-40ab-94c8-0c0fb7f23e84|3|[?]|ORVERLN|Organ Vertical Length|[?]|mV*min|FURTHER ENLARGEMENT FROM NADIR|1|SQU/mL|CENTRIFUGATION|||ADJUDICATOR|ADJUDICATOR 3|N|3|Visit_3|40|7|TREATMENT|2021-01-13|40
e|TR|955188f1-b434-40ab-94c8-0c0fb7f23e84|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|BU|DECREASED|1|mol/day|LC-FL|||STUDY SUBJECT|READER 3|N|4|Visit_4|65|3|FOLLOW-UP|2021-02-07|65
e|TR|955188f1-b434-40ab-94c8-0c0fb7f23e84|5|[?]|LDIAM|Longest Diameter|[?]|mmHg|UNEQUIVOCAL|1|APL U|INTERRUPTER TECHNIQUE|||FRIEND|RATER 1|N|5|Visit_5|90|6|TREATMENT|2021-03-04|90
e|TR|5a384b5e-954c-4af9-bd60-96aadc72ca44|1|[?]|LNSTATE|Lymph Node State|[?]|mEq/g|ABSENT|1|Gravitational Unit|CALCOFLUOR WHITE STAIN||Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|1|Visit_1|10|4|TREATMENT|2020-10-09|10
e|TR|5a384b5e-954c-4af9-bd60-96aadc72ca44|2|[?]|TUMSTATE|Tumor State|[?]|mg/kg/day|INCREASED|1|damol/L|CONTRAST ENHANCED X-RAY|Y|Y|PARENT|RATER|NA|2|Visit_2|25|3|TREATMENT|2020-10-24|25
e|TR|5a384b5e-954c-4af9-bd60-96aadc72ca44|3|[?]|DIAMETER|Diameter|[?]|DNA copies/ug|NON-PATHOLOGICAL|1|mL/animal/day|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||CHILD|ADJUDICATOR 3|NA|3|Visit_3|40|3|WASHOUT|2020-11-08|40
e|TR|5a384b5e-954c-4af9-bd60-96aadc72ca44|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|kHz|FURTHER ENLARGEMENT FROM NADIR|1|mEq/uL|MAGNETIC RESONANCE ANGIOGRAPHY|||SIGNIFICANT OTHER|READER 1|N|4|Visit_4|65|6|TREATMENT|2020-12-03|65
e|TR|5a384b5e-954c-4af9-bd60-96aadc72ca44|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|mol/day|NORMAL|1|Bq/kg|CLINICAL EVALUATION|Y||SIBLING|ADJUDICATOR|N|5|Visit_5|90|7|TREATMENT|2020-12-28|90
e|TR|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|1|[?]|PPD|Product of Perpendicular Diameters|[?]|MONTHS|NORMAL|1|grain|HEMOCYTOMETRY||Y|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|1|Visit_1|10|1|SCREENING|2020-07-02|10
e|TR|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|10^3 CFU|UNEQUIVOCAL|1|kg/m2|SANGER SEQUENCING|||SPOUSE|OPTOMETRIST|Y|2|Visit_2|25|7|SCREENING|2020-07-17|25
e|TR|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|PNU/mL|DIFFUSELY INCREASED|1|Ci/g|QUANTITATIVE CORONARY ANGIOGRAPHY|||CLINICAL RESEARCH COORDINATOR|UROLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-08-01|40
e|TR|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|1/(s*kPa)|FURTHER ENLARGEMENT|1|IU/mL|CONTRAST ENHANCED SPIRAL CT SCAN|||PARENT|ADJUDICATOR 2|U|4|Visit_4|65|3|FOLLOW-UP|2020-08-26|65
e|TR|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|dpm/mL|FURTHER ENLARGEMENT|1|ppm|SLOAN LETTER EYE CHART 1.25%|||INVESTIGATOR|ONCOLOGIST 2|Y|5|Visit_5|90|4|FOLLOW-UP|2020-09-20|90
e|TR|f9432d72-f7d7-4cdf-a173-2e2029258474|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|ukat/L|PALPABLE|1|BOTTLE|MUGA|||ADJUDICATION COMMITTEE|ADJUDICATOR 3|N|1|Visit_1|10|6|SCREENING|2020-11-20|10
e|TR|f9432d72-f7d7-4cdf-a173-2e2029258474|2|[?]|SUMVOL|Sum of Volume|[?]|ng|UNCHANGED|1|EIA unit|CONTRAST ENHANCED PET/CT SCAN|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-12-05|25
e|TR|f9432d72-f7d7-4cdf-a173-2e2029258474|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|in2|UNEQUIVOCAL|1|CYLINDER|ETDRS EYE CHART|||SIBLING|OPHTHALMOLOGIST|U|3|Visit_3|40|4|FOLLOW-UP|2020-12-20|40
e|TR|f9432d72-f7d7-4cdf-a173-2e2029258474|4|[?]|DIAMETER|Diameter|[?]|cal|ENLARGEMENT FROM NADIR|1|mmHg/L/min|FLUORESCEIN STAIN||Y|SIBLING|ONCOLOGIST 1|U|4|Visit_4|65|7|SCREENING|2021-01-14|65
e|TR|f9432d72-f7d7-4cdf-a173-2e2029258474|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mL/min/mmHg|NORMAL|1|mCi|ERGOSPIROMETRY|Y|Y|SIGNIFICANT OTHER|RATER 2|Y|5|Visit_5|90|5|FOLLOW-UP|2021-02-08|90
e|TR|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mmol/g|ENLARGEMENT FROM NADIR|1|nm|MAGNETIC RESONANCE ENTEROGRAPHY|||PROXY|PATHOLOGIST 2|Y|1|Visit_1|10|1|SCREENING|2020-12-19|10
e|TR|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|2|[?]|LNSTATE|Lymph Node State|[?]|/500 WBC|TUMOR MERGED|1|ug/cm2|SPIROMETRY|Y||INDEPENDENT ASSESSOR|MICROSCOPIST 2|Y|2|Visit_2|25|2|WASHOUT|2021-01-03|25
e|TR|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|mL/sec/1.73m2|FURTHER ENLARGEMENT|1|10^8 PFU|QUANTITATIVE PERIPHERAL ANGIOGRAPHY||Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|U|3|Visit_3|40|7|WASHOUT|2021-01-18|40
e|TR|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|4|[?]|VOLUME|Volume|[?]|uL/mL|PATHOLOGICAL|1|DDU|MAPH||Y|HEALTH CARE PROFESSIONAL|READER 1|U|4|Visit_4|65|1|FOLLOW-UP|2021-02-12|65
e|TR|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|pmol|NORMAL|1|mg2/dL2|CALCOFLUOR WHITE STAIN|||INVESTIGATOR|RATER 2|NA|5|Visit_5|90|6|TREATMENT|2021-03-09|90
e|TR|0fc0650f-ed95-422d-b407-dcee93178780|1|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|gMFI|PATHOLOGICAL|1|keV|CONTACT SPECULAR MICROSCOPY||Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|N|1|Visit_1|10|1|TREATMENT|2020-08-23|10
e|TR|0fc0650f-ed95-422d-b407-dcee93178780|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|/day|DIFFUSELY INCREASED|1|fmol/L/sec|PHYSICAL EXAMINATION||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|NA|2|Visit_2|25|1|WASHOUT|2020-09-07|25
e|TR|0fc0650f-ed95-422d-b407-dcee93178780|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|uL|UNCHANGED|1|L/min/m2|CONTRAST ENHANCED MRI|||STUDY SUBJECT|DERMATOLOGIST|U|3|Visit_3|40|5|WASHOUT|2020-09-22|40
e|TR|0fc0650f-ed95-422d-b407-dcee93178780|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|CUP|UNCHANGED|1|ohm|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||CLINICAL RESEARCH COORDINATOR|READER 1|U|4|Visit_4|65|3|WASHOUT|2020-10-17|65
e|TR|0fc0650f-ed95-422d-b407-dcee93178780|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mg/min|PALPABLE|1|mCi/L|TOLUIDINE BLUE STAIN|Y|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|Y|5|Visit_5|90|6|SCREENING|2020-11-11|90
e|TR|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|L/day|PALPABLE|1|dram|BAC ACGH|||ADJUDICATOR|OPHTHALMOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-06-03|10
e|TR|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|2|[?]|PALPSTAT|Palpable State|[?]|Ci/g|ENLARGEMENT FROM NADIR|1|CCID 50/mL|IN SITU HYBRIDIZATION|||CLINICAL RESEARCH COORDINATOR|READER|NA|2|Visit_2|25|5|TREATMENT|2020-06-18|25
e|TR|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|3|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mV/sec|DECREASED|1|cup eq|IRON HEMATOXYLIN STAIN||Y|INVESTIGATOR|ADJUDICATOR 3|U|3|Visit_3|40|3|FOLLOW-UP|2020-07-03|40
e|TR|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|STRIP|NONPALPABLE|1|cy/cm|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||Y|SIBLING|RATER 2|NA|4|Visit_4|65|7|SCREENING|2020-07-28|65
e|TR|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|MBq/uL|PRESENT|1|mol/L|TRYPAN BLUE STAIN|||ADJUDICATION COMMITTEE|ONCOLOGIST 2|N|5|Visit_5|90|5|SCREENING|2020-08-22|90
e|TR|a6f48290-787a-46ad-bee1-ae263ad3c121|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|BOX|TUMOR MERGED|1|uIU/dL|FLUORESCENT SPOT TEST|Y|Y|SIBLING|ADJUDICATOR 2|Y|1|Visit_1|10|1|TREATMENT|2021-01-19|10
e|TR|a6f48290-787a-46ad-bee1-ae263ad3c121|2|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|10^9 CFU|PALPABLE|1|mL/(min*100mL)|SLIT LAMP PHOTOGRAPHY|||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|2|Visit_2|25|2|TREATMENT|2021-02-03|25
e|TR|a6f48290-787a-46ad-bee1-ae263ad3c121|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|/ms|DIFFUSELY INCREASED|1|Log10 ELISA unit/dose|FARNSWORTH-MUNSELL 100 HUE TEST|||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|1|FOLLOW-UP|2021-02-18|40
e|TR|a6f48290-787a-46ad-bee1-ae263ad3c121|4|[?]|ORSTATE|Organ State|[?]|um2|PALPABLE|1|ng|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||ADJUDICATOR|READER 2|Y|4|Visit_4|65|1|FOLLOW-UP|2021-03-15|65
e|TR|a6f48290-787a-46ad-bee1-ae263ad3c121|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mL/kg/day|FURTHER ENLARGEMENT FROM NADIR|1|10^9 CFU|MANUAL CLOT DETECTION|||CLINICAL STUDY SPONSOR|READER 2|NA|5|Visit_5|90|6|TREATMENT|2021-04-09|90
e|TR|565e5c83-9c67-4718-bd54-af34be936427|1|[?]|RADIODEN|Radiodensity|[?]|pt_us|ENLARGEMENT|1|anti-Xa IU/mL|TARGETED GENOME SEQUENCING|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|1|Visit_1|10|5|FOLLOW-UP|2020-06-09|10
e|TR|565e5c83-9c67-4718-bd54-af34be936427|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|CFU/g|PATHOLOGICAL|1|g/animal/day|COMPUTERIZED CORNEAL TOPOGRAPHY||Y|FRIEND|MICROSCOPIST 3|N|2|Visit_2|25|5|TREATMENT|2020-06-24|25
e|TR|565e5c83-9c67-4718-bd54-af34be936427|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|in|DECREASED|1|/mm|CLAUSS METHOD|||STUDY SUBJECT|PATHOLOGIST 1|Y|3|Visit_3|40|7|TREATMENT|2020-07-09|40
e|TR|565e5c83-9c67-4718-bd54-af34be936427|4|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|10^4/hpf|NORMAL|1|Farad|MICROBIAL BIOCHEMICAL IDENTIFICATION|Y|Y|STUDY SUBJECT|MICROSCOPIST|Y|4|Visit_4|65|5|SCREENING|2020-08-03|65
e|TR|565e5c83-9c67-4718-bd54-af34be936427|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|10^7 CFU|PALPABLE|1|vp/mL|INDIRECT IMMUNOFLUORESCENCE|||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|U|5|Visit_5|90|3|WASHOUT|2020-08-28|90
e|TR|b238304c-15ef-4c6e-a32c-9cd583a233a9|1|[?]|VDIAM|Viable Diameter|[?]|HEP|NON-PATHOLOGICAL|1|g/g/day|ELECTROGASTROGRAPHY||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|NA|1|Visit_1|10|7|FOLLOW-UP|2021-01-07|10
e|TR|b238304c-15ef-4c6e-a32c-9cd583a233a9|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|/ms|UNCHANGED|1|MnFI|DISK DIFFUSION|||GUARDIAN|OTOLARYNGOLOGIST|U|2|Visit_2|25|7|TREATMENT|2021-01-22|25
e|TR|b238304c-15ef-4c6e-a32c-9cd583a233a9|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|BOLUS|DECREASED|1|10^7/L|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y|SPOUSE|PATHOLOGIST|U|3|Visit_3|40|2|TREATMENT|2021-02-06|40
e|TR|b238304c-15ef-4c6e-a32c-9cd583a233a9|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|uEq|NORMAL|1|BU/mL|NEPHELOMETRY||Y|INTERVIEWER|ADJUDICATOR 2|N|4|Visit_4|65|6|TREATMENT|2021-03-03|65
e|TR|b238304c-15ef-4c6e-a32c-9cd583a233a9|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|Gauss|ENLARGEMENT|1|g/cage/wk|CONTACT SPECULAR MICROSCOPY|Y||ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|N|5|Visit_5|90|5|WASHOUT|2021-03-28|90
e|TR|c273f039-bca9-4d55-8620-5c5db32a6c4b|1|[?]|LPERP|Longest Perpendicular|[?]|GPL U/mL|EQUIVOCAL|1|10^6 RNA copies/mL|ELECTROPHORESIS|||SIGNIFICANT OTHER|MICROSCOPIST 1|N|1|Visit_1|10|4|TREATMENT|2020-09-23|10
e|TR|c273f039-bca9-4d55-8620-5c5db32a6c4b|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|Torr|FURTHER ENLARGEMENT FROM NADIR|1|10^6 organisms/mL|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||NON-HEALTH CARE PROFESSIONAL|RATER 2|NA|2|Visit_2|25|1|FOLLOW-UP|2020-10-08|25
e|TR|c273f039-bca9-4d55-8620-5c5db32a6c4b|3|[?]|LNSTATE|Lymph Node State|[?]|kIU|FOCALLY INCREASED|1|U/m2/min|ANGIOGRAPHY|Y||CAREGIVER|ADJUDICATOR 1|NA|3|Visit_3|40|4|TREATMENT|2020-10-23|40
e|TR|c273f039-bca9-4d55-8620-5c5db32a6c4b|4|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|HOURS|ABSENT|1|BAR|IMMUNODIFFUSION|Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|4|Visit_4|65|3|TREATMENT|2020-11-17|65
e|TR|c273f039-bca9-4d55-8620-5c5db32a6c4b|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mg/min|FURTHER ENLARGEMENT FROM NADIR|1|FIU|AUDIOMETRY|||GUARDIAN|READER 1|N|5|Visit_5|90|4|TREATMENT|2020-12-12|90
e|TR|2cdb5053-2108-4f50-8906-8afabc855a36|1|[?]|DIAMETER|Diameter|[?]|GBq/g|TUMOR MERGED|1|ug/day|RAJI CELL EIA|Y|Y|FRIEND|RADIOLOGIST 1|NA|1|Visit_1|10|1|FOLLOW-UP|2020-08-28|10
e|TR|2cdb5053-2108-4f50-8906-8afabc855a36|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|U/kg|INCREASED|1|/cmH2O|SPIROMETRY|||DOMESTIC PARTNER|UROLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-09-12|25
e|TR|2cdb5053-2108-4f50-8906-8afabc855a36|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|deg/mm|FOCALLY INCREASED|1|L/min/m2|X-RAY|||ADJUDICATOR|RATER 1|NA|3|Visit_3|40|4|TREATMENT|2020-09-27|40
e|TR|2cdb5053-2108-4f50-8906-8afabc855a36|4|[?]|LDIAM|Longest Diameter|[?]|titer|INCREASED|1|ms2|AMSLER GRID|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|N|4|Visit_4|65|6|TREATMENT|2020-10-22|65
e|TR|2cdb5053-2108-4f50-8906-8afabc855a36|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|10^9 organisms/mL|UNCHANGED|1|cg|ELECTROCHEMILUMINESCENCE|||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-11-16|90
e|TR|fce7149a-503e-4209-8c62-8044a2ad1c1c|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|lx|DECREASED|1|/cmH2O|OLIGO ACGH|||ADJUDICATION COMMITTEE|READER 3|N|1|Visit_1|10|3|TREATMENT|2020-08-06|10
e|TR|fce7149a-503e-4209-8c62-8044a2ad1c1c|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|pg|NONPALPABLE|1|EIA unit|MICRONEUTRALIZATION ASSAY|||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|3|WASHOUT|2020-08-21|25
e|TR|fce7149a-503e-4209-8c62-8044a2ad1c1c|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mmol/g|UNCHANGED|1|mmol/min/kPa|ACCELERATOR MASS SPECTROMETRY|||PARENT|OPTOMETRIST|Y|3|Visit_3|40|4|SCREENING|2020-09-05|40
e|TR|fce7149a-503e-4209-8c62-8044a2ad1c1c|4|[?]|LDIAM|Longest Diameter|[?]|%(w/w)|NON-PATHOLOGICAL|1|uCi/L|PULMONARY ANGIOGRAPHY||Y|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|Y|4|Visit_4|65|4|WASHOUT|2020-09-30|65
e|TR|fce7149a-503e-4209-8c62-8044a2ad1c1c|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|AFU|TUMOR MERGED|1|m|ERGOSPIROMETRY|||SPOUSE|ONCOLOGIST|Y|5|Visit_5|90|4|FOLLOW-UP|2020-10-25|90
e|TR|c8aad550-11a1-4473-8b35-79b7dfb08122|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|grain|NORMAL|1|mL|RADIATION DOSIMETRY|Y||INTERVIEWER|NEUROLOGIST|N|1|Visit_1|10|1|FOLLOW-UP|2020-06-09|10
e|TR|c8aad550-11a1-4473-8b35-79b7dfb08122|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|CFU/mL|DIFFUSELY INCREASED|1|mL/breath|TRIPLE-PHASE MRI SCAN|||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|U|2|Visit_2|25|6|TREATMENT|2020-06-24|25
e|TR|c8aad550-11a1-4473-8b35-79b7dfb08122|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mg/mL/day|INCREASED|1|umol/min|OBSERVATION|||ADJUDICATION COMMITTEE|MICROSCOPIST|Y|3|Visit_3|40|1|SCREENING|2020-07-09|40
e|TR|c8aad550-11a1-4473-8b35-79b7dfb08122|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mg/animal|FOCALLY INCREASED|1|WEEKS|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||CHILD|ONCOLOGIST 1|NA|4|Visit_4|65|3|TREATMENT|2020-08-03|65
e|TR|c8aad550-11a1-4473-8b35-79b7dfb08122|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|ug/day|UNCHANGED|1|nU/cL|INTERRUPTER TECHNIQUE|||FRIEND|ADJUDICATOR|NA|5|Visit_5|90|6|WASHOUT|2020-08-28|90
e|TR|f1967c6e-c520-4482-be7e-01ada4380d87|1|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|Frames/s|PALPABLE|1|mg/m2/min|STRESS ECHOCARDIOGRAPHY|Y||NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|Y|1|Visit_1|10|5|WASHOUT|2021-01-05|10
e|TR|f1967c6e-c520-4482-be7e-01ada4380d87|2|[?]|ORVERLN|Organ Vertical Length|[?]|10^6 DNA copies/mL|NON-PATHOLOGICAL|1|kg|U-HPLC/MS/MS|||CLINICAL STUDY SPONSOR|PATHOLOGIST 2|Y|2|Visit_2|25|4|SCREENING|2021-01-20|25
e|TR|f1967c6e-c520-4482-be7e-01ada4380d87|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mmol/day|DECREASED|1|cmol/L|CHROMATOGRAPHY|Y||DOMESTIC PARTNER|MICROSCOPIST|NA|3|Visit_3|40|5|FOLLOW-UP|2021-02-04|40
e|TR|f1967c6e-c520-4482-be7e-01ada4380d87|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|FINGERTIP UNIT|EQUIVOCAL|1|mmol/s|CHROMOGENIC ASSAY|||CAREGIVER|CARDIOLOGIST|N|4|Visit_4|65|4|TREATMENT|2021-03-01|65
e|TR|f1967c6e-c520-4482-be7e-01ada4380d87|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|pptr|ENLARGEMENT|1|OD Unit|ENZYMATIC COLORIMETRY|||INDEPENDENT ASSESSOR|ADJUDICATOR 3|Y|5|Visit_5|90|1|WASHOUT|2021-03-26|90
e|TR|2a5a1c03-f54e-47da-8dda-2104c9423e94|1|[?]|VDIAM|Viable Diameter|[?]|AU/mL|FURTHER ENLARGEMENT FROM NADIR|1|ukat/L|HANSEL STAIN|||INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|1|Visit_1|10|1|SCREENING|2021-01-01|10
e|TR|2a5a1c03-f54e-47da-8dda-2104c9423e94|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mg/kg/dose|ABSENT|1|EP U|NO INFORMATION|Y||SIGNIFICANT OTHER|RADIOLOGIST 1|N|2|Visit_2|25|5|TREATMENT|2021-01-16|25
e|TR|2a5a1c03-f54e-47da-8dda-2104c9423e94|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|umol/mg/min|TUMOR MERGED|1|tsp eq|GC/MS/MS|Y||SIGNIFICANT OTHER|RADIOLOGIST 2|NA|3|Visit_3|40|5|TREATMENT|2021-01-31|40
e|TR|2a5a1c03-f54e-47da-8dda-2104c9423e94|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|/mm|PRESENT|1|umol/L/h|ERGOSPIROMETRY|||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|4|Visit_4|65|2|SCREENING|2021-02-25|65
e|TR|2a5a1c03-f54e-47da-8dda-2104c9423e94|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|U/g/day|DIFFUSELY INCREASED|1|ug/g/day|CALIPER MEASUREMENT METHOD|||INVESTIGATOR|RADIOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2021-03-22|90
e|TR|8f98bac3-8010-4902-8ae1-783dc5fea72d|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|DIOPTER|PRESENT|1|10^7 CFU|SANGER SEQUENCING|||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|U|1|Visit_1|10|3|WASHOUT|2020-06-29|10
e|TR|8f98bac3-8010-4902-8ae1-783dc5fea72d|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|CAN|PRESENT|1|Coulomb|SNELLEN EYE CHART|||INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|2|Visit_2|25|7|TREATMENT|2020-07-14|25
e|TR|8f98bac3-8010-4902-8ae1-783dc5fea72d|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|U/cL|FURTHER ENLARGEMENT FROM NADIR|1|s/h|TEMPLATE INCISION METHOD|||ADJUDICATOR|ADJUDICATOR 2|U|3|Visit_3|40|4|FOLLOW-UP|2020-07-29|40
e|TR|8f98bac3-8010-4902-8ae1-783dc5fea72d|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mL/m2|NORMAL|1|cd*s/m2|TOTAL BODY IRRADIATION|||SIGNIFICANT OTHER|READER 1|N|4|Visit_4|65|1|TREATMENT|2020-08-23|65
e|TR|8f98bac3-8010-4902-8ae1-783dc5fea72d|5|[?]|ORVERLN|Organ Vertical Length|[?]|IU/mmol|UNEQUIVOCAL|1|ug/min|PALPATION|Y||FRIEND|ADJUDICATOR|Y|5|Visit_5|90|1|WASHOUT|2020-09-17|90
e|TR|0fd7cece-4d9d-4d8c-82e0-df0c75613888|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|hr/day|DECREASED|1|lm|DARK FIELD MICROSCOPY|||ADJUDICATION COMMITTEE|RADIOLOGIST 1|U|1|Visit_1|10|1|TREATMENT|2020-12-11|10
e|TR|0fd7cece-4d9d-4d8c-82e0-df0c75613888|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|STRIP|ABSENT|1|uL/mL|AURAMINE STAIN|||INTERVIEWER|OPHTHALMOLOGIST|N|2|Visit_2|25|7|TREATMENT|2020-12-26|25
e|TR|0fd7cece-4d9d-4d8c-82e0-df0c75613888|3|[?]|LPERP|Longest Perpendicular|[?]|MET*h|PALPABLE|1|ohm|JAEGER EYE CHART|||VENDOR|ADJUDICATOR 3|N|3|Visit_3|40|2|FOLLOW-UP|2021-01-10|40
e|TR|0fd7cece-4d9d-4d8c-82e0-df0c75613888|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|mL/cm3/min|ABSENT|1|pmol/day|MYELOPEROXIDASE STAIN|Y||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|6|SCREENING|2021-02-04|65
e|TR|0fd7cece-4d9d-4d8c-82e0-df0c75613888|5|[?]|SUMVOL|Sum of Volume|[?]|Shock Wave|FURTHER ENLARGEMENT FROM NADIR|1|mmol/mol|ELECTRONEUROGRAPHY|||INDEPENDENT ASSESSOR|ONCOLOGIST 2|Y|5|Visit_5|90|1|SCREENING|2021-03-01|90
e|TR|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|1|[?]|AREA|Area|[?]|GPL U|ENLARGEMENT|1|Enzyme U/g Hb|LISSAMINE GREEN STAIN|||PARENT|READER 1|Y|1|Visit_1|10|3|WASHOUT|2020-06-13|10
e|TR|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|2|[?]|VOLUME|Volume|[?]|CFU/g|ABSENT|1|mmol/day|ICC|||SIBLING|FORENSIC PATHOLOGIST|N|2|Visit_2|25|1|TREATMENT|2020-06-28|25
e|TR|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|3|[?]|RADIODEN|Radiodensity|[?]|Rad|UNCHANGED|1|10^3 CFU/g|SPECTROPHOTOMETRY|||STUDY SUBJECT|PATHOLOGIST 2|U|3|Visit_3|40|3|TREATMENT|2020-07-13|40
e|TR|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|COAT|PATHOLOGICAL|1|Frames/s|CLOT DETECTION|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|Y|4|Visit_4|65|7|TREATMENT|2020-08-07|65
e|TR|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|APL U/mL|PRESENT|1|MBq|POLYMERASE CHAIN REACTION|||PROXY|PATHOLOGIST|N|5|Visit_5|90|2|SCREENING|2020-09-01|90
e|TR|4be1ea69-9baf-45b4-873b-13a879544d9c|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|log10 TCID 50/uL|ENLARGEMENT|1|ng|IMMUNE REPERTOIRE DEEP SEQUENCING|||FRIEND|RADIOLOGIST 2|Y|1|Visit_1|10|7|WASHOUT|2021-01-26|10
e|TR|4be1ea69-9baf-45b4-873b-13a879544d9c|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|uCi/L|PATHOLOGICAL|1|ms/mmHg|ULTRASONOGRAPHIC ELASTOGRAPHY|Y||ADJUDICATION COMMITTEE|MICROSCOPIST 1|Y|2|Visit_2|25|4|SCREENING|2021-02-10|25
e|TR|4be1ea69-9baf-45b4-873b-13a879544d9c|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|mmol/kg|PALPABLE|1|BEAM BREAKS|ELISA|||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|NA|3|Visit_3|40|3|SCREENING|2021-02-25|40
e|TR|4be1ea69-9baf-45b4-873b-13a879544d9c|4|[?]|LESSCIND|Lesion Success Indicator|[?]|mOsm/L|FOCALLY INCREASED|1|ng/mol|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y||STUDY SUBJECT|NEUROLOGIST 2|U|4|Visit_4|65|2|FOLLOW-UP|2021-03-22|65
e|TR|4be1ea69-9baf-45b4-873b-13a879544d9c|5|[?]|LNSTATE|Lymph Node State|[?]|/2500 WBC|FURTHER ENLARGEMENT|1|fL|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||GUARDIAN|CARDIOLOGIST|N|5|Visit_5|90|7|FOLLOW-UP|2021-04-16|90
e|TR|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|mg/mol|NORMAL|1|mg/kg|SPECT SCAN|||SIGNIFICANT OTHER|HEMATOLOGIST|N|1|Visit_1|10|3|TREATMENT|2020-10-29|10
e|TR|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|cm/min|DIFFUSELY INCREASED|1|10^5/hpf|ERGOSPIROMETRY|Y||DOMESTIC PARTNER|READER 3|N|2|Visit_2|25|4|SCREENING|2020-11-13|25
e|TR|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|3|[?]|PPD|Product of Perpendicular Diameters|[?]|/10^5|TUMOR MERGED|1|mkat|ELASTOGRAPHY|||SPOUSE|ONCOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-11-28|40
e|TR|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|mm3/mm2/year|NON-PATHOLOGICAL|1|EP U|KNEMOMETRY||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|NA|4|Visit_4|65|5|WASHOUT|2020-12-23|65
e|TR|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|RNA copies/mL|PATHOLOGICAL|1|FINGERTIP UNIT|TOLUIDINE BLUE STAIN|Y|Y|SIBLING|RADIOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2021-01-17|90
e|TR|16720f71-55b5-478f-b041-00b61ae19ac9|1|[?]|LPERP|Longest Perpendicular|[?]|breaths/min|UNEQUIVOCAL|1|IU/kg|AUDIOMETRY|||STUDY SUBJECT|READER|NA|1|Visit_1|10|6|TREATMENT|2021-01-10|10
e|TR|16720f71-55b5-478f-b041-00b61ae19ac9|2|[?]|PCHGBL|Percent Change From Baseline|[?]|mL/dose|NON-PATHOLOGICAL|1|ugEq/L|HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y||ADJUDICATOR|MICROSCOPIST 3|N|2|Visit_2|25|1|SCREENING|2021-01-25|25
e|TR|16720f71-55b5-478f-b041-00b61ae19ac9|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mg/animal|TUMOR MERGED|1|mL/cm H2O|ANALYTICAL ULTRACENTRIFUGATION|||SIGNIFICANT OTHER|NEUROLOGIST|NA|3|Visit_3|40|2|WASHOUT|2021-02-09|40
e|TR|16720f71-55b5-478f-b041-00b61ae19ac9|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|pkat|PALPABLE|1|mmol/g|HILLMEN COLOR CHART|||INDEPENDENT ASSESSOR|HEMATOLOGIST|N|4|Visit_4|65|4|TREATMENT|2021-03-06|65
e|TR|16720f71-55b5-478f-b041-00b61ae19ac9|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|ohm|UNEQUIVOCAL|1|IU/g|WRIGHT-GIEMSA STAIN|Y||ADJUDICATION COMMITTEE|RADIOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2021-03-31|90
e|TR|4349f45e-f18b-4606-9a72-fd45e64e17dc|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|BP|UNEQUIVOCAL|1|Bq/uL|SLOAN LETTER EYE CHART 100%|Y||FAMILY MEMBER|FORENSIC PATHOLOGIST|N|1|Visit_1|10|6|SCREENING|2021-01-11|10
e|TR|4349f45e-f18b-4606-9a72-fd45e64e17dc|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|nmol/kg/day|NORMAL|1|Bq/uL|CENTRIFUGATION|Y||CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|U|2|Visit_2|25|6|TREATMENT|2021-01-26|25
e|TR|4349f45e-f18b-4606-9a72-fd45e64e17dc|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|Absorbance U|FURTHER ENLARGEMENT FROM NADIR|1|MnFI|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||VENDOR|ONCOLOGIST 2|U|3|Visit_3|40|1|SCREENING|2021-02-10|40
e|TR|4349f45e-f18b-4606-9a72-fd45e64e17dc|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|L/h/m2|DECREASED|1|mL/g/h|DIRECT SEQUENCING||Y|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|6|TREATMENT|2021-03-07|65
e|TR|4349f45e-f18b-4606-9a72-fd45e64e17dc|5|[?]|VOLUME|Volume|[?]|pt_br|ENLARGEMENT|1|mCi|CENTRIFUGATION||Y|INDEPENDENT ASSESSOR|READER|U|5|Visit_5|90|4|WASHOUT|2021-04-01|90
e|TR|32e36ec1-6895-42ff-bf33-52977e72b338|1|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mL/day|ENLARGEMENT FROM NADIR|1|mg/kg/day|CELL OF ORIGIN ASSAY||Y|SIBLING|READER|N|1|Visit_1|10|4|FOLLOW-UP|2020-09-05|10
e|TR|32e36ec1-6895-42ff-bf33-52977e72b338|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mol/mL|FURTHER ENLARGEMENT FROM NADIR|1|IU|ECHOCARDIOGRAPHY||Y|FRIEND|ADJUDICATOR 2|Y|2|Visit_2|25|4|TREATMENT|2020-09-20|25
e|TR|32e36ec1-6895-42ff-bf33-52977e72b338|3|[?]|PALPSTAT|Palpable State|[?]|U/mL|PALPABLE|1|amp|BRDU CELLULAR PROLIFERATION ASSAY|Y|Y|CHILD|MICROSCOPIST 2|NA|3|Visit_3|40|1|SCREENING|2020-10-05|40
e|TR|32e36ec1-6895-42ff-bf33-52977e72b338|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|Rad|FURTHER ENLARGEMENT|1|MBq/uL|IMMUNOBLOT|||INDEPENDENT ASSESSOR|RATER 2|N|4|Visit_4|65|7|SCREENING|2020-10-30|65
e|TR|32e36ec1-6895-42ff-bf33-52977e72b338|5|[?]|ORSTATE|Organ State|[?]|BOWL|TUMOR MERGED|1|kUSP|SINGLE-SLICE SPIRAL CT|||ADJUDICATION COMMITTEE|NEUROLOGIST|Y|5|Visit_5|90|6|WASHOUT|2020-11-24|90
e|TR|e546f2d8-baea-4a6e-93cb-c7ec7292b423|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|VIRTUAL PIXEL|PRESENT|1|g/cage/day|MAMMOGRAPHY|||CAREGIVER|RADIOLOGIST 1|Y|1|Visit_1|10|1|WASHOUT|2020-10-25|10
e|TR|e546f2d8-baea-4a6e-93cb-c7ec7292b423|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|10^7 TCID 50/dose|FURTHER ENLARGEMENT|1|10^3 organisms/mL|U-HPLC/MS/MS||Y|PROXY|PATHOLOGIST 1|N|2|Visit_2|25|4|FOLLOW-UP|2020-11-09|25
e|TR|e546f2d8-baea-4a6e-93cb-c7ec7292b423|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|V/sec|DECREASED|1|10^4/hpf|DIFFUSION WEIGHTED MRI|Y||PARENT|MICROSCOPIST 1|NA|3|Visit_3|40|1|TREATMENT|2020-11-24|40
e|TR|e546f2d8-baea-4a6e-93cb-c7ec7292b423|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|RNA copies/mL|PRESENT|1|pmol/L|GIEMSA STAIN|||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|2|WASHOUT|2020-12-19|65
e|TR|e546f2d8-baea-4a6e-93cb-c7ec7292b423|5|[?]|ORSTATE|Organ State|[?]|AFU|ENLARGEMENT|1|km|TRANSTHORACIC ECHOCARDIOGRAPHY||Y|INTERVIEWER|MICROSCOPIST 3|Y|5|Visit_5|90|1|TREATMENT|2021-01-13|90
e|TR|0329de16-fc7a-4941-900c-b390dac637aa|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|umol/L/h|INCREASED|1|mEq/uL|ORCHIDOMETERY|||INTERVIEWER|MICROSCOPIST 2|N|1|Visit_1|10|4|WASHOUT|2020-09-27|10
e|TR|0329de16-fc7a-4941-900c-b390dac637aa|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|ug|FURTHER ENLARGEMENT FROM NADIR|1|pmol/10^9 cells|FLUORESCENCE ANGIOGRAPHY|Y||SPOUSE|ENDOCRINOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-10-12|25
e|TR|0329de16-fc7a-4941-900c-b390dac637aa|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|genEq|TUMOR MERGED|1|PELLET|MICRO BROTH DILUTION|Y||CAREGIVER|NEUROLOGIST 1|Y|3|Visit_3|40|4|SCREENING|2020-10-27|40
e|TR|0329de16-fc7a-4941-900c-b390dac637aa|4|[?]|RADIODEN|Radiodensity|[?]|Hz|INCREASED|1|V/sec|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|STUDY SUBJECT|OTOLARYNGOLOGIST|U|4|Visit_4|65|4|SCREENING|2020-11-21|65
e|TR|0329de16-fc7a-4941-900c-b390dac637aa|5|[?]|BNLNUM|Number of Bone Lesions|[?]|Sv|TUMOR MERGED|1|10^7 CFU/mL|CLIP SEQUENCING|||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|5|TREATMENT|2020-12-16|90
e|TR|89d364c9-1338-472b-af0b-19280e45508b|1|[?]|RADIODEN|Radiodensity|[?]|cP|NONPALPABLE|1|TRACE|FLOW MICROSCOPY|||CLINICAL RESEARCH COORDINATOR|RATER 1|N|1|Visit_1|10|4|TREATMENT|2020-10-15|10
e|TR|89d364c9-1338-472b-af0b-19280e45508b|2|[?]|PPD|Product of Perpendicular Diameters|[?]|kHz|UNEQUIVOCAL|1|10^3 CFU/g|TELLER ACUITY CARDS|||CLINICAL STUDY SPONSOR|RATER 1|N|2|Visit_2|25|2|TREATMENT|2020-10-30|25
e|TR|89d364c9-1338-472b-af0b-19280e45508b|3|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|umol/min|DECREASED|1|L/day|KNEMOMETRY|||CHILD|MICROSCOPIST 3|NA|3|Visit_3|40|5|TREATMENT|2020-11-14|40
e|TR|89d364c9-1338-472b-af0b-19280e45508b|4|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mL/kg/min|PRESENT|1|mg/mol|INTERRUPTER TECHNIQUE|||INVESTIGATOR|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|4|SCREENING|2020-12-09|65
e|TR|89d364c9-1338-472b-af0b-19280e45508b|5|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|DPM|FURTHER ENLARGEMENT|1|Farad|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y||FRIEND|CARDIOLOGIST|U|5|Visit_5|90|4|WASHOUT|2021-01-03|90
e|TR|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|APPLICATION|NON-PATHOLOGICAL|1|oz eq|TARGETED GENOME SEQUENCING||Y|VENDOR|CLINICAL PATHOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-05-27|10
e|TR|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|2|[?]|PCHGBL|Percent Change From Baseline|[?]|dram|NONPALPABLE|1|IMPLANT|REBOUND TONOMETRY|||PROXY|OTOLARYNGOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-06-11|25
e|TR|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|3|[?]|ORVERLN|Organ Vertical Length|[?]|kcal/day|PRESENT|1|foz_us|TRANSCRIPTION-MEDIATED AMPLIFICATION|Y||SIGNIFICANT OTHER|ONCOLOGIST 1|NA|3|Visit_3|40|7|TREATMENT|2020-06-26|40
e|TR|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|4|[?]|DIAMETER|Diameter|[?]|umol/L/sec|FURTHER ENLARGEMENT|1|umol/mol|PERFUSION MRI||Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|NA|4|Visit_4|65|4|SCREENING|2020-07-21|65
e|TR|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|5|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|/ms|EQUIVOCAL|1|mL/animal|SCINTIGRAPHY|Y||SPOUSE|MICROSCOPIST|NA|5|Visit_5|90|4|TREATMENT|2020-08-15|90
e|TR|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|PFU|DIFFUSELY INCREASED|1|cmHg|ULTRASONOGRAPHIC ELASTOGRAPHY|||DOMESTIC PARTNER|PATHOLOGIST|NA|1|Visit_1|10|7|WASHOUT|2020-10-12|10
e|TR|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|2|[?]|ACHNAD|Absolute Change From Nadir|[?]|cup eq|UNCHANGED|1|umol/L/min|DIGITAL PCR|||DOMESTIC PARTNER|PHYSIOTHERAPIST|N|2|Visit_2|25|6|SCREENING|2020-10-27|25
e|TR|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|aMFI|ENLARGEMENT|1|ngEq/L|AUTOMATED COUNT|||VENDOR|ONCOLOGIST 1|Y|3|Visit_3|40|1|TREATMENT|2020-11-11|40
e|TR|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|cmol/L|INCREASED|1|mL/mmHg/min/L|ELASTOGRAPHY|||FRIEND|PHYSIOTHERAPIST|NA|4|Visit_4|65|5|TREATMENT|2020-12-06|65
e|TR|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|/LPF|NORMAL|1|days/wk|LIGHT SCATTERING SPECTROSCOPY|||FAMILY MEMBER|RADIOLOGIST 2|NA|5|Visit_5|90|2|WASHOUT|2020-12-31|90
e|TR|0c103005-efae-48ed-91e3-35d38fa1d359|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|cmH2O/mL|FOCALLY INCREASED|1|nmol/g|ELECTROGASTROGRAPHY||Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|U|1|Visit_1|10|2|SCREENING|2020-05-28|10
e|TR|0c103005-efae-48ed-91e3-35d38fa1d359|2|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|ohm|FOCALLY INCREASED|1|INHALATION|POPULATION SEQUENCING|||INDEPENDENT ASSESSOR|MICROSCOPIST 3|Y|2|Visit_2|25|3|WASHOUT|2020-06-12|25
e|TR|0c103005-efae-48ed-91e3-35d38fa1d359|3|[?]|LESSCIND|Lesion Success Indicator|[?]|BLOCKS|PALPABLE|1|g/mol|WEBER GREEN STAIN|||FRIEND|ENDOCRINOLOGIST|U|3|Visit_3|40|2|SCREENING|2020-06-27|40
e|TR|0c103005-efae-48ed-91e3-35d38fa1d359|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|SCOOPFUL|ENLARGEMENT FROM NADIR|1|BU|GC/MS|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|2|WASHOUT|2020-07-22|65
e|TR|0c103005-efae-48ed-91e3-35d38fa1d359|5|[?]|PALPSTAT|Palpable State|[?]|aMFI|ENLARGEMENT|1|nsec|WEBER GREEN STAIN|||FAMILY MEMBER|RADIOLOGIST 2|N|5|Visit_5|90|4|FOLLOW-UP|2020-08-16|90
e|TR|c9808184-3432-448c-a5e5-50176715effa|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|in2|UNEQUIVOCAL|1|ag|PHOTOMETRIC CLOT DETECTION|||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|U|1|Visit_1|10|4|TREATMENT|2020-12-29|10
e|TR|c9808184-3432-448c-a5e5-50176715effa|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|U/mL|EQUIVOCAL|1|Ci|WEBER GREEN STAIN|||INTERVIEWER|MICROSCOPIST|N|2|Visit_2|25|2|SCREENING|2021-01-13|25
e|TR|c9808184-3432-448c-a5e5-50176715effa|3|[?]|NEWCONF|New Tumor Confirmed|[?]|aMFI|DECREASED|1|ug/h|IVY INCISION METHOD||Y|FRIEND|MICROSCOPIST|NA|3|Visit_3|40|2|TREATMENT|2021-01-28|40
e|TR|c9808184-3432-448c-a5e5-50176715effa|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|OD Unit|FURTHER ENLARGEMENT FROM NADIR|1|mmol2/L2|MICRO BROTH DILUTION|||CLINICAL RESEARCH COORDINATOR|RATER 1|U|4|Visit_4|65|7|TREATMENT|2021-02-22|65
e|TR|c9808184-3432-448c-a5e5-50176715effa|5|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|10^4/hpf|FURTHER ENLARGEMENT FROM NADIR|1|ECL unit|DC SHEATH FLOW|||INVESTIGATOR|READER|U|5|Visit_5|90|5|TREATMENT|2021-03-19|90
e|TR|c3d7d293-975f-44de-bd35-0168eec40ac9|1|[?]|LDIAM|Longest Diameter|[?]|10^7 CFU|DECREASED|1|mL/cage/wk|PET/SPECT SCAN|Y|Y|INTERVIEWER|NEUROLOGIST 2|N|1|Visit_1|10|3|TREATMENT|2021-01-04|10
e|TR|c3d7d293-975f-44de-bd35-0168eec40ac9|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|titer|FURTHER ENLARGEMENT FROM NADIR|1|mL/kg/h|PATHOLOGICAL EVALUATION||Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|6|TREATMENT|2021-01-19|25
e|TR|c3d7d293-975f-44de-bd35-0168eec40ac9|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|mm2|NON-PATHOLOGICAL|1|mmHg|CONFOCAL MICROSCOPY|||INTERVIEWER|RADIOLOGIST|U|3|Visit_3|40|4|WASHOUT|2021-02-03|40
e|TR|c3d7d293-975f-44de-bd35-0168eec40ac9|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|mEq/dL|PATHOLOGICAL|1|cGy|WESTERN BLOT|Y||ADJUDICATION COMMITTEE|PATHOLOGIST|NA|4|Visit_4|65|1|SCREENING|2021-02-28|65
e|TR|c3d7d293-975f-44de-bd35-0168eec40ac9|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|mL/sec/1.73m2|TUMOR MERGED|1|CAN|JAEGER EYE CHART|||STUDY SUBJECT|OPHTHALMOLOGIST|U|5|Visit_5|90|5|FOLLOW-UP|2021-03-25|90
e|TR|2db1f07d-a7db-4cc3-8943-536e24378f08|1|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|10^7/L|NON-PATHOLOGICAL|1|GPS U|JAEGER EYE CHART|||ADJUDICATOR|ONCOLOGIST 2|NA|1|Visit_1|10|7|WASHOUT|2020-06-12|10
e|TR|2db1f07d-a7db-4cc3-8943-536e24378f08|2|[?]|SUMVOL|Sum of Volume|[?]|/cmH2O|NONPALPABLE|1|log10 TCID 50/uL|RAJI CELL RIA|||DOMESTIC PARTNER|ONCOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-06-27|25
e|TR|2db1f07d-a7db-4cc3-8943-536e24378f08|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|ug/kg|FURTHER ENLARGEMENT|1|umol/min|CORONARY ANGIOGRAPHY||Y|PROXY|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|5|FOLLOW-UP|2020-07-12|40
e|TR|2db1f07d-a7db-4cc3-8943-536e24378f08|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|Enzyme U|PALPABLE|1|10^6 IU/mL|MALDI-TOF|Y||CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|N|4|Visit_4|65|6|WASHOUT|2020-08-06|65
e|TR|2db1f07d-a7db-4cc3-8943-536e24378f08|5|[?]|PALPSTAT|Palpable State|[?]|NEEDLE GAUGE|DECREASED|1|BOWL|HPLC/IEX||Y|SIBLING|ENDOCRINOLOGIST|Y|5|Visit_5|90|2|SCREENING|2020-08-31|90
e|TR|c343ba98-87d7-40bc-b0e8-b866e42d3a21|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|ug/m2/min|FURTHER ENLARGEMENT|1|PIPE|WESTERGREN|Y|Y|SIBLING|CARDIOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-12-15|10
e|TR|c343ba98-87d7-40bc-b0e8-b866e42d3a21|2|[?]|ORVERLN|Organ Vertical Length|[?]|mg/min|DECREASED|1|mg/kg/h|CARDIAC THERMODILUTION|Y||ADJUDICATION COMMITTEE|ONCOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-12-30|25
e|TR|c343ba98-87d7-40bc-b0e8-b866e42d3a21|3|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|U/animal|INCREASED|1|ohm|MRS|||INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|3|Visit_3|40|7|WASHOUT|2021-01-14|40
e|TR|c343ba98-87d7-40bc-b0e8-b866e42d3a21|4|[?]|SUMDIAM|Sum of Diameter|[?]|pg/cell|NONPALPABLE|1|10^8/L|ELECTROPHORESIS|||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|NA|4|Visit_4|65|6|FOLLOW-UP|2021-02-08|65
e|TR|c343ba98-87d7-40bc-b0e8-b866e42d3a21|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mL/breath|DIFFUSELY INCREASED|1|Gravitational Unit|DARK FIELD MICROSCOPY|||PROXY|ADJUDICATOR 1|Y|5|Visit_5|90|1|TREATMENT|2021-03-05|90
e|TR|d2b31ba9-9718-43ce-82ca-3276c28ac42a|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|Sv|FURTHER ENLARGEMENT|1|U/m2|SNELLEN EYE CHART|||CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-12-04|10
e|TR|d2b31ba9-9718-43ce-82ca-3276c28ac42a|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|ELISA unit|INCREASED|1|10^3 CFU|STATIC PERIMETRY|Y||SPOUSE|ONCOLOGIST|N|2|Visit_2|25|3|WASHOUT|2020-12-19|25
e|TR|d2b31ba9-9718-43ce-82ca-3276c28ac42a|3|[?]|RADIODEN|Radiodensity|[?]|C|FOCALLY INCREASED|1|QUANTITY SUFFICIENT|IVY INCISION METHOD||Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|3|Visit_3|40|4|SCREENING|2021-01-03|40
e|TR|d2b31ba9-9718-43ce-82ca-3276c28ac42a|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|nkat|NONPALPABLE|1|10^9 CFU|FLUORESCENT IMMUNOASSAY|Y||SIGNIFICANT OTHER|OPHTHALMOLOGIST|N|4|Visit_4|65|3|TREATMENT|2021-01-28|65
e|TR|d2b31ba9-9718-43ce-82ca-3276c28ac42a|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|nCi|PRESENT|1|uSiemens|DOUBLE IMMUNODIFFUSION|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|Y|5|Visit_5|90|1|TREATMENT|2021-02-22|90
e|TR|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|kcal/day|ENLARGEMENT|1|ng/L|DC SHEATH FLOW|Y||DOMESTIC PARTNER|ONCOLOGIST 1|N|1|Visit_1|10|4|TREATMENT|2020-07-23|10
e|TR|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|2|[?]|LESSCIND|Lesion Success Indicator|[?]|log10 TCID 50/dose|FURTHER ENLARGEMENT FROM NADIR|1|uL/kg/day|U-HPLC/MS/MS|||DOMESTIC PARTNER|ADJUDICATOR 2|NA|2|Visit_2|25|1|TREATMENT|2020-08-07|25
e|TR|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|Ci/ug|EQUIVOCAL|1|TRANSDUCING UNIT|ELECTROMYOGRAPHY|||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|N|3|Visit_3|40|1|WASHOUT|2020-08-22|40
e|TR|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|mEq/dL|ENLARGEMENT FROM NADIR|1|fraction of 1|SCINTIGRAPHY|Y|Y|CHILD|MICROSCOPIST 2|U|4|Visit_4|65|3|FOLLOW-UP|2020-09-16|65
e|TR|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|5|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|Enzyme U|FURTHER ENLARGEMENT FROM NADIR|1|BLOCKS|RULER MEASUREMENT METHOD||Y|STUDY SUBJECT|PHYSIOTHERAPIST|NA|5|Visit_5|90|7|WASHOUT|2020-10-11|90
e|TR|0a42f96a-49c3-492f-a272-bf9989e53e9d|1|[?]|CALCFIND|Calcification Indicator|[?]|log10 TCID 50/dose|FOCALLY INCREASED|1|s/h|CAPILLARY ELECTROPHORESIS|||ADJUDICATION COMMITTEE|NEUROLOGIST|Y|1|Visit_1|10|4|SCREENING|2021-01-26|10
e|TR|0a42f96a-49c3-492f-a272-bf9989e53e9d|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|mg/mol|ENLARGEMENT|1|mol|PLETHYSMOGRAPHY|Y||ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|7|SCREENING|2021-02-10|25
e|TR|0a42f96a-49c3-492f-a272-bf9989e53e9d|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|breaths/30s|UNCHANGED|1|U/m2|MAGNETIC RESONANCE ANGIOGRAPHY|Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|3|Visit_3|40|5|SCREENING|2021-02-25|40
e|TR|0a42f96a-49c3-492f-a272-bf9989e53e9d|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|10^6 copies/mL|UNCHANGED|1|/100 WBC|CLOT DETECTION|||ADJUDICATOR|CARDIOLOGIST|N|4|Visit_4|65|4|TREATMENT|2021-03-22|65
e|TR|0a42f96a-49c3-492f-a272-bf9989e53e9d|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|mg/m2|FURTHER ENLARGEMENT|1|U/kg|PET SCAN|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|5|Visit_5|90|4|TREATMENT|2021-04-16|90
e|TR|a78e7287-581c-4bf2-b3ca-ad2476c010cd|1|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|vp/dose|NORMAL|1|BOWL|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|Y||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|NA|1|Visit_1|10|4|SCREENING|2021-01-08|10
e|TR|a78e7287-581c-4bf2-b3ca-ad2476c010cd|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|Ci/kg|ABSENT|1|mL/animal/wk|RULER MEASUREMENT METHOD|||SPOUSE|ENDOCRINOLOGIST|N|2|Visit_2|25|3|TREATMENT|2021-01-23|25
e|TR|a78e7287-581c-4bf2-b3ca-ad2476c010cd|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|keV|UNCHANGED|1|ug/g/day|WRIGHT-GIEMSA STAIN|Y||PROXY|ONCOLOGIST 2|Y|3|Visit_3|40|1|FOLLOW-UP|2021-02-07|40
e|TR|a78e7287-581c-4bf2-b3ca-ad2476c010cd|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|nkat/L|PALPABLE|1|kIU|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|N|4|Visit_4|65|7|WASHOUT|2021-03-04|65
e|TR|a78e7287-581c-4bf2-b3ca-ad2476c010cd|5|[?]|LESSCIND|Lesion Success Indicator|[?]|PLUG|TUMOR MERGED|1|days/month|GEL ELECTROPHORESIS|||INVESTIGATOR|ADJUDICATOR 2|NA|5|Visit_5|90|3|FOLLOW-UP|2021-03-29|90
e|TR|d3651e5f-bc38-4c96-afbf-5a65873ff306|1|[?]|ORSTATE|Organ State|[?]|umol/L|PATHOLOGICAL|1|F|CLAUSS METHOD|||GUARDIAN|NEUROLOGIST 2|NA|1|Visit_1|10|6|TREATMENT|2020-07-28|10
e|TR|d3651e5f-bc38-4c96-afbf-5a65873ff306|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|MPL U|UNEQUIVOCAL|1|cmHg|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|||CHILD|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-08-12|25
e|TR|d3651e5f-bc38-4c96-afbf-5a65873ff306|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|mL/s|EQUIVOCAL|1|kat|PET/CT SCAN WITHOUT CONTRAST|||FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|5|TREATMENT|2020-08-27|40
e|TR|d3651e5f-bc38-4c96-afbf-5a65873ff306|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|nkat/L|NONPALPABLE|1|vg/kg|TRYPAN BLUE STAIN|||FAMILY MEMBER|DERMATOLOGIST|NA|4|Visit_4|65|7|WASHOUT|2020-09-21|65
e|TR|d3651e5f-bc38-4c96-afbf-5a65873ff306|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|pmol/L|PATHOLOGICAL|1|AFU|LC-FL|Y||PROXY|MICROSCOPIST 3|Y|5|Visit_5|90|2|TREATMENT|2020-10-16|90
e|TR|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|1|[?]|SUMVOL|Sum of Volume|[?]|BOLUS|EQUIVOCAL|1|tsp eq|INTRAVASCULAR ULTRASOUND|||INTERVIEWER|READER 2|Y|1|Visit_1|10|7|TREATMENT|2020-06-11|10
e|TR|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|2|[?]|NEWCONF|New Tumor Confirmed|[?]|usec|FURTHER ENLARGEMENT FROM NADIR|1|mL/animal|LEAD CITRATE STAIN|||SPOUSE|MICROSCOPIST 1|U|2|Visit_2|25|2|TREATMENT|2020-06-26|25
e|TR|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|uL/kg/day|EQUIVOCAL|1|cup eq|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||FRIEND|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-07-11|40
e|TR|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|4|[?]|AREA|Area|[?]|vp/dose|NORMAL|1|AU/mL|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||Y|CAREGIVER|RATER 2|U|4|Visit_4|65|5|TREATMENT|2020-08-05|65
e|TR|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|mg/min|INCREASED|1|mmol/L|HPLC-UV|Y||HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|5|TREATMENT|2020-08-30|90
e|TR|f50537d2-e098-4dae-8f91-16f2357d709c|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|fmol/g|PATHOLOGICAL|1|P|INTRAVASCULAR ULTRASOUND|||PROXY|MICROSCOPIST|N|1|Visit_1|10|6|SCREENING|2020-12-07|10
e|TR|f50537d2-e098-4dae-8f91-16f2357d709c|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|yd|EQUIVOCAL|1|Ci/L|COMPUTERIZED CORNEAL TOPOGRAPHY|||CLINICAL STUDY SPONSOR|PATHOLOGIST 2|NA|2|Visit_2|25|6|TREATMENT|2020-12-22|25
e|TR|f50537d2-e098-4dae-8f91-16f2357d709c|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|CIGAR|NONPALPABLE|1|Gy|ENZYMATIC ULTRACENTRIFUGATION|||FAMILY MEMBER|RADIOLOGIST 2|N|3|Visit_3|40|5|TREATMENT|2021-01-06|40
e|TR|f50537d2-e098-4dae-8f91-16f2357d709c|4|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|/40 HPFs|FURTHER ENLARGEMENT|1|pkat/L|MANUAL CLOT DETECTION|Y||PROXY|NEUROLOGIST|N|4|Visit_4|65|7|SCREENING|2021-01-31|65
e|TR|f50537d2-e098-4dae-8f91-16f2357d709c|5|[?]|CALCFIND|Calcification Indicator|[?]|mm/sec|DECREASED|1|s^-1(%O2)^-1|THIN SMEAR|||SPOUSE|READER|U|5|Visit_5|90|1|TREATMENT|2021-02-25|90
e|TR|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|Torr|NONPALPABLE|1|/200 HPFs|CONTRAST ENHANCED PET SCAN|||HEALTH CARE PROFESSIONAL|INTERNIST|U|1|Visit_1|10|6|WASHOUT|2020-07-19|10
e|TR|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|mg2/dL2|UNEQUIVOCAL|1|mL/cm|MAGNETIC RESONANCE ELASTOGRAPHY|Y||CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|7|WASHOUT|2020-08-03|25
e|TR|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|3|[?]|AREA|Area|[?]|kg|ENLARGEMENT|1|/40 HPFs|VENTILATION PERFUSION LUNG SCAN|Y||ADJUDICATION COMMITTEE|INTERNIST|Y|3|Visit_3|40|7|TREATMENT|2020-08-18|40
e|TR|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|4|[?]|CALCFIND|Calcification Indicator|[?]|10^9/dose|FURTHER ENLARGEMENT|1|ft2|IRON HEMATOXYLIN STAIN|||FAMILY MEMBER|ONCOLOGIST 1|U|4|Visit_4|65|4|TREATMENT|2020-09-12|65
e|TR|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|Log10 ELISA unit/dose|NONPALPABLE|1|CARTRIDGE|PERCUSSION|||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|1|FOLLOW-UP|2020-10-07|90
e|TR|489870ed-9da5-4df6-a5ef-17821c449c84|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|10^9 organisms/mg|DECREASED|1|MHz|CHROMATOGRAPHY|Y||FAMILY MEMBER|NEUROLOGIST 1|Y|1|Visit_1|10|4|SCREENING|2020-07-30|10
e|TR|489870ed-9da5-4df6-a5ef-17821c449c84|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|mEq/mL|DECREASED|1|10^7 CFU/mL|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|Y|INTERVIEWER|PATHOLOGIST 1|NA|2|Visit_2|25|1|TREATMENT|2020-08-14|25
e|TR|489870ed-9da5-4df6-a5ef-17821c449c84|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mmol/kg|PATHOLOGICAL|1|g/kg/day|GIEMSA STAIN|||FRIEND|RATER 1|U|3|Visit_3|40|3|FOLLOW-UP|2020-08-29|40
e|TR|489870ed-9da5-4df6-a5ef-17821c449c84|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|PA|ENLARGEMENT FROM NADIR|1|g/L|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|Y|4|Visit_4|65|3|SCREENING|2020-09-23|65
e|TR|489870ed-9da5-4df6-a5ef-17821c449c84|5|[?]|PCHGBL|Percent Change From Baseline|[?]|mol/L|NONPALPABLE|1|PHERESIS UNIT|GC/MS-EI||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|5|Visit_5|90|6|FOLLOW-UP|2020-10-18|90
e|TR|90fe992f-5a11-4829-b3b0-1c8314f53012|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|cP|FURTHER ENLARGEMENT|1|CCID 50/dose|ICP-MS|||STUDY SUBJECT|OPHTHALMOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-09-23|10
e|TR|90fe992f-5a11-4829-b3b0-1c8314f53012|2|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|FEU|EQUIVOCAL|1|mOsm|AUDIOMETRY|Y|Y|PARENT|DERMATOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2020-10-08|25
e|TR|90fe992f-5a11-4829-b3b0-1c8314f53012|3|[?]|PCHGBL|Percent Change From Baseline|[?]|QUANTITY SUFFICIENT|DIFFUSELY INCREASED|1|mV|ENZYMATIC COLORIMETRY|Y|Y|INDEPENDENT ASSESSOR|RADIOLOGIST 1|Y|3|Visit_3|40|6|SCREENING|2020-10-23|40
e|TR|90fe992f-5a11-4829-b3b0-1c8314f53012|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|pt_us|UNCHANGED|1|umol/dL|FORCED OSCILLATION TECHNIQUE|||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|7|WASHOUT|2020-11-17|65
e|TR|90fe992f-5a11-4829-b3b0-1c8314f53012|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|10^10/L|ENLARGEMENT|1|um/day|CLAUSS METHOD|||ADJUDICATOR|PATHOLOGIST 2|Y|5|Visit_5|90|1|WASHOUT|2020-12-12|90
e|TR|74be8de0-3307-4cc3-9044-05068b60f7e0|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|ukat|DIFFUSELY INCREASED|1|mL/m2/day|DIFFUSION WEIGHTED MRI|Y||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|1|Visit_1|10|7|TREATMENT|2020-10-20|10
e|TR|74be8de0-3307-4cc3-9044-05068b60f7e0|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|U/g Hb|TUMOR MERGED|1|Hounsfield Unit|ELECTRONEUROGRAPHY|||FRIEND|NEUROLOGIST 2|Y|2|Visit_2|25|6|TREATMENT|2020-11-04|25
e|TR|74be8de0-3307-4cc3-9044-05068b60f7e0|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|V/sec|ABSENT|1|MET|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-11-19|40
e|TR|74be8de0-3307-4cc3-9044-05068b60f7e0|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|/4.0 mL|UNCHANGED|1|g/day|FARR ASSAY|||SIGNIFICANT OTHER|ADJUDICATOR 2|NA|4|Visit_4|65|2|TREATMENT|2020-12-14|65
e|TR|74be8de0-3307-4cc3-9044-05068b60f7e0|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|nmol/mL/min|EQUIVOCAL|1|U/kg/h|CONTRAST ENHANCED X-RAY|||GUARDIAN|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|5|FOLLOW-UP|2021-01-08|90
e|TR|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|CIGARETTE|PALPABLE|1|mL/breath|DXA SCAN|||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|U|1|Visit_1|10|7|FOLLOW-UP|2020-06-11|10
e|TR|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|2|[?]|CALCFIND|Calcification Indicator|[?]|steps/min|UNCHANGED|1|BLOCKS|SCINTIGRAPHY|||SIBLING|ONCOLOGIST 1|U|2|Visit_2|25|2|FOLLOW-UP|2020-06-26|25
e|TR|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mmol/day|DECREASED|1|pm|WHOLE EXOME SEQUENCING|||GUARDIAN|ADJUDICATOR 3|Y|3|Visit_3|40|3|FOLLOW-UP|2020-07-11|40
e|TR|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|4|[?]|VOLUME|Volume|[?]|PRESSOR UNITS|FURTHER ENLARGEMENT FROM NADIR|1|uEq/L|CLAUSS METHOD||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|NA|4|Visit_4|65|4|TREATMENT|2020-08-05|65
e|TR|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|VIRTUAL PIXEL|FOCALLY INCREASED|1|dpm/100mg|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||ADJUDICATOR|RATER 1|NA|5|Visit_5|90|3|FOLLOW-UP|2020-08-30|90
e|TR|8825b806-fa76-49d7-b281-d36fc42fee1e|1|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|umol/kg/min|EQUIVOCAL|1|Weber|MRS||Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|U|1|Visit_1|10|1|TREATMENT|2020-08-29|10
e|TR|8825b806-fa76-49d7-b281-d36fc42fee1e|2|[?]|VOLUME|Volume|[?]|CARTRIDGE|NONPALPABLE|1|GPL U/mL|ELECTROCHEMILUMINESCENCE|||HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|2|Visit_2|25|3|SCREENING|2020-09-13|25
e|TR|8825b806-fa76-49d7-b281-d36fc42fee1e|3|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|DAYS|FURTHER ENLARGEMENT FROM NADIR|1|PRESSOR UNITS|MECHANICAL CLOT DETECTION|||SIGNIFICANT OTHER|NEUROLOGIST 2|Y|3|Visit_3|40|6|TREATMENT|2020-09-28|40
e|TR|8825b806-fa76-49d7-b281-d36fc42fee1e|4|[?]|DIAMETER|Diameter|[?]|mL*cmH2O|ENLARGEMENT|1|AMPULE|IMMUNOFLUORESCENT STAIN|||PARENT|ONCOLOGIST 2|Y|4|Visit_4|65|4|TREATMENT|2020-10-23|65
e|TR|8825b806-fa76-49d7-b281-d36fc42fee1e|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|Arbitrary U|TUMOR MERGED|1|cmH2O/mL|STRESS ECHOCARDIOGRAPHY|Y||CAREGIVER|OPHTHALMOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2020-11-17|90
e|TR|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|1|[?]|AREA|Area|[?]|uL/dose|FURTHER ENLARGEMENT|1|10^5/hpf|ALCIAN BLUE STAIN|||PROXY|ADJUDICATOR 1|NA|1|Visit_1|10|5|FOLLOW-UP|2020-05-19|10
e|TR|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|2|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|nmol/day|PATHOLOGICAL|1|ug/mol|ICP-MS|||NON-HEALTH CARE PROFESSIONAL|RATER|U|2|Visit_2|25|3|TREATMENT|2020-06-03|25
e|TR|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|3|[?]|PPD|Product of Perpendicular Diameters|[?]|g/cm2|FURTHER ENLARGEMENT FROM NADIR|1|gtt|ATOMIC ABSORPTION SPECTROMETRY|||INTERVIEWER|MICROSCOPIST 3|U|3|Visit_3|40|2|SCREENING|2020-06-18|40
e|TR|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|4|[?]|RADIODEN|Radiodensity|[?]|ng/L|FOCALLY INCREASED|1|g/g/day|GC/FID|||CAREGIVER|MICROSCOPIST 1|N|4|Visit_4|65|3|TREATMENT|2020-07-13|65
e|TR|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|BEAM BREAKS|FOCALLY INCREASED|1|nCi|DIRECT SEQUENCING|||SPOUSE|MICROSCOPIST 3|U|5|Visit_5|90|1|FOLLOW-UP|2020-08-07|90
e|TR|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|U/m2/min|FURTHER ENLARGEMENT|1|m|IMMUNOCHROMATOGRAPHY|||FAMILY MEMBER|INTERNIST|Y|1|Visit_1|10|4|FOLLOW-UP|2021-01-14|10
e|TR|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|Farad|PRESENT|1|pg/dL|ENZYMATIC COLORIMETRY|Y||FRIEND|CARDIOLOGIST|Y|2|Visit_2|25|1|SCREENING|2021-01-29|25
e|TR|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|amp|PATHOLOGICAL|1|mol/mL|CONTRAST ENHANCED PET SCAN|Y||CLINICAL STUDY SPONSOR|INTERNIST|Y|3|Visit_3|40|5|TREATMENT|2021-02-13|40
e|TR|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|nmol/L|DIFFUSELY INCREASED|1|mL/100g/min|ELECTROGASTROGRAPHY||Y|CAREGIVER|RADIOLOGIST|N|4|Visit_4|65|5|TREATMENT|2021-03-10|65
e|TR|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|5|[?]|LESSCIND|Lesion Success Indicator|[?]|um/day|NON-PATHOLOGICAL|1|10^3 organisms/mL|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|5|Visit_5|90|2|SCREENING|2021-04-04|90
e|TR|b36220d8-c129-48bf-8c41-542a954b819a|1|[?]|CALCFIND|Calcification Indicator|[?]|umol/mg/min|EQUIVOCAL|1|ug/m2|FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|NA|1|Visit_1|10|2|SCREENING|2020-05-24|10
e|TR|b36220d8-c129-48bf-8c41-542a954b819a|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|gpELISA unit/mL|FOCALLY INCREASED|1|cd*s/m2|FLOCCULATION, CHARCOAL ENHANCED|||GUARDIAN|NEUROLOGIST 1|Y|2|Visit_2|25|4|TREATMENT|2020-06-08|25
e|TR|b36220d8-c129-48bf-8c41-542a954b819a|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|ug/dL|TUMOR MERGED|1|pmol|IMMUNOCHEMILUMINOMETRIC ASSAY|||PARENT|READER 3|Y|3|Visit_3|40|2|TREATMENT|2020-06-23|40
e|TR|b36220d8-c129-48bf-8c41-542a954b819a|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|Gy/min|INCREASED|1|ukat/L|CALIPER MEASUREMENT METHOD|||SIGNIFICANT OTHER|PATHOLOGIST 2|Y|4|Visit_4|65|6|TREATMENT|2020-07-18|65
e|TR|b36220d8-c129-48bf-8c41-542a954b819a|5|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mMU/mL|FOCALLY INCREASED|1|dyn|QUANTITATIVE ULTRASOUND|Y||VENDOR|READER|N|5|Visit_5|90|1|TREATMENT|2020-08-12|90
e|TR|92d3477b-7460-4ce8-b237-38ca4c55fc91|1|[?]|SUMVOL|Sum of Volume|[?]|mg/day|TUMOR MERGED|1|10^6 organisms/mL|SMEAR|||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|U|1|Visit_1|10|3|FOLLOW-UP|2020-08-14|10
e|TR|92d3477b-7460-4ce8-b237-38ca4c55fc91|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|/7.5 mL|ABSENT|1|mg/kg/week|HPLC/MS|||INTERVIEWER|HEMATOLOGIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-08-29|25
e|TR|92d3477b-7460-4ce8-b237-38ca4c55fc91|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|10^4 CFU/mL|FURTHER ENLARGEMENT|1|L/kg|TWO-COLOR MICROARRAY|||ADJUDICATION COMMITTEE|RATER|N|3|Visit_3|40|3|TREATMENT|2020-09-13|40
e|TR|92d3477b-7460-4ce8-b237-38ca4c55fc91|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|IU/mL|PRESENT|1|10^7 CFU|PULMONARY ANGIOGRAPHY|Y||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|U|4|Visit_4|65|2|FOLLOW-UP|2020-10-08|65
e|TR|92d3477b-7460-4ce8-b237-38ca4c55fc91|5|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|GLOBULE|INCREASED|1|AMPULE|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||PARENT|INTERNIST|NA|5|Visit_5|90|2|FOLLOW-UP|2020-11-02|90
e|TR|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|10^9 CFU|EQUIVOCAL|1|copies/ug|PERIPHERAL ANGIOGRAPHY|||FAMILY MEMBER|RATER 1|Y|1|Visit_1|10|2|FOLLOW-UP|2020-12-16|10
e|TR|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|2|[?]|LESSCIND|Lesion Success Indicator|[?]|deg2|PALPABLE|1|U/mL|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y||INVESTIGATOR|RATER 2|NA|2|Visit_2|25|1|TREATMENT|2020-12-31|25
e|TR|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|CCID 50/mL|PATHOLOGICAL|1|JDF Unit|PHOROPTER|||VENDOR|MICROSCOPIST 1|U|3|Visit_3|40|4|SCREENING|2021-01-15|40
e|TR|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|/LPF|NONPALPABLE|1|10^6 CFU/mL|DYNAMIC LIGHT SCATTERING|||INDEPENDENT ASSESSOR|RATER 1|NA|4|Visit_4|65|4|SCREENING|2021-02-09|65
e|TR|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|IU/mg|DIFFUSELY INCREASED|1|pg/L|PET/CT SCAN WITHOUT CONTRAST|Y||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|4|WASHOUT|2021-03-06|90
e|TR|db13afe0-14f6-445b-869a-b0d9fe87e5b9|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|/LPF|DIFFUSELY INCREASED|1|OD Unit|MICROARRAY|||FRIEND|ADJUDICATOR 2|U|1|Visit_1|10|4|FOLLOW-UP|2020-08-22|10
e|TR|db13afe0-14f6-445b-869a-b0d9fe87e5b9|2|[?]|ORSTATE|Organ State|[?]|TUBE|NON-PATHOLOGICAL|1|hPa|CYSTOSCOPY||Y|DOMESTIC PARTNER|OPTOMETRIST|N|2|Visit_2|25|4|WASHOUT|2020-09-06|25
e|TR|db13afe0-14f6-445b-869a-b0d9fe87e5b9|3|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|AMPULE|ABSENT|1|10^10/L|SNP ARRAY|||SPOUSE|PHYSIOTHERAPIST|NA|3|Visit_3|40|4|TREATMENT|2020-09-21|40
e|TR|db13afe0-14f6-445b-869a-b0d9fe87e5b9|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|PA|PALPABLE|1|anti-Xa IU/mL|CHROMOGENIC ASSAY|||PROXY|OPHTHALMOLOGIST|NA|4|Visit_4|65|1|WASHOUT|2020-10-16|65
e|TR|db13afe0-14f6-445b-869a-b0d9fe87e5b9|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|yd|NONPALPABLE|1|10^12/L|MICRO BROTH DILUTION|Y|Y|SIGNIFICANT OTHER|NEUROLOGIST 1|U|5|Visit_5|90|7|TREATMENT|2020-11-10|90
e|TR|3f75a463-1348-4c7f-8b29-7472d29628c8|1|[?]|PALPSTAT|Palpable State|[?]|%(v/v)|TUMOR MERGED|1|10^6/L|AUDIOMETRY||Y|FRIEND|ADJUDICATOR 1|NA|1|Visit_1|10|2|SCREENING|2020-07-12|10
e|TR|3f75a463-1348-4c7f-8b29-7472d29628c8|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|WAFER|UNEQUIVOCAL|1|mOsm/L|RYAN BLUE STAIN||Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|2|Visit_2|25|2|FOLLOW-UP|2020-07-27|25
e|TR|3f75a463-1348-4c7f-8b29-7472d29628c8|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|kg/cm|DIFFUSELY INCREASED|1|MPL U|NON-CONTACT SPECULAR MICROSCOPY|||INVESTIGATOR|ONCOLOGIST 2|N|3|Visit_3|40|2|WASHOUT|2020-08-11|40
e|TR|3f75a463-1348-4c7f-8b29-7472d29628c8|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|cm2|FURTHER ENLARGEMENT|1|ug/m2/day|RYAN BLUE STAIN|Y|Y|INDEPENDENT ASSESSOR|NEUROLOGIST 1|N|4|Visit_4|65|3|SCREENING|2020-09-05|65
e|TR|3f75a463-1348-4c7f-8b29-7472d29628c8|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|eq|FURTHER ENLARGEMENT|1|pg/L|U-HPLC/MS/MS|||SPOUSE|RATER|U|5|Visit_5|90|4|WASHOUT|2020-09-30|90
e|TR|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|1|[?]|PALPSTAT|Palpable State|[?]|IU/L|FURTHER ENLARGEMENT|1|CCID 50/dose|PHYSICAL EXAMINATION|||INTERVIEWER|NEUROLOGIST 1|Y|1|Visit_1|10|7|TREATMENT|2021-01-30|10
e|TR|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|2|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mL/h|UNCHANGED|1|grain|CELLULOSE TAPE|||DOMESTIC PARTNER|RADIOLOGIST|N|2|Visit_2|25|1|FOLLOW-UP|2021-02-14|25
e|TR|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|3|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|/500 WBC|DIFFUSELY INCREASED|1|mL/mmHg/min/L|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|Y||CHILD|PATHOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2021-03-01|40
e|TR|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|PIXEL|DIFFUSELY INCREASED|1|um2|MASS SPECTROMETRY|||PARENT|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2021-03-26|65
e|TR|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|AMPULE|FURTHER ENLARGEMENT FROM NADIR|1|DAYS|PERCUSSION|Y||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|5|Visit_5|90|2|SCREENING|2021-04-20|90
e|TR|4b00b9ef-ddc3-4669-8a73-f69c73743bce|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|SUPPOSITORY|UNEQUIVOCAL|1|mg/cm2|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-07-23|10
e|TR|4b00b9ef-ddc3-4669-8a73-f69c73743bce|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|vp/dose|TUMOR MERGED|1|BAU/mL|PERIPHERAL ANGIOGRAPHY||Y|ADJUDICATION COMMITTEE|MICROSCOPIST 3|N|2|Visit_2|25|7|TREATMENT|2020-08-07|25
e|TR|4b00b9ef-ddc3-4669-8a73-f69c73743bce|3|[?]|ORVERLN|Organ Vertical Length|[?]|amp|TUMOR MERGED|1|CCID 50/dose|SPECT SCAN|||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|Y|3|Visit_3|40|4|SCREENING|2020-08-22|40
e|TR|4b00b9ef-ddc3-4669-8a73-f69c73743bce|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|cm2|EQUIVOCAL|1|cpm|SPIROMETRY|Y||SPOUSE|PATHOLOGIST 2|NA|4|Visit_4|65|3|TREATMENT|2020-09-16|65
e|TR|4b00b9ef-ddc3-4669-8a73-f69c73743bce|5|[?]|LPERP|Longest Perpendicular|[?]|/VF|PALPABLE|1|BAU/mL|SNELLEN EYE CHART|||CLINICAL STUDY SPONSOR|DERMATOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-10-11|90
e|TR|a125efdf-aec8-47a1-b492-cdaf8b619a78|1|[?]|NEWCONF|New Tumor Confirmed|[?]|ohm|EQUIVOCAL|1|mCi/kg|MASS SPECTROMETRY||Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|1|Visit_1|10|4|FOLLOW-UP|2020-09-30|10
e|TR|a125efdf-aec8-47a1-b492-cdaf8b619a78|2|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|genEq|PRESENT|1|U/mg|CONFOCAL MICROSCOPY|Y|Y|DOMESTIC PARTNER|UROLOGIST|N|2|Visit_2|25|7|TREATMENT|2020-10-15|25
e|TR|a125efdf-aec8-47a1-b492-cdaf8b619a78|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|kg/mol|NON-PATHOLOGICAL|1|DIP|MRI WITHOUT CONTRAST|||CAREGIVER|UROLOGIST|U|3|Visit_3|40|7|FOLLOW-UP|2020-10-30|40
e|TR|a125efdf-aec8-47a1-b492-cdaf8b619a78|4|[?]|LNSTATE|Lymph Node State|[?]|g/kg/day|DECREASED|1|ug/dL|CLINICAL EVALUATION|||CLINICAL STUDY SPONSOR|NEUROLOGIST|N|4|Visit_4|65|3|TREATMENT|2020-11-24|65
e|TR|a125efdf-aec8-47a1-b492-cdaf8b619a78|5|[?]|SUMVOL|Sum of Volume|[?]|CCID 50/mL|FURTHER ENLARGEMENT|1|ft|PERFUSION MRI|||INVESTIGATOR|ONCOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-12-19|90
e|TR|9171362e-0166-46f2-ab2d-2748d8c291d5|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|kPa/L/sec|PATHOLOGICAL|1|psi|SISH|||INDEPENDENT ASSESSOR|MICROSCOPIST|NA|1|Visit_1|10|5|WASHOUT|2021-01-12|10
e|TR|9171362e-0166-46f2-ab2d-2748d8c291d5|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|pmol/dL|DIFFUSELY INCREASED|1|Hz/s|MAGNETIC RESONANCE ENTEROGRAPHY||Y|ADJUDICATOR|CARDIOLOGIST|U|2|Visit_2|25|2|WASHOUT|2021-01-27|25
e|TR|9171362e-0166-46f2-ab2d-2748d8c291d5|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|ug/m2/h|EQUIVOCAL|1|dyn|CT SCAN WITHOUT CONTRAST|||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2021-02-11|40
e|TR|9171362e-0166-46f2-ab2d-2748d8c291d5|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|cm H2O|DECREASED|1|ngEq/L|WRIGHT-GIEMSA STAIN||Y|SPOUSE|ONCOLOGIST|Y|4|Visit_4|65|4|TREATMENT|2021-03-08|65
e|TR|9171362e-0166-46f2-ab2d-2748d8c291d5|5|[?]|AREA|Area|[?]|mOsm/kg|UNCHANGED|1|Antibody Unit|CLIP|Y||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|N|5|Visit_5|90|7|WASHOUT|2021-04-02|90
e|TR|9b150e38-dc85-4a28-aad3-43f7620be460|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|CAN|FURTHER ENLARGEMENT FROM NADIR|1|pg|DIFFUSION TENSOR MRI||Y|INVESTIGATOR|CLINICAL PATHOLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-07-22|10
e|TR|9b150e38-dc85-4a28-aad3-43f7620be460|2|[?]|ORVERLN|Organ Vertical Length|[?]|PIXEL|EQUIVOCAL|1|BAG|COLORIMETRY||Y|STUDY SUBJECT|OTOLARYNGOLOGIST|U|2|Visit_2|25|5|SCREENING|2020-08-06|25
e|TR|9b150e38-dc85-4a28-aad3-43f7620be460|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|Ci/kg|DIFFUSELY INCREASED|1|10^6/L|U-HPLC/MS/MS||Y|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|4|WASHOUT|2020-08-21|40
e|TR|9b150e38-dc85-4a28-aad3-43f7620be460|4|[?]|ACHNAD|Absolute Change From Nadir|[?]|U/m2/h|FOCALLY INCREASED|1|P|IMMUNOCHEMILUMINOMETRIC ASSAY||Y|ADJUDICATION COMMITTEE|ONCOLOGIST|NA|4|Visit_4|65|7|TREATMENT|2020-09-15|65
e|TR|9b150e38-dc85-4a28-aad3-43f7620be460|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|IU/mL|FURTHER ENLARGEMENT|1|g/kg/day|ENZYMATIC COLORIMETRY||Y|SIGNIFICANT OTHER|ADJUDICATOR 2|Y|5|Visit_5|90|2|SCREENING|2020-10-10|90
e|TR|2a595fc0-7621-4ec9-bd77-74444886052e|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|/40 HPFs|UNEQUIVOCAL|1|uCi|HEMOCYTOMETRY|||CHILD|RADIOLOGIST|N|1|Visit_1|10|3|TREATMENT|2020-10-25|10
e|TR|2a595fc0-7621-4ec9-bd77-74444886052e|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|10^8 PFU|NON-PATHOLOGICAL|1|dmol|CHROMATOGRAPHY|||INVESTIGATOR|RADIOLOGIST|N|2|Visit_2|25|6|SCREENING|2020-11-09|25
e|TR|2a595fc0-7621-4ec9-bd77-74444886052e|3|[?]|LESSCIND|Lesion Success Indicator|[?]|Linear ft*LB|NORMAL|1|um|NUCLEIC ACID SEQUENCING|Y||FAMILY MEMBER|MICROSCOPIST 2|Y|3|Visit_3|40|3|SCREENING|2020-11-24|40
e|TR|2a595fc0-7621-4ec9-bd77-74444886052e|4|[?]|ORSTATE|Organ State|[?]|amol|FOCALLY INCREASED|1|umol/L/min|PATHOLOGICAL EVALUATION|Y||VENDOR|HEMATOLOGIST|Y|4|Visit_4|65|2|FOLLOW-UP|2020-12-19|65
e|TR|2a595fc0-7621-4ec9-bd77-74444886052e|5|[?]|LDIAM|Longest Diameter|[?]|HEP|ABSENT|1|BE/mL|ACID FAST STAIN|||GUARDIAN|PATHOLOGIST 1|Y|5|Visit_5|90|4|WASHOUT|2021-01-13|90
e|TR|0bab89c8-cf57-4d19-9b95-884a2e9da523|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|mOsm/L|PRESENT|1|U/g/h|DROPLET DIGITAL PCR||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-12-20|10
e|TR|0bab89c8-cf57-4d19-9b95-884a2e9da523|2|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|K|PRESENT|1|umol/day|AUTOREFRACTION||Y|ADJUDICATOR|READER|NA|2|Visit_2|25|5|FOLLOW-UP|2021-01-04|25
e|TR|0bab89c8-cf57-4d19-9b95-884a2e9da523|3|[?]|LPERP|Longest Perpendicular|[?]|fg|DIFFUSELY INCREASED|1|HOURS|ENZYMATIC SPECTROPHOTOMETRY||Y|INVESTIGATOR|ONCOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2021-01-19|40
e|TR|0bab89c8-cf57-4d19-9b95-884a2e9da523|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|uV2|UNCHANGED|1|U/kg|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||Y|DOMESTIC PARTNER|ADJUDICATOR 1|U|4|Visit_4|65|4|FOLLOW-UP|2021-02-13|65
e|TR|0bab89c8-cf57-4d19-9b95-884a2e9da523|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mL/cm3/min|INCREASED|1|Shock Wave|MULTI-SLICE SPIRAL CT|||CAREGIVER|ONCOLOGIST|Y|5|Visit_5|90|1|TREATMENT|2021-03-10|90
e|TR|84edaa9d-ce48-4866-ab43-af91bee126ae|1|[?]|PPD|Product of Perpendicular Diameters|[?]|DNA copies/ug|FURTHER ENLARGEMENT|1|vg/kg|CT SCAN WITHOUT CONTRAST|||DOMESTIC PARTNER|HEMATOLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-05-11|10
e|TR|84edaa9d-ce48-4866-ab43-af91bee126ae|2|[?]|VOLUME|Volume|[?]|ft|UNEQUIVOCAL|1|uU/dL|NUCLEIC ACID HYBRIDIZATION||Y|SIBLING|PATHOLOGIST 1|Y|2|Visit_2|25|3|FOLLOW-UP|2020-05-26|25
e|TR|84edaa9d-ce48-4866-ab43-af91bee126ae|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mIU/L|FOCALLY INCREASED|1|10^9/g|FLUORESCENT IMMUNOASSAY|Y||STUDY SUBJECT|OTOLARYNGOLOGIST|N|3|Visit_3|40|3|SCREENING|2020-06-10|40
e|TR|84edaa9d-ce48-4866-ab43-af91bee126ae|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|ms2|PALPABLE|1|10^6/g|NEPHELOMETRY|||CLINICAL RESEARCH ASSOCIATE|UROLOGIST|U|4|Visit_4|65|2|FOLLOW-UP|2020-07-05|65
e|TR|84edaa9d-ce48-4866-ab43-af91bee126ae|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|log10 copies/mL|DECREASED|1|NEEDLE GAUGE|FREEZING POINT DEPRESSION||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|N|5|Visit_5|90|5|TREATMENT|2020-07-30|90
e|TR|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|BAG|DECREASED|1|grain|IMMUNOASSAY|||INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|1|Visit_1|10|7|TREATMENT|2020-08-03|10
e|TR|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|EP U|DIFFUSELY INCREASED|1|hr/day|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||VENDOR|ADJUDICATOR|N|2|Visit_2|25|7|TREATMENT|2020-08-18|25
e|TR|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|/ms|ABSENT|1|uEq/L|INTRAVASCULAR ULTRASOUND||Y|ADJUDICATOR|READER|NA|3|Visit_3|40|2|TREATMENT|2020-09-02|40
e|TR|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|CCID 50/dose|INCREASED|1|ug/g/day|CONGO RED STAIN|||ADJUDICATION COMMITTEE|ADJUDICATOR 3|NA|4|Visit_4|65|7|FOLLOW-UP|2020-09-27|65
e|TR|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|vg/dose|INCREASED|1|10^3 CFU|PHYSICAL EXAMINATION|||CLINICAL STUDY SPONSOR|PATHOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2020-10-22|90
e|TR|9734ec2a-d06b-43e1-82a5-37764af17890|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|POINT|TUMOR MERGED|1|mL/(min*100mL)|OBSERVATION|||STUDY SUBJECT|ENDOCRINOLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-09-29|10
e|TR|9734ec2a-d06b-43e1-82a5-37764af17890|2|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|ug/L|EQUIVOCAL|1|uCi/kg|CT SCAN WITHOUT CONTRAST|||FRIEND|ONCOLOGIST 2|U|2|Visit_2|25|6|WASHOUT|2020-10-14|25
e|TR|9734ec2a-d06b-43e1-82a5-37764af17890|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|AU/mL|DECREASED|1|EP U|CELLULAR PROLIFERATION ASSAY|||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-10-29|40
e|TR|9734ec2a-d06b-43e1-82a5-37764af17890|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|mmol/s|FURTHER ENLARGEMENT FROM NADIR|1|/month|KNEMOMETRY||Y|SPOUSE|FORENSIC PATHOLOGIST|NA|4|Visit_4|65|1|WASHOUT|2020-11-23|65
e|TR|9734ec2a-d06b-43e1-82a5-37764af17890|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mAmp|ABSENT|1|Mile|MULTI-SLICE SPIRAL CT||Y|CAREGIVER|FORENSIC PATHOLOGIST|N|5|Visit_5|90|5|TREATMENT|2020-12-18|90
e|TR|9a0ce525-7f10-4651-885a-f64bd9c8925e|1|[?]|ACHNAD|Absolute Change From Nadir|[?]|umol/h/mmol|ENLARGEMENT|1|U/animal|REFRACTOMETRY|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-11-28|10
e|TR|9a0ce525-7f10-4651-885a-f64bd9c8925e|2|[?]|SUMDIAM|Sum of Diameter|[?]|SCOOPFUL|NORMAL|1|BAR|NUCLEIC ACID BASED METHOD|Y||SIBLING|NEUROLOGIST 2|Y|2|Visit_2|25|6|TREATMENT|2020-12-13|25
e|TR|9a0ce525-7f10-4651-885a-f64bd9c8925e|3|[?]|SUMVOL|Sum of Volume|[?]|gtt|EQUIVOCAL|1|mg2/dL2|LYMPHANGIOGRAPHY|||STUDY SUBJECT|RATER 1|Y|3|Visit_3|40|2|WASHOUT|2020-12-28|40
e|TR|9a0ce525-7f10-4651-885a-f64bd9c8925e|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|umol/dL|DECREASED|1|Bq/g|REVERSE TRANSCRIPTASE PCR|||CLINICAL RESEARCH COORDINATOR|READER|N|4|Visit_4|65|4|TREATMENT|2021-01-22|65
e|TR|9a0ce525-7f10-4651-885a-f64bd9c8925e|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mL/animal/wk|NON-PATHOLOGICAL|1|dpm/mg|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y||FAMILY MEMBER|OPHTHALMOLOGIST|NA|5|Visit_5|90|3|WASHOUT|2021-02-16|90
e|TR|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|1|[?]|RADIODEN|Radiodensity|[?]|oz|FURTHER ENLARGEMENT FROM NADIR|1|lm|IN SITU HYBRIDIZATION|||CLINICAL RESEARCH ASSOCIATE|UROLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-07-15|10
e|TR|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|2|[?]|NBNLNUM|Number of New Bone Lesions|[?]|IU|INCREASED|1|cm/min|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|Y|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|Y|2|Visit_2|25|1|FOLLOW-UP|2020-07-30|25
e|TR|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|3|[?]|SUMVOL|Sum of Volume|[?]|ug/m2/h|FOCALLY INCREASED|1|/4.0 mL|CHROMATOGRAPHY|||PARENT|READER 2|NA|3|Visit_3|40|4|TREATMENT|2020-08-14|40
e|TR|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|nmol/day|DECREASED|1|DAgU/mL|MICROBIAL BIOCHEMICAL IDENTIFICATION|||ADJUDICATOR|ENDOCRINOLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-09-08|65
e|TR|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|Absorbance U/mL|FURTHER ENLARGEMENT FROM NADIR|1|ug/dose|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||CLINICAL RESEARCH COORDINATOR|UROLOGIST|NA|5|Visit_5|90|2|TREATMENT|2020-10-03|90
e|TR|4ba88073-0003-461a-a950-4504ef7680e7|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|psi|INCREASED|1|amol|IMMUNODIFFUSION||Y|STUDY SUBJECT|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|3|TREATMENT|2020-09-02|10
e|TR|4ba88073-0003-461a-a950-4504ef7680e7|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mU/L|ENLARGEMENT FROM NADIR|1|C|CELL OF ORIGIN ASSAY|||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|6|SCREENING|2020-09-17|25
e|TR|4ba88073-0003-461a-a950-4504ef7680e7|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|Coulomb|ENLARGEMENT FROM NADIR|1|10^9 organisms/g|FARR ASSAY||Y|HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|3|Visit_3|40|7|TREATMENT|2020-10-02|40
e|TR|4ba88073-0003-461a-a950-4504ef7680e7|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mL/min|FURTHER ENLARGEMENT FROM NADIR|1|tsp|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y|DOMESTIC PARTNER|ONCOLOGIST|Y|4|Visit_4|65|7|WASHOUT|2020-10-27|65
e|TR|4ba88073-0003-461a-a950-4504ef7680e7|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|Joule|UNEQUIVOCAL|1|Ci/ug|ECHOCARDIOGRAPHY|||INTERVIEWER|READER 1|N|5|Visit_5|90|7|TREATMENT|2020-11-21|90
e|TR|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|1|[?]|ACHNAD|Absolute Change From Nadir|[?]|IU/kg/h|ENLARGEMENT FROM NADIR|1|10^12/L|NUCLEIC ACID BASED METHOD|||CAREGIVER|NEUROLOGIST|Y|1|Visit_1|10|5|WASHOUT|2020-09-01|10
e|TR|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|2|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|RNA copies/mL|DECREASED|1|uCi|X-RAY FLUORESCENCE SPECTROMETRY|||SPOUSE|MICROSCOPIST|NA|2|Visit_2|25|2|TREATMENT|2020-09-16|25
e|TR|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|GPL U/mL|UNCHANGED|1|uV*sec|MRI WITHOUT CONTRAST||Y|CLINICAL RESEARCH ASSOCIATE|READER|NA|3|Visit_3|40|1|TREATMENT|2020-10-01|40
e|TR|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|4|[?]|LDIAM|Longest Diameter|[?]|mL/mmHg/min/L|PRESENT|1|nL|MICRO BROTH DILUTION||Y|PARENT|RATER 2|N|4|Visit_4|65|2|TREATMENT|2020-10-26|65
e|TR|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|INHALATION|FURTHER ENLARGEMENT|1|Pa|PET/SPECT SCAN|||PARENT|READER 3|U|5|Visit_5|90|3|TREATMENT|2020-11-20|90
e|TR|f552fa78-d78f-44c5-9590-30a737e6652d|1|[?]|PALPSTAT|Palpable State|[?]|U/L|TUMOR MERGED|1|Pa|FUNCTIONAL MRI|Y||DOMESTIC PARTNER|READER|NA|1|Visit_1|10|3|TREATMENT|2020-10-05|10
e|TR|f552fa78-d78f-44c5-9590-30a737e6652d|2|[?]|NEWCONF|New Tumor Confirmed|[?]|mCi/kg|ABSENT|1|uV*sec|ELECTRICAL IMPEDANCE MYOGRAPHY|Y||FAMILY MEMBER|OPHTHALMOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-10-20|25
e|TR|f552fa78-d78f-44c5-9590-30a737e6652d|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|fmol|NORMAL|1|U/kg/h|ALCIAN BLUE STAIN|||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2020-11-04|40
e|TR|f552fa78-d78f-44c5-9590-30a737e6652d|4|[?]|VOLUME|Volume|[?]|RFU|ENLARGEMENT FROM NADIR|1|nmol BCE/L|TRANSMISSION ELECTRON MICROSCOPY|Y|Y|SIGNIFICANT OTHER|OPHTHALMOLOGIST|Y|4|Visit_4|65|4|SCREENING|2020-11-29|65
e|TR|f552fa78-d78f-44c5-9590-30a737e6652d|5|[?]|LESSCIND|Lesion Success Indicator|[?]|cm|ENLARGEMENT FROM NADIR|1|PA|AURAMINE STAIN||Y|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|N|5|Visit_5|90|6|SCREENING|2020-12-24|90
e|TR|38d83f86-d8ce-461a-a288-95aebe498d22|1|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|Bq/mg|ENLARGEMENT FROM NADIR|1|BU|FARNSWORTH-MUNSELL 100 HUE TEST|||ADJUDICATION COMMITTEE|NEUROLOGIST 2|Y|1|Visit_1|10|3|TREATMENT|2020-08-25|10
e|TR|38d83f86-d8ce-461a-a288-95aebe498d22|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|log10 CFU/mL|FURTHER ENLARGEMENT|1|ug/kg|GEL ELECTROPHORESIS|Y||SPOUSE|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-09-09|25
e|TR|38d83f86-d8ce-461a-a288-95aebe498d22|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|genEq|ENLARGEMENT FROM NADIR|1|U/dL|ELECTROCHEMILUMINESCENCE|Y||PROXY|MICROSCOPIST 2|Y|3|Visit_3|40|7|TREATMENT|2020-09-24|40
e|TR|38d83f86-d8ce-461a-a288-95aebe498d22|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|ug/min|INCREASED|1|VOXEL|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|4|Visit_4|65|1|FOLLOW-UP|2020-10-19|65
e|TR|38d83f86-d8ce-461a-a288-95aebe498d22|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|VIRTUAL PIXEL|FURTHER ENLARGEMENT FROM NADIR|1|V/sec|LASER CAPTURE MICRODISSECTION|||CLINICAL STUDY SPONSOR|RADIOLOGIST|U|5|Visit_5|90|7|TREATMENT|2020-11-13|90
e|TR|b31e8820-cc17-4ce5-af30-358dbeb12ba2|1|[?]|ORVERLN|Organ Vertical Length|[?]|MET*h|PALPABLE|1|JAR|MICROBIAL CULTURE|||PROXY|OTOLARYNGOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-08-13|10
e|TR|b31e8820-cc17-4ce5-af30-358dbeb12ba2|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|CFU/mL|PALPABLE|1|mgEq|LASER CAPTURE MICRODISSECTION|||SPOUSE|RATER 1|N|2|Visit_2|25|6|TREATMENT|2020-08-28|25
e|TR|b31e8820-cc17-4ce5-af30-358dbeb12ba2|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|um|TUMOR MERGED|1|cm|RULER MEASUREMENT METHOD|Y|Y|INTERVIEWER|PATHOLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-09-12|40
e|TR|b31e8820-cc17-4ce5-af30-358dbeb12ba2|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|mL/min/1.73m2|FOCALLY INCREASED|1|deg/s|TRANSMISSION ELECTRON MICROSCOPY||Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|U|4|Visit_4|65|1|TREATMENT|2020-10-07|65
e|TR|b31e8820-cc17-4ce5-af30-358dbeb12ba2|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|LENS|ENLARGEMENT FROM NADIR|1|deg/mm|ENZYMATIC ULTRACENTRIFUGATION|||CAREGIVER|PATHOLOGIST 1|U|5|Visit_5|90|5|SCREENING|2020-11-01|90
e|TR|cf39d5bd-7682-4546-8495-5bcf48600a69|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|U/m2/min|FOCALLY INCREASED|1|L|EEG|Y||CAREGIVER|OTOLARYNGOLOGIST|Y|1|Visit_1|10|7|SCREENING|2021-01-20|10
e|TR|cf39d5bd-7682-4546-8495-5bcf48600a69|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mol|FOCALLY INCREASED|1|Weber|SPECT/CT SCAN|Y||ADJUDICATION COMMITTEE|MICROSCOPIST 3|NA|2|Visit_2|25|7|WASHOUT|2021-02-04|25
e|TR|cf39d5bd-7682-4546-8495-5bcf48600a69|3|[?]|LPERP|Longest Perpendicular|[?]|IU/mmol|PRESENT|1|kHz|DC SHEATH FLOW|||VENDOR|READER 2|Y|3|Visit_3|40|2|TREATMENT|2021-02-19|40
e|TR|cf39d5bd-7682-4546-8495-5bcf48600a69|4|[?]|RADIODEN|Radiodensity|[?]|uL|FURTHER ENLARGEMENT|1|TRACE|ELISA|||SIGNIFICANT OTHER|DERMATOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2021-03-16|65
e|TR|cf39d5bd-7682-4546-8495-5bcf48600a69|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|mL/dose|PRESENT|1|RING|MALDI-TOF|||PARENT|ADJUDICATOR 3|U|5|Visit_5|90|4|TREATMENT|2021-04-10|90
e|TR|84c17e7b-8d56-4726-96a5-9ca41fb9d894|1|[?]|TUMSTATE|Tumor State|[?]|pg|FOCALLY INCREASED|1|mm2|MECHANICAL CLOT DETECTION|||INDEPENDENT ASSESSOR|MICROSCOPIST|N|1|Visit_1|10|6|SCREENING|2020-11-24|10
e|TR|84c17e7b-8d56-4726-96a5-9ca41fb9d894|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|/10^3|PALPABLE|1|usec|PULSE OXIMETRY|||INTERVIEWER|PATHOLOGIST 1|N|2|Visit_2|25|3|FOLLOW-UP|2020-12-09|25
e|TR|84c17e7b-8d56-4726-96a5-9ca41fb9d894|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|copies/mL|PALPABLE|1|ng/L|PHASE CONTRAST MICROSCOPY|||INDEPENDENT ASSESSOR|READER|Y|3|Visit_3|40|6|SCREENING|2020-12-24|40
e|TR|84c17e7b-8d56-4726-96a5-9ca41fb9d894|4|[?]|LPERP|Longest Perpendicular|[?]|ug/L FEU|PALPABLE|1|%|LANDOLT RING||Y|VENDOR|CARDIOLOGIST|N|4|Visit_4|65|1|SCREENING|2021-01-18|65
e|TR|84c17e7b-8d56-4726-96a5-9ca41fb9d894|5|[?]|LNSTATE|Lymph Node State|[?]|ugEq/L|NORMAL|1|/MBP|STATIC PERIMETRY|Y||VENDOR|RADIOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2021-02-12|90
e|TR|6e557fd7-efaf-4c86-806d-9bd66c7de7da|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mU|PRESENT|1|SUPPOSITORY|HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y||PARENT|PATHOLOGIST 1|Y|1|Visit_1|10|3|WASHOUT|2021-01-27|10
e|TR|6e557fd7-efaf-4c86-806d-9bd66c7de7da|2|[?]|BNLNUM|Number of Bone Lesions|[?]|mmol/mol|ENLARGEMENT FROM NADIR|1|ug/kg/day|DUKE INCISION METHOD|||PARENT|ADJUDICATOR 2|Y|2|Visit_2|25|1|SCREENING|2021-02-11|25
e|TR|6e557fd7-efaf-4c86-806d-9bd66c7de7da|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|PNU/mL|UNCHANGED|1|EU|NUCLEAR RADIOLOGY|||STUDY SUBJECT|NEUROLOGIST 1|N|3|Visit_3|40|6|TREATMENT|2021-02-26|40
e|TR|6e557fd7-efaf-4c86-806d-9bd66c7de7da|4|[?]|SUMDIAM|Sum of Diameter|[?]|CAPFUL|UNCHANGED|1|10^6 U|THIN SMEAR|Y||SPOUSE|RATER 2|Y|4|Visit_4|65|4|WASHOUT|2021-03-23|65
e|TR|6e557fd7-efaf-4c86-806d-9bd66c7de7da|5|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|cd/m2|ENLARGEMENT FROM NADIR|1|cd/m2|FLUORESCENT ENZYME IMMUNOASSAY|Y|Y|SIGNIFICANT OTHER|RADIOLOGIST 2|U|5|Visit_5|90|3|SCREENING|2021-04-17|90
e|TR|2b25e1f9-929c-4bdc-8758-79f33b832026|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|mg/kg/min|FURTHER ENLARGEMENT|1|RING|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||INVESTIGATOR|READER 1|Y|1|Visit_1|10|6|SCREENING|2020-10-19|10
e|TR|2b25e1f9-929c-4bdc-8758-79f33b832026|2|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|NEEDLE GAUGE|NON-PATHOLOGICAL|1|10^6 IU/mL|DOUBLE IMMUNODIFFUSION||Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|2|Visit_2|25|4|WASHOUT|2020-11-03|25
e|TR|2b25e1f9-929c-4bdc-8758-79f33b832026|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mJoule/cm2|PATHOLOGICAL|1|mmol/min/kPa/L|COMPUTERIZED CORNEAL TOPOGRAPHY|||INDEPENDENT ASSESSOR|RADIOLOGIST|N|3|Visit_3|40|7|TREATMENT|2020-11-18|40
e|TR|2b25e1f9-929c-4bdc-8758-79f33b832026|4|[?]|VDIAM|Viable Diameter|[?]|uCi/L|FURTHER ENLARGEMENT|1|10^5/hpf|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||CLINICAL RESEARCH ASSOCIATE|READER|NA|4|Visit_4|65|1|SCREENING|2020-12-13|65
e|TR|2b25e1f9-929c-4bdc-8758-79f33b832026|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|Bq/mg|INCREASED|1|10^12/L|TRANSTHORACIC ECHOCARDIOGRAPHY|Y||INVESTIGATOR|PHYSIOTHERAPIST|NA|5|Visit_5|90|5|FOLLOW-UP|2021-01-07|90
e|TR|d02c7553-17f5-44ec-8c24-469234d080e8|1|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|NEBULE|INCREASED|1|anti-Xa IU/mL|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y||GUARDIAN|INTERNIST|N|1|Visit_1|10|6|FOLLOW-UP|2021-01-26|10
e|TR|d02c7553-17f5-44ec-8c24-469234d080e8|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|EIA unit|FURTHER ENLARGEMENT|1|/MBP|REFLECTANCE SPECTROSCOPY||Y|GUARDIAN|READER 2|Y|2|Visit_2|25|7|WASHOUT|2021-02-10|25
e|TR|d02c7553-17f5-44ec-8c24-469234d080e8|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mV/sec|TUMOR MERGED|1|PFU|SANGER SEQUENCING|||DOMESTIC PARTNER|RADIOLOGIST 2|N|3|Visit_3|40|2|TREATMENT|2021-02-25|40
e|TR|d02c7553-17f5-44ec-8c24-469234d080e8|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|/LSQN|DECREASED|1|IMPLANT|NON-INVASIVE DIELECTRIC SENSING|Y||INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|7|FOLLOW-UP|2021-03-22|65
e|TR|d02c7553-17f5-44ec-8c24-469234d080e8|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|/VF|ABSENT|1|CYLINDER|WRIGHT-GIEMSA STAIN|||VENDOR|ONCOLOGIST 1|U|5|Visit_5|90|7|WASHOUT|2021-04-16|90
e|TR|e819939e-548d-4e05-83e3-7976790de7e1|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|Log10 ELISA unit|EQUIVOCAL|1|nmol/L|CYSTOMETRY||Y|PARENT|PATHOLOGIST 1|Y|1|Visit_1|10|4|SCREENING|2020-09-07|10
e|TR|e819939e-548d-4e05-83e3-7976790de7e1|2|[?]|DIAMETER|Diameter|[?]|mL/beat|UNEQUIVOCAL|1|mL/mmHg/min/L|PERCUSSION|Y|Y|PROXY|READER 3|N|2|Visit_2|25|6|FOLLOW-UP|2020-09-22|25
e|TR|e819939e-548d-4e05-83e3-7976790de7e1|3|[?]|LESSCIND|Lesion Success Indicator|[?]|CUP|NON-PATHOLOGICAL|1|log10 IU/mL|SANGER SEQUENCING||Y|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|Y|3|Visit_3|40|4|FOLLOW-UP|2020-10-07|40
e|TR|e819939e-548d-4e05-83e3-7976790de7e1|4|[?]|TUMSTATE|Tumor State|[?]|uCi/kg|UNCHANGED|1|PIXELS/cm|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||INVESTIGATOR|MICROSCOPIST 1|N|4|Visit_4|65|7|TREATMENT|2020-11-01|65
e|TR|e819939e-548d-4e05-83e3-7976790de7e1|5|[?]|CALCFIND|Calcification Indicator|[?]|log10 TCID 50/mL|PALPABLE|1|dL|WESTERN BLOT|Y|Y|PARENT|RATER 2|U|5|Visit_5|90|5|FOLLOW-UP|2020-11-26|90
e|TR|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|cmol|FOCALLY INCREASED|1|Bq/kg|GC/MS||Y|NON-HEALTH CARE PROFESSIONAL|INTERNIST|U|1|Visit_1|10|3|TREATMENT|2020-08-18|10
e|TR|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|g/kg|NORMAL|1|U/mL|HPLC/MS|||ADJUDICATOR|RATER|NA|2|Visit_2|25|6|FOLLOW-UP|2020-09-02|25
e|TR|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|cal|PRESENT|1|L/h|GC/MS-CI||Y|STUDY SUBJECT|ADJUDICATOR|NA|3|Visit_3|40|5|TREATMENT|2020-09-17|40
e|TR|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|4|[?]|NEWCONF|New Tumor Confirmed|[?]|m3|INCREASED|1|g/g/day|HIGH RESOLUTION CT|Y||CLINICAL STUDY SPONSOR|PATHOLOGIST 2|Y|4|Visit_4|65|5|TREATMENT|2020-10-12|65
e|TR|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|kIU|PATHOLOGICAL|1|mU|FLUORESCENT MICROSCOPY||Y|SIBLING|ONCOLOGIST 2|NA|5|Visit_5|90|6|FOLLOW-UP|2020-11-06|90
e|TR|ea5229ad-6469-4147-be40-546d27c04c4c|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|Sv|ENLARGEMENT|1|uEq/L|SNP ARRAY|||ADJUDICATOR|OTOLARYNGOLOGIST|N|1|Visit_1|10|5|TREATMENT|2020-06-09|10
e|TR|ea5229ad-6469-4147-be40-546d27c04c4c|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|ug/day|ENLARGEMENT|1|IU/g Hb|REFLECTANCE SPECTROSCOPY|Y||SPOUSE|ENDOCRINOLOGIST|N|2|Visit_2|25|3|FOLLOW-UP|2020-06-24|25
e|TR|ea5229ad-6469-4147-be40-546d27c04c4c|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|10^8/L|NORMAL|1|ug/dose|GC/FID|Y|Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|3|WASHOUT|2020-07-09|40
e|TR|ea5229ad-6469-4147-be40-546d27c04c4c|4|[?]|PALPSTAT|Palpable State|[?]|mL/cm3/min|INCREASED|1|DAgU|MAMMOGRAPHY||Y|PARENT|OPTOMETRIST|N|4|Visit_4|65|4|FOLLOW-UP|2020-08-03|65
e|TR|ea5229ad-6469-4147-be40-546d27c04c4c|5|[?]|PCHGBL|Percent Change From Baseline|[?]|foz_us|FOCALLY INCREASED|1|10^3 organisms|ELLA|||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|5|Visit_5|90|5|TREATMENT|2020-08-28|90
e|TR|0a566742-0f71-4603-85f0-875e2c3395e7|1|[?]|RADIODEN|Radiodensity|[?]|g/m2|NONPALPABLE|1|VIAL|LAPAROSCOPY|Y||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|1|Visit_1|10|6|TREATMENT|2021-01-08|10
e|TR|0a566742-0f71-4603-85f0-875e2c3395e7|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|cg|EQUIVOCAL|1|10^9 CFU/g|NEXT GENERATION SEQUENCING|||INTERVIEWER|MICROSCOPIST 2|N|2|Visit_2|25|4|TREATMENT|2021-01-23|25
e|TR|0a566742-0f71-4603-85f0-875e2c3395e7|3|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|TRANSDUCING UNIT|ENLARGEMENT FROM NADIR|1|CONTAINER|PHASE-CONTRAST MRI|||ADJUDICATOR|ONCOLOGIST 1|Y|3|Visit_3|40|7|TREATMENT|2021-02-07|40
e|TR|0a566742-0f71-4603-85f0-875e2c3395e7|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|L|UNEQUIVOCAL|1|mL/animal|HEMATOXYLIN AND EOSIN STAIN|||FAMILY MEMBER|NEUROLOGIST 2|NA|4|Visit_4|65|1|SCREENING|2021-03-04|65
e|TR|0a566742-0f71-4603-85f0-875e2c3395e7|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|g/m2|PATHOLOGICAL|1|100 IU/mL|DIRECT SEQUENCING|Y||CLINICAL STUDY SPONSOR|MICROSCOPIST|NA|5|Visit_5|90|4|TREATMENT|2021-03-29|90
e|TR|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|1|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|ug/m2/min|UNCHANGED|1|mCi/kg|TELLER ACUITY CARDS|||GUARDIAN|RATER 2|N|1|Visit_1|10|6|TREATMENT|2020-05-14|10
e|TR|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|MBq/uL|EQUIVOCAL|1|foz_us|PERCUSSION|||CLINICAL RESEARCH ASSOCIATE|RATER 2|U|2|Visit_2|25|4|SCREENING|2020-05-29|25
e|TR|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|3|[?]|AREA|Area|[?]|CCID 50/mL|FURTHER ENLARGEMENT|1|U/m2/day|DYNAMIC CONTRAST ENHANCED MRI||Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|3|Visit_3|40|1|WASHOUT|2020-06-13|40
e|TR|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|IU/g|FOCALLY INCREASED|1|Pa|INDIRECT IMMUNOFLUORESCENCE|||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|6|SCREENING|2020-07-08|65
e|TR|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|5|[?]|LDIAM|Longest Diameter|[?]|titer|PATHOLOGICAL|1|mg/g/h|IMMUNOFLUORESCENT STAIN|Y||NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|NA|5|Visit_5|90|4|WASHOUT|2020-08-02|90
e|TR|48103500-0f3d-4108-9167-6afee1098773|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|10^6/L|PRESENT|1|CFU/mL|CARDIAC THERMODILUTION||Y|FAMILY MEMBER|UROLOGIST|U|1|Visit_1|10|5|SCREENING|2020-05-15|10
e|TR|48103500-0f3d-4108-9167-6afee1098773|2|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|EID 50/dose|FURTHER ENLARGEMENT|1|mg/g/min|CONTRAST ENHANCED PET SCAN|Y||PARENT|RATER 1|U|2|Visit_2|25|6|WASHOUT|2020-05-30|25
e|TR|48103500-0f3d-4108-9167-6afee1098773|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|pt_us|PRESENT|1|mU|INDIA INK STAIN||Y|GUARDIAN|MICROSCOPIST 2|U|3|Visit_3|40|5|TREATMENT|2020-06-14|40
e|TR|48103500-0f3d-4108-9167-6afee1098773|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|anti-Xa IU/mL|ABSENT|1|mg/cm2|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|Y||PROXY|READER|Y|4|Visit_4|65|2|FOLLOW-UP|2020-07-09|65
e|TR|48103500-0f3d-4108-9167-6afee1098773|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|POUCH|NON-PATHOLOGICAL|1|mmHg|CELL BASED BIOASSAY|Y||CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|Y|5|Visit_5|90|5|TREATMENT|2020-08-03|90
e|TR|9855fc59-f162-48ba-8c51-e8c6c54b72f3|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|deg|FOCALLY INCREASED|1|days/month|VIRUS PLAQUE ASSAY|||INDEPENDENT ASSESSOR|NEUROLOGIST|Y|1|Visit_1|10|4|FOLLOW-UP|2020-07-25|10
e|TR|9855fc59-f162-48ba-8c51-e8c6c54b72f3|2|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|mV*min|TUMOR MERGED|1|keV|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y||HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-08-09|25
e|TR|9855fc59-f162-48ba-8c51-e8c6c54b72f3|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|kPa|ENLARGEMENT FROM NADIR|1|nmol BCE/L|IMMUNOCHEMILUMINOMETRIC ASSAY|||INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|3|TREATMENT|2020-08-24|40
e|TR|9855fc59-f162-48ba-8c51-e8c6c54b72f3|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|10^7 PFU|ENLARGEMENT|1|FINGERTIP UNIT|AGAR DILUTION|||ADJUDICATION COMMITTEE|ADJUDICATOR|NA|4|Visit_4|65|1|TREATMENT|2020-09-18|65
e|TR|9855fc59-f162-48ba-8c51-e8c6c54b72f3|5|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|YEARS|EQUIVOCAL|1|umol|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|NA|5|Visit_5|90|5|TREATMENT|2020-10-13|90
e|TR|ceab42b0-3a7e-4aad-b599-5da311398148|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|yd|PRESENT|1|mL/min/1.73m2|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-06-21|10
e|TR|ceab42b0-3a7e-4aad-b599-5da311398148|2|[?]|CALCFIND|Calcification Indicator|[?]|/2500 WBC|NORMAL|1|10^9 CFU/mL|POLYSOMNOGRAPHY||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|2|Visit_2|25|5|FOLLOW-UP|2020-07-06|25
e|TR|ceab42b0-3a7e-4aad-b599-5da311398148|3|[?]|NEWCONF|New Tumor Confirmed|[?]|s*kPa|UNEQUIVOCAL|1|Siemens|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|Y||CLINICAL RESEARCH COORDINATOR|READER 3|Y|3|Visit_3|40|6|TREATMENT|2020-07-21|40
e|TR|ceab42b0-3a7e-4aad-b599-5da311398148|4|[?]|LDIAM|Longest Diameter|[?]|kIU|PRESENT|1|U|ECHOCARDIOGRAPHY||Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|4|Visit_4|65|5|WASHOUT|2020-08-15|65
e|TR|ceab42b0-3a7e-4aad-b599-5da311398148|5|[?]|AREA|Area|[?]|ng/dL|TUMOR MERGED|1|mg/mol|KARYOTYPING|Y||NON-HEALTH CARE PROFESSIONAL|RATER|Y|5|Visit_5|90|3|FOLLOW-UP|2020-09-09|90
e|TR|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|mg/kg/day|ENLARGEMENT FROM NADIR|1|ppm|CONTRAST ENHANCED SPIRAL CT SCAN|||SPOUSE|ADJUDICATOR 1|Y|1|Visit_1|10|3|WASHOUT|2020-07-09|10
e|TR|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|2|[?]|PALPSTAT|Palpable State|[?]|umol/L/min|UNEQUIVOCAL|1|pmol/L/h|SPECT SCAN|Y|Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|2|Visit_2|25|5|WASHOUT|2020-07-24|25
e|TR|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|U/g/h|INCREASED|1|dmol|IHC|||INDEPENDENT ASSESSOR|UROLOGIST|U|3|Visit_3|40|6|WASHOUT|2020-08-08|40
e|TR|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|4|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|kN/cm2|UNEQUIVOCAL|1|Pack Year|ELECTRONEUROGRAPHY||Y|FAMILY MEMBER|PATHOLOGIST|Y|4|Visit_4|65|3|WASHOUT|2020-09-02|65
e|TR|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|5|[?]|PPD|Product of Perpendicular Diameters|[?]|nmol|FOCALLY INCREASED|1|nmol BCE/L|BETA LACTAMASE||Y|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|U|5|Visit_5|90|3|FOLLOW-UP|2020-09-27|90
e|TR|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|1|[?]|PPD|Product of Perpendicular Diameters|[?]|uU/dL|FURTHER ENLARGEMENT FROM NADIR|1|HOMEOPATHIC DILUTION|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||PARENT|ADJUDICATOR 1|N|1|Visit_1|10|1|TREATMENT|2020-07-10|10
e|TR|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|2|[?]|RADIODEN|Radiodensity|[?]|mL/cm|PRESENT|1|ukat/10^12 RBC|PET/CT SCAN WITHOUT CONTRAST|||PROXY|ONCOLOGIST 1|Y|2|Visit_2|25|3|WASHOUT|2020-07-25|25
e|TR|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|CFU/g|DIFFUSELY INCREASED|1|CAPFUL|MOUSE PROTECTION ASSAY|Y||FRIEND|RATER 1|Y|3|Visit_3|40|7|TREATMENT|2020-08-09|40
e|TR|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mL/g/day|PATHOLOGICAL|1|cd*s/m2|HILLMEN COLOR CHART|||GUARDIAN|RATER 2|U|4|Visit_4|65|7|FOLLOW-UP|2020-09-03|65
e|TR|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|5|[?]|PCHGBL|Percent Change From Baseline|[?]|Ci|UNEQUIVOCAL|1|Mile|PET/CT SCAN WITHOUT CONTRAST|||NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-09-28|90
e|TR|36a54b72-6368-460e-ab4c-952923e0fd14|1|[?]|LDIAM|Longest Diameter|[?]|/2000 RBC|DECREASED|1|mCi/L|PANENDOSCOPY|Y|Y|CHILD|ONCOLOGIST 2|U|1|Visit_1|10|3|WASHOUT|2020-05-15|10
e|TR|36a54b72-6368-460e-ab4c-952923e0fd14|2|[?]|TUMSTATE|Tumor State|[?]|cm/min|DECREASED|1|mU/g|DNA MICROARRAY||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|2|Visit_2|25|3|TREATMENT|2020-05-30|25
e|TR|36a54b72-6368-460e-ab4c-952923e0fd14|3|[?]|ORVERLN|Organ Vertical Length|[?]|L|NONPALPABLE|1|U.CARR|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||CAREGIVER|ADJUDICATOR|N|3|Visit_3|40|1|WASHOUT|2020-06-14|40
e|TR|36a54b72-6368-460e-ab4c-952923e0fd14|4|[?]|PPD|Product of Perpendicular Diameters|[?]|nmol/mL/min|UNEQUIVOCAL|1|TCID 50/dose|EPSILOMETER|||PARENT|RATER|U|4|Visit_4|65|7|TREATMENT|2020-07-09|65
e|TR|36a54b72-6368-460e-ab4c-952923e0fd14|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|Arbitrary U|INCREASED|1|mmol/min/kPa/L|CHROMATOGRAPHY|||DOMESTIC PARTNER|READER 3|N|5|Visit_5|90|5|TREATMENT|2020-08-03|90
e|TR|84e56692-9a33-472a-9ddc-545d3342da34|1|[?]|AREA|Area|[?]|mCi|PALPABLE|1|mEq/L|GRAM STAIN|||GUARDIAN|INTERNIST|Y|1|Visit_1|10|5|TREATMENT|2020-12-19|10
e|TR|84e56692-9a33-472a-9ddc-545d3342da34|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|SACHET|FURTHER ENLARGEMENT|1|SPRAY|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|Y||FRIEND|PHYSIOTHERAPIST|N|2|Visit_2|25|6|SCREENING|2021-01-03|25
e|TR|84e56692-9a33-472a-9ddc-545d3342da34|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|pg/L|FOCALLY INCREASED|1|ng/day|LAPAROSCOPY||Y|FAMILY MEMBER|NEUROLOGIST 1|N|3|Visit_3|40|1|WASHOUT|2021-01-18|40
e|TR|84e56692-9a33-472a-9ddc-545d3342da34|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mL/kg|NORMAL|1|nmol|IMPEDANCE CONDUCTIVITY||Y|INDEPENDENT ASSESSOR|NEUROLOGIST|NA|4|Visit_4|65|2|FOLLOW-UP|2021-02-12|65
e|TR|84e56692-9a33-472a-9ddc-545d3342da34|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|ug/day|FURTHER ENLARGEMENT FROM NADIR|1|m3|AURAMINE STAIN|||INTERVIEWER|READER 3|N|5|Visit_5|90|4|TREATMENT|2021-03-09|90
e|TR|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|1|[?]|BNLNUM|Number of Bone Lesions|[?]|BU/mL|TUMOR MERGED|1|10^6 organisms/g|SPIRAL CT SCAN WITHOUT CONTRAST|||CLINICAL RESEARCH ASSOCIATE|READER|NA|1|Visit_1|10|1|FOLLOW-UP|2020-05-31|10
e|TR|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|cmH2O*s/mL|FOCALLY INCREASED|1|U.CARR|FLUORESCENT SPOT TEST|||INVESTIGATOR|INTERNIST|N|2|Visit_2|25|6|SCREENING|2020-06-15|25
e|TR|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|3|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|Torr|DECREASED|1|Osm|HPLC-UV|Y||SIBLING|HEMATOLOGIST|Y|3|Visit_3|40|6|FOLLOW-UP|2020-06-30|40
e|TR|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mAnson U/mL|DECREASED|1|uIU/dL|SMEAR|Y||CAREGIVER|MICROSCOPIST 2|Y|4|Visit_4|65|2|TREATMENT|2020-07-25|65
e|TR|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|ELISA unit/dose|NON-PATHOLOGICAL|1|g/cage/day|WESTERN BLOT|Y|Y|INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-08-19|90
e|TR|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|DAYS|NON-PATHOLOGICAL|1|OI50|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||CLINICAL STUDY SPONSOR|READER 3|N|1|Visit_1|10|6|FOLLOW-UP|2020-06-10|10
e|TR|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|10^6 RNA copies/mL|PATHOLOGICAL|1|dB|LASER CAPTURE MICRODISSECTION|||CLINICAL RESEARCH ASSOCIATE|UROLOGIST|Y|2|Visit_2|25|4|SCREENING|2020-06-25|25
e|TR|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|m3|DECREASED|1|PACK|DYNAMIC CONTRAST ENHANCED MRI|Y|Y|CHILD|ONCOLOGIST 1|N|3|Visit_3|40|6|SCREENING|2020-07-10|40
e|TR|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mol/mL|PRESENT|1|mL/animal/wk|IMMUNOTURBIDIMETRY|||SPOUSE|FORENSIC PATHOLOGIST|NA|4|Visit_4|65|7|FOLLOW-UP|2020-08-04|65
e|TR|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|mol/day|NONPALPABLE|1|10^6 RNA copies/mL|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|5|Visit_5|90|5|WASHOUT|2020-08-29|90
e|TR|ae0e05c1-3953-4406-bfae-299295c1fa4c|1|[?]|PPD|Product of Perpendicular Diameters|[?]|HOURS|PALPABLE|1|ug/kg/day|SPECTROPHOTOMETRY||Y|SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|1|WASHOUT|2021-01-12|10
e|TR|ae0e05c1-3953-4406-bfae-299295c1fa4c|2|[?]|ORVERLN|Organ Vertical Length|[?]|ppb|DIFFUSELY INCREASED|1|kDa|MICRONEUTRALIZATION ASSAY|Y|Y|PROXY|READER 3|N|2|Visit_2|25|2|WASHOUT|2021-01-27|25
e|TR|ae0e05c1-3953-4406-bfae-299295c1fa4c|3|[?]|AREA|Area|[?]|mg/kg|NORMAL|1|mL/animal|URANYL ACETATE STAIN|Y||SIGNIFICANT OTHER|MICROSCOPIST|NA|3|Visit_3|40|3|FOLLOW-UP|2021-02-11|40
e|TR|ae0e05c1-3953-4406-bfae-299295c1fa4c|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|kBq/uL|NONPALPABLE|1|tsp|MEDIASTINOSCOPY|||SIBLING|RADIOLOGIST 1|NA|4|Visit_4|65|6|FOLLOW-UP|2021-03-08|65
e|TR|ae0e05c1-3953-4406-bfae-299295c1fa4c|5|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|HOURS|FOCALLY INCREASED|1|dyn|IODINE STAIN|Y||PARENT|ONCOLOGIST 1|NA|5|Visit_5|90|3|FOLLOW-UP|2021-04-02|90
e|TR|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|MASK|PATHOLOGICAL|1|IU/kg|MULTI-SLICE SPIRAL CT|Y|Y|GUARDIAN|ENDOCRINOLOGIST|U|1|Visit_1|10|4|TREATMENT|2021-01-16|10
e|TR|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|10^6 CFU/mL|PATHOLOGICAL|1|DDU|TEMPLATE INCISION METHOD|||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|Y|2|Visit_2|25|5|WASHOUT|2021-01-31|25
e|TR|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|cmol|NON-PATHOLOGICAL|1|anti-Xa IU|TRIPLE-PHASE SPIRAL CT SCAN|||VENDOR|NEUROLOGIST|Y|3|Visit_3|40|2|TREATMENT|2021-02-15|40
e|TR|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|mV|PALPABLE|1|ppth|NUCLEAR RADIOLOGY|||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|Y|4|Visit_4|65|7|TREATMENT|2021-03-12|65
e|TR|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|CAPLET|FOCALLY INCREASED|1|keV|ELECTROGASTROGRAPHY|Y||INVESTIGATOR|MICROSCOPIST|N|5|Visit_5|90|4|TREATMENT|2021-04-06|90
e|TR|ab09e76d-8bbf-4126-a60d-08d6b5292836|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|ug/kg/h|PALPABLE|1|mEq/kg|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y|INTERVIEWER|UROLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-12-25|10
e|TR|ab09e76d-8bbf-4126-a60d-08d6b5292836|2|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|Absorbance U|UNCHANGED|1|mg/m2/min|SINGLE-SLICE SPIRAL CT|||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2021-01-09|25
e|TR|ab09e76d-8bbf-4126-a60d-08d6b5292836|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|10^8/L|PALPABLE|1|mg/animal|OPTICAL COHERENCE TOMOGRAPHY||Y|STUDY SUBJECT|PHYSIOTHERAPIST|NA|3|Visit_3|40|7|SCREENING|2021-01-24|40
e|TR|ab09e76d-8bbf-4126-a60d-08d6b5292836|4|[?]|LNSTATE|Lymph Node State|[?]|GPL U/mL|DIFFUSELY INCREASED|1|log10 IU/mL|IMMUNODIFFUSION|||INTERVIEWER|CARDIOLOGIST|U|4|Visit_4|65|7|TREATMENT|2021-02-18|65
e|TR|ab09e76d-8bbf-4126-a60d-08d6b5292836|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|Absorbance U|ENLARGEMENT FROM NADIR|1|ft|FLOCCULATION|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|5|Visit_5|90|1|FOLLOW-UP|2021-03-15|90
e|TR|8b7e3909-4115-4736-b07a-e0b6c382aa7e|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|gMFI|ENLARGEMENT FROM NADIR|1|Anson U|ISHIHARA COLOR PLATES|Y|Y|PROXY|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|2|FOLLOW-UP|2020-07-11|10
e|TR|8b7e3909-4115-4736-b07a-e0b6c382aa7e|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|IU/dL|ENLARGEMENT FROM NADIR|1|IU/kg/h|FREEZING POINT DEPRESSION|||GUARDIAN|HEMATOLOGIST|NA|2|Visit_2|25|6|WASHOUT|2020-07-26|25
e|TR|8b7e3909-4115-4736-b07a-e0b6c382aa7e|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|10^7 PFU|NORMAL|1|ms/mmHg|NUCLEIC ACID BASED METHOD|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|Y|3|Visit_3|40|3|WASHOUT|2020-08-10|40
e|TR|8b7e3909-4115-4736-b07a-e0b6c382aa7e|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|CFU/mL|PATHOLOGICAL|1|mm3/mm2/year|AUTOMATED COUNT|||DOMESTIC PARTNER|MICROSCOPIST 2|N|4|Visit_4|65|1|SCREENING|2020-09-04|65
e|TR|8b7e3909-4115-4736-b07a-e0b6c382aa7e|5|[?]|LDIAM|Longest Diameter|[?]|/LSQN|NON-PATHOLOGICAL|1|mmHg|FREEZING POINT DEPRESSION|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|5|Visit_5|90|2|FOLLOW-UP|2020-09-29|90
e|TR|187b2279-526f-4978-89d4-d2da56cc2257|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|dram|FURTHER ENLARGEMENT|1|EID 50/dose|MODIFIED ACID FAST STAIN|Y||FAMILY MEMBER|RATER 1|U|1|Visit_1|10|1|FOLLOW-UP|2020-06-21|10
e|TR|187b2279-526f-4978-89d4-d2da56cc2257|2|[?]|VDIAM|Viable Diameter|[?]|bel|PRESENT|1|foz_us|TRIPLE-PHASE MRI SCAN|||DOMESTIC PARTNER|INTERNIST|N|2|Visit_2|25|1|WASHOUT|2020-07-06|25
e|TR|187b2279-526f-4978-89d4-d2da56cc2257|3|[?]|CALCFIND|Calcification Indicator|[?]|Log10 ELISA unit/dose|ABSENT|1|10^6 organisms/g|MICROBIAL CULTURE, SOLID||Y|CHILD|DERMATOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-07-21|40
e|TR|187b2279-526f-4978-89d4-d2da56cc2257|4|[?]|DIAMETER|Diameter|[?]|mN|PATHOLOGICAL|1|nmol/day|FISH|Y|Y|PROXY|ADJUDICATOR 2|NA|4|Visit_4|65|7|WASHOUT|2020-08-15|65
e|TR|187b2279-526f-4978-89d4-d2da56cc2257|5|[?]|NEWCONF|New Tumor Confirmed|[?]|uL/mL|TUMOR MERGED|1|GBq/g|FLUORESCEIN STAIN|Y||CHILD|READER|U|5|Visit_5|90|7|WASHOUT|2020-09-09|90
e|TR|53506a04-dedb-495b-8e35-0576cdf1b323|1|[?]|LNSTATE|Lymph Node State|[?]|PACKAGE|INCREASED|1|PELLET|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|N|1|Visit_1|10|3|WASHOUT|2020-11-07|10
e|TR|53506a04-dedb-495b-8e35-0576cdf1b323|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|HOMEOPATHIC DILUTION|INCREASED|1|in|PULSE OXIMETRY|||CHILD|MICROSCOPIST 3|N|2|Visit_2|25|4|TREATMENT|2020-11-22|25
e|TR|53506a04-dedb-495b-8e35-0576cdf1b323|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|pkat/L|ABSENT|1|ug/mL/h|RULER MEASUREMENT METHOD|Y||SIBLING|READER 2|Y|3|Visit_3|40|6|WASHOUT|2020-12-07|40
e|TR|53506a04-dedb-495b-8e35-0576cdf1b323|4|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|ms2|DIFFUSELY INCREASED|1|mL/animal/day|ATOMIC ABSORPTION SPECTROMETRY||Y|SIGNIFICANT OTHER|MICROSCOPIST 1|N|4|Visit_4|65|2|WASHOUT|2021-01-01|65
e|TR|53506a04-dedb-495b-8e35-0576cdf1b323|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|dyn|PALPABLE|1|mL/kg|BIOPSY||Y|INDEPENDENT ASSESSOR|HEMATOLOGIST|U|5|Visit_5|90|1|SCREENING|2021-01-26|90
e|TR|defa600c-4205-476e-a40c-690cb16769b3|1|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|TROCHE|NONPALPABLE|1|mL/sec/1.73m2|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||SIGNIFICANT OTHER|NEUROLOGIST 2|U|1|Visit_1|10|6|FOLLOW-UP|2021-01-24|10
e|TR|defa600c-4205-476e-a40c-690cb16769b3|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|RING|FOCALLY INCREASED|1|ug/m2/min|RADIOIMMUNOPRECIPITATION ASSAY|||PARENT|DERMATOLOGIST|N|2|Visit_2|25|5|TREATMENT|2021-02-08|25
e|TR|defa600c-4205-476e-a40c-690cb16769b3|3|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|mm2|FURTHER ENLARGEMENT|1|10^4/hpf|FLUORESCENT ENZYME IMMUNOASSAY|||INTERVIEWER|RADIOLOGIST 2|NA|3|Visit_3|40|3|SCREENING|2021-02-23|40
e|TR|defa600c-4205-476e-a40c-690cb16769b3|4|[?]|LDIAM|Longest Diameter|[?]|SACHET|FURTHER ENLARGEMENT FROM NADIR|1|HOMEOPATHIC DILUTION|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y||PROXY|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|6|WASHOUT|2021-03-20|65
e|TR|defa600c-4205-476e-a40c-690cb16769b3|5|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|pt_us|EQUIVOCAL|1|RATIO|CONTRAST ENHANCED PET SCAN|||FRIEND|READER|NA|5|Visit_5|90|5|TREATMENT|2021-04-14|90
e|TR|e5092583-4259-40ba-a6a2-eeef6607263b|1|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mCi|FOCALLY INCREASED|1|amp|X-RAY|||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|NA|1|Visit_1|10|4|WASHOUT|2020-09-16|10
e|TR|e5092583-4259-40ba-a6a2-eeef6607263b|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|ug/min|NON-PATHOLOGICAL|1|pkat/L|PHOROPTER||Y|ADJUDICATION COMMITTEE|NEUROLOGIST 1|U|2|Visit_2|25|5|FOLLOW-UP|2020-10-01|25
e|TR|e5092583-4259-40ba-a6a2-eeef6607263b|3|[?]|CALCFIND|Calcification Indicator|[?]|10^6 IU|ENLARGEMENT|1|%/s|LIGHT SCATTERING SPECTROSCOPY||Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-10-16|40
e|TR|e5092583-4259-40ba-a6a2-eeef6607263b|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|pt_br|PRESENT|1|amu|FUNCTIONAL MRI|||CHILD|RADIOLOGIST|N|4|Visit_4|65|4|TREATMENT|2020-11-10|65
e|TR|e5092583-4259-40ba-a6a2-eeef6607263b|5|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|g/g|ABSENT|1|usec|INTRAVASCULAR ULTRASOUND||Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|5|Visit_5|90|5|SCREENING|2020-12-05|90
e|TR|461196d1-1213-4e5f-9bac-71f097b6cfdb|1|[?]|ORSTATE|Organ State|[?]|100 IU/mL|NORMAL|1|Roentgen|MICROBIAL CULTURE, SOLID|||INVESTIGATOR|RATER 2|N|1|Visit_1|10|6|SCREENING|2020-11-13|10
e|TR|461196d1-1213-4e5f-9bac-71f097b6cfdb|2|[?]|DIAMETER|Diameter|[?]|L|NON-PATHOLOGICAL|1|ms/mmHg|HEMAGGLUTINATION ASSAY||Y|FRIEND|PHYSIOTHERAPIST|N|2|Visit_2|25|6|FOLLOW-UP|2020-11-28|25
e|TR|461196d1-1213-4e5f-9bac-71f097b6cfdb|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|g/U|NONPALPABLE|1|L/s|PET/SPECT SCAN|Y||FRIEND|READER 3|NA|3|Visit_3|40|7|TREATMENT|2020-12-13|40
e|TR|461196d1-1213-4e5f-9bac-71f097b6cfdb|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|kBq/uL|TUMOR MERGED|1|TRACE|POLYMERASE CHAIN REACTION|||FRIEND|ADJUDICATOR 3|N|4|Visit_4|65|2|TREATMENT|2021-01-07|65
e|TR|461196d1-1213-4e5f-9bac-71f097b6cfdb|5|[?]|SUMDIAM|Sum of Diameter|[?]|/100 HPFs|INCREASED|1|IMPLANT|STATIC PERIMETRY|||DOMESTIC PARTNER|OPTOMETRIST|Y|5|Visit_5|90|6|TREATMENT|2021-02-01|90
e|TR|4c82922a-55d0-45b9-a7bb-4edac32b0f68|1|[?]|PPD|Product of Perpendicular Diameters|[?]|PIXEL|UNEQUIVOCAL|1|mL/100g/min|CORONARY ANGIOGRAPHY|||CAREGIVER|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-12-09|10
e|TR|4c82922a-55d0-45b9-a7bb-4edac32b0f68|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|uU/dL|ABSENT|1|Newton|DUKE INCISION METHOD|||CHILD|INTERNIST|U|2|Visit_2|25|4|FOLLOW-UP|2020-12-24|25
e|TR|4c82922a-55d0-45b9-a7bb-4edac32b0f68|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mMU/mL|FURTHER ENLARGEMENT|1|dB|X-RAY|||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2021-01-08|40
e|TR|4c82922a-55d0-45b9-a7bb-4edac32b0f68|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|ms2|ABSENT|1|mPa|MALDI-TOF|||ADJUDICATOR|RADIOLOGIST 2|Y|4|Visit_4|65|7|WASHOUT|2021-02-02|65
e|TR|4c82922a-55d0-45b9-a7bb-4edac32b0f68|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|mL/kg/h|ENLARGEMENT FROM NADIR|1|Watt|TARGETED TRANSCRIPTOME SEQUENCING||Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|U|5|Visit_5|90|4|TREATMENT|2021-02-27|90
e|TR|57971bdc-14df-4d9e-a59a-2665703c12ab|1|[?]|ACHNAD|Absolute Change From Nadir|[?]|cd*s/m2|PRESENT|1|mL/dose|DIFFUSION WEIGHTED MRI||Y|ADJUDICATION COMMITTEE|INTERNIST|Y|1|Visit_1|10|4|FOLLOW-UP|2020-05-30|10
e|TR|57971bdc-14df-4d9e-a59a-2665703c12ab|2|[?]|NEWCONF|New Tumor Confirmed|[?]|tuberculin unit|FURTHER ENLARGEMENT|1|s^-1(%O2)^-1|ELISA|||FRIEND|MICROSCOPIST 1|Y|2|Visit_2|25|2|TREATMENT|2020-06-14|25
e|TR|57971bdc-14df-4d9e-a59a-2665703c12ab|3|[?]|PALPSTAT|Palpable State|[?]|mAmp|TUMOR MERGED|1|DISK|IN VITRO GENE EXPRESSION ASSAY|||DOMESTIC PARTNER|MICROSCOPIST|NA|3|Visit_3|40|3|FOLLOW-UP|2020-06-29|40
e|TR|57971bdc-14df-4d9e-a59a-2665703c12ab|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|Log10 ELISA unit|INCREASED|1|C|OPTICAL MAPPING|Y|Y|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|3|TREATMENT|2020-07-24|65
e|TR|57971bdc-14df-4d9e-a59a-2665703c12ab|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|g/cm2|INCREASED|1|nmol BCE/nmol|GC/MS/MS|||PARENT|OPTOMETRIST|U|5|Visit_5|90|4|TREATMENT|2020-08-18|90
e|TR|dacea2da-9101-41e9-97aa-1cb8445b1320|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|TCID 50/dose|EQUIVOCAL|1|cpm|INCISION-INDUCED BLEEDING METHOD||Y|INTERVIEWER|ADJUDICATOR 1|NA|1|Visit_1|10|2|WASHOUT|2020-10-09|10
e|TR|dacea2da-9101-41e9-97aa-1cb8445b1320|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|U/L|EQUIVOCAL|1|mL/(min*100mL)|SLIT LAMP|||ADJUDICATOR|ONCOLOGIST|N|2|Visit_2|25|2|TREATMENT|2020-10-24|25
e|TR|dacea2da-9101-41e9-97aa-1cb8445b1320|3|[?]|SUMDIAM|Sum of Diameter|[?]|EID 50/dose|NONPALPABLE|1|dyn|PAP STAIN||Y|INTERVIEWER|ONCOLOGIST 1|Y|3|Visit_3|40|4|TREATMENT|2020-11-08|40
e|TR|dacea2da-9101-41e9-97aa-1cb8445b1320|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|10^3 RNA copies/mL|PRESENT|1|10^5/hpf|SPIRAL CT|||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|4|Visit_4|65|6|TREATMENT|2020-12-03|65
e|TR|dacea2da-9101-41e9-97aa-1cb8445b1320|5|[?]|DIAMETER|Diameter|[?]|CCID 50/mL|INCREASED|1|mg/animal|RADIATION DOSIMETRY||Y|ADJUDICATION COMMITTEE|ADJUDICATOR|U|5|Visit_5|90|2|SCREENING|2020-12-28|90
e|TR|cbf5d05e-e934-4946-b991-5fef63a01888|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|U/g/h|PRESENT|1|mg/kg/day|RIA|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|U|1|Visit_1|10|4|TREATMENT|2020-11-06|10
e|TR|cbf5d05e-e934-4946-b991-5fef63a01888|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|U/L|NONPALPABLE|1|Hz|PH METER MEASUREMENT METHOD||Y|INTERVIEWER|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-11-21|25
e|TR|cbf5d05e-e934-4946-b991-5fef63a01888|3|[?]|ORVERLN|Organ Vertical Length|[?]|ppm|ENLARGEMENT|1|deg/mm|REFRACTOMETRY||Y|SPOUSE|ADJUDICATOR 1|Y|3|Visit_3|40|6|WASHOUT|2020-12-06|40
e|TR|cbf5d05e-e934-4946-b991-5fef63a01888|4|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|SYRINGE|NORMAL|1|mL/mmHg/min/L|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||GUARDIAN|READER 2|U|4|Visit_4|65|7|TREATMENT|2020-12-31|65
e|TR|cbf5d05e-e934-4946-b991-5fef63a01888|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|Rad|DIFFUSELY INCREASED|1|mMU/mL|BRDU CELLULAR PROLIFERATION ASSAY|||INTERVIEWER|RATER 1|N|5|Visit_5|90|2|FOLLOW-UP|2021-01-25|90
e|TR|be18633c-0ff9-4775-9737-dc8a9524fd2c|1|[?]|LMBFLIND|Limb Failure Indicator|[?]|nmol/kg/day|PALPABLE|1|fmol/L|ULTRASONOGRAPHIC ELASTOGRAPHY|Y||DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|5|TREATMENT|2020-10-18|10
e|TR|be18633c-0ff9-4775-9737-dc8a9524fd2c|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|%(v/v)|INCREASED|1|DAgU/mL|ANTIMICROBIAL COMBINATION TESTING|||PARENT|PATHOLOGIST 1|N|2|Visit_2|25|3|TREATMENT|2020-11-02|25
e|TR|be18633c-0ff9-4775-9737-dc8a9524fd2c|3|[?]|PCHGNAD|Percent Change From Nadir|[?]|ug/m2/day|ABSENT|1|DPM|DROPLET DIGITAL PCR||Y|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|3|TREATMENT|2020-11-17|40
e|TR|be18633c-0ff9-4775-9737-dc8a9524fd2c|4|[?]|BNLNUM|Number of Bone Lesions|[?]|OI50|INCREASED|1|10^3 organisms/mL|GIEMSA STAIN|||NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|N|4|Visit_4|65|5|FOLLOW-UP|2020-12-12|65
e|TR|be18633c-0ff9-4775-9737-dc8a9524fd2c|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|PACKAGE|PALPABLE|1|mIU/L|LEAD CITRATE STAIN|Y||CHILD|ONCOLOGIST 1|U|5|Visit_5|90|2|SCREENING|2021-01-06|90
e|TR|f7eba9b8-94fb-46b8-842a-0322eb68a355|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|10^3 organisms|EQUIVOCAL|1|ug/cm2|TARGETED GENOME SEQUENCING||Y|DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|7|SCREENING|2020-05-12|10
e|TR|f7eba9b8-94fb-46b8-842a-0322eb68a355|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|lm|PRESENT|1|PNU/mL|SLOAN LETTER EYE CHART 2.5%|||SIGNIFICANT OTHER|ONCOLOGIST 1|N|2|Visit_2|25|2|TREATMENT|2020-05-27|25
e|TR|f7eba9b8-94fb-46b8-842a-0322eb68a355|3|[?]|PALPSTAT|Palpable State|[?]|Siemens|DECREASED|1|kBq/uL|MOUSE PROTECTION ASSAY||Y|PROXY|ONCOLOGIST 1|Y|3|Visit_3|40|1|FOLLOW-UP|2020-06-11|40
e|TR|f7eba9b8-94fb-46b8-842a-0322eb68a355|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|cd/m2|TUMOR MERGED|1|v/v|FLUORIMETRY||Y|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|2|WASHOUT|2020-07-06|65
e|TR|f7eba9b8-94fb-46b8-842a-0322eb68a355|5|[?]|DIAMETER|Diameter|[?]|log10 copies/mL|INCREASED|1|MET|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||STUDY SUBJECT|NEUROLOGIST 1|N|5|Visit_5|90|6|TREATMENT|2020-07-31|90
e|TR|903199e2-56e1-41e4-8904-d33cc6846ee3|1|[?]|VSLPIND|Vessel Patency Indicator|[?]|10^6/Ejaculate U|FURTHER ENLARGEMENT|1|mJoule/cm2|TURBIDIMETRY|||SIBLING|CARDIOLOGIST|Y|1|Visit_1|10|5|WASHOUT|2021-01-18|10
e|TR|903199e2-56e1-41e4-8904-d33cc6846ee3|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|days/wk|DIFFUSELY INCREASED|1|PRESSOR UNITS|CONTRAST ENHANCED MRI|||FRIEND|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|3|TREATMENT|2021-02-02|25
e|TR|903199e2-56e1-41e4-8904-d33cc6846ee3|3|[?]|VDIAM|Viable Diameter|[?]|cg|UNCHANGED|1|dmol|ELECTRONEUROGRAPHY|Y||SIGNIFICANT OTHER|MICROSCOPIST 3|Y|3|Visit_3|40|5|FOLLOW-UP|2021-02-17|40
e|TR|903199e2-56e1-41e4-8904-d33cc6846ee3|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|ng/dL|NORMAL|1|copies/mL|INTRAVASCULAR ULTRASOUND|||INTERVIEWER|PATHOLOGIST|U|4|Visit_4|65|4|WASHOUT|2021-03-14|65
e|TR|903199e2-56e1-41e4-8904-d33cc6846ee3|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|10^3 organisms/mL|DIFFUSELY INCREASED|1|ug/g/min|HEMAGGLUTINATION ASSAY|Y||ADJUDICATOR|ONCOLOGIST 1|N|5|Visit_5|90|5|TREATMENT|2021-04-08|90
e|TR|32567f8d-e746-44e1-a269-d95ba3bb0b11|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|min|NON-PATHOLOGICAL|1|mm/sec|NEXT GENERATION TARGETED SEQUENCING|||PARENT|ADJUDICATOR 3|N|1|Visit_1|10|3|TREATMENT|2020-11-02|10
e|TR|32567f8d-e746-44e1-a269-d95ba3bb0b11|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|log10 TCID 50/uL|PATHOLOGICAL|1|PFU|MRS|Y|Y|CAREGIVER|MICROSCOPIST 3|N|2|Visit_2|25|5|SCREENING|2020-11-17|25
e|TR|32567f8d-e746-44e1-a269-d95ba3bb0b11|3|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|mV/sec|EQUIVOCAL|1|10^6 CFU|LINE PROBE ASSAY|||PARENT|ONCOLOGIST 1|Y|3|Visit_3|40|7|TREATMENT|2020-12-02|40
e|TR|32567f8d-e746-44e1-a269-d95ba3bb0b11|4|[?]|LDIAM|Longest Diameter|[?]|MBP|DECREASED|1|uV|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|3|FOLLOW-UP|2020-12-27|65
e|TR|32567f8d-e746-44e1-a269-d95ba3bb0b11|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|ug/h|ENLARGEMENT|1|Ci|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||Y|GUARDIAN|PATHOLOGIST 1|NA|5|Visit_5|90|6|WASHOUT|2021-01-21|90
e|TR|ecdc54eb-c02f-4112-8e85-8a3352470b3b|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|Ci/L|NONPALPABLE|1|mL|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|1|Visit_1|10|7|WASHOUT|2020-11-11|10
e|TR|ecdc54eb-c02f-4112-8e85-8a3352470b3b|2|[?]|AREA|Area|[?]|CAPFUL|TUMOR MERGED|1|WEEKS|TRANSMISSION ELECTRON MICROSCOPY||Y|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|U|2|Visit_2|25|1|TREATMENT|2020-11-26|25
e|TR|ecdc54eb-c02f-4112-8e85-8a3352470b3b|3|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|10^9 organisms|ENLARGEMENT|1|Ci|FLOCCULATION, CHARCOAL ENHANCED||Y|INTERVIEWER|OPHTHALMOLOGIST|N|3|Visit_3|40|5|FOLLOW-UP|2020-12-11|40
e|TR|ecdc54eb-c02f-4112-8e85-8a3352470b3b|4|[?]|AREA|Area|[?]|DRINK|UNCHANGED|1|Bq/kg|ANGIOGRAPHY|||STUDY SUBJECT|MICROSCOPIST 3|N|4|Visit_4|65|2|WASHOUT|2021-01-05|65
e|TR|ecdc54eb-c02f-4112-8e85-8a3352470b3b|5|[?]|LESSCIND|Lesion Success Indicator|[?]|ug/kg/day|ENLARGEMENT|1|PFU|HIGH RESOLUTION CT|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|5|Visit_5|90|7|TREATMENT|2021-01-30|90
e|TR|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mg/L|EQUIVOCAL|1|10^3/L|LINE PROBE ASSAY|||SIBLING|NEUROLOGIST|NA|1|Visit_1|10|5|SCREENING|2020-07-09|10
e|TR|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|2|[?]|PPD|Product of Perpendicular Diameters|[?]|%/min|UNCHANGED|1|VIRTUAL PIXEL|CT SCAN|Y||SPOUSE|CARDIOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-07-24|25
e|TR|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|mg/cm2|PALPABLE|1|cL|CALCOFLUOR WHITE STAIN|Y||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|5|SCREENING|2020-08-08|40
e|TR|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|pg/cell|DIFFUSELY INCREASED|1|mg/m2/day|OPTICAL MAPPING|||VENDOR|MICROSCOPIST 2|U|4|Visit_4|65|1|FOLLOW-UP|2020-09-02|65
e|TR|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|5|[?]|LESSCIND|Lesion Success Indicator|[?]|anti-Xa IU|PATHOLOGICAL|1|U|DUKE INCISION METHOD|Y||HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|5|Visit_5|90|7|WASHOUT|2020-09-27|90
e|TR|5d7241ec-120d-486d-ab39-b9e14ab4ce90|1|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|PIXELS/in|ENLARGEMENT FROM NADIR|1|QUANTITY SUFFICIENT|IRON HEMATOXYLIN STAIN|||CHILD|MICROSCOPIST 2|Y|1|Visit_1|10|1|WASHOUT|2020-08-01|10
e|TR|5d7241ec-120d-486d-ab39-b9e14ab4ce90|2|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|AU/mL|UNEQUIVOCAL|1|g/animal/wk|FLUORESCENT MICROSCOPY|||INTERVIEWER|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-08-16|25
e|TR|5d7241ec-120d-486d-ab39-b9e14ab4ce90|3|[?]|DIAMETER|Diameter|[?]|L/s|TUMOR MERGED|1|10^9 CFU/g|TOTAL BODY RADIOGRAPHY|||ADJUDICATION COMMITTEE|RADIOLOGIST 1|N|3|Visit_3|40|4|FOLLOW-UP|2020-08-31|40
e|TR|5d7241ec-120d-486d-ab39-b9e14ab4ce90|4|[?]|LESSCIND|Lesion Success Indicator|[?]|tsp|UNCHANGED|1|g/L|AGAR DILUTION|Y||ADJUDICATION COMMITTEE|RATER 2|U|4|Visit_4|65|3|WASHOUT|2020-09-25|65
e|TR|5d7241ec-120d-486d-ab39-b9e14ab4ce90|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|mN|ENLARGEMENT|1|Bq/ug|ENDPOINT DILUTION ASSAY||Y|SIGNIFICANT OTHER|PATHOLOGIST|N|5|Visit_5|90|4|TREATMENT|2020-10-20|90
e|TR|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|ppm|NONPALPABLE|1|Watt|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||Y|VENDOR|OPHTHALMOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-06-01|10
e|TR|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|hr/day|DECREASED|1|Joule|AUTOREFRACTION|||VENDOR|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|5|FOLLOW-UP|2020-06-16|25
e|TR|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|dmol|ABSENT|1|Tesla|SPECTROPHOTOMETRY|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|6|SCREENING|2020-07-01|40
e|TR|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mmol/kg|DIFFUSELY INCREASED|1|CCID 50/dose|INDIRECT IMMUNOFLUORESCENCE||Y|SIBLING|PHYSIOTHERAPIST|U|4|Visit_4|65|7|WASHOUT|2020-07-26|65
e|TR|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|5|[?]|LMBFLIND|Limb Failure Indicator|[?]|cP|NONPALPABLE|1|uL/kg/day|TARGETED TRANSCRIPTOME SEQUENCING|||FRIEND|CARDIOLOGIST|U|5|Visit_5|90|6|TREATMENT|2020-08-20|90
e|TR|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|1|[?]|AREA|Area|[?]|L/s|DECREASED|1|umol/kg/min|PELLI-ROBSON EYE CHART|||VENDOR|ENDOCRINOLOGIST|N|1|Visit_1|10|2|WASHOUT|2020-07-04|10
e|TR|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|fL|PALPABLE|1|IU/kg|CONTRAST ENHANCED X-RAY|||ADJUDICATOR|OPHTHALMOLOGIST|U|2|Visit_2|25|4|FOLLOW-UP|2020-07-19|25
e|TR|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|g|INCREASED|1|g/U|IMPULSE OSCILLOMETRY|||CHILD|MICROSCOPIST 2|NA|3|Visit_3|40|5|WASHOUT|2020-08-03|40
e|TR|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|4|[?]|AREA|Area|[?]|pmol|NONPALPABLE|1|Tbsp|NEPHELOMETRY|||SIBLING|MICROSCOPIST 3|Y|4|Visit_4|65|3|TREATMENT|2020-08-28|65
e|TR|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|GBq|FURTHER ENLARGEMENT FROM NADIR|1|DNA copies/mL|DROPLET DIGITAL PCR|Y|Y|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|N|5|Visit_5|90|5|WASHOUT|2020-09-22|90
e|TR|a69c6182-9c35-4365-b732-b238e0584ba7|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|log EID 50/dose|PATHOLOGICAL|1|mg/g/min|THICK SMEAR|||VENDOR|ADJUDICATOR 1|U|1|Visit_1|10|2|SCREENING|2020-08-07|10
e|TR|a69c6182-9c35-4365-b732-b238e0584ba7|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|/HPF|TUMOR MERGED|1|s/h|PERIPHERAL ANGIOGRAPHY|||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|3|FOLLOW-UP|2020-08-22|25
e|TR|a69c6182-9c35-4365-b732-b238e0584ba7|3|[?]|LDIAM|Longest Diameter|[?]|mOsm/L|EQUIVOCAL|1|log10 CFU/g|KLEIHAUER-BETKE|||INVESTIGATOR|ADJUDICATOR 2|N|3|Visit_3|40|2|TREATMENT|2020-09-06|40
e|TR|a69c6182-9c35-4365-b732-b238e0584ba7|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|fg|NONPALPABLE|1|fraction of 1|KINYOUN STAIN||Y|INVESTIGATOR|RADIOLOGIST 1|U|4|Visit_4|65|6|TREATMENT|2020-10-01|65
e|TR|a69c6182-9c35-4365-b732-b238e0584ba7|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|hPa|ENLARGEMENT FROM NADIR|1|genEq|FARR ASSAY|||FRIEND|MICROSCOPIST 2|N|5|Visit_5|90|2|TREATMENT|2020-10-26|90
e|TR|1b9896cf-160e-4a56-8737-9759cd83e784|1|[?]|ORVERLN|Organ Vertical Length|[?]|uV*sec|TUMOR MERGED|1|Bq/uL|FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y|Y|SIGNIFICANT OTHER|ADJUDICATOR 3|U|1|Visit_1|10|6|TREATMENT|2020-12-11|10
e|TR|1b9896cf-160e-4a56-8737-9759cd83e784|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|ELISA unit|DIFFUSELY INCREASED|1|10^9 organisms/g|REBOUND TONOMETRY|||GUARDIAN|MICROSCOPIST 1|U|2|Visit_2|25|5|SCREENING|2020-12-26|25
e|TR|1b9896cf-160e-4a56-8737-9759cd83e784|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|ng/L|INCREASED|1|mN|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||NON-HEALTH CARE PROFESSIONAL|READER 2|NA|3|Visit_3|40|5|SCREENING|2021-01-10|40
e|TR|1b9896cf-160e-4a56-8737-9759cd83e784|4|[?]|LDIAM|Longest Diameter|[?]|Arbitrary U|UNCHANGED|1|g/animal/day|HANSEL STAIN|Y||NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|6|FOLLOW-UP|2021-02-04|65
e|TR|1b9896cf-160e-4a56-8737-9759cd83e784|5|[?]|PPD|Product of Perpendicular Diameters|[?]|ug/kg/h|FOCALLY INCREASED|1|mEq/mmol|NEURAMINIDASE INHIBITION ASSAY|||FAMILY MEMBER|HEMATOLOGIST|NA|5|Visit_5|90|1|TREATMENT|2021-03-01|90
e|TR|ea87b553-e331-40cf-bd86-d2bd22694476|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|Gy|FOCALLY INCREASED|1|umol/min|CENTRIFUGATION||Y|CAREGIVER|READER|N|1|Visit_1|10|5|FOLLOW-UP|2020-08-05|10
e|TR|ea87b553-e331-40cf-bd86-d2bd22694476|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|cd*s/m2|DECREASED|1|10^3 DNA copies/mL|STRESS ECHOCARDIOGRAPHY|Y|Y|GUARDIAN|UROLOGIST|Y|2|Visit_2|25|5|WASHOUT|2020-08-20|25
e|TR|ea87b553-e331-40cf-bd86-d2bd22694476|3|[?]|ACHNAD|Absolute Change From Nadir|[?]|/10^3|PATHOLOGICAL|1|kcal/day|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|N|3|Visit_3|40|2|TREATMENT|2020-09-04|40
e|TR|ea87b553-e331-40cf-bd86-d2bd22694476|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|Mile|NON-PATHOLOGICAL|1|log10 CFU/g|MECHANICAL CLOT DETECTION|Y||CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|U|4|Visit_4|65|3|SCREENING|2020-09-29|65
e|TR|ea87b553-e331-40cf-bd86-d2bd22694476|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|AU/mL|EQUIVOCAL|1|cmH2O*s/mL|PHOTOGRAPHY|||ADJUDICATOR|RATER 1|U|5|Visit_5|90|7|TREATMENT|2020-10-24|90
e|TR|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|1|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|oz|INCREASED|1|kg/cm|HIGH RESOLUTION CT|||ADJUDICATION COMMITTEE|ADJUDICATOR|U|1|Visit_1|10|3|TREATMENT|2020-07-30|10
e|TR|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|%(v/v)|FURTHER ENLARGEMENT FROM NADIR|1|Bq/L|WRIGHT STAIN|Y||FAMILY MEMBER|MICROSCOPIST|NA|2|Visit_2|25|4|SCREENING|2020-08-14|25
e|TR|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|vp/dose|ABSENT|1|tsp eq|TEST STRIP|Y||FRIEND|ONCOLOGIST 1|N|3|Visit_3|40|2|FOLLOW-UP|2020-08-29|40
e|TR|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|cmol|DIFFUSELY INCREASED|1|APPLICATION|IN SITU HYBRIDIZATION||Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|4|Visit_4|65|5|WASHOUT|2020-09-23|65
e|TR|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|log10 IU/mL|FURTHER ENLARGEMENT FROM NADIR|1|umol/dL|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Y||NON-HEALTH CARE PROFESSIONAL|INTERNIST|Y|5|Visit_5|90|2|TREATMENT|2020-10-18|90
e|TR|051dc064-be6f-43eb-aa51-7ed8634d6e23|1|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|uEq/L|UNCHANGED|1|U/m2|DISK DIFFUSION||Y|FAMILY MEMBER|READER 1|N|1|Visit_1|10|2|WASHOUT|2020-07-08|10
e|TR|051dc064-be6f-43eb-aa51-7ed8634d6e23|2|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|10^12 IU/L|ENLARGEMENT FROM NADIR|1|U/dL|HPLC/MS/MS|Y||DOMESTIC PARTNER|ONCOLOGIST 2|Y|2|Visit_2|25|1|TREATMENT|2020-07-23|25
e|TR|051dc064-be6f-43eb-aa51-7ed8634d6e23|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|nkat/L|DECREASED|1|um|RYAN BLUE STAIN|||INDEPENDENT ASSESSOR|OPTOMETRIST|U|3|Visit_3|40|5|FOLLOW-UP|2020-08-07|40
e|TR|051dc064-be6f-43eb-aa51-7ed8634d6e23|4|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|vg/dose|NON-PATHOLOGICAL|1|umol|ISHIHARA COLOR PLATES|||ADJUDICATION COMMITTEE|ADJUDICATOR|N|4|Visit_4|65|6|WASHOUT|2020-09-01|65
e|TR|051dc064-be6f-43eb-aa51-7ed8634d6e23|5|[?]|LDIAM|Longest Diameter|[?]|ug/m2/h|FURTHER ENLARGEMENT|1|Bq/kg|DNA MICROARRAY|||SPOUSE|RATER|NA|5|Visit_5|90|2|SCREENING|2020-09-26|90
e|TR|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|1|[?]|LPERP|Longest Perpendicular|[?]|%/s|INCREASED|1|g|OLIGO ACGH||Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|6|SCREENING|2020-06-03|10
e|TR|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|2|[?]|SUMVOL|Sum of Volume|[?]|uL|PRESENT|1|CCID 50/mL|ANTIMICROBIAL COMBINATION TESTING||Y|CHILD|ADJUDICATOR 2|NA|2|Visit_2|25|6|TREATMENT|2020-06-18|25
e|TR|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|%/s|TUMOR MERGED|1|TROCHE|POLYGRAPHY|||STUDY SUBJECT|CLINICAL PATHOLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-07-03|40
e|TR|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|4|[?]|PPD|Product of Perpendicular Diameters|[?]|mg2/dL2|TUMOR MERGED|1|AMPULE|WHOLE EXOME SEQUENCING|||HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-07-28|65
e|TR|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|nmol/day|INCREASED|1|LENS|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||INTERVIEWER|INTERNIST|NA|5|Visit_5|90|6|TREATMENT|2020-08-22|90
e|TR|7a17fe21-b640-4bc5-bf19-b1bceb393dab|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mg/cm2|UNCHANGED|1|Bq/uL|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||VENDOR|NEUROLOGIST 1|N|1|Visit_1|10|3|SCREENING|2020-09-02|10
e|TR|7a17fe21-b640-4bc5-bf19-b1bceb393dab|2|[?]|AREA|Area|[?]|Ci/L|EQUIVOCAL|1|mm/h|AUTOREFRACTION|Y||ADJUDICATION COMMITTEE|READER 3|U|2|Visit_2|25|5|TREATMENT|2020-09-17|25
e|TR|7a17fe21-b640-4bc5-bf19-b1bceb393dab|3|[?]|TUMSTATE|Tumor State|[?]|BE/mL|NORMAL|1|L/h/m2|LEAD CITRATE STAIN|||ADJUDICATION COMMITTEE|RATER 1|NA|3|Visit_3|40|4|TREATMENT|2020-10-02|40
e|TR|7a17fe21-b640-4bc5-bf19-b1bceb393dab|4|[?]|VSLFLIND|Vessel Failure Indicator|[?]|Rad|UNCHANGED|1|mg/m2/day|CALCOFLUOR WHITE STAIN|||CHILD|READER 3|U|4|Visit_4|65|1|SCREENING|2020-10-27|65
e|TR|7a17fe21-b640-4bc5-bf19-b1bceb393dab|5|[?]|RADIODEN|Radiodensity|[?]|damol/L|FURTHER ENLARGEMENT|1|10^6 CFU/g|ACID FAST STAIN|||CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|NA|5|Visit_5|90|5|TREATMENT|2020-11-21|90
e|TR|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|1|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|sec|ABSENT|1|m/sec2|CONTRAST ENHANCED MRI|||INVESTIGATOR|ONCOLOGIST 1|U|1|Visit_1|10|1|TREATMENT|2021-01-20|10
e|TR|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|2|[?]|PCHGBL|Percent Change From Baseline|[?]|ug/day|EQUIVOCAL|1|mOsm/kg|ELLA||Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|2|Visit_2|25|2|TREATMENT|2021-02-04|25
e|TR|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|pmol/10^9 cells|ABSENT|1|MPS U|NUCLEIC ACID HYBRIDIZATION||Y|FRIEND|RADIOLOGIST 1|N|3|Visit_3|40|5|WASHOUT|2021-02-19|40
e|TR|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|Enzyme U/L|UNCHANGED|1|FFU|IHC||Y|INTERVIEWER|DERMATOLOGIST|U|4|Visit_4|65|6|TREATMENT|2021-03-16|65
e|TR|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|5|[?]|BNLNUM|Number of Bone Lesions|[?]|10^6 IU|PRESENT|1|U/10^12 RBC|AUDIOMETRY|||INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|7|TREATMENT|2021-04-10|90
e|TR|f1d0daec-aa97-4838-9c53-e16dae3e17b2|1|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|% INHIBITION|ABSENT|1|vp/mL|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||SPOUSE|RADIOLOGIST 2|Y|1|Visit_1|10|5|TREATMENT|2020-06-23|10
e|TR|f1d0daec-aa97-4838-9c53-e16dae3e17b2|2|[?]|ACHNAD|Absolute Change From Nadir|[?]|JAR|NON-PATHOLOGICAL|1|gtt|IMMUNOCHEMILUMINOMETRIC ASSAY|||SIGNIFICANT OTHER|RADIOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-07-08|25
e|TR|f1d0daec-aa97-4838-9c53-e16dae3e17b2|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mV2/Hz|DIFFUSELY INCREASED|1|gpELISA unit/mL|FUNCTIONAL MRI|Y|Y|CLINICAL STUDY SPONSOR|INTERNIST|Y|3|Visit_3|40|2|FOLLOW-UP|2020-07-23|40
e|TR|f1d0daec-aa97-4838-9c53-e16dae3e17b2|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|nmol/mol|FURTHER ENLARGEMENT FROM NADIR|1|cmol|BRDU CELLULAR PROLIFERATION ASSAY|Y||STUDY SUBJECT|PATHOLOGIST 2|Y|4|Visit_4|65|4|WASHOUT|2020-08-17|65
e|TR|f1d0daec-aa97-4838-9c53-e16dae3e17b2|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|nsec|INCREASED|1|ELISA unit/dose|BIOPSY|||ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|1|SCREENING|2020-09-11|90
e|TR|835594ab-e93c-402b-8129-6af659be5ae1|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|uL/dose|NORMAL|1|mPa|RADIATION DOSIMETRY|||PROXY|HEMATOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-11-01|10
e|TR|835594ab-e93c-402b-8129-6af659be5ae1|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|SPRAY|PATHOLOGICAL|1|IU|PERIPHERAL ANGIOGRAPHY|||PARENT|UROLOGIST|U|2|Visit_2|25|2|WASHOUT|2020-11-16|25
e|TR|835594ab-e93c-402b-8129-6af659be5ae1|3|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|STRIP|ABSENT|1|mm3/mm2/year|CLIP|||DOMESTIC PARTNER|PHYSIOTHERAPIST|N|3|Visit_3|40|6|TREATMENT|2020-12-01|40
e|TR|835594ab-e93c-402b-8129-6af659be5ae1|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|s/h|UNEQUIVOCAL|1|nmol/g|CINEANGIOGRAPHY|Y|Y|INTERVIEWER|ENDOCRINOLOGIST|U|4|Visit_4|65|6|TREATMENT|2020-12-26|65
e|TR|835594ab-e93c-402b-8129-6af659be5ae1|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|uCi/L|FURTHER ENLARGEMENT FROM NADIR|1|kg/cm2|MASS SPECTROMETRY|Y||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|NA|5|Visit_5|90|7|FOLLOW-UP|2021-01-20|90
e|TR|c3c85786-d24b-4620-9ee0-c13b1cc4f951|1|[?]|ORVERLN|Organ Vertical Length|[?]|mg/m2/day|DECREASED|1|/ms|ELECTRICAL IMPEDANCE MYOGRAPHY||Y|DOMESTIC PARTNER|RADIOLOGIST|U|1|Visit_1|10|2|FOLLOW-UP|2020-10-07|10
e|TR|c3c85786-d24b-4620-9ee0-c13b1cc4f951|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|mmol/min/kPa|NORMAL|1|keV|CONTRAST ENHANCED PET/CT SCAN|||INVESTIGATOR|OPTOMETRIST|U|2|Visit_2|25|4|WASHOUT|2020-10-22|25
e|TR|c3c85786-d24b-4620-9ee0-c13b1cc4f951|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|GBq/mg|TUMOR MERGED|1|Bq/L|SMEAR|||ADJUDICATOR|ADJUDICATOR|U|3|Visit_3|40|3|FOLLOW-UP|2020-11-06|40
e|TR|c3c85786-d24b-4620-9ee0-c13b1cc4f951|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|cy/cm|TUMOR MERGED|1|mol/L|AUDIOMETRY|Y||INTERVIEWER|MICROSCOPIST 1|Y|4|Visit_4|65|5|TREATMENT|2020-12-01|65
e|TR|c3c85786-d24b-4620-9ee0-c13b1cc4f951|5|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|MPL U/mL|INCREASED|1|g/U|CARDIAC THERMODILUTION|Y||FRIEND|RATER 2|U|5|Visit_5|90|1|TREATMENT|2020-12-26|90
e|TR|5354e3c4-4106-4e4c-85c3-2dbbd001688c|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|ft3|PRESENT|1|uL/kg/day|FLUORIMETRY|Y||CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-11-15|10
e|TR|5354e3c4-4106-4e4c-85c3-2dbbd001688c|2|[?]|PCHGBL|Percent Change From Baseline|[?]|NFIU|FURTHER ENLARGEMENT|1|BAR|DYNAMOMETRY|||VENDOR|ONCOLOGIST|U|2|Visit_2|25|5|WASHOUT|2020-11-30|25
e|TR|5354e3c4-4106-4e4c-85c3-2dbbd001688c|3|[?]|LESSCIND|Lesion Success Indicator|[?]|mL/beat|ABSENT|1|Coulomb|PET/MRI SCAN|||CHILD|NEUROLOGIST 2|NA|3|Visit_3|40|2|SCREENING|2020-12-15|40
e|TR|5354e3c4-4106-4e4c-85c3-2dbbd001688c|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|umol/mg/min|UNCHANGED|1|umol|SCINTIGRAPHY|||DOMESTIC PARTNER|PATHOLOGIST 2|U|4|Visit_4|65|6|WASHOUT|2021-01-09|65
e|TR|5354e3c4-4106-4e4c-85c3-2dbbd001688c|5|[?]|PCHGBL|Percent Change From Baseline|[?]|APL U/mL|ABSENT|1|kg/m2|OPHTHALMOSCOPY|Y||FAMILY MEMBER|DERMATOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2021-02-03|90
e|TR|f10e9188-ef7b-46f9-a80a-0669436eb4dd|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|nsec|DIFFUSELY INCREASED|1|dpm/mL|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|NA|1|Visit_1|10|3|SCREENING|2020-06-24|10
e|TR|f10e9188-ef7b-46f9-a80a-0669436eb4dd|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|ppm|ENLARGEMENT|1|uCi|MEDIASTINOSCOPY|||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-07-09|25
e|TR|f10e9188-ef7b-46f9-a80a-0669436eb4dd|3|[?]|LPERP|Longest Perpendicular|[?]|L/s|PALPABLE|1|dpm/mL|MAMMOGRAPHY|Y||CHILD|ONCOLOGIST 1|Y|3|Visit_3|40|7|WASHOUT|2020-07-24|40
e|TR|f10e9188-ef7b-46f9-a80a-0669436eb4dd|4|[?]|ORSTATE|Organ State|[?]|kPa/L/sec|ENLARGEMENT|1|PACKET|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||FRIEND|PATHOLOGIST 1|N|4|Visit_4|65|1|TREATMENT|2020-08-18|65
e|TR|f10e9188-ef7b-46f9-a80a-0669436eb4dd|5|[?]|LESSCIND|Lesion Success Indicator|[?]|ug/h|PRESENT|1|Bq/L|BETA LACTAMASE|Y||INDEPENDENT ASSESSOR|NEUROLOGIST|U|5|Visit_5|90|4|TREATMENT|2020-09-12|90
e|TR|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|1|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|ft|UNCHANGED|1|Torr|BRDU CELLULAR PROLIFERATION ASSAY|Y||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-08-13|10
e|TR|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|2|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mCi/kg|ENLARGEMENT FROM NADIR|1|10^7 CFU|ACRIDINE ORANGE STAIN|||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|2|FOLLOW-UP|2020-08-28|25
e|TR|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|g/L|FOCALLY INCREASED|1|NEBULE|NUCLEIC ACID AMPLIFICATION TEST|||INVESTIGATOR|READER 1|Y|3|Visit_3|40|7|WASHOUT|2020-09-12|40
e|TR|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|4|[?]|NEWCONF|New Tumor Confirmed|[?]|nL|TUMOR MERGED|1|pg|HEMAGGLUTINATION INHIBITION ASSAY|Y|Y|SPOUSE|PATHOLOGIST|N|4|Visit_4|65|5|TREATMENT|2020-10-07|65
e|TR|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|Coulomb|ENLARGEMENT|1|Absorbance U|LIGHT MICROSCOPY|Y||PARENT|DERMATOLOGIST|U|5|Visit_5|90|4|WASHOUT|2020-11-01|90
e|TR|000b5b99-a92d-4c84-9edc-ee08930d8a2e|1|[?]|RADIODEN|Radiodensity|[?]|umol/L/h|PALPABLE|1|GBq/ug|PERIODIC ACID SCHIFF STAIN|Y||SPOUSE|PATHOLOGIST 2|NA|1|Visit_1|10|3|TREATMENT|2020-10-15|10
e|TR|000b5b99-a92d-4c84-9edc-ee08930d8a2e|2|[?]|SUMDIAM|Sum of Diameter|[?]|nkat/L|PRESENT|1|min/day|WESTERGREN|||STUDY SUBJECT|ADJUDICATOR 1|U|2|Visit_2|25|3|TREATMENT|2020-10-30|25
e|TR|000b5b99-a92d-4c84-9edc-ee08930d8a2e|3|[?]|BNLNUM|Number of Bone Lesions|[?]|umol/mg/min|DECREASED|1|Pack Year|PET/CT SCAN|||NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-11-14|40
e|TR|000b5b99-a92d-4c84-9edc-ee08930d8a2e|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|Frames/s|ENLARGEMENT|1|mg/day|ENZYMATIC ULTRACENTRIFUGATION|||SIGNIFICANT OTHER|NEUROLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-12-09|65
e|TR|000b5b99-a92d-4c84-9edc-ee08930d8a2e|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mL/cage|UNCHANGED|1|L/s|IN SITU HYBRIDIZATION|Y|Y|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2021-01-03|90
e|TR|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|1|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|BEAM BREAKS|NONPALPABLE|1|10^7/L|ANGIOGRAPHY|Y||HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|1|Visit_1|10|7|FOLLOW-UP|2020-06-01|10
e|TR|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|10^9/dose|PALPABLE|1|tuberculin unit/mL|MICROBIAL CULTURE, LIQUID||Y|CAREGIVER|ONCOLOGIST 1|U|2|Visit_2|25|1|WASHOUT|2020-06-16|25
e|TR|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|3|[?]|AREA|Area|[?]|umol/L/h|ABSENT|1|Gy/h|SISH|||CAREGIVER|READER 1|NA|3|Visit_3|40|6|TREATMENT|2020-07-01|40
e|TR|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|nmol/L/min|PALPABLE|1|BLOCKS|QUANTITATIVE COMPUTED TOMOGRAPHY|||INVESTIGATOR|RATER 2|NA|4|Visit_4|65|4|TREATMENT|2020-07-26|65
e|TR|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|/HPF|FURTHER ENLARGEMENT FROM NADIR|1|cmol/L|FLOW CYTOMETRY|||SIGNIFICANT OTHER|PATHOLOGIST 1|U|5|Visit_5|90|6|FOLLOW-UP|2020-08-20|90
e|TR|11b2b359-d4a1-411d-a676-075b26e1453c|1|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|m|UNCHANGED|1|POUCH|RYAN BLUE STAIN|Y|Y|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|1|Visit_1|10|4|TREATMENT|2020-09-20|10
e|TR|11b2b359-d4a1-411d-a676-075b26e1453c|2|[?]|SUMDIAM|Sum of Diameter|[?]|MET*h|PALPABLE|1|10^6 IU/mL|BIOPSY||Y|INTERVIEWER|PATHOLOGIST 2|NA|2|Visit_2|25|5|TREATMENT|2020-10-05|25
e|TR|11b2b359-d4a1-411d-a676-075b26e1453c|3|[?]|DIAMETER|Diameter|[?]|nkat/g Hb|FURTHER ENLARGEMENT FROM NADIR|1|10^6 DNA copies/mL|SXA SCAN|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|3|Visit_3|40|7|TREATMENT|2020-10-20|40
e|TR|11b2b359-d4a1-411d-a676-075b26e1453c|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|pg/L|NORMAL|1|nmol/L|MRI WITHOUT CONTRAST|||ADJUDICATOR|HEMATOLOGIST|U|4|Visit_4|65|1|WASHOUT|2020-11-14|65
e|TR|11b2b359-d4a1-411d-a676-075b26e1453c|5|[?]|ORVERLN|Organ Vertical Length|[?]|/200 HPFs|NORMAL|1|uIU/dL|IVY INCISION METHOD|||INTERVIEWER|NEUROLOGIST 2|Y|5|Visit_5|90|1|FOLLOW-UP|2020-12-09|90
e|TR|293f673d-af6a-473e-8bce-118bb85bbd9e|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mL/h|PATHOLOGICAL|1|min*mg/mL|OLIGO ACGH|||SIGNIFICANT OTHER|OPTOMETRIST|U|1|Visit_1|10|4|TREATMENT|2020-10-19|10
e|TR|293f673d-af6a-473e-8bce-118bb85bbd9e|2|[?]|PALPSTAT|Palpable State|[?]|lx|DIFFUSELY INCREASED|1|mkat|ORCHIDOMETERY|||ADJUDICATOR|MICROSCOPIST 2|U|2|Visit_2|25|3|TREATMENT|2020-11-03|25
e|TR|293f673d-af6a-473e-8bce-118bb85bbd9e|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|nmol/g|NON-PATHOLOGICAL|1|pt_br|SMEAR|||SPOUSE|READER 2|Y|3|Visit_3|40|6|TREATMENT|2020-11-18|40
e|TR|293f673d-af6a-473e-8bce-118bb85bbd9e|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|10^7/L|PALPABLE|1|F|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||Y|ADJUDICATION COMMITTEE|ADJUDICATOR 2|U|4|Visit_4|65|1|WASHOUT|2020-12-13|65
e|TR|293f673d-af6a-473e-8bce-118bb85bbd9e|5|[?]|SUMDIAM|Sum of Diameter|[?]|uL/kg/day|ENLARGEMENT FROM NADIR|1|Bq/mL|LC-FL||Y|INVESTIGATOR|READER 3|Y|5|Visit_5|90|7|FOLLOW-UP|2021-01-07|90
e|TR|0f60ab31-ee13-4846-93d2-6bcac139006f|1|[?]|TUMSTATE|Tumor State|[?]|ug/mL/h|PALPABLE|1|/10^5|ICP-MS|Y||CHILD|CARDIOLOGIST|U|1|Visit_1|10|1|SCREENING|2020-07-02|10
e|TR|0f60ab31-ee13-4846-93d2-6bcac139006f|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|Gauss|FURTHER ENLARGEMENT FROM NADIR|1|ug/cm2|RADIOIMMUNOPRECIPITATION ASSAY|||GUARDIAN|RADIOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-07-17|25
e|TR|0f60ab31-ee13-4846-93d2-6bcac139006f|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|deg2|ABSENT|1|EU|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|Y||CAREGIVER|READER 1|NA|3|Visit_3|40|1|FOLLOW-UP|2020-08-01|40
e|TR|0f60ab31-ee13-4846-93d2-6bcac139006f|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|mg/mL/day|FURTHER ENLARGEMENT FROM NADIR|1|foz_br|DIGITAL PCR ARRAY|Y||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|NA|4|Visit_4|65|5|WASHOUT|2020-08-26|65
e|TR|0f60ab31-ee13-4846-93d2-6bcac139006f|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|Ci/ug|UNEQUIVOCAL|1|mAnson U/mL|ENZYMATIC ULTRACENTRIFUGATION|||CAREGIVER|OTOLARYNGOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2020-09-20|90
e|TR|d49f37ce-2d6e-4ebb-91af-7ed32322f824|1|[?]|DIAMETER|Diameter|[?]|/2000 RBC|DIFFUSELY INCREASED|1|nm|THERMAL IONIZATION MASS SPECTROMETRY|||INDEPENDENT ASSESSOR|INTERNIST|NA|1|Visit_1|10|5|TREATMENT|2020-08-31|10
e|TR|d49f37ce-2d6e-4ebb-91af-7ed32322f824|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|ug/L FEU|FURTHER ENLARGEMENT FROM NADIR|1|CAPSULE|AURAMINE STAIN|||PARENT|MICROSCOPIST 2|Y|2|Visit_2|25|2|TREATMENT|2020-09-15|25
e|TR|d49f37ce-2d6e-4ebb-91af-7ed32322f824|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|BOWL|UNEQUIVOCAL|1|kg|FORCED OSCILLATION TECHNIQUE|||ADJUDICATION COMMITTEE|ONCOLOGIST 1|U|3|Visit_3|40|5|WASHOUT|2020-09-30|40
e|TR|d49f37ce-2d6e-4ebb-91af-7ed32322f824|4|[?]|RADIODEN|Radiodensity|[?]|ng/day|TUMOR MERGED|1|log10 copies/mL|BIOPSY|||FAMILY MEMBER|READER 3|N|4|Visit_4|65|3|FOLLOW-UP|2020-10-25|65
e|TR|d49f37ce-2d6e-4ebb-91af-7ed32322f824|5|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|ug/animal|NONPALPABLE|1|kcal/day|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y||FAMILY MEMBER|ADJUDICATOR|Y|5|Visit_5|90|6|TREATMENT|2020-11-19|90
e|TR|76dd2fe2-bc9e-48e4-870c-af7ece70009a|1|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|fmol/L|ABSENT|1|g/animal/day|CLINICAL EVALUATION|||SPOUSE|UROLOGIST|NA|1|Visit_1|10|5|WASHOUT|2020-07-06|10
e|TR|76dd2fe2-bc9e-48e4-870c-af7ece70009a|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|L/h|DECREASED|1|mL/min/1.73m2|REFLECTANCE SPECTROSCOPY|||SIBLING|RADIOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-07-21|25
e|TR|76dd2fe2-bc9e-48e4-870c-af7ece70009a|3|[?]|TUMSTATE|Tumor State|[?]|PUFF|ABSENT|1|NFIU|AMSLER GRID|||VENDOR|READER 3|NA|3|Visit_3|40|1|TREATMENT|2020-08-05|40
e|TR|76dd2fe2-bc9e-48e4-870c-af7ece70009a|4|[?]|LESFLIND|Lesion Failure Indicator|[?]|Enzyme U/m2|FURTHER ENLARGEMENT FROM NADIR|1|/HPF|FLUORESCENT MICROSCOPY|Y|Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|1|SCREENING|2020-08-30|65
e|TR|76dd2fe2-bc9e-48e4-870c-af7ece70009a|5|[?]|SUMVOL|Sum of Volume|[?]|MASK|NON-PATHOLOGICAL|1|pkat/L|CYSTOSCOPY|||PARENT|READER 1|N|5|Visit_5|90|7|FOLLOW-UP|2020-09-24|90
e|TR|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|vp/dose|FURTHER ENLARGEMENT FROM NADIR|1|umol/day|ATOMIC ABSORPTION SPECTROMETRY|||CHILD|PATHOLOGIST 1|N|1|Visit_1|10|4|TREATMENT|2020-11-24|10
e|TR|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|TCID 50/dose|PRESENT|1|mN|HPLC-UV|||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|N|2|Visit_2|25|2|SCREENING|2020-12-09|25
e|TR|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|3|[?]|VDIAM|Viable Diameter|[?]|mL/kg/h|FOCALLY INCREASED|1|C|HIGH RESOLUTION MELT ANALYSIS|Y|Y|SIBLING|READER|Y|3|Visit_3|40|1|TREATMENT|2020-12-24|40
e|TR|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|VIAL|DECREASED|1|uL/mL|SANGER SEQUENCING|Y||ADJUDICATOR|PATHOLOGIST|Y|4|Visit_4|65|7|FOLLOW-UP|2021-01-18|65
e|TR|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|5|[?]|CALCFIND|Calcification Indicator|[?]|YEARS|EQUIVOCAL|1|10^5/L|URANYL ACETATE STAIN||Y|INTERVIEWER|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|7|SCREENING|2021-02-12|90
e|TR|78778706-6b5b-4ad8-90af-f56d602863ae|1|[?]|SUMVOL|Sum of Volume|[?]|KALLIKREIN INHIBITOR UNIT|FURTHER ENLARGEMENT FROM NADIR|1|NFIU|ANTIMICROBIAL COMBINATION TESTING|||FRIEND|ADJUDICATOR 3|N|1|Visit_1|10|1|WASHOUT|2020-05-13|10
e|TR|78778706-6b5b-4ad8-90af-f56d602863ae|2|[?]|CALCFIND|Calcification Indicator|[?]|/VF|PRESENT|1|CAN|CINEANGIOGRAPHY|||CHILD|MICROSCOPIST 3|Y|2|Visit_2|25|5|FOLLOW-UP|2020-05-28|25
e|TR|78778706-6b5b-4ad8-90af-f56d602863ae|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|pmol/day|PALPABLE|1|Hz|JAFFE REACTION|||FAMILY MEMBER|RATER 2|U|3|Visit_3|40|6|SCREENING|2020-06-12|40
e|TR|78778706-6b5b-4ad8-90af-f56d602863ae|4|[?]|NBNLNUM|Number of New Bone Lesions|[?]|Enzyme U/L|FURTHER ENLARGEMENT FROM NADIR|1|m3|CALCOFLUOR WHITE STAIN|Y||CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|N|4|Visit_4|65|7|TREATMENT|2020-07-07|65
e|TR|78778706-6b5b-4ad8-90af-f56d602863ae|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|Enzyme U/L|ENLARGEMENT FROM NADIR|1|mL/g/min|CONTRAST ENHANCED SPIRAL CT SCAN|||PROXY|RATER|U|5|Visit_5|90|3|FOLLOW-UP|2020-08-01|90
e|TR|a6954aa1-4860-412a-b988-7f708aca2ab2|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|m3|FOCALLY INCREASED|1|DNA copies/mL|PEAK FLOWMETRY|Y||ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|7|TREATMENT|2020-09-17|10
e|TR|a6954aa1-4860-412a-b988-7f708aca2ab2|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|BU/mL|UNCHANGED|1|Tesla|AUTOREFRACTION|||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|NA|2|Visit_2|25|7|TREATMENT|2020-10-02|25
e|TR|a6954aa1-4860-412a-b988-7f708aca2ab2|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|cd|PATHOLOGICAL|1|breaths/min|MEDIASTINOSCOPY|||FRIEND|ADJUDICATOR 2|U|3|Visit_3|40|5|TREATMENT|2020-10-17|40
e|TR|a6954aa1-4860-412a-b988-7f708aca2ab2|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|mL/cm3/min|DECREASED|1|lx|DIGITAL PCR|||ADJUDICATION COMMITTEE|MICROSCOPIST 2|N|4|Visit_4|65|2|TREATMENT|2020-11-11|65
e|TR|a6954aa1-4860-412a-b988-7f708aca2ab2|5|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mg/m2/min|FURTHER ENLARGEMENT|1|WAFER|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|N|5|Visit_5|90|1|WASHOUT|2020-12-06|90
e|TR|0a970eb4-f958-42ad-ad8b-60bb427c9cba|1|[?]|SUMVOL|Sum of Volume|[?]|rpm|PRESENT|1|V|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|1|Visit_1|10|7|TREATMENT|2020-05-14|10
e|TR|0a970eb4-f958-42ad-ad8b-60bb427c9cba|2|[?]|LDIAM|Longest Diameter|[?]|nmol/kg/day|DIFFUSELY INCREASED|1|log EID 50/dose|PET/CT SCAN|||DOMESTIC PARTNER|NEUROLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-05-29|25
e|TR|0a970eb4-f958-42ad-ad8b-60bb427c9cba|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|fraction of 1|PALPABLE|1|U/g/h|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||PARENT|PATHOLOGIST|Y|3|Visit_3|40|6|SCREENING|2020-06-13|40
e|TR|0a970eb4-f958-42ad-ad8b-60bb427c9cba|4|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|ft2|PATHOLOGICAL|1|mL/min|RYAN BLUE STAIN|||GUARDIAN|OTOLARYNGOLOGIST|N|4|Visit_4|65|2|WASHOUT|2020-07-08|65
e|TR|0a970eb4-f958-42ad-ad8b-60bb427c9cba|5|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|gMFI|ABSENT|1|Enzyme U/m2|AUDIOMETRY||Y|DOMESTIC PARTNER|ENDOCRINOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2020-08-02|90
e|TR|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|uCi|FURTHER ENLARGEMENT FROM NADIR|1|TAMPON|OPTICAL DENSITY MEASUREMENT|||STUDY SUBJECT|ONCOLOGIST|N|1|Visit_1|10|3|TREATMENT|2021-01-26|10
e|TR|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|PA|NONPALPABLE|1|mm/h|FUNCTIONAL MRI|||HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|2|Visit_2|25|2|TREATMENT|2021-02-10|25
e|TR|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|IU/g|PATHOLOGICAL|1|kcal|RAJI CELL EIA|||CLINICAL STUDY SPONSOR|RATER|Y|3|Visit_3|40|1|WASHOUT|2021-02-25|40
e|TR|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|10^3 RNA copies/mL|UNEQUIVOCAL|1|pmol/10^10 cells|MICRODENSITOMETRY|||DOMESTIC PARTNER|PATHOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2021-03-22|65
e|TR|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|5|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|/HPF|TUMOR MERGED|1|dpm/100mg|CONTRAST ENHANCED SPIRAL CT SCAN|Y||FAMILY MEMBER|INTERNIST|Y|5|Visit_5|90|1|FOLLOW-UP|2021-04-16|90
e|TR|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|1|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|mL/cm H2O|NON-PATHOLOGICAL|1|CONTAINER|AUSCULTATION|||SIGNIFICANT OTHER|CARDIOLOGIST|Y|1|Visit_1|10|3|SCREENING|2020-08-24|10
e|TR|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|2|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|umol/L/sec|ENLARGEMENT FROM NADIR|1|cL|CALCULATION||Y|FRIEND|OPHTHALMOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-09-08|25
e|TR|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|3|[?]|PCHGBL|Percent Change From Baseline|[?]|CIGARETTE|TUMOR MERGED|1|PHERESIS UNIT|GC/MS-CI||Y|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-09-23|40
e|TR|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|ng/day|UNCHANGED|1|days/month|HPLC|Y||STUDY SUBJECT|MICROSCOPIST 1|U|4|Visit_4|65|6|TREATMENT|2020-10-18|65
e|TR|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|5|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|mg/mL/day|INCREASED|1|mV|MICROBIAL CULTURE, LIQUID|||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|5|Visit_5|90|7|FOLLOW-UP|2020-11-12|90
e|TR|9b268a13-dc40-4eb6-8729-c131ac302dd3|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|mmol/mol|ENLARGEMENT FROM NADIR|1|U/cL|DIGITAL PCR||Y|STUDY SUBJECT|RATER 2|NA|1|Visit_1|10|1|WASHOUT|2020-05-15|10
e|TR|9b268a13-dc40-4eb6-8729-c131ac302dd3|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|10^7 TCID 50/dose|ABSENT|1|AFU|CLIP|||SIBLING|UROLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-05-30|25
e|TR|9b268a13-dc40-4eb6-8729-c131ac302dd3|3|[?]|VSLFLIND|Vessel Failure Indicator|[?]|kBq|FURTHER ENLARGEMENT|1|mPa|QUANTITATIVE CORONARY ANGIOGRAPHY||Y|INTERVIEWER|RADIOLOGIST 2|Y|3|Visit_3|40|2|FOLLOW-UP|2020-06-14|40
e|TR|9b268a13-dc40-4eb6-8729-c131ac302dd3|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|L/min/m2|EQUIVOCAL|1|amp|LINE PROBE ASSAY|Y||GUARDIAN|OPHTHALMOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-07-09|65
e|TR|9b268a13-dc40-4eb6-8729-c131ac302dd3|5|[?]|LNSTATE|Lymph Node State|[?]|ng/day|EQUIVOCAL|1|TRACE|FUNDUS PHOTOGRAPHY|||CLINICAL STUDY SPONSOR|PATHOLOGIST 2|Y|5|Visit_5|90|7|WASHOUT|2020-08-03|90
e|TR|fa11534a-92f9-4887-828b-25b7637b8f57|1|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|g/kg/day|PALPABLE|1|10^3 CFU/mL|CLINICAL EVALUATION|||GUARDIAN|RATER|U|1|Visit_1|10|2|TREATMENT|2020-12-13|10
e|TR|fa11534a-92f9-4887-828b-25b7637b8f57|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|cm/s|UNEQUIVOCAL|1|Ci|FLUORESCENT ENZYME IMMUNOASSAY|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|U|2|Visit_2|25|3|TREATMENT|2020-12-28|25
e|TR|fa11534a-92f9-4887-828b-25b7637b8f57|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|CYLINDER|PATHOLOGICAL|1|nL|CISH|Y||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|5|FOLLOW-UP|2021-01-12|40
e|TR|fa11534a-92f9-4887-828b-25b7637b8f57|4|[?]|TUMSTATE|Tumor State|[?]|tuberculin unit|FOCALLY INCREASED|1|10^12 IU/L|ICC|Y||DOMESTIC PARTNER|HEMATOLOGIST|NA|4|Visit_4|65|5|FOLLOW-UP|2021-02-06|65
e|TR|fa11534a-92f9-4887-828b-25b7637b8f57|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mg/day|ABSENT|1|ukat/L|GC/MS-EI||Y|SIGNIFICANT OTHER|RATER 2|U|5|Visit_5|90|6|TREATMENT|2021-03-03|90
e|TR|f305f7a3-8c8b-4eca-afb2-4a376f811170|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|NEBULE|NONPALPABLE|1|CFU/mL|SMEAR||Y|INVESTIGATOR|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|6|SCREENING|2020-10-04|10
e|TR|f305f7a3-8c8b-4eca-afb2-4a376f811170|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|ng/L|FOCALLY INCREASED|1|SFC/10^6 PBMC|MICRO BROTH DILUTION|Y||INVESTIGATOR|PATHOLOGIST 1|U|2|Visit_2|25|1|TREATMENT|2020-10-19|25
e|TR|f305f7a3-8c8b-4eca-afb2-4a376f811170|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|days/month|INCREASED|1|kPa/L/sec|MODIFIED ACID FAST STAIN|||FRIEND|PATHOLOGIST 1|U|3|Visit_3|40|4|TREATMENT|2020-11-03|40
e|TR|f305f7a3-8c8b-4eca-afb2-4a376f811170|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|eq|DECREASED|1|dpm/mg|ERGOSPIROMETRY|||ADJUDICATOR|ADJUDICATOR 1|NA|4|Visit_4|65|7|TREATMENT|2020-11-28|65
e|TR|f305f7a3-8c8b-4eca-afb2-4a376f811170|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|g|PRESENT|1|pmol/L/h|URANYL ACETATE STAIN||Y|FRIEND|CARDIOLOGIST|NA|5|Visit_5|90|5|TREATMENT|2020-12-23|90
e|TR|6e4ed6b3-e419-464c-a40e-f100a6894baa|1|[?]|AREA|Area|[?]|nU/cL|DECREASED|1|min/day|IRON HEMATOXYLIN STAIN|||GUARDIAN|RADIOLOGIST|NA|1|Visit_1|10|6|WASHOUT|2020-06-07|10
e|TR|6e4ed6b3-e419-464c-a40e-f100a6894baa|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mol/g|ENLARGEMENT|1|GLOBULE|CRYOSCOPY||Y|SIBLING|OPHTHALMOLOGIST|U|2|Visit_2|25|5|WASHOUT|2020-06-22|25
e|TR|6e4ed6b3-e419-464c-a40e-f100a6894baa|3|[?]|PCHGBL|Percent Change From Baseline|[?]|GBq/ug|ENLARGEMENT FROM NADIR|1|CAPSULE|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||INVESTIGATOR|NEUROLOGIST 1|U|3|Visit_3|40|4|FOLLOW-UP|2020-07-07|40
e|TR|6e4ed6b3-e419-464c-a40e-f100a6894baa|4|[?]|VDIAM|Viable Diameter|[?]|ug/g/h|PRESENT|1|mEq/g|ELASTOGRAPHY|||SIBLING|READER|Y|4|Visit_4|65|6|TREATMENT|2020-08-01|65
e|TR|6e4ed6b3-e419-464c-a40e-f100a6894baa|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mg/m2|INCREASED|1|nmol/L|U-HPLC/MS/MS|||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|U|5|Visit_5|90|4|TREATMENT|2020-08-26|90
e|TR|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|1|[?]|SUMDIAM|Sum of Diameter|[?]|PFU|ENLARGEMENT FROM NADIR|1|Bq/mg|VENTILATION PERFUSION LUNG SCAN|||DOMESTIC PARTNER|PATHOLOGIST 1|N|1|Visit_1|10|4|TREATMENT|2020-08-08|10
e|TR|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|2|[?]|CALCFIND|Calcification Indicator|[?]|km/h|NON-PATHOLOGICAL|1|OD Unit|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||VENDOR|ADJUDICATOR|U|2|Visit_2|25|7|WASHOUT|2020-08-23|25
e|TR|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|3|[?]|PCHGBL|Percent Change From Baseline|[?]|kg/m2|TUMOR MERGED|1|ug/day|IMMUNOCHEMILUMINOMETRIC ASSAY||Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|3|Visit_3|40|2|TREATMENT|2020-09-07|40
e|TR|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mL/animal|PATHOLOGICAL|1|log10 CFU/g|FLUORESCENT IMMUNOASSAY||Y|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2020-10-02|65
e|TR|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|L/s/kPa|INCREASED|1|dpm/mL|PATHOLOGICAL EVALUATION||Y|FRIEND|RATER 2|NA|5|Visit_5|90|7|WASHOUT|2020-10-27|90
e|TR|5d25ac6d-428d-41eb-9549-c23df035a54e|1|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|U/dL|NORMAL|1|U.CARR|KNEMOMETRY|||SPOUSE|NEUROLOGIST 1|NA|1|Visit_1|10|4|WASHOUT|2020-05-13|10
e|TR|5d25ac6d-428d-41eb-9549-c23df035a54e|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|mmHg*min/L|UNCHANGED|1|DIP|IMPEDANCE CONDUCTIVITY||Y|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-05-28|25
e|TR|5d25ac6d-428d-41eb-9549-c23df035a54e|3|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|10^7/L|NORMAL|1|cs|MICROARRAY|||ADJUDICATOR|READER 1|Y|3|Visit_3|40|6|WASHOUT|2020-06-12|40
e|TR|5d25ac6d-428d-41eb-9549-c23df035a54e|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|cGy|NON-PATHOLOGICAL|1|10^7 TCID 50/dose|OLIGO ACGH||Y|GUARDIAN|RADIOLOGIST 2|N|4|Visit_4|65|3|TREATMENT|2020-07-07|65
e|TR|5d25ac6d-428d-41eb-9549-c23df035a54e|5|[?]|VOLUME|Volume|[?]|mm/min|PALPABLE|1|Pack Year|DYNAMIC CONTRAST ENHANCED MRI|||INVESTIGATOR|OPHTHALMOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-08-01|90
e|TR|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|1|[?]|SUMDIAM|Sum of Diameter|[?]|mL/(min*100mL)|PATHOLOGICAL|1|mL/mmHg|TEMPLATE INCISION METHOD|||GUARDIAN|RADIOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-10-30|10
e|TR|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|kat|DECREASED|1|mEq/mL|ALCIAN BLUE STAIN|||FAMILY MEMBER|HEMATOLOGIST|U|2|Visit_2|25|5|WASHOUT|2020-11-14|25
e|TR|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|3|[?]|SUMVOL|Sum of Volume|[?]|Enzyme U|PRESENT|1|SBE/mL|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||VENDOR|UROLOGIST|U|3|Visit_3|40|7|FOLLOW-UP|2020-11-29|40
e|TR|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|4|[?]|PCHGBL|Percent Change From Baseline|[?]|MnFI|UNCHANGED|1|dyn|SANGER SEQUENCING||Y|INTERVIEWER|PATHOLOGIST 1|U|4|Visit_4|65|2|TREATMENT|2020-12-24|65
e|TR|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|5|[?]|PALPSTAT|Palpable State|[?]|cd*s/m2|FURTHER ENLARGEMENT|1|ukat/10^12 RBC|FLOW CYTOMETRY|||CAREGIVER|NEUROLOGIST|N|5|Visit_5|90|5|FOLLOW-UP|2021-01-18|90
e|TR|173aea61-964d-4f4a-8d48-56a1a58de6d8|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|10^9 organisms|ENLARGEMENT FROM NADIR|1|ugEq/L|COLORIMETRY|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|NA|1|Visit_1|10|7|TREATMENT|2020-10-13|10
e|TR|173aea61-964d-4f4a-8d48-56a1a58de6d8|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|PELLET|ENLARGEMENT FROM NADIR|1|cmol/L|IMMUNOTURBIDIMETRY|||DOMESTIC PARTNER|OPHTHALMOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-10-28|25
e|TR|173aea61-964d-4f4a-8d48-56a1a58de6d8|3|[?]|SUMVOL|Sum of Volume|[?]|kBq/uL|ENLARGEMENT FROM NADIR|1|Enzyme U/L|IMMUNOFIXATION ELECTROPHORESIS||Y|ADJUDICATION COMMITTEE|PATHOLOGIST 1|N|3|Visit_3|40|7|FOLLOW-UP|2020-11-12|40
e|TR|173aea61-964d-4f4a-8d48-56a1a58de6d8|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|days/month|ENLARGEMENT FROM NADIR|1|L/L|PET/MRI SCAN|||INTERVIEWER|ENDOCRINOLOGIST|N|4|Visit_4|65|5|TREATMENT|2020-12-07|65
e|TR|173aea61-964d-4f4a-8d48-56a1a58de6d8|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|uL/dose|FURTHER ENLARGEMENT|1|um|HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|5|Visit_5|90|5|TREATMENT|2021-01-01|90
e|TR|45d1adb8-9b3b-4f06-87cb-740205448680|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|uCi|FURTHER ENLARGEMENT FROM NADIR|1|pg|MASS SPECTROMETRY|||GUARDIAN|ONCOLOGIST 2|N|1|Visit_1|10|6|TREATMENT|2020-07-17|10
e|TR|45d1adb8-9b3b-4f06-87cb-740205448680|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|ug/day|FOCALLY INCREASED|1|umol/mg/min|IMPEDANCE CONDUCTIVITY|||INVESTIGATOR|PATHOLOGIST 2|NA|2|Visit_2|25|2|FOLLOW-UP|2020-08-01|25
e|TR|45d1adb8-9b3b-4f06-87cb-740205448680|3|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|10^6 RNA copies/mL|UNEQUIVOCAL|1|cg|EIA|||SIGNIFICANT OTHER|NEUROLOGIST 2|N|3|Visit_3|40|7|WASHOUT|2020-08-16|40
e|TR|45d1adb8-9b3b-4f06-87cb-740205448680|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|g/day|ENLARGEMENT|1|U/mL|MAGNETIC RESONANCE ANGIOGRAPHY||Y|SPOUSE|RATER|N|4|Visit_4|65|2|TREATMENT|2020-09-10|65
e|TR|45d1adb8-9b3b-4f06-87cb-740205448680|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|pmol/L/h|NON-PATHOLOGICAL|1|/LPF|CONGO RED STAIN|||PROXY|ONCOLOGIST 1|U|5|Visit_5|90|6|TREATMENT|2020-10-05|90
e|TR|7403ad67-7ed5-4716-a874-c360429845bc|1|[?]|ACHNAD|Absolute Change From Nadir|[?]|PFU/dose|EQUIVOCAL|1|TABLET|MICROPARTICLE ENZYME IMMUNOASSAY|||SIBLING|PATHOLOGIST 1|U|1|Visit_1|10|6|TREATMENT|2020-05-30|10
e|TR|7403ad67-7ed5-4716-a874-c360429845bc|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|PFU/animal|ABSENT|1|g/animal/day|KLEIHAUER-BETKE|||FRIEND|NEUROLOGIST 1|NA|2|Visit_2|25|6|TREATMENT|2020-06-14|25
e|TR|7403ad67-7ed5-4716-a874-c360429845bc|3|[?]|LESSCIND|Lesion Success Indicator|[?]|/wk|PATHOLOGICAL|1|TRACE|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||STUDY SUBJECT|RADIOLOGIST 1|Y|3|Visit_3|40|2|FOLLOW-UP|2020-06-29|40
e|TR|7403ad67-7ed5-4716-a874-c360429845bc|4|[?]|CALCFIND|Calcification Indicator|[?]|Hz/s|DIFFUSELY INCREASED|1|U/kg/h|RADIAL IMMUNODIFFUSION|||SIGNIFICANT OTHER|INTERNIST|U|4|Visit_4|65|4|FOLLOW-UP|2020-07-24|65
e|TR|7403ad67-7ed5-4716-a874-c360429845bc|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mL/(min*100mL)|INCREASED|1|TRACE|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|N|5|Visit_5|90|3|FOLLOW-UP|2020-08-18|90
e|TR|8be919ce-34da-4e49-ac7a-3679c7af632d|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|JDF Unit|EQUIVOCAL|1|fg|STATIC PERIMETRY|Y||INDEPENDENT ASSESSOR|CARDIOLOGIST|N|1|Visit_1|10|1|TREATMENT|2021-01-13|10
e|TR|8be919ce-34da-4e49-ac7a-3679c7af632d|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|mm/min|EQUIVOCAL|1|EID 50/mL|FUNCTIONAL MRI|||INDEPENDENT ASSESSOR|ADJUDICATOR 1|N|2|Visit_2|25|3|SCREENING|2021-01-28|25
e|TR|8be919ce-34da-4e49-ac7a-3679c7af632d|3|[?]|LDIAM|Longest Diameter|[?]|Gy/h|UNEQUIVOCAL|1|10^7 CFU|TURBIDIMETRY|Y|Y|SIGNIFICANT OTHER|MICROSCOPIST 2|Y|3|Visit_3|40|2|FOLLOW-UP|2021-02-12|40
e|TR|8be919ce-34da-4e49-ac7a-3679c7af632d|4|[?]|NEWCONF|New Tumor Confirmed|[?]|nm|INCREASED|1|mg/L|CT SCAN WITHOUT CONTRAST|Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|N|4|Visit_4|65|1|TREATMENT|2021-03-09|65
e|TR|8be919ce-34da-4e49-ac7a-3679c7af632d|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|IU/mmol|ABSENT|1|Ci/L|ACCELERATOR MASS SPECTROMETRY|Y||ADJUDICATION COMMITTEE|MICROSCOPIST 1|Y|5|Visit_5|90|6|FOLLOW-UP|2021-04-03|90
e|TR|9c44967b-914e-43d5-be1e-6829804e04ab|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|nmol BCE/L|TUMOR MERGED|1|mg/dose|KINYOUN STAIN|||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2021-01-24|10
e|TR|9c44967b-914e-43d5-be1e-6829804e04ab|2|[?]|SUMDIAM|Sum of Diameter|[?]|NEEDLE GAUGE|ENLARGEMENT FROM NADIR|1|PA|WHOLE EXOME SEQUENCING|Y||SPOUSE|PATHOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2021-02-08|25
e|TR|9c44967b-914e-43d5-be1e-6829804e04ab|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|APPLICATION|PATHOLOGICAL|1|uCi/kg|OPTICAL COHERENCE TOMOGRAPHY|Y||PROXY|ONCOLOGIST 2|Y|3|Visit_3|40|1|WASHOUT|2021-02-23|40
e|TR|9c44967b-914e-43d5-be1e-6829804e04ab|4|[?]|VOLUME|Volume|[?]|g/g|FURTHER ENLARGEMENT FROM NADIR|1|pg/dL|MICROBIAL CULTURE, SOLID|Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|4|Visit_4|65|1|TREATMENT|2021-03-20|65
e|TR|9c44967b-914e-43d5-be1e-6829804e04ab|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|uL/dose|NORMAL|1|RATIO|MACRO BROTH DILUTION|Y|Y|PARENT|OTOLARYNGOLOGIST|U|5|Visit_5|90|2|TREATMENT|2021-04-14|90
e|TR|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|1|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|GBq|PALPABLE|1|Ci|NON-INVASIVE DIELECTRIC SENSING|||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|N|1|Visit_1|10|7|TREATMENT|2020-07-31|10
e|TR|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|kBq|NORMAL|1|pmol/g|NUCLEAR RADIOLOGY|||STUDY SUBJECT|HEMATOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-08-15|25
e|TR|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|/sec|UNCHANGED|1|EP U|TRIPLE-PHASE SPIRAL CT SCAN|Y||FRIEND|PATHOLOGIST 2|NA|3|Visit_3|40|6|FOLLOW-UP|2020-08-30|40
e|TR|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mmHg*min/L|TUMOR MERGED|1|ft2|SIZE EXCLUSION CHROMATOGRAPHY||Y|PARENT|UROLOGIST|N|4|Visit_4|65|7|SCREENING|2020-09-24|65
e|TR|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|ms/mmHg|FURTHER ENLARGEMENT|1|Watt|PALM METHOD|Y|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|N|5|Visit_5|90|4|TREATMENT|2020-10-19|90
e|TR|cad8c553-739f-4046-a898-d939eb286dba|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|10^6/hpf|ENLARGEMENT|1|min*mg/mL|SPIROMETRY|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|Y|1|Visit_1|10|3|WASHOUT|2020-05-17|10
e|TR|cad8c553-739f-4046-a898-d939eb286dba|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|IU/dL|UNCHANGED|1|cmol/L|GC/MS|||ADJUDICATION COMMITTEE|ONCOLOGIST|NA|2|Visit_2|25|3|FOLLOW-UP|2020-06-01|25
e|TR|cad8c553-739f-4046-a898-d939eb286dba|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|cmHg|ENLARGEMENT|1|YEARS|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y|CHILD|UROLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-06-16|40
e|TR|cad8c553-739f-4046-a898-d939eb286dba|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|PACKET|ENLARGEMENT FROM NADIR|1|10^6/g|SPECTROPHOTOMETRY|||FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-07-11|65
e|TR|cad8c553-739f-4046-a898-d939eb286dba|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|PIXEL|ENLARGEMENT|1|dpm/100mg|MICRODENSITOMETRY|||ADJUDICATION COMMITTEE|HEMATOLOGIST|NA|5|Visit_5|90|2|FOLLOW-UP|2020-08-05|90
e|TR|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|1|[?]|LNSTATE|Lymph Node State|[?]|10^9 CFU/g|UNCHANGED|1|copies/mL|HILLMEN COLOR CHART||Y|SPOUSE|OPTOMETRIST|NA|1|Visit_1|10|6|SCREENING|2020-09-11|10
e|TR|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|2|[?]|SUMDIAM|Sum of Diameter|[?]|ft|ENLARGEMENT|1|10^4/hpf|BETA LACTAMASE|||CHILD|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|3|WASHOUT|2020-09-26|25
e|TR|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|3|[?]|PPD|Product of Perpendicular Diameters|[?]|mol/mol|EQUIVOCAL|1|PFU/animal|SMEAR|Y||VENDOR|RADIOLOGIST 2|N|3|Visit_3|40|4|TREATMENT|2020-10-11|40
e|TR|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|4|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|ng/dL|ENLARGEMENT FROM NADIR|1|lx|TURBIDIMETRY|||PARENT|RADIOLOGIST 2|NA|4|Visit_4|65|4|TREATMENT|2020-11-05|65
e|TR|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|U/animal|FURTHER ENLARGEMENT FROM NADIR|1|kUSP|FLUORESCEIN STAIN|Y|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|NA|5|Visit_5|90|3|SCREENING|2020-11-30|90
e|TR|81e934f8-7bcc-48d2-8d15-5270e51f2870|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|ug/m2/h|ENLARGEMENT FROM NADIR|1|IU/dL|SCANNING ELECTRON MICROSCOPY|Y||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|Y|1|Visit_1|10|4|TREATMENT|2021-01-24|10
e|TR|81e934f8-7bcc-48d2-8d15-5270e51f2870|2|[?]|LPERP|Longest Perpendicular|[?]|ug/g/min|NORMAL|1|Bq|ENZYMATIC ULTRACENTRIFUGATION|||FRIEND|PATHOLOGIST|U|2|Visit_2|25|1|SCREENING|2021-02-08|25
e|TR|81e934f8-7bcc-48d2-8d15-5270e51f2870|3|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|C|ABSENT|1|scm|POLYSOMNOGRAPHY|||CLINICAL RESEARCH COORDINATOR|RATER|N|3|Visit_3|40|2|SCREENING|2021-02-23|40
e|TR|81e934f8-7bcc-48d2-8d15-5270e51f2870|4|[?]|NEWCONF|New Tumor Confirmed|[?]|ms/mmHg|DECREASED|1|mol/L|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y|DOMESTIC PARTNER|ONCOLOGIST 1|Y|4|Visit_4|65|5|TREATMENT|2021-03-20|65
e|TR|81e934f8-7bcc-48d2-8d15-5270e51f2870|5|[?]|TUMSTATE|Tumor State|[?]|10^6 DNA copies/mL|DIFFUSELY INCREASED|1|PFU/dose|MULTI-SLICE SPIRAL CT|||CAREGIVER|PATHOLOGIST 1|NA|5|Visit_5|90|6|WASHOUT|2021-04-14|90
e|TR|5713cabe-4d79-4f77-8ddc-daad1242a837|1|[?]|PPD|Product of Perpendicular Diameters|[?]|g/animal|INCREASED|1|steps/min|HEMOCYTOMETRY|||FAMILY MEMBER|RATER 1|N|1|Visit_1|10|4|TREATMENT|2020-09-09|10
e|TR|5713cabe-4d79-4f77-8ddc-daad1242a837|2|[?]|LNSTATE|Lymph Node State|[?]|U/kg/h|NORMAL|1|deg2|SLOAN LETTER EYE CHART 1.25%|Y||VENDOR|MICROSCOPIST 3|U|2|Visit_2|25|1|TREATMENT|2020-09-24|25
e|TR|5713cabe-4d79-4f77-8ddc-daad1242a837|3|[?]|SUMVOL|Sum of Volume|[?]|POINT|TUMOR MERGED|1|uIU/dL|EIA|||INDEPENDENT ASSESSOR|CARDIOLOGIST|Y|3|Visit_3|40|2|SCREENING|2020-10-09|40
e|TR|5713cabe-4d79-4f77-8ddc-daad1242a837|4|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|Ci/mL|TUMOR MERGED|1|nkat/g Hb|AGAR DILUTION|||INVESTIGATOR|NEUROLOGIST|N|4|Visit_4|65|5|SCREENING|2020-11-03|65
e|TR|5713cabe-4d79-4f77-8ddc-daad1242a837|5|[?]|LDIAM|Longest Diameter|[?]|cd/m2|DECREASED|1|MBP|CLINICAL EVALUATION|Y||CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-11-28|90
e|TR|414d20c7-8dc8-49ad-8ae9-f113b9610109|1|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|10^5/L|UNEQUIVOCAL|1|mL/(min*100mL)|URANYL ACETATE STAIN|||SPOUSE|ADJUDICATOR|U|1|Visit_1|10|4|WASHOUT|2020-07-10|10
e|TR|414d20c7-8dc8-49ad-8ae9-f113b9610109|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|kPa/L/sec|FURTHER ENLARGEMENT FROM NADIR|1|mL/animal|DIFFUSION WEIGHTED MRI||Y|PROXY|ONCOLOGIST|N|2|Visit_2|25|2|FOLLOW-UP|2020-07-25|25
e|TR|414d20c7-8dc8-49ad-8ae9-f113b9610109|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|10^6 organisms/mL|FURTHER ENLARGEMENT|1|ugEq/L|PHASE CONTRAST MICROSCOPY|||FAMILY MEMBER|RADIOLOGIST 1|U|3|Visit_3|40|5|SCREENING|2020-08-09|40
e|TR|414d20c7-8dc8-49ad-8ae9-f113b9610109|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mCi|UNEQUIVOCAL|1|grain|IMMUNOPRECIPITATION|||INDEPENDENT ASSESSOR|INTERNIST|Y|4|Visit_4|65|5|FOLLOW-UP|2020-09-03|65
e|TR|414d20c7-8dc8-49ad-8ae9-f113b9610109|5|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|cmH2O/mL|UNCHANGED|1|10^3 DNA copies/mL|DIRECT SEQUENCING|||INVESTIGATOR|ONCOLOGIST|NA|5|Visit_5|90|2|SCREENING|2020-09-28|90
e|TR|21e16094-23bd-4d20-b5f8-10d45858160e|1|[?]|ORVERLN|Organ Vertical Length|[?]|ug/m2/h|UNEQUIVOCAL|1|Enzyme U|REFRACTOMETRY|Y||INVESTIGATOR|ADJUDICATOR 3|NA|1|Visit_1|10|4|WASHOUT|2020-09-17|10
e|TR|21e16094-23bd-4d20-b5f8-10d45858160e|2|[?]|RADIODEN|Radiodensity|[?]|cmH2O/mL|DECREASED|1|ft3|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y||ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|Y|2|Visit_2|25|5|FOLLOW-UP|2020-10-02|25
e|TR|21e16094-23bd-4d20-b5f8-10d45858160e|3|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|nmol|EQUIVOCAL|1|V|HEMAGGLUTINATION ASSAY|||SIBLING|ONCOLOGIST|Y|3|Visit_3|40|5|FOLLOW-UP|2020-10-17|40
e|TR|21e16094-23bd-4d20-b5f8-10d45858160e|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|BAG|PATHOLOGICAL|1|nmol/mL/min|SINGLE-MOLECULE ARRAY||Y|SIBLING|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|2|TREATMENT|2020-11-11|65
e|TR|21e16094-23bd-4d20-b5f8-10d45858160e|5|[?]|LDIAM|Longest Diameter|[?]|BAU|DECREASED|1|Ci/uL|DYNAMIC CONTRAST ENHANCED MRI|||CAREGIVER|INTERNIST|NA|5|Visit_5|90|2|FOLLOW-UP|2020-12-06|90
e|TR|2346613e-6734-476a-a414-511606c2d753|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|uCi|DIFFUSELY INCREASED|1|INHALATION|PERIODIC ACID SCHIFF STAIN|||PROXY|NEUROLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-09-22|10
e|TR|2346613e-6734-476a-a414-511606c2d753|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|IU/g|FURTHER ENLARGEMENT FROM NADIR|1|mL/sec/1.73m2|CINEANGIOGRAPHY|||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-10-07|25
e|TR|2346613e-6734-476a-a414-511606c2d753|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mL*cmH2O|ENLARGEMENT|1|pt_us|HILLMEN COLOR CHART|||GUARDIAN|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|4|WASHOUT|2020-10-22|40
e|TR|2346613e-6734-476a-a414-511606c2d753|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|Ci/ug|UNCHANGED|1|NFIU|ATOMIC ABSORPTION SPECTROMETRY|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|4|Visit_4|65|3|WASHOUT|2020-11-16|65
e|TR|2346613e-6734-476a-a414-511606c2d753|5|[?]|PCHGBL|Percent Change From Baseline|[?]|10^6 CFU|NORMAL|1|CAPSULE|LIQUID SCINTILLATION COUNTING|||SIBLING|OPTOMETRIST|NA|5|Visit_5|90|6|TREATMENT|2020-12-11|90
e|TR|6a8bda83-1b5a-481e-af4f-77fe74bc37be|1|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|SQU/mL|UNCHANGED|1|um/day|FISH|Y|Y|VENDOR|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|5|FOLLOW-UP|2020-11-26|10
e|TR|6a8bda83-1b5a-481e-af4f-77fe74bc37be|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mm3/mm2/year|INCREASED|1|Ci/mg|COMPLEMENT FIXATION|||CHILD|NEUROLOGIST|NA|2|Visit_2|25|2|WASHOUT|2020-12-11|25
e|TR|6a8bda83-1b5a-481e-af4f-77fe74bc37be|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|h/wk|TUMOR MERGED|1|mL/s|OPTICAL MAPPING|||CHILD|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-12-26|40
e|TR|6a8bda83-1b5a-481e-af4f-77fe74bc37be|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|CCID 50/dose|FOCALLY INCREASED|1|WAFER|WHOLE GENOME SEQUENCING||Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|7|FOLLOW-UP|2021-01-20|65
e|TR|6a8bda83-1b5a-481e-af4f-77fe74bc37be|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|in2|PATHOLOGICAL|1|g/cage/day|OPTICAL MAPPING|||ADJUDICATOR|ADJUDICATOR 2|U|5|Visit_5|90|2|TREATMENT|2021-02-14|90
e|TR|748ef401-3def-4674-8d5e-4a198709d672|1|[?]|VDIAM|Viable Diameter|[?]|MAC50|ENLARGEMENT|1|EU|ALCIAN BLUE STAIN|Y|Y|ADJUDICATOR|DERMATOLOGIST|Y|1|Visit_1|10|7|WASHOUT|2020-06-08|10
e|TR|748ef401-3def-4674-8d5e-4a198709d672|2|[?]|TUMSTATE|Tumor State|[?]|psec|NONPALPABLE|1|NFIU|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||NON-HEALTH CARE PROFESSIONAL|RATER|N|2|Visit_2|25|3|TREATMENT|2020-06-23|25
e|TR|748ef401-3def-4674-8d5e-4a198709d672|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|IU/dL|PALPABLE|1|PIXELS/cm|ANTIBIOTIC AGAR SCREEN|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|3|Visit_3|40|3|TREATMENT|2020-07-08|40
e|TR|748ef401-3def-4674-8d5e-4a198709d672|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|kPa/L/sec|DECREASED|1|mL/h|SISH|||VENDOR|READER 3|U|4|Visit_4|65|7|WASHOUT|2020-08-02|65
e|TR|748ef401-3def-4674-8d5e-4a198709d672|5|[?]|ORVERLN|Organ Vertical Length|[?]|uCi/kg|FOCALLY INCREASED|1|10^9 CFU/g|ACRIDINE ORANGE STAIN|||SIBLING|RADIOLOGIST 1|U|5|Visit_5|90|1|WASHOUT|2020-08-27|90
e|TR|03c399c1-77b9-4879-a6e8-42ba58ca68d4|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mL/cm3/min|FURTHER ENLARGEMENT|1|mU/L|WHOLE GENOME SEQUENCING|Y|Y|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|5|WASHOUT|2020-07-15|10
e|TR|03c399c1-77b9-4879-a6e8-42ba58ca68d4|2|[?]|LMBFLIND|Limb Failure Indicator|[?]|nmol/day|DIFFUSELY INCREASED|1|PIXELS/in|CALIPER MEASUREMENT METHOD||Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|2|Visit_2|25|5|WASHOUT|2020-07-30|25
e|TR|03c399c1-77b9-4879-a6e8-42ba58ca68d4|3|[?]|VOLUME|Volume|[?]|CONTAINER|PRESENT|1|kg|FUNDUS PHOTOGRAPHY|||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|U|3|Visit_3|40|1|TREATMENT|2020-08-14|40
e|TR|03c399c1-77b9-4879-a6e8-42ba58ca68d4|4|[?]|AREA|Area|[?]|mol/mol|DIFFUSELY INCREASED|1|Hounsfield Unit|CONGO RED STAIN|||PARENT|OTOLARYNGOLOGIST|U|4|Visit_4|65|3|SCREENING|2020-09-08|65
e|TR|03c399c1-77b9-4879-a6e8-42ba58ca68d4|5|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mL|PALPABLE|1|mOsm/kg|SINGLE-SLICE SPIRAL CT|||STUDY SUBJECT|ONCOLOGIST|N|5|Visit_5|90|2|WASHOUT|2020-10-03|90
e|TR|b8afdaf1-5c4d-408f-b8ba-381461f15bde|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|cm/s|ENLARGEMENT|1|cmol|IMMUNORADIOMETRIC ASSAY||Y|FAMILY MEMBER|OTOLARYNGOLOGIST|NA|1|Visit_1|10|6|TREATMENT|2020-11-13|10
e|TR|b8afdaf1-5c4d-408f-b8ba-381461f15bde|2|[?]|CALCFIND|Calcification Indicator|[?]|mg|FURTHER ENLARGEMENT FROM NADIR|1|/ms|NON-CONTACT SPECULAR MICROSCOPY||Y|FRIEND|OPHTHALMOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-11-28|25
e|TR|b8afdaf1-5c4d-408f-b8ba-381461f15bde|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|cpm|ENLARGEMENT FROM NADIR|1|MET*h|CARDIAC THERMODILUTION|||CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-12-13|40
e|TR|b8afdaf1-5c4d-408f-b8ba-381461f15bde|4|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|BAU|DIFFUSELY INCREASED|1|Gauss|ALCIAN BLUE STAIN|Y|Y|FRIEND|ONCOLOGIST 2|Y|4|Visit_4|65|7|WASHOUT|2021-01-07|65
e|TR|b8afdaf1-5c4d-408f-b8ba-381461f15bde|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|10^6 organisms/g|DECREASED|1|ug/mol|IMMUNOPRECIPITATION|||STUDY SUBJECT|PATHOLOGIST 1|U|5|Visit_5|90|4|TREATMENT|2021-02-01|90
e|TR|8115d6e8-0908-4491-a82a-08f43ccf1f0d|1|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|log10 IU/mL|ABSENT|1|BISCUIT|ECHOCARDIOGRAPHY|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|N|1|Visit_1|10|1|TREATMENT|2020-11-28|10
e|TR|8115d6e8-0908-4491-a82a-08f43ccf1f0d|2|[?]|ORSTATE|Organ State|[?]|CCID 50/dose|ABSENT|1|mg/day|SIZE EXCLUSION CHROMATOGRAPHY|||ADJUDICATION COMMITTEE|DERMATOLOGIST|Y|2|Visit_2|25|7|FOLLOW-UP|2020-12-13|25
e|TR|8115d6e8-0908-4491-a82a-08f43ccf1f0d|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|mL/beat|PATHOLOGICAL|1|mL/s|DARK FIELD MICROSCOPY|||GUARDIAN|ADJUDICATOR 2|NA|3|Visit_3|40|2|TREATMENT|2020-12-28|40
e|TR|8115d6e8-0908-4491-a82a-08f43ccf1f0d|4|[?]|VDIAM|Viable Diameter|[?]|mm/2h|PALPABLE|1|bel|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||INDEPENDENT ASSESSOR|PATHOLOGIST 2|N|4|Visit_4|65|4|SCREENING|2021-01-22|65
e|TR|8115d6e8-0908-4491-a82a-08f43ccf1f0d|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|BOLUS|FURTHER ENLARGEMENT|1|CIGARETTE|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|5|Visit_5|90|4|WASHOUT|2021-02-16|90
e|TR|fbd7ecb2-905f-40a9-babc-ebaf310cc372|1|[?]|VDIAM|Viable Diameter|[?]|10^8/L|PATHOLOGICAL|1|mOsm|LANDOLT RING|Y|Y|FAMILY MEMBER|RATER 2|N|1|Visit_1|10|1|WASHOUT|2020-06-30|10
e|TR|fbd7ecb2-905f-40a9-babc-ebaf310cc372|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|nmol/L/min|ENLARGEMENT FROM NADIR|1|uL/mL|RAJI CELL EIA|||GUARDIAN|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|4|SCREENING|2020-07-15|25
e|TR|fbd7ecb2-905f-40a9-babc-ebaf310cc372|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|DROP|ABSENT|1|cy/cm|NUCLEIC ACID SEQUENCING|Y||ADJUDICATOR|RADIOLOGIST|Y|3|Visit_3|40|5|SCREENING|2020-07-30|40
e|TR|fbd7ecb2-905f-40a9-babc-ebaf310cc372|4|[?]|ORSTATE|Organ State|[?]|COAT|DECREASED|1|MPL U|FORCED OSCILLATION TECHNIQUE|||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-08-24|65
e|TR|fbd7ecb2-905f-40a9-babc-ebaf310cc372|5|[?]|CALCFIND|Calcification Indicator|[?]|umol/min|UNEQUIVOCAL|1|mgEq|SPECULAR MICROSCOPY|||INVESTIGATOR|MICROSCOPIST 1|NA|5|Visit_5|90|4|TREATMENT|2020-09-18|90
e|TR|1a0e1a66-82dd-4945-9c9f-179fba9d781e|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|/2500 WBC|DIFFUSELY INCREASED|1|uCi/L|POLYSOMNOGRAPHY|||SPOUSE|ONCOLOGIST 1|U|1|Visit_1|10|1|TREATMENT|2020-12-09|10
e|TR|1a0e1a66-82dd-4945-9c9f-179fba9d781e|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|genEq|PALPABLE|1|Ci/uL|LINE PROBE ASSAY|Y|Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|1|WASHOUT|2020-12-24|25
e|TR|1a0e1a66-82dd-4945-9c9f-179fba9d781e|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|ug/m2|ENLARGEMENT FROM NADIR|1|IU|RIA|Y||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2021-01-08|40
e|TR|1a0e1a66-82dd-4945-9c9f-179fba9d781e|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|mmol/g|ABSENT|1|DAgU|KINETIC CHROMOGENIC ASSAY|||DOMESTIC PARTNER|ONCOLOGIST 2|NA|4|Visit_4|65|2|FOLLOW-UP|2021-02-02|65
e|TR|1a0e1a66-82dd-4945-9c9f-179fba9d781e|5|[?]|ACHNAD|Absolute Change From Nadir|[?]|PACK|PATHOLOGICAL|1|mAmp|DROPLET DIGITAL PCR|Y|Y|SIGNIFICANT OTHER|MICROSCOPIST|N|5|Visit_5|90|4|TREATMENT|2021-02-27|90
e|TR|b3ab1879-3dc7-41fa-be53-f4484af21fbd|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|GBq/ug|FOCALLY INCREASED|1|CARTRIDGE|PUPILLOMETRY|||PROXY|PATHOLOGIST 2|Y|1|Visit_1|10|5|TREATMENT|2020-11-19|10
e|TR|b3ab1879-3dc7-41fa-be53-f4484af21fbd|2|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|uL|ENLARGEMENT FROM NADIR|1|copies/uL|FLUORIMETRY|||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|7|WASHOUT|2020-12-04|25
e|TR|b3ab1879-3dc7-41fa-be53-f4484af21fbd|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|mg/L FEU|PRESENT|1|s^-1(%O2)^-1|REFRACTOMETRY|Y||STUDY SUBJECT|MICROSCOPIST|N|3|Visit_3|40|6|TREATMENT|2020-12-19|40
e|TR|b3ab1879-3dc7-41fa-be53-f4484af21fbd|4|[?]|VDIAM|Viable Diameter|[?]|dpm/mL|ABSENT|1|10^9 organisms|NON-CONTACT SPECULAR MICROSCOPY|||DOMESTIC PARTNER|ADJUDICATOR 2|NA|4|Visit_4|65|6|TREATMENT|2021-01-13|65
e|TR|b3ab1879-3dc7-41fa-be53-f4484af21fbd|5|[?]|ORVERLN|Organ Vertical Length|[?]|copies/mL|ENLARGEMENT FROM NADIR|1|10^3 organisms|CELLULOSE TAPE||Y|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|5|Visit_5|90|6|FOLLOW-UP|2021-02-07|90
e|TR|bc71ddfa-c71c-447b-9684-005e4c112172|1|[?]|VOLUME|Volume|[?]|U/m2|NORMAL|1|nm|SLIT LAMP||Y|INTERVIEWER|READER 2|U|1|Visit_1|10|2|SCREENING|2020-07-11|10
e|TR|bc71ddfa-c71c-447b-9684-005e4c112172|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|pkat|NORMAL|1|Log10 ELISA unit|GC/FID|||HEALTH CARE PROFESSIONAL|READER 1|N|2|Visit_2|25|3|FOLLOW-UP|2020-07-26|25
e|TR|bc71ddfa-c71c-447b-9684-005e4c112172|3|[?]|RADIODEN|Radiodensity|[?]|/4.0 mL|FURTHER ENLARGEMENT|1|cy/cm|TRIPLE-PHASE SPIRAL CT SCAN|||HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|3|Visit_3|40|3|WASHOUT|2020-08-10|40
e|TR|bc71ddfa-c71c-447b-9684-005e4c112172|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|/10^3|ENLARGEMENT FROM NADIR|1|ug/L FEU|LISSAMINE GREEN STAIN|||ADJUDICATOR|READER 3|U|4|Visit_4|65|7|TREATMENT|2020-09-04|65
e|TR|bc71ddfa-c71c-447b-9684-005e4c112172|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|m/sec2|TUMOR MERGED|1|FEU|SICKLE CELL SOLUBILITY TEST||Y|INDEPENDENT ASSESSOR|INTERNIST|N|5|Visit_5|90|4|TREATMENT|2020-09-29|90
e|TR|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|F|ENLARGEMENT|1|copies/uL|IN SITU HYBRIDIZATION|Y|Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|N|1|Visit_1|10|3|SCREENING|2020-12-09|10
e|TR|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|2|[?]|TUMSTATE|Tumor State|[?]|kBq/uL|FURTHER ENLARGEMENT FROM NADIR|1|ng/L|SINGLE-SLICE SPIRAL CT|Y|Y|HEALTH CARE PROFESSIONAL|RATER 2|NA|2|Visit_2|25|4|SCREENING|2020-12-24|25
e|TR|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|3|[?]|PCHGBL|Percent Change From Baseline|[?]|kPa/L/sec|NORMAL|1|U/mg|GC/MS/MS|||FAMILY MEMBER|ONCOLOGIST 1|Y|3|Visit_3|40|2|TREATMENT|2021-01-08|40
e|TR|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|4|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|nmol/g|INCREASED|1|ug/m2|PULSE OXIMETRY|||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|U|4|Visit_4|65|6|TREATMENT|2021-02-02|65
e|TR|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|5|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|cm H2O|NONPALPABLE|1|kg/m2|IMPULSE OSCILLOMETRY|Y||INTERVIEWER|ONCOLOGIST|N|5|Visit_5|90|6|TREATMENT|2021-02-27|90
e|TR|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|1|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|AFU|DECREASED|1|ms2|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||STUDY SUBJECT|ADJUDICATOR|Y|1|Visit_1|10|5|TREATMENT|2020-09-06|10
e|TR|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|IU/mL|PALPABLE|1|mol/mg|CALCULATION||Y|FRIEND|RATER|NA|2|Visit_2|25|4|SCREENING|2020-09-21|25
e|TR|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|nmol/L/h|UNEQUIVOCAL|1|ng/L|CELL OF ORIGIN ASSAY|||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-10-06|40
e|TR|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|%|UNCHANGED|1|10^3 RNA copies/mL|IN VITRO GENE EXPRESSION ASSAY||Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|4|Visit_4|65|5|TREATMENT|2020-10-31|65
e|TR|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|ug/L DDU|ENLARGEMENT|1|mg/mL/min|TRYPAN BLUE STAIN|||CHILD|MICROSCOPIST 3|U|5|Visit_5|90|7|TREATMENT|2020-11-25|90
e|TR|b1b3e113-8c73-4446-8095-3341f8912bd7|1|[?]|DIAMETER|Diameter|[?]|mg/mL/day|FURTHER ENLARGEMENT FROM NADIR|1|PNU/mL|ECHOCARDIOGRAPHY|||CHILD|OPTOMETRIST|N|1|Visit_1|10|2|TREATMENT|2021-01-27|10
e|TR|b1b3e113-8c73-4446-8095-3341f8912bd7|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|Log10 ELISA unit/dose|NON-PATHOLOGICAL|1|Anson U|CELL OF ORIGIN ASSAY||Y|INDEPENDENT ASSESSOR|ONCOLOGIST 2|U|2|Visit_2|25|1|TREATMENT|2021-02-11|25
e|TR|b1b3e113-8c73-4446-8095-3341f8912bd7|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|ft|ENLARGEMENT FROM NADIR|1|10^6 CFU/mL|SPIRAL CT||Y|INTERVIEWER|ONCOLOGIST 1|NA|3|Visit_3|40|6|SCREENING|2021-02-26|40
e|TR|b1b3e113-8c73-4446-8095-3341f8912bd7|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|dpm/mg|UNCHANGED|1|Roentgen|DUKE INCISION METHOD|||SIBLING|OTOLARYNGOLOGIST|N|4|Visit_4|65|6|SCREENING|2021-03-23|65
e|TR|b1b3e113-8c73-4446-8095-3341f8912bd7|5|[?]|PALPSTAT|Palpable State|[?]|g/animal|NON-PATHOLOGICAL|1|FINGERTIP UNIT|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||DOMESTIC PARTNER|RATER 2|Y|5|Visit_5|90|7|WASHOUT|2021-04-17|90
e|TR|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|1|[?]|ORSTATE|Organ State|[?]|PFU/animal|DIFFUSELY INCREASED|1|1/(s*kPa)|GRAM STAIN|Y||DOMESTIC PARTNER|ENDOCRINOLOGIST|NA|1|Visit_1|10|7|WASHOUT|2020-11-22|10
e|TR|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|2|[?]|LESSCIND|Lesion Success Indicator|[?]|ug/L DDU|FOCALLY INCREASED|1|mN|POLYSOMNOGRAPHY|||CHILD|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|2|WASHOUT|2020-12-07|25
e|TR|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|3|[?]|PALPSTAT|Palpable State|[?]|10^7 PFU|NORMAL|1|pptr|DYNAMIC CONTRAST ENHANCED MRI|Y||ADJUDICATION COMMITTEE|PATHOLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-12-22|40
e|TR|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|4|[?]|VDIAM|Viable Diameter|[?]|BEAM BREAKS|INCREASED|1|/10^4|TONOMETRY||Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|Y|4|Visit_4|65|1|FOLLOW-UP|2021-01-16|65
e|TR|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|5|[?]|CALCFIND|Calcification Indicator|[?]|MdFI|TUMOR MERGED|1|Ci/kg|IN SITU HYBRIDIZATION||Y|PARENT|MICROSCOPIST 1|U|5|Visit_5|90|3|TREATMENT|2021-02-10|90
e|TR|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|msec|PALPABLE|1|Gy|PULMONARY ANGIOGRAPHY|||STUDY SUBJECT|RADIOLOGIST 1|Y|1|Visit_1|10|4|TREATMENT|2020-08-06|10
e|TR|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|2|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|HEP|NONPALPABLE|1|mg/dose|DC SHEATH FLOW|Y||CHILD|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-08-21|25
e|TR|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|3|[?]|ORVERLN|Organ Vertical Length|[?]|10^3/hpf|INCREASED|1|AgU/mL|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||PARENT|ADJUDICATOR 2|Y|3|Visit_3|40|1|FOLLOW-UP|2020-09-05|40
e|TR|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|4|[?]|RADIODEN|Radiodensity|[?]|mL/day|FURTHER ENLARGEMENT|1|amp|CLINICAL EVALUATION|||CHILD|ENDOCRINOLOGIST|N|4|Visit_4|65|5|WASHOUT|2020-09-30|65
e|TR|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|5|[?]|PALPSTAT|Palpable State|[?]|g/animal/wk|PATHOLOGICAL|1|mL/cage/wk|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y||PROXY|NEUROLOGIST 1|N|5|Visit_5|90|5|SCREENING|2020-10-25|90
e|TR|3b83c7a0-e22b-45b1-b065-71971f014039|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|pg/dL|NONPALPABLE|1|cd*s/m2|COLORIMETRY|Y||CHILD|CARDIOLOGIST|N|1|Visit_1|10|2|FOLLOW-UP|2020-09-01|10
e|TR|3b83c7a0-e22b-45b1-b065-71971f014039|2|[?]|PCHGBL|Percent Change From Baseline|[?]|EU|UNCHANGED|1|/h|FLUORESCENT SPOT TEST|||CAREGIVER|READER 3|U|2|Visit_2|25|2|TREATMENT|2020-09-16|25
e|TR|3b83c7a0-e22b-45b1-b065-71971f014039|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|nsec|NONPALPABLE|1|V/sec|IMMUNODIFFUSION||Y|CLINICAL STUDY SPONSOR|ONCOLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-10-01|40
e|TR|3b83c7a0-e22b-45b1-b065-71971f014039|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|mg/m2/h|NONPALPABLE|1|IU/g Hb|PHOTOGRAPHY||Y|FAMILY MEMBER|ENDOCRINOLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-10-26|65
e|TR|3b83c7a0-e22b-45b1-b065-71971f014039|5|[?]|PCHGBL|Percent Change From Baseline|[?]|10^5/hpf|NON-PATHOLOGICAL|1|log10 TCID 50/dose|TELLER ACUITY CARDS|Y||ADJUDICATOR|PHYSIOTHERAPIST|U|5|Visit_5|90|2|TREATMENT|2020-11-20|90
e|TR|92c849ce-12b8-4c38-baab-f91c44a007b9|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|SBE/mL|TUMOR MERGED|1|cmH2O*s/mL|GC/MS/MS|||CLINICAL RESEARCH COORDINATOR|READER 2|Y|1|Visit_1|10|7|WASHOUT|2020-11-12|10
e|TR|92c849ce-12b8-4c38-baab-f91c44a007b9|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|mV2/Hz|NORMAL|1|Ci/ug|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y|Y|FAMILY MEMBER|HEMATOLOGIST|N|2|Visit_2|25|6|WASHOUT|2020-11-27|25
e|TR|92c849ce-12b8-4c38-baab-f91c44a007b9|3|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|BE/mL|INCREASED|1|mL/100g/min|IMMUNO-PET SCAN|Y||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|NA|3|Visit_3|40|7|SCREENING|2020-12-12|40
e|TR|92c849ce-12b8-4c38-baab-f91c44a007b9|4|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|ug/dose|UNCHANGED|1|MBq/uL|IMMUNOTURBIDIMETRY|Y||CHILD|NEUROLOGIST 1|NA|4|Visit_4|65|1|TREATMENT|2021-01-06|65
e|TR|92c849ce-12b8-4c38-baab-f91c44a007b9|5|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mL/day|ENLARGEMENT FROM NADIR|1|BOWL|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y|ADJUDICATION COMMITTEE|RATER 1|N|5|Visit_5|90|4|SCREENING|2021-01-31|90
e|TR|f2101018-c983-435e-a453-148f182388f7|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|pmol/10^9 cells|ENLARGEMENT|1|nmol/L/min|VIRUS PLAQUE ASSAY|||DOMESTIC PARTNER|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|2|FOLLOW-UP|2020-09-01|10
e|TR|f2101018-c983-435e-a453-148f182388f7|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|amp|INCREASED|1|GBq/ug|POTENTIOMETRY||Y|SIBLING|RADIOLOGIST 2|NA|2|Visit_2|25|2|TREATMENT|2020-09-16|25
e|TR|f2101018-c983-435e-a453-148f182388f7|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|log10 TCID 50/dose|ENLARGEMENT FROM NADIR|1|U/mL|SINGLE-MOLECULE ARRAY||Y|ADJUDICATOR|READER|U|3|Visit_3|40|7|FOLLOW-UP|2020-10-01|40
e|TR|f2101018-c983-435e-a453-148f182388f7|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|DAgU|FOCALLY INCREASED|1|umol/L|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|1|TREATMENT|2020-10-26|65
e|TR|f2101018-c983-435e-a453-148f182388f7|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|nmol/day|PALPABLE|1|10^3 organisms|PYROSEQUENCING|Y||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|NA|5|Visit_5|90|4|TREATMENT|2020-11-20|90
e|TR|613284eb-edbe-446b-b4fe-f96f1510e626|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|L/s/kPa|PATHOLOGICAL|1|HOURS|CORONARY ANGIOGRAPHY||Y|INTERVIEWER|INTERNIST|Y|1|Visit_1|10|4|WASHOUT|2020-11-07|10
e|TR|613284eb-edbe-446b-b4fe-f96f1510e626|2|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|ug/m2|PALPABLE|1|U/kg/min|FUNDUS PHOTOGRAPHY|||SPOUSE|READER|N|2|Visit_2|25|6|FOLLOW-UP|2020-11-22|25
e|TR|613284eb-edbe-446b-b4fe-f96f1510e626|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|ug|EQUIVOCAL|1|Anson U|CONTACT SPECULAR MICROSCOPY|Y||INVESTIGATOR|HEMATOLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-12-07|40
e|TR|613284eb-edbe-446b-b4fe-f96f1510e626|4|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|mmol/kg|PRESENT|1|tuberculin unit|OPTICAL COHERENCE TOMOGRAPHY|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|4|Visit_4|65|5|SCREENING|2021-01-01|65
e|TR|613284eb-edbe-446b-b4fe-f96f1510e626|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|mL/cm3/min|UNCHANGED|1|10^4/hpf|PHASE CONTRAST MICROSCOPY|||CAREGIVER|RATER 2|NA|5|Visit_5|90|4|TREATMENT|2021-01-26|90
e|TR|65e8391b-0c34-4687-a0ab-cb291a4cdf36|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|g/cm2|FURTHER ENLARGEMENT|1|uIU/dL|CINEANGIOGRAPHY|||SIGNIFICANT OTHER|UROLOGIST|U|1|Visit_1|10|6|WASHOUT|2020-07-15|10
e|TR|65e8391b-0c34-4687-a0ab-cb291a4cdf36|2|[?]|PCHGBL|Percent Change From Baseline|[?]|log10 TCID 50/mL|TUMOR MERGED|1|ug/g/day|PALM METHOD|||PARENT|PHYSIOTHERAPIST|NA|2|Visit_2|25|1|FOLLOW-UP|2020-07-30|25
e|TR|65e8391b-0c34-4687-a0ab-cb291a4cdf36|3|[?]|PPD|Product of Perpendicular Diameters|[?]|Ci/L|UNEQUIVOCAL|1|mV2/Hz|NEURAMINIDASE INHIBITION ASSAY|||FAMILY MEMBER|MICROSCOPIST 3|U|3|Visit_3|40|2|TREATMENT|2020-08-14|40
e|TR|65e8391b-0c34-4687-a0ab-cb291a4cdf36|4|[?]|LPERP|Longest Perpendicular|[?]|cm/s|INCREASED|1|pmol/day|NEXT GENERATION TARGETED SEQUENCING|||PARENT|ONCOLOGIST|NA|4|Visit_4|65|7|TREATMENT|2020-09-08|65
e|TR|65e8391b-0c34-4687-a0ab-cb291a4cdf36|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|CIGARETTE|EQUIVOCAL|1|scm|TOLUIDINE BLUE STAIN|Y||INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|6|TREATMENT|2020-10-03|90
e|TR|2350438a-0bc8-4da5-b6c9-99a6c012b454|1|[?]|DIAMETER|Diameter|[?]|pmol/g|FOCALLY INCREASED|1|RATIO|WESTERGREN|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|1|Visit_1|10|7|TREATMENT|2020-08-21|10
e|TR|2350438a-0bc8-4da5-b6c9-99a6c012b454|2|[?]|VDIAM|Viable Diameter|[?]|CYLINDER|DECREASED|1|L/min|FLUORIMETRY||Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|NA|2|Visit_2|25|1|FOLLOW-UP|2020-09-05|25
e|TR|2350438a-0bc8-4da5-b6c9-99a6c012b454|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|kV|ABSENT|1|FFU|IMMUNOFIXATION ELECTROPHORESIS|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|3|Visit_3|40|3|WASHOUT|2020-09-20|40
e|TR|2350438a-0bc8-4da5-b6c9-99a6c012b454|4|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|kat|FOCALLY INCREASED|1|dB|AUDIOMETRY||Y|SIBLING|CLINICAL PATHOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-10-15|65
e|TR|2350438a-0bc8-4da5-b6c9-99a6c012b454|5|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|/5x10^4 WBC|ENLARGEMENT|1|genEq/mL|U-HPLC/MS/MS|||CHILD|ONCOLOGIST 1|U|5|Visit_5|90|4|TREATMENT|2020-11-09|90
e|TR|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|1|[?]|BNLNUM|Number of Bone Lesions|[?]|cL|FURTHER ENLARGEMENT FROM NADIR|1|/wk|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|1|Visit_1|10|6|TREATMENT|2020-11-16|10
e|TR|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|ug/cm2|NONPALPABLE|1|RNA copies/mL|LEAD CITRATE STAIN|||CLINICAL STUDY SPONSOR|HEMATOLOGIST|N|2|Visit_2|25|5|TREATMENT|2020-12-01|25
e|TR|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|3|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|VOXEL|ABSENT|1|V/sec|FLOW MICROSCOPY|Y|Y|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|7|SCREENING|2020-12-16|40
e|TR|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|4|[?]|LNSTATE|Lymph Node State|[?]|ug/m2|PRESENT|1|DPM|SLOAN LETTER EYE CHART 1.25%|||NON-HEALTH CARE PROFESSIONAL|RATER 1|Y|4|Visit_4|65|5|FOLLOW-UP|2021-01-10|65
e|TR|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|5|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|10^6 organisms/g|UNEQUIVOCAL|1|%|MAPH|Y||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|N|5|Visit_5|90|3|FOLLOW-UP|2021-02-04|90
e|TR|416fe99b-1258-4e72-b1df-48b989f8f8ed|1|[?]|LPERP|Longest Perpendicular|[?]|ukat/10^12 RBC|NORMAL|1|TRANSDUCING UNIT|SLIT LAMP PHOTOGRAPHY|||HEALTH CARE PROFESSIONAL|READER 3|Y|1|Visit_1|10|7|TREATMENT|2020-08-28|10
e|TR|416fe99b-1258-4e72-b1df-48b989f8f8ed|2|[?]|LESSCIND|Lesion Success Indicator|[?]|mg/cm2|UNEQUIVOCAL|1|mEq/uL|PEAK FLOWMETRY|Y||INVESTIGATOR|READER 3|N|2|Visit_2|25|6|SCREENING|2020-09-12|25
e|TR|416fe99b-1258-4e72-b1df-48b989f8f8ed|3|[?]|PCHGBL|Percent Change From Baseline|[?]|mAmp|FURTHER ENLARGEMENT FROM NADIR|1|mm|IN VITRO GENE EXPRESSION ASSAY|||NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2020-09-27|40
e|TR|416fe99b-1258-4e72-b1df-48b989f8f8ed|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|mEq/mmol|DIFFUSELY INCREASED|1|g/cage/wk|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|STUDY SUBJECT|ONCOLOGIST|N|4|Visit_4|65|1|TREATMENT|2020-10-22|65
e|TR|416fe99b-1258-4e72-b1df-48b989f8f8ed|5|[?]|BNLNUM|Number of Bone Lesions|[?]|mL/cage|FURTHER ENLARGEMENT|1|umol|WEBER GREEN STAIN|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|N|5|Visit_5|90|5|FOLLOW-UP|2020-11-16|90
e|TR|16a9e070-3e5d-444c-9ac1-6a1abfac0370|1|[?]|ORVERLN|Organ Vertical Length|[?]|cm|NORMAL|1|MAC50|DYNAMIC CONTRAST ENHANCED MRI||Y|PARENT|INTERNIST|U|1|Visit_1|10|7|FOLLOW-UP|2020-05-26|10
e|TR|16a9e070-3e5d-444c-9ac1-6a1abfac0370|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|/MBP|DIFFUSELY INCREASED|1|10^9 CFU/mL|HEMOCYTOMETRY|||CAREGIVER|NEUROLOGIST|U|2|Visit_2|25|5|WASHOUT|2020-06-10|25
e|TR|16a9e070-3e5d-444c-9ac1-6a1abfac0370|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|mg/L|INCREASED|1|g|IMPEDANCE CONDUCTIVITY|||ADJUDICATION COMMITTEE|ONCOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-06-25|40
e|TR|16a9e070-3e5d-444c-9ac1-6a1abfac0370|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|L/min|FURTHER ENLARGEMENT FROM NADIR|1|CUP|RADIOGRAPHY||Y|GUARDIAN|RADIOLOGIST 2|U|4|Visit_4|65|3|WASHOUT|2020-07-20|65
e|TR|16a9e070-3e5d-444c-9ac1-6a1abfac0370|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|s^-1(%O2)^-1|UNCHANGED|1|MONTHS|CARDIAC THERMODILUTION|||INDEPENDENT ASSESSOR|READER|U|5|Visit_5|90|5|WASHOUT|2020-08-14|90
e|TR|1497a00d-55b1-4e02-a957-cf15e3d15512|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|Ejaculate U|UNEQUIVOCAL|1|10^3 organisms/mL|FARR ASSAY||Y|SIGNIFICANT OTHER|ADJUDICATOR 1|NA|1|Visit_1|10|6|TREATMENT|2021-01-25|10
e|TR|1497a00d-55b1-4e02-a957-cf15e3d15512|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mU|UNCHANGED|1|days/wk|PERFUSION MRI||Y|PARENT|MICROSCOPIST 1|N|2|Visit_2|25|2|TREATMENT|2021-02-09|25
e|TR|1497a00d-55b1-4e02-a957-cf15e3d15512|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|ug/g/h|NONPALPABLE|1|U/kg/h|OPTICAL COHERENCE TOMOGRAPHY|||SIGNIFICANT OTHER|ONCOLOGIST|N|3|Visit_3|40|6|SCREENING|2021-02-24|40
e|TR|1497a00d-55b1-4e02-a957-cf15e3d15512|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|ug/m2|PRESENT|1|PIXEL|ELISPOT||Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|4|Visit_4|65|7|FOLLOW-UP|2021-03-21|65
e|TR|1497a00d-55b1-4e02-a957-cf15e3d15512|5|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|Hounsfield Unit|DECREASED|1|Arbitrary U|GC/MS/MS||Y|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2021-04-15|90
e|TR|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|10^6 CFU/mL|FOCALLY INCREASED|1|pmol/dL|NON-INVASIVE DIELECTRIC SENSING|Y||PARENT|READER 3|Y|1|Visit_1|10|4|WASHOUT|2020-07-21|10
e|TR|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|2|[?]|VDIAM|Viable Diameter|[?]|10^3 organisms/g|PATHOLOGICAL|1|MONTHS|LC/MS/MS|||CLINICAL RESEARCH COORDINATOR|READER 1|U|2|Visit_2|25|3|TREATMENT|2020-08-05|25
e|TR|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|EID 50/dose|EQUIVOCAL|1|h*%|IMMUNOTURBIDIMETRY|||PARENT|CLINICAL PATHOLOGIST|N|3|Visit_3|40|5|FOLLOW-UP|2020-08-20|40
e|TR|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|4|[?]|PCHGBL|Percent Change From Baseline|[?]|anti-Xa IU/mL|NON-PATHOLOGICAL|1|kBq/uL|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||SIBLING|READER 2|U|4|Visit_4|65|5|SCREENING|2020-09-14|65
e|TR|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|ug/kg|INCREASED|1|U/mL|GIEMSA STAIN|Y||STUDY SUBJECT|READER 2|NA|5|Visit_5|90|5|TREATMENT|2020-10-09|90
e|TR|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|1|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|kat|ABSENT|1|g/mol|DNA MICROARRAY|Y||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-12-09|10
e|TR|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|2|[?]|VDIAM|Viable Diameter|[?]|mL/g/day|FOCALLY INCREASED|1|Bq/uL|HEMATOXYLIN AND EOSIN STAIN|||INDEPENDENT ASSESSOR|ADJUDICATOR|N|2|Visit_2|25|1|TREATMENT|2020-12-24|25
e|TR|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|mL|UNCHANGED|1|pptr|CONGO RED STAIN|Y|Y|CAREGIVER|ONCOLOGIST 1|Y|3|Visit_3|40|3|FOLLOW-UP|2021-01-08|40
e|TR|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|4|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|ug/m2/h|ENLARGEMENT|1|uL/mL|MODIFIED ACID FAST STAIN|||INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|U|4|Visit_4|65|4|TREATMENT|2021-02-02|65
e|TR|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|5|[?]|SUMDIAM|Sum of Diameter|[?]|cmH2O*s2/mL|ENLARGEMENT FROM NADIR|1|PFU/mL|ELISPOT|||ADJUDICATOR|PHYSIOTHERAPIST|NA|5|Visit_5|90|1|FOLLOW-UP|2021-02-27|90
e|TR|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|1|[?]|RADIODEN|Radiodensity|[?]|damol/L|DECREASED|1|ms2|CLIP|||INDEPENDENT ASSESSOR|NEUROLOGIST 1|U|1|Visit_1|10|2|TREATMENT|2020-11-05|10
e|TR|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|2|[?]|VDIAM|Viable Diameter|[?]|TUBE|NONPALPABLE|1|days/wk|LC/MS|||CAREGIVER|MICROSCOPIST|N|2|Visit_2|25|2|FOLLOW-UP|2020-11-20|25
e|TR|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|ug/m2/h|FOCALLY INCREASED|1|DNA copies/ug|CONTRAST ENHANCED PET/CT SCAN|||STUDY SUBJECT|PATHOLOGIST|Y|3|Visit_3|40|2|WASHOUT|2020-12-05|40
e|TR|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|HOMEOPATHIC DILUTION|UNCHANGED|1|U/10^12 RBC|TRIPLE-PHASE MRI SCAN|||CLINICAL STUDY SPONSOR|UROLOGIST|U|4|Visit_4|65|4|WASHOUT|2020-12-30|65
e|TR|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|g/cm2|ABSENT|1|ECL unit|IMMUNOBLOT|||FRIEND|OPTOMETRIST|Y|5|Visit_5|90|6|TREATMENT|2021-01-24|90
e|TR|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|1|[?]|TUMSTATE|Tumor State|[?]|scm|FURTHER ENLARGEMENT|1|VOXEL|MICROBIAL CONCENTRATION|||DOMESTIC PARTNER|NEUROLOGIST 2|Y|1|Visit_1|10|1|TREATMENT|2020-05-27|10
e|TR|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|mU/L|ENLARGEMENT FROM NADIR|1|L/kg|PERIODIC ACID SCHIFF STAIN|||PROXY|NEUROLOGIST 2|U|2|Visit_2|25|7|WASHOUT|2020-06-11|25
e|TR|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|HOMEOPATHIC DILUTION|PRESENT|1|mol/mL|ACRIDINE ORANGE STAIN|Y||CAREGIVER|ADJUDICATOR 1|NA|3|Visit_3|40|5|FOLLOW-UP|2020-06-26|40
e|TR|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mL/min/mmHg|ENLARGEMENT|1|10^9 CFU/g|LAPAROSCOPY|||INTERVIEWER|READER 1|U|4|Visit_4|65|2|SCREENING|2020-07-21|65
e|TR|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|Log10 ELISA unit|UNCHANGED|1|kV|POLYGRAPHY|Y||STUDY SUBJECT|ADJUDICATOR 1|Y|5|Visit_5|90|5|TREATMENT|2020-08-15|90
e|TR|2216086b-197e-4780-8e10-28123eb090c5|1|[?]|PCHGNAD|Percent Change From Nadir|[?]|mV2/Hz|FURTHER ENLARGEMENT FROM NADIR|1|cP|SINGLE-MOLECULE ARRAY|||VENDOR|READER 2|U|1|Visit_1|10|4|TREATMENT|2020-12-12|10
e|TR|2216086b-197e-4780-8e10-28123eb090c5|2|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|WEEKS|UNEQUIVOCAL|1|ug/day|HILLMEN COLOR CHART|||CAREGIVER|NEUROLOGIST 2|U|2|Visit_2|25|5|SCREENING|2020-12-27|25
e|TR|2216086b-197e-4780-8e10-28123eb090c5|3|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|ug/mL/h|PATHOLOGICAL|1|pt_us|ACRIDINE ORANGE STAIN|||CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|4|TREATMENT|2021-01-11|40
e|TR|2216086b-197e-4780-8e10-28123eb090c5|4|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|/100 WBC|ABSENT|1|10^6 copies/mL|NUCLEIC ACID SEQUENCING|||FRIEND|ADJUDICATOR 3|N|4|Visit_4|65|6|TREATMENT|2021-02-05|65
e|TR|2216086b-197e-4780-8e10-28123eb090c5|5|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|KIT|PATHOLOGICAL|1|Bq/mL|VIRUS PLAQUE ASSAY|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|5|Visit_5|90|7|TREATMENT|2021-03-02|90
e|TR|7280f69c-a0f4-48b5-b714-1e272193168c|1|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mL/cm H2O|DIFFUSELY INCREASED|1|ug/g/day|TURBIDIMETRY|Y||HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|1|Visit_1|10|3|WASHOUT|2020-08-19|10
e|TR|7280f69c-a0f4-48b5-b714-1e272193168c|2|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mg/kg/min|UNEQUIVOCAL|1|10^3 CFU/mL|MODIFIED ACID FAST STAIN|||PROXY|FORENSIC PATHOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-09-03|25
e|TR|7280f69c-a0f4-48b5-b714-1e272193168c|3|[?]|ACHNAD|Absolute Change From Nadir|[?]|mL/m2|EQUIVOCAL|1|K|CINEANGIOGRAPHY|||DOMESTIC PARTNER|DERMATOLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-09-18|40
e|TR|7280f69c-a0f4-48b5-b714-1e272193168c|4|[?]|SUMVOL|Sum of Volume|[?]|mg/m2/min|NON-PATHOLOGICAL|1|PNU/mL|PHASE CONTRAST MICROSCOPY|||FRIEND|READER 2|U|4|Visit_4|65|3|TREATMENT|2020-10-13|65
e|TR|7280f69c-a0f4-48b5-b714-1e272193168c|5|[?]|PCHGNAD|Percent Change From Nadir|[?]|HEP|PALPABLE|1|10^8 PFU|MAGNETIC RESONANCE ELASTOGRAPHY|||VENDOR|NEUROLOGIST 2|Y|5|Visit_5|90|4|WASHOUT|2020-11-07|90
e|TR|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|1|[?]|LDIAM|Longest Diameter|[?]|cal|FURTHER ENLARGEMENT|1|ug/kg|HPLC-UV|||PARENT|READER|U|1|Visit_1|10|2|FOLLOW-UP|2020-08-01|10
e|TR|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|2|[?]|BNLNUM|Number of Bone Lesions|[?]|EU|TUMOR MERGED|1|/mm2|VENTILATION PERFUSION LUNG SCAN||Y|INTERVIEWER|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-08-16|25
e|TR|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|3|[?]|RADIODEN|Radiodensity|[?]|mg2/dL2|NON-PATHOLOGICAL|1|mg/kg/h|DC SHEATH FLOW|||CHILD|NEUROLOGIST 1|NA|3|Visit_3|40|4|WASHOUT|2020-08-31|40
e|TR|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|ug/kg/min|ENLARGEMENT FROM NADIR|1|breaths/30s|PAP STAIN||Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|4|Visit_4|65|7|WASHOUT|2020-09-25|65
e|TR|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|5|[?]|LNSTATE|Lymph Node State|[?]|mEq/ug|INCREASED|1|amu|TEST STRIP||Y|CLINICAL STUDY SPONSOR|RADIOLOGIST|N|5|Visit_5|90|4|FOLLOW-UP|2020-10-20|90
e|TR|25c6812b-9200-4dc4-a954-6879183a2c54|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|mL/min/mmHg|FOCALLY INCREASED|1|/200 HPFs|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|U|1|Visit_1|10|6|TREATMENT|2020-12-24|10
e|TR|25c6812b-9200-4dc4-a954-6879183a2c54|2|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|10^3 CFU/g|DECREASED|1|kg/cm|ELISA|||SPOUSE|PATHOLOGIST 2|NA|2|Visit_2|25|6|TREATMENT|2021-01-08|25
e|TR|25c6812b-9200-4dc4-a954-6879183a2c54|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|mL/sec/1.73m2|ENLARGEMENT|1|mL/g/day|WRIGHT STAIN||Y|SIGNIFICANT OTHER|PATHOLOGIST 2|N|3|Visit_3|40|3|WASHOUT|2021-01-23|40
e|TR|25c6812b-9200-4dc4-a954-6879183a2c54|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|BU|FOCALLY INCREASED|1|Osm|FLUORESCENT SPOT TEST|||CHILD|OTOLARYNGOLOGIST|Y|4|Visit_4|65|1|SCREENING|2021-02-17|65
e|TR|25c6812b-9200-4dc4-a954-6879183a2c54|5|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|/2500 WBC|ABSENT|1|msec|CONTRAST ENHANCED MRI|||INDEPENDENT ASSESSOR|ADJUDICATOR 2|Y|5|Visit_5|90|3|TREATMENT|2021-03-14|90
e|TR|10dca475-f364-42f3-9192-faf762832adf|1|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|cd*s/m2|DIFFUSELY INCREASED|1|mL/m2/day|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||Y|PARENT|MICROSCOPIST 1|Y|1|Visit_1|10|2|TREATMENT|2020-09-25|10
e|TR|10dca475-f364-42f3-9192-faf762832adf|2|[?]|ACHNAD|Absolute Change From Nadir|[?]|10^8 PFU|NON-PATHOLOGICAL|1|SCOOPFUL|FLOCCULATION|Y|Y|NON-HEALTH CARE PROFESSIONAL|RATER|U|2|Visit_2|25|7|WASHOUT|2020-10-10|25
e|TR|10dca475-f364-42f3-9192-faf762832adf|3|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|10^6/L|FURTHER ENLARGEMENT|1|1/(s*kPa)|IN VITRO GENE EXPRESSION ASSAY|Y||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-10-25|40
e|TR|10dca475-f364-42f3-9192-faf762832adf|4|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mol/g|FOCALLY INCREASED|1|10^11/L|FLUORESCENT ENZYME IMMUNOASSAY|||FRIEND|NEUROLOGIST 1|N|4|Visit_4|65|3|SCREENING|2020-11-19|65
e|TR|10dca475-f364-42f3-9192-faf762832adf|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|U/g/min|EQUIVOCAL|1|10^9/L|ANGIOGRAPHY||Y|PARENT|DERMATOLOGIST|N|5|Visit_5|90|6|WASHOUT|2020-12-14|90
e|TR|caf54095-56c3-428f-8342-ce45c6c9a287|1|[?]|PPD|Product of Perpendicular Diameters|[?]|genEq|NON-PATHOLOGICAL|1|m3|COLORIMETRY|||INTERVIEWER|ADJUDICATOR|Y|1|Visit_1|10|2|FOLLOW-UP|2020-12-20|10
e|TR|caf54095-56c3-428f-8342-ce45c6c9a287|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|kBq/uL|PATHOLOGICAL|1|m/sec|CHROMATOGRAPHY|||ADJUDICATOR|MICROSCOPIST|N|2|Visit_2|25|3|TREATMENT|2021-01-04|25
e|TR|caf54095-56c3-428f-8342-ce45c6c9a287|3|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|Gravitational Unit|TUMOR MERGED|1|ug|HEMAGGLUTINATION ASSAY|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|N|3|Visit_3|40|7|TREATMENT|2021-01-19|40
e|TR|caf54095-56c3-428f-8342-ce45c6c9a287|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|mL/dose|TUMOR MERGED|1|DAgU/mL|TONOMETRY||Y|ADJUDICATOR|RADIOLOGIST 1|N|4|Visit_4|65|6|SCREENING|2021-02-13|65
e|TR|caf54095-56c3-428f-8342-ce45c6c9a287|5|[?]|DIAMETER|Diameter|[?]|DPM|FURTHER ENLARGEMENT|1|U/kg|IMMUNOTURBIDIMETRY|||SIGNIFICANT OTHER|DERMATOLOGIST|NA|5|Visit_5|90|4|FOLLOW-UP|2021-03-10|90
e|TR|f833ca56-d426-420b-a6d3-fedeabc02734|1|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|mg/kg/h|PALPABLE|1|10^3/hpf|IMMUNOTURBIDIMETRY|||DOMESTIC PARTNER|RATER 1|NA|1|Visit_1|10|1|FOLLOW-UP|2020-06-20|10
e|TR|f833ca56-d426-420b-a6d3-fedeabc02734|2|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|EVENTS|FURTHER ENLARGEMENT|1|kUSP|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||INTERVIEWER|ONCOLOGIST 2|N|2|Visit_2|25|7|TREATMENT|2020-07-05|25
e|TR|f833ca56-d426-420b-a6d3-fedeabc02734|3|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|BLOCKS|UNEQUIVOCAL|1|/HPF|MAGNETIC RESONANCE ANGIOGRAPHY|||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|3|TREATMENT|2020-07-20|40
e|TR|f833ca56-d426-420b-a6d3-fedeabc02734|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|MPS U|FOCALLY INCREASED|1|MASK|DROPLET DIGITAL PCR|||DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|2|TREATMENT|2020-08-14|65
e|TR|f833ca56-d426-420b-a6d3-fedeabc02734|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|cmH2O*s/mL|DIFFUSELY INCREASED|1|AMPULE|DIGITAL PCR ARRAY|||VENDOR|ONCOLOGIST|U|5|Visit_5|90|5|FOLLOW-UP|2020-09-08|90
e|TR|03c8e2c7-b70d-4d46-8064-c99370eab232|1|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|CONTAINER|INCREASED|1|nmol/mol|NUCLEIC ACID BASED METHOD||Y|ADJUDICATOR|MICROSCOPIST 1|NA|1|Visit_1|10|6|WASHOUT|2020-11-29|10
e|TR|03c8e2c7-b70d-4d46-8064-c99370eab232|2|[?]|VOLUME|Volume|[?]|mL/dose|FURTHER ENLARGEMENT|1|STRIP|JAEGER EYE CHART|Y||GUARDIAN|ADJUDICATOR|N|2|Visit_2|25|1|TREATMENT|2020-12-14|25
e|TR|03c8e2c7-b70d-4d46-8064-c99370eab232|3|[?]|AREA|Area|[?]|Watt|NORMAL|1|mm/sec|CONGO RED STAIN||Y|ADJUDICATION COMMITTEE|READER 2|N|3|Visit_3|40|1|TREATMENT|2020-12-29|40
e|TR|03c8e2c7-b70d-4d46-8064-c99370eab232|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|IU/day|FURTHER ENLARGEMENT FROM NADIR|1|kHz|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||SIGNIFICANT OTHER|ONCOLOGIST 2|NA|4|Visit_4|65|2|TREATMENT|2021-01-23|65
e|TR|03c8e2c7-b70d-4d46-8064-c99370eab232|5|[?]|PCBSOREN|Percent Change Baseline in Organ Enlarge|[?]|cm2|ABSENT|1|ug/kg/day|MAGNETIC RESONANCE ANGIOGRAPHY|Y|Y|FAMILY MEMBER|CLINICAL PATHOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2021-02-17|90
e|TR|944617c7-c5e6-4e06-b114-499c3020dbbd|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|cmHg|NON-PATHOLOGICAL|1|PIXELS/cm|CONTRAST ENHANCED X-RAY|Y||INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-10-22|10
e|TR|944617c7-c5e6-4e06-b114-499c3020dbbd|2|[?]|DIAMETER|Diameter|[?]|mV|EQUIVOCAL|1|foz_us|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||Y|INTERVIEWER|RADIOLOGIST 1|NA|2|Visit_2|25|1|TREATMENT|2020-11-06|25
e|TR|944617c7-c5e6-4e06-b114-499c3020dbbd|3|[?]|LESFLIND|Lesion Failure Indicator|[?]|grain|TUMOR MERGED|1|kat|POLYMERASE CHAIN REACTION|||CHILD|ADJUDICATOR 1|N|3|Visit_3|40|7|TREATMENT|2020-11-21|40
e|TR|944617c7-c5e6-4e06-b114-499c3020dbbd|4|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|kg/mol|DIFFUSELY INCREASED|1|anti-Xa IU|TARGETED TRANSCRIPTOME SEQUENCING|||PARENT|INTERNIST|N|4|Visit_4|65|3|TREATMENT|2020-12-16|65
e|TR|944617c7-c5e6-4e06-b114-499c3020dbbd|5|[?]|NBNLNUM|Number of New Bone Lesions|[?]|kg/cm2|INCREASED|1|SUPPOSITORY|ENDOSCOPY|||SIBLING|MICROSCOPIST 2|Y|5|Visit_5|90|6|WASHOUT|2021-01-10|90
e|TR|e4878c66-1e2b-49bb-838e-85139d160dd4|1|[?]|LNSTATE|Lymph Node State|[?]|mL/(min*100mL)|TUMOR MERGED|1|ug|CENTRIFUGATION|Y||INVESTIGATOR|ADJUDICATOR 1|NA|1|Visit_1|10|6|FOLLOW-UP|2020-10-21|10
e|TR|e4878c66-1e2b-49bb-838e-85139d160dd4|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|BAR|UNCHANGED|1|RNA copies/mL|MAPH|||INVESTIGATOR|OPTOMETRIST|NA|2|Visit_2|25|3|WASHOUT|2020-11-05|25
e|TR|e4878c66-1e2b-49bb-838e-85139d160dd4|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|KALLIKREIN INHIBITOR UNIT|NORMAL|1|/10^5|HIGH RESOLUTION CT||Y|INTERVIEWER|ONCOLOGIST 1|NA|3|Visit_3|40|7|SCREENING|2020-11-20|40
e|TR|e4878c66-1e2b-49bb-838e-85139d160dd4|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|aMFI|NORMAL|1|U/mg|TOTAL BODY IRRADIATION|||CLINICAL STUDY SPONSOR|NEUROLOGIST|NA|4|Visit_4|65|1|SCREENING|2020-12-15|65
e|TR|e4878c66-1e2b-49bb-838e-85139d160dd4|5|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|EVENTS|PALPABLE|1|ug/g/min|IMMUNOPRECIPITATION|Y|Y|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|N|5|Visit_5|90|5|TREATMENT|2021-01-09|90
e|TR|6873e227-baef-4d6e-8600-0bb61d60fe49|1|[?]|BNLNUM|Number of Bone Lesions|[?]|mAnson U/mL|DECREASED|1|DAYS|LC/MS|||STUDY SUBJECT|READER 3|NA|1|Visit_1|10|1|FOLLOW-UP|2020-06-06|10
e|TR|6873e227-baef-4d6e-8600-0bb61d60fe49|2|[?]|AREA|Area|[?]|ug/animal|UNCHANGED|1|log10 CFU/mL|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|||VENDOR|ADJUDICATOR|NA|2|Visit_2|25|6|WASHOUT|2020-06-21|25
e|TR|6873e227-baef-4d6e-8600-0bb61d60fe49|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mEq/kg|PRESENT|1|titer|ACID FAST STAIN||Y|STUDY SUBJECT|DERMATOLOGIST|N|3|Visit_3|40|7|SCREENING|2020-07-06|40
e|TR|6873e227-baef-4d6e-8600-0bb61d60fe49|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|10^9/L|ABSENT|1|mL/sec/1.73m2|CLINICAL EVALUATION|||HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|4|Visit_4|65|3|FOLLOW-UP|2020-07-31|65
e|TR|6873e227-baef-4d6e-8600-0bb61d60fe49|5|[?]|DIAMETER|Diameter|[?]|nU/cL|INCREASED|1|foz_us|RAJI CELL EIA|||SIBLING|RATER|N|5|Visit_5|90|1|SCREENING|2020-08-25|90
e|TR|bad01879-9b97-4d9c-9eec-58871168bd57|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|10^6 IU/mL|PALPABLE|1|scm|PET/SPECT SCAN|||INTERVIEWER|NEUROLOGIST|NA|1|Visit_1|10|3|FOLLOW-UP|2020-10-15|10
e|TR|bad01879-9b97-4d9c-9eec-58871168bd57|2|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|mL/breath|ENLARGEMENT|1|mL/cage/wk|KARYOTYPING|||INTERVIEWER|CLINICAL PATHOLOGIST|N|2|Visit_2|25|3|TREATMENT|2020-10-30|25
e|TR|bad01879-9b97-4d9c-9eec-58871168bd57|3|[?]|NEWCONF|New Tumor Confirmed|[?]|10^11/L|INCREASED|1|mol/mol|IN SITU HYBRIDIZATION|||FRIEND|NEUROLOGIST 2|N|3|Visit_3|40|2|TREATMENT|2020-11-14|40
e|TR|bad01879-9b97-4d9c-9eec-58871168bd57|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|g/kg|PATHOLOGICAL|1|mmHg/sec|IMMUNOFLUORESCENT STAIN||Y|SPOUSE|NEUROLOGIST 1|U|4|Visit_4|65|2|TREATMENT|2020-12-09|65
e|TR|bad01879-9b97-4d9c-9eec-58871168bd57|5|[?]|AREA|Area|[?]|Gauss|DECREASED|1|beats/min|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||SIGNIFICANT OTHER|INTERNIST|Y|5|Visit_5|90|5|TREATMENT|2021-01-03|90
e|TR|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|1/(s*kPa)|ENLARGEMENT FROM NADIR|1|titer|ACCELERATOR MASS SPECTROMETRY|||PROXY|ONCOLOGIST|Y|1|Visit_1|10|2|WASHOUT|2020-11-05|10
e|TR|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|/min|ABSENT|1|s*kPa|HIGH LEVEL AMINOGLYCOSIDE SCREEN||Y|DOMESTIC PARTNER|RADIOLOGIST|N|2|Visit_2|25|2|WASHOUT|2020-11-20|25
e|TR|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|lm|FOCALLY INCREASED|1|kPa/L/sec|RADIAL IMMUNODIFFUSION|||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|4|TREATMENT|2020-12-05|40
e|TR|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|4|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|L/kg|ENLARGEMENT|1|ug/m2/day|PYROSEQUENCING|||SPOUSE|ADJUDICATOR|Y|4|Visit_4|65|2|TREATMENT|2020-12-30|65
e|TR|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|5|[?]|PCHGBL|Percent Change From Baseline|[?]|foz_us|EQUIVOCAL|1|/VF|TOTAL BODY IRRADIATION|||DOMESTIC PARTNER|RADIOLOGIST 2|U|5|Visit_5|90|5|WASHOUT|2021-01-24|90
e|TR|0df77775-6e65-4f77-9f8f-7faaa1471141|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|RNA copies/mL|DIFFUSELY INCREASED|1|Tesla|QUANTITATIVE CORONARY ANGIOGRAPHY|||PARENT|MICROSCOPIST|U|1|Visit_1|10|4|TREATMENT|2020-08-24|10
e|TR|0df77775-6e65-4f77-9f8f-7faaa1471141|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|MAC50|EQUIVOCAL|1|U/mg|PHOTOGRAPHY|Y||PARENT|HEMATOLOGIST|Y|2|Visit_2|25|6|SCREENING|2020-09-08|25
e|TR|0df77775-6e65-4f77-9f8f-7faaa1471141|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|10^3/hpf|PATHOLOGICAL|1|mEq/dL|RAJI CELL EIA|||VENDOR|PATHOLOGIST 2|NA|3|Visit_3|40|1|SCREENING|2020-09-23|40
e|TR|0df77775-6e65-4f77-9f8f-7faaa1471141|4|[?]|AREA|Area|[?]|PFU|PRESENT|1|ug/g/h|DIFFUSION TENSOR MRI|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|NA|4|Visit_4|65|6|SCREENING|2020-10-18|65
e|TR|0df77775-6e65-4f77-9f8f-7faaa1471141|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|amp|FOCALLY INCREASED|1|EID 50/mL|FLUORESCENT ENZYME IMMUNOASSAY|Y||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-11-12|90
e|TR|adc5359a-f1d5-428b-97d8-fce67cfeeaea|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|cm|PATHOLOGICAL|1|min|CLOT DETECTION|||GUARDIAN|READER 3|NA|1|Visit_1|10|5|WASHOUT|2020-08-22|10
e|TR|adc5359a-f1d5-428b-97d8-fce67cfeeaea|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|GBq/g|UNEQUIVOCAL|1|kg|NEURAMINIDASE INHIBITION ASSAY||Y|VENDOR|PATHOLOGIST|NA|2|Visit_2|25|5|SCREENING|2020-09-06|25
e|TR|adc5359a-f1d5-428b-97d8-fce67cfeeaea|3|[?]|SUMDIAM|Sum of Diameter|[?]|Enzyme U/L|ENLARGEMENT|1|damol/L|TARGETED TRANSCRIPTOME SEQUENCING|||SPOUSE|PATHOLOGIST 1|Y|3|Visit_3|40|2|SCREENING|2020-09-21|40
e|TR|adc5359a-f1d5-428b-97d8-fce67cfeeaea|4|[?]|VDIAM|Viable Diameter|[?]|fmol/g|NON-PATHOLOGICAL|1|log10 PFU/mL|IODINE STAIN|Y|Y|ADJUDICATOR|MICROSCOPIST|N|4|Visit_4|65|6|FOLLOW-UP|2020-10-16|65
e|TR|adc5359a-f1d5-428b-97d8-fce67cfeeaea|5|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|gMFI|NORMAL|1|10^6 organisms/mg|CAPILLARY ELECTROPHORESIS|||FAMILY MEMBER|RADIOLOGIST 2|U|5|Visit_5|90|5|FOLLOW-UP|2020-11-10|90
e|TR|cd68296c-95d4-489e-8b64-b2404f16316c|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|nmol/day|PRESENT|1|10^9 organisms/mL|PYROSEQUENCING||Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|N|1|Visit_1|10|5|WASHOUT|2020-12-20|10
e|TR|cd68296c-95d4-489e-8b64-b2404f16316c|2|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|FFU|PALPABLE|1|log10 PFU|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|2|Visit_2|25|1|TREATMENT|2021-01-04|25
e|TR|cd68296c-95d4-489e-8b64-b2404f16316c|3|[?]|DIAMETER|Diameter|[?]|nmol BCE/mmol|NONPALPABLE|1|kg/mol|PANENDOSCOPY|||VENDOR|RATER 2|N|3|Visit_3|40|4|TREATMENT|2021-01-19|40
e|TR|cd68296c-95d4-489e-8b64-b2404f16316c|4|[?]|LDIAM|Longest Diameter|[?]|v/v|NONPALPABLE|1|10^6 copies/mL|TRANSMISSION ELECTRON MICROSCOPY|||SPOUSE|CLINICAL PATHOLOGIST|U|4|Visit_4|65|4|TREATMENT|2021-02-13|65
e|TR|cd68296c-95d4-489e-8b64-b2404f16316c|5|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|MdFI|INCREASED|1|mg2/dL2|AUTOMATED COUNT|||FAMILY MEMBER|PATHOLOGIST 1|U|5|Visit_5|90|1|FOLLOW-UP|2021-03-10|90
e|TR|fe137506-d1ce-4b08-a043-9366d86c421e|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|AU/mL|INCREASED|1|uU/dL|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|SPOUSE|NEUROLOGIST 1|Y|1|Visit_1|10|2|FOLLOW-UP|2020-07-03|10
e|TR|fe137506-d1ce-4b08-a043-9366d86c421e|2|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|/HPF|NON-PATHOLOGICAL|1|mph|SURFACE PLASMON RESONANCE|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|Y|2|Visit_2|25|3|WASHOUT|2020-07-18|25
e|TR|fe137506-d1ce-4b08-a043-9366d86c421e|3|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|Pa|PRESENT|1|Absorbance U/mL|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||SIBLING|ENDOCRINOLOGIST|N|3|Visit_3|40|4|WASHOUT|2020-08-02|40
e|TR|fe137506-d1ce-4b08-a043-9366d86c421e|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|nkat/g Hb|UNEQUIVOCAL|1|U/kg/min|ICC||Y|CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2020-08-27|65
e|TR|fe137506-d1ce-4b08-a043-9366d86c421e|5|[?]|TUMSTATE|Tumor State|[?]|MET*min|TUMOR MERGED|1|anti-Xa IU|TOLUIDINE BLUE STAIN|||CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|Y|5|Visit_5|90|5|FOLLOW-UP|2020-09-21|90
e|TR|b112c524-42c8-4e9e-8699-209e739972a7|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|SUPPOSITORY|TUMOR MERGED|1|ms2|ELISPOT|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|1|Visit_1|10|7|TREATMENT|2021-01-03|10
e|TR|b112c524-42c8-4e9e-8699-209e739972a7|2|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|PIXELS/in|UNCHANGED|1|ug/L DDU|CALCOFLUOR WHITE STAIN|||INVESTIGATOR|ADJUDICATOR|NA|2|Visit_2|25|3|WASHOUT|2021-01-18|25
e|TR|b112c524-42c8-4e9e-8699-209e739972a7|3|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|IU/mmol|EQUIVOCAL|1|SPRAY|NON-CONTACT SPECULAR MICROSCOPY|||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|1|FOLLOW-UP|2021-02-02|40
e|TR|b112c524-42c8-4e9e-8699-209e739972a7|4|[?]|PCHGNAD|Percent Change From Nadir|[?]|Gauss|UNCHANGED|1|cup eq|CENTRIFUGATION|||HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|4|Visit_4|65|4|FOLLOW-UP|2021-02-27|65
e|TR|b112c524-42c8-4e9e-8699-209e739972a7|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|umol/mol|DIFFUSELY INCREASED|1|/mm|FLUORIMETRY|||INVESTIGATOR|MICROSCOPIST|NA|5|Visit_5|90|2|TREATMENT|2021-03-24|90
e|TR|e6e32df8-8b66-49a5-a626-fd385297dd6f|1|[?]|PPD|Product of Perpendicular Diameters|[?]|MBP|ENLARGEMENT|1|pmol/L/h|ELISPOT||Y|VENDOR|MICROSCOPIST 1|U|1|Visit_1|10|6|FOLLOW-UP|2020-09-02|10
e|TR|e6e32df8-8b66-49a5-a626-fd385297dd6f|2|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|nmol/g|UNCHANGED|1|log10 TCID 50/uL|MRI WITHOUT CONTRAST|||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|3|WASHOUT|2020-09-17|25
e|TR|e6e32df8-8b66-49a5-a626-fd385297dd6f|3|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mg/m2/min|ENLARGEMENT|1|10^3/L|LIGHT MICROSCOPY|||PARENT|RATER 2|Y|3|Visit_3|40|6|TREATMENT|2020-10-02|40
e|TR|e6e32df8-8b66-49a5-a626-fd385297dd6f|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|lx|ENLARGEMENT FROM NADIR|1|deg2|LIQUID SCINTILLATION COUNTING||Y|GUARDIAN|RATER 1|NA|4|Visit_4|65|7|TREATMENT|2020-10-27|65
e|TR|e6e32df8-8b66-49a5-a626-fd385297dd6f|5|[?]|RADIODEN|Radiodensity|[?]|pt_us|ENLARGEMENT FROM NADIR|1|U/10^12 RBC|PHOROPTER|||PARENT|HEMATOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2020-11-21|90
e|TR|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|1|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|mg/kg/dose|INCREASED|1|mL/(min*100mL)|CLAUSS METHOD|Y||INTERVIEWER|READER 2|U|1|Visit_1|10|4|TREATMENT|2020-09-18|10
e|TR|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|2|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|log EID 50/dose|DIFFUSELY INCREASED|1|10^3 CFU/mL|HEMAGGLUTINATION INHIBITION ASSAY|Y||SIBLING|MICROSCOPIST 2|U|2|Visit_2|25|4|SCREENING|2020-10-03|25
e|TR|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|10^6 IU|FURTHER ENLARGEMENT|1|Gravitational Unit|MYELOPEROXIDASE STAIN|Y||VENDOR|CLINICAL PATHOLOGIST|U|3|Visit_3|40|2|SCREENING|2020-10-18|40
e|TR|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|4|[?]|VOLUME|Volume|[?]|mol|TUMOR MERGED|1|km|DYNAMIC LIGHT SCATTERING|||CLINICAL STUDY SPONSOR|MICROSCOPIST 2|U|4|Visit_4|65|7|TREATMENT|2020-11-12|65
e|TR|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|5|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|PACKAGE|DECREASED|1|Gravitational Unit|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||Y|CLINICAL STUDY SPONSOR|ONCOLOGIST|N|5|Visit_5|90|5|WASHOUT|2020-12-07|90
e|TR|5002de57-45df-4525-a6b7-b6cc33c22229|1|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|mL/dL|ENLARGEMENT|1|L/s|REFRACTOMETRY|Y||CLINICAL STUDY SPONSOR|NEUROLOGIST 1|U|1|Visit_1|10|2|SCREENING|2021-01-12|10
e|TR|5002de57-45df-4525-a6b7-b6cc33c22229|2|[?]|LPERP|Longest Perpendicular|[?]|mol/g|FURTHER ENLARGEMENT|1|mmol/day|WEBER GREEN STAIN|||ADJUDICATOR|ONCOLOGIST 1|NA|2|Visit_2|25|6|TREATMENT|2021-01-27|25
e|TR|5002de57-45df-4525-a6b7-b6cc33c22229|3|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|10^6/Ejaculate U|UNCHANGED|1|SYRINGE|IRON HEMATOXYLIN STAIN|Y||INVESTIGATOR|READER|U|3|Visit_3|40|3|TREATMENT|2021-02-11|40
e|TR|5002de57-45df-4525-a6b7-b6cc33c22229|4|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|L/h|EQUIVOCAL|1|ug/g/day|ANTIMICROBIAL COMBINATION TESTING|||FAMILY MEMBER|RATER|NA|4|Visit_4|65|6|TREATMENT|2021-03-08|65
e|TR|5002de57-45df-4525-a6b7-b6cc33c22229|5|[?]|PCHGBL|Percent Change From Baseline|[?]|deg/s|ENLARGEMENT FROM NADIR|1|APS U|SIZE EXCLUSION CHROMATOGRAPHY|Y|Y|SIBLING|CLINICAL PATHOLOGIST|N|5|Visit_5|90|6|TREATMENT|2021-04-02|90
e|TR|298f2081-bb11-4856-9e88-4be3b9b2250d|1|[?]|LNSTATE|Lymph Node State|[?]|EID 50/mL|ABSENT|1|uV|IMMUNORADIOMETRIC ASSAY||Y|PARENT|ONCOLOGIST|NA|1|Visit_1|10|5|SCREENING|2020-10-05|10
e|TR|298f2081-bb11-4856-9e88-4be3b9b2250d|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|LENS|PALPABLE|1|Ci/mL|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|Y|2|Visit_2|25|6|TREATMENT|2020-10-20|25
e|TR|298f2081-bb11-4856-9e88-4be3b9b2250d|3|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|VIRTUAL PIXEL|TUMOR MERGED|1|U.CARR|SCANNING ELECTRON MICROSCOPY|||INDEPENDENT ASSESSOR|RATER 2|U|3|Visit_3|40|3|FOLLOW-UP|2020-11-04|40
e|TR|298f2081-bb11-4856-9e88-4be3b9b2250d|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|m|DECREASED|1|dB|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||Y|SIBLING|PATHOLOGIST 2|U|4|Visit_4|65|7|TREATMENT|2020-11-29|65
e|TR|298f2081-bb11-4856-9e88-4be3b9b2250d|5|[?]|LDIAM|Longest Diameter|[?]|genEq|TUMOR MERGED|1|V/sec|TEMPLATE INCISION METHOD|Y||CAREGIVER|OPTOMETRIST|NA|5|Visit_5|90|3|WASHOUT|2020-12-24|90
e|TR|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|1|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|CAN|NON-PATHOLOGICAL|1|mkat|HILLMEN COLOR CHART||Y|PARENT|ADJUDICATOR 2|NA|1|Visit_1|10|5|TREATMENT|2020-12-29|10
e|TR|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|2|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|lx|ENLARGEMENT FROM NADIR|1|Newton|SNELLEN EYE CHART|||VENDOR|PATHOLOGIST|Y|2|Visit_2|25|7|FOLLOW-UP|2021-01-13|25
e|TR|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|pmol/10^10 cells|FURTHER ENLARGEMENT|1|Linear ft*LB|HILLMEN COLOR CHART|||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|NA|3|Visit_3|40|5|TREATMENT|2021-01-28|40
e|TR|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|/cmH2O|ENLARGEMENT FROM NADIR|1|MnFI|REBOUND TONOMETRY|||GUARDIAN|RADIOLOGIST|Y|4|Visit_4|65|1|WASHOUT|2021-02-22|65
e|TR|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|5|[?]|TUMSTATE|Tumor State|[?]|log10 IU/mL|PALPABLE|1|PFU|GEL ELECTROPHORESIS|Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|5|Visit_5|90|1|TREATMENT|2021-03-19|90
e|TR|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|1|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|L/kg|NORMAL|1|dpm/mg|CELL BASED BIOASSAY|Y|Y|GUARDIAN|MICROSCOPIST 3|U|1|Visit_1|10|6|SCREENING|2020-05-12|10
e|TR|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|2|[?]|SUMVOL|Sum of Volume|[?]|nCi|NON-PATHOLOGICAL|1|um2|PERIODIC ACID SCHIFF STAIN|Y||SIBLING|ADJUDICATOR 2|Y|2|Visit_2|25|2|SCREENING|2020-05-27|25
e|TR|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|3|[?]|AREA|Area|[?]|umol/min|DIFFUSELY INCREASED|1|AMPULE|LIQUID SCINTILLATION COUNTING|||CHILD|INTERNIST|N|3|Visit_3|40|4|SCREENING|2020-06-11|40
e|TR|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|IMPLANT|UNEQUIVOCAL|1|min*mg/mL|PALPATION||Y|STUDY SUBJECT|ONCOLOGIST 2|Y|4|Visit_4|65|7|SCREENING|2020-07-06|65
e|TR|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|mg/cm2|ENLARGEMENT|1|mmol2/L2|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|||SIBLING|RATER|Y|5|Visit_5|90|7|TREATMENT|2020-07-31|90
e|TR|18c21176-db5e-4650-a1af-beb2042c31d8|1|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|GBq|ENLARGEMENT|1|Bq/mL|AUTOREFRACTION|||CLINICAL STUDY SPONSOR|READER|N|1|Visit_1|10|2|TREATMENT|2020-08-30|10
e|TR|18c21176-db5e-4650-a1af-beb2042c31d8|2|[?]|PALPSTAT|Palpable State|[?]|umol/L/sec|NONPALPABLE|1|Absorbance U/mL|SANGER SEQUENCING|||CAREGIVER|PATHOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-09-14|25
e|TR|18c21176-db5e-4650-a1af-beb2042c31d8|3|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|fmol/g|EQUIVOCAL|1|DRINK|DOUBLE IMMUNODIFFUSION|Y|Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|Y|3|Visit_3|40|4|WASHOUT|2020-09-29|40
e|TR|18c21176-db5e-4650-a1af-beb2042c31d8|4|[?]|LMNDPNUM|Number of Lymph Nodes Positive|[?]|U/dL|ENLARGEMENT FROM NADIR|1|mg/animal|BRDU CELLULAR PROLIFERATION ASSAY||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|4|Visit_4|65|4|TREATMENT|2020-10-24|65
e|TR|18c21176-db5e-4650-a1af-beb2042c31d8|5|[?]|LESFLIND|Lesion Failure Indicator|[?]|uSiemens|FURTHER ENLARGEMENT FROM NADIR|1|/kg|IMMUNOCHEMILUMINOMETRIC ASSAY|Y||INTERVIEWER|ONCOLOGIST 1|N|5|Visit_5|90|5|TREATMENT|2020-11-18|90
e|TR|7808abd1-7d6f-4090-aa08-916a804c95f5|1|[?]|LESSCIND|Lesion Success Indicator|[?]|mCi/kg|EQUIVOCAL|1|ug/g/min|GC/MS-EI|Y||SIGNIFICANT OTHER|READER 3|NA|1|Visit_1|10|7|TREATMENT|2020-06-20|10
e|TR|7808abd1-7d6f-4090-aa08-916a804c95f5|2|[?]|PCHGBL|Percent Change From Baseline|[?]|IU/kg/h|NORMAL|1|Gy/h|ELECTROPHORESIS|Y||SPOUSE|MICROSCOPIST|N|2|Visit_2|25|3|WASHOUT|2020-07-05|25
e|TR|7808abd1-7d6f-4090-aa08-916a804c95f5|3|[?]|TUMSTATE|Tumor State|[?]|/mm|ENLARGEMENT|1|Hz|CONTRAST ENHANCED PET SCAN|Y||STUDY SUBJECT|PATHOLOGIST|NA|3|Visit_3|40|1|SCREENING|2020-07-20|40
e|TR|7808abd1-7d6f-4090-aa08-916a804c95f5|4|[?]|PALPSTAT|Palpable State|[?]|PLUG|NONPALPABLE|1|%(w/v)|SANGER SEQUENCING|Y|Y|FRIEND|RATER 1|U|4|Visit_4|65|1|TREATMENT|2020-08-14|65
e|TR|7808abd1-7d6f-4090-aa08-916a804c95f5|5|[?]|SUMDIAM|Sum of Diameter|[?]|mmHg/L/min|NORMAL|1|ug/L DDU|IRON HEMATOXYLIN STAIN|||FAMILY MEMBER|INTERNIST|Y|5|Visit_5|90|4|SCREENING|2020-09-08|90
e|TR|57553b78-e761-4577-aae2-5c693a2dc303|1|[?]|LNSTATE|Lymph Node State|[?]|GPL U|DIFFUSELY INCREASED|1|K|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|U|1|Visit_1|10|3|SCREENING|2021-01-01|10
e|TR|57553b78-e761-4577-aae2-5c693a2dc303|2|[?]|LNSTATE|Lymph Node State|[?]|ug/L FEU|FOCALLY INCREASED|1|nL|ELECTROGASTROGRAPHY|||INTERVIEWER|READER 2|Y|2|Visit_2|25|4|SCREENING|2021-01-16|25
e|TR|57553b78-e761-4577-aae2-5c693a2dc303|3|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|mL/min|NONPALPABLE|1|deg|CYSTOSCOPY||Y|ADJUDICATOR|FORENSIC PATHOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2021-01-31|40
e|TR|57553b78-e761-4577-aae2-5c693a2dc303|4|[?]|PCHGBL|Percent Change From Baseline|[?]|U/kg/day|NONPALPABLE|1|DDU|EPSILOMETER|Y||PARENT|PHYSIOTHERAPIST|Y|4|Visit_4|65|1|WASHOUT|2021-02-25|65
e|TR|57553b78-e761-4577-aae2-5c693a2dc303|5|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|mg/kg|PRESENT|1|s/h|DYNAMIC CONTRAST ENHANCED MRI|||SPOUSE|RADIOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2021-03-22|90
e|TR|40883550-4627-4f92-974a-7eeb5bde74c5|1|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|mAnson U/mL|UNEQUIVOCAL|1|10^6 RNA copies/mL|NEPHELOMETRY|||ADJUDICATOR|HEMATOLOGIST|U|1|Visit_1|10|1|SCREENING|2020-10-13|10
e|TR|40883550-4627-4f92-974a-7eeb5bde74c5|2|[?]|CALCFIND|Calcification Indicator|[?]|10^3 CFU|ENLARGEMENT|1|mL/cm|TRICHROME STAIN||Y|INDEPENDENT ASSESSOR|READER 2|N|2|Visit_2|25|3|FOLLOW-UP|2020-10-28|25
e|TR|40883550-4627-4f92-974a-7eeb5bde74c5|3|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|U|ENLARGEMENT FROM NADIR|1|Enzyme U/L|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|3|Visit_3|40|6|TREATMENT|2020-11-12|40
e|TR|40883550-4627-4f92-974a-7eeb5bde74c5|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|mg/min|FOCALLY INCREASED|1|mg/g/h|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||ADJUDICATION COMMITTEE|ONCOLOGIST 2|U|4|Visit_4|65|2|FOLLOW-UP|2020-12-07|65
e|TR|40883550-4627-4f92-974a-7eeb5bde74c5|5|[?]|SUMVOL|Sum of Volume|[?]|uU/dL|PRESENT|1|U/kg/day|CONFOCAL MICROSCOPY|||FRIEND|ONCOLOGIST 2|U|5|Visit_5|90|3|FOLLOW-UP|2021-01-01|90
e|TR|4199b549-d021-4bfd-97e6-95630d407183|1|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|ppb|NON-PATHOLOGICAL|1|kIU|SPECT SCAN|||ADJUDICATION COMMITTEE|MICROSCOPIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-12-02|10
e|TR|4199b549-d021-4bfd-97e6-95630d407183|2|[?]|VOLUME|Volume|[?]|g/animal/day|NON-PATHOLOGICAL|1|amu|WESTERGREN|||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|4|FOLLOW-UP|2020-12-17|25
e|TR|4199b549-d021-4bfd-97e6-95630d407183|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|umol/h/mmol|PALPABLE|1|in|SNP ARRAY|Y||SIGNIFICANT OTHER|ADJUDICATOR 3|U|3|Visit_3|40|6|SCREENING|2021-01-01|40
e|TR|4199b549-d021-4bfd-97e6-95630d407183|4|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|/MBP|TUMOR MERGED|1|PNU/mL|SINGLE-SLICE SPIRAL CT|Y||PROXY|ADJUDICATOR 1|NA|4|Visit_4|65|3|TREATMENT|2021-01-26|65
e|TR|4199b549-d021-4bfd-97e6-95630d407183|5|[?]|PPD|Product of Perpendicular Diameters|[?]|deg/s|NONPALPABLE|1|mL/s/m2|MICROBIAL CULTURE, LIQUID|Y||FRIEND|OPTOMETRIST|U|5|Visit_5|90|6|TREATMENT|2021-02-20|90
e|TR|6366647f-62fa-48dc-9d77-1677fce62fc7|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mL/beat|PRESENT|1|/7.5 mL|DYNAMIC LIGHT SCATTERING|Y||PARENT|PATHOLOGIST 2|U|1|Visit_1|10|7|WASHOUT|2020-07-14|10
e|TR|6366647f-62fa-48dc-9d77-1677fce62fc7|2|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|Ci|FOCALLY INCREASED|1|L/L|RAJI CELL EIA|||VENDOR|READER 1|Y|2|Visit_2|25|4|WASHOUT|2020-07-29|25
e|TR|6366647f-62fa-48dc-9d77-1677fce62fc7|3|[?]|AREA|Area|[?]|kg/m2|NON-PATHOLOGICAL|1|GPS U|CONTRAST ENHANCED X-RAY|||ADJUDICATOR|READER|Y|3|Visit_3|40|5|TREATMENT|2020-08-13|40
e|TR|6366647f-62fa-48dc-9d77-1677fce62fc7|4|[?]|AREA|Area|[?]|damol/L|EQUIVOCAL|1|Bq|TARGETED GENOME SEQUENCING|||INTERVIEWER|MICROSCOPIST 2|U|4|Visit_4|65|6|TREATMENT|2020-09-07|65
e|TR|6366647f-62fa-48dc-9d77-1677fce62fc7|5|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mL/cm|UNCHANGED|1|mAnson U/mL|REFRACTOMETRY||Y|CLINICAL STUDY SPONSOR|NEUROLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-10-02|90
e|TR|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|1|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|mL/m2|DECREASED|1|OI50|MALDI||Y|ADJUDICATOR|RATER 2|Y|1|Visit_1|10|5|TREATMENT|2020-05-13|10
e|TR|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|2|[?]|LPERP|Longest Perpendicular|[?]|10^6/hpf|PRESENT|1|L/h/m2|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||INTERVIEWER|FORENSIC PATHOLOGIST|N|2|Visit_2|25|5|TREATMENT|2020-05-28|25
e|TR|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|10^9 organisms/mg|ENLARGEMENT FROM NADIR|1|IU/kg|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|3|Visit_3|40|1|SCREENING|2020-06-12|40
e|TR|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|4|[?]|PALPSTAT|Palpable State|[?]|kN/cm2|ENLARGEMENT|1|mol/mol|EIA|Y||ADJUDICATOR|ONCOLOGIST 1|N|4|Visit_4|65|7|TREATMENT|2020-07-07|65
e|TR|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|5|[?]|VSLFLIND|Vessel Failure Indicator|[?]|sec|NORMAL|1|CCID 50/dose|GEL ELECTROPHORESIS||Y|VENDOR|ENDOCRINOLOGIST|NA|5|Visit_5|90|1|TREATMENT|2020-08-01|90
e|TR|637d7d5f-78d3-47fb-b6dc-d877d92b9001|1|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|cy/cm|ENLARGEMENT|1|10^4/L|ZIEHL NEELSEN ACID FAST STAIN|Y||PARENT|RADIOLOGIST|NA|1|Visit_1|10|6|FOLLOW-UP|2020-06-03|10
e|TR|637d7d5f-78d3-47fb-b6dc-d877d92b9001|2|[?]|PCHGNAD|Percent Change From Nadir|[?]|km|TUMOR MERGED|1|10^9/g|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y||NON-HEALTH CARE PROFESSIONAL|RATER|NA|2|Visit_2|25|4|SCREENING|2020-06-18|25
e|TR|637d7d5f-78d3-47fb-b6dc-d877d92b9001|3|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|10^6 organisms/mg|EQUIVOCAL|1|mL/kg/day|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||CAREGIVER|NEUROLOGIST 2|N|3|Visit_3|40|1|SCREENING|2020-07-03|40
e|TR|637d7d5f-78d3-47fb-b6dc-d877d92b9001|4|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|msec|INCREASED|1|DPM|THERMAL IONIZATION MASS SPECTROMETRY|||INDEPENDENT ASSESSOR|HEMATOLOGIST|U|4|Visit_4|65|5|FOLLOW-UP|2020-07-28|65
e|TR|637d7d5f-78d3-47fb-b6dc-d877d92b9001|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|KIT|TUMOR MERGED|1|cmH2O*s2/mL|LASER CAPTURE MICRODISSECTION|||PARENT|FORENSIC PATHOLOGIST|U|5|Visit_5|90|2|SCREENING|2020-08-22|90
e|TR|696cd04a-cde7-4481-b5e2-fad1877ec284|1|[?]|ORVERLN|Organ Vertical Length|[?]|nmol/kg/day|INCREASED|1|mm3/mm2/year|QUANTITATIVE ULTRASOUND|||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|1|WASHOUT|2020-08-31|10
e|TR|696cd04a-cde7-4481-b5e2-fad1877ec284|2|[?]|ORSTATE|Organ State|[?]|SCOOPFUL|FOCALLY INCREASED|1|Joule|MICROBIAL CULTURE, SOLID|||ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|Y|2|Visit_2|25|1|WASHOUT|2020-09-15|25
e|TR|696cd04a-cde7-4481-b5e2-fad1877ec284|3|[?]|LMBFLIND|Limb Failure Indicator|[?]|log10 IU/mL|PALPABLE|1|IMPLANT|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||NON-HEALTH CARE PROFESSIONAL|READER 1|Y|3|Visit_3|40|5|SCREENING|2020-09-30|40
e|TR|696cd04a-cde7-4481-b5e2-fad1877ec284|4|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|MESF|NONPALPABLE|1|LENS|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||FRIEND|READER 2|NA|4|Visit_4|65|1|FOLLOW-UP|2020-10-25|65
e|TR|696cd04a-cde7-4481-b5e2-fad1877ec284|5|[?]|VDIAM|Viable Diameter|[?]|umol/L/min|DIFFUSELY INCREASED|1|PIXELS/in|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|7|FOLLOW-UP|2020-11-19|90
e|TR|ce4699cb-66f1-4c13-8428-84064255b765|1|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|EU|PATHOLOGICAL|1|mol/g|HEMOCYTOMETRY|Y|Y|GUARDIAN|NEUROLOGIST 1|U|1|Visit_1|10|5|WASHOUT|2020-12-02|10
e|TR|ce4699cb-66f1-4c13-8428-84064255b765|2|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|g/cage/wk|NON-PATHOLOGICAL|1|/kg|KINETIC MICROPARTICLE IMMUNOASSAY|||INVESTIGATOR|PATHOLOGIST|Y|2|Visit_2|25|1|WASHOUT|2020-12-17|25
e|TR|ce4699cb-66f1-4c13-8428-84064255b765|3|[?]|DIAMETER|Diameter|[?]|ag|INCREASED|1|BAU/mL|BAC ACGH|||ADJUDICATOR|READER 2|U|3|Visit_3|40|5|WASHOUT|2021-01-01|40
e|TR|ce4699cb-66f1-4c13-8428-84064255b765|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|10^3 CFU|NON-PATHOLOGICAL|1|Enzyme U|AUTOREFRACTION|||INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|4|WASHOUT|2021-01-26|65
e|TR|ce4699cb-66f1-4c13-8428-84064255b765|5|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|10^6/L|ENLARGEMENT|1|mL/beat|AGAR PROPORTION|||ADJUDICATOR|ONCOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2021-02-20|90
e|TR|015b391b-23c7-478d-b9d1-226d3cb9edcf|1|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|mL/min|INCREASED|1|gpELISA unit/mL|KNEMOMETRY|||STUDY SUBJECT|READER 2|U|1|Visit_1|10|3|SCREENING|2020-11-29|10
e|TR|015b391b-23c7-478d-b9d1-226d3cb9edcf|2|[?]|DIAMETER|Diameter|[?]|ft2|NORMAL|1|kIU|NEXT GENERATION SEQUENCING|||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|N|2|Visit_2|25|7|SCREENING|2020-12-14|25
e|TR|015b391b-23c7-478d-b9d1-226d3cb9edcf|3|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|10^8/L|TUMOR MERGED|1|U/kg/day|RADIOGRAPHY|Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|3|Visit_3|40|2|SCREENING|2020-12-29|40
e|TR|015b391b-23c7-478d-b9d1-226d3cb9edcf|4|[?]|LESSCIND|Lesion Success Indicator|[?]|Ejaculate U|NONPALPABLE|1|kDa|URANYL ACETATE STAIN|Y|Y|ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|4|Visit_4|65|5|TREATMENT|2021-01-23|65
e|TR|015b391b-23c7-478d-b9d1-226d3cb9edcf|5|[?]|LDIAM|Longest Diameter|[?]|CFU/g|PRESENT|1|ppm|CT SCAN WITHOUT CONTRAST|Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST|NA|5|Visit_5|90|2|WASHOUT|2021-02-17|90
e|TR|b510a277-c5ee-4a32-b111-b2dbc72c8a27|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|umol/kg/min|DIFFUSELY INCREASED|1|nsec|SPECT/CT SCAN||Y|SPOUSE|READER 2|NA|1|Visit_1|10|7|TREATMENT|2020-06-07|10
e|TR|b510a277-c5ee-4a32-b111-b2dbc72c8a27|2|[?]|LESSCIND|Lesion Success Indicator|[?]|STEPS|DECREASED|1|mmol/L|HPLC/IEX|||INDEPENDENT ASSESSOR|ONCOLOGIST 1|NA|2|Visit_2|25|4|WASHOUT|2020-06-22|25
e|TR|b510a277-c5ee-4a32-b111-b2dbc72c8a27|3|[?]|SUMLDIAM|Sum of Longest Diameter|[?]|nmol BCE/mmol|PALPABLE|1|/7.5 mL|CLAUSS METHOD|||CLINICAL STUDY SPONSOR|OPTOMETRIST|N|3|Visit_3|40|3|SCREENING|2020-07-07|40
e|TR|b510a277-c5ee-4a32-b111-b2dbc72c8a27|4|[?]|VSLPIND|Vessel Patency Indicator|[?]|ug/m2/day|DECREASED|1|log10 IU/mL|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||INTERVIEWER|ADJUDICATOR 1|NA|4|Visit_4|65|2|WASHOUT|2020-08-01|65
e|TR|b510a277-c5ee-4a32-b111-b2dbc72c8a27|5|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|L/h|UNEQUIVOCAL|1|U|URANYL ACETATE STAIN|||NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-08-26|90
e|TR|9e9acf6b-d29a-4c11-96d6-b580c721f462|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|grain|FOCALLY INCREASED|1|U/g/day|FLUORESCENT ENZYME IMMUNOASSAY||Y|FAMILY MEMBER|ADJUDICATOR 3|N|1|Visit_1|10|6|TREATMENT|2020-08-20|10
e|TR|9e9acf6b-d29a-4c11-96d6-b580c721f462|2|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|L/day|NONPALPABLE|1|g/day|ELECTROMYOGRAPHY|||PROXY|RATER 2|NA|2|Visit_2|25|2|TREATMENT|2020-09-04|25
e|TR|9e9acf6b-d29a-4c11-96d6-b580c721f462|3|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|EIA unit|ENLARGEMENT|1|kHz|ELECTROGASTROGRAPHY|Y|Y|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|3|SCREENING|2020-09-19|40
e|TR|9e9acf6b-d29a-4c11-96d6-b580c721f462|4|[?]|VOLUME|Volume|[?]|BU/mL|PRESENT|1|IU/g Hb|PET SCAN|Y||NON-HEALTH CARE PROFESSIONAL|READER 1|NA|4|Visit_4|65|5|WASHOUT|2020-10-14|65
e|TR|9e9acf6b-d29a-4c11-96d6-b580c721f462|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|ug/kg/day|NORMAL|1|mmol/min/kPa|REFRACTOMETRY|||CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-11-08|90
e|TR|da69b157-7dab-49c5-b8fb-bd312a21fcf0|1|[?]|PALPSTAT|Palpable State|[?]|ug/h|ENLARGEMENT|1|10^6 CFU/g|KNEMOMETRY|Y|Y|FRIEND|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|5|WASHOUT|2020-07-18|10
e|TR|da69b157-7dab-49c5-b8fb-bd312a21fcf0|2|[?]|PCBSLD|Percent Change Baseline Sum Longest Diam|[?]|umol/L|FURTHER ENLARGEMENT|1|Weber|COMPLEMENT FIXATION|||STUDY SUBJECT|RATER 2|N|2|Visit_2|25|4|SCREENING|2020-08-02|25
e|TR|da69b157-7dab-49c5-b8fb-bd312a21fcf0|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|pL|ENLARGEMENT FROM NADIR|1|ELISA unit|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|4|TREATMENT|2020-08-17|40
e|TR|da69b157-7dab-49c5-b8fb-bd312a21fcf0|4|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|10^6 CFU/mL|INCREASED|1|10^6/hpf|MICRONEUTRALIZATION ASSAY|||GUARDIAN|DERMATOLOGIST|NA|4|Visit_4|65|7|WASHOUT|2020-09-11|65
e|TR|da69b157-7dab-49c5-b8fb-bd312a21fcf0|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|kUSP|NORMAL|1|MET*min|KINETIC CHROMOGENIC ASSAY|||STUDY SUBJECT|MICROSCOPIST|NA|5|Visit_5|90|4|TREATMENT|2020-10-06|90
e|TR|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|nm|NON-PATHOLOGICAL|1|in|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y|Y|SIGNIFICANT OTHER|PATHOLOGIST|U|1|Visit_1|10|4|WASHOUT|2020-05-29|10
e|TR|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|2|[?]|PCNDOREN|Percent Change Nadir in Organ Enlarge|[?]|mEq/ug|DIFFUSELY INCREASED|1|L/h/m2|ETDRS EYE CHART|||CHILD|HEMATOLOGIST|NA|2|Visit_2|25|6|WASHOUT|2020-06-13|25
e|TR|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|3|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|pmol/day|NORMAL|1|mg/kg/dose|INTRAVASCULAR ULTRASOUND|||DOMESTIC PARTNER|OPHTHALMOLOGIST|N|3|Visit_3|40|7|WASHOUT|2020-06-28|40
e|TR|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|4|[?]|SUMDIAM|Sum of Diameter|[?]|dmol|PRESENT|1|MnFI|DIGITAL PCR|||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|NA|4|Visit_4|65|6|FOLLOW-UP|2020-07-23|65
e|TR|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|5|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|ka_u/dL|PRESENT|1|%(v/v)|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|GUARDIAN|MICROSCOPIST 3|N|5|Visit_5|90|4|TREATMENT|2020-08-17|90
e|TR|77c97d1e-e223-4485-b2de-59daa4e5b01f|1|[?]|LESSCIND|Lesion Success Indicator|[?]|GPL U/mL|PALPABLE|1|log10 PFU|POTENTIOMETRY|Y||SIBLING|MICROSCOPIST|Y|1|Visit_1|10|4|FOLLOW-UP|2020-06-19|10
e|TR|77c97d1e-e223-4485-b2de-59daa4e5b01f|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|TAMPON|DIFFUSELY INCREASED|1|pmol/g|MICROBIAL CONCENTRATION|||ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|2|TREATMENT|2020-07-04|25
e|TR|77c97d1e-e223-4485-b2de-59daa4e5b01f|3|[?]|PCHGBL|Percent Change From Baseline|[?]|umol/L/min|DECREASED|1|ug/kg/day|CONTRAST ENHANCED CT SCAN|||DOMESTIC PARTNER|NEUROLOGIST|N|3|Visit_3|40|2|WASHOUT|2020-07-19|40
e|TR|77c97d1e-e223-4485-b2de-59daa4e5b01f|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|U.CARR|ABSENT|1|umol/h/mmol|MULTIPLE BREATH WASHOUT|Y||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|NA|4|Visit_4|65|2|TREATMENT|2020-08-13|65
e|TR|77c97d1e-e223-4485-b2de-59daa4e5b01f|5|[?]|LDIAM|Longest Diameter|[?]|U/cL|DECREASED|1|mmol2/L2|MAGNETIC RESONANCE ANGIOGRAPHY||Y|INTERVIEWER|ONCOLOGIST 2|U|5|Visit_5|90|2|SCREENING|2020-09-07|90
e|TR|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|1|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|10^4 CFU|INCREASED|1|/100 HPFs|SPECT SCAN|||CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-10-14|10
e|TR|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|2|[?]|CALCFIND|Calcification Indicator|[?]|MBq|UNCHANGED|1|uL|ACCELERATOR MASS SPECTROMETRY|Y||INDEPENDENT ASSESSOR|READER 1|NA|2|Visit_2|25|6|TREATMENT|2020-10-29|25
e|TR|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|3|[?]|VDIAM|Viable Diameter|[?]|CFU/mL|DIFFUSELY INCREASED|1|MET|DROPLET DIGITAL PCR|Y||INVESTIGATOR|READER 3|N|3|Visit_3|40|6|FOLLOW-UP|2020-11-13|40
e|TR|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|4|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|log10 copies/mL|ENLARGEMENT|1|10^6 RNA copies/mL|INDIA INK STAIN|||FRIEND|INTERNIST|Y|4|Visit_4|65|6|FOLLOW-UP|2020-12-08|65
e|TR|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|5|[?]|BNLNUM|Number of Bone Lesions|[?]|10^6 CFU/mL|ENLARGEMENT FROM NADIR|1|log10 PFU/mL|PERCUSSION|||STUDY SUBJECT|FORENSIC PATHOLOGIST|U|5|Visit_5|90|2|SCREENING|2021-01-02|90
e|TR|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|1|[?]|AREA|Area|[?]|mm3/mm2/year|FURTHER ENLARGEMENT|1|nmol BCE/nmol|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y|SPOUSE|READER|N|1|Visit_1|10|4|SCREENING|2020-11-01|10
e|TR|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|2|[?]|VOLUME|Volume|[?]|mL/animal/wk|NON-PATHOLOGICAL|1|mm/h|SINGLE-SLICE SPIRAL CT|Y|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|N|2|Visit_2|25|7|TREATMENT|2020-11-16|25
e|TR|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|cm/min|PATHOLOGICAL|1|/10^3|DROPLET DIGITAL PCR|||CHILD|RATER 1|U|3|Visit_3|40|7|TREATMENT|2020-12-01|40
e|TR|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|4|[?]|PALPSTAT|Palpable State|[?]|10^6 organisms/mg|FURTHER ENLARGEMENT|1|IU/kg/h|RYAN BLUE STAIN|||FAMILY MEMBER|NEUROLOGIST 2|Y|4|Visit_4|65|3|TREATMENT|2020-12-26|65
e|TR|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|10^6 IU|NONPALPABLE|1|Ci/g|MALDI|Y||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|U|5|Visit_5|90|6|SCREENING|2021-01-20|90
e|TR|9eb6e591-d266-4e05-85b6-230e8a02d494|1|[?]|PCHGBL|Percent Change From Baseline|[?]|/h|DIFFUSELY INCREASED|1|nmol/L/h|POTENTIOMETRY||Y|PARENT|INTERNIST|Y|1|Visit_1|10|7|TREATMENT|2020-06-28|10
e|TR|9eb6e591-d266-4e05-85b6-230e8a02d494|2|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|kV|PRESENT|1|mmol/g|LC/MS|||FAMILY MEMBER|PHYSIOTHERAPIST|Y|2|Visit_2|25|5|TREATMENT|2020-07-13|25
e|TR|9eb6e591-d266-4e05-85b6-230e8a02d494|3|[?]|LDIAM|Longest Diameter|[?]|Arbitrary U|UNEQUIVOCAL|1|/MBP|CALIPER MEASUREMENT METHOD|||ADJUDICATION COMMITTEE|READER|N|3|Visit_3|40|4|TREATMENT|2020-07-28|40
e|TR|9eb6e591-d266-4e05-85b6-230e8a02d494|4|[?]|ORSTATE|Organ State|[?]|ft2|PALPABLE|1|uCi|SLOAN LETTER EYE CHART 100%|Y||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|6|SCREENING|2020-08-22|65
e|TR|9eb6e591-d266-4e05-85b6-230e8a02d494|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|hr/day|DECREASED|1|log10 IU/mL|IMPULSE OSCILLOMETRY||Y|PROXY|OPHTHALMOLOGIST|Y|5|Visit_5|90|4|FOLLOW-UP|2020-09-16|90
e|TR|6a6e040d-6a09-4004-9fab-f4f82ba00eae|1|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|mg/m2/day|UNCHANGED|1|mEq|PET/CT SCAN WITHOUT CONTRAST|||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|1|Visit_1|10|6|TREATMENT|2020-06-30|10
e|TR|6a6e040d-6a09-4004-9fab-f4f82ba00eae|2|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|DNA copies/ug|ENLARGEMENT|1|dpm/mg|TRANSCRIPTION-MEDIATED AMPLIFICATION|Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|Y|2|Visit_2|25|5|SCREENING|2020-07-15|25
e|TR|6a6e040d-6a09-4004-9fab-f4f82ba00eae|3|[?]|OTRCUPCB|Overall Tracer Uptake Compared to BL|[?]|nU/cL|ENLARGEMENT|1|deg2|CLIP SEQUENCING|||INDEPENDENT ASSESSOR|RATER 1|NA|3|Visit_3|40|3|TREATMENT|2020-07-30|40
e|TR|6a6e040d-6a09-4004-9fab-f4f82ba00eae|4|[?]|LNSTATE|Lymph Node State|[?]|mOsm/L|FURTHER ENLARGEMENT FROM NADIR|1|Hz/s|TRANSVAGINAL ULTRASOUND|Y|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST|Y|4|Visit_4|65|3|TREATMENT|2020-08-24|65
e|TR|6a6e040d-6a09-4004-9fab-f4f82ba00eae|5|[?]|RADIODEN|Radiodensity|[?]|ft2|TUMOR MERGED|1|U/g/h|TELLER ACUITY CARDS||Y|INTERVIEWER|RATER 1|N|5|Visit_5|90|6|SCREENING|2020-09-18|90
e|TR|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|cs|DIFFUSELY INCREASED|1|cL|AGAR DILUTION|Y||SIBLING|ADJUDICATOR 1|N|1|Visit_1|10|7|WASHOUT|2020-08-17|10
e|TR|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|2|[?]|VDIAM|Viable Diameter|[?]|mL/m2/h|FOCALLY INCREASED|1|vg/kg|IMMUNOPRECIPITATION|||PARENT|PATHOLOGIST 1|Y|2|Visit_2|25|7|FOLLOW-UP|2020-09-01|25
e|TR|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|3|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|10^6/g|UNCHANGED|1|mg/kg/dose|HPLC-FL|||STUDY SUBJECT|PATHOLOGIST|U|3|Visit_3|40|1|FOLLOW-UP|2020-09-16|40
e|TR|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|4|[?]|PCNSPPD|Percent Change Nadir in Sum of PPD|[?]|DIOPTER|PALPABLE|1|g/animal/day|COLORIMETRY||Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|7|FOLLOW-UP|2020-10-11|65
e|TR|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|5|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|PUFF|NORMAL|1|ms2|PHASE CONTRAST MICROSCOPY||Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|U|5|Visit_5|90|4|TREATMENT|2020-11-05|90
e|TR|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|1|[?]|RADIODEN|Radiodensity|[?]|nU/cL|DECREASED|1|Enzyme U/g Hb|JAEGER EYE CHART|Y||FRIEND|ADJUDICATOR 3|Y|1|Visit_1|10|2|TREATMENT|2021-01-19|10
e|TR|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|2|[?]|NEWCONF|New Tumor Confirmed|[?]|P|FOCALLY INCREASED|1|Bq/ug|LC/MS/MS||Y|VENDOR|MICROSCOPIST 1|U|2|Visit_2|25|5|TREATMENT|2021-02-03|25
e|TR|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|3|[?]|NEWCONF|New Tumor Confirmed|[?]|C|INCREASED|1|POUCH|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|Y||SIGNIFICANT OTHER|OPHTHALMOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2021-02-18|40
e|TR|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|4|[?]|SUMDIAM|Sum of Diameter|[?]|/ms|ABSENT|1|days/wk|SPIROMETRY|||INDEPENDENT ASSESSOR|MICROSCOPIST 3|Y|4|Visit_4|65|2|TREATMENT|2021-03-15|65
e|TR|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|5|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|mg/g/h|TUMOR MERGED|1|log10 TCID 50/mL|TRANSMISSION ELECTRON MICROSCOPY||Y|ADJUDICATION COMMITTEE|RATER 2|N|5|Visit_5|90|6|WASHOUT|2021-04-09|90
e|TR|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|1|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|amol|FOCALLY INCREASED|1|g/cage/day|TRANSTHORACIC ECHOCARDIOGRAPHY|||FRIEND|READER 1|U|1|Visit_1|10|6|WASHOUT|2020-05-12|10
e|TR|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|2|[?]|AREA|Area|[?]|kg/mol|PRESENT|1|LB|PET/MRI SCAN||Y|CAREGIVER|CLINICAL PATHOLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-05-27|25
e|TR|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|3|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|IMPLANT|INCREASED|1|hr/day|SPIRAL CT|||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-06-11|40
e|TR|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|4|[?]|SUMDIAM|Sum of Diameter|[?]|kg/cm|FURTHER ENLARGEMENT FROM NADIR|1|MBP|IMMUNOFIXATION ELECTROPHORESIS||Y|GUARDIAN|ONCOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-07-06|65
e|TR|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|5|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|grain|UNEQUIVOCAL|1|mEq/kg|MANUAL CLOT DETECTION|Y||FRIEND|PATHOLOGIST 2|NA|5|Visit_5|90|5|TREATMENT|2020-07-31|90
e|TR|ba99022a-d398-4c60-828c-876f119459e1|1|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|L/s/kPa|TUMOR MERGED|1|10^3 organisms/mL|SPECULAR MICROSCOPY||Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-12-01|10
e|TR|ba99022a-d398-4c60-828c-876f119459e1|2|[?]|CALCFIND|Calcification Indicator|[?]|Bq/ug|ENLARGEMENT|1|m|TRICHROME STAIN|||ADJUDICATOR|RATER 1|NA|2|Visit_2|25|2|WASHOUT|2020-12-16|25
e|TR|ba99022a-d398-4c60-828c-876f119459e1|3|[?]|BNLNUM|Number of Bone Lesions|[?]|dpm/0.5 mL|PALPABLE|1|GBq|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||PROXY|RATER 1|NA|3|Visit_3|40|2|FOLLOW-UP|2020-12-31|40
e|TR|ba99022a-d398-4c60-828c-876f119459e1|4|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|F|NON-PATHOLOGICAL|1|amp|PALM METHOD|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|N|4|Visit_4|65|6|TREATMENT|2021-01-25|65
e|TR|ba99022a-d398-4c60-828c-876f119459e1|5|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mL/s/m2|PRESENT|1|pmol/10^10 cells|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||SPOUSE|PHYSIOTHERAPIST|NA|5|Visit_5|90|3|FOLLOW-UP|2021-02-19|90
e|TR|d713869e-061c-4e95-8a50-da2e1ec47b3c|1|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|g/L|NORMAL|1|GPL U|ANTIMICROBIAL COMBINATION TESTING|||INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|1|Visit_1|10|6|TREATMENT|2020-06-06|10
e|TR|d713869e-061c-4e95-8a50-da2e1ec47b3c|2|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|/mm2|DECREASED|1|SCOOPFUL|TELLER ACUITY CARDS||Y|DOMESTIC PARTNER|HEMATOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-06-21|25
e|TR|d713869e-061c-4e95-8a50-da2e1ec47b3c|3|[?]|NBNL2IND|Two or More New Bone Lesions Indicator|[?]|mmol/day|UNCHANGED|1|mmol/mol|SLOAN LETTER EYE CHART 1.25%|Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|3|Visit_3|40|3|WASHOUT|2020-07-06|40
e|TR|d713869e-061c-4e95-8a50-da2e1ec47b3c|4|[?]|NEWCONF|New Tumor Confirmed|[?]|PACKET|FOCALLY INCREASED|1|mol/L|TRIPLE-PHASE MRI SCAN|Y||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|Y|4|Visit_4|65|3|TREATMENT|2020-07-31|65
e|TR|d713869e-061c-4e95-8a50-da2e1ec47b3c|5|[?]|SUMDIAM|Sum of Diameter|[?]|10^3/L|NONPALPABLE|1|L|ANTIMICROBIAL COMBINATION TESTING|||VENDOR|ADJUDICATOR 2|N|5|Visit_5|90|1|TREATMENT|2020-08-25|90
e|TR|fcebb64c-e0e6-4f29-9c52-15fa91f60018|1|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|IU/mg|NORMAL|1|mL/cage|MECHANICAL CLOT DETECTION|||GUARDIAN|ADJUDICATOR|N|1|Visit_1|10|7|WASHOUT|2020-07-11|10
e|TR|fcebb64c-e0e6-4f29-9c52-15fa91f60018|2|[?]|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|[?]|MnFI|TUMOR MERGED|1|TABLET|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||Y|CLINICAL RESEARCH COORDINATOR|RATER 1|U|2|Visit_2|25|5|TREATMENT|2020-07-26|25
e|TR|fcebb64c-e0e6-4f29-9c52-15fa91f60018|3|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|L/h|EQUIVOCAL|1|mV|ELECTROCHEMILUMINESCENCE|||HEALTH CARE PROFESSIONAL|PATHOLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-08-10|40
e|TR|fcebb64c-e0e6-4f29-9c52-15fa91f60018|4|[?]|LDIAM|Longest Diameter|[?]|gpELISA unit/mL|DECREASED|1|10^3/L|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||PARENT|NEUROLOGIST|Y|4|Visit_4|65|5|TREATMENT|2020-09-04|65
e|TR|fcebb64c-e0e6-4f29-9c52-15fa91f60018|5|[?]|ACNSD|Absolute Change Nadir in Sum of Diam|[?]|MBq/uL|NORMAL|1|mL/s|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|4|TREATMENT|2020-09-29|90
e|TR|e443f82e-43a8-4710-bff4-fd2b2f4d512f|1|[?]|ACHNAD|Absolute Change From Nadir|[?]|in|UNCHANGED|1|mkat|ORCHIDOMETERY|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|1|Visit_1|10|2|SCREENING|2021-01-01|10
e|TR|e443f82e-43a8-4710-bff4-fd2b2f4d512f|2|[?]|BNLNUM|Number of Bone Lesions|[?]|10^3 copies/mL|FURTHER ENLARGEMENT|1|CAPSULE|FLUORESCENT MICROSCOPY|||INTERVIEWER|READER 1|N|2|Visit_2|25|7|TREATMENT|2021-01-16|25
e|TR|e443f82e-43a8-4710-bff4-fd2b2f4d512f|3|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|uEq/L|ENLARGEMENT|1|MAC50|QUANTITATIVE ULTRASOUND||Y|INDEPENDENT ASSESSOR|ADJUDICATOR 1|NA|3|Visit_3|40|1|TREATMENT|2021-01-31|40
e|TR|e443f82e-43a8-4710-bff4-fd2b2f4d512f|4|[?]|NEWCONF|New Tumor Confirmed|[?]|g|NON-PATHOLOGICAL|1|mg/g/h|SINGLE-MOLECULE ARRAY|||CHILD|HEMATOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2021-02-25|65
e|TR|e443f82e-43a8-4710-bff4-fd2b2f4d512f|5|[?]|SUMVOL|Sum of Volume|[?]|in2|UNEQUIVOCAL|1|MBq/uL|PHOTOMETRIC CLOT DETECTION|Y||INVESTIGATOR|ADJUDICATOR 3|N|5|Visit_5|90|5|TREATMENT|2021-03-22|90
e|TR|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|1|[?]|PCHGBL|Percent Change From Baseline|[?]|L/min/m2|NORMAL|1|pm|MUGA|||SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-06-22|10
e|TR|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|Bq/mg|NORMAL|1|uCi/kg|IN VITRO GENE EXPRESSION ASSAY|Y||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|7|SCREENING|2020-07-07|25
e|TR|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|3|[?]|TUMSTATE|Tumor State|[?]|mmol/L|DECREASED|1|L|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|3|Visit_3|40|7|TREATMENT|2020-07-22|40
e|TR|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|4|[?]|ORSTATE|Organ State|[?]|nL|PALPABLE|1|nmol/L|CINEANGIOGRAPHY|||STUDY SUBJECT|READER 1|N|4|Visit_4|65|6|FOLLOW-UP|2020-08-16|65
e|TR|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|5|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|ug/L/h|DIFFUSELY INCREASED|1|pptr|AURAMINE STAIN|||SPOUSE|RATER|Y|5|Visit_5|90|2|TREATMENT|2020-09-10|90
e|TR|8a2147b1-2deb-410e-a298-d028a5efc555|1|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|ug/kg/h|ENLARGEMENT|1|uV2|MICROBIAL CULTURE, SOLID||Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|7|SCREENING|2020-10-30|10
e|TR|8a2147b1-2deb-410e-a298-d028a5efc555|2|[?]|LESFLIND|Lesion Failure Indicator|[?]|kg/L|PRESENT|1|mg/mL/min|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||GUARDIAN|MICROSCOPIST 3|U|2|Visit_2|25|1|TREATMENT|2020-11-14|25
e|TR|8a2147b1-2deb-410e-a298-d028a5efc555|3|[?]|ORVERLN|Organ Vertical Length|[?]|cd|FOCALLY INCREASED|1|cal|BIOPSY|||FRIEND|RADIOLOGIST 2|U|3|Visit_3|40|5|TREATMENT|2020-11-29|40
e|TR|8a2147b1-2deb-410e-a298-d028a5efc555|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|RNA copies/mL|PALPABLE|1|MAC50|TRANSMISSION ELECTRON MICROSCOPY|||CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|2|TREATMENT|2020-12-24|65
e|TR|8a2147b1-2deb-410e-a298-d028a5efc555|5|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|ukat/10^12 RBC|NONPALPABLE|1|Roentgen|PALM METHOD|||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|2|TREATMENT|2021-01-18|90
e|TR|033db3bf-17fb-4872-afdb-1eea3dac6d85|1|[?]|ORSTATE|Organ State|[?]|Tesla|PATHOLOGICAL|1|mL*cmH2O|NUCLEIC ACID BASED METHOD|||INTERVIEWER|ONCOLOGIST|NA|1|Visit_1|10|6|TREATMENT|2020-07-05|10
e|TR|033db3bf-17fb-4872-afdb-1eea3dac6d85|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|/kg|FURTHER ENLARGEMENT|1|min/day|RULER MEASUREMENT METHOD|||GUARDIAN|PATHOLOGIST 2|NA|2|Visit_2|25|1|SCREENING|2020-07-20|25
e|TR|033db3bf-17fb-4872-afdb-1eea3dac6d85|3|[?]|ORVERLN|Organ Vertical Length|[?]|FFU|DIFFUSELY INCREASED|1|deg/mm|MICROARRAY||Y|FAMILY MEMBER|ADJUDICATOR|N|3|Visit_3|40|6|FOLLOW-UP|2020-08-04|40
e|TR|033db3bf-17fb-4872-afdb-1eea3dac6d85|4|[?]|SUMPPD|Sum of Products of Perpendicular Diam|[?]|HOMEOPATHIC DILUTION|INCREASED|1|g/cage/day|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|Y|4|Visit_4|65|4|FOLLOW-UP|2020-08-29|65
e|TR|033db3bf-17fb-4872-afdb-1eea3dac6d85|5|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|tsp eq|ENLARGEMENT FROM NADIR|1|kV|CONTRAST ENHANCED X-RAY|Y||DOMESTIC PARTNER|ADJUDICATOR 3|N|5|Visit_5|90|2|TREATMENT|2020-09-23|90
e|TR|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|1|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|AU/mL|NORMAL|1|steps/min|LINE PROBE ASSAY||Y|FRIEND|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-06-19|10
e|TR|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|2|[?]|SUMDIAM|Sum of Diameter|[?]|CUP|INCREASED|1|pkat/L|AMSLER GRID||Y|ADJUDICATOR|ONCOLOGIST|N|2|Visit_2|25|4|WASHOUT|2020-07-04|25
e|TR|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|POINT|NORMAL|1|s^-1(%O2)^-1|DNA MICROARRAY|Y||PROXY|ADJUDICATOR|NA|3|Visit_3|40|6|TREATMENT|2020-07-19|40
e|TR|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|4|[?]|LMBFLIND|Limb Failure Indicator|[?]|oz|UNCHANGED|1|SACHET|GC/MS-CI||Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|4|Visit_4|65|4|TREATMENT|2020-08-13|65
e|TR|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|5|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|%/s|INCREASED|1|ms2|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||INTERVIEWER|READER 3|N|5|Visit_5|90|2|WASHOUT|2020-09-07|90
e|TR|8dd493b7-a892-4cab-8f69-701471c51d99|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|TRANSDUCING UNIT/mL|DECREASED|1|VIRTUAL PIXEL|LIGHT SCATTERING SPECTROSCOPY|||CAREGIVER|RADIOLOGIST 2|N|1|Visit_1|10|1|WASHOUT|2021-01-12|10
e|TR|8dd493b7-a892-4cab-8f69-701471c51d99|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|10^6 U|FOCALLY INCREASED|1|BP|NON-CONTACT SPECULAR MICROSCOPY|||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|4|TREATMENT|2021-01-27|25
e|TR|8dd493b7-a892-4cab-8f69-701471c51d99|3|[?]|NBNLNUM|Number of New Bone Lesions|[?]|ug/min|NON-PATHOLOGICAL|1|SCOOPFUL|IMPULSE OSCILLOMETRY|||INTERVIEWER|READER 1|N|3|Visit_3|40|4|TREATMENT|2021-02-11|40
e|TR|8dd493b7-a892-4cab-8f69-701471c51d99|4|[?]|VOLUME|Volume|[?]|MET*min|NORMAL|1|10^3 organisms/g|PALM METHOD|||SIBLING|ONCOLOGIST|NA|4|Visit_4|65|7|WASHOUT|2021-03-08|65
e|TR|8dd493b7-a892-4cab-8f69-701471c51d99|5|[?]|RADIODEN|Radiodensity|[?]|keV|FOCALLY INCREASED|1|Farad|ANTIMICROBIAL COMBINATION TESTING|||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|5|FOLLOW-UP|2021-04-02|90
e|TR|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|1|[?]|LPERP|Longest Perpendicular|[?]|oz|DIFFUSELY INCREASED|1|kg/cm|PULMONARY ANGIOGRAPHY|Y||VENDOR|PHYSIOTHERAPIST|N|1|Visit_1|10|1|SCREENING|2020-11-07|10
e|TR|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|2|[?]|PPD|Product of Perpendicular Diameters|[?]|L/min|EQUIVOCAL|1|PLUG|INDIA INK STAIN|||SIBLING|PATHOLOGIST 1|Y|2|Visit_2|25|4|TREATMENT|2020-11-22|25
e|TR|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|3|[?]|LRISCIND|Lesion Revas Ischemia Indicator|[?]|10^6 U|INCREASED|1|g/cm2|KLEIHAUER-BETKE|||DOMESTIC PARTNER|RATER|NA|3|Visit_3|40|6|WASHOUT|2020-12-07|40
e|TR|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|4|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|umol/kg/min|DIFFUSELY INCREASED|1|mAnson U/mL|DYNAMIC LIGHT SCATTERING|Y||GUARDIAN|CARDIOLOGIST|U|4|Visit_4|65|6|TREATMENT|2021-01-01|65
e|TR|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|5|[?]|NEWCONF|New Tumor Confirmed|[?]|U/kg/day|ENLARGEMENT FROM NADIR|1|mL/sec/1.73m2|WHOLE GENOME SEQUENCING|||FRIEND|ADJUDICATOR 2|Y|5|Visit_5|90|5|TREATMENT|2021-01-26|90
e|TR|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|1|[?]|DIAMETER|Diameter|[?]|pkat/L|ENLARGEMENT FROM NADIR|1|g/mol|JAFFE REACTION|||SIGNIFICANT OTHER|CARDIOLOGIST|Y|1|Visit_1|10|4|FOLLOW-UP|2020-09-04|10
e|TR|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|2|[?]|SUMVOL|Sum of Volume|[?]|umol/mg/min|FURTHER ENLARGEMENT FROM NADIR|1|ugEq|PERIODIC ACID SCHIFF STAIN|||INTERVIEWER|FORENSIC PATHOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-09-19|25
e|TR|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|3|[?]|ORSTATE|Organ State|[?]|dram|INCREASED|1|mL/cm|ENZYMATIC SPECTROPHOTOMETRY|||NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|2|WASHOUT|2020-10-04|40
e|TR|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|4|[?]|SUMVOL|Sum of Volume|[?]|atm|EQUIVOCAL|1|10^9/dose|CAPILLARY ELECTROPHORESIS|||CAREGIVER|OPTOMETRIST|NA|4|Visit_4|65|2|TREATMENT|2020-10-29|65
e|TR|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|5|[?]|ORENLQN|Organ Enlargement, Quantitative|[?]|FFU|FURTHER ENLARGEMENT FROM NADIR|1|10^5/L|AUSCULTATION|Y||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|U|5|Visit_5|90|6|WASHOUT|2020-11-23|90
e|TR|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|1|[?]|PCHGBL|Percent Change From Baseline|[?]|cd|ABSENT|1|JAR|CINEANGIOGRAPHY|||ADJUDICATION COMMITTEE|UROLOGIST|NA|1|Visit_1|10|6|TREATMENT|2020-11-20|10
e|TR|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|2|[?]|LESSCLSV|Lesion Scaling Severity/Intensity|[?]|Hz/s|DECREASED|1|ug/L FEU|ORCHIDOMETERY|||PROXY|PATHOLOGIST 2|Y|2|Visit_2|25|7|TREATMENT|2020-12-05|25
e|TR|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|3|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|10^9/dose|NORMAL|1|ms/mmHg|FARNSWORTH-MUNSELL 100 HUE TEST|Y||INVESTIGATOR|ONCOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2020-12-20|40
e|TR|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|4|[?]|LESERYSV|Lesion Erythema Severity/Intensity|[?]|10^9/g|PRESENT|1|pkat/L|SISH|||INVESTIGATOR|ADJUDICATOR|Y|4|Visit_4|65|6|FOLLOW-UP|2021-01-14|65
e|TR|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|uOsm|FURTHER ENLARGEMENT|1|in2|IMMUNORADIOMETRIC ASSAY|||SIGNIFICANT OTHER|RATER|N|5|Visit_5|90|4|TREATMENT|2021-02-08|90
e|TR|b49ef90c-a17e-4554-9fa6-af72b4d56a06|1|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|Bq/ug|PRESENT|1|VIAL|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y|SPOUSE|NEUROLOGIST 2|N|1|Visit_1|10|7|SCREENING|2021-01-05|10
e|TR|b49ef90c-a17e-4554-9fa6-af72b4d56a06|2|[?]|PCNSLD|Percent Change Nadir in Sum Longest Diam|[?]|ngEq/L|FOCALLY INCREASED|1|nmol/day|DROPLET DIGITAL PCR|||FRIEND|NEUROLOGIST 1|N|2|Visit_2|25|7|TREATMENT|2021-01-20|25
e|TR|b49ef90c-a17e-4554-9fa6-af72b4d56a06|3|[?]|SUMVOL|Sum of Volume|[?]|mU|FURTHER ENLARGEMENT|1|genEq/mL|ATOMIC ABSORPTION SPECTROMETRY|||FAMILY MEMBER|RATER 2|N|3|Visit_3|40|1|TREATMENT|2021-02-04|40
e|TR|b49ef90c-a17e-4554-9fa6-af72b4d56a06|4|[?]|LESELESV|Lesion Elevation Severity/Intensity|[?]|titer|ENLARGEMENT|1|RFU|ELECTRONEUROGRAPHY|||ADJUDICATOR|INTERNIST|NA|4|Visit_4|65|2|TREATMENT|2021-03-01|65
e|TR|b49ef90c-a17e-4554-9fa6-af72b4d56a06|5|[?]|LRVCLIND|Lesion Revas Clinical Indicator|[?]|CIGAR|ENLARGEMENT FROM NADIR|1|FEU|ORCHIDOMETERY||Y|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|5|Visit_5|90|2|SCREENING|2021-03-26|90
e|TR|df041193-ee4e-4835-8db9-5be9b832ded0|1|[?]|BNLNUM|Number of Bone Lesions|[?]|mEq/L|FURTHER ENLARGEMENT|1|GBq/mg|ARTERIAL SPIN LABELING FUNCTIONAL MRI||Y|VENDOR|UROLOGIST|U|1|Visit_1|10|2|FOLLOW-UP|2020-11-25|10
e|TR|df041193-ee4e-4835-8db9-5be9b832ded0|2|[?]|PCHGBL|Percent Change From Baseline|[?]|uIU/dL|NONPALPABLE|1|mmol/mol|PET/CT SCAN WITHOUT CONTRAST||Y|CAREGIVER|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-12-10|25
e|TR|df041193-ee4e-4835-8db9-5be9b832ded0|3|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|ft3|ENLARGEMENT|1|h*%|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|N|3|Visit_3|40|2|FOLLOW-UP|2020-12-25|40
e|TR|df041193-ee4e-4835-8db9-5be9b832ded0|4|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|uIU/L|NONPALPABLE|1|mmol/mol|MANUAL COUNT||Y|CLINICAL STUDY SPONSOR|RATER|Y|4|Visit_4|65|4|TREATMENT|2021-01-19|65
e|TR|df041193-ee4e-4835-8db9-5be9b832ded0|5|[?]|PCHGBL|Percent Change From Baseline|[?]|VOXEL|TUMOR MERGED|1|min/day|DIRECT SEQUENCING|Y||CHILD|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|1|TREATMENT|2021-02-13|90
e|TR|e41a4505-a5aa-4cac-895b-04fe85737ca9|1|[?]|PCHGBL|Percent Change From Baseline|[?]|Ci/mL|UNEQUIVOCAL|1|PNU/mL|ELECTRONEUROGRAPHY|||STUDY SUBJECT|RATER 1|U|1|Visit_1|10|3|TREATMENT|2021-01-13|10
e|TR|e41a4505-a5aa-4cac-895b-04fe85737ca9|2|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|10^3 RNA copies/mL|DIFFUSELY INCREASED|1|mg2/dL2|THICK SMEAR|||SIBLING|READER 2|Y|2|Visit_2|25|3|TREATMENT|2021-01-28|25
e|TR|e41a4505-a5aa-4cac-895b-04fe85737ca9|3|[?]|AREA|Area|[?]|mEq|ABSENT|1|fmol|IMMUNE REPERTOIRE DEEP SEQUENCING|||SIBLING|RATER 1|N|3|Visit_3|40|7|WASHOUT|2021-02-12|40
e|TR|e41a4505-a5aa-4cac-895b-04fe85737ca9|4|[?]|OTRCUPCN|Overall Tracer Uptake Compared to Nadir|[?]|ft|PALPABLE|1|10^6 IU|BETA LACTAMASE|||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|Y|4|Visit_4|65|1|TREATMENT|2021-03-09|65
e|TR|e41a4505-a5aa-4cac-895b-04fe85737ca9|5|[?]|BMUPTAKE|Bone Marrow Tracer Uptake|[?]|cal|EQUIVOCAL|1|NFIU|PHOTOGRAPHY|||SIGNIFICANT OTHER|HEMATOLOGIST|NA|5|Visit_5|90|6|WASHOUT|2021-04-03|90
e|TR|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|1|[?]|ORSTATE|Organ State|[?]|nmol/g|NORMAL|1|ag|BETA LACTAMASE|||CHILD|CARDIOLOGIST|U|1|Visit_1|10|5|SCREENING|2021-01-15|10
e|TR|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|2|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|MET*min|FOCALLY INCREASED|1|umol/L|MAGNETIC RESONANCE ELASTOGRAPHY|Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR|NA|2|Visit_2|25|4|TREATMENT|2021-01-30|25
e|TR|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|3|[?]|VSLPIND|Vessel Patency Indicator|[?]|sec|UNEQUIVOCAL|1|pmol/L|SPECULAR MICROSCOPY|Y||INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|3|Visit_3|40|3|FOLLOW-UP|2021-02-14|40
e|TR|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|4|[?]|PCBSV|Percent Change Baseline in Sum of Volume|[?]|cm/s|FURTHER ENLARGEMENT|1|Linear ft*LB|GC/MS-EI|||STUDY SUBJECT|PATHOLOGIST 1|Y|4|Visit_4|65|1|TREATMENT|2021-03-11|65
e|TR|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|5|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|nmol BCE/mmol|ENLARGEMENT|1|IMPLANT|PULSE OXIMETRY|||CAREGIVER|RATER 2|N|5|Visit_5|90|2|SCREENING|2021-04-05|90
e|TR|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|1|[?]|NBNLNUM|Number of New Bone Lesions|[?]|mL/cm3/min|TUMOR MERGED|1|mIU/L|PHOTOGRAPHY|||INVESTIGATOR|UROLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-12-12|10
e|TR|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|2|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|uL/kg/day|EQUIVOCAL|1|PNU/mL|TARGETED GENOME SEQUENCING|||ADJUDICATION COMMITTEE|READER|NA|2|Visit_2|25|7|TREATMENT|2020-12-27|25
e|TR|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|3|[?]|AREA|Area|[?]|CCID 50/dose|UNEQUIVOCAL|1|HEP|ECHOCARDIOGRAPHY|||NON-HEALTH CARE PROFESSIONAL|INTERNIST|Y|3|Visit_3|40|4|TREATMENT|2021-01-11|40
e|TR|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|4|[?]|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|[?]|BOWL|PRESENT|1|mmol/min/kPa/L|WESTERN BLOT|||STUDY SUBJECT|OPTOMETRIST|U|4|Visit_4|65|3|SCREENING|2021-02-05|65
e|TR|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|5|[?]|LNSTATE|Lymph Node State|[?]|Ci/kg|ABSENT|1|Bq|CALIPER MEASUREMENT METHOD|||ADJUDICATOR|ONCOLOGIST 1|N|5|Visit_5|90|7|TREATMENT|2021-03-02|90
e|TR|5abbbb78-2eeb-4d21-85ac-f5d18294c603|1|[?]|LESFLIND|Lesion Failure Indicator|[?]|Bq|TUMOR MERGED|1|vp/dose|CONTRAST ENHANCED X-RAY|||ADJUDICATION COMMITTEE|PATHOLOGIST 1|U|1|Visit_1|10|2|FOLLOW-UP|2021-01-25|10
e|TR|5abbbb78-2eeb-4d21-85ac-f5d18294c603|2|[?]|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|[?]|breaths/30s|UNCHANGED|1|umol/kg/min|PET/MRI SCAN|||CLINICAL STUDY SPONSOR|DERMATOLOGIST|U|2|Visit_2|25|1|FOLLOW-UP|2021-02-09|25
e|TR|5abbbb78-2eeb-4d21-85ac-f5d18294c603|3|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|mMU/mL|ABSENT|1|umol/min|NUCLEAR RADIOLOGY|||CAREGIVER|DERMATOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2021-02-24|40
e|TR|5abbbb78-2eeb-4d21-85ac-f5d18294c603|4|[?]|LESSCIND|Lesion Success Indicator|[?]|Gy/min|NON-PATHOLOGICAL|1|Bq/uL|DYNAMOMETRY|Y|Y|INVESTIGATOR|RATER 1|Y|4|Visit_4|65|2|WASHOUT|2021-03-21|65
e|TR|5abbbb78-2eeb-4d21-85ac-f5d18294c603|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|nmol BCE/mmol|PATHOLOGICAL|1|copies/mL|TURBIDIMETRY|||DOMESTIC PARTNER|UROLOGIST|Y|5|Visit_5|90|2|SCREENING|2021-04-15|90
e|TR|109fe46d-ac1f-47fe-8ecb-6049a577d38c|1|[?]|PCBSD|Percent Change Baseline in Sum of Diam|[?]|Pa|TUMOR MERGED|1|CIGARETTE|SCANNING ELECTRON MICROSCOPY|||CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-05-20|10
e|TR|109fe46d-ac1f-47fe-8ecb-6049a577d38c|2|[?]|ORVERLN|Organ Vertical Length|[?]|mL/h|PATHOLOGICAL|1|vp/dose|REFLECTANCE SPECTROSCOPY|||CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|4|FOLLOW-UP|2020-06-04|25
e|TR|109fe46d-ac1f-47fe-8ecb-6049a577d38c|3|[?]|LESSCIND|Lesion Success Indicator|[?]|mg/day|NON-PATHOLOGICAL|1|amu|HPLC/MS|||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-06-19|40
e|TR|109fe46d-ac1f-47fe-8ecb-6049a577d38c|4|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mmol/min/kPa/L|FOCALLY INCREASED|1|U/g/h|PULSE OXIMETRY|Y||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|4|Visit_4|65|5|FOLLOW-UP|2020-07-14|65
e|TR|109fe46d-ac1f-47fe-8ecb-6049a577d38c|5|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|Gy/h|ENLARGEMENT FROM NADIR|1|mL/g/day|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|||SIBLING|READER 3|NA|5|Visit_5|90|3|TREATMENT|2020-08-08|90
e|TR|cdb18d0a-5fca-4437-9b6e-0e46b0930521|1|[?]|VSLFLIND|Vessel Failure Indicator|[?]|ug/animal|UNCHANGED|1|MESF|TRANSVAGINAL ULTRASOUND||Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-09-03|10
e|TR|cdb18d0a-5fca-4437-9b6e-0e46b0930521|2|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|mN|PRESENT|1|mEq/mmol|LIQUID SCINTILLATION COUNTING|||GUARDIAN|RATER|U|2|Visit_2|25|2|FOLLOW-UP|2020-09-18|25
e|TR|cdb18d0a-5fca-4437-9b6e-0e46b0930521|3|[?]|LDIAM|Longest Diameter|[?]|/2000 RBC|UNEQUIVOCAL|1|fmol/g|DISK DIFFUSION|||SPOUSE|NEUROLOGIST|NA|3|Visit_3|40|6|FOLLOW-UP|2020-10-03|40
e|TR|cdb18d0a-5fca-4437-9b6e-0e46b0930521|4|[?]|SUMVDIAM|Sum of Viable Diameter|[?]|10^7 TCID 50/dose|UNCHANGED|1|mg/m2/h|FORCED OSCILLATION TECHNIQUE|||STUDY SUBJECT|NEUROLOGIST 1|U|4|Visit_4|65|2|TREATMENT|2020-10-28|65
e|TR|cdb18d0a-5fca-4437-9b6e-0e46b0930521|5|[?]|LDIAM|Longest Diameter|[?]|100 IU/mL|UNCHANGED|1|ug/dose|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||CHILD|DERMATOLOGIST|Y|5|Visit_5|90|5|WASHOUT|2020-11-22|90
e|TR|e515b916-5d28-4236-8835-2ff43b498ab3|1|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|nmol BCE/mmol|NONPALPABLE|1|mL/min/mmHg|FLUORESCENT ENZYME IMMUNOASSAY||Y|CLINICAL RESEARCH COORDINATOR|READER|Y|1|Visit_1|10|3|TREATMENT|2020-05-23|10
e|TR|e515b916-5d28-4236-8835-2ff43b498ab3|2|[?]|LNSTATE|Lymph Node State|[?]|mm/min|FOCALLY INCREASED|1|anti-Xa IU/mL|MICRODENSITOMETRY|Y||PROXY|OTOLARYNGOLOGIST|N|2|Visit_2|25|5|TREATMENT|2020-06-07|25
e|TR|e515b916-5d28-4236-8835-2ff43b498ab3|3|[?]|PCNPPD|Percent Change Nadir in PPD|[?]|SUPPOSITORY|EQUIVOCAL|1|g/cage/day|DNA MICROARRAY|Y||FRIEND|HEMATOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2020-06-22|40
e|TR|e515b916-5d28-4236-8835-2ff43b498ab3|4|[?]|ACNDOREN|Absolute Change Nadir in Organ Enlarge|[?]|U/m2|DIFFUSELY INCREASED|1|kg/cm2|PALM METHOD|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|U|4|Visit_4|65|6|FOLLOW-UP|2020-07-17|65
e|TR|e515b916-5d28-4236-8835-2ff43b498ab3|5|[?]|VDIAM|Viable Diameter|[?]|g/L|INCREASED|1|/day|DIFFUSION WEIGHTED MRI|Y|Y|SPOUSE|RATER 2|N|5|Visit_5|90|2|TREATMENT|2020-08-11|90
e|TR|158af2a8-d447-45e5-8c58-3b950f1bd889|1|[?]|CALCFIND|Calcification Indicator|[?]|mol/g|FURTHER ENLARGEMENT FROM NADIR|1|10^3 CFU/mL|CORONARY ANGIOGRAPHY|||STUDY SUBJECT|ENDOCRINOLOGIST|NA|1|Visit_1|10|3|SCREENING|2020-05-30|10
e|TR|158af2a8-d447-45e5-8c58-3b950f1bd889|2|[?]|CALCFIND|Calcification Indicator|[?]|SUPPOSITORY|UNEQUIVOCAL|1|mg|ACRIDINE ORANGE STAIN|||PARENT|READER 2|U|2|Visit_2|25|5|WASHOUT|2020-06-14|25
e|TR|158af2a8-d447-45e5-8c58-3b950f1bd889|3|[?]|TUMSTATE|Tumor State|[?]|uU/dL|PATHOLOGICAL|1|uEq|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y||SIBLING|MICROSCOPIST 3|N|3|Visit_3|40|1|TREATMENT|2020-06-29|40
e|TR|158af2a8-d447-45e5-8c58-3b950f1bd889|4|[?]|TUMSTATE|Tumor State|[?]|nU/cL|PALPABLE|1|%/min|GRAM STAIN|||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|4|Visit_4|65|7|TREATMENT|2020-07-24|65
e|TR|158af2a8-d447-45e5-8c58-3b950f1bd889|5|[?]|SUMDIAM|Sum of Diameter|[?]|ug/kg/min|NORMAL|1|mL/min/mmHg|RADIATION DOSIMETRY||Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|6|FOLLOW-UP|2020-08-18|90
e|TR|e9a930d5-ca57-4069-8251-c164273df082|1|[?]|FDPL5PS|FDG PET Lymphoma 5PS Score|[?]|10^3 DNA copies/mL|PALPABLE|1|ug/h|COULOMETRIC TITRATION|||SIBLING|PATHOLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-05-21|10
e|TR|e9a930d5-ca57-4069-8251-c164273df082|2|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|NEBULE|EQUIVOCAL|1|BAR|NON-CONTACT SPECULAR MICROSCOPY||Y|FAMILY MEMBER|MICROSCOPIST 1|Y|2|Visit_2|25|3|WASHOUT|2020-06-05|25
e|TR|e9a930d5-ca57-4069-8251-c164273df082|3|[?]|CALCFIND|Calcification Indicator|[?]|m/sec2|UNCHANGED|1|keV|NUCLEIC ACID AMPLIFICATION TEST|||ADJUDICATOR|RADIOLOGIST 2|U|3|Visit_3|40|5|FOLLOW-UP|2020-06-20|40
e|TR|e9a930d5-ca57-4069-8251-c164273df082|4|[?]|PBNL2IND|Two or More Persist New Bone Lesions Ind|[?]|mEq|PALPABLE|1|WEEKS|KINETIC MICROPARTICLE IMMUNOASSAY|||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|2|SCREENING|2020-07-15|65
e|TR|e9a930d5-ca57-4069-8251-c164273df082|5|[?]|VOLUME|Volume|[?]|Arbitrary U|EQUIVOCAL|1|U/kg/min|ULTRASOUND|||NON-HEALTH CARE PROFESSIONAL|RATER|N|5|Visit_5|90|2|TREATMENT|2020-08-09|90
e|TR|e654e37e-1c95-4f25-83b1-9233186626c6|1|[?]|VSLRVIND|Vessel Revascularization Indicator|[?]|Enzyme U|FURTHER ENLARGEMENT|1|10^9 organisms/mL|GEL ELECTROPHORESIS|||VENDOR|HEMATOLOGIST|NA|1|Visit_1|10|7|WASHOUT|2020-08-04|10
e|TR|e654e37e-1c95-4f25-83b1-9233186626c6|2|[?]|AVMETSUV|Average Metabolic Standard Uptake Value|[?]|uV2|NORMAL|1|F|OPTICAL DENSITY MEASUREMENT||Y|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-08-19|25
e|TR|e654e37e-1c95-4f25-83b1-9233186626c6|3|[?]|PCNSD|Percent Change Nadir in Sum of Diam|[?]|mL/(min*100mL)|FOCALLY INCREASED|1|atm|KINYOUN STAIN|||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|3|Visit_3|40|4|WASHOUT|2020-09-03|40
e|TR|e654e37e-1c95-4f25-83b1-9233186626c6|4|[?]|LESRVIND|Lesion Revascularization Indicator|[?]|STRIP|FURTHER ENLARGEMENT|1|FEU|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||FRIEND|MICROSCOPIST 3|U|4|Visit_4|65|3|TREATMENT|2020-09-28|65
e|TR|e654e37e-1c95-4f25-83b1-9233186626c6|5|[?]|SUMLPERP|Sum of Longest Perpendicular|[?]|pmol/dL|ENLARGEMENT FROM NADIR|1|mIU/L|IMMUNE REPERTOIRE DEEP SEQUENCING||Y|FRIEND|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|5|SCREENING|2020-10-23|90
e|TR|808ee0ac-e668-4e8e-aa0a-889476cbe631|1|[?]|LMNDEXAM|Number of Lymph Nodes Examined|[?]|/7.5 mL|INCREASED|1|mL/animal/wk|CALCULATION||Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|NA|1|Visit_1|10|2|SCREENING|2020-06-19|10
e|TR|808ee0ac-e668-4e8e-aa0a-889476cbe631|2|[?]|VSLPIND|Vessel Patency Indicator|[?]|WAFER|PRESENT|1|ug/dose|FLUORESCENT MICROSCOPY|||ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|3|FOLLOW-UP|2020-07-04|25
e|TR|808ee0ac-e668-4e8e-aa0a-889476cbe631|3|[?]|VDIAM|Viable Diameter|[?]|kat|INCREASED|1|mPa|PHOROPTER|||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|U|3|Visit_3|40|3|TREATMENT|2020-07-19|40
e|TR|808ee0ac-e668-4e8e-aa0a-889476cbe631|4|[?]|PCBSPPD|Percent Change Baseline in Sum of PPD|[?]|mg2/dL2|ENLARGEMENT|1|PATCH|IMMUNODIFFUSION|Y||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|N|4|Visit_4|65|4|SCREENING|2020-08-13|65
e|TR|808ee0ac-e668-4e8e-aa0a-889476cbe631|5|[?]|VSLPIND|Vessel Patency Indicator|[?]|mm|EQUIVOCAL|1|L|SINGLE-SLICE SPIRAL CT|||CHILD|PHYSIOTHERAPIST|NA|5|Visit_5|90|2|TREATMENT|2020-09-07|90
